{"doc_id": "10084639_2", "wnd_id": "10084639_2_1", "text": "CONCLUSION : The results suggest that olanzapine may be useful in treating patients with clozapine - induced granulocytopenia without the risk of recurrence of hematologic side effects .", "tokens": ["CONCLUSION", ":", "The", "results", "suggest", "that", "olanzapine", "may", "be", "useful", "in", "treating", "patients", "with", "clozapine", "-", "induced", "granulocytopenia", "without", "the", "risk", "of", "recurrence", "of", "hematologic", "side", "effects", "."], "event_mentions": [{"id": "10084639_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 11, "end": 12}, "arguments": [{"entity_id": "10084639_2_Ent2", "role": "Treatment", "text": "olanzapine", "start": 6, "end": 7}, {"entity_id": "10084639_2_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 6, "end": 7}, {"entity_id": "10084639_2_Ent0", "role": "Subject", "text": "patients with clozapine - induced granulocytopenia", "start": 12, "end": 18}, {"entity_id": "10084639_2_Ent1", "role": "Effect", "text": "without the risk of recurrence of hematologic side effects", "start": 18, "end": 27}]}, {"id": "10084639_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "10084639_2_Ent5", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "10084639_2_Ent7", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "10084639_2_Ent6", "role": "Treatment_Disorder", "text": "clozapine - induced granulocytopenia", "start": 14, "end": 18}, {"entity_id": "10084639_2_Ent4", "role": "Effect", "text": "granulocytopenia", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10084639_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10084639_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10084639_2_Ent0", "text": "patients with clozapine - induced granulocytopenia", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "10084639_2_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10084639_2_Ent7", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10084639_2_Ent6", "text": "clozapine - induced granulocytopenia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10084639_2_Ent4", "text": "granulocytopenia", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10084639_2_Ent1", "text": "without the risk of recurrence of hematologic side effects", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "10099659_2", "wnd_id": "10099659_2_1", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck , breast , ovarian , and colon cancer .", "tokens": ["5", "-", "Fluorouracil", "(", "5", "-", "FU", ")", "is", "an", "analogue", "of", "pyrimidine", "nucleosides", "that", "is", "widely", "used", "in", "the", "treatment", "of", "head", "and", "neck", ",", "breast", ",", "ovarian", ",", "and", "colon", "cancer", "."], "event_mentions": [{"id": "10099659_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 17, "end": 18}, "arguments": [{"entity_id": "10099659_2_Ent1", "role": "Treatment_Drug", "text": "5 - Fluorouracil ( 5 - FU )", "start": 0, "end": 8}, {"entity_id": "10099659_2_Ent0", "role": "Treatment", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides", "start": 0, "end": 14}, {"entity_id": "10099659_2_Ent2", "role": "Treatment_Disorder", "text": "head and neck , breast , ovarian , and colon cancer", "start": 22, "end": 33}]}], "entity_mentions": [{"id": "10099659_2_Ent1", "text": "5 - Fluorouracil ( 5 - FU )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10099659_2_Ent0", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "10099659_2_Ent2", "text": "head and neck , breast , ovarian , and colon cancer", "entity_type": "Entity", "start": 22, "end": 33}], "lang": "en"}
{"doc_id": "10099659_7", "wnd_id": "10099659_7_1", "text": "Cancer patients who are receiving 5 - FU treatment and are DPD deficient can develop severe side effects .", "tokens": ["Cancer", "patients", "who", "are", "receiving", "5", "-", "FU", "treatment", "and", "are", "DPD", "deficient", "can", "develop", "severe", "side", "effects", "."], "event_mentions": [{"id": "10099659_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 14, "end": 15}, "arguments": [{"entity_id": "10099659_7_Ent6", "role": "Treatment_Disorder", "text": "Cancer", "start": 0, "end": 1}, {"entity_id": "10099659_7_Ent0", "role": "Subject", "text": "Cancer patients", "start": 0, "end": 2}, {"entity_id": "10099659_7_Ent4", "role": "Treatment", "text": "receiving 5 - FU", "start": 4, "end": 8}, {"entity_id": "10099659_7_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 5, "end": 8}, {"entity_id": "10099659_7_Ent1", "role": "Subject", "text": "are DPD deficient", "start": 10, "end": 13}, {"entity_id": "10099659_7_Ent2", "role": "Subject_Disorder", "text": "DPD deficient", "start": 11, "end": 13}, {"entity_id": "10099659_7_Ent3", "role": "Effect", "text": "severe side effects", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10099659_7_Ent6", "text": "Cancer", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10099659_7_Ent0", "text": "Cancer patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10099659_7_Ent4", "text": "receiving 5 - FU", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10099659_7_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10099659_7_Ent1", "text": "are DPD deficient", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10099659_7_Ent2", "text": "DPD deficient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10099659_7_Ent3", "text": "severe side effects", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10225085_1", "wnd_id": "10225085_1_1", "text": "Although the two local anesthetics usually do not cause methemoglobinemia , we suspect that the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants , was the reason for the development of methemoglobinemia .", "tokens": ["Although", "the", "two", "local", "anesthetics", "usually", "do", "not", "cause", "methemoglobinemia", ",", "we", "suspect", "that", "the", "displacement", "of", "lidocaine", "from", "protein", "binding", "by", "bupivacaine", ",", "in", "combination", "with", "metabolic", "acidosis", "and", "treatment", "with", "other", "oxidants", ",", "was", "the", "reason", "for", "the", "development", "of", "methemoglobinemia", "."], "event_mentions": [{"id": "10225085_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reason", "start": 37, "end": 38}, "arguments": [{"entity_id": "10225085_1_Ent1", "role": "Treatment", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "start": 14, "end": 34}, {"entity_id": "10225085_1_Ent3", "role": "Treatment_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent9", "role": "Combination_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent2", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent8", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent4", "role": "Treatment_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent6", "role": "Combination_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent5", "role": "Treatment_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent7", "role": "Combination_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent0", "role": "Effect", "text": "methemoglobinemia", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "10225085_1_Ent1", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "entity_type": "Entity", "start": 14, "end": 34}, {"id": "10225085_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent9", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent2", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent8", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent4", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent6", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent5", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent7", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent0", "text": "methemoglobinemia", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "10327035_1", "wnd_id": "10327035_1_1", "text": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX ) is reported in a young adult with metastastic gastric cancer .", "tokens": ["An", "episode", "of", "subacute", "encephalopathy", "after", "the", "infusion", "of", "a", "moderate", "dose", "of", "methotrexate", "(", "1500", "mg", "/", "m2", ")", "(", "MTX", ")", "is", "reported", "in", "a", "young", "adult", "with", "metastastic", "gastric", "cancer", "."], "event_mentions": [{"id": "10327035_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "10327035_1_Ent2", "role": "Effect", "text": "subacute encephalopathy", "start": 3, "end": 5}, {"entity_id": "10327035_1_Ent3", "role": "Treatment", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "start": 9, "end": 23}, {"entity_id": "10327035_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "10327035_1_Ent4", "role": "Treatment_Dosage", "text": "1500 mg / m2", "start": 15, "end": 19}, {"entity_id": "10327035_1_Ent0", "role": "Subject", "text": "a young adult with metastastic gastric cancer", "start": 26, "end": 33}, {"entity_id": "10327035_1_Ent1", "role": "Subject_Age", "text": "young adult", "start": 27, "end": 29}, {"entity_id": "10327035_1_Ent6", "role": "Treatment_Disorder", "text": "metastastic gastric cancer", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "10327035_1_Ent2", "text": "subacute encephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10327035_1_Ent3", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10327035_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10327035_1_Ent4", "text": "1500 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "10327035_1_Ent0", "text": "a young adult with metastastic gastric cancer", "entity_type": "Entity", "start": 26, "end": 33}, {"id": "10327035_1_Ent1", "text": "young adult", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10327035_1_Ent6", "text": "metastastic gastric cancer", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "10337682_1", "wnd_id": "10337682_1_1", "text": "A 14 - year - old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone .", "tokens": ["A", "14", "-", "year", "-", "old", "girl", "with", "newly", "diagnosed", "SLE", "developed", "a", "pruritic", "bullous", "eruption", "while", "on", "prednisone", "."], "event_mentions": [{"id": "10337682_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "10337682_1_Ent0", "role": "Subject", "text": "A 14 - year - old girl with newly diagnosed SLE", "start": 0, "end": 11}, {"entity_id": "10337682_1_Ent1", "role": "Subject_Age", "text": "14 - year - old", "start": 1, "end": 6}, {"entity_id": "10337682_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "10337682_1_Ent6", "role": "Treatment_Disorder", "text": "SLE", "start": 10, "end": 11}, {"entity_id": "10337682_1_Ent3", "role": "Effect", "text": "a pruritic bullous eruption", "start": 12, "end": 16}, {"entity_id": "10337682_1_Ent4", "role": "Treatment", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "10337682_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10337682_1_Ent0", "text": "A 14 - year - old girl with newly diagnosed SLE", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "10337682_1_Ent1", "text": "14 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10337682_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10337682_1_Ent6", "text": "SLE", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10337682_1_Ent3", "text": "a pruritic bullous eruption", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "10337682_1_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10337682_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10357715_3", "wnd_id": "10357715_3_1", "text": "The present observation suggests , that a batch of different testing doses , including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol .", "tokens": ["The", "present", "observation", "suggests", ",", "that", "a", "batch", "of", "different", "testing", "doses", ",", "including", "lower", "testing", "doses", "may", "help", "to", "differentiate", "between", "an", "allergic", "type", "of", "contact", "dermatitis", "and", "an", "irritant", "type", "of", "reaction", "after", "treatment", "with", "calcipotriol", "."], "event_mentions": [{"id": "10357715_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after treatment", "start": 34, "end": 36}, "arguments": [{"entity_id": "10357715_3_Ent0", "role": "Effect", "text": "an allergic type of contact dermatitis", "start": 22, "end": 28}, {"entity_id": "10357715_3_Ent1", "role": "Effect", "text": "an irritant type of reaction", "start": 29, "end": 34}, {"entity_id": "10357715_3_Ent2", "role": "Treatment", "text": "calcipotriol", "start": 37, "end": 38}, {"entity_id": "10357715_3_Ent3", "role": "Treatment_Drug", "text": "calcipotriol", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "10357715_3_Ent0", "text": "an allergic type of contact dermatitis", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "10357715_3_Ent1", "text": "an irritant type of reaction", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "10357715_3_Ent2", "text": "calcipotriol", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "10357715_3_Ent3", "text": "calcipotriol", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "10395123_3", "wnd_id": "10395123_3_1", "text": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment .", "tokens": ["The", "objective", "of", "this", "report", "is", "to", "describe", "a", "case", "of", "fixed", "drug", "eruption", "that", "occurred", "during", "omeprazole", "treatment", "."], "event_mentions": [{"id": "10395123_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 15, "end": 16}, "arguments": [{"entity_id": "10395123_3_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 11, "end": 14}, {"entity_id": "10395123_3_Ent1", "role": "Treatment", "text": "during omeprazole treatment", "start": 16, "end": 19}, {"entity_id": "10395123_3_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10395123_3_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10395123_3_Ent1", "text": "during omeprazole treatment", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "10395123_3_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10405480_2", "wnd_id": "10405480_2_1", "text": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis .", "tokens": ["Acute", "generalized", "exanthematous", "pustulosis", "induced", "by", "salazosulfapyridine", "in", "a", "patient", "with", "ulcerative", "colitis", "."], "event_mentions": [{"id": "10405480_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "10405480_2_Ent1", "role": "Effect", "text": "Acute generalized exanthematous pustulosis", "start": 0, "end": 4}, {"entity_id": "10405480_2_Ent2", "role": "Treatment", "text": "salazosulfapyridine", "start": 6, "end": 7}, {"entity_id": "10405480_2_Ent3", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 6, "end": 7}, {"entity_id": "10405480_2_Ent0", "role": "Subject", "text": "a patient with ulcerative colitis", "start": 8, "end": 13}, {"entity_id": "10405480_2_Ent4", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10405480_2_Ent1", "text": "Acute generalized exanthematous pustulosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10405480_2_Ent2", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10405480_2_Ent3", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10405480_2_Ent0", "text": "a patient with ulcerative colitis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10405480_2_Ent4", "text": "ulcerative colitis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10435399_1", "wnd_id": "10435399_1_1", "text": "It carries a well - known risk of neutropenia and agranulocytosis , which necessitates the immediate discontinuation of clozapine .", "tokens": ["It", "carries", "a", "well", "-", "known", "risk", "of", "neutropenia", "and", "agranulocytosis", ",", "which", "necessitates", "the", "immediate", "discontinuation", "of", "clozapine", "."], "event_mentions": [{"id": "10435399_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 6, "end": 7}, "arguments": [{"entity_id": "10435399_1_Ent0", "role": "Effect", "text": "neutropenia and agranulocytosis", "start": 8, "end": 11}, {"entity_id": "10435399_1_Ent1", "role": "Treatment", "text": "clozapine", "start": 18, "end": 19}, {"entity_id": "10435399_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10435399_1_Ent0", "text": "neutropenia and agranulocytosis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10435399_1_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10435399_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10442258_3", "wnd_id": "10442258_3_1", "text": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors ( SSRIs ) , but none deal specifically with paroxetine .", "tokens": ["There", "are", "a", "few", "case", "reports", "on", "hair", "loss", "associated", "with", "tricyclic", "antidepressants", "and", "serotonin", "selective", "reuptake", "inhibitors", "(", "SSRIs", ")", ",", "but", "none", "deal", "specifically", "with", "paroxetine", "."], "event_mentions": [{"id": "10442258_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "10442258_3_Ent0", "role": "Effect", "text": "hair loss", "start": 7, "end": 9}, {"entity_id": "10442258_3_Ent2", "role": "Treatment_Drug", "text": "tricyclic antidepressants", "start": 11, "end": 13}, {"entity_id": "10442258_3_Ent4", "role": "Combination_Drug", "text": "tricyclic antidepressants", "start": 11, "end": 13}, {"entity_id": "10442258_3_Ent1", "role": "Treatment", "text": "tricyclic antidepressants and serotonin selective reuptake inhibitors", "start": 11, "end": 18}, {"entity_id": "10442258_3_Ent3", "role": "Treatment_Drug", "text": "serotonin selective reuptake inhibitors", "start": 14, "end": 18}, {"entity_id": "10442258_3_Ent5", "role": "Combination_Drug", "text": "serotonin selective reuptake inhibitors", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10442258_3_Ent0", "text": "hair loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10442258_3_Ent2", "text": "tricyclic antidepressants", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10442258_3_Ent4", "text": "tricyclic antidepressants", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10442258_3_Ent1", "text": "tricyclic antidepressants and serotonin selective reuptake inhibitors", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "10442258_3_Ent3", "text": "serotonin selective reuptake inhibitors", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10442258_3_Ent5", "text": "serotonin selective reuptake inhibitors", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10452772_5", "wnd_id": "10452772_5_1", "text": "Protamine allergy as a complication of insulin hypersensitivity : A case report .", "tokens": ["Protamine", "allergy", "as", "a", "complication", "of", "insulin", "hypersensitivity", ":", "A", "case", "report", "."], "event_mentions": [{"id": "10452772_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "10452772_5_Ent1", "role": "Effect", "text": "Protamine allergy", "start": 0, "end": 2}, {"entity_id": "10452772_5_Ent2", "role": "Treatment", "text": "insulin", "start": 6, "end": 7}, {"entity_id": "10452772_5_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 6, "end": 7}, {"entity_id": "10452772_5_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10452772_5_Ent1", "text": "Protamine allergy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10452772_5_Ent2", "text": "insulin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10452772_5_Ent3", "text": "insulin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10452772_5_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10458196_2", "wnd_id": "10458196_2_1", "text": "An 11 - day - old infant became lethargic and apneic after a single drop of brimonidine .", "tokens": ["An", "11", "-", "day", "-", "old", "infant", "became", "lethargic", "and", "apneic", "after", "a", "single", "drop", "of", "brimonidine", "."], "event_mentions": [{"id": "10458196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 7, "end": 8}, "arguments": [{"entity_id": "10458196_2_Ent0", "role": "Subject", "text": "An 11 - day - old infant", "start": 0, "end": 7}, {"entity_id": "10458196_2_Ent1", "role": "Subject_Age", "text": "11 - day - old", "start": 1, "end": 6}, {"entity_id": "10458196_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "10458196_2_Ent3", "role": "Effect", "text": "lethargic and apneic", "start": 8, "end": 11}, {"entity_id": "10458196_2_Ent4", "role": "Treatment", "text": "a single drop of brimonidine", "start": 12, "end": 17}, {"entity_id": "10458196_2_Ent5", "role": "Treatment_Dosage", "text": "single drop", "start": 13, "end": 15}, {"entity_id": "10458196_2_Ent6", "role": "Treatment_Drug", "text": "brimonidine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10458196_2_Ent0", "text": "An 11 - day - old infant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10458196_2_Ent1", "text": "11 - day - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10458196_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_2_Ent3", "text": "lethargic and apneic", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10458196_2_Ent4", "text": "a single drop of brimonidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10458196_2_Ent5", "text": "single drop", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10458196_2_Ent6", "text": "brimonidine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10461415_1", "wnd_id": "10461415_1_1", "text": "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato - biliary enzymes and transient biliary stasis .", "tokens": ["Ceftriaxone", "was", "approved", "in", "1997", "for", "the", "treatment", "of", "otitis", "media", "despite", "previous", "studies", "that", "documented", "an", "association", "of", "ceftriaxone", "with", "elevated", "hepato", "-", "biliary", "enzymes", "and", "transient", "biliary", "stasis", "."], "event_mentions": [{"id": "10461415_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association of", "start": 17, "end": 19}, "arguments": [{"entity_id": "10461415_1_Ent2", "role": "Treatment_Disorder", "text": "otitis media", "start": 9, "end": 11}, {"entity_id": "10461415_1_Ent1", "role": "Treatment", "text": "ceftriaxone", "start": 19, "end": 20}, {"entity_id": "10461415_1_Ent3", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 19, "end": 20}, {"entity_id": "10461415_1_Ent0", "role": "Effect", "text": "elevated hepato - biliary enzymes and transient biliary stasis", "start": 21, "end": 30}]}], "entity_mentions": [{"id": "10461415_1_Ent2", "text": "otitis media", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10461415_1_Ent1", "text": "ceftriaxone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10461415_1_Ent3", "text": "ceftriaxone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10461415_1_Ent0", "text": "elevated hepato - biliary enzymes and transient biliary stasis", "entity_type": "Entity", "start": 21, "end": 30}], "lang": "en"}
{"doc_id": "10465148_6", "wnd_id": "10465148_6_1", "text": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment .", "tokens": ["The", "clinical", "data", "suggest", "that", "anterior", "lumbosacral", "radiculopathy", "is", "also", "a", "type", "of", "neurologic", "complication", "associated", "with", "intrathecal", "methotrexate", "treatment", "."], "event_mentions": [{"id": "10465148_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "10465148_6_Ent0", "role": "Effect", "text": "anterior lumbosacral radiculopathy", "start": 5, "end": 8}, {"entity_id": "10465148_6_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 17, "end": 18}, {"entity_id": "10465148_6_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 17, "end": 19}, {"entity_id": "10465148_6_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10465148_6_Ent0", "text": "anterior lumbosacral radiculopathy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10465148_6_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10465148_6_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10465148_6_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10466445_1", "wnd_id": "10466445_1_1", "text": "Successful treatment with arsenic trioxide of a patient with ATRA - resistant relapse of acute promyelocytic leukemia .", "tokens": ["Successful", "treatment", "with", "arsenic", "trioxide", "of", "a", "patient", "with", "ATRA", "-", "resistant", "relapse", "of", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "10466445_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "10466445_1_Ent1", "role": "Treatment", "text": "arsenic trioxide", "start": 3, "end": 5}, {"entity_id": "10466445_1_Ent2", "role": "Treatment_Drug", "text": "arsenic trioxide", "start": 3, "end": 5}, {"entity_id": "10466445_1_Ent0", "role": "Subject", "text": "a patient with ATRA - resistant relapse of acute promyelocytic leukemia", "start": 6, "end": 17}, {"entity_id": "10466445_1_Ent3", "role": "Treatment_Disorder", "text": "ATRA - resistant relapse of acute promyelocytic leukemia", "start": 9, "end": 17}]}], "entity_mentions": [{"id": "10466445_1_Ent1", "text": "arsenic trioxide", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10466445_1_Ent2", "text": "arsenic trioxide", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10466445_1_Ent0", "text": "a patient with ATRA - resistant relapse of acute promyelocytic leukemia", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "10466445_1_Ent3", "text": "ATRA - resistant relapse of acute promyelocytic leukemia", "entity_type": "Entity", "start": 9, "end": 17}], "lang": "en"}
{"doc_id": "10475726_2", "wnd_id": "10475726_2_1", "text": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties .", "tokens": ["The", "association", "of", "venlafaxine", "treatment", "with", "ischaemic", "events", "could", "be", "explained", "by", "its", "unique", "pharmacological", "and", "haemodynamic", "properties", "."], "event_mentions": [{"id": "10475726_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10475726_2_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 3, "end": 4}, {"entity_id": "10475726_2_Ent1", "role": "Treatment", "text": "venlafaxine treatment", "start": 3, "end": 5}, {"entity_id": "10475726_2_Ent0", "role": "Effect", "text": "ischaemic events", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10475726_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10475726_2_Ent1", "text": "venlafaxine treatment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10475726_2_Ent0", "text": "ischaemic events", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10475726_4", "wnd_id": "10475726_4_1", "text": "We present a case of an elderly woman with a pre - existing history of ischaemic heart disease , who was treated with venlafaxine , and developed acute myocardial ischaemia within the first week of treatment .", "tokens": ["We", "present", "a", "case", "of", "an", "elderly", "woman", "with", "a", "pre", "-", "existing", "history", "of", "ischaemic", "heart", "disease", ",", "who", "was", "treated", "with", "venlafaxine", ",", "and", "developed", "acute", "myocardial", "ischaemia", "within", "the", "first", "week", "of", "treatment", "."], "event_mentions": [{"id": "10475726_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 26, "end": 27}, "arguments": [{"entity_id": "10475726_4_Ent0", "role": "Subject", "text": "an elderly woman with a pre - existing history of ischaemic heart disease", "start": 5, "end": 18}, {"entity_id": "10475726_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "10475726_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "10475726_4_Ent3", "role": "Subject_Disorder", "text": "ischaemic heart disease", "start": 15, "end": 18}, {"entity_id": "10475726_4_Ent5", "role": "Treatment", "text": "venlafaxine", "start": 23, "end": 24}, {"entity_id": "10475726_4_Ent6", "role": "Treatment_Drug", "text": "venlafaxine", "start": 23, "end": 24}, {"entity_id": "10475726_4_Ent4", "role": "Effect", "text": "acute myocardial ischaemia within the first week of treatment", "start": 27, "end": 36}, {"entity_id": "10475726_4_Ent7", "role": "Treatment_Duration", "text": "within the first week", "start": 30, "end": 34}]}], "entity_mentions": [{"id": "10475726_4_Ent0", "text": "an elderly woman with a pre - existing history of ischaemic heart disease", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "10475726_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10475726_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10475726_4_Ent3", "text": "ischaemic heart disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10475726_4_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10475726_4_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10475726_4_Ent4", "text": "acute myocardial ischaemia within the first week of treatment", "entity_type": "Entity", "start": 27, "end": 36}, {"id": "10475726_4_Ent7", "text": "within the first week", "entity_type": "Entity", "start": 30, "end": 34}], "lang": "en"}
{"doc_id": "10492493_1", "wnd_id": "10492493_1_1", "text": "CONCLUSIONS : This case suggests that losartan can induce late - onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms .", "tokens": ["CONCLUSIONS", ":", "This", "case", "suggests", "that", "losartan", "can", "induce", "late", "-", "onset", "angioedema", "in", "patients", "with", "normal", "renal", "function", "and", "that", "the", "reaction", "can", "recur", "after", "initial", "resolution", "of", "the", "symptoms", "."], "event_mentions": [{"id": "10492493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_1_Ent2", "role": "Treatment", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent1", "role": "Effect", "text": "late - onset angioedema", "start": 9, "end": 13}, {"entity_id": "10492493_1_Ent0", "role": "Subject", "text": "patients with normal renal function", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "10492493_1_Ent2", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent1", "text": "late - onset angioedema", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10492493_1_Ent0", "text": "patients with normal renal function", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "10510017_1", "wnd_id": "10510017_1_1", "text": "Heparin - induced thrombocytopenia is a rare and serious complication of anticoagulation therapy .", "tokens": ["Heparin", "-", "induced", "thrombocytopenia", "is", "a", "rare", "and", "serious", "complication", "of", "anticoagulation", "therapy", "."], "event_mentions": [{"id": "10510017_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "10510017_1_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "10510017_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "10510017_1_Ent1", "role": "Treatment", "text": "anticoagulation therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10510017_1_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10510017_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10510017_1_Ent1", "text": "anticoagulation therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10516999_2", "wnd_id": "10516999_2_1", "text": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema ) .", "tokens": ["We", "report", "a", "case", "of", "acute", "hyperphosphatemia", "secondary", "to", "rectal", "administration", "of", "sodium", "phosphate", "and", "sodium", "biphosphate", "(", "Fleet", "enema", ")", "."], "event_mentions": [{"id": "10516999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "10516999_2_Ent0", "role": "Effect", "text": "acute hyperphosphatemia", "start": 5, "end": 7}, {"entity_id": "10516999_2_Ent2", "role": "Treatment_Route", "text": "rectal", "start": 9, "end": 10}, {"entity_id": "10516999_2_Ent1", "role": "Treatment", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "start": 9, "end": 21}, {"entity_id": "10516999_2_Ent3", "role": "Treatment_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent5", "role": "Combination_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent4", "role": "Treatment_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}, {"entity_id": "10516999_2_Ent6", "role": "Combination_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "10516999_2_Ent0", "text": "acute hyperphosphatemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10516999_2_Ent2", "text": "rectal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10516999_2_Ent1", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "10516999_2_Ent3", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent5", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent4", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10516999_2_Ent6", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "10530201_9", "wnd_id": "10530201_9_1", "text": "Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned .", "tokens": ["Emphasis", "is", "given", "to", "the", "differentiation", "of", "diphenylhydantoin", "induced", "gingival", "hyperplasia", "from", "the", "angiomatous", "enlargement", "of", "the", "gingiva", "before", "any", "treatment", "is", "planned", "."], "event_mentions": [{"id": "10530201_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10530201_9_Ent2", "role": "Treatment", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent3", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 9, "end": 11}, {"entity_id": "10530201_9_Ent1", "role": "Effect", "text": "the angiomatous enlargement of the gingiva", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "10530201_9_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent3", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10530201_9_Ent1", "text": "the angiomatous enlargement of the gingiva", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "10546851_5", "wnd_id": "10546851_5_1", "text": "Six patients at steady state in treatment with indinavir participated in the study .", "tokens": ["Six", "patients", "at", "steady", "state", "in", "treatment", "with", "indinavir", "participated", "in", "the", "study", "."], "event_mentions": [{"id": "10546851_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "10546851_5_Ent1", "role": "Subject_Population", "text": "Six", "start": 0, "end": 1}, {"entity_id": "10546851_5_Ent0", "role": "Subject", "text": "Six patients", "start": 0, "end": 2}, {"entity_id": "10546851_5_Ent2", "role": "Treatment", "text": "indinavir", "start": 8, "end": 9}, {"entity_id": "10546851_5_Ent3", "role": "Treatment_Drug", "text": "indinavir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10546851_5_Ent1", "text": "Six", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10546851_5_Ent0", "text": "Six patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10546851_5_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10546851_5_Ent3", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10573314_3", "wnd_id": "10573314_3_1", "text": "Two patients , each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation , developed adverse effects after the initiation of tolterodine for urinary disorders .", "tokens": ["Two", "patients", ",", "each", "receiving", "warfarin", "for", "stroke", "prophylaxis", "in", "association", "with", "chronic", "atrial", "fibrillation", ",", "developed", "adverse", "effects", "after", "the", "initiation", "of", "tolterodine", "for", "urinary", "disorders", "."], "event_mentions": [{"id": "10573314_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10573314_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "10573314_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "10573314_3_Ent4", "role": "Treatment", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "start": 4, "end": 15}, {"entity_id": "10573314_3_Ent9", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent11", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent6", "role": "Treatment_Disorder", "text": "stroke", "start": 7, "end": 8}, {"entity_id": "10573314_3_Ent2", "role": "Subject_Disorder", "text": "chronic atrial fibrillation", "start": 12, "end": 15}, {"entity_id": "10573314_3_Ent3", "role": "Effect", "text": "adverse effects", "start": 17, "end": 19}, {"entity_id": "10573314_3_Ent5", "role": "Treatment", "text": "after the initiation of tolterodine for urinary disorders", "start": 19, "end": 27}, {"entity_id": "10573314_3_Ent8", "role": "Treatment_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent10", "role": "Combination_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent7", "role": "Treatment_Disorder", "text": "urinary disorders", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "10573314_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10573314_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10573314_3_Ent4", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10573314_3_Ent9", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent11", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent6", "text": "stroke", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_3_Ent2", "text": "chronic atrial fibrillation", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10573314_3_Ent3", "text": "adverse effects", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10573314_3_Ent5", "text": "after the initiation of tolterodine for urinary disorders", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "10573314_3_Ent8", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent10", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent7", "text": "urinary disorders", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "10589077_5", "wnd_id": "10589077_5_1", "text": "We conclude that low - dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions .", "tokens": ["We", "conclude", "that", "low", "-", "dose", "HU", "therapy", "in", "patients", "with", "thalassemia", "intermedia", "may", "increase", "total", "Hb", "levels", "sufficiently", "to", "eliminate", "the", "need", "for", "transfusions", "."], "event_mentions": [{"id": "10589077_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 7, "end": 8}, "arguments": [{"entity_id": "10589077_5_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "10589077_5_Ent2", "role": "Treatment", "text": "low - dose HU therapy", "start": 3, "end": 8}, {"entity_id": "10589077_5_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 6, "end": 7}, {"entity_id": "10589077_5_Ent0", "role": "Subject", "text": "in patients with thalassemia intermedia", "start": 8, "end": 13}, {"entity_id": "10589077_5_Ent3", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 11, "end": 13}, {"entity_id": "10589077_5_Ent1", "role": "Effect", "text": "increase total Hb levels", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10589077_5_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10589077_5_Ent2", "text": "low - dose HU therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10589077_5_Ent4", "text": "HU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10589077_5_Ent0", "text": "in patients with thalassemia intermedia", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10589077_5_Ent3", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10589077_5_Ent1", "text": "increase total Hb levels", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10592946_1", "wnd_id": "10592946_1_1", "text": "A 36 - y - o patient with schizophrenia , who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day , became delirious and was admitted to a psychiatric hospital .", "tokens": ["A", "36", "-", "y", "-", "o", "patient", "with", "schizophrenia", ",", "who", "had", "consumed", "gradually", "increasing", "quantities", "of", "oolong", "tea", "that", "eventually", "reached", "15", "L", "each", "day", ",", "became", "delirious", "and", "was", "admitted", "to", "a", "psychiatric", "hospital", "."], "event_mentions": [{"id": "10592946_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 27, "end": 28}, "arguments": [{"entity_id": "10592946_1_Ent0", "role": "Subject", "text": "A 36 - y - o patient with schizophrenia", "start": 0, "end": 9}, {"entity_id": "10592946_1_Ent1", "role": "Subject_Age", "text": "36 - y - o", "start": 1, "end": 6}, {"entity_id": "10592946_1_Ent2", "role": "Subject_Disorder", "text": "schizophrenia", "start": 8, "end": 9}, {"entity_id": "10592946_1_Ent4", "role": "Treatment", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "start": 13, "end": 26}, {"entity_id": "10592946_1_Ent7", "role": "Treatment_Drug", "text": "oolong tea", "start": 17, "end": 19}, {"entity_id": "10592946_1_Ent5", "role": "Treatment_Dosage", "text": "15 L", "start": 22, "end": 24}, {"entity_id": "10592946_1_Ent6", "role": "Treatment_Freq", "text": "each day", "start": 24, "end": 26}, {"entity_id": "10592946_1_Ent3", "role": "Effect", "text": "delirious", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "10592946_1_Ent0", "text": "A 36 - y - o patient with schizophrenia", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "10592946_1_Ent1", "text": "36 - y - o", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10592946_1_Ent2", "text": "schizophrenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10592946_1_Ent4", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "10592946_1_Ent7", "text": "oolong tea", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10592946_1_Ent5", "text": "15 L", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10592946_1_Ent6", "text": "each day", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "10592946_1_Ent3", "text": "delirious", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "10592946_2", "wnd_id": "10592946_2_1", "text": "After abstinence from oolong tea his delirium resolved .", "tokens": ["After", "abstinence", "from", "oolong", "tea", "his", "delirium", "resolved", "."], "event_mentions": [{"id": "10592946_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10592946_2_Ent0", "role": "Treatment", "text": "oolong tea", "start": 3, "end": 5}, {"entity_id": "10592946_2_Ent1", "role": "Treatment_Disorder", "text": "delirium", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10592946_2_Ent0", "text": "oolong tea", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10592946_6", "wnd_id": "10592946_6_1", "text": "We hypothesize that caffeine toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis .", "tokens": ["We", "hypothesize", "that", "caffeine", "toxicity", "injured", "the", "muscle", "cells", ",", "which", "were", "fragile", "due", "to", "the", "potassium", "depletion", "induced", "by", "the", "coexisting", "hyponatremia", ",", "to", "result", "in", "unusually", "severe", "rhabdomyolysis", "."], "event_mentions": [{"id": "10592946_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "injured", "start": 5, "end": 6}, "arguments": [{"entity_id": "10592946_6_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 3, "end": 4}, {"entity_id": "10592946_6_Ent1", "role": "Treatment", "text": "caffeine toxicity", "start": 3, "end": 5}, {"entity_id": "10592946_6_Ent0", "role": "Effect", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "start": 7, "end": 30}]}], "entity_mentions": [{"id": "10592946_6_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_6_Ent1", "text": "caffeine toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_6_Ent0", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 30}], "lang": "en"}
{"doc_id": "10599932_2", "wnd_id": "10599932_2_1", "text": "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine , was noted in a patient treated for major depression and obsessive - compulsive disorder .", "tokens": ["A", "pharmacokinetic", "interaction", "between", "the", "selective", "serotonin", "reuptake", "inhibitor", "citalopram", "and", "a", "tricyclic", "antidepressant", ",", "clomipramine", ",", "was", "noted", "in", "a", "patient", "treated", "for", "major", "depression", "and", "obsessive", "-", "compulsive", "disorder", "."], "event_mentions": [{"id": "10599932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 2, "end": 3}, "arguments": [{"entity_id": "10599932_2_Ent1", "role": "Effect", "text": "A pharmacokinetic interaction", "start": 0, "end": 3}, {"entity_id": "10599932_2_Ent2", "role": "Treatment", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "start": 4, "end": 16}, {"entity_id": "10599932_2_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent4", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent8", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent0", "role": "Subject", "text": "a patient treated for major depression and obsessive - compulsive disorder", "start": 20, "end": 31}, {"entity_id": "10599932_2_Ent5", "role": "Treatment_Disorder", "text": "depression", "start": 25, "end": 26}, {"entity_id": "10599932_2_Ent6", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "10599932_2_Ent1", "text": "A pharmacokinetic interaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10599932_2_Ent2", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "10599932_2_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent4", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent8", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent0", "text": "a patient treated for major depression and obsessive - compulsive disorder", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "10599932_2_Ent5", "text": "depression", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10599932_2_Ent6", "text": "obsessive - compulsive disorder", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "10614572_1", "wnd_id": "10614572_1_1", "text": "Intravenous valproate associated with significant hypotension in the treatment of status epilepticus .", "tokens": ["Intravenous", "valproate", "associated", "with", "significant", "hypotension", "in", "the", "treatment", "of", "status", "epilepticus", "."], "event_mentions": [{"id": "10614572_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10614572_1_Ent3", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10614572_1_Ent1", "role": "Treatment", "text": "Intravenous valproate", "start": 0, "end": 2}, {"entity_id": "10614572_1_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 1, "end": 2}, {"entity_id": "10614572_1_Ent0", "role": "Effect", "text": "significant hypotension", "start": 4, "end": 6}, {"entity_id": "10614572_1_Ent2", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10614572_1_Ent3", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10614572_1_Ent1", "text": "Intravenous valproate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10614572_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10614572_1_Ent0", "text": "significant hypotension", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10614572_1_Ent2", "text": "status epilepticus", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10646879_2", "wnd_id": "10646879_2_1", "text": "Ten to 15 % of patients treated with ifosfamide develop an encephalopathy .", "tokens": ["Ten", "to", "15", "%", "of", "patients", "treated", "with", "ifosfamide", "develop", "an", "encephalopathy", "."], "event_mentions": [{"id": "10646879_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10646879_2_Ent1", "role": "Subject_Population", "text": "Ten to 15 %", "start": 0, "end": 4}, {"entity_id": "10646879_2_Ent0", "role": "Subject", "text": "Ten to 15 % of patients", "start": 0, "end": 6}, {"entity_id": "10646879_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent2", "role": "Effect", "text": "encephalopathy .", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10646879_2_Ent1", "text": "Ten to 15 %", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10646879_2_Ent0", "text": "Ten to 15 % of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10646879_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent2", "text": "encephalopathy .", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10656221_2", "wnd_id": "10656221_2_1", "text": "There are few reports in the literature related to sulfonylurea - induced hepatotoxicity .", "tokens": ["There", "are", "few", "reports", "in", "the", "literature", "related", "to", "sulfonylurea", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "10656221_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "10656221_2_Ent1", "role": "Treatment", "text": "sulfonylurea", "start": 9, "end": 10}, {"entity_id": "10656221_2_Ent2", "role": "Treatment_Drug", "text": "sulfonylurea", "start": 9, "end": 10}, {"entity_id": "10656221_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10656221_2_Ent1", "text": "sulfonylurea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10656221_2_Ent2", "text": "sulfonylurea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10656221_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10656221_4", "wnd_id": "10656221_4_1", "text": "A 60 - year - old woman with diabetes mellitus ( type 2 ) developed an acute icteric hepatitis - like illness 6 weeks after the initiation of gliclazide therapy .", "tokens": ["A", "60", "-", "year", "-", "old", "woman", "with", "diabetes", "mellitus", "(", "type", "2", ")", "developed", "an", "acute", "icteric", "hepatitis", "-", "like", "illness", "6", "weeks", "after", "the", "initiation", "of", "gliclazide", "therapy", "."], "event_mentions": [{"id": "10656221_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "10656221_4_Ent0", "role": "Subject", "text": "A 60 - year - old woman with diabetes mellitus ( type 2 )", "start": 0, "end": 14}, {"entity_id": "10656221_4_Ent1", "role": "Subject_Age", "text": "60 - year - old", "start": 1, "end": 6}, {"entity_id": "10656221_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10656221_4_Ent7", "role": "Treatment_Disorder", "text": "diabetes mellitus ( type 2 )", "start": 8, "end": 14}, {"entity_id": "10656221_4_Ent3", "role": "Effect", "text": "an acute icteric hepatitis - like illness", "start": 15, "end": 22}, {"entity_id": "10656221_4_Ent5", "role": "Treatment_Time_elapsed", "text": "6 weeks", "start": 22, "end": 24}, {"entity_id": "10656221_4_Ent4", "role": "Treatment", "text": "6 weeks after the initiation of gliclazide therapy", "start": 22, "end": 30}, {"entity_id": "10656221_4_Ent6", "role": "Treatment_Drug", "text": "gliclazide", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "10656221_4_Ent0", "text": "A 60 - year - old woman with diabetes mellitus ( type 2 )", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "10656221_4_Ent1", "text": "60 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10656221_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10656221_4_Ent7", "text": "diabetes mellitus ( type 2 )", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10656221_4_Ent3", "text": "an acute icteric hepatitis - like illness", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10656221_4_Ent5", "text": "6 weeks", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10656221_4_Ent4", "text": "6 weeks after the initiation of gliclazide therapy", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10656221_4_Ent6", "text": "gliclazide", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "10656221_9", "wnd_id": "10656221_9_1", "text": "We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites .", "tokens": ["We", "believe", "that", "this", "is", "the", "first", "description", "of", "acute", "hepatitis", "caused", "by", "an", "idiosyncratic", "adverse", "reaction", "to", "gliclazide", "or", "to", "one", "of", "its", "metabolites", "."], "event_mentions": [{"id": "10656221_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "idiosyncratic adverse reaction", "start": 14, "end": 17}, "arguments": [{"entity_id": "10656221_9_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 9, "end": 11}, {"entity_id": "10656221_9_Ent1", "role": "Treatment", "text": "gliclazide", "start": 18, "end": 19}, {"entity_id": "10656221_9_Ent2", "role": "Treatment_Drug", "text": "gliclazide", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10656221_9_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10656221_9_Ent1", "text": "gliclazide", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10656221_9_Ent2", "text": "gliclazide", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10660641_7", "wnd_id": "10660641_7_1", "text": "The infection tended to subside with the AMPH administration .", "tokens": ["The", "infection", "tended", "to", "subside", "with", "the", "AMPH", "administration", "."], "event_mentions": [{"id": "10660641_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subside", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_7_Ent0", "role": "Effect", "text": "infection tended", "start": 1, "end": 3}, {"entity_id": "10660641_7_Ent2", "role": "Treatment_Drug", "text": "AMPH", "start": 7, "end": 8}, {"entity_id": "10660641_7_Ent1", "role": "Treatment", "text": "AMPH administration", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10660641_7_Ent0", "text": "infection tended", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_7_Ent2", "text": "AMPH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10660641_7_Ent1", "text": "AMPH administration", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10682234_1", "wnd_id": "10682234_1_1", "text": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon - alpha .", "tokens": ["Intravenous", "administration", "of", "levodopa", "ameliorated", "a", "refractory", "akathisia", "case", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "10682234_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_1_Ent0", "role": "Treatment", "text": "Intravenous administration of levodopa", "start": 0, "end": 4}, {"entity_id": "10682234_1_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "10682234_1_Ent1", "role": "Treatment_Disorder", "text": "a refractory akathisia case induced by interferon - alpha", "start": 5, "end": 14}]}, {"id": "10682234_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "10682234_1_Ent4", "role": "Effect", "text": "refractory akathisia", "start": 6, "end": 8}, {"entity_id": "10682234_1_Ent6", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 11, "end": 14}, {"entity_id": "10682234_1_Ent5", "role": "Treatment", "text": "interferon - alpha .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10682234_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_1_Ent0", "text": "Intravenous administration of levodopa", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_1_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_1_Ent1", "text": "a refractory akathisia case induced by interferon - alpha", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10682234_1_Ent4", "text": "refractory akathisia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_1_Ent6", "text": "interferon - alpha", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10682234_1_Ent5", "text": "interferon - alpha .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10698143_1", "wnd_id": "10698143_1_1", "text": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone .", "tokens": ["Central", "nervous", "system", "manifestations", "of", "an", "ibuprofen", "overdose", "reversed", "by", "naloxone", "."], "event_mentions": [{"id": "10698143_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "by", "start": 9, "end": 10}, "arguments": [{"entity_id": "10698143_1_Ent1", "role": "Treatment_Disorder", "text": "Central nervous system manifestations", "start": 0, "end": 4}, {"entity_id": "10698143_1_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 6, "end": 7}, {"entity_id": "10698143_1_Ent0", "role": "Treatment", "text": "naloxone", "start": 10, "end": 11}, {"entity_id": "10698143_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10698143_1_Ent1", "text": "Central nervous system manifestations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10698143_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10698143_1_Ent0", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10698143_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10715308_10", "wnd_id": "10715308_10_1", "text": "The tirapazamine - plus - cisplatin regimen was associated with mild to moderate adverse events , including acute , reversible hearing loss , reversible , intermittent muscle cramping , diarrhea , skin rash , nausea , and vomiting .", "tokens": ["The", "tirapazamine", "-", "plus", "-", "cisplatin", "regimen", "was", "associated", "with", "mild", "to", "moderate", "adverse", "events", ",", "including", "acute", ",", "reversible", "hearing", "loss", ",", "reversible", ",", "intermittent", "muscle", "cramping", ",", "diarrhea", ",", "skin", "rash", ",", "nausea", ",", "and", "vomiting", "."], "event_mentions": [{"id": "10715308_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "10715308_10_Ent2", "role": "Treatment_Drug", "text": "tirapazamine", "start": 1, "end": 2}, {"entity_id": "10715308_10_Ent4", "role": "Combination_Drug", "text": "tirapazamine", "start": 1, "end": 2}, {"entity_id": "10715308_10_Ent1", "role": "Treatment", "text": "tirapazamine - plus - cisplatin regimen", "start": 1, "end": 7}, {"entity_id": "10715308_10_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 5, "end": 6}, {"entity_id": "10715308_10_Ent5", "role": "Combination_Drug", "text": "cisplatin", "start": 5, "end": 6}, {"entity_id": "10715308_10_Ent0", "role": "Effect", "text": "mild to moderate adverse events , including acute , reversible hearing loss , reversible , intermittent muscle cramping , diarrhea , skin rash , nausea , and vomiting", "start": 10, "end": 38}]}], "entity_mentions": [{"id": "10715308_10_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10715308_10_Ent4", "text": "tirapazamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10715308_10_Ent1", "text": "tirapazamine - plus - cisplatin regimen", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "10715308_10_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10715308_10_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10715308_10_Ent0", "text": "mild to moderate adverse events , including acute , reversible hearing loss , reversible , intermittent muscle cramping , diarrhea , skin rash , nausea , and vomiting", "entity_type": "Entity", "start": 10, "end": 38}], "lang": "en"}
{"doc_id": "10715308_11", "wnd_id": "10715308_11_1", "text": "There were no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths related to tirapazamine .", "tokens": ["There", "were", "no", "incremental", "increases", "in", "myelosuppression", ",", "peripheral", "neuropathy", ",", "or", "renal", ",", "hepatic", ",", "or", "cardiac", "toxicity", "and", "no", "deaths", "related", "to", "tirapazamine", "."], "event_mentions": [{"id": "10715308_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "related", "start": 22, "end": 23}, "arguments": [{"entity_id": "10715308_11_Ent0", "role": "Effect", "text": "no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths", "start": 2, "end": 22}, {"entity_id": "10715308_11_Ent1", "role": "Treatment", "text": "tirapazamine", "start": 24, "end": 25}, {"entity_id": "10715308_11_Ent2", "role": "Treatment_Drug", "text": "tirapazamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "10715308_11_Ent0", "text": "no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths", "entity_type": "Entity", "start": 2, "end": 22}, {"id": "10715308_11_Ent1", "text": "tirapazamine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10715308_11_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "10717401_1", "wnd_id": "10717401_1_1", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L - asparaginase treatment : case report and review of the literature .", "tokens": ["Sagittal", "sinus", "thrombosis", "associated", "with", "transient", "free", "protein", "S", "deficiency", "after", "L", "-", "asparaginase", "treatment", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "10717401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "10717401_1_Ent0", "role": "Effect", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency", "start": 0, "end": 10}, {"entity_id": "10717401_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "10717401_1_Ent1", "role": "Treatment", "text": "L - asparaginase treatment", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10717401_1_Ent0", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10717401_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10717401_1_Ent1", "text": "L - asparaginase treatment", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10723699_1", "wnd_id": "10723699_1_1", "text": "Tetracycline - induced benign intracranial hypertension .", "tokens": ["Tetracycline", "-", "induced", "benign", "intracranial", "hypertension", "."], "event_mentions": [{"id": "10723699_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10723699_1_Ent1", "role": "Treatment", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent2", "role": "Treatment_Drug", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent0", "role": "Effect", "text": "benign intracranial hypertension", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "10723699_1_Ent1", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent2", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent0", "text": "benign intracranial hypertension", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "10755579_1", "wnd_id": "10755579_1_1", "text": "Fluoxetine - related death in a child with cytochrome P - 450 2D6 genetic deficiency .", "tokens": ["Fluoxetine", "-", "related", "death", "in", "a", "child", "with", "cytochrome", "P", "-", "450", "2D6", "genetic", "deficiency", "."], "event_mentions": [{"id": "10755579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "10755579_1_Ent4", "role": "Treatment", "text": "Fluoxetine", "start": 0, "end": 1}, {"entity_id": "10755579_1_Ent5", "role": "Treatment_Drug", "text": "Fluoxetine", "start": 0, "end": 1}, {"entity_id": "10755579_1_Ent3", "role": "Effect", "text": "death", "start": 3, "end": 4}, {"entity_id": "10755579_1_Ent1", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "10755579_1_Ent0", "role": "Subject", "text": "child with cytochrome P - 450 2D6 genetic deficiency", "start": 6, "end": 15}, {"entity_id": "10755579_1_Ent2", "role": "Subject_Disorder", "text": "cytochrome P - 450 2D6 genetic deficiency", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "10755579_1_Ent4", "text": "Fluoxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10755579_1_Ent5", "text": "Fluoxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10755579_1_Ent3", "text": "death", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10755579_1_Ent1", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10755579_1_Ent0", "text": "child with cytochrome P - 450 2D6 genetic deficiency", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "10755579_1_Ent2", "text": "cytochrome P - 450 2D6 genetic deficiency", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "10755579_2", "wnd_id": "10755579_2_1", "text": "The medical examiner 's report indicated death caused by fluoxetine toxicity .", "tokens": ["The", "medical", "examiner", "'s", "report", "indicated", "death", "caused", "by", "fluoxetine", "toxicity", "."], "event_mentions": [{"id": "10755579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "10755579_2_Ent0", "role": "Effect", "text": "death", "start": 6, "end": 7}, {"entity_id": "10755579_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "10755579_2_Ent1", "role": "Treatment", "text": "fluoxetine toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10755579_2_Ent0", "text": "death", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10755579_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10755579_2_Ent1", "text": "fluoxetine toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10759907_2", "wnd_id": "10759907_2_1", "text": "Spinal cord infarction during use of zolmitriptan : a case report .", "tokens": ["Spinal", "cord", "infarction", "during", "use", "of", "zolmitriptan", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10759907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "10759907_2_Ent0", "role": "Effect", "text": "Spinal cord infarction", "start": 0, "end": 3}, {"entity_id": "10759907_2_Ent1", "role": "Treatment", "text": "use of zolmitriptan", "start": 4, "end": 7}, {"entity_id": "10759907_2_Ent2", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10759907_2_Ent0", "text": "Spinal cord infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10759907_2_Ent1", "text": "use of zolmitriptan", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10759907_2_Ent2", "text": "zolmitriptan", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10772434_1", "wnd_id": "10772434_1_1", "text": "CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses .", "tokens": ["CASE", "SUMMARY", ":", "A", "10", "-", "year", "-", "old", "white", "girl", "with", "bilateral", "optic", "glioma", "developed", "a", "hypersensitivity", "reaction", "to", "carboplatin", "after", "nine", "courses", "."], "event_mentions": [{"id": "10772434_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "10772434_1_Ent0", "role": "Subject", "text": "A 10 - year - old white girl with bilateral optic glioma", "start": 3, "end": 15}, {"entity_id": "10772434_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 4, "end": 9}, {"entity_id": "10772434_1_Ent3", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "10772434_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 10, "end": 11}, {"entity_id": "10772434_1_Ent6", "role": "Treatment_Disorder", "text": "bilateral optic glioma", "start": 12, "end": 15}, {"entity_id": "10772434_1_Ent4", "role": "Effect", "text": "hypersensitivity reaction", "start": 17, "end": 19}, {"entity_id": "10772434_1_Ent7", "role": "Treatment_Drug", "text": "carboplatin", "start": 20, "end": 21}, {"entity_id": "10772434_1_Ent5", "role": "Treatment", "text": "carboplatin after nine courses", "start": 20, "end": 24}, {"entity_id": "10772434_1_Ent8", "role": "Treatment_Duration", "text": "nine courses", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "10772434_1_Ent0", "text": "A 10 - year - old white girl with bilateral optic glioma", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "10772434_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10772434_1_Ent3", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10772434_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10772434_1_Ent6", "text": "bilateral optic glioma", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10772434_1_Ent4", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10772434_1_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10772434_1_Ent5", "text": "carboplatin after nine courses", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "10772434_1_Ent8", "text": "nine courses", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "10774758_2", "wnd_id": "10774758_2_1", "text": "This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide .", "tokens": ["This", "is", "the", "first", "report", "of", "an", "adverse", "effect", "of", "fetal", "renal", "circulation", "by", "maternal", "ingestion", "of", "nimesulide", "."], "event_mentions": [{"id": "10774758_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "10774758_2_Ent0", "role": "Subject", "text": "first report of an adverse effect of fetal renal circulation", "start": 3, "end": 13}, {"entity_id": "10774758_2_Ent1", "role": "Effect", "text": "fetal renal circulation", "start": 10, "end": 13}, {"entity_id": "10774758_2_Ent5", "role": "Treatment_Route", "text": "maternal ingestion", "start": 14, "end": 16}, {"entity_id": "10774758_2_Ent2", "role": "Treatment", "text": "maternal ingestion of nimesulide", "start": 14, "end": 18}, {"entity_id": "10774758_2_Ent3", "role": "Treatment", "text": "nimesulide", "start": 17, "end": 18}, {"entity_id": "10774758_2_Ent4", "role": "Treatment_Drug", "text": "nimesulide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10774758_2_Ent0", "text": "first report of an adverse effect of fetal renal circulation", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "10774758_2_Ent1", "text": "fetal renal circulation", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10774758_2_Ent5", "text": "maternal ingestion", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10774758_2_Ent2", "text": "maternal ingestion of nimesulide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10774758_2_Ent3", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10774758_2_Ent4", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10779995_3", "wnd_id": "10779995_3_1", "text": "The authors present a case of t - AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide , given for palliation purpose .", "tokens": ["The", "authors", "present", "a", "case", "of", "t", "-", "AML", "that", "developed", "in", "a", "child", "with", "metastatic", "neuroblastoma", "18", "months", "after", "he", "received", "oral", "etoposide", ",", "given", "for", "palliation", "purpose", "."], "event_mentions": [{"id": "10779995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10779995_3_Ent2", "role": "Effect", "text": "t - AML", "start": 6, "end": 9}, {"entity_id": "10779995_3_Ent0", "role": "Subject", "text": "a child with metastatic neuroblastoma", "start": 12, "end": 17}, {"entity_id": "10779995_3_Ent1", "role": "Subject_Age", "text": "child", "start": 13, "end": 14}, {"entity_id": "10779995_3_Ent7", "role": "Treatment_Disorder", "text": "metastatic neuroblastoma", "start": 15, "end": 17}, {"entity_id": "10779995_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 17, "end": 19}, {"entity_id": "10779995_3_Ent5", "role": "Treatment_Route", "text": "oral", "start": 22, "end": 23}, {"entity_id": "10779995_3_Ent3", "role": "Treatment", "text": "oral etoposide", "start": 22, "end": 24}, {"entity_id": "10779995_3_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10779995_3_Ent2", "text": "t - AML", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10779995_3_Ent0", "text": "a child with metastatic neuroblastoma", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10779995_3_Ent1", "text": "child", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10779995_3_Ent7", "text": "metastatic neuroblastoma", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10779995_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10779995_3_Ent5", "text": "oral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10779995_3_Ent3", "text": "oral etoposide", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10779995_3_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10803790_2", "wnd_id": "10803790_2_1", "text": "Case 2 : A 43 - year - old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue .", "tokens": ["Case", "2", ":", "A", "43", "-", "year", "-", "old", "male", "alcoholic", "remained", "completely", "abstinent", "with", "cyanamide", "treatment", "for", "5", "years", "and", "complained", "of", "general", "fatigue", "."], "event_mentions": [{"id": "10803790_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 21, "end": 22}, "arguments": [{"entity_id": "10803790_2_Ent0", "role": "Subject", "text": "A 43 - year - old male alcoholic", "start": 3, "end": 11}, {"entity_id": "10803790_2_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "10803790_2_Ent5", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_2_Ent4", "role": "Treatment", "text": "completely abstinent with cyanamide treatment for 5 years", "start": 12, "end": 20}, {"entity_id": "10803790_2_Ent6", "role": "Treatment_Drug", "text": "cyanamide", "start": 15, "end": 16}, {"entity_id": "10803790_2_Ent7", "role": "Treatment_Duration", "text": "5 years", "start": 18, "end": 20}, {"entity_id": "10803790_2_Ent3", "role": "Effect", "text": "general fatigue", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "10803790_2_Ent0", "text": "A 43 - year - old male alcoholic", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "10803790_2_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_2_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_2_Ent5", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_2_Ent4", "text": "completely abstinent with cyanamide treatment for 5 years", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "10803790_2_Ent6", "text": "cyanamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10803790_2_Ent7", "text": "5 years", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10803790_2_Ent3", "text": "general fatigue", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "10870095_2", "wnd_id": "10870095_2_1", "text": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise - induced asthma .", "tokens": ["Zafirlukast", "is", "a", "cysteinyl", "leukotriene", "antagonist", "used", "to", "treat", "allergic", "and", "exercise", "-", "induced", "asthma", "."], "event_mentions": [{"id": "10870095_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 8, "end": 9}, "arguments": [{"entity_id": "10870095_2_Ent2", "role": "Treatment_Drug", "text": "Zafirlukast", "start": 0, "end": 1}, {"entity_id": "10870095_2_Ent0", "role": "Treatment", "text": "Zafirlukast is a cysteinyl leukotriene antagonist", "start": 0, "end": 6}, {"entity_id": "10870095_2_Ent1", "role": "Treatment_Disorder", "text": "allergic and exercise - induced asthma", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "10870095_2_Ent2", "text": "Zafirlukast", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10870095_2_Ent0", "text": "Zafirlukast is a cysteinyl leukotriene antagonist", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10870095_2_Ent1", "text": "allergic and exercise - induced asthma", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "1087773_1", "wnd_id": "1087773_1_1", "text": "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor .", "tokens": ["After", "seven", "months", "'", "continuous", "treatment", "for", "suspected", "tuberculosis", "with", "rifampicin", "and", "ethambutol", "a", "nine", "-", "year", "-", "old", "boy", "developed", "polyarthritis", ",", "rash", "and", "hepatitis", "in", "association", "with", "anti", "-", "native", "DNA", "antibodies", "and", "positive", "antinuclear", "factor", "."], "event_mentions": [{"id": "1087773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "1087773_1_Ent9", "role": "Treatment_Time_elapsed", "text": "seven months", "start": 1, "end": 3}, {"entity_id": "1087773_1_Ent4", "role": "Treatment", "text": "seven months ' continuous treatment", "start": 1, "end": 6}, {"entity_id": "1087773_1_Ent8", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "1087773_1_Ent5", "role": "Treatment", "text": "with rifampicin and ethambutol", "start": 9, "end": 13}, {"entity_id": "1087773_1_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent11", "role": "Combination_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent7", "role": "Treatment_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent10", "role": "Combination_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent0", "role": "Subject", "text": "a nine - year - old boy", "start": 13, "end": 20}, {"entity_id": "1087773_1_Ent1", "role": "Subject_Age", "text": "nine - year - old", "start": 14, "end": 19}, {"entity_id": "1087773_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 19, "end": 20}, {"entity_id": "1087773_1_Ent3", "role": "Effect", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "start": 21, "end": 38}]}], "entity_mentions": [{"id": "1087773_1_Ent9", "text": "seven months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1087773_1_Ent4", "text": "seven months ' continuous treatment", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1087773_1_Ent8", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1087773_1_Ent5", "text": "with rifampicin and ethambutol", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1087773_1_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent11", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent10", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent0", "text": "a nine - year - old boy", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "1087773_1_Ent1", "text": "nine - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1087773_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1087773_1_Ent3", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "entity_type": "Entity", "start": 21, "end": 38}], "lang": "en"}
{"doc_id": "10879669_1", "wnd_id": "10879669_1_1", "text": "A case of normotensive scleroderma renal crisis after high - dose methylprednisolone treatment .", "tokens": ["A", "case", "of", "normotensive", "scleroderma", "renal", "crisis", "after", "high", "-", "dose", "methylprednisolone", "treatment", "."], "event_mentions": [{"id": "10879669_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "10879669_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "10879669_1_Ent1", "role": "Effect", "text": "normotensive scleroderma renal crisis", "start": 3, "end": 7}, {"entity_id": "10879669_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 8, "end": 11}, {"entity_id": "10879669_1_Ent2", "role": "Treatment", "text": "high - dose methylprednisolone treatment", "start": 8, "end": 13}, {"entity_id": "10879669_1_Ent4", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10879669_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10879669_1_Ent1", "text": "normotensive scleroderma renal crisis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10879669_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10879669_1_Ent2", "text": "high - dose methylprednisolone treatment", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10879669_1_Ent4", "text": "methylprednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10891991_3", "wnd_id": "10891991_3_1", "text": "CONCLUSIONS : The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy .", "tokens": ["CONCLUSIONS", ":", "The", "3", "cases", "presented", "here", "illustrate", "the", "development", "of", "reproductive", "endocrine", "disorders", "after", "the", "initiation", "of", "valproate", "therapy", "in", "women", "with", "epilepsy", "."], "event_mentions": [{"id": "10891991_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "10891991_3_Ent0", "role": "Subject", "text": "The 3 cases", "start": 2, "end": 5}, {"entity_id": "10891991_3_Ent2", "role": "Subject_Population", "text": "3", "start": 3, "end": 4}, {"entity_id": "10891991_3_Ent4", "role": "Effect", "text": "reproductive endocrine disorders", "start": 11, "end": 14}, {"entity_id": "10891991_3_Ent5", "role": "Treatment", "text": "after the initiation of valproate therapy", "start": 14, "end": 20}, {"entity_id": "10891991_3_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 18, "end": 19}, {"entity_id": "10891991_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 21, "end": 22}, {"entity_id": "10891991_3_Ent1", "role": "Subject", "text": "women with epilepsy", "start": 21, "end": 24}, {"entity_id": "10891991_3_Ent7", "role": "Treatment_Disorder", "text": "epilepsy", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10891991_3_Ent0", "text": "The 3 cases", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10891991_3_Ent2", "text": "3", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10891991_3_Ent4", "text": "reproductive endocrine disorders", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10891991_3_Ent5", "text": "after the initiation of valproate therapy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "10891991_3_Ent6", "text": "valproate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10891991_3_Ent3", "text": "women", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10891991_3_Ent1", "text": "women with epilepsy", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "10891991_3_Ent7", "text": "epilepsy", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10891991_6", "wnd_id": "10891991_6_1", "text": "RESULTS : Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women .", "tokens": ["RESULTS", ":", "Replacing", "valproate", "with", "lamotrigine", "resulted", "in", "a", "decrease", "in", "serum", "testosterone", "concentrations", "in", "all", "3", "women", "."], "event_mentions": [{"id": "10891991_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "10891991_6_Ent4", "role": "Treatment", "text": "Replacing valproate with lamotrigine", "start": 2, "end": 6}, {"entity_id": "10891991_6_Ent5", "role": "Treatment_Drug", "text": "lamotrigine", "start": 5, "end": 6}, {"entity_id": "10891991_6_Ent3", "role": "Effect", "text": "a decrease in serum testosterone concentrations", "start": 8, "end": 14}, {"entity_id": "10891991_6_Ent0", "role": "Subject", "text": "all 3 women", "start": 15, "end": 18}, {"entity_id": "10891991_6_Ent1", "role": "Subject_Population", "text": "3", "start": 16, "end": 17}, {"entity_id": "10891991_6_Ent2", "role": "Subject_Gender", "text": "women", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10891991_6_Ent4", "text": "Replacing valproate with lamotrigine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10891991_6_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10891991_6_Ent3", "text": "a decrease in serum testosterone concentrations", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10891991_6_Ent0", "text": "all 3 women", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10891991_6_Ent1", "text": "3", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10891991_6_Ent2", "text": "women", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10897389_2", "wnd_id": "10897389_2_1", "text": "Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis .", "tokens": ["Recurrent", "septicemia", "with", "lethal", "outcome", "during", "and", "after", "cyclosporine", "therapy", "in", "severe", "ulcerative", "colitis", "."], "event_mentions": [{"id": "10897389_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "10897389_2_Ent0", "role": "Effect", "text": "Recurrent septicemia with lethal outcome", "start": 0, "end": 5}, {"entity_id": "10897389_2_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "10897389_2_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "10897389_2_Ent2", "role": "Treatment_Disorder", "text": "severe ulcerative colitis", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10897389_2_Ent0", "text": "Recurrent septicemia with lethal outcome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10897389_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_2_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_2_Ent2", "text": "severe ulcerative colitis", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10923593_1", "wnd_id": "10923593_1_1", "text": "Skin manifestations of a case of phenylbutazone - induced serum sickness - like reactions .", "tokens": ["Skin", "manifestations", "of", "a", "case", "of", "phenylbutazone", "-", "induced", "serum", "sickness", "-", "like", "reactions", "."], "event_mentions": [{"id": "10923593_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10923593_1_Ent1", "role": "Treatment", "text": "phenylbutazone", "start": 6, "end": 7}, {"entity_id": "10923593_1_Ent2", "role": "Treatment_Drug", "text": "phenylbutazone", "start": 6, "end": 7}, {"entity_id": "10923593_1_Ent0", "role": "Effect", "text": "serum sickness - like reactions", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "10923593_1_Ent1", "text": "phenylbutazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10923593_1_Ent2", "text": "phenylbutazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10923593_1_Ent0", "text": "serum sickness - like reactions", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "11020127_3", "wnd_id": "11020127_3_1", "text": "Ritonavir acted as a CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity .", "tokens": ["Ritonavir", "acted", "as", "a", "CYP3A4", "inhibitor", ",", "diminishing", "carbamazepine", "metabolism", "and", "provoking", "an", "increase", "in", "serum", "levels", "and", "clinical", "toxicity", "."], "event_mentions": [{"id": "11020127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "acted", "start": 1, "end": 2}, "arguments": [{"entity_id": "11020127_3_Ent1", "role": "Treatment", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent2", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent0", "role": "Effect", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "start": 4, "end": 20}]}], "entity_mentions": [{"id": "11020127_3_Ent1", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent2", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent0", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "entity_type": "Entity", "start": 4, "end": 20}], "lang": "en"}
{"doc_id": "11022272_4", "wnd_id": "11022272_4_1", "text": "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ) .", "tokens": ["We", "introduce", "a", "case", "of", "a", "sixty", "years", "old", "woman", "with", "several", "previous", "episodes", "of", "rhinitis", ",", "conjunctivitis", "and", "perspiration", "immediately", "after", "the", "administration", "of", "salmon", "calcitonin", "with", "nasal", "spray", "or", "intramuscular", "administration", "(", "Calsynar", ")", "."], "event_mentions": [{"id": "11022272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "11022272_4_Ent0", "role": "Subject", "text": "a sixty years old woman", "start": 5, "end": 10}, {"entity_id": "11022272_4_Ent1", "role": "Subject_Age", "text": "sixty years old", "start": 6, "end": 9}, {"entity_id": "11022272_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "11022272_4_Ent3", "role": "Effect", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "start": 11, "end": 21}, {"entity_id": "11022272_4_Ent7", "role": "Treatment_Drug", "text": "salmon calcitonin", "start": 25, "end": 27}, {"entity_id": "11022272_4_Ent4", "role": "Treatment", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "start": 25, "end": 36}, {"entity_id": "11022272_4_Ent5", "role": "Treatment_Route", "text": "nasal spray", "start": 28, "end": 30}, {"entity_id": "11022272_4_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "11022272_4_Ent0", "text": "a sixty years old woman", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11022272_4_Ent1", "text": "sixty years old", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11022272_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11022272_4_Ent3", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11022272_4_Ent7", "text": "salmon calcitonin", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11022272_4_Ent4", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "11022272_4_Ent5", "text": "nasal spray", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "11022272_4_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "11105373_2", "wnd_id": "11105373_2_1", "text": "Nail staining from hydroquinone cream .", "tokens": ["Nail", "staining", "from", "hydroquinone", "cream", "."], "event_mentions": [{"id": "11105373_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "11105373_2_Ent0", "role": "Effect", "text": "Nail staining", "start": 0, "end": 2}, {"entity_id": "11105373_2_Ent2", "role": "Treatment_Drug", "text": "hydroquinone", "start": 3, "end": 4}, {"entity_id": "11105373_2_Ent1", "role": "Treatment", "text": "hydroquinone cream", "start": 3, "end": 5}, {"entity_id": "11105373_2_Ent3", "role": "Treatment_Route", "text": "cream", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11105373_2_Ent0", "text": "Nail staining", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11105373_2_Ent2", "text": "hydroquinone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11105373_2_Ent1", "text": "hydroquinone cream", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11105373_2_Ent3", "text": "cream", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11109149_3", "wnd_id": "11109149_3_1", "text": "We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy ( bleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx .", "tokens": ["We", "describe", "a", "57", "-", "year", "-", "old", "man", "with", "acral", "erythrocyanosis", "progressing", "to", "acute", "digital", "ischemia", "and", "gangrene", "that", "developed", "after", "combined", "chemotherapy", "(", "bleomycin", "and", "methotrexate", ")", "used", "to", "treat", "a", "metastatic", "squamous", "cell", "carcinoma", "of", "the", "hypopharynx", "."], "event_mentions": [{"id": "11109149_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "11109149_3_Ent0", "role": "Subject", "text": "a 57 - year - old man with acral erythrocyanosis", "start": 2, "end": 12}, {"entity_id": "11109149_3_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 3, "end": 8}, {"entity_id": "11109149_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "11109149_3_Ent3", "role": "Subject_Disorder", "text": "acral erythrocyanosis", "start": 10, "end": 12}, {"entity_id": "11109149_3_Ent4", "role": "Effect", "text": "acute digital ischemia and gangrene", "start": 14, "end": 19}, {"entity_id": "11109149_3_Ent5", "role": "Treatment", "text": "combined chemotherapy ( bleomycin and methotrexate )", "start": 22, "end": 29}, {"entity_id": "11109149_3_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "11109149_3_Ent9", "role": "Combination_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "11109149_3_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 27, "end": 28}, {"entity_id": "11109149_3_Ent10", "role": "Combination_Drug", "text": "methotrexate", "start": 27, "end": 28}, {"entity_id": "11109149_3_Ent8", "role": "Treatment_Disorder", "text": "metastatic squamous cell carcinoma of the hypopharynx", "start": 33, "end": 40}]}], "entity_mentions": [{"id": "11109149_3_Ent0", "text": "a 57 - year - old man with acral erythrocyanosis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11109149_3_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11109149_3_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11109149_3_Ent3", "text": "acral erythrocyanosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11109149_3_Ent4", "text": "acute digital ischemia and gangrene", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11109149_3_Ent5", "text": "combined chemotherapy ( bleomycin and methotrexate )", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "11109149_3_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11109149_3_Ent9", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11109149_3_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11109149_3_Ent10", "text": "methotrexate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11109149_3_Ent8", "text": "metastatic squamous cell carcinoma of the hypopharynx", "entity_type": "Entity", "start": 33, "end": 40}], "lang": "en"}
{"doc_id": "11126885_1", "wnd_id": "11126885_1_1", "text": "Occult quinine - induced thrombocytopenia .", "tokens": ["Occult", "quinine", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "11126885_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11126885_1_Ent1", "role": "Treatment", "text": "quinine", "start": 1, "end": 2}, {"entity_id": "11126885_1_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 1, "end": 2}, {"entity_id": "11126885_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11126885_1_Ent1", "text": "quinine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11126885_1_Ent2", "text": "quinine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11126885_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11126885_7", "wnd_id": "11126885_7_1", "text": "Only after three subsequent episodes of severe , symptomatic thrombocytopenia over the next four weeks did he say , upon repeat questioning , that he had continued to take quinine for night leg cramps .", "tokens": ["Only", "after", "three", "subsequent", "episodes", "of", "severe", ",", "symptomatic", "thrombocytopenia", "over", "the", "next", "four", "weeks", "did", "he", "say", ",", "upon", "repeat", "questioning", ",", "that", "he", "had", "continued", "to", "take", "quinine", "for", "night", "leg", "cramps", "."], "event_mentions": [{"id": "11126885_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "take", "start": 28, "end": 29}, "arguments": [{"entity_id": "11126885_7_Ent3", "role": "Effect", "text": "symptomatic thrombocytopenia", "start": 8, "end": 10}, {"entity_id": "11126885_7_Ent7", "role": "Treatment_Time_elapsed", "text": "over the next four weeks", "start": 10, "end": 15}, {"entity_id": "11126885_7_Ent0", "role": "Subject", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent2", "role": "Subject_Gender", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent4", "role": "Treatment", "text": "continued to take quinine", "start": 26, "end": 30}, {"entity_id": "11126885_7_Ent5", "role": "Treatment_Drug", "text": "quinine", "start": 29, "end": 30}, {"entity_id": "11126885_7_Ent1", "role": "Subject", "text": "night leg cramps", "start": 31, "end": 34}, {"entity_id": "11126885_7_Ent6", "role": "Treatment_Disorder", "text": "night leg cramps", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11126885_7_Ent3", "text": "symptomatic thrombocytopenia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11126885_7_Ent7", "text": "over the next four weeks", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11126885_7_Ent0", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent2", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent4", "text": "continued to take quinine", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "11126885_7_Ent5", "text": "quinine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11126885_7_Ent1", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "11126885_7_Ent6", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11126885_8", "wnd_id": "11126885_8_1", "text": "Even after a strict warning , he took another quinine tablet that evening , which triggered his fifth episode of severe thrombocytopenia , and confirmed the etiology of quinine - induced thrombocytopenia .", "tokens": ["Even", "after", "a", "strict", "warning", ",", "he", "took", "another", "quinine", "tablet", "that", "evening", ",", "which", "triggered", "his", "fifth", "episode", "of", "severe", "thrombocytopenia", ",", "and", "confirmed", "the", "etiology", "of", "quinine", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "11126885_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 15, "end": 16}, "arguments": [{"entity_id": "11126885_8_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 9, "end": 10}, {"entity_id": "11126885_8_Ent1", "role": "Treatment", "text": "quinine tablet", "start": 9, "end": 11}, {"entity_id": "11126885_8_Ent3", "role": "Treatment_Route", "text": "tablet", "start": 10, "end": 11}, {"entity_id": "11126885_8_Ent0", "role": "Effect", "text": "severe thrombocytopenia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "11126885_8_Ent2", "text": "quinine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11126885_8_Ent1", "text": "quinine tablet", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11126885_8_Ent3", "text": "tablet", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11126885_8_Ent0", "text": "severe thrombocytopenia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "11144696_4", "wnd_id": "11144696_4_1", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d , she was hospitalized because of seizures suggesting a secondary generalized grand - mal episode .", "tokens": ["Eleven", "days", "after", "increase", "of", "the", "trimipramine", "dosage", "to", "100", "mg", "/", "d", ",", "she", "was", "hospitalized", "because", "of", "seizures", "suggesting", "a", "secondary", "generalized", "grand", "-", "mal", "episode", "."], "event_mentions": [{"id": "11144696_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hospitalized", "start": 16, "end": 17}, "arguments": [{"entity_id": "11144696_4_Ent4", "role": "Treatment_Time_elapsed", "text": "Eleven days", "start": 0, "end": 2}, {"entity_id": "11144696_4_Ent3", "role": "Treatment", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d", "start": 0, "end": 13}, {"entity_id": "11144696_4_Ent6", "role": "Treatment_Drug", "text": "trimipramine", "start": 6, "end": 7}, {"entity_id": "11144696_4_Ent5", "role": "Treatment_Dosage", "text": "100 mg / d", "start": 9, "end": 13}, {"entity_id": "11144696_4_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "11144696_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "11144696_4_Ent2", "role": "Effect", "text": "seizures suggesting a secondary generalized grand - mal episode", "start": 19, "end": 28}]}], "entity_mentions": [{"id": "11144696_4_Ent4", "text": "Eleven days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11144696_4_Ent3", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "11144696_4_Ent6", "text": "trimipramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11144696_4_Ent5", "text": "100 mg / d", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "11144696_4_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_4_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_4_Ent2", "text": "seizures suggesting a secondary generalized grand - mal episode", "entity_type": "Entity", "start": 19, "end": 28}], "lang": "en"}
{"doc_id": "1115340_6", "wnd_id": "1115340_6_1", "text": "There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability .", "tokens": ["There", "is", "the", "risk", "of", "convulsions", "occurring", "in", "susceptible", "patients", "following", "the", "use", "of", "the", "new", "anaesthetic", "agents", "which", "are", "capable", "of", "inducing", "CNS", "excitability", "."], "event_mentions": [{"id": "1115340_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "1115340_6_Ent1", "role": "Effect", "text": "convulsions", "start": 5, "end": 6}, {"entity_id": "1115340_6_Ent0", "role": "Subject", "text": "susceptible patients", "start": 8, "end": 10}, {"entity_id": "1115340_6_Ent2", "role": "Treatment", "text": "the use of the new anaesthetic agents which are capable of inducing CNS excitability", "start": 11, "end": 25}, {"entity_id": "1115340_6_Ent3", "role": "Treatment_Drug", "text": "anaesthetic", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1115340_6_Ent1", "text": "convulsions", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1115340_6_Ent0", "text": "susceptible patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1115340_6_Ent2", "text": "the use of the new anaesthetic agents which are capable of inducing CNS excitability", "entity_type": "Entity", "start": 11, "end": 25}, {"id": "1115340_6_Ent3", "text": "anaesthetic", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11171531_2", "wnd_id": "11171531_2_1", "text": "It also highlights a current major etiologic question , that is , whether and to what degree lead exposure contributes to the development of hypertension , and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium .", "tokens": ["It", "also", "highlights", "a", "current", "major", "etiologic", "question", ",", "that", "is", ",", "whether", "and", "to", "what", "degree", "lead", "exposure", "contributes", "to", "the", "development", "of", "hypertension", ",", "and", "raises", "the", "issue", "of", "whether", "lead", "-", "induced", "hypertension", "constitutes", "a", "subset", "of", "hypertension", "that", "is", "especially", "amenable", "to", "therapy", "with", "dietary", "calcium", "."], "event_mentions": [{"id": "11171531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributes", "start": 19, "end": 20}, "arguments": [{"entity_id": "11171531_2_Ent2", "role": "Treatment_Drug", "text": "lead", "start": 17, "end": 18}, {"entity_id": "11171531_2_Ent1", "role": "Treatment", "text": "lead exposure", "start": 17, "end": 19}, {"entity_id": "11171531_2_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 18, "end": 19}, {"entity_id": "11171531_2_Ent0", "role": "Effect", "text": "hypertension", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11171531_2_Ent2", "text": "lead", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11171531_2_Ent1", "text": "lead exposure", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11171531_2_Ent3", "text": "exposure", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11171531_2_Ent0", "text": "hypertension", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11174414_1", "wnd_id": "11174414_1_1", "text": "Stevens - Johnson syndrome caused by the antiretroviral drug nevirapine .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "caused", "by", "the", "antiretroviral", "drug", "nevirapine", "."], "event_mentions": [{"id": "11174414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused by", "start": 4, "end": 6}, "arguments": [{"entity_id": "11174414_1_Ent0", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "11174414_1_Ent1", "role": "Treatment", "text": "antiretroviral drug nevirapine", "start": 7, "end": 10}, {"entity_id": "11174414_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11174414_1_Ent0", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11174414_1_Ent1", "text": "antiretroviral drug nevirapine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11174414_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11191005_1", "wnd_id": "11191005_1_1", "text": "There is evidence that the angiotensin II receptor antagonist , losartan , increases urate excretion by reducing reabsorption of urate in the renal proximal tubule .", "tokens": ["There", "is", "evidence", "that", "the", "angiotensin", "II", "receptor", "antagonist", ",", "losartan", ",", "increases", "urate", "excretion", "by", "reducing", "reabsorption", "of", "urate", "in", "the", "renal", "proximal", "tubule", "."], "event_mentions": [{"id": "11191005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increases", "start": 12, "end": 13}, "arguments": [{"entity_id": "11191005_1_Ent2", "role": "Treatment", "text": "angiotensin II receptor antagonist , losartan", "start": 5, "end": 11}, {"entity_id": "11191005_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "11191005_1_Ent0", "role": "Effect", "text": "increases urate excretion", "start": 12, "end": 15}, {"entity_id": "11191005_1_Ent1", "role": "Effect", "text": "reducing reabsorption of urate in the renal proximal tubule .", "start": 16, "end": 26}]}], "entity_mentions": [{"id": "11191005_1_Ent2", "text": "angiotensin II receptor antagonist , losartan", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11191005_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11191005_1_Ent0", "text": "increases urate excretion", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11191005_1_Ent1", "text": "reducing reabsorption of urate in the renal proximal tubule .", "entity_type": "Entity", "start": 16, "end": 26}], "lang": "en"}
{"doc_id": "11202801_2", "wnd_id": "11202801_2_1", "text": "Hepatic angiosarcoma occurring after cyclophosphamide therapy : case report and review of the literature .", "tokens": ["Hepatic", "angiosarcoma", "occurring", "after", "cyclophosphamide", "therapy", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "11202801_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 2, "end": 3}, "arguments": [{"entity_id": "11202801_2_Ent0", "role": "Effect", "text": "Hepatic angiosarcoma", "start": 0, "end": 2}, {"entity_id": "11202801_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "11202801_2_Ent1", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "11202801_2_Ent0", "text": "Hepatic angiosarcoma", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11202801_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11202801_2_Ent1", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "11206417_1", "wnd_id": "11206417_1_1", "text": "Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans .", "tokens": ["Glucose", "and", "insulin", "exert", "additive", "ocular", "and", "renal", "vasodilator", "effects", "on", "healthy", "humans", "."], "event_mentions": [{"id": "11206417_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exert", "start": 3, "end": 4}, "arguments": [{"entity_id": "11206417_1_Ent3", "role": "Treatment_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent5", "role": "Combination_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent2", "role": "Treatment", "text": "Glucose and insulin", "start": 0, "end": 3}, {"entity_id": "11206417_1_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent6", "role": "Combination_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent1", "role": "Effect", "text": "additive ocular and renal vasodilator effects", "start": 4, "end": 10}, {"entity_id": "11206417_1_Ent0", "role": "Subject", "text": "healthy humans", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11206417_1_Ent3", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent5", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent2", "text": "Glucose and insulin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11206417_1_Ent4", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent6", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent1", "text": "additive ocular and renal vasodilator effects", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "11206417_1_Ent0", "text": "healthy humans", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11215836_3", "wnd_id": "11215836_3_1", "text": "Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine .", "tokens": ["Possible", "serotonin", "syndrome", "associated", "with", "clomipramine", "after", "withdrawal", "of", "clozapine", "."], "event_mentions": [{"id": "11215836_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "11215836_3_Ent0", "role": "Effect", "text": "serotonin syndrome associated with clomipramine", "start": 1, "end": 6}, {"entity_id": "11215836_3_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 5, "end": 6}, {"entity_id": "11215836_3_Ent1", "role": "Treatment", "text": "withdrawal of clozapine", "start": 7, "end": 10}, {"entity_id": "11215836_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11215836_3_Ent0", "text": "serotonin syndrome associated with clomipramine", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11215836_3_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11215836_3_Ent1", "text": "withdrawal of clozapine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11215836_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11243427_3", "wnd_id": "11243427_3_1", "text": "DISCUSSION : Patients with 5 - FU - induced ectropion experience tender , red , scaled lids , making contact lens wear difficult .", "tokens": ["DISCUSSION", ":", "Patients", "with", "5", "-", "FU", "-", "induced", "ectropion", "experience", "tender", ",", "red", ",", "scaled", "lids", ",", "making", "contact", "lens", "wear", "difficult", "."], "event_mentions": [{"id": "11243427_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "11243427_3_Ent0", "role": "Subject", "text": "Patients with 5 - FU - induced ectropion", "start": 2, "end": 10}, {"entity_id": "11243427_3_Ent3", "role": "Treatment", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent1", "role": "Effect", "text": "ectropion", "start": 9, "end": 10}, {"entity_id": "11243427_3_Ent2", "role": "Effect", "text": "tender , red , scaled lids", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "11243427_3_Ent0", "text": "Patients with 5 - FU - induced ectropion", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "11243427_3_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent1", "text": "ectropion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11243427_3_Ent2", "text": "tender , red , scaled lids", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "1124417_2", "wnd_id": "1124417_2_1", "text": "Renal failure associated with acetazolamide therapy for glaucoma .", "tokens": ["Renal", "failure", "associated", "with", "acetazolamide", "therapy", "for", "glaucoma", "."], "event_mentions": [{"id": "1124417_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1124417_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "1124417_2_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1124417_2_Ent1", "role": "Treatment", "text": "acetazolamide therapy", "start": 4, "end": 6}, {"entity_id": "1124417_2_Ent3", "role": "Treatment_Disorder", "text": "glaucoma", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1124417_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1124417_2_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1124417_2_Ent1", "text": "acetazolamide therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1124417_2_Ent3", "text": "glaucoma", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11247558_1", "wnd_id": "11247558_1_1", "text": "Ischaemic colitis in a patient taking meloxicam .", "tokens": ["Ischaemic", "colitis", "in", "a", "patient", "taking", "meloxicam", "."], "event_mentions": [{"id": "11247558_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_1_Ent1", "role": "Effect", "text": "Ischaemic colitis", "start": 0, "end": 2}, {"entity_id": "11247558_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "11247558_1_Ent2", "role": "Treatment", "text": "meloxicam", "start": 6, "end": 7}, {"entity_id": "11247558_1_Ent3", "role": "Treatment_Drug", "text": "meloxicam", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11247558_1_Ent1", "text": "Ischaemic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11247558_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11247558_1_Ent2", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11247558_1_Ent3", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11283125_3", "wnd_id": "11283125_3_1", "text": "After completion of induction - consolidation phase , children with increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX ( 5 g / m(2 ) over 24 hours every 2 weeks ) and four intrathecal administrations of MTX ( Arm A ) or the same treatment schedule with additional HD IV Ara - C ( 1 g / m(2 ) in bolus injection 12 and 24 hours after the start of each MTX infusion ) ( Arm B ) .", "tokens": ["After", "completion", "of", "induction", "-", "consolidation", "phase", ",", "children", "with", "increased", "-", "risk", "(", "risk", "factor", ">", "0.8", "or", "T", "-", "lineage", ")", "ALL", "or", "stage", "III", "and", "IV", "lymphoblastic", "lymphoma", "were", "randomized", "to", "receive", "four", "courses", "of", "HD", "MTX", "(", "5", "g", "/", "m(2", ")", "over", "24", "hours", "every", "2", "weeks", ")", "and", "four", "intrathecal", "administrations", "of", "MTX", "(", "Arm", "A", ")", "or", "the", "same", "treatment", "schedule", "with", "additional", "HD", "IV", "Ara", "-", "C", "(", "1", "g", "/", "m(2", ")", "in", "bolus", "injection", "12", "and", "24", "hours", "after", "the", "start", "of", "each", "MTX", "infusion", ")", "(", "Arm", "B", ")", "."], "event_mentions": [{"id": "11283125_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 34, "end": 35}, "arguments": [{"entity_id": "11283125_3_Ent2", "role": "Treatment", "text": "After completion of induction - consolidation phase", "start": 0, "end": 7}, {"entity_id": "11283125_3_Ent1", "role": "Subject_Age", "text": "children", "start": 8, "end": 9}, {"entity_id": "11283125_3_Ent0", "role": "Subject", "text": "children with increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma", "start": 8, "end": 31}, {"entity_id": "11283125_3_Ent4", "role": "Treatment_Disorder", "text": "lymphoblastic lymphoma", "start": 29, "end": 31}, {"entity_id": "11283125_3_Ent3", "role": "Treatment", "text": "four courses of HD MTX ( 5 g / m(2 ) over 24 hours every 2 weeks ) and four intrathecal administrations of MTX ( Arm A ) or the same treatment schedule with additional HD IV Ara - C ( 1 g / m(2 ) in bolus injection 12 and 24 hours after the start of each MTX infusion ) ( Arm B )", "start": 35, "end": 100}, {"entity_id": "11283125_3_Ent5", "role": "Treatment_Drug", "text": "HD MTX", "start": 38, "end": 40}, {"entity_id": "11283125_3_Ent9", "role": "Treatment_Dosage", "text": "5 g / m(2 )", "start": 41, "end": 46}, {"entity_id": "11283125_3_Ent11", "role": "Treatment_Freq", "text": "over 24 hours every 2 weeks", "start": 46, "end": 52}, {"entity_id": "11283125_3_Ent6", "role": "Treatment_Drug", "text": "MTX", "start": 58, "end": 59}, {"entity_id": "11283125_3_Ent13", "role": "Combination_Drug", "text": "MTX", "start": 58, "end": 59}, {"entity_id": "11283125_3_Ent7", "role": "Treatment_Drug", "text": "HD IV Ara - C", "start": 70, "end": 75}, {"entity_id": "11283125_3_Ent14", "role": "Combination_Drug", "text": "HD IV Ara - C", "start": 70, "end": 75}, {"entity_id": "11283125_3_Ent10", "role": "Treatment_Dosage", "text": "1 g / m(2 )", "start": 76, "end": 81}, {"entity_id": "11283125_3_Ent12", "role": "Treatment_Route", "text": "bolus injection", "start": 82, "end": 84}, {"entity_id": "11283125_3_Ent8", "role": "Treatment_Drug", "text": "MTX", "start": 93, "end": 94}]}], "entity_mentions": [{"id": "11283125_3_Ent2", "text": "After completion of induction - consolidation phase", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11283125_3_Ent1", "text": "children", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11283125_3_Ent0", "text": "children with increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 8, "end": 31}, {"id": "11283125_3_Ent4", "text": "lymphoblastic lymphoma", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "11283125_3_Ent3", "text": "four courses of HD MTX ( 5 g / m(2 ) over 24 hours every 2 weeks ) and four intrathecal administrations of MTX ( Arm A ) or the same treatment schedule with additional HD IV Ara - C ( 1 g / m(2 ) in bolus injection 12 and 24 hours after the start of each MTX infusion ) ( Arm B )", "entity_type": "Entity", "start": 35, "end": 100}, {"id": "11283125_3_Ent5", "text": "HD MTX", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "11283125_3_Ent9", "text": "5 g / m(2 )", "entity_type": "Entity", "start": 41, "end": 46}, {"id": "11283125_3_Ent11", "text": "over 24 hours every 2 weeks", "entity_type": "Entity", "start": 46, "end": 52}, {"id": "11283125_3_Ent6", "text": "MTX", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_3_Ent13", "text": "MTX", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_3_Ent7", "text": "HD IV Ara - C", "entity_type": "Entity", "start": 70, "end": 75}, {"id": "11283125_3_Ent14", "text": "HD IV Ara - C", "entity_type": "Entity", "start": 70, "end": 75}, {"id": "11283125_3_Ent10", "text": "1 g / m(2 )", "entity_type": "Entity", "start": 76, "end": 81}, {"id": "11283125_3_Ent12", "text": "bolus injection", "entity_type": "Entity", "start": 82, "end": 84}, {"id": "11283125_3_Ent8", "text": "MTX", "entity_type": "Entity", "start": 93, "end": 94}], "lang": "en"}
{"doc_id": "11292139_1", "wnd_id": "11292139_1_1", "text": "We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin .", "tokens": ["We", "report", "a", "patient", "with", "advanced", "colonic", "carcinoma", "who", "was", "treated", "with", "concomitant", "chemoirradiation", "with", "oxaliplatin", "and", "developed", "a", "peculiar", "dermnatitis", "in", "the", "irradiated", "field", "after", "being", "exposed", "to", "subsequent", "chemotherapy", "with", "oxaliplatin", "."], "event_mentions": [{"id": "11292139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "11292139_1_Ent0", "role": "Subject", "text": "a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin", "start": 2, "end": 16}, {"entity_id": "11292139_1_Ent3", "role": "Treatment_Disorder", "text": "advanced colonic carcinoma", "start": 5, "end": 8}, {"entity_id": "11292139_1_Ent4", "role": "Treatment_Drug", "text": "concomitant chemoirradiation", "start": 12, "end": 14}, {"entity_id": "11292139_1_Ent5", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 15, "end": 16}, {"entity_id": "11292139_1_Ent1", "role": "Effect", "text": "a peculiar dermnatitis in the irradiated field", "start": 18, "end": 25}, {"entity_id": "11292139_1_Ent2", "role": "Treatment", "text": "exposed to subsequent chemotherapy with oxaliplatin", "start": 27, "end": 33}, {"entity_id": "11292139_1_Ent6", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11292139_1_Ent0", "text": "a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin", "entity_type": "Entity", "start": 2, "end": 16}, {"id": "11292139_1_Ent3", "text": "advanced colonic carcinoma", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11292139_1_Ent4", "text": "concomitant chemoirradiation", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11292139_1_Ent5", "text": "oxaliplatin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11292139_1_Ent1", "text": "a peculiar dermnatitis in the irradiated field", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "11292139_1_Ent2", "text": "exposed to subsequent chemotherapy with oxaliplatin", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "11292139_1_Ent6", "text": "oxaliplatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11295724_1", "wnd_id": "11295724_1_1", "text": "An 11 - year - old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft - versus - host disease .", "tokens": ["An", "11", "-", "year", "-", "old", "boy", "developed", "a", "severe", "enteropathy", "2", "years", "after", "initiation", "of", "clofazimine", "treatment", "for", "graft", "-", "versus", "-", "host", "disease", "."], "event_mentions": [{"id": "11295724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "11295724_1_Ent0", "role": "Subject", "text": "An 11 - year - old boy", "start": 0, "end": 7}, {"entity_id": "11295724_1_Ent2", "role": "Subject_Age", "text": "11 - year - old", "start": 1, "end": 6}, {"entity_id": "11295724_1_Ent3", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "11295724_1_Ent4", "role": "Effect", "text": "severe enteropathy", "start": 9, "end": 11}, {"entity_id": "11295724_1_Ent6", "role": "Treatment_Time_elapsed", "text": "2 years", "start": 11, "end": 13}, {"entity_id": "11295724_1_Ent7", "role": "Treatment_Drug", "text": "clofazimine", "start": 16, "end": 17}, {"entity_id": "11295724_1_Ent5", "role": "Treatment", "text": "clofazimine treatment", "start": 16, "end": 18}, {"entity_id": "11295724_1_Ent1", "role": "Subject", "text": "graft - versus - host disease", "start": 19, "end": 25}, {"entity_id": "11295724_1_Ent8", "role": "Treatment_Disorder", "text": "graft - versus - host disease", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "11295724_1_Ent0", "text": "An 11 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11295724_1_Ent2", "text": "11 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11295724_1_Ent3", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11295724_1_Ent4", "text": "severe enteropathy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11295724_1_Ent6", "text": "2 years", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11295724_1_Ent7", "text": "clofazimine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11295724_1_Ent5", "text": "clofazimine treatment", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "11295724_1_Ent1", "text": "graft - versus - host disease", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "11295724_1_Ent8", "text": "graft - versus - host disease", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "11332679_1", "wnd_id": "11332679_1_1", "text": "An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported .", "tokens": ["An", "infant", "who", "developed", "pancreatitis", "during", "meglumine", "antimoniate", "treatment", "for", "visceral", "leishmaniasis", "and", "who", "was", "successfully", "treated", "with", "a", "combination", "of", "allopurinol", "and", "ketoconazole", "is", "reported", "."], "event_mentions": [{"id": "11332679_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 16, "end": 17}, "arguments": [{"entity_id": "11332679_1_Ent0", "role": "Subject", "text": "An infant", "start": 0, "end": 2}, {"entity_id": "11332679_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 1, "end": 2}, {"entity_id": "11332679_1_Ent2", "role": "Effect", "text": "pancreatitis", "start": 4, "end": 5}, {"entity_id": "11332679_1_Ent3", "role": "Treatment", "text": "a combination of allopurinol and ketoconazole", "start": 18, "end": 24}, {"entity_id": "11332679_1_Ent4", "role": "Treatment_Drug", "text": "allopurinol", "start": 21, "end": 22}, {"entity_id": "11332679_1_Ent6", "role": "Combination_Drug", "text": "allopurinol", "start": 21, "end": 22}, {"entity_id": "11332679_1_Ent5", "role": "Treatment_Drug", "text": "ketoconazole", "start": 23, "end": 24}, {"entity_id": "11332679_1_Ent7", "role": "Combination_Drug", "text": "ketoconazole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11332679_1_Ent0", "text": "An infant", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11332679_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11332679_1_Ent2", "text": "pancreatitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11332679_1_Ent3", "text": "a combination of allopurinol and ketoconazole", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "11332679_1_Ent4", "text": "allopurinol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11332679_1_Ent6", "text": "allopurinol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11332679_1_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11332679_1_Ent7", "text": "ketoconazole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11335880_1", "wnd_id": "11335880_1_1", "text": "CONCLUSIONS : This case report showed that the clinical appearance of Hashimoto 's disease after IFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology .", "tokens": ["CONCLUSIONS", ":", "This", "case", "report", "showed", "that", "the", "clinical", "appearance", "of", "Hashimoto", "'s", "disease", "after", "IFN", "-", "alpha", "therapy", "for", "chronic", "C", "hepatitis", "in", "our", "patient", "was", "associated", "with", "a", "specific", "genetic", "predisposition", "(", "DR5", ")", "for", "this", "pathology", "."], "event_mentions": [{"id": "11335880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "11335880_1_Ent2", "role": "Effect", "text": "clinical appearance of Hashimoto 's disease", "start": 8, "end": 14}, {"entity_id": "11335880_1_Ent3", "role": "Treatment", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent4", "role": "Treatment_Disorder", "text": "chronic C hepatitis", "start": 20, "end": 23}, {"entity_id": "11335880_1_Ent0", "role": "Subject", "text": "our patient", "start": 24, "end": 26}, {"entity_id": "11335880_1_Ent1", "role": "Subject_Disorder", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "start": 29, "end": 39}]}], "entity_mentions": [{"id": "11335880_1_Ent2", "text": "clinical appearance of Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "11335880_1_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent4", "text": "chronic C hepatitis", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11335880_1_Ent0", "text": "our patient", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "11335880_1_Ent1", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "entity_type": "Entity", "start": 29, "end": 39}], "lang": "en"}
{"doc_id": "11335880_3", "wnd_id": "11335880_3_1", "text": "Hashimoto 's disease during interferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease .", "tokens": ["Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "therapy", "in", "a", "patient", "with", "pre", "-", "treatment", "negative", "anti", "-", "thyroid", "autoantibodies", "and", "with", "the", "specific", "genetic", "susceptibility", "to", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "11335880_3_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 0, "end": 3}, {"entity_id": "11335880_3_Ent3", "role": "Treatment", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent0", "role": "Subject", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "start": 9, "end": 30}, {"entity_id": "11335880_3_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility to the thyroid disease", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "11335880_3_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11335880_3_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent0", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 9, "end": 30}, {"id": "11335880_3_Ent1", "text": "specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "11335880_4", "wnd_id": "11335880_4_1", "text": "OBJECTIVES : The authors described a case of Hashimoto 's disease during interferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease .", "tokens": ["OBJECTIVES", ":", "The", "authors", "described", "a", "case", "of", "Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "for", "chronic", "viral", "C", "hepatitis", "in", "a", "patient", "with", "the", "specific", "genetic", "susceptibility", "associated", "with", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "11335880_4_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 8, "end": 11}, {"entity_id": "11335880_4_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "11335880_4_Ent3", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha ) treatment", "start": 12, "end": 21}, {"entity_id": "11335880_4_Ent5", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 22, "end": 26}, {"entity_id": "11335880_4_Ent0", "role": "Subject", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "start": 27, "end": 39}, {"entity_id": "11335880_4_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11335880_4_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11335880_4_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11335880_4_Ent3", "text": "interferon - alpha ( IFN - alpha ) treatment", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "11335880_4_Ent5", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "11335880_4_Ent0", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "entity_type": "Entity", "start": 27, "end": 39}, {"id": "11335880_4_Ent1", "text": "specific genetic susceptibility", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11352235_4", "wnd_id": "11352235_4_1", "text": "OBJECTIVE : To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center .", "tokens": ["OBJECTIVE", ":", "To", "determine", "the", "frequency", "of", "weight", "loss", "in", "patients", "treated", "with", "leflunomide", "for", "rheumatoid", "arthritis", "at", "an", "arthritis", "referral", "center", "."], "event_mentions": [{"id": "11352235_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "loss", "start": 8, "end": 9}, "arguments": [{"entity_id": "11352235_4_Ent1", "role": "Effect", "text": "weight loss", "start": 7, "end": 9}, {"entity_id": "11352235_4_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "11352235_4_Ent2", "role": "Treatment", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11352235_4_Ent1", "text": "weight loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11352235_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11352235_4_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11359026_2", "wnd_id": "11359026_2_1", "text": "Neurotoxicity of valacyclovir in peritoneal dialysis : a pharmacokinetic study .", "tokens": ["Neurotoxicity", "of", "valacyclovir", "in", "peritoneal", "dialysis", ":", "a", "pharmacokinetic", "study", "."], "event_mentions": [{"id": "11359026_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Neurotoxicity", "start": 0, "end": 1}, "arguments": [{"entity_id": "11359026_2_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "11359026_2_Ent2", "role": "Treatment_Drug", "text": "valacyclovir", "start": 2, "end": 3}, {"entity_id": "11359026_2_Ent1", "role": "Treatment", "text": "valacyclovir in peritoneal dialysis", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "11359026_2_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11359026_2_Ent2", "text": "valacyclovir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11359026_2_Ent1", "text": "valacyclovir in peritoneal dialysis", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "11373877_2", "wnd_id": "11373877_2_1", "text": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation , and who subsequently developed femoral head avascular necrosis .", "tokens": ["We", "report", "the", "case", "histories", "of", "two", "patients", "with", "histologically", "confirmed", "adenocarcinoma", "of", "the", "prostate", ",", "both", "of", "whom", "had", "been", "treated", "with", "steroidal", "anti", "-", "androgen", "therapy", "in", "the", "form", "of", "cyproterone", "acetate", "prior", "to", "radical", "or", "palliative", "pelvic", "irradiation", ",", "and", "who", "subsequently", "developed", "femoral", "head", "avascular", "necrosis", "."], "event_mentions": [{"id": "11373877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11373877_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "11373877_2_Ent0", "role": "Subject", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "start": 6, "end": 15}, {"entity_id": "11373877_2_Ent4", "role": "Treatment_Disorder", "text": "adenocarcinoma of the prostate", "start": 11, "end": 15}, {"entity_id": "11373877_2_Ent3", "role": "Treatment", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "start": 23, "end": 41}, {"entity_id": "11373877_2_Ent5", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 32, "end": 34}, {"entity_id": "11373877_2_Ent2", "role": "Effect", "text": "femoral head avascular necrosis .", "start": 46, "end": 51}]}], "entity_mentions": [{"id": "11373877_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11373877_2_Ent0", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "11373877_2_Ent4", "text": "adenocarcinoma of the prostate", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11373877_2_Ent3", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "entity_type": "Entity", "start": 23, "end": 41}, {"id": "11373877_2_Ent5", "text": "cyproterone acetate", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "11373877_2_Ent2", "text": "femoral head avascular necrosis .", "entity_type": "Entity", "start": 46, "end": 51}], "lang": "en"}
{"doc_id": "11399735_1", "wnd_id": "11399735_1_1", "text": "So far , few cases of pulmonary side effects caused by ticlopidine have been reported .", "tokens": ["So", "far", ",", "few", "cases", "of", "pulmonary", "side", "effects", "caused", "by", "ticlopidine", "have", "been", "reported", "."], "event_mentions": [{"id": "11399735_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "11399735_1_Ent0", "role": "Effect", "text": "pulmonary side effects", "start": 6, "end": 9}, {"entity_id": "11399735_1_Ent1", "role": "Treatment", "text": "ticlopidine", "start": 11, "end": 12}, {"entity_id": "11399735_1_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11399735_1_Ent0", "text": "pulmonary side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11399735_1_Ent1", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11399735_1_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11399735_2", "wnd_id": "11399735_2_1", "text": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment .", "tokens": ["Special", "care", "should", "be", "taken", "when", "pulmonary", "symptoms", "appear", "in", "association", "with", "ticlopidine", "treatment", "."], "event_mentions": [{"id": "11399735_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 8, "end": 9}, "arguments": [{"entity_id": "11399735_2_Ent0", "role": "Effect", "text": "pulmonary symptoms", "start": 6, "end": 8}, {"entity_id": "11399735_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 12, "end": 13}, {"entity_id": "11399735_2_Ent1", "role": "Treatment", "text": "ticlopidine treatment", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11399735_2_Ent0", "text": "pulmonary symptoms", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11399735_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11399735_2_Ent1", "text": "ticlopidine treatment", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11406880_2", "wnd_id": "11406880_2_1", "text": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine , which are attributed to active metabolites .", "tokens": ["Methadone", "is", "recommended", "as", "being", "free", "of", "some", "of", "the", "neuropsychological", "side", "effects", "noticed", "with", "morphine", ",", "which", "are", "attributed", "to", "active", "metabolites", "."], "event_mentions": [{"id": "11406880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noticed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11406880_2_Ent0", "role": "Effect", "text": "neuropsychological side effects", "start": 10, "end": 13}, {"entity_id": "11406880_2_Ent1", "role": "Treatment", "text": "morphine", "start": 15, "end": 16}, {"entity_id": "11406880_2_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11406880_2_Ent0", "text": "neuropsychological side effects", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11406880_2_Ent1", "text": "morphine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11406880_2_Ent2", "text": "morphine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11450788_1", "wnd_id": "11450788_1_1", "text": "Antiretroviral - induced hepatic steatosis and lactic acidosis : case report and review of the literature .", "tokens": ["Antiretroviral", "-", "induced", "hepatic", "steatosis", "and", "lactic", "acidosis", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "11450788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11450788_1_Ent2", "role": "Treatment", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent3", "role": "Treatment_Drug", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent1", "role": "Effect", "text": "hepatic steatosis and lactic acidosis", "start": 3, "end": 8}, {"entity_id": "11450788_1_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11450788_1_Ent2", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent3", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent1", "text": "hepatic steatosis and lactic acidosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11450788_1_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11452688_1", "wnd_id": "11452688_1_1", "text": "This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving ' standard ' doses of dexamethasone as part of the antiemetic regimen used in cisplatin - based combination chemotherapy .", "tokens": ["This", "report", "details", "a", "case", "of", "bilateral", "avascular", "necrosis", "of", "the", "femoral", "heads", "in", "a", "patient", "receiving", "'", "standard", "'", "doses", "of", "dexamethasone", "as", "part", "of", "the", "antiemetic", "regimen", "used", "in", "cisplatin", "-", "based", "combination", "chemotherapy", "."], "event_mentions": [{"id": "11452688_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "11452688_1_Ent1", "role": "Effect", "text": "bilateral avascular necrosis of the femoral heads", "start": 6, "end": 13}, {"entity_id": "11452688_1_Ent0", "role": "Subject", "text": "a patient", "start": 14, "end": 16}, {"entity_id": "11452688_1_Ent3", "role": "Treatment_Dosage", "text": "' standard ' doses", "start": 17, "end": 21}, {"entity_id": "11452688_1_Ent2", "role": "Treatment", "text": "' standard ' doses of dexamethasone", "start": 17, "end": 23}, {"entity_id": "11452688_1_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11452688_1_Ent1", "text": "bilateral avascular necrosis of the femoral heads", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "11452688_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11452688_1_Ent3", "text": "' standard ' doses", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11452688_1_Ent2", "text": "' standard ' doses of dexamethasone", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "11452688_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11468878_1", "wnd_id": "11468878_1_1", "text": "Although no coagulation study was done and the Meckel 's diverticulum is normally associated with bleeding , the particular intensity of the following hemorrhage may have been favored by metformin .", "tokens": ["Although", "no", "coagulation", "study", "was", "done", "and", "the", "Meckel", "'s", "diverticulum", "is", "normally", "associated", "with", "bleeding", ",", "the", "particular", "intensity", "of", "the", "following", "hemorrhage", "may", "have", "been", "favored", "by", "metformin", "."], "event_mentions": [{"id": "11468878_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "favored", "start": 27, "end": 28}, "arguments": [{"entity_id": "11468878_1_Ent0", "role": "Effect", "text": "hemorrhage", "start": 23, "end": 24}, {"entity_id": "11468878_1_Ent1", "role": "Treatment", "text": "metformin", "start": 29, "end": 30}, {"entity_id": "11468878_1_Ent2", "role": "Treatment_Drug", "text": "metformin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "11468878_1_Ent0", "text": "hemorrhage", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11468878_1_Ent1", "text": "metformin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11468878_1_Ent2", "text": "metformin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "11485141_2", "wnd_id": "11485141_2_1", "text": "CONCLUSIONS : We report the first case of gemcitabine - induced LABD .", "tokens": ["CONCLUSIONS", ":", "We", "report", "the", "first", "case", "of", "gemcitabine", "-", "induced", "LABD", "."], "event_mentions": [{"id": "11485141_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "11485141_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "11485141_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "11485141_2_Ent0", "role": "Effect", "text": "LABD", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11485141_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11485141_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11485141_2_Ent0", "text": "LABD", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11485141_3", "wnd_id": "11485141_3_1", "text": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine .", "tokens": ["Linear", "immunoglobulin", "A", "bullous", "dermatosis", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "11485141_3_Ent0", "role": "Effect", "text": "Linear immunoglobulin A bullous dermatosis", "start": 0, "end": 5}, {"entity_id": "11485141_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 7, "end": 8}, {"entity_id": "11485141_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11485141_3_Ent0", "text": "Linear immunoglobulin A bullous dermatosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11485141_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11485141_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "115078_1", "wnd_id": "115078_1_1", "text": "A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate .", "tokens": ["A", "patient", "with", "rheumatoid", "arthritis", "developed", "an", "acute", "intrahepatic", "cholestasis", "after", "100", "mg", "of", "sodium", "aurothiomalate", "."], "event_mentions": [{"id": "115078_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "115078_1_Ent0", "role": "Subject", "text": "A patient with rheumatoid arthritis", "start": 0, "end": 5}, {"entity_id": "115078_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 3, "end": 5}, {"entity_id": "115078_1_Ent1", "role": "Effect", "text": "acute intrahepatic cholestasis", "start": 7, "end": 10}, {"entity_id": "115078_1_Ent4", "role": "Treatment_Dosage", "text": "100 mg", "start": 11, "end": 13}, {"entity_id": "115078_1_Ent2", "role": "Treatment", "text": "100 mg of sodium aurothiomalate", "start": 11, "end": 16}, {"entity_id": "115078_1_Ent5", "role": "Treatment_Drug", "text": "sodium aurothiomalate", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "115078_1_Ent0", "text": "A patient with rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "115078_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "115078_1_Ent1", "text": "acute intrahepatic cholestasis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "115078_1_Ent4", "text": "100 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "115078_1_Ent2", "text": "100 mg of sodium aurothiomalate", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "115078_1_Ent5", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11510798_1", "wnd_id": "11510798_1_1", "text": "Acute lung injury associated with 5 - fluorouracil and oxaliplatinum combined chemotherapy .", "tokens": ["Acute", "lung", "injury", "associated", "with", "5", "-", "fluorouracil", "and", "oxaliplatinum", "combined", "chemotherapy", "."], "event_mentions": [{"id": "11510798_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11510798_1_Ent0", "role": "Effect", "text": "Acute lung injury", "start": 0, "end": 3}, {"entity_id": "11510798_1_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent5", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "start": 5, "end": 12}, {"entity_id": "11510798_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent6", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11510798_1_Ent0", "text": "Acute lung injury", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11510798_1_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent1", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11510798_1_Ent2", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent6", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11545487_1", "wnd_id": "11545487_1_1", "text": "An asymptomatic HIV - infected woman experienced right - sided renal colicky pain during treatment with indinavir .", "tokens": ["An", "asymptomatic", "HIV", "-", "infected", "woman", "experienced", "right", "-", "sided", "renal", "colicky", "pain", "during", "treatment", "with", "indinavir", "."], "event_mentions": [{"id": "11545487_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11545487_1_Ent0", "role": "Subject", "text": "An asymptomatic HIV - infected woman", "start": 0, "end": 6}, {"entity_id": "11545487_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 2, "end": 3}, {"entity_id": "11545487_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "11545487_1_Ent2", "role": "Effect", "text": "right - sided renal colicky pain", "start": 7, "end": 13}, {"entity_id": "11545487_1_Ent3", "role": "Treatment", "text": "indinavir", "start": 16, "end": 17}, {"entity_id": "11545487_1_Ent4", "role": "Treatment_Drug", "text": "indinavir", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11545487_1_Ent0", "text": "An asymptomatic HIV - infected woman", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11545487_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11545487_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_1_Ent2", "text": "right - sided renal colicky pain", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11545487_1_Ent3", "text": "indinavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11545487_1_Ent4", "text": "indinavir", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11554897_3", "wnd_id": "11554897_3_1", "text": "METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets .", "tokens": ["METHODS", ":", "A", "55", "-", "year", "-", "old", "woman", "became", "stuporous", "after", "overdose", "with", "lamotrigine", "(", "LTG", ")", "and", "valproic", "acid", "(", "VPA", ")", "tablets", "."], "event_mentions": [{"id": "11554897_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 9, "end": 10}, "arguments": [{"entity_id": "11554897_3_Ent0", "role": "Subject", "text": "A 55 - year - old woman", "start": 2, "end": 9}, {"entity_id": "11554897_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 3, "end": 8}, {"entity_id": "11554897_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "11554897_3_Ent3", "role": "Effect", "text": "stuporous", "start": 10, "end": 11}, {"entity_id": "11554897_3_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "11554897_3_Ent4", "role": "Treatment", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "start": 12, "end": 25}, {"entity_id": "11554897_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent9", "role": "Combination_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent7", "role": "Treatment_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent10", "role": "Combination_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent8", "role": "Treatment_Route", "text": "tablets", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11554897_3_Ent0", "text": "A 55 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "11554897_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11554897_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11554897_3_Ent3", "text": "stuporous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11554897_3_Ent5", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11554897_3_Ent4", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "11554897_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent9", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent7", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent10", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent8", "text": "tablets", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11563738_1", "wnd_id": "11563738_1_1", "text": "The cause of death was determined to be acute intoxication by olanzapine , and the manner of death was accidental .", "tokens": ["The", "cause", "of", "death", "was", "determined", "to", "be", "acute", "intoxication", "by", "olanzapine", ",", "and", "the", "manner", "of", "death", "was", "accidental", "."], "event_mentions": [{"id": "11563738_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 10, "end": 11}, "arguments": [{"entity_id": "11563738_1_Ent0", "role": "Effect", "text": "death", "start": 3, "end": 4}, {"entity_id": "11563738_1_Ent1", "role": "Effect", "text": "acute intoxication", "start": 8, "end": 10}, {"entity_id": "11563738_1_Ent2", "role": "Treatment", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "11563738_1_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11563738_1_Ent0", "text": "death", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11563738_1_Ent1", "text": "acute intoxication", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11563738_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11563738_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11573852_1", "wnd_id": "11573852_1_1", "text": "Amphotericin B - induced seizures in a patient with AIDS .", "tokens": ["Amphotericin", "B", "-", "induced", "seizures", "in", "a", "patient", "with", "AIDS", "."], "event_mentions": [{"id": "11573852_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11573852_1_Ent3", "role": "Treatment", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "11573852_1_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "11573852_1_Ent2", "role": "Effect", "text": "seizures", "start": 4, "end": 5}, {"entity_id": "11573852_1_Ent0", "role": "Subject", "text": "a patient with AIDS", "start": 6, "end": 10}, {"entity_id": "11573852_1_Ent1", "role": "Subject_Disorder", "text": "AIDS", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11573852_1_Ent3", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11573852_1_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11573852_1_Ent2", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11573852_1_Ent0", "text": "a patient with AIDS", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11573852_1_Ent1", "text": "AIDS", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11675845_4", "wnd_id": "11675845_4_1", "text": "Ropinirole was added to his current therapy for Parkinson disease , with a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing .", "tokens": ["Ropinirole", "was", "added", "to", "his", "current", "therapy", "for", "Parkinson", "disease", ",", "with", "a", "corresponding", "decrease", "in", "the", "dose", "of", "levodopa", "/", "carbidopa", "to", "allow", "levodopa", "sparing", "."], "event_mentions": [{"id": "11675845_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "added", "start": 2, "end": 3}, "arguments": [{"entity_id": "11675845_4_Ent0", "role": "Treatment", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent2", "role": "Treatment_Drug", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent6", "role": "Combination_Drug", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent5", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 8, "end": 10}, {"entity_id": "11675845_4_Ent1", "role": "Treatment", "text": "a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing", "start": 12, "end": 26}, {"entity_id": "11675845_4_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 19, "end": 20}, {"entity_id": "11675845_4_Ent7", "role": "Combination_Drug", "text": "levodopa", "start": 19, "end": 20}, {"entity_id": "11675845_4_Ent4", "role": "Treatment_Drug", "text": "carbidopa", "start": 21, "end": 22}, {"entity_id": "11675845_4_Ent8", "role": "Combination_Drug", "text": "carbidopa", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11675845_4_Ent0", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent2", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent6", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent5", "text": "Parkinson disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11675845_4_Ent1", "text": "a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing", "entity_type": "Entity", "start": 12, "end": 26}, {"id": "11675845_4_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11675845_4_Ent7", "text": "levodopa", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11675845_4_Ent4", "text": "carbidopa", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11675845_4_Ent8", "text": "carbidopa", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11703329_1", "wnd_id": "11703329_1_1", "text": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening vincristine neurotoxicity .", "tokens": ["Early", "recognition", "of", "hereditary", "motor", "and", "sensory", "neuropathy", "type", "1", "can", "avoid", "life", "-", "threatening", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "11703329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "can", "start": 10, "end": 11}, "arguments": [{"entity_id": "11703329_1_Ent0", "role": "Treatment", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "start": 0, "end": 10}]}], "entity_mentions": [{"id": "11703329_1_Ent0", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "entity_type": "Entity", "start": 0, "end": 10}], "lang": "en"}
{"doc_id": "11706664_1", "wnd_id": "11706664_1_1", "text": "Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate .", "tokens": ["Acute", "asymptomatic", "hepatitis", "in", "a", "healthy", "normal", "volunteer", "exposed", "to", "2", "oral", "doses", "of", "amodiaquine", "and", "artesunate", "."], "event_mentions": [{"id": "11706664_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11706664_1_Ent1", "role": "Effect", "text": "Acute asymptomatic hepatitis", "start": 0, "end": 3}, {"entity_id": "11706664_1_Ent0", "role": "Subject", "text": "a healthy normal volunteer", "start": 4, "end": 8}, {"entity_id": "11706664_1_Ent4", "role": "Treatment_Dosage", "text": "2", "start": 10, "end": 11}, {"entity_id": "11706664_1_Ent2", "role": "Treatment", "text": "2 oral doses of amodiaquine and artesunate", "start": 10, "end": 17}, {"entity_id": "11706664_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "11706664_1_Ent5", "role": "Treatment_Drug", "text": "amodiaquine", "start": 14, "end": 15}, {"entity_id": "11706664_1_Ent8", "role": "Combination_Drug", "text": "amodiaquine", "start": 14, "end": 15}, {"entity_id": "11706664_1_Ent6", "role": "Treatment_Drug", "text": "artesunate", "start": 16, "end": 17}, {"entity_id": "11706664_1_Ent7", "role": "Combination_Drug", "text": "artesunate", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11706664_1_Ent1", "text": "Acute asymptomatic hepatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11706664_1_Ent0", "text": "a healthy normal volunteer", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "11706664_1_Ent4", "text": "2", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11706664_1_Ent2", "text": "2 oral doses of amodiaquine and artesunate", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "11706664_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11706664_1_Ent5", "text": "amodiaquine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11706664_1_Ent8", "text": "amodiaquine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11706664_1_Ent6", "text": "artesunate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11706664_1_Ent7", "text": "artesunate", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11720625_1", "wnd_id": "11720625_1_1", "text": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin .", "tokens": ["Torsades", "de", "pointes", "due", "to", "drug", "interaction", "between", "disopyramide", "and", "clarithromycin", "."], "event_mentions": [{"id": "11720625_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 3, "end": 5}, "arguments": [{"entity_id": "11720625_1_Ent0", "role": "Effect", "text": "Torsades de pointes", "start": 0, "end": 3}, {"entity_id": "11720625_1_Ent1", "role": "Treatment", "text": "drug interaction between disopyramide and clarithromycin", "start": 5, "end": 11}, {"entity_id": "11720625_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent4", "role": "Combination_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 10, "end": 11}, {"entity_id": "11720625_1_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11720625_1_Ent0", "text": "Torsades de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11720625_1_Ent1", "text": "drug interaction between disopyramide and clarithromycin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11720625_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent4", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11720625_1_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11749112_2", "wnd_id": "11749112_2_1", "text": "This case report describes the development of asymptomatic visual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment .", "tokens": ["This", "case", "report", "describes", "the", "development", "of", "asymptomatic", "visual", "field", "defects", "(", "VFDs", ")", "in", "a", "psychiatric", "patient", "with", "bipolar", "disorder", "receiving", "adjunctive", "tiagabine", "treatment", "."], "event_mentions": [{"id": "11749112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "11749112_2_Ent1", "role": "Effect", "text": "asymptomatic visual field defects", "start": 7, "end": 11}, {"entity_id": "11749112_2_Ent0", "role": "Subject", "text": "patient", "start": 17, "end": 18}, {"entity_id": "11749112_2_Ent3", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 19, "end": 21}, {"entity_id": "11749112_2_Ent2", "role": "Treatment", "text": "tiagabine", "start": 23, "end": 24}, {"entity_id": "11749112_2_Ent4", "role": "Treatment_Drug", "text": "tiagabine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11749112_2_Ent1", "text": "asymptomatic visual field defects", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11749112_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11749112_2_Ent3", "text": "bipolar disorder", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11749112_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11749112_2_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11762672_1", "wnd_id": "11762672_1_1", "text": "An adult male presented with central blindness after ingesting methanol .", "tokens": ["An", "adult", "male", "presented", "with", "central", "blindness", "after", "ingesting", "methanol", "."], "event_mentions": [{"id": "11762672_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 3, "end": 4}, "arguments": [{"entity_id": "11762672_1_Ent0", "role": "Subject", "text": "An adult male", "start": 0, "end": 3}, {"entity_id": "11762672_1_Ent1", "role": "Subject_Age", "text": "adult", "start": 1, "end": 2}, {"entity_id": "11762672_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "11762672_1_Ent3", "role": "Effect", "text": "central blindness", "start": 5, "end": 7}, {"entity_id": "11762672_1_Ent5", "role": "Treatment_Route", "text": "ingesting", "start": 8, "end": 9}, {"entity_id": "11762672_1_Ent4", "role": "Treatment", "text": "ingesting methanol", "start": 8, "end": 10}, {"entity_id": "11762672_1_Ent6", "role": "Treatment_Drug", "text": "methanol", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11762672_1_Ent0", "text": "An adult male", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11762672_1_Ent1", "text": "adult", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11762672_1_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11762672_1_Ent3", "text": "central blindness", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11762672_1_Ent5", "text": "ingesting", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11762672_1_Ent4", "text": "ingesting methanol", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11762672_1_Ent6", "text": "methanol", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11762672_2", "wnd_id": "11762672_2_1", "text": "Reversal of severe methanol - induced visual impairment : no evidence of retinal toxicity due to fomepizole .", "tokens": ["Reversal", "of", "severe", "methanol", "-", "induced", "visual", "impairment", ":", "no", "evidence", "of", "retinal", "toxicity", "due", "to", "fomepizole", "."], "event_mentions": [{"id": "11762672_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "11762672_2_Ent1", "role": "Treatment", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "11762672_2_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "11762672_2_Ent0", "role": "Effect", "text": "visual impairment", "start": 6, "end": 8}]}, {"id": "11762672_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 14, "end": 16}, "arguments": [{"entity_id": "11762672_2_Ent3", "role": "Effect", "text": "retinal toxicity", "start": 12, "end": 14}, {"entity_id": "11762672_2_Ent4", "role": "Treatment", "text": "fomepizole", "start": 16, "end": 17}, {"entity_id": "11762672_2_Ent5", "role": "Treatment_Drug", "text": "fomepizole", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11762672_2_Ent1", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11762672_2_Ent2", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11762672_2_Ent0", "text": "visual impairment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11762672_2_Ent3", "text": "retinal toxicity", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11762672_2_Ent4", "text": "fomepizole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11762672_2_Ent5", "text": "fomepizole", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11816261_5", "wnd_id": "11816261_5_1", "text": "She was administered metoclopramide because of nausea and , within 2 hours , developed agitation , dysarthria , diaphoresis , and a movement disorder .", "tokens": ["She", "was", "administered", "metoclopramide", "because", "of", "nausea", "and", ",", "within", "2", "hours", ",", "developed", "agitation", ",", "dysarthria", ",", "diaphoresis", ",", "and", "a", "movement", "disorder", "."], "event_mentions": [{"id": "11816261_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11816261_5_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent3", "role": "Treatment_Disorder", "text": "nausea", "start": 6, "end": 7}, {"entity_id": "11816261_5_Ent4", "role": "Treatment_Time_elapsed", "text": "within 2 hours", "start": 9, "end": 12}, {"entity_id": "11816261_5_Ent0", "role": "Effect", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "11816261_5_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent3", "text": "nausea", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11816261_5_Ent4", "text": "within 2 hours", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11816261_5_Ent0", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "11834188_4", "wnd_id": "11834188_4_1", "text": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test .", "tokens": ["We", "presented", "the", "case", "of", "a", "patient", "who", "developed", "a", "cutaneous", "reaction", "induced", "by", "captopril", "with", "positive", "patch", "test", "."], "event_mentions": [{"id": "11834188_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "11834188_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "11834188_4_Ent1", "role": "Effect", "text": "cutaneous reaction", "start": 10, "end": 12}, {"entity_id": "11834188_4_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "11834188_4_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11834188_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11834188_4_Ent1", "text": "cutaneous reaction", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11834188_4_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11834188_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11837564_1", "wnd_id": "11837564_1_1", "text": "A 62 - year - old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia ; his international normalized ratio ( INR ) was 1.74 .", "tokens": ["A", "62", "-", "year", "-", "old", "Caucasian", "man", "with", "atrial", "fibrillation", "who", "was", "taking", "warfarin", "reported", "an", "episode", "of", "hematochezia", ";", "his", "international", "normalized", "ratio", "(", "INR", ")", "was", "1.74", "."], "event_mentions": [{"id": "11837564_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "episode", "start": 17, "end": 18}, "arguments": [{"entity_id": "11837564_1_Ent0", "role": "Subject", "text": "A 62 - year - old Caucasian man with atrial fibrillation", "start": 0, "end": 11}, {"entity_id": "11837564_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "11837564_1_Ent2", "role": "Subject_Race", "text": "Caucasian", "start": 6, "end": 7}, {"entity_id": "11837564_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "11837564_1_Ent6", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 9, "end": 11}, {"entity_id": "11837564_1_Ent5", "role": "Treatment", "text": "warfarin", "start": 14, "end": 15}, {"entity_id": "11837564_1_Ent7", "role": "Treatment_Drug", "text": "warfarin", "start": 14, "end": 15}, {"entity_id": "11837564_1_Ent4", "role": "Effect", "text": "hematochezia", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "11837564_1_Ent0", "text": "A 62 - year - old Caucasian man with atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "11837564_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11837564_1_Ent2", "text": "Caucasian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11837564_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11837564_1_Ent6", "text": "atrial fibrillation", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11837564_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11837564_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11837564_1_Ent4", "text": "hematochezia", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "11876387_2", "wnd_id": "11876387_2_1", "text": "Since tamoxifen therapy can induce endometrial disorders , surveillance schemes of women taking tamoxifen have been recommended .", "tokens": ["Since", "tamoxifen", "therapy", "can", "induce", "endometrial", "disorders", ",", "surveillance", "schemes", "of", "women", "taking", "tamoxifen", "have", "been", "recommended", "."], "event_mentions": [{"id": "11876387_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 4, "end": 5}, "arguments": [{"entity_id": "11876387_2_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 1, "end": 2}, {"entity_id": "11876387_2_Ent3", "role": "Treatment", "text": "tamoxifen therapy", "start": 1, "end": 3}, {"entity_id": "11876387_2_Ent2", "role": "Effect", "text": "endometrial disorders", "start": 5, "end": 7}, {"entity_id": "11876387_2_Ent0", "role": "Subject", "text": "women", "start": 11, "end": 12}, {"entity_id": "11876387_2_Ent1", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11876387_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11876387_2_Ent3", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11876387_2_Ent2", "text": "endometrial disorders", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11876387_2_Ent0", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11876387_2_Ent1", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11881322_6", "wnd_id": "11881322_6_1", "text": "We report on three patients who developed acute liver damage during therapy with itraconazole , and in whom liver biopsy specimens were obtained .", "tokens": ["We", "report", "on", "three", "patients", "who", "developed", "acute", "liver", "damage", "during", "therapy", "with", "itraconazole", ",", "and", "in", "whom", "liver", "biopsy", "specimens", "were", "obtained", "."], "event_mentions": [{"id": "11881322_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "11881322_6_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "11881322_6_Ent0", "role": "Subject", "text": "three patients", "start": 3, "end": 5}, {"entity_id": "11881322_6_Ent2", "role": "Effect", "text": "acute liver damage", "start": 7, "end": 10}, {"entity_id": "11881322_6_Ent3", "role": "Treatment", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "11881322_6_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11881322_6_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_6_Ent0", "text": "three patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11881322_6_Ent2", "text": "acute liver damage", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11881322_6_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11881322_6_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11881322_7", "wnd_id": "11881322_7_1", "text": "We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug - induced vanishing bile duct syndrome .", "tokens": ["We", "suggest", "that", "itraconazole", "should", "be", "added", "to", "the", "list", "of", "drugs", "that", "may", "be", "responsible", "for", "a", "drug", "-", "induced", "vanishing", "bile", "duct", "syndrome", "."], "event_mentions": [{"id": "11881322_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 15, "end": 16}, "arguments": [{"entity_id": "11881322_7_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent0", "role": "Effect", "text": "drug - induced vanishing bile duct syndrome", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11881322_7_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent0", "text": "drug - induced vanishing bile duct syndrome", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11886466_1", "wnd_id": "11886466_1_1", "text": "Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia .", "tokens": ["Thrombotic", "stroke", "associated", "with", "the", "use", "of", "porcine", "factor", "VIII", "in", "a", "patient", "with", "acquired", "haemophilia", "."], "event_mentions": [{"id": "11886466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11886466_1_Ent1", "role": "Effect", "text": "Thrombotic stroke", "start": 0, "end": 2}, {"entity_id": "11886466_1_Ent2", "role": "Treatment", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent3", "role": "Treatment_Drug", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent0", "role": "Subject", "text": "patient with acquired haemophilia", "start": 12, "end": 16}, {"entity_id": "11886466_1_Ent4", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11886466_1_Ent1", "text": "Thrombotic stroke", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11886466_1_Ent2", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent3", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent0", "text": "patient with acquired haemophilia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11886466_1_Ent4", "text": "acquired haemophilia", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11886466_5", "wnd_id": "11886466_5_1", "text": "We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors .", "tokens": ["We", "speculate", "that", "platelet", "activation", "induced", "by", "pFVIII", "may", "have", "contributed", "to", "thrombosis", "and", "suggest", "that", "pFVIII", "be", "used", "with", "caution", "in", "elderly", "patients", "with", "pre", "-", "existing", "cardiovascular", "risk", "factors", "."], "event_mentions": [{"id": "11886466_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11886466_5_Ent1", "role": "Treatment", "text": "pFVIII", "start": 7, "end": 8}, {"entity_id": "11886466_5_Ent2", "role": "Treatment_Drug", "text": "pFVIII", "start": 7, "end": 8}, {"entity_id": "11886466_5_Ent0", "role": "Effect", "text": "thrombosis", "start": 12, "end": 13}, {"entity_id": "11886466_5_Ent3", "role": "Treatment_Disorder", "text": "cardiovascular", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11886466_5_Ent1", "text": "pFVIII", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11886466_5_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11886466_5_Ent0", "text": "thrombosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11886466_5_Ent3", "text": "cardiovascular", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11889149_4", "wnd_id": "11889149_4_1", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period ) received placebo , RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined .", "tokens": ["Women", "(", "aged", "<", "or", "=", "75", "yr", ";", ">", "or", "=", "2", "yr", "since", "their", "last", "menstrual", "period", ")", "received", "placebo", ",", "RLX", "60", "mg", "/", "d", ",", "ALN", "10", "mg", "/", "d", ",", "or", "RLX", "60", "mg", "/", "d", "and", "ALN", "10", "mg", "/", "d", "combined", "."], "event_mentions": [{"id": "11889149_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "11889149_4_Ent1", "role": "Subject_Gender", "text": "Women", "start": 0, "end": 1}, {"entity_id": "11889149_4_Ent0", "role": "Subject", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "start": 0, "end": 20}, {"entity_id": "11889149_4_Ent2", "role": "Subject_Age", "text": "aged < or = 75 yr ; > or = 2 yr", "start": 2, "end": 14}, {"entity_id": "11889149_4_Ent8", "role": "Treatment_Drug", "text": "RLX", "start": 23, "end": 24}, {"entity_id": "11889149_4_Ent3", "role": "Treatment", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "start": 23, "end": 48}, {"entity_id": "11889149_4_Ent4", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 24, "end": 28}, {"entity_id": "11889149_4_Ent9", "role": "Treatment_Drug", "text": "ALN", "start": 29, "end": 30}, {"entity_id": "11889149_4_Ent5", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 30, "end": 34}, {"entity_id": "11889149_4_Ent10", "role": "Treatment_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent13", "role": "Combination_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent6", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 37, "end": 41}, {"entity_id": "11889149_4_Ent11", "role": "Treatment_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent12", "role": "Combination_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent7", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 43, "end": 47}]}], "entity_mentions": [{"id": "11889149_4_Ent1", "text": "Women", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_4_Ent0", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "11889149_4_Ent2", "text": "aged < or = 75 yr ; > or = 2 yr", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "11889149_4_Ent8", "text": "RLX", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11889149_4_Ent3", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "entity_type": "Entity", "start": 23, "end": 48}, {"id": "11889149_4_Ent4", "text": "60 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11889149_4_Ent9", "text": "ALN", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11889149_4_Ent5", "text": "10 mg / d", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "11889149_4_Ent10", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent13", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent6", "text": "60 mg / d", "entity_type": "Entity", "start": 37, "end": 41}, {"id": "11889149_4_Ent11", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent12", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent7", "text": "10 mg / d", "entity_type": "Entity", "start": 43, "end": 47}], "lang": "en"}
{"doc_id": "11918514_1", "wnd_id": "11918514_1_1", "text": "CONCLUSIONS : Although mirtazapine offers clinicians a combination of strong efficacy and good safety , we suggest bearing SS in mind when prescribing this drug , especially in frail , elderly patients with underlying chronic conditions .", "tokens": ["CONCLUSIONS", ":", "Although", "mirtazapine", "offers", "clinicians", "a", "combination", "of", "strong", "efficacy", "and", "good", "safety", ",", "we", "suggest", "bearing", "SS", "in", "mind", "when", "prescribing", "this", "drug", ",", "especially", "in", "frail", ",", "elderly", "patients", "with", "underlying", "chronic", "conditions", "."], "event_mentions": [{"id": "11918514_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "bearing", "start": 17, "end": 18}, "arguments": [{"entity_id": "11918514_1_Ent4", "role": "Treatment", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent5", "role": "Treatment_Drug", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent3", "role": "Effect", "text": "SS", "start": 18, "end": 19}, {"entity_id": "11918514_1_Ent0", "role": "Subject", "text": "frail , elderly patients with underlying chronic conditions", "start": 28, "end": 36}, {"entity_id": "11918514_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 30, "end": 31}, {"entity_id": "11918514_1_Ent2", "role": "Subject_Disorder", "text": "underlying chronic conditions", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "11918514_1_Ent4", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent5", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent3", "text": "SS", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11918514_1_Ent0", "text": "frail , elderly patients with underlying chronic conditions", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "11918514_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11918514_1_Ent2", "text": "underlying chronic conditions", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "11972105_1", "wnd_id": "11972105_1_1", "text": "The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin , with severe toxicity .", "tokens": ["The", "authors", "report", "two", "cases", "of", "delayed", "elimination", "of", "methotrexate", "in", "patients", "receiving", "ciprofloxacin", ",", "with", "severe", "toxicity", "."], "event_mentions": [{"id": "11972105_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "11972105_1_Ent1", "role": "Effect", "text": "delayed elimination", "start": 6, "end": 8}, {"entity_id": "11972105_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11972105_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11972105_1_Ent0", "role": "Subject", "text": "patients receiving ciprofloxacin", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11972105_1_Ent1", "text": "delayed elimination", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11972105_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11972105_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11972105_1_Ent0", "text": "patients receiving ciprofloxacin", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "12022905_2", "wnd_id": "12022905_2_1", "text": "CONCLUSIONS : Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners , as with many other antipsychotics , should be aware of .", "tokens": ["CONCLUSIONS", ":", "Priapism", "is", "an", "uncommon", "but", "potentially", "serious", "adverse", "effect", "of", "zuclopenthixol", "that", "practitioners", ",", "as", "with", "many", "other", "antipsychotics", ",", "should", "be", "aware", "of", "."], "event_mentions": [{"id": "12022905_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "serious adverse effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "12022905_2_Ent0", "role": "Effect", "text": "Priapism", "start": 2, "end": 3}, {"entity_id": "12022905_2_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 12, "end": 13}, {"entity_id": "12022905_2_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12022905_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12022905_2_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12022905_2_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12078977_1", "wnd_id": "12078977_1_1", "text": "A 31 - year - old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin , vinblastine and bleomycin for germ cell ovarian cancer stage Ic .", "tokens": ["A", "31", "-", "year", "-", "old", "female", "developed", "multiple", "episodes", "of", "grand", "mal", "seizures", "after", "combination", "chemotherapy", "with", "cisplatin", ",", "vinblastine", "and", "bleomycin", "for", "germ", "cell", "ovarian", "cancer", "stage", "Ic", "."], "event_mentions": [{"id": "12078977_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12078977_1_Ent0", "role": "Subject", "text": "A 31 - year - old female", "start": 0, "end": 7}, {"entity_id": "12078977_1_Ent1", "role": "Subject_Age", "text": "31 - year - old", "start": 1, "end": 6}, {"entity_id": "12078977_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "12078977_1_Ent3", "role": "Effect", "text": "multiple episodes of grand mal seizures", "start": 8, "end": 14}, {"entity_id": "12078977_1_Ent4", "role": "Treatment", "text": "combination chemotherapy with cisplatin , vinblastine and bleomycin", "start": 15, "end": 23}, {"entity_id": "12078977_1_Ent8", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "12078977_1_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "12078977_1_Ent7", "role": "Treatment_Drug", "text": "vinblastine", "start": 20, "end": 21}, {"entity_id": "12078977_1_Ent10", "role": "Combination_Drug", "text": "vinblastine", "start": 20, "end": 21}, {"entity_id": "12078977_1_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 22, "end": 23}, {"entity_id": "12078977_1_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 22, "end": 23}, {"entity_id": "12078977_1_Ent5", "role": "Treatment_Disorder", "text": "germ cell ovarian cancer stage Ic", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "12078977_1_Ent0", "text": "A 31 - year - old female", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12078977_1_Ent1", "text": "31 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12078977_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12078977_1_Ent3", "text": "multiple episodes of grand mal seizures", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12078977_1_Ent4", "text": "combination chemotherapy with cisplatin , vinblastine and bleomycin", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "12078977_1_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12078977_1_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12078977_1_Ent7", "text": "vinblastine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12078977_1_Ent10", "text": "vinblastine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12078977_1_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12078977_1_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12078977_1_Ent5", "text": "germ cell ovarian cancer stage Ic", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "12095907_1", "wnd_id": "12095907_1_1", "text": "The authors describe valproate - induced hyperammonemia and mental status changes in an 88 - year - old man , the first known reported case in an elderly patient .", "tokens": ["The", "authors", "describe", "valproate", "-", "induced", "hyperammonemia", "and", "mental", "status", "changes", "in", "an", "88", "-", "year", "-", "old", "man", ",", "the", "first", "known", "reported", "case", "in", "an", "elderly", "patient", "."], "event_mentions": [{"id": "12095907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "12095907_1_Ent4", "role": "Treatment", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent3", "role": "Effect", "text": "hyperammonemia and mental status changes", "start": 6, "end": 11}, {"entity_id": "12095907_1_Ent0", "role": "Subject", "text": "an 88 - year - old man", "start": 12, "end": 19}, {"entity_id": "12095907_1_Ent1", "role": "Subject_Age", "text": "88 - year - old", "start": 13, "end": 18}, {"entity_id": "12095907_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12095907_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent3", "text": "hyperammonemia and mental status changes", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "12095907_1_Ent0", "text": "an 88 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12095907_1_Ent1", "text": "88 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "12095907_1_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12107858_1", "wnd_id": "12107858_1_1", "text": "The epivodes of NMS occured under treatment with clozapine , risperidone , and amisulpride .", "tokens": ["The", "epivodes", "of", "NMS", "occured", "under", "treatment", "with", "clozapine", ",", "risperidone", ",", "and", "amisulpride", "."], "event_mentions": [{"id": "12107858_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occured", "start": 4, "end": 5}, "arguments": [{"entity_id": "12107858_1_Ent0", "role": "Effect", "text": "NMS", "start": 3, "end": 4}, {"entity_id": "12107858_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "12107858_1_Ent5", "role": "Combination_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "12107858_1_Ent1", "role": "Treatment", "text": "clozapine , risperidone , and amisulpride", "start": 8, "end": 14}, {"entity_id": "12107858_1_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12107858_1_Ent6", "role": "Combination_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12107858_1_Ent4", "role": "Treatment_Drug", "text": "amisulpride", "start": 13, "end": 14}, {"entity_id": "12107858_1_Ent7", "role": "Combination_Drug", "text": "amisulpride", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12107858_1_Ent0", "text": "NMS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12107858_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12107858_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12107858_1_Ent1", "text": "clozapine , risperidone , and amisulpride", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12107858_1_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12107858_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12107858_1_Ent4", "text": "amisulpride", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12107858_1_Ent7", "text": "amisulpride", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12111771_2", "wnd_id": "12111771_2_1", "text": "Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine .", "tokens": ["Fludarabine", "induced", "lung", "toxicity", "must", "be", "considered", "in", "all", "patients", "who", "develop", "unexplained", "lung", "disease", "while", "receiving", "fludarabine", "."], "event_mentions": [{"id": "12111771_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "12111771_2_Ent2", "role": "Effect", "text": "Fludarabine induced lung toxicity", "start": 0, "end": 4}, {"entity_id": "12111771_2_Ent0", "role": "Subject", "text": "all patients who develop unexplained lung disease", "start": 8, "end": 15}, {"entity_id": "12111771_2_Ent1", "role": "Subject_Disorder", "text": "lung disease", "start": 13, "end": 15}, {"entity_id": "12111771_2_Ent3", "role": "Treatment", "text": "fludarabine", "start": 17, "end": 18}, {"entity_id": "12111771_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "12111771_2_Ent2", "text": "Fludarabine induced lung toxicity", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12111771_2_Ent0", "text": "all patients who develop unexplained lung disease", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "12111771_2_Ent1", "text": "lung disease", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12111771_2_Ent3", "text": "fludarabine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12111771_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "12111771_3", "wnd_id": "12111771_3_1", "text": "Multiple pulmonary nodules : an unusual presentation of fludarabine pulmonary toxicity : case report and review of literature .", "tokens": ["Multiple", "pulmonary", "nodules", ":", "an", "unusual", "presentation", "of", "fludarabine", "pulmonary", "toxicity", ":", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "12111771_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presentation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12111771_3_Ent0", "role": "Effect", "text": "Multiple pulmonary nodules", "start": 0, "end": 3}, {"entity_id": "12111771_3_Ent1", "role": "Treatment", "text": "fludarabine", "start": 8, "end": 9}, {"entity_id": "12111771_3_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12111771_3_Ent0", "text": "Multiple pulmonary nodules", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12111771_3_Ent1", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12111771_3_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12149193_1", "wnd_id": "12149193_1_1", "text": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide : implications for therapy .", "tokens": ["Thrombogenic", "activity", "of", "doxorubicin", "in", "myeloma", "patients", "receiving", "thalidomide", ":", "implications", "for", "therapy", "."], "event_mentions": [{"id": "12149193_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_1_Ent1", "role": "Effect", "text": "Thrombogenic activity", "start": 0, "end": 2}, {"entity_id": "12149193_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent4", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_1_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_1_Ent3", "role": "Treatment", "text": "thalidomide", "start": 8, "end": 9}, {"entity_id": "12149193_1_Ent6", "role": "Treatment_Drug", "text": "thalidomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12149193_1_Ent1", "text": "Thrombogenic activity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent4", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_1_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_1_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_1_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12149193_8", "wnd_id": "12149193_8_1", "text": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin ( P = .02 ) was observed ; this association was confirmed on multivariate analysis .", "tokens": ["A", "statistical", "association", "between", "the", "incidence", "of", "DVT", "and", "combination", "chemotherapy", "including", "doxorubicin", "(", "P", "=", ".02", ")", "was", "observed", ";", "this", "association", "was", "confirmed", "on", "multivariate", "analysis", "."], "event_mentions": [{"id": "12149193_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "12149193_8_Ent0", "role": "Effect", "text": "DVT", "start": 7, "end": 8}, {"entity_id": "12149193_8_Ent1", "role": "Treatment", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "start": 9, "end": 18}, {"entity_id": "12149193_8_Ent2", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent4", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 12, "end": 13}, {"entity_id": "12149193_8_Ent5", "role": "Combination_Drug", "text": "doxorubicin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12149193_8_Ent0", "text": "DVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_8_Ent1", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12149193_8_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_8_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12187348_3", "wnd_id": "12187348_3_1", "text": "The authors report the first case of bucillamine - induced giant mammary hyperplasia .", "tokens": ["The", "authors", "report", "the", "first", "case", "of", "bucillamine", "-", "induced", "giant", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "12187348_3_Ent1", "role": "Treatment", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent0", "role": "Effect", "text": "giant mammary hyperplasia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12187348_3_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent0", "text": "giant mammary hyperplasia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "12187348_8", "wnd_id": "12187348_8_1", "text": "Retrospectively , bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia .", "tokens": ["Retrospectively", ",", "bucillamine", "was", "believed", "to", "be", "the", "cause", "of", "the", "giant", "hypertrophy", "because", "of", "its", "structural", "similarity", "to", "D", "-", "penicillamine", ",", "which", "was", "the", "subject", "of", "an", "abundance", "of", "reports", "of", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause of", "start": 8, "end": 10}, "arguments": [{"entity_id": "12187348_8_Ent1", "role": "Treatment", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent0", "role": "Effect", "text": "giant hypertrophy", "start": 11, "end": 13}, {"entity_id": "12187348_8_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "12187348_8_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent0", "text": "giant hypertrophy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12187348_8_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "12196060_1", "wnd_id": "12196060_1_1", "text": "Phenytoin / isradipine interaction causing severe neurologic toxicity .", "tokens": ["Phenytoin", "/", "isradipine", "interaction", "causing", "severe", "neurologic", "toxicity", "."], "event_mentions": [{"id": "12196060_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 4, "end": 5}, "arguments": [{"entity_id": "12196060_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "12196060_1_Ent5", "role": "Combination_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "12196060_1_Ent1", "role": "Treatment", "text": "Phenytoin / isradipine interaction", "start": 0, "end": 4}, {"entity_id": "12196060_1_Ent3", "role": "Treatment_Drug", "text": "isradipine", "start": 2, "end": 3}, {"entity_id": "12196060_1_Ent4", "role": "Combination_Drug", "text": "isradipine", "start": 2, "end": 3}, {"entity_id": "12196060_1_Ent0", "role": "Effect", "text": "neurologic toxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "12196060_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12196060_1_Ent5", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12196060_1_Ent1", "text": "Phenytoin / isradipine interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12196060_1_Ent3", "text": "isradipine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12196060_1_Ent4", "text": "isradipine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12196060_1_Ent0", "text": "neurologic toxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "12218252_1", "wnd_id": "12218252_1_1", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept .", "tokens": ["Generalised", "pustular", "psoriasis", "induced", "by", "cyclosporin", "a", "withdrawal", "responding", "to", "the", "tumour", "necrosis", "factor", "alpha", "inhibitor", "etanercept", "."], "event_mentions": [{"id": "12218252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12218252_1_Ent0", "role": "Effect", "text": "Generalised pustular psoriasis", "start": 0, "end": 3}, {"entity_id": "12218252_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporin", "start": 5, "end": 6}, {"entity_id": "12218252_1_Ent1", "role": "Treatment", "text": "cyclosporin a withdrawal", "start": 5, "end": 8}]}, {"id": "12218252_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responding", "start": 8, "end": 9}, "arguments": [{"entity_id": "12218252_1_Ent4", "role": "Treatment_Disorder", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal", "start": 0, "end": 8}, {"entity_id": "12218252_1_Ent3", "role": "Treatment", "text": "the tumour necrosis factor alpha inhibitor etanercept", "start": 10, "end": 17}, {"entity_id": "12218252_1_Ent5", "role": "Treatment_Drug", "text": "etanercept", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12218252_1_Ent0", "text": "Generalised pustular psoriasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12218252_1_Ent4", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12218252_1_Ent2", "text": "cyclosporin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12218252_1_Ent1", "text": "cyclosporin a withdrawal", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12218252_1_Ent3", "text": "the tumour necrosis factor alpha inhibitor etanercept", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "12218252_1_Ent5", "text": "etanercept", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12234159_1", "wnd_id": "12234159_1_1", "text": "Fixed drug eruption to rofecoxib .", "tokens": ["Fixed", "drug", "eruption", "to", "rofecoxib", "."], "event_mentions": [{"id": "12234159_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "12234159_1_Ent0", "role": "Effect", "text": "Fixed drug eruption", "start": 0, "end": 3}, {"entity_id": "12234159_1_Ent1", "role": "Treatment", "text": "rofecoxib", "start": 4, "end": 5}, {"entity_id": "12234159_1_Ent2", "role": "Treatment_Drug", "text": "rofecoxib", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12234159_1_Ent0", "text": "Fixed drug eruption", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12234159_1_Ent1", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12234159_1_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12243603_10", "wnd_id": "12243603_10_1", "text": "We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis , thought to be secondary to a drug interaction between atorvastatin and diltiazem .", "tokens": ["We", "describe", "a", "patient", "with", "a", "complex", "medication", "regimen", "who", "was", "admitted", "for", "rhabdomyolysis", "and", "accompanying", "acute", "renal", "failure", ",", "along", "with", "acute", "hepatitis", ",", "thought", "to", "be", "secondary", "to", "a", "drug", "interaction", "between", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 28, "end": 29}, "arguments": [{"entity_id": "12243603_10_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12243603_10_Ent1", "role": "Effect", "text": "rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis", "start": 13, "end": 24}, {"entity_id": "12243603_10_Ent2", "role": "Treatment", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent4", "role": "Treatment_Drug", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent6", "role": "Combination_Drug", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent3", "role": "Treatment", "text": "diltiazem", "start": 36, "end": 37}, {"entity_id": "12243603_10_Ent5", "role": "Treatment_Drug", "text": "diltiazem", "start": 36, "end": 37}, {"entity_id": "12243603_10_Ent7", "role": "Combination_Drug", "text": "diltiazem", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "12243603_10_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12243603_10_Ent1", "text": "rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis", "entity_type": "Entity", "start": 13, "end": 24}, {"id": "12243603_10_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent6", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "12243603_10_Ent5", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "12243603_10_Ent7", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "12324937_4", "wnd_id": "12324937_4_1", "text": "Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 + / - 3.5 months , or 21.9 + / - 10.9 doses of gemcitabine .", "tokens": ["Mean", "time", "between", "initiation", "of", "gemcitabine", "therapy", "and", "onset", "of", "HUS", "was", "7.4", "+", "/", "-", "3.5", "months", ",", "or", "21.9", "+", "/", "-", "10.9", "doses", "of", "gemcitabine", "."], "event_mentions": [{"id": "12324937_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 8, "end": 9}, "arguments": [{"entity_id": "12324937_4_Ent0", "role": "Effect", "text": "HUS", "start": 10, "end": 11}, {"entity_id": "12324937_4_Ent3", "role": "Treatment_Time_elapsed", "text": "7.4 + / - 3.5 months", "start": 12, "end": 18}, {"entity_id": "12324937_4_Ent1", "role": "Treatment", "text": "7.4 + / - 3.5 months , or 21.9 + / - 10.9 doses of gemcitabine", "start": 12, "end": 28}, {"entity_id": "12324937_4_Ent4", "role": "Treatment_Dosage", "text": "21.9 + / - 10.9 doses", "start": 20, "end": 26}, {"entity_id": "12324937_4_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12324937_4_Ent0", "text": "HUS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12324937_4_Ent3", "text": "7.4 + / - 3.5 months", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "12324937_4_Ent1", "text": "7.4 + / - 3.5 months , or 21.9 + / - 10.9 doses of gemcitabine", "entity_type": "Entity", "start": 12, "end": 28}, {"id": "12324937_4_Ent4", "text": "21.9 + / - 10.9 doses", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "12324937_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12399645_3", "wnd_id": "12399645_3_1", "text": "In summary , we report herein the first case of SIADH believed to be an adverse effect of mizoribin , which may therefore needed to be added to the list of drugs which can induce SIADH .", "tokens": ["In", "summary", ",", "we", "report", "herein", "the", "first", "case", "of", "SIADH", "believed", "to", "be", "an", "adverse", "effect", "of", "mizoribin", ",", "which", "may", "therefore", "needed", "to", "be", "added", "to", "the", "list", "of", "drugs", "which", "can", "induce", "SIADH", "."], "event_mentions": [{"id": "12399645_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 15, "end": 17}, "arguments": [{"entity_id": "12399645_3_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "12399645_3_Ent1", "role": "Effect", "text": "SIADH", "start": 10, "end": 11}, {"entity_id": "12399645_3_Ent2", "role": "Treatment", "text": "mizoribin", "start": 18, "end": 19}, {"entity_id": "12399645_3_Ent3", "role": "Treatment_Drug", "text": "mizoribin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12399645_3_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12399645_3_Ent1", "text": "SIADH", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12399645_3_Ent2", "text": "mizoribin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12399645_3_Ent3", "text": "mizoribin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12399645_4", "wnd_id": "12399645_4_1", "text": "We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1.5 months after commencement of mizoribin prescription when his arthritis was improved .", "tokens": ["We", "describe", "a", "74", "-", "year", "-", "old", "man", "with", "rheumatoid", "arthritis", "(", "RA", ")", "who", "developed", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", "1.5", "months", "after", "commencement", "of", "mizoribin", "prescription", "when", "his", "arthritis", "was", "improved", "."], "event_mentions": [{"id": "12399645_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "12399645_4_Ent0", "role": "Subject", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "start": 2, "end": 15}, {"entity_id": "12399645_4_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 3, "end": 8}, {"entity_id": "12399645_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "12399645_4_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}, {"entity_id": "12399645_4_Ent3", "role": "Effect", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "start": 17, "end": 27}, {"entity_id": "12399645_4_Ent5", "role": "Treatment_Time_elapsed", "text": "1.5 months after", "start": 27, "end": 30}, {"entity_id": "12399645_4_Ent4", "role": "Treatment", "text": "1.5 months after commencement of mizoribin prescription", "start": 27, "end": 34}, {"entity_id": "12399645_4_Ent6", "role": "Treatment_Drug", "text": "mizoribin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "12399645_4_Ent0", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "12399645_4_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12399645_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12399645_4_Ent7", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12399645_4_Ent3", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "12399645_4_Ent5", "text": "1.5 months after", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12399645_4_Ent4", "text": "1.5 months after commencement of mizoribin prescription", "entity_type": "Entity", "start": 27, "end": 34}, {"id": "12399645_4_Ent6", "text": "mizoribin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "12424571_1", "wnd_id": "12424571_1_1", "text": "Acute onset of nephrotic syndrome during interferon - alpha retreatment for chronic active hepatitis C.", "tokens": ["Acute", "onset", "of", "nephrotic", "syndrome", "during", "interferon", "-", "alpha", "retreatment", "for", "chronic", "active", "hepatitis", "C."], "event_mentions": [{"id": "12424571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "12424571_1_Ent0", "role": "Effect", "text": "Acute onset of nephrotic syndrome", "start": 0, "end": 5}, {"entity_id": "12424571_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 6, "end": 9}, {"entity_id": "12424571_1_Ent1", "role": "Treatment", "text": "interferon - alpha retreatment", "start": 6, "end": 10}, {"entity_id": "12424571_1_Ent3", "role": "Treatment_Disorder", "text": "chronic active hepatitis C.", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "12424571_1_Ent0", "text": "Acute onset of nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12424571_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12424571_1_Ent1", "text": "interferon - alpha retreatment", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12424571_1_Ent3", "text": "chronic active hepatitis C.", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "12432978_2", "wnd_id": "12432978_2_1", "text": "Seizures and extrapyramidal symptoms in a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis treated with interferon beta - 1a and clomipramine .", "tokens": ["Seizures", "and", "extrapyramidal", "symptoms", "in", "a", "patient", "with", "Tourette", "'s", "syndrome", ",", "Asperger", "'s", "syndrome", ",", "and", "multiple", "sclerosis", "treated", "with", "interferon", "beta", "-", "1a", "and", "clomipramine", "."], "event_mentions": [{"id": "12432978_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "12432978_2_Ent1", "role": "Effect", "text": "Seizures and extrapyramidal symptoms", "start": 0, "end": 4}, {"entity_id": "12432978_2_Ent0", "role": "Subject", "text": "a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis", "start": 5, "end": 19}, {"entity_id": "12432978_2_Ent5", "role": "Treatment_Disorder", "text": "Tourette 's syndrome", "start": 8, "end": 11}, {"entity_id": "12432978_2_Ent6", "role": "Treatment_Disorder", "text": "Asperger 's syndrome", "start": 12, "end": 15}, {"entity_id": "12432978_2_Ent7", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 17, "end": 19}, {"entity_id": "12432978_2_Ent4", "role": "Treatment_Drug", "text": "interferon beta - 1a", "start": 21, "end": 25}, {"entity_id": "12432978_2_Ent8", "role": "Combination_Drug", "text": "interferon beta - 1a", "start": 21, "end": 25}, {"entity_id": "12432978_2_Ent2", "role": "Treatment", "text": "interferon beta - 1a and clomipramine", "start": 21, "end": 27}, {"entity_id": "12432978_2_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 26, "end": 27}, {"entity_id": "12432978_2_Ent9", "role": "Combination_Drug", "text": "clomipramine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "12432978_2_Ent1", "text": "Seizures and extrapyramidal symptoms", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12432978_2_Ent0", "text": "a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "12432978_2_Ent5", "text": "Tourette 's syndrome", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12432978_2_Ent6", "text": "Asperger 's syndrome", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12432978_2_Ent7", "text": "multiple sclerosis", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "12432978_2_Ent4", "text": "interferon beta - 1a", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "12432978_2_Ent8", "text": "interferon beta - 1a", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "12432978_2_Ent2", "text": "interferon beta - 1a and clomipramine", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "12432978_2_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12432978_2_Ent9", "text": "clomipramine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "12452753_5", "wnd_id": "12452753_5_1", "text": "OBJECTIVE : To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "safe", "use", "of", "fluorouracil", "in", "a", "patient", "with", "breast", "cancer", "who", "had", "allergic", "reactions", "to", "capecitabine", "."], "event_mentions": [{"id": "12452753_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "safe", "start": 5, "end": 6}, "arguments": [{"entity_id": "12452753_5_Ent2", "role": "Treatment", "text": "fluorouracil", "start": 8, "end": 9}, {"entity_id": "12452753_5_Ent3", "role": "Treatment_Drug", "text": "fluorouracil", "start": 8, "end": 9}, {"entity_id": "12452753_5_Ent0", "role": "Subject", "text": "a patient with breast cancer who had allergic reactions to capecitabine", "start": 10, "end": 21}, {"entity_id": "12452753_5_Ent4", "role": "Treatment_Disorder", "text": "breast cancer", "start": 13, "end": 15}, {"entity_id": "12452753_5_Ent1", "role": "Subject_Disorder", "text": "allergic reactions to capecitabine", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "12452753_5_Ent2", "text": "fluorouracil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12452753_5_Ent3", "text": "fluorouracil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12452753_5_Ent0", "text": "a patient with breast cancer who had allergic reactions to capecitabine", "entity_type": "Entity", "start": 10, "end": 21}, {"id": "12452753_5_Ent4", "text": "breast cancer", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12452753_5_Ent1", "text": "allergic reactions to capecitabine", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "12452753_6", "wnd_id": "12452753_6_1", "text": "She developed a generalized rash and itching , sore throat , and dizziness approximately 4 hours after the first dose of capecitabine .", "tokens": ["She", "developed", "a", "generalized", "rash", "and", "itching", ",", "sore", "throat", ",", "and", "dizziness", "approximately", "4", "hours", "after", "the", "first", "dose", "of", "capecitabine", "."], "event_mentions": [{"id": "12452753_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "12452753_6_Ent0", "role": "Effect", "text": "a generalized rash and itching , sore throat , and dizziness", "start": 2, "end": 13}, {"entity_id": "12452753_6_Ent1", "role": "Treatment", "text": "approximately 4 hours after the first dose of capecitabine", "start": 13, "end": 22}, {"entity_id": "12452753_6_Ent2", "role": "Treatment_Time_elapsed", "text": "4 hours", "start": 14, "end": 16}, {"entity_id": "12452753_6_Ent3", "role": "Treatment_Drug", "text": "capecitabine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12452753_6_Ent0", "text": "a generalized rash and itching , sore throat , and dizziness", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "12452753_6_Ent1", "text": "approximately 4 hours after the first dose of capecitabine", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "12452753_6_Ent2", "text": "4 hours", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12452753_6_Ent3", "text": "capecitabine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12460237_5", "wnd_id": "12460237_5_1", "text": "Contrary to previous recommendations , our experience cautions against the further use of high - dose cytarabine in patients who develop PPE , and is a timely reminder of the potential toxicity of this agent , which is now increasingly being used as first - line treatment in the management of haematologic malignancies .", "tokens": ["Contrary", "to", "previous", "recommendations", ",", "our", "experience", "cautions", "against", "the", "further", "use", "of", "high", "-", "dose", "cytarabine", "in", "patients", "who", "develop", "PPE", ",", "and", "is", "a", "timely", "reminder", "of", "the", "potential", "toxicity", "of", "this", "agent", ",", "which", "is", "now", "increasingly", "being", "used", "as", "first", "-", "line", "treatment", "in", "the", "management", "of", "haematologic", "malignancies", "."], "event_mentions": [{"id": "12460237_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 31, "end": 32}, "arguments": [{"entity_id": "12460237_5_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 13, "end": 16}, {"entity_id": "12460237_5_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 13, "end": 17}, {"entity_id": "12460237_5_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "12460237_5_Ent0", "role": "Effect", "text": "PPE", "start": 21, "end": 22}, {"entity_id": "12460237_5_Ent4", "role": "Treatment_Disorder", "text": "haematologic malignancies", "start": 51, "end": 53}]}], "entity_mentions": [{"id": "12460237_5_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12460237_5_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "12460237_5_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12460237_5_Ent0", "text": "PPE", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12460237_5_Ent4", "text": "haematologic malignancies", "entity_type": "Entity", "start": 51, "end": 53}], "lang": "en"}
{"doc_id": "12477460_3", "wnd_id": "12477460_3_1", "text": "CONCLUSION : Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state .", "tokens": ["CONCLUSION", ":", "Tamoxifen", "may", "cause", "malignant", "transformation", "of", "endometriosis", "through", "atypical", "endometriosis", "even", "in", "the", "postmenopausal", "state", "."], "event_mentions": [{"id": "12477460_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "12477460_3_Ent1", "role": "Treatment", "text": "Tamoxifen", "start": 2, "end": 3}, {"entity_id": "12477460_3_Ent2", "role": "Treatment_Drug", "text": "Tamoxifen", "start": 2, "end": 3}, {"entity_id": "12477460_3_Ent0", "role": "Effect", "text": "malignant transformation of endometriosis through atypical endometriosis", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "12477460_3_Ent1", "text": "Tamoxifen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12477460_3_Ent2", "text": "Tamoxifen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12477460_3_Ent0", "text": "malignant transformation of endometriosis through atypical endometriosis", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "12488741_3", "wnd_id": "12488741_3_1", "text": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy .", "tokens": ["Reversible", "MR", "imaging", "and", "MR", "spectroscopy", "abnormalities", "in", "association", "with", "metronidazole", "therapy", "."], "event_mentions": [{"id": "12488741_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 8, "end": 9}, "arguments": [{"entity_id": "12488741_3_Ent0", "role": "Effect", "text": "Reversible MR imaging and MR spectroscopy abnormalities", "start": 0, "end": 7}, {"entity_id": "12488741_3_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 10, "end": 11}, {"entity_id": "12488741_3_Ent1", "role": "Treatment", "text": "metronidazole therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "12488741_3_Ent0", "text": "Reversible MR imaging and MR spectroscopy abnormalities", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12488741_3_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12488741_3_Ent1", "text": "metronidazole therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "12503933_2", "wnd_id": "12503933_2_1", "text": "A second possibility is an interaction between clarithromycin and isradipine , potentially increasing the hepatic toxicity of isradipine .", "tokens": ["A", "second", "possibility", "is", "an", "interaction", "between", "clarithromycin", "and", "isradipine", ",", "potentially", "increasing", "the", "hepatic", "toxicity", "of", "isradipine", "."], "event_mentions": [{"id": "12503933_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increasing", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_2_Ent1", "role": "Treatment", "text": "interaction between clarithromycin and isradipine", "start": 5, "end": 10}, {"entity_id": "12503933_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent4", "role": "Combination_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent3", "role": "Treatment_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent5", "role": "Combination_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent0", "role": "Effect", "text": "hepatic toxicity", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12503933_2_Ent1", "text": "interaction between clarithromycin and isradipine", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12503933_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent3", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent5", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent0", "text": "hepatic toxicity", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12503933_3", "wnd_id": "12503933_3_1", "text": "CASE SUMMARY : A 58 - year - old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia .", "tokens": ["CASE", "SUMMARY", ":", "A", "58", "-", "year", "-", "old", "white", "woman", "developed", "fulminant", "liver", "failure", "while", "being", "treated", "with", "the", "macrolide", "antibiotic", "clarithromycin", "for", "pneumonia", "."], "event_mentions": [{"id": "12503933_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "12503933_3_Ent0", "role": "Subject", "text": "A 58 - year - old white woman", "start": 3, "end": 11}, {"entity_id": "12503933_3_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 4, "end": 9}, {"entity_id": "12503933_3_Ent2", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "12503933_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12503933_3_Ent4", "role": "Effect", "text": "fulminant liver failure", "start": 12, "end": 15}, {"entity_id": "12503933_3_Ent5", "role": "Treatment", "text": "macrolide antibiotic clarithromycin for pneumonia", "start": 20, "end": 25}, {"entity_id": "12503933_3_Ent7", "role": "Treatment_Drug", "text": "clarithromycin", "start": 22, "end": 23}, {"entity_id": "12503933_3_Ent6", "role": "Treatment_Disorder", "text": "pneumonia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12503933_3_Ent0", "text": "A 58 - year - old white woman", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "12503933_3_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "12503933_3_Ent2", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12503933_3_Ent4", "text": "fulminant liver failure", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12503933_3_Ent5", "text": "macrolide antibiotic clarithromycin for pneumonia", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "12503933_3_Ent7", "text": "clarithromycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12503933_3_Ent6", "text": "pneumonia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "12504711_3", "wnd_id": "12504711_3_1", "text": "PURPOSE : We report an unusual paradoxical effect of brimonidine .", "tokens": ["PURPOSE", ":", "We", "report", "an", "unusual", "paradoxical", "effect", "of", "brimonidine", "."], "event_mentions": [{"id": "12504711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "12504711_3_Ent0", "role": "Effect", "text": "unusual paradoxical effect", "start": 5, "end": 8}, {"entity_id": "12504711_3_Ent1", "role": "Treatment", "text": "brimonidine", "start": 9, "end": 10}, {"entity_id": "12504711_3_Ent2", "role": "Treatment_Drug", "text": "brimonidine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12504711_3_Ent0", "text": "unusual paradoxical effect", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12504711_3_Ent1", "text": "brimonidine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12504711_3_Ent2", "text": "brimonidine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12507063_1", "wnd_id": "12507063_1_1", "text": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and palpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal .", "tokens": ["Although", "gabapentin", "withdrawal", "has", "been", "previously", "reported", "and", "usually", "consists", "of", "anxiety", ",", "diaphoresis", ",", "and", "palpitations", ",", "this", "is", "the", "first", "reported", "patient", "with", "generalized", "seizures", "and", "status", "epilepticus", "secondary", "to", "gabapentin", "withdrawal", "."], "event_mentions": [{"id": "12507063_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 24, "end": 25}, "arguments": [{"entity_id": "12507063_1_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}, {"entity_id": "12507063_1_Ent1", "role": "Effect", "text": "generalized seizures and status epilepticus", "start": 25, "end": 30}, {"entity_id": "12507063_1_Ent2", "role": "Treatment", "text": "secondary to gabapentin withdrawal", "start": 30, "end": 34}, {"entity_id": "12507063_1_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 32, "end": 33}, {"entity_id": "12507063_1_Ent4", "role": "Treatment_Dosage", "text": "withdrawal", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "12507063_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12507063_1_Ent1", "text": "generalized seizures and status epilepticus", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "12507063_1_Ent2", "text": "secondary to gabapentin withdrawal", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "12507063_1_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "12507063_1_Ent4", "text": "withdrawal", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "12523465_1", "wnd_id": "12523465_1_1", "text": "Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .", "tokens": ["Although", "visual", "hallucinations", "have", "not", "been", "reported", "as", "an", "adverse", "effect", "of", "this", "agent", ",", "we", "describe", "three", "patients", "who", "experienced", "complex", "visual", "hallucinations", "and", "altered", "mental", "status", "after", "zonisamide", "treatment", "was", "begun", "or", "its", "dosage", "increased", "."], "event_mentions": [{"id": "12523465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 28, "end": 29}, "arguments": [{"entity_id": "12523465_1_Ent0", "role": "Effect", "text": "complex visual hallucinations and altered mental status", "start": 21, "end": 28}, {"entity_id": "12523465_1_Ent1", "role": "Treatment", "text": "zonisamide", "start": 29, "end": 30}, {"entity_id": "12523465_1_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12523465_1_Ent0", "text": "complex visual hallucinations and altered mental status", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12523465_1_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12523465_1_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12523465_2", "wnd_id": "12523465_2_1", "text": "Visual hallucinations associated with zonisamide .", "tokens": ["Visual", "hallucinations", "associated", "with", "zonisamide", "."], "event_mentions": [{"id": "12523465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "12523465_2_Ent0", "role": "Effect", "text": "Visual hallucinations", "start": 0, "end": 2}, {"entity_id": "12523465_2_Ent1", "role": "Treatment", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "12523465_2_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12523465_2_Ent0", "text": "Visual hallucinations", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12523465_2_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12523465_2_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12546343_2", "wnd_id": "12546343_2_1", "text": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria , facial swelling , cough , and chest tightness .", "tokens": ["He", "had", "an", "immediate", "hypersensitivity", "reaction", "during", "the", "initiation", "of", "the", "MTX", "infusion", "with", "diffuse", "urticaria", ",", "facial", "swelling", ",", "cough", ",", "and", "chest", "tightness", "."], "event_mentions": [{"id": "12546343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "12546343_2_Ent3", "role": "Treatment_Time_elapsed", "text": "immediate", "start": 3, "end": 4}, {"entity_id": "12546343_2_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 4, "end": 6}, {"entity_id": "12546343_2_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 11, "end": 12}, {"entity_id": "12546343_2_Ent2", "role": "Treatment", "text": "MTX infusion", "start": 11, "end": 13}, {"entity_id": "12546343_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 12, "end": 13}, {"entity_id": "12546343_2_Ent1", "role": "Effect", "text": "with diffuse urticaria , facial swelling , cough , and chest tightness", "start": 13, "end": 25}]}], "entity_mentions": [{"id": "12546343_2_Ent3", "text": "immediate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12546343_2_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12546343_2_Ent4", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12546343_2_Ent2", "text": "MTX infusion", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12546343_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12546343_2_Ent1", "text": "with diffuse urticaria , facial swelling , cough , and chest tightness", "entity_type": "Entity", "start": 13, "end": 25}], "lang": "en"}
{"doc_id": "12546343_5", "wnd_id": "12546343_5_1", "text": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases .", "tokens": ["The", "successful", "development", "and", "implementation", "of", "this", "protocol", "will", "have", "impact", "on", "patients", "who", "have", "anaphylactic", "reactions", "to", "MTX", "but", "require", "this", "medication", "for", "specific", "diseases", "."], "event_mentions": [{"id": "12546343_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 14, "end": 15}, "arguments": [{"entity_id": "12546343_5_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "12546343_5_Ent1", "role": "Effect", "text": "anaphylactic reactions", "start": 15, "end": 17}, {"entity_id": "12546343_5_Ent2", "role": "Treatment", "text": "MTX", "start": 18, "end": 19}, {"entity_id": "12546343_5_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12546343_5_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12546343_5_Ent1", "text": "anaphylactic reactions", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12546343_5_Ent2", "text": "MTX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12546343_5_Ent3", "text": "MTX", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12584153_3", "wnd_id": "12584153_3_1", "text": "Amprenavir is a human immunodeficiency virus - 1 ( HIV - 1 ) protease inhibitor intended to be used to treat HIV - infected children .", "tokens": ["Amprenavir", "is", "a", "human", "immunodeficiency", "virus", "-", "1", "(", "HIV", "-", "1", ")", "protease", "inhibitor", "intended", "to", "be", "used", "to", "treat", "HIV", "-", "infected", "children", "."], "event_mentions": [{"id": "12584153_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 20, "end": 21}, "arguments": [{"entity_id": "12584153_3_Ent2", "role": "Treatment", "text": "Amprenavir", "start": 0, "end": 1}, {"entity_id": "12584153_3_Ent4", "role": "Treatment_Drug", "text": "Amprenavir", "start": 0, "end": 1}, {"entity_id": "12584153_3_Ent3", "role": "Treatment_Disorder", "text": "HIV - infected", "start": 21, "end": 24}, {"entity_id": "12584153_3_Ent0", "role": "Subject", "text": "children", "start": 24, "end": 25}, {"entity_id": "12584153_3_Ent1", "role": "Subject_Age", "text": "children", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12584153_3_Ent2", "text": "Amprenavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12584153_3_Ent4", "text": "Amprenavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12584153_3_Ent3", "text": "HIV - infected", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "12584153_3_Ent0", "text": "children", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12584153_3_Ent1", "text": "children", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "12590235_2", "wnd_id": "12590235_2_1", "text": "Hepatotoxicity associated with 6 - thioguanine therapy for Crohn 's disease .", "tokens": ["Hepatotoxicity", "associated", "with", "6", "-", "thioguanine", "therapy", "for", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "12590235_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12590235_2_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "12590235_2_Ent1", "role": "Treatment", "text": "6 - thioguanine", "start": 3, "end": 6}, {"entity_id": "12590235_2_Ent2", "role": "Treatment_Drug", "text": "6 - thioguanine", "start": 3, "end": 6}, {"entity_id": "12590235_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12590235_2_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12590235_2_Ent1", "text": "6 - thioguanine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12590235_2_Ent2", "text": "6 - thioguanine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12590235_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12590235_5", "wnd_id": "12590235_5_1", "text": "We describe a case of significant elevation of serum transaminases in a patient treated with 6 - TG for a flare of Crohn 's disease .", "tokens": ["We", "describe", "a", "case", "of", "significant", "elevation", "of", "serum", "transaminases", "in", "a", "patient", "treated", "with", "6", "-", "TG", "for", "a", "flare", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "12590235_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elevation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12590235_5_Ent1", "role": "Effect", "text": "significant elevation of serum transaminases", "start": 5, "end": 10}, {"entity_id": "12590235_5_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "12590235_5_Ent2", "role": "Treatment", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent4", "role": "Treatment_Drug", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "12590235_5_Ent1", "text": "significant elevation of serum transaminases", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12590235_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12590235_5_Ent2", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent4", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "1261772_2", "wnd_id": "1261772_2_1", "text": "Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil .", "tokens": ["Fulminant", "hepatitis", "and", "lymphocyte", "sensitization", "due", "to", "propylthiouracil", "."], "event_mentions": [{"id": "1261772_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 5, "end": 6}, "arguments": [{"entity_id": "1261772_2_Ent0", "role": "Effect", "text": "Fulminant hepatitis", "start": 0, "end": 2}, {"entity_id": "1261772_2_Ent1", "role": "Effect", "text": "lymphocyte sensitization", "start": 3, "end": 5}, {"entity_id": "1261772_2_Ent2", "role": "Treatment", "text": "propylthiouracil", "start": 7, "end": 8}, {"entity_id": "1261772_2_Ent3", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1261772_2_Ent0", "text": "Fulminant hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1261772_2_Ent1", "text": "lymphocyte sensitization", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1261772_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1261772_2_Ent3", "text": "propylthiouracil", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12625995_1", "wnd_id": "12625995_1_1", "text": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents , particularly clozapine , and is easily misdiagnosed in children .", "tokens": ["Akathisia", "is", "a", "relatively", "rare", "side", "effect", "with", "the", "newer", "atypical", "antipsychotic", "agents", ",", "particularly", "clozapine", ",", "and", "is", "easily", "misdiagnosed", "in", "children", "."], "event_mentions": [{"id": "12625995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_1_Ent1", "role": "Effect", "text": "Akathisia", "start": 0, "end": 1}, {"entity_id": "12625995_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent0", "role": "Subject", "text": "children", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12625995_1_Ent1", "text": "Akathisia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent0", "text": "children", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12639299_1", "wnd_id": "12639299_1_1", "text": "Interferon - alpha ( IFN - alpha ) may precipitate or exacerbate the occurrence of MPGN .", "tokens": ["Interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "may", "precipitate", "or", "exacerbate", "the", "occurrence", "of", "MPGN", "."], "event_mentions": [{"id": "12639299_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 13, "end": 14}, "arguments": [{"entity_id": "12639299_1_Ent1", "role": "Treatment", "text": "Interferon - alpha ( IFN - alpha )", "start": 0, "end": 8}, {"entity_id": "12639299_1_Ent2", "role": "Treatment_Drug", "text": "Interferon - alpha ( IFN - alpha )", "start": 0, "end": 8}, {"entity_id": "12639299_1_Ent0", "role": "Effect", "text": "MPGN", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12639299_1_Ent1", "text": "Interferon - alpha ( IFN - alpha )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12639299_1_Ent2", "text": "Interferon - alpha ( IFN - alpha )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12639299_1_Ent0", "text": "MPGN", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12659609_3", "wnd_id": "12659609_3_1", "text": "CASE SUMMARY : A febrile 36 - year - old seaman from Mumbai ( Bombay ) was prescribed > 5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship .", "tokens": ["CASE", "SUMMARY", ":", "A", "febrile", "36", "-", "year", "-", "old", "seaman", "from", "Mumbai", "(", "Bombay", ")", "was", "prescribed", ">", "5", "times", "the", "usual", "dose", "of", "chloroquine", "for", "malaria", "diagnosed", "empirically", "onboard", "ship", "."], "event_mentions": [{"id": "12659609_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 17, "end": 18}, "arguments": [{"entity_id": "12659609_3_Ent0", "role": "Subject", "text": "A febrile 36 - year - old seaman from Mumbai ( Bombay )", "start": 3, "end": 16}, {"entity_id": "12659609_3_Ent1", "role": "Subject_Disorder", "text": "febrile", "start": 4, "end": 5}, {"entity_id": "12659609_3_Ent2", "role": "Subject_Age", "text": "36 - year - old", "start": 5, "end": 10}, {"entity_id": "12659609_3_Ent3", "role": "Subject_Race", "text": "Mumbai ( Bombay )", "start": 12, "end": 16}, {"entity_id": "12659609_3_Ent7", "role": "Treatment_Dosage", "text": "> 5 times the usual dose", "start": 18, "end": 24}, {"entity_id": "12659609_3_Ent4", "role": "Treatment", "text": "> 5 times the usual dose of chloroquine", "start": 18, "end": 26}, {"entity_id": "12659609_3_Ent6", "role": "Treatment_Drug", "text": "chloroquine", "start": 25, "end": 26}, {"entity_id": "12659609_3_Ent5", "role": "Treatment_Disorder", "text": "malaria", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12659609_3_Ent0", "text": "A febrile 36 - year - old seaman from Mumbai ( Bombay )", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "12659609_3_Ent1", "text": "febrile", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12659609_3_Ent2", "text": "36 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12659609_3_Ent3", "text": "Mumbai ( Bombay )", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12659609_3_Ent7", "text": "> 5 times the usual dose", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "12659609_3_Ent4", "text": "> 5 times the usual dose of chloroquine", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "12659609_3_Ent6", "text": "chloroquine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12659609_3_Ent5", "text": "malaria", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12659609_4", "wnd_id": "12659609_4_1", "text": "His fever resolved , but he developed symptoms consistent with those of chloroquine toxicity .", "tokens": ["His", "fever", "resolved", ",", "but", "he", "developed", "symptoms", "consistent", "with", "those", "of", "chloroquine", "toxicity", "."], "event_mentions": [{"id": "12659609_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12659609_4_Ent0", "role": "Subject", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent1", "role": "Subject_Gender", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent2", "role": "Effect", "text": "symptoms consistent with those of chloroquine toxicity", "start": 7, "end": 14}, {"entity_id": "12659609_4_Ent3", "role": "Treatment", "text": "chloroquine", "start": 12, "end": 13}, {"entity_id": "12659609_4_Ent4", "role": "Treatment_Drug", "text": "chloroquine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12659609_4_Ent0", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent1", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent2", "text": "symptoms consistent with those of chloroquine toxicity", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "12659609_4_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12659609_4_Ent4", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12661801_2", "wnd_id": "12661801_2_1", "text": "Treatment of carbimazole - induced agranulocytosis and sepsis with granulocyte colony stimulating factor .", "tokens": ["Treatment", "of", "carbimazole", "-", "induced", "agranulocytosis", "and", "sepsis", "with", "granulocyte", "colony", "stimulating", "factor", "."], "event_mentions": [{"id": "12661801_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment", "start": 0, "end": 1}, "arguments": [{"entity_id": "12661801_2_Ent1", "role": "Treatment_Disorder", "text": "carbimazole - induced agranulocytosis and sepsis", "start": 2, "end": 8}, {"entity_id": "12661801_2_Ent0", "role": "Treatment", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}, {"entity_id": "12661801_2_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "12661801_2_Ent1", "text": "carbimazole - induced agranulocytosis and sepsis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "12661801_2_Ent0", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12661801_2_Ent2", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "12692521_1", "wnd_id": "12692521_1_1", "text": "Systemic capillary leak syndrome after granulocyte colony - stimulating factor ( G - CSF ) .", "tokens": ["Systemic", "capillary", "leak", "syndrome", "after", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "12692521_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "12692521_1_Ent0", "role": "Effect", "text": "Systemic capillary leak syndrome", "start": 0, "end": 4}, {"entity_id": "12692521_1_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 5, "end": 10}, {"entity_id": "12692521_1_Ent1", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 5, "end": 15}]}], "entity_mentions": [{"id": "12692521_1_Ent0", "text": "Systemic capillary leak syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12692521_1_Ent2", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12692521_1_Ent1", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 5, "end": 15}], "lang": "en"}
{"doc_id": "12699871_2", "wnd_id": "12699871_2_1", "text": "Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss .", "tokens": ["Rapid", "identification", "of", "speech", "loss", "linked", "to", "FK506", "may", "be", "important", "because", "reduction", "or", "cessation", "of", "the", "drug", "may", "be", "associated", "with", "reverse", "of", "speech", "loss", "."], "event_mentions": [{"id": "12699871_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "linked", "start": 5, "end": 6}, "arguments": [{"entity_id": "12699871_2_Ent0", "role": "Effect", "text": "speech loss", "start": 3, "end": 5}, {"entity_id": "12699871_2_Ent1", "role": "Treatment", "text": "FK506", "start": 7, "end": 8}, {"entity_id": "12699871_2_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12699871_2_Ent0", "text": "speech loss", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12699871_2_Ent1", "text": "FK506", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12699871_2_Ent2", "text": "FK506", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12699871_3", "wnd_id": "12699871_3_1", "text": "Tacrolimus ( FK506 ) , an immunosuppressant , has been associated with mutism in adults after liver transplant .", "tokens": ["Tacrolimus", "(", "FK506", ")", ",", "an", "immunosuppressant", ",", "has", "been", "associated", "with", "mutism", "in", "adults", "after", "liver", "transplant", "."], "event_mentions": [{"id": "12699871_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 10, "end": 12}, "arguments": [{"entity_id": "12699871_3_Ent5", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "12699871_3_Ent4", "role": "Treatment", "text": "Tacrolimus ( FK506 ) , an immunosuppressant", "start": 0, "end": 7}, {"entity_id": "12699871_3_Ent3", "role": "Effect", "text": "mutism", "start": 12, "end": 13}, {"entity_id": "12699871_3_Ent1", "role": "Subject_Age", "text": "adults", "start": 14, "end": 15}, {"entity_id": "12699871_3_Ent0", "role": "Subject", "text": "adults after liver transplant", "start": 14, "end": 18}, {"entity_id": "12699871_3_Ent2", "role": "Subject_Disorder", "text": "liver transplant .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "12699871_3_Ent5", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12699871_3_Ent4", "text": "Tacrolimus ( FK506 ) , an immunosuppressant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12699871_3_Ent3", "text": "mutism", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12699871_3_Ent1", "text": "adults", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12699871_3_Ent0", "text": "adults after liver transplant", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "12699871_3_Ent2", "text": "liver transplant .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "12702914_4", "wnd_id": "12702914_4_1", "text": "We conjectured that the side effects of insulin , such as anti - natriuresis and increased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity , hyperinsulinaemia and hypoalbuminaemia .", "tokens": ["We", "conjectured", "that", "the", "side", "effects", "of", "insulin", ",", "such", "as", "anti", "-", "natriuresis", "and", "increased", "vascular", "permeability", ",", "might", "be", "pronounced", "in", "the", "presence", "of", "the", "hepatic", "dysfunction", "that", "accompanies", "insulin", "insensitivity", ",", "hyperinsulinaemia", "and", "hypoalbuminaemia", "."], "event_mentions": [{"id": "12702914_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 4, "end": 6}, "arguments": [{"entity_id": "12702914_4_Ent1", "role": "Treatment", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "12702914_4_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "12702914_4_Ent0", "role": "Effect", "text": "anti - natriuresis and increased vascular permeability", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "12702914_4_Ent1", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_4_Ent0", "text": "anti - natriuresis and increased vascular permeability", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "12763355_3", "wnd_id": "12763355_3_1", "text": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5 - ASA .", "tokens": ["This", "clinical", "course", "suggests", "that", "the", "sensorimotor", "polyneuropathy", "may", "have", "been", "caused", "by", "5", "-", "ASA", "."], "event_mentions": [{"id": "12763355_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "12763355_3_Ent0", "role": "Effect", "text": "sensorimotor polyneuropathy", "start": 6, "end": 8}, {"entity_id": "12763355_3_Ent1", "role": "Treatment", "text": "5 - ASA", "start": 13, "end": 16}, {"entity_id": "12763355_3_Ent2", "role": "Treatment_Drug", "text": "5 - ASA", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12763355_3_Ent0", "text": "sensorimotor polyneuropathy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12763355_3_Ent1", "text": "5 - ASA", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12763355_3_Ent2", "text": "5 - ASA", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12776809_4", "wnd_id": "12776809_4_1", "text": "Here , we report on the drug safety of coumarin with special respect to liver reaction .", "tokens": ["Here", ",", "we", "report", "on", "the", "drug", "safety", "of", "coumarin", "with", "special", "respect", "to", "liver", "reaction", "."], "event_mentions": [{"id": "12776809_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "respect", "start": 12, "end": 13}, "arguments": [{"entity_id": "12776809_4_Ent1", "role": "Treatment", "text": "coumarin", "start": 9, "end": 10}, {"entity_id": "12776809_4_Ent2", "role": "Treatment_Drug", "text": "coumarin", "start": 9, "end": 10}, {"entity_id": "12776809_4_Ent0", "role": "Effect", "text": "liver reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12776809_4_Ent1", "text": "coumarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12776809_4_Ent2", "text": "coumarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12776809_4_Ent0", "text": "liver reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12792223_3", "wnd_id": "12792223_3_1", "text": "Infliximab therapy may cause a lupus - like syndrome that is reversible upon discontinuing this agent .", "tokens": ["Infliximab", "therapy", "may", "cause", "a", "lupus", "-", "like", "syndrome", "that", "is", "reversible", "upon", "discontinuing", "this", "agent", "."], "event_mentions": [{"id": "12792223_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12792223_3_Ent2", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "12792223_3_Ent1", "role": "Treatment", "text": "Infliximab therapy", "start": 0, "end": 2}, {"entity_id": "12792223_3_Ent0", "role": "Effect", "text": "lupus - like syndrome", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "12792223_3_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12792223_3_Ent1", "text": "Infliximab therapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12792223_3_Ent0", "text": "lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "12796597_2", "wnd_id": "12796597_2_1", "text": "Despite the underlying hepatitis C , this case represents renal abnormalities consistent with IFNalpha therapy for CML .", "tokens": ["Despite", "the", "underlying", "hepatitis", "C", ",", "this", "case", "represents", "renal", "abnormalities", "consistent", "with", "IFNalpha", "therapy", "for", "CML", "."], "event_mentions": [{"id": "12796597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent", "start": 11, "end": 12}, "arguments": [{"entity_id": "12796597_2_Ent0", "role": "Subject", "text": "this case", "start": 6, "end": 8}, {"entity_id": "12796597_2_Ent1", "role": "Effect", "text": "renal abnormalities", "start": 9, "end": 11}, {"entity_id": "12796597_2_Ent3", "role": "Treatment_Drug", "text": "IFNalpha", "start": 13, "end": 14}, {"entity_id": "12796597_2_Ent2", "role": "Treatment", "text": "IFNalpha therapy", "start": 13, "end": 15}, {"entity_id": "12796597_2_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12796597_2_Ent0", "text": "this case", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12796597_2_Ent1", "text": "renal abnormalities", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12796597_2_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12796597_2_Ent2", "text": "IFNalpha therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12796597_2_Ent4", "text": "CML", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12796597_4", "wnd_id": "12796597_4_1", "text": "The renal biopsy showed focal segmental glomerulosclerosis , which has only been previously reported in two cases of CML treated with IFNalpha .", "tokens": ["The", "renal", "biopsy", "showed", "focal", "segmental", "glomerulosclerosis", ",", "which", "has", "only", "been", "previously", "reported", "in", "two", "cases", "of", "CML", "treated", "with", "IFNalpha", "."], "event_mentions": [{"id": "12796597_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 13, "end": 14}, "arguments": [{"entity_id": "12796597_4_Ent2", "role": "Effect", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "start": 0, "end": 7}, {"entity_id": "12796597_4_Ent1", "role": "Subject_Population", "text": "two", "start": 15, "end": 16}, {"entity_id": "12796597_4_Ent0", "role": "Subject", "text": "two cases", "start": 15, "end": 17}, {"entity_id": "12796597_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 18, "end": 19}, {"entity_id": "12796597_4_Ent3", "role": "Treatment", "text": "IFNalpha", "start": 21, "end": 22}, {"entity_id": "12796597_4_Ent5", "role": "Treatment_Drug", "text": "IFNalpha", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12796597_4_Ent2", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12796597_4_Ent1", "text": "two", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12796597_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12796597_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12796597_4_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12796597_4_Ent5", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12802933_2", "wnd_id": "12802933_2_1", "text": "The pathophysiological mechanisms remain unknown , although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab .", "tokens": ["The", "pathophysiological", "mechanisms", "remain", "unknown", ",", "although", "the", "drug", "could", "act", "through", "massive", "cytokines", "liberation", "after", "destruction", "of", "CD20", "positive", "cells", "by", "rituximab", "."], "event_mentions": [{"id": "12802933_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "act", "start": 10, "end": 11}, "arguments": [{"entity_id": "12802933_2_Ent0", "role": "Effect", "text": "massive cytokines liberation", "start": 12, "end": 15}, {"entity_id": "12802933_2_Ent1", "role": "Effect", "text": "destruction of CD20 positive cells", "start": 16, "end": 21}, {"entity_id": "12802933_2_Ent2", "role": "Treatment", "text": "rituximab", "start": 22, "end": 23}, {"entity_id": "12802933_2_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12802933_2_Ent0", "text": "massive cytokines liberation", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12802933_2_Ent1", "text": "destruction of CD20 positive cells", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "12802933_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12802933_2_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12802933_3", "wnd_id": "12802933_3_1", "text": "We report the first case , to our knowledge , of rituximab - related autoimmune hemolytic anemia .", "tokens": ["We", "report", "the", "first", "case", ",", "to", "our", "knowledge", ",", "of", "rituximab", "-", "related", "autoimmune", "hemolytic", "anemia", "."], "event_mentions": [{"id": "12802933_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "12802933_3_Ent1", "role": "Treatment", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent0", "role": "Effect", "text": "autoimmune hemolytic anemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "12802933_3_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent0", "text": "autoimmune hemolytic anemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "12836099_1", "wnd_id": "12836099_1_1", "text": "Stevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "in", "a", "boy", "with", "nephrotic", "syndrome", "during", "prednisolone", "therapy", "."], "event_mentions": [{"id": "12836099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "12836099_1_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "12836099_1_Ent0", "role": "Subject", "text": "a boy with nephrotic syndrome", "start": 5, "end": 10}, {"entity_id": "12836099_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12836099_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "12836099_1_Ent3", "role": "Treatment", "text": "prednisolone", "start": 11, "end": 12}, {"entity_id": "12836099_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12836099_1_Ent2", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12836099_1_Ent0", "text": "a boy with nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12836099_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12836099_1_Ent5", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12836099_1_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12836099_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12847760_1", "wnd_id": "12847760_1_1", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented .", "tokens": ["A", "25", "-", "year", "-", "old", "man", "with", "a", "history", "of", "mid", "-", "borderline", "(", "BB", ")", "Hansen", "'s", "disease", "developing", "a", "reversal", "reaction", "after", "starting", "dapsone", "and", "rifampin", "therapy", "is", "presented", "."], "event_mentions": [{"id": "12847760_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "12847760_1_Ent0", "role": "Subject", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease", "start": 0, "end": 20}, {"entity_id": "12847760_1_Ent1", "role": "Subject_Age", "text": "25 - year - old", "start": 1, "end": 6}, {"entity_id": "12847760_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12847760_1_Ent3", "role": "Subject_Disorder", "text": "mid - borderline ( BB ) Hansen 's disease", "start": 11, "end": 20}, {"entity_id": "12847760_1_Ent4", "role": "Effect", "text": "a reversal reaction", "start": 21, "end": 24}, {"entity_id": "12847760_1_Ent6", "role": "Treatment_Drug", "text": "dapsone", "start": 26, "end": 27}, {"entity_id": "12847760_1_Ent8", "role": "Combination_Drug", "text": "dapsone", "start": 26, "end": 27}, {"entity_id": "12847760_1_Ent5", "role": "Treatment", "text": "dapsone and rifampin therapy", "start": 26, "end": 30}, {"entity_id": "12847760_1_Ent7", "role": "Treatment_Drug", "text": "rifampin", "start": 28, "end": 29}, {"entity_id": "12847760_1_Ent9", "role": "Combination_Drug", "text": "rifampin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "12847760_1_Ent0", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "12847760_1_Ent1", "text": "25 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12847760_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12847760_1_Ent3", "text": "mid - borderline ( BB ) Hansen 's disease", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "12847760_1_Ent4", "text": "a reversal reaction", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "12847760_1_Ent6", "text": "dapsone", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12847760_1_Ent8", "text": "dapsone", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12847760_1_Ent5", "text": "dapsone and rifampin therapy", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "12847760_1_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12847760_1_Ent9", "text": "rifampin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "12854039_5", "wnd_id": "12854039_5_1", "text": "Multiple sclerosis - like disease secondary to alpha interferon .", "tokens": ["Multiple", "sclerosis", "-", "like", "disease", "secondary", "to", "alpha", "interferon", "."], "event_mentions": [{"id": "12854039_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 5, "end": 6}, "arguments": [{"entity_id": "12854039_5_Ent0", "role": "Effect", "text": "Multiple sclerosis - like disease", "start": 0, "end": 5}, {"entity_id": "12854039_5_Ent1", "role": "Treatment", "text": "alpha interferon", "start": 7, "end": 9}, {"entity_id": "12854039_5_Ent2", "role": "Treatment_Drug", "text": "alpha interferon", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12854039_5_Ent0", "text": "Multiple sclerosis - like disease", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12854039_5_Ent1", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12854039_5_Ent2", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12860350_1", "wnd_id": "12860350_1_1", "text": "Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen .", "tokens": ["Acute", "abdomen", "due", "to", "endometriosis", "in", "a", "premenopausal", "woman", "taking", "tamoxifen", "."], "event_mentions": [{"id": "12860350_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 9, "end": 10}, "arguments": [{"entity_id": "12860350_1_Ent0", "role": "Effect", "text": "Acute abdomen due to endometriosis", "start": 0, "end": 5}, {"entity_id": "12860350_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "12860350_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12860350_1_Ent0", "text": "Acute abdomen due to endometriosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12860350_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12860350_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12880504_2", "wnd_id": "12880504_2_1", "text": "Obsessive - compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation .", "tokens": ["Obsessive", "-", "compulsive", "symptoms", "suddenly", "emerged", "10", "days", "after", "starting", "risperidone", "and", "resolved", "within", "3", "days", "of", "discontinuation", "."], "event_mentions": [{"id": "12880504_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerged", "start": 5, "end": 6}, "arguments": [{"entity_id": "12880504_2_Ent0", "role": "Effect", "text": "Obsessive - compulsive symptoms", "start": 0, "end": 4}, {"entity_id": "12880504_2_Ent1", "role": "Treatment", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12880504_2_Ent2", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12880504_2_Ent0", "text": "Obsessive - compulsive symptoms", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12880504_2_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12880504_2_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12891225_2", "wnd_id": "12891225_2_1", "text": "Aprepitant is a neurokinin(1 ) receptor antagonist that enhances prevention of chemotherapy - induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist .", "tokens": ["Aprepitant", "is", "a", "neurokinin(1", ")", "receptor", "antagonist", "that", "enhances", "prevention", "of", "chemotherapy", "-", "induced", "nausea", "and", "vomiting", "when", "added", "to", "conventional", "therapy", "with", "a", "corticosteroid", "and", "a", "5", "-", "hydroxytryptamine(3", ")", "(", "5", "-", "HT(3", ")", ")", "antagonist", "."], "event_mentions": [{"id": "12891225_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhances", "start": 8, "end": 9}, "arguments": [{"entity_id": "12891225_2_Ent1", "role": "Treatment", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent3", "role": "Treatment_Drug", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent6", "role": "Combination_Drug", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent0", "role": "Effect", "text": "prevention of chemotherapy - induced nausea and vomiting", "start": 9, "end": 17}, {"entity_id": "12891225_2_Ent2", "role": "Treatment", "text": "added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 18, "end": 38}, {"entity_id": "12891225_2_Ent4", "role": "Treatment_Drug", "text": "corticosteroid", "start": 24, "end": 25}, {"entity_id": "12891225_2_Ent7", "role": "Combination_Drug", "text": "corticosteroid", "start": 24, "end": 25}, {"entity_id": "12891225_2_Ent5", "role": "Treatment_Drug", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 27, "end": 38}, {"entity_id": "12891225_2_Ent8", "role": "Combination_Drug", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 27, "end": 38}]}], "entity_mentions": [{"id": "12891225_2_Ent1", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent3", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent6", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent0", "text": "prevention of chemotherapy - induced nausea and vomiting", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "12891225_2_Ent2", "text": "added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 18, "end": 38}, {"id": "12891225_2_Ent4", "text": "corticosteroid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12891225_2_Ent7", "text": "corticosteroid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12891225_2_Ent5", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 27, "end": 38}, {"id": "12891225_2_Ent8", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 27, "end": 38}], "lang": "en"}
{"doc_id": "12923827_4", "wnd_id": "12923827_4_1", "text": "This finding suggests that fluvoxamine can precipitate Schneiderian first - rank symptoms in some susceptible patients .", "tokens": ["This", "finding", "suggests", "that", "fluvoxamine", "can", "precipitate", "Schneiderian", "first", "-", "rank", "symptoms", "in", "some", "susceptible", "patients", "."], "event_mentions": [{"id": "12923827_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_4_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_4_Ent0", "role": "Subject", "text": "some susceptible patients", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12923827_4_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_4_Ent0", "text": "some susceptible patients", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12932249_2", "wnd_id": "12932249_2_1", "text": "These skin lesions may be induced or worsened during antiviral therapy with interferon - alpha ( IFN ) .", "tokens": ["These", "skin", "lesions", "may", "be", "induced", "or", "worsened", "during", "antiviral", "therapy", "with", "interferon", "-", "alpha", "(", "IFN", ")", "."], "event_mentions": [{"id": "12932249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "12932249_2_Ent0", "role": "Effect", "text": "skin lesions", "start": 1, "end": 3}, {"entity_id": "12932249_2_Ent1", "role": "Treatment", "text": "antiviral therapy with interferon - alpha ( IFN )", "start": 9, "end": 18}, {"entity_id": "12932249_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha ( IFN ) .", "start": 12, "end": 19}]}], "entity_mentions": [{"id": "12932249_2_Ent0", "text": "skin lesions", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12932249_2_Ent1", "text": "antiviral therapy with interferon - alpha ( IFN )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12932249_2_Ent2", "text": "interferon - alpha ( IFN ) .", "entity_type": "Entity", "start": 12, "end": 19}], "lang": "en"}
{"doc_id": "12932249_3", "wnd_id": "12932249_3_1", "text": "We describe two dark - skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin .", "tokens": ["We", "describe", "two", "dark", "-", "skinned", "patients", "who", "developed", "hyperpigmented", "skin", "and", "tongue", "lesions", "during", "combination", "therapy", "with", "IFN", "and", "ribavirin", "."], "event_mentions": [{"id": "12932249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "12932249_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12932249_3_Ent0", "role": "Subject", "text": "two dark - skinned patients", "start": 2, "end": 7}, {"entity_id": "12932249_3_Ent2", "role": "Subject_Race", "text": "dark - skinned", "start": 3, "end": 6}, {"entity_id": "12932249_3_Ent3", "role": "Effect", "text": "hyperpigmented skin and tongue lesions", "start": 9, "end": 14}, {"entity_id": "12932249_3_Ent4", "role": "Treatment", "text": "combination therapy with IFN and ribavirin .", "start": 15, "end": 22}, {"entity_id": "12932249_3_Ent5", "role": "Treatment_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent7", "role": "Combination_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 20, "end": 21}, {"entity_id": "12932249_3_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12932249_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12932249_3_Ent0", "text": "two dark - skinned patients", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12932249_3_Ent2", "text": "dark - skinned", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12932249_3_Ent3", "text": "hyperpigmented skin and tongue lesions", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12932249_3_Ent4", "text": "combination therapy with IFN and ribavirin .", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "12932249_3_Ent5", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent7", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12932249_3_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12944250_3", "wnd_id": "12944250_3_1", "text": "Thrombocytosis under ciprofloxacin and tazobactam / piperacillin .", "tokens": ["Thrombocytosis", "under", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "."], "event_mentions": [{"id": "12944250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 1, "end": 2}, "arguments": [{"entity_id": "12944250_3_Ent0", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "12944250_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent1", "role": "Treatment", "text": "ciprofloxacin and tazobactam / piperacillin", "start": 2, "end": 7}, {"entity_id": "12944250_3_Ent3", "role": "Treatment_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent6", "role": "Combination_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent4", "role": "Treatment_Drug", "text": "piperacillin", "start": 6, "end": 7}, {"entity_id": "12944250_3_Ent7", "role": "Combination_Drug", "text": "piperacillin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12944250_3_Ent0", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12944250_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent1", "text": "ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12944250_3_Ent3", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent6", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent4", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12944250_3_Ent7", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12951892_2", "wnd_id": "12951892_2_1", "text": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range .", "tokens": ["The", "newborn", "manifested", "a", "four", "day", "course", "of", "lethargy", "with", "unexplained", "high", "lithium", "levels", "in", "the", "adult", "toxic", "range", "."], "event_mentions": [{"id": "12951892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 2, "end": 3}, "arguments": [{"entity_id": "12951892_2_Ent0", "role": "Subject", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent1", "role": "Subject_Age", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent2", "role": "Effect", "text": "four day course of lethargy with unexplained high lithium levels", "start": 4, "end": 14}, {"entity_id": "12951892_2_Ent3", "role": "Treatment", "text": "lithium", "start": 12, "end": 13}, {"entity_id": "12951892_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12951892_2_Ent0", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent1", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent2", "text": "four day course of lethargy with unexplained high lithium levels", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "12951892_2_Ent3", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12951892_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12962465_3", "wnd_id": "12962465_3_1", "text": "Isoniazid associated , painful , bilateral gynaecomastia .", "tokens": ["Isoniazid", "associated", ",", "painful", ",", "bilateral", "gynaecomastia", "."], "event_mentions": [{"id": "12962465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12962465_3_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12962465_3_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12962465_3_Ent0", "role": "Effect", "text": "painful , bilateral gynaecomastia", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "12962465_3_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12962465_3_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12962465_3_Ent0", "text": "painful , bilateral gynaecomastia", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "1310879_3", "wnd_id": "1310879_3_1", "text": "Heparin - associated thrombocytopenia : successful therapy with the heparinoid Org 10172 in a patient showing cross - reaction to LMW heparins .", "tokens": ["Heparin", "-", "associated", "thrombocytopenia", ":", "successful", "therapy", "with", "the", "heparinoid", "Org", "10172", "in", "a", "patient", "showing", "cross", "-", "reaction", "to", "LMW", "heparins", "."], "event_mentions": [{"id": "1310879_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1310879_3_Ent2", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent3", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "1310879_3_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "1310879_3_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent3", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1310879_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "1316047_1", "wnd_id": "1316047_1_1", "text": "Hemodynamic collapse following labetalol administration in preeclampsia .", "tokens": ["Hemodynamic", "collapse", "following", "labetalol", "administration", "in", "preeclampsia", "."], "event_mentions": [{"id": "1316047_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "1316047_1_Ent0", "role": "Effect", "text": "Hemodynamic collapse", "start": 0, "end": 2}, {"entity_id": "1316047_1_Ent1", "role": "Treatment", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent2", "role": "Treatment_Drug", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent3", "role": "Treatment_Disorder", "text": "preeclampsia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1316047_1_Ent0", "text": "Hemodynamic collapse", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1316047_1_Ent1", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent2", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent3", "text": "preeclampsia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1348483_2", "wnd_id": "1348483_2_1", "text": "Pleuropulmonary changes during treatment of Parkinson 's disease with a long - acting ergot derivative , cabergoline .", "tokens": ["Pleuropulmonary", "changes", "during", "treatment", "of", "Parkinson", "'s", "disease", "with", "a", "long", "-", "acting", "ergot", "derivative", ",", "cabergoline", "."], "event_mentions": [{"id": "1348483_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "1348483_2_Ent0", "role": "Effect", "text": "Pleuropulmonary changes", "start": 0, "end": 2}, {"entity_id": "1348483_2_Ent2", "role": "Treatment_Disorder", "text": "Parkinson 's disease", "start": 5, "end": 8}, {"entity_id": "1348483_2_Ent1", "role": "Treatment", "text": "cabergoline", "start": 16, "end": 17}, {"entity_id": "1348483_2_Ent3", "role": "Treatment_Drug", "text": "cabergoline", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1348483_2_Ent0", "text": "Pleuropulmonary changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1348483_2_Ent2", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1348483_2_Ent1", "text": "cabergoline", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1348483_2_Ent3", "text": "cabergoline", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1356045_1", "wnd_id": "1356045_1_1", "text": "Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium .", "tokens": ["Acute", "myopathy", "with", "selective", "degeneration", "of", "myosin", "filaments", "following", "status", "asthmaticus", "treated", "with", "methylprednisolone", "and", "vecuronium", "."], "event_mentions": [{"id": "1356045_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "1356045_1_Ent0", "role": "Effect", "text": "Acute myopathy with selective degeneration of myosin filaments", "start": 0, "end": 8}, {"entity_id": "1356045_1_Ent3", "role": "Treatment_Disorder", "text": "asthmaticus", "start": 10, "end": 11}, {"entity_id": "1356045_1_Ent1", "role": "Treatment", "text": "methylprednisolone", "start": 13, "end": 14}, {"entity_id": "1356045_1_Ent4", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 13, "end": 14}, {"entity_id": "1356045_1_Ent7", "role": "Combination_Drug", "text": "methylprednisolone", "start": 13, "end": 14}, {"entity_id": "1356045_1_Ent2", "role": "Treatment", "text": "vecuronium", "start": 15, "end": 16}, {"entity_id": "1356045_1_Ent5", "role": "Treatment_Drug", "text": "vecuronium", "start": 15, "end": 16}, {"entity_id": "1356045_1_Ent6", "role": "Combination_Drug", "text": "vecuronium", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "1356045_1_Ent0", "text": "Acute myopathy with selective degeneration of myosin filaments", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "1356045_1_Ent3", "text": "asthmaticus", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1356045_1_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1356045_1_Ent4", "text": "methylprednisolone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1356045_1_Ent7", "text": "methylprednisolone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1356045_1_Ent2", "text": "vecuronium", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1356045_1_Ent5", "text": "vecuronium", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1356045_1_Ent6", "text": "vecuronium", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1356045_2", "wnd_id": "1356045_2_1", "text": "Flaccid quadriparesis was noted after discontinuation of vecuronium .", "tokens": ["Flaccid", "quadriparesis", "was", "noted", "after", "discontinuation", "of", "vecuronium", "."], "event_mentions": [{"id": "1356045_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 3, "end": 4}, "arguments": [{"entity_id": "1356045_2_Ent0", "role": "Effect", "text": "Flaccid quadriparesis", "start": 0, "end": 2}, {"entity_id": "1356045_2_Ent1", "role": "Treatment", "text": "vecuronium", "start": 7, "end": 8}, {"entity_id": "1356045_2_Ent2", "role": "Treatment_Drug", "text": "vecuronium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1356045_2_Ent0", "text": "Flaccid quadriparesis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1356045_2_Ent1", "text": "vecuronium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1356045_2_Ent2", "text": "vecuronium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "13680140_1", "wnd_id": "13680140_1_1", "text": "Reversible sclerotic changes of lumbar spine and femur due to long - term oral isotretinoin therapy .", "tokens": ["Reversible", "sclerotic", "changes", "of", "lumbar", "spine", "and", "femur", "due", "to", "long", "-", "term", "oral", "isotretinoin", "therapy", "."], "event_mentions": [{"id": "13680140_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "13680140_1_Ent0", "role": "Effect", "text": "Reversible sclerotic changes of lumbar spine and femur", "start": 0, "end": 8}, {"entity_id": "13680140_1_Ent4", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "13680140_1_Ent1", "role": "Treatment", "text": "long - term oral isotretinoin", "start": 10, "end": 15}, {"entity_id": "13680140_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "13680140_1_Ent2", "role": "Treatment_Drug", "text": "isotretinoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "13680140_1_Ent0", "text": "Reversible sclerotic changes of lumbar spine and femur", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "13680140_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "13680140_1_Ent1", "text": "long - term oral isotretinoin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "13680140_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "13680140_1_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1378497_1", "wnd_id": "1378497_1_1", "text": "Although an association between exposure to bleomycin and the development of scleroderma has been suspected , few cases are reported .", "tokens": ["Although", "an", "association", "between", "exposure", "to", "bleomycin", "and", "the", "development", "of", "scleroderma", "has", "been", "suspected", ",", "few", "cases", "are", "reported", "."], "event_mentions": [{"id": "1378497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "1378497_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 6, "end": 7}, {"entity_id": "1378497_1_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 6, "end": 7}, {"entity_id": "1378497_1_Ent1", "role": "Effect", "text": "scleroderma", "start": 11, "end": 12}, {"entity_id": "1378497_1_Ent0", "role": "Subject", "text": "few cases", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1378497_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1378497_1_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1378497_1_Ent1", "text": "scleroderma", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1378497_1_Ent0", "text": "few cases", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "1401493_1", "wnd_id": "1401493_1_1", "text": "We report a case of acne fulminans occurring during treatment with 13 - cis - retinoic acid for cystic acne .", "tokens": ["We", "report", "a", "case", "of", "acne", "fulminans", "occurring", "during", "treatment", "with", "13", "-", "cis", "-", "retinoic", "acid", "for", "cystic", "acne", "."], "event_mentions": [{"id": "1401493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "1401493_1_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1401493_1_Ent1", "role": "Effect", "text": "acne fulminans", "start": 5, "end": 7}, {"entity_id": "1401493_1_Ent2", "role": "Treatment", "text": "13 - cis - retinoic acid", "start": 11, "end": 17}, {"entity_id": "1401493_1_Ent3", "role": "Treatment_Drug", "text": "13 - cis - retinoic acid", "start": 11, "end": 17}, {"entity_id": "1401493_1_Ent4", "role": "Treatment_Disorder", "text": "cystic acne", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "1401493_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1401493_1_Ent1", "text": "acne fulminans", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1401493_1_Ent2", "text": "13 - cis - retinoic acid", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "1401493_1_Ent3", "text": "13 - cis - retinoic acid", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "1401493_1_Ent4", "text": "cystic acne", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "1420650_3", "wnd_id": "1420650_3_1", "text": "We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .", "tokens": ["We", "consider", "asterixis", "to", "be", "an", "easily", "overlooked", "sign", "of", "neurotoxicity", ",", "which", "may", "occur", "even", "at", "low", "or", "moderate", "dosage", "levels", ",", "if", "certain", "drugs", "as", "lithium", "or", "clozapine", "are", "used", "in", "combination", "with", "CBZ", "."], "event_mentions": [{"id": "1420650_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 14, "end": 15}, "arguments": [{"entity_id": "1420650_3_Ent0", "role": "Effect", "text": "asterixis", "start": 2, "end": 3}, {"entity_id": "1420650_3_Ent1", "role": "Treatment", "text": "even at low or moderate dosage levels", "start": 15, "end": 22}, {"entity_id": "1420650_3_Ent6", "role": "Treatment_Dosage", "text": "low or moderate dosage", "start": 17, "end": 21}, {"entity_id": "1420650_3_Ent2", "role": "Treatment", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "start": 24, "end": 36}, {"entity_id": "1420650_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent10", "role": "Combination_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent3", "role": "Treatment_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent7", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent9", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "1420650_3_Ent0", "text": "asterixis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1420650_3_Ent1", "text": "even at low or moderate dosage levels", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1420650_3_Ent6", "text": "low or moderate dosage", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "1420650_3_Ent2", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "entity_type": "Entity", "start": 24, "end": 36}, {"id": "1420650_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent8", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent10", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent7", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent9", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "1422497_4", "wnd_id": "1422497_4_1", "text": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum .", "tokens": ["We", "report", "four", "cases", "of", "encephalopathy", "coincident", "with", "elevated", "aluminum", "levels", "as", "well", "as", "one", "patient", "who", "developed", "seizures", "while", "receiving", "continuous", "bladder", "irrigations", "with", "alum", "."], "event_mentions": [{"id": "1422497_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "1422497_4_Ent1", "role": "Subject_Population", "text": "one", "start": 14, "end": 15}, {"entity_id": "1422497_4_Ent0", "role": "Subject", "text": "one patient", "start": 14, "end": 16}, {"entity_id": "1422497_4_Ent2", "role": "Effect", "text": "seizures", "start": 18, "end": 19}, {"entity_id": "1422497_4_Ent3", "role": "Treatment", "text": "receiving continuous bladder irrigations with alum", "start": 20, "end": 26}, {"entity_id": "1422497_4_Ent4", "role": "Treatment_Drug", "text": "alum", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1422497_4_Ent1", "text": "one", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1422497_4_Ent0", "text": "one patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "1422497_4_Ent2", "text": "seizures", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1422497_4_Ent3", "text": "receiving continuous bladder irrigations with alum", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "1422497_4_Ent4", "text": "alum", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "14526130_1", "wnd_id": "14526130_1_1", "text": "Can roxithromycin and betamethasone induce acute pancreatitis ? A case report .", "tokens": ["Can", "roxithromycin", "and", "betamethasone", "induce", "acute", "pancreatitis", "?", "A", "case", "report", "."], "event_mentions": [{"id": "14526130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 4, "end": 5}, "arguments": [{"entity_id": "14526130_1_Ent2", "role": "Treatment_Drug", "text": "roxithromycin", "start": 1, "end": 2}, {"entity_id": "14526130_1_Ent4", "role": "Combination_Drug", "text": "roxithromycin", "start": 1, "end": 2}, {"entity_id": "14526130_1_Ent1", "role": "Treatment", "text": "roxithromycin and betamethasone", "start": 1, "end": 4}, {"entity_id": "14526130_1_Ent3", "role": "Treatment_Drug", "text": "betamethasone", "start": 3, "end": 4}, {"entity_id": "14526130_1_Ent5", "role": "Combination_Drug", "text": "betamethasone", "start": 3, "end": 4}, {"entity_id": "14526130_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "14526130_1_Ent2", "text": "roxithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14526130_1_Ent4", "text": "roxithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14526130_1_Ent1", "text": "roxithromycin and betamethasone", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "14526130_1_Ent3", "text": "betamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14526130_1_Ent5", "text": "betamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14526130_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "14530108_1", "wnd_id": "14530108_1_1", "text": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation : a case report .", "tokens": ["Renal", "tubular", "acidosis", "secondary", "to", "FK506", "in", "living", "donor", "liver", "transplantation", ":", "a", "case", "report", "."], "event_mentions": [{"id": "14530108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 3, "end": 4}, "arguments": [{"entity_id": "14530108_1_Ent1", "role": "Effect", "text": "Renal tubular acidosis", "start": 0, "end": 3}, {"entity_id": "14530108_1_Ent2", "role": "Treatment", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent0", "role": "Subject", "text": "a case", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14530108_1_Ent1", "text": "Renal tubular acidosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14530108_1_Ent2", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent3", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "14530108_4", "wnd_id": "14530108_4_1", "text": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated .", "tokens": ["The", "mechanism", "of", "RTA", "induced", "by", "FK506", "has", "not", "yet", "been", "clearly", "elucidated", "."], "event_mentions": [{"id": "14530108_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14530108_4_Ent0", "role": "Effect", "text": "RTA", "start": 3, "end": 4}, {"entity_id": "14530108_4_Ent1", "role": "Treatment", "text": "FK506", "start": 6, "end": 7}, {"entity_id": "14530108_4_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14530108_4_Ent0", "text": "RTA", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14530108_4_Ent1", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14530108_4_Ent2", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14530108_6", "wnd_id": "14530108_6_1", "text": "We report a case of RTA secondary to FK506 administration in liver transplantation .", "tokens": ["We", "report", "a", "case", "of", "RTA", "secondary", "to", "FK506", "administration", "in", "liver", "transplantation", "."], "event_mentions": [{"id": "14530108_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "14530108_6_Ent0", "role": "Subject", "text": "a case of RTA", "start": 2, "end": 6}, {"entity_id": "14530108_6_Ent1", "role": "Effect", "text": "RTA", "start": 5, "end": 6}, {"entity_id": "14530108_6_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 8, "end": 9}, {"entity_id": "14530108_6_Ent2", "role": "Treatment", "text": "FK506 administration in liver transplantation", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "14530108_6_Ent0", "text": "a case of RTA", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "14530108_6_Ent1", "text": "RTA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_6_Ent3", "text": "FK506", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14530108_6_Ent2", "text": "FK506 administration in liver transplantation", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "14557583_1", "wnd_id": "14557583_1_1", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease was evaluated for unintended sleep episodes that occurred after long - term treatment with 400 mg / day of L - dopa .", "tokens": ["A", "74", "-", "year", "-", "old", "patient", "with", "idiopathic", "Parkinson", "'s", "disease", "was", "evaluated", "for", "unintended", "sleep", "episodes", "that", "occurred", "after", "long", "-", "term", "treatment", "with", "400", "mg", "/", "day", "of", "L", "-", "dopa", "."], "event_mentions": [{"id": "14557583_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "14557583_1_Ent0", "role": "Subject", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease", "start": 0, "end": 12}, {"entity_id": "14557583_1_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "14557583_1_Ent4", "role": "Treatment_Disorder", "text": "idiopathic Parkinson 's disease", "start": 8, "end": 12}, {"entity_id": "14557583_1_Ent2", "role": "Effect", "text": "unintended sleep episodes", "start": 15, "end": 18}, {"entity_id": "14557583_1_Ent7", "role": "Treatment_Duration", "text": "long - term treatment", "start": 21, "end": 25}, {"entity_id": "14557583_1_Ent3", "role": "Treatment", "text": "long - term treatment with 400 mg / day of L - dopa", "start": 21, "end": 34}, {"entity_id": "14557583_1_Ent5", "role": "Treatment_Dosage", "text": "400 mg / day", "start": 26, "end": 30}, {"entity_id": "14557583_1_Ent6", "role": "Treatment_Drug", "text": "L - dopa", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "14557583_1_Ent0", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "14557583_1_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14557583_1_Ent4", "text": "idiopathic Parkinson 's disease", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "14557583_1_Ent2", "text": "unintended sleep episodes", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "14557583_1_Ent7", "text": "long - term treatment", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "14557583_1_Ent3", "text": "long - term treatment with 400 mg / day of L - dopa", "entity_type": "Entity", "start": 21, "end": 34}, {"id": "14557583_1_Ent5", "text": "400 mg / day", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "14557583_1_Ent6", "text": "L - dopa", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "14601701_4", "wnd_id": "14601701_4_1", "text": "We describe a 43 - year - old man who developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol .", "tokens": ["We", "describe", "a", "43", "-", "year", "-", "old", "man", "who", "developed", "signs", "and", "symptoms", "of", "bilateral", "optic", "neuropathy", "during", "treatment", "with", "ethambutol", "."], "event_mentions": [{"id": "14601701_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "14601701_4_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 3, "end": 8}, {"entity_id": "14601701_4_Ent0", "role": "Subject", "text": "43 - year - old man", "start": 3, "end": 9}, {"entity_id": "14601701_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "14601701_4_Ent3", "role": "Effect", "text": "bilateral optic neuropathy", "start": 15, "end": 18}, {"entity_id": "14601701_4_Ent4", "role": "Treatment", "text": "ethambutol", "start": 21, "end": 22}, {"entity_id": "14601701_4_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "14601701_4_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14601701_4_Ent0", "text": "43 - year - old man", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "14601701_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14601701_4_Ent3", "text": "bilateral optic neuropathy", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "14601701_4_Ent4", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14601701_4_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "14601701_5", "wnd_id": "14601701_5_1", "text": "This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring .", "tokens": ["This", "case", "and", "a", "review", "of", "the", "literature", "show", "the", "severe", "and", "unpredictable", "nature", "of", "ethambutol", "toxicity", "and", "its", "potential", "for", "irreversible", "vision", "loss", "despite", "careful", "ophthalmologic", "monitoring", "."], "event_mentions": [{"id": "14601701_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "unpredictable", "start": 12, "end": 13}, "arguments": [{"entity_id": "14601701_5_Ent1", "role": "Treatment", "text": "ethambutol", "start": 15, "end": 16}, {"entity_id": "14601701_5_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 15, "end": 16}, {"entity_id": "14601701_5_Ent0", "role": "Effect", "text": "irreversible vision loss", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "14601701_5_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14601701_5_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14601701_5_Ent0", "text": "irreversible vision loss", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "14641354_1", "wnd_id": "14641354_1_1", "text": "Angioedema and dysphagia caused by contact allergy to inhaled budesonide .", "tokens": ["Angioedema", "and", "dysphagia", "caused", "by", "contact", "allergy", "to", "inhaled", "budesonide", "."], "event_mentions": [{"id": "14641354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhaled", "start": 8, "end": 9}, "arguments": [{"entity_id": "14641354_1_Ent1", "role": "Effect", "text": "Angioedema and dysphagia", "start": 0, "end": 3}, {"entity_id": "14641354_1_Ent0", "role": "Effect", "text": "contact allergy", "start": 5, "end": 7}, {"entity_id": "14641354_1_Ent2", "role": "Treatment", "text": "budesonide", "start": 9, "end": 10}, {"entity_id": "14641354_1_Ent3", "role": "Treatment_Drug", "text": "budesonide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14641354_1_Ent1", "text": "Angioedema and dysphagia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14641354_1_Ent0", "text": "contact allergy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14641354_1_Ent2", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14641354_1_Ent3", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14674674_2", "wnd_id": "14674674_2_1", "text": "Infliximab - induced lupus in Crohn 's disease : a case report .", "tokens": ["Infliximab", "-", "induced", "lupus", "in", "Crohn", "'s", "disease", ":", "a", "case", "report", "."], "event_mentions": [{"id": "14674674_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14674674_2_Ent2", "role": "Treatment", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "14674674_2_Ent3", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "14674674_2_Ent1", "role": "Effect", "text": "lupus", "start": 3, "end": 4}, {"entity_id": "14674674_2_Ent0", "role": "Subject", "text": "a case", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14674674_2_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14674674_2_Ent3", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14674674_2_Ent1", "text": "lupus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14679124_1", "wnd_id": "14679124_1_1", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially : randomized phase III trial in postmenopausal node - positive breast cancer patients .", "tokens": ["Epirubicin", "-", "cyclophosphamide", "adjuvant", "chemotherapy", "plus", "tamoxifen", "administered", "concurrently", "versus", "sequentially", ":", "randomized", "phase", "III", "trial", "in", "postmenopausal", "node", "-", "positive", "breast", "cancer", "patients", "."], "event_mentions": [{"id": "14679124_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 7, "end": 8}, "arguments": [{"entity_id": "14679124_1_Ent3", "role": "Treatment_Drug", "text": "Epirubicin - cyclophosphamide", "start": 0, "end": 3}, {"entity_id": "14679124_1_Ent6", "role": "Combination_Drug", "text": "Epirubicin - cyclophosphamide", "start": 0, "end": 3}, {"entity_id": "14679124_1_Ent1", "role": "Treatment", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently", "start": 0, "end": 9}, {"entity_id": "14679124_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "14679124_1_Ent5", "role": "Combination_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "14679124_1_Ent0", "role": "Subject", "text": "postmenopausal node - positive breast cancer patients", "start": 17, "end": 24}, {"entity_id": "14679124_1_Ent4", "role": "Treatment_Disorder", "text": "node - positive breast cancer", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14679124_1_Ent3", "text": "Epirubicin - cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14679124_1_Ent6", "text": "Epirubicin - cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14679124_1_Ent1", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "14679124_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14679124_1_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14679124_1_Ent0", "text": "postmenopausal node - positive breast cancer patients", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "14679124_1_Ent4", "text": "node - positive breast cancer", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14684937_1", "wnd_id": "14684937_1_1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions , both the serum level of calcium and urinary excretion of calcium increased gradually .", "tokens": ["After", "initiation", "of", "topical", "vitamin", "D3", "ointment", "(", "20", "micro", "g", "/", "g", "of", "tacalcitol", ")", "10", "g", "/", "day", "for", "the", "skin", "lesions", ",", "both", "the", "serum", "level", "of", "calcium", "and", "urinary", "excretion", "of", "calcium", "increased", "gradually", "."], "event_mentions": [{"id": "14684937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 36, "end": 37}, "arguments": [{"entity_id": "14684937_1_Ent1", "role": "Treatment", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "start": 0, "end": 20}, {"entity_id": "14684937_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 3, "end": 4}, {"entity_id": "14684937_1_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_1_Ent5", "role": "Treatment_Dosage", "text": "20 micro g / g", "start": 8, "end": 13}, {"entity_id": "14684937_1_Ent6", "role": "Treatment_Dosage", "text": "10 g", "start": 16, "end": 18}, {"entity_id": "14684937_1_Ent7", "role": "Treatment_Freq", "text": "10 g / day", "start": 16, "end": 20}, {"entity_id": "14684937_1_Ent2", "role": "Treatment_Disorder", "text": "skin lesions ,", "start": 22, "end": 25}, {"entity_id": "14684937_1_Ent0", "role": "Effect", "text": "serum level of calcium and urinary excretion of calcium increased", "start": 27, "end": 37}]}], "entity_mentions": [{"id": "14684937_1_Ent1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "14684937_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_1_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_1_Ent5", "text": "20 micro g / g", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "14684937_1_Ent6", "text": "10 g", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "14684937_1_Ent7", "text": "10 g / day", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "14684937_1_Ent2", "text": "skin lesions ,", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "14684937_1_Ent0", "text": "serum level of calcium and urinary excretion of calcium increased", "entity_type": "Entity", "start": 27, "end": 37}], "lang": "en"}
{"doc_id": "14684937_4", "wnd_id": "14684937_4_1", "text": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide , respectively , resulting in hypercalciuria and hypercalcemia .", "tokens": ["We", "experienced", "a", "male", "patient", "with", "psoriasis", "and", "hypertension", "whose", "conditions", "were", "treated", "with", "tacalcitol", "ointment", "and", "thiazide", ",", "respectively", ",", "resulting", "in", "hypercalciuria", "and", "hypercalcemia", "."], "event_mentions": [{"id": "14684937_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 21, "end": 22}, "arguments": [{"entity_id": "14684937_4_Ent0", "role": "Subject", "text": "a male patient with psoriasis and hypertension", "start": 2, "end": 9}, {"entity_id": "14684937_4_Ent1", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "14684937_4_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 6, "end": 7}, {"entity_id": "14684937_4_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 8, "end": 9}, {"entity_id": "14684937_4_Ent6", "role": "Treatment_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent9", "role": "Combination_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent3", "role": "Treatment", "text": "tacalcitol ointment and thiazide", "start": 14, "end": 18}, {"entity_id": "14684937_4_Ent8", "role": "Treatment_Route", "text": "ointment", "start": 15, "end": 16}, {"entity_id": "14684937_4_Ent7", "role": "Treatment_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent10", "role": "Combination_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent2", "role": "Effect", "text": "hypercalciuria and hypercalcemia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "14684937_4_Ent0", "text": "a male patient with psoriasis and hypertension", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14684937_4_Ent1", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_4_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_4_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14684937_4_Ent6", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent9", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent3", "text": "tacalcitol ointment and thiazide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14684937_4_Ent8", "text": "ointment", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14684937_4_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent10", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent2", "text": "hypercalciuria and hypercalcemia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "14690166_2", "wnd_id": "14690166_2_1", "text": "There is currently no consensus on the best treatment for unresectable hyaline - vascular variant or for multicentric Castleman 's disease ( MCD ) , because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients In the present study , we report on the use of 2 - CdA ( 2 - chloro - deoxyadenosine ) in three patients , two of them with MCD and one with unresectable hyaline - vascular type disease .", "tokens": ["There", "is", "currently", "no", "consensus", "on", "the", "best", "treatment", "for", "unresectable", "hyaline", "-", "vascular", "variant", "or", "for", "multicentric", "Castleman", "'s", "disease", "(", "MCD", ")", ",", "because", "none", "of", "the", "reported", "regimens", "have", "consistently", "produced", "complete", "response", "or", "durable", "remission", "in", "the", "majority", "of", "patients", "In", "the", "present", "study", ",", "we", "report", "on", "the", "use", "of", "2", "-", "CdA", "(", "2", "-", "chloro", "-", "deoxyadenosine", ")", "in", "three", "patients", ",", "two", "of", "them", "with", "MCD", "and", "one", "with", "unresectable", "hyaline", "-", "vascular", "type", "disease", "."], "event_mentions": [{"id": "14690166_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "use", "start": 53, "end": 54}, "arguments": [{"entity_id": "14690166_2_Ent0", "role": "Subject", "text": "one", "start": 75, "end": 76}, {"entity_id": "14690166_2_Ent1", "role": "Subject_Population", "text": "one", "start": 75, "end": 76}]}, {"id": "14690166_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "use", "start": 53, "end": 54}, "arguments": [{"entity_id": "14690166_2_Ent6", "role": "Treatment_Drug", "text": "2 - CdA", "start": 55, "end": 58}, {"entity_id": "14690166_2_Ent7", "role": "Treatment_Drug", "text": "2 - CdA", "start": 55, "end": 58}, {"entity_id": "14690166_2_Ent4", "role": "Treatment", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "start": 55, "end": 65}, {"entity_id": "14690166_2_Ent5", "role": "Treatment", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "start": 55, "end": 65}, {"entity_id": "14690166_2_Ent2", "role": "Subject", "text": "two", "start": 69, "end": 70}, {"entity_id": "14690166_2_Ent3", "role": "Subject_Population", "text": "two", "start": 69, "end": 70}, {"entity_id": "14690166_2_Ent8", "role": "Treatment_Disorder", "text": "MCD", "start": 73, "end": 74}, {"entity_id": "14690166_2_Ent9", "role": "Treatment_Disorder", "text": "unresectable hyaline - vascular type disease", "start": 77, "end": 83}]}], "entity_mentions": [{"id": "14690166_2_Ent6", "text": "2 - CdA", "entity_type": "Entity", "start": 55, "end": 58}, {"id": "14690166_2_Ent7", "text": "2 - CdA", "entity_type": "Entity", "start": 55, "end": 58}, {"id": "14690166_2_Ent4", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "entity_type": "Entity", "start": 55, "end": 65}, {"id": "14690166_2_Ent5", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "entity_type": "Entity", "start": 55, "end": 65}, {"id": "14690166_2_Ent2", "text": "two", "entity_type": "Entity", "start": 69, "end": 70}, {"id": "14690166_2_Ent3", "text": "two", "entity_type": "Entity", "start": 69, "end": 70}, {"id": "14690166_2_Ent8", "text": "MCD", "entity_type": "Entity", "start": 73, "end": 74}, {"id": "14690166_2_Ent0", "text": "one", "entity_type": "Entity", "start": 75, "end": 76}, {"id": "14690166_2_Ent1", "text": "one", "entity_type": "Entity", "start": 75, "end": 76}, {"id": "14690166_2_Ent9", "text": "unresectable hyaline - vascular type disease", "entity_type": "Entity", "start": 77, "end": 83}], "lang": "en"}
{"doc_id": "14693027_1", "wnd_id": "14693027_1_1", "text": "All patients had taken phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the skin lesions first appeared .", "tokens": ["All", "patients", "had", "taken", "phenytoin", "for", "variable", "time", "periods", "(", "range", "16", "-", "80", "days", ";", "mean", ":", "40", ")", "and", "were", "on", "the", "medication", "when", "the", "skin", "lesions", "first", "appeared", "."], "event_mentions": [{"id": "14693027_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 30, "end": 31}, "arguments": [{"entity_id": "14693027_1_Ent0", "role": "Subject", "text": "All patients", "start": 0, "end": 2}, {"entity_id": "14693027_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "14693027_1_Ent2", "role": "Treatment", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "start": 4, "end": 20}, {"entity_id": "14693027_1_Ent4", "role": "Treatment_Duration", "text": "16 - 80 days ;", "start": 11, "end": 16}, {"entity_id": "14693027_1_Ent5", "role": "Treatment_Duration", "text": "40", "start": 18, "end": 19}, {"entity_id": "14693027_1_Ent1", "role": "Effect", "text": "skin lesions", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "14693027_1_Ent0", "text": "All patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14693027_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14693027_1_Ent2", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "entity_type": "Entity", "start": 4, "end": 20}, {"id": "14693027_1_Ent4", "text": "16 - 80 days ;", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "14693027_1_Ent5", "text": "40", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "14693027_1_Ent1", "text": "skin lesions", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "14697943_1", "wnd_id": "14697943_1_1", "text": "In conclusion , RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or tacrolimus ) , even under monotherapy or with a low steroid dose .", "tokens": ["In", "conclusion", ",", "RSDS", "is", "a", "relevant", "osteoarticular", "complication", "in", "patients", "receiving", "either", "anticalcineurinic", "drug", "(", "CyA", "or", "tacrolimus", ")", ",", "even", "under", "monotherapy", "or", "with", "a", "low", "steroid", "dose", "."], "event_mentions": [{"id": "14697943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "osteoarticular complication", "start": 7, "end": 9}, "arguments": [{"entity_id": "14697943_1_Ent0", "role": "Effect", "text": "RSDS", "start": 3, "end": 4}, {"entity_id": "14697943_1_Ent1", "role": "Treatment", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "start": 13, "end": 20}, {"entity_id": "14697943_1_Ent2", "role": "Treatment_Drug", "text": "CyA", "start": 16, "end": 17}, {"entity_id": "14697943_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14697943_1_Ent0", "text": "RSDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14697943_1_Ent1", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "14697943_1_Ent2", "text": "CyA", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "14697943_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14740795_2", "wnd_id": "14740795_2_1", "text": "Amifostine - induced fever : case report and review of the literature .", "tokens": ["Amifostine", "-", "induced", "fever", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "14740795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14740795_2_Ent1", "role": "Treatment", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent2", "role": "Treatment_Drug", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14740795_2_Ent1", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent2", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14740795_3", "wnd_id": "14740795_3_1", "text": "Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction , as well as for sepsis and fevers of neutropenia , and it may be necessary to discontinue the drug .", "tokens": ["Patients", "receiving", "amifostine", "who", "develop", "only", "fever", "should", "be", "evaluated", "for", "an", "adverse", "drug", "reaction", ",", "as", "well", "as", "for", "sepsis", "and", "fevers", "of", "neutropenia", ",", "and", "it", "may", "be", "necessary", "to", "discontinue", "the", "drug", "."], "event_mentions": [{"id": "14740795_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 4, "end": 5}, "arguments": [{"entity_id": "14740795_3_Ent2", "role": "Treatment", "text": "amifostine", "start": 2, "end": 3}, {"entity_id": "14740795_3_Ent3", "role": "Treatment_Drug", "text": "amifostine", "start": 2, "end": 3}, {"entity_id": "14740795_3_Ent0", "role": "Effect", "text": "fever", "start": 6, "end": 7}, {"entity_id": "14740795_3_Ent1", "role": "Effect", "text": "sepsis and fevers of neutropenia", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "14740795_3_Ent2", "text": "amifostine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14740795_3_Ent3", "text": "amifostine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14740795_3_Ent0", "text": "fever", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14740795_3_Ent1", "text": "sepsis and fevers of neutropenia", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "14742791_2", "wnd_id": "14742791_2_1", "text": "After 5 weeks of therapy , she stopped taking pantoprazole due to general malaise .", "tokens": ["After", "5", "weeks", "of", "therapy", ",", "she", "stopped", "taking", "pantoprazole", "due", "to", "general", "malaise", "."], "event_mentions": [{"id": "14742791_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 10, "end": 12}, "arguments": [{"entity_id": "14742791_2_Ent2", "role": "Treatment", "text": "After 5 weeks of therapy", "start": 0, "end": 5}, {"entity_id": "14742791_2_Ent3", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 1, "end": 3}, {"entity_id": "14742791_2_Ent1", "role": "Treatment", "text": "taking pantoprazole", "start": 8, "end": 10}, {"entity_id": "14742791_2_Ent4", "role": "Treatment_Drug", "text": "pantoprazole", "start": 9, "end": 10}, {"entity_id": "14742791_2_Ent0", "role": "Effect", "text": "general malaise", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14742791_2_Ent2", "text": "After 5 weeks of therapy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14742791_2_Ent3", "text": "5 weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14742791_2_Ent1", "text": "taking pantoprazole", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14742791_2_Ent4", "text": "pantoprazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14742791_2_Ent0", "text": "general malaise", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "14968106_1", "wnd_id": "14968106_1_1", "text": "CONCLUSION : This is , to our knowledge , the first report of severe myelopathy following accidental intrathecal administration of doxorubicin .", "tokens": ["CONCLUSION", ":", "This", "is", ",", "to", "our", "knowledge", ",", "the", "first", "report", "of", "severe", "myelopathy", "following", "accidental", "intrathecal", "administration", "of", "doxorubicin", "."], "event_mentions": [{"id": "14968106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "14968106_1_Ent0", "role": "Effect", "text": "severe myelopathy", "start": 13, "end": 15}, {"entity_id": "14968106_1_Ent3", "role": "Treatment_Route", "text": "intrathecal administration", "start": 17, "end": 19}, {"entity_id": "14968106_1_Ent1", "role": "Treatment", "text": "intrathecal administration of doxorubicin", "start": 17, "end": 21}, {"entity_id": "14968106_1_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14968106_1_Ent0", "text": "severe myelopathy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14968106_1_Ent3", "text": "intrathecal administration", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14968106_1_Ent1", "text": "intrathecal administration of doxorubicin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "14968106_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14996269_2", "wnd_id": "14996269_2_1", "text": "We describe two ELBW infants affected by hyperkalaemia , treated with Kayexalate , who developed serious hypernatraemia , that has never been reported before in preterm infants .", "tokens": ["We", "describe", "two", "ELBW", "infants", "affected", "by", "hyperkalaemia", ",", "treated", "with", "Kayexalate", ",", "who", "developed", "serious", "hypernatraemia", ",", "that", "has", "never", "been", "reported", "before", "in", "preterm", "infants", "."], "event_mentions": [{"id": "14996269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "14996269_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "14996269_2_Ent0", "role": "Subject", "text": "two ELBW infants affected by hyperkalaemia", "start": 2, "end": 8}, {"entity_id": "14996269_2_Ent3", "role": "Subject_Disorder", "text": "ELBW", "start": 3, "end": 4}, {"entity_id": "14996269_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 4, "end": 5}, {"entity_id": "14996269_2_Ent6", "role": "Treatment_Disorder", "text": "hyperkalaemia", "start": 7, "end": 8}, {"entity_id": "14996269_2_Ent5", "role": "Treatment", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent4", "role": "Effect", "text": "serious hypernatraemia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14996269_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14996269_2_Ent0", "text": "two ELBW infants affected by hyperkalaemia", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "14996269_2_Ent3", "text": "ELBW", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14996269_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14996269_2_Ent6", "text": "hyperkalaemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14996269_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent4", "text": "serious hypernatraemia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15013892_1", "wnd_id": "15013892_1_1", "text": "Bull's - eye maculopathy associated with quinacrine therapy for malaria .", "tokens": ["Bull's", "-", "eye", "maculopathy", "associated", "with", "quinacrine", "therapy", "for", "malaria", "."], "event_mentions": [{"id": "15013892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_1_Ent0", "role": "Effect", "text": "Bull's - eye maculopathy", "start": 0, "end": 4}, {"entity_id": "15013892_1_Ent1", "role": "Treatment", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent2", "role": "Treatment_Drug", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent3", "role": "Treatment_Disorder", "text": "malaria", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15013892_1_Ent0", "text": "Bull's - eye maculopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15013892_1_Ent1", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent2", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent3", "text": "malaria", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15013892_2", "wnd_id": "15013892_2_1", "text": "CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed , severe maculopathy indistinguishable from chloroquine maculopathy in certain patients .", "tokens": ["CONCLUSIONS", ":", "Low", "dosages", "of", "quinacrine", "used", "for", "malaria", "prophylaxis", "can", "be", "associated", "with", "a", "delayed", ",", "severe", "maculopathy", "indistinguishable", "from", "chloroquine", "maculopathy", "in", "certain", "patients", "."], "event_mentions": [{"id": "15013892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "15013892_2_Ent3", "role": "Treatment_Dosage", "text": "Low dosages", "start": 2, "end": 4}, {"entity_id": "15013892_2_Ent1", "role": "Treatment", "text": "Low dosages of quinacrine used for malaria prophylaxis", "start": 2, "end": 10}, {"entity_id": "15013892_2_Ent4", "role": "Treatment_Drug", "text": "quinacrine", "start": 5, "end": 6}, {"entity_id": "15013892_2_Ent5", "role": "Treatment_Disorder", "text": "malaria prophylaxis", "start": 8, "end": 10}, {"entity_id": "15013892_2_Ent0", "role": "Effect", "text": "a delayed , severe maculopathy", "start": 14, "end": 19}, {"entity_id": "15013892_2_Ent2", "role": "Treatment_Time_elapsed", "text": "delayed", "start": 15, "end": 16}]}, {"id": "15013892_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "15013892_2_Ent10", "role": "Treatment_Dosage", "text": "Low dosages", "start": 2, "end": 4}, {"entity_id": "15013892_2_Ent8", "role": "Treatment", "text": "Low dosages of quinacrine used for malaria prophylaxis", "start": 2, "end": 10}, {"entity_id": "15013892_2_Ent11", "role": "Treatment_Drug", "text": "quinacrine", "start": 5, "end": 6}, {"entity_id": "15013892_2_Ent12", "role": "Treatment_Disorder", "text": "malaria prophylaxis", "start": 8, "end": 10}, {"entity_id": "15013892_2_Ent9", "role": "Treatment_Time_elapsed", "text": "delayed", "start": 15, "end": 16}, {"entity_id": "15013892_2_Ent7", "role": "Effect", "text": "chloroquine maculopathy", "start": 21, "end": 23}, {"entity_id": "15013892_2_Ent6", "role": "Subject", "text": "certain patients .", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "15013892_2_Ent3", "text": "Low dosages", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_2_Ent10", "text": "Low dosages", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_2_Ent1", "text": "Low dosages of quinacrine used for malaria prophylaxis", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15013892_2_Ent8", "text": "Low dosages of quinacrine used for malaria prophylaxis", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15013892_2_Ent4", "text": "quinacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15013892_2_Ent11", "text": "quinacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15013892_2_Ent5", "text": "malaria prophylaxis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15013892_2_Ent12", "text": "malaria prophylaxis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15013892_2_Ent0", "text": "a delayed , severe maculopathy", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "15013892_2_Ent2", "text": "delayed", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15013892_2_Ent9", "text": "delayed", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15013892_2_Ent7", "text": "chloroquine maculopathy", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15013892_2_Ent6", "text": "certain patients .", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "15013892_3", "wnd_id": "15013892_3_1", "text": "RESULTS : A patient developed a bilaterally symmetric bull's - eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria .", "tokens": ["RESULTS", ":", "A", "patient", "developed", "a", "bilaterally", "symmetric", "bull's", "-", "eye", "maculopathy", "45", "years", "after", "taking", "quinacrine", "for", "18", "months", "as", "prophylaxis", "against", "malaria", "."], "event_mentions": [{"id": "15013892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_3_Ent0", "role": "Effect", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "15013892_3_Ent1", "role": "Effect", "text": "bilaterally symmetric bull's - eye maculopathy", "start": 6, "end": 12}, {"entity_id": "15013892_3_Ent3", "role": "Treatment_Time_elapsed", "text": "45 years after", "start": 12, "end": 15}, {"entity_id": "15013892_3_Ent2", "role": "Treatment", "text": "45 years after taking quinacrine for 18 months", "start": 12, "end": 20}, {"entity_id": "15013892_3_Ent5", "role": "Treatment_Drug", "text": "quinacrine", "start": 16, "end": 17}, {"entity_id": "15013892_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 18, "end": 20}, {"entity_id": "15013892_3_Ent6", "role": "Treatment_Disorder", "text": "malaria", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15013892_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_3_Ent1", "text": "bilaterally symmetric bull's - eye maculopathy", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15013892_3_Ent3", "text": "45 years after", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15013892_3_Ent2", "text": "45 years after taking quinacrine for 18 months", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15013892_3_Ent5", "text": "quinacrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15013892_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15013892_3_Ent6", "text": "malaria", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15028328_2", "wnd_id": "15028328_2_1", "text": "Phenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other neurologic events .", "tokens": ["Phenylpropanolamine", "(", "PPA", ")", "recently", "has", "been", "publicly", "implicated", "as", "a", "cause", "of", "stroke", "and", "other", "neurologic", "events", "."], "event_mentions": [{"id": "15028328_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "15028328_2_Ent2", "role": "Treatment_Drug", "text": "Phenylpropanolamine", "start": 0, "end": 1}, {"entity_id": "15028328_2_Ent1", "role": "Treatment", "text": "Phenylpropanolamine ( PPA )", "start": 0, "end": 4}, {"entity_id": "15028328_2_Ent0", "role": "Effect", "text": "stroke and other neurologic events", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "15028328_2_Ent2", "text": "Phenylpropanolamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15028328_2_Ent1", "text": "Phenylpropanolamine ( PPA )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15028328_2_Ent0", "text": "stroke and other neurologic events", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "15028964_5", "wnd_id": "15028964_5_1", "text": "We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone - induced thyrotoxicosis heralded by a significant decrease in warfarin requirements .", "tokens": ["We", "describe", "3", "patients", "on", "concomitant", "amiodarone", "and", "warfarin", "who", "developed", "amiodarone", "-", "induced", "thyrotoxicosis", "heralded", "by", "a", "significant", "decrease", "in", "warfarin", "requirements", "."], "event_mentions": [{"id": "15028964_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15028964_5_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "15028964_5_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "15028964_5_Ent3", "role": "Treatment", "text": "concomitant amiodarone and warfarin", "start": 5, "end": 9}, {"entity_id": "15028964_5_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "15028964_5_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "15028964_5_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "15028964_5_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "15028964_5_Ent2", "role": "Effect", "text": "amiodarone - induced thyrotoxicosis", "start": 11, "end": 15}]}, {"id": "15028964_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "15028964_5_Ent9", "role": "Treatment", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_5_Ent10", "role": "Treatment_Drug", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_5_Ent8", "role": "Effect", "text": "thyrotoxicosis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15028964_5_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15028964_5_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15028964_5_Ent3", "text": "concomitant amiodarone and warfarin", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "15028964_5_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15028964_5_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15028964_5_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028964_5_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028964_5_Ent9", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_5_Ent10", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_5_Ent2", "text": "amiodarone - induced thyrotoxicosis", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15028964_5_Ent8", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1504404_4", "wnd_id": "1504404_4_1", "text": "OBJECTIVE : To report a case of ciprofloxacin - induced psychosis and to discuss occurrence rates , risk factors , possible etiologies , preventive measures , and treatment courses for this adverse reaction .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "ciprofloxacin", "-", "induced", "psychosis", "and", "to", "discuss", "occurrence", "rates", ",", "risk", "factors", ",", "possible", "etiologies", ",", "preventive", "measures", ",", "and", "treatment", "courses", "for", "this", "adverse", "reaction", "."], "event_mentions": [{"id": "1504404_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "1504404_4_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "1504404_4_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "1504404_4_Ent0", "role": "Effect", "text": "psychosis", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "1504404_4_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1504404_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1504404_4_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "15053046_1", "wnd_id": "15053046_1_1", "text": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD .", "tokens": ["Agranulocytosis", "induced", "by", "vancomycin", "in", "an", "ESRD", "patient", "on", "CAPD", "."], "event_mentions": [{"id": "15053046_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "15053046_1_Ent2", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "15053046_1_Ent3", "role": "Treatment", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "15053046_1_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "15053046_1_Ent1", "role": "Subject_Disorder", "text": "ESRD", "start": 6, "end": 7}, {"entity_id": "15053046_1_Ent0", "role": "Subject", "text": "ESRD patient on CAPD", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "15053046_1_Ent2", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15053046_1_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15053046_1_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15053046_1_Ent1", "text": "ESRD", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15053046_1_Ent0", "text": "ESRD patient on CAPD", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "15053046_2", "wnd_id": "15053046_2_1", "text": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy , and is potentially serious , especially in end stage renal disease ( ESRD ) patients .", "tokens": ["Agranulocytosis", "is", "a", "rare", "adverse", "effect", "associated", "with", "prolonged", "vancomycin", "therapy", ",", "and", "is", "potentially", "serious", ",", "especially", "in", "end", "stage", "renal", "disease", "(", "ESRD", ")", "patients", "."], "event_mentions": [{"id": "15053046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15053046_2_Ent1", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "15053046_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 8, "end": 9}, {"entity_id": "15053046_2_Ent2", "role": "Treatment", "text": "prolonged vancomycin therapy", "start": 8, "end": 11}, {"entity_id": "15053046_2_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 9, "end": 10}, {"entity_id": "15053046_2_Ent5", "role": "Treatment_Disorder", "text": "end stage renal disease ( ESRD )", "start": 19, "end": 26}, {"entity_id": "15053046_2_Ent0", "role": "Subject", "text": "end stage renal disease ( ESRD ) patients", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "15053046_2_Ent1", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15053046_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15053046_2_Ent2", "text": "prolonged vancomycin therapy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15053046_2_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15053046_2_Ent5", "text": "end stage renal disease ( ESRD )", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15053046_2_Ent0", "text": "end stage renal disease ( ESRD ) patients", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "15061230_1", "wnd_id": "15061230_1_1", "text": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients .", "tokens": ["It", "is", "very", "likely", "that", "the", "dexamethasone", "used", "in", "the", "antiemetic", "drug", "regimen", "contributed", "to", "the", "development", "of", "osteonecrosis", "in", "these", "patients", "."], "event_mentions": [{"id": "15061230_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 13, "end": 14}, "arguments": [{"entity_id": "15061230_1_Ent2", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "15061230_1_Ent3", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "15061230_1_Ent1", "role": "Effect", "text": "osteonecrosis", "start": 18, "end": 19}, {"entity_id": "15061230_1_Ent0", "role": "Subject", "text": "these patients", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "15061230_1_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15061230_1_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15061230_1_Ent1", "text": "osteonecrosis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15061230_1_Ent0", "text": "these patients", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "15061230_3", "wnd_id": "15061230_3_1", "text": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug .", "tokens": ["Patients", "should", "be", "informed", "about", "the", "risk", "of", "osteonecrosis", "when", "taking", "dexamethasone", "as", "an", "antiemetic", "drug", "."], "event_mentions": [{"id": "15061230_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 6, "end": 7}, "arguments": [{"entity_id": "15061230_3_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "15061230_3_Ent1", "role": "Effect", "text": "osteonecrosis", "start": 8, "end": 9}, {"entity_id": "15061230_3_Ent2", "role": "Treatment", "text": "dexamethasone", "start": 11, "end": 12}, {"entity_id": "15061230_3_Ent3", "role": "Treatment_Drug", "text": "dexamethasone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15061230_3_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15061230_3_Ent1", "text": "osteonecrosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15061230_3_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15061230_3_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15072497_1", "wnd_id": "15072497_1_1", "text": "Development of Peyronie 's disease during long - term colchicine treatment .", "tokens": ["Development", "of", "Peyronie", "'s", "disease", "during", "long", "-", "term", "colchicine", "treatment", "."], "event_mentions": [{"id": "15072497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "15072497_1_Ent0", "role": "Effect", "text": "Peyronie 's disease", "start": 2, "end": 5}, {"entity_id": "15072497_1_Ent3", "role": "Treatment_Freq", "text": "long - term", "start": 6, "end": 9}, {"entity_id": "15072497_1_Ent1", "role": "Treatment", "text": "long - term colchicine treatment", "start": 6, "end": 11}, {"entity_id": "15072497_1_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15072497_1_Ent0", "text": "Peyronie 's disease", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15072497_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15072497_1_Ent1", "text": "long - term colchicine treatment", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15072497_1_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15112258_14", "wnd_id": "15112258_14_1", "text": "In contrast , other common agents for the most part trigger cutaneous inflammation .", "tokens": ["In", "contrast", ",", "other", "common", "agents", "for", "the", "most", "part", "trigger", "cutaneous", "inflammation", "."], "event_mentions": [{"id": "15112258_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 10, "end": 11}, "arguments": [{"entity_id": "15112258_14_Ent2", "role": "Treatment_Drug", "text": "other common agents", "start": 3, "end": 6}, {"entity_id": "15112258_14_Ent1", "role": "Treatment", "text": "other common agents for the most part", "start": 3, "end": 10}, {"entity_id": "15112258_14_Ent0", "role": "Effect", "text": "cutaneous inflammation", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15112258_14_Ent2", "text": "other common agents", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15112258_14_Ent1", "text": "other common agents for the most part", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "15112258_14_Ent0", "text": "cutaneous inflammation", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15126179_2", "wnd_id": "15126179_2_1", "text": "METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema .", "tokens": ["METHODS", ":", "A", "68", "-", "year", "-", "old", "man", "developed", "intense", "conjunctival", "hyperemia", "and", "cystoid", "macula", "edema", "after", "switching", "from", "latanoprost", "to", "bimatoprost", "9", "months", "after", "cataract", "surgery", "in", "an", "eye", "at", "low", "-", "risk", "for", "this", "cystoid", "macular", "edema", "."], "event_mentions": [{"id": "15126179_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "15126179_2_Ent0", "role": "Subject", "text": "A 68 - year - old man", "start": 2, "end": 9}, {"entity_id": "15126179_2_Ent1", "role": "Subject_Age", "text": "68 - year - old", "start": 3, "end": 8}, {"entity_id": "15126179_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "15126179_2_Ent3", "role": "Effect", "text": "intense conjunctival hyperemia and cystoid macula edema", "start": 10, "end": 17}, {"entity_id": "15126179_2_Ent4", "role": "Treatment", "text": "bimatoprost", "start": 22, "end": 23}, {"entity_id": "15126179_2_Ent6", "role": "Treatment_Drug", "text": "bimatoprost", "start": 22, "end": 23}, {"entity_id": "15126179_2_Ent5", "role": "Treatment_Disorder", "text": "cataract surgery", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "15126179_2_Ent0", "text": "A 68 - year - old man", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "15126179_2_Ent1", "text": "68 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15126179_2_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15126179_2_Ent3", "text": "intense conjunctival hyperemia and cystoid macula edema", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15126179_2_Ent4", "text": "bimatoprost", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15126179_2_Ent6", "text": "bimatoprost", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15126179_2_Ent5", "text": "cataract surgery", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "15133245_3", "wnd_id": "15133245_3_1", "text": "Recently , it has been reported that terfenadine and astemizole , which have antiallergic actions similar to those of oxatomide , show side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest .", "tokens": ["Recently", ",", "it", "has", "been", "reported", "that", "terfenadine", "and", "astemizole", ",", "which", "have", "antiallergic", "actions", "similar", "to", "those", "of", "oxatomide", ",", "show", "side", "effects", "on", "the", "cardiovascular", "system", ",", "such", "as", "QT", "prolongation", ",", "ventricular", "arrhythmia", "and", "cardiac", "arrest", "."], "event_mentions": [{"id": "15133245_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "show", "start": 21, "end": 22}, "arguments": [{"entity_id": "15133245_3_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent4", "role": "Combination_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent1", "role": "Treatment", "text": "terfenadine and astemizole", "start": 7, "end": 10}, {"entity_id": "15133245_3_Ent3", "role": "Treatment_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent5", "role": "Combination_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent0", "role": "Effect", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "start": 22, "end": 39}]}], "entity_mentions": [{"id": "15133245_3_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent4", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent1", "text": "terfenadine and astemizole", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15133245_3_Ent3", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent5", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent0", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "entity_type": "Entity", "start": 22, "end": 39}], "lang": "en"}
{"doc_id": "15157248_1", "wnd_id": "15157248_1_1", "text": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin .", "tokens": ["An", "immediate", "hemolytic", "reaction", "induced", "by", "repeated", "administration", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15157248_1_Ent0", "role": "Effect", "text": "immediate hemolytic reaction", "start": 1, "end": 4}, {"entity_id": "15157248_1_Ent2", "role": "Treatment_Freq", "text": "repeated", "start": 6, "end": 7}, {"entity_id": "15157248_1_Ent1", "role": "Treatment", "text": "repeated administration of oxaliplatin", "start": 6, "end": 10}, {"entity_id": "15157248_1_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15157248_1_Ent0", "text": "immediate hemolytic reaction", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15157248_1_Ent2", "text": "repeated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15157248_1_Ent1", "text": "repeated administration of oxaliplatin", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15157248_1_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15162903_2", "wnd_id": "15162903_2_1", "text": "Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment , as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "signs", "and", "symptoms", "of", "neurotoxicity", "during", "treatment", ",", "as", "well", "as", "predisposing", "factors", "that", "put", "patients", "receiving", "methotrexate", "at", "risk", "for", "neurotoxic", "effects", "."], "event_mentions": [{"id": "15162903_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 25, "end": 26}, "arguments": [{"entity_id": "15162903_2_Ent0", "role": "Subject", "text": "patients", "start": 21, "end": 22}, {"entity_id": "15162903_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent1", "role": "Effect", "text": "neurotoxic effects", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "15162903_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15162903_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent1", "text": "neurotoxic effects", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "1517501_4", "wnd_id": "1517501_4_1", "text": "We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN .", "tokens": ["We", "report", "a", "third", "case", "of", "a", "6", "-", "week", "-", "old", "infant", "with", "Escherichia", "coli", "sepsis", "who", "received", "ampicillin", "and", "other", "antibiotics", "and", "subsequently", "developed", "TEN", "."], "event_mentions": [{"id": "1517501_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "1517501_4_Ent1", "role": "Subject_Age", "text": "6 - week - old", "start": 7, "end": 12}, {"entity_id": "1517501_4_Ent0", "role": "Subject", "text": "6 - week - old infant with Escherichia coli sepsis", "start": 7, "end": 17}, {"entity_id": "1517501_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "1517501_4_Ent7", "role": "Treatment_Disorder", "text": "Escherichia coli sepsis", "start": 14, "end": 17}, {"entity_id": "1517501_4_Ent4", "role": "Treatment", "text": "received ampicillin and other antibiotics", "start": 18, "end": 23}, {"entity_id": "1517501_4_Ent5", "role": "Treatment_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent8", "role": "Combination_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent6", "role": "Treatment_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent9", "role": "Combination_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent3", "role": "Effect", "text": "TEN", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "1517501_4_Ent1", "text": "6 - week - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1517501_4_Ent0", "text": "6 - week - old infant with Escherichia coli sepsis", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "1517501_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1517501_4_Ent7", "text": "Escherichia coli sepsis", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "1517501_4_Ent4", "text": "received ampicillin and other antibiotics", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "1517501_4_Ent5", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent8", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent6", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent9", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent3", "text": "TEN", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "15190230_3", "wnd_id": "15190230_3_1", "text": "Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders .", "tokens": ["Therapy", "with", "IFN", "-", "alpha", "may", "be", "associated", "with", "a", "number", "of", "neuropsychiatric", "symptoms", ",", "such", "as", "Parkinsonism", ",", "akathisia", ",", "seizure", ",", "and", "depressive", "disorders", "."], "event_mentions": [{"id": "15190230_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 7, "end": 9}, "arguments": [{"entity_id": "15190230_3_Ent1", "role": "Treatment", "text": "Therapy with IFN - alpha", "start": 0, "end": 5}, {"entity_id": "15190230_3_Ent2", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 2, "end": 5}, {"entity_id": "15190230_3_Ent0", "role": "Effect", "text": "neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders", "start": 12, "end": 26}]}], "entity_mentions": [{"id": "15190230_3_Ent1", "text": "Therapy with IFN - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15190230_3_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15190230_3_Ent0", "text": "neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders", "entity_type": "Entity", "start": 12, "end": 26}], "lang": "en"}
{"doc_id": "15197722_2", "wnd_id": "15197722_2_1", "text": "Restless legs syndrome due to interferon - alpha .", "tokens": ["Restless", "legs", "syndrome", "due", "to", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "15197722_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "15197722_2_Ent0", "role": "Effect", "text": "Restless legs syndrome", "start": 0, "end": 3}, {"entity_id": "15197722_2_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 5, "end": 8}, {"entity_id": "15197722_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "15197722_2_Ent0", "text": "Restless legs syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15197722_2_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15197722_2_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "15224368_1", "wnd_id": "15224368_1_1", "text": "Sweet 's syndrome associated with sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment .", "tokens": ["Sweet", "'s", "syndrome", "associated", "with", "sargramostim", "(", "granulocyte", "-", "macrophage", "colony", "stimulating", "factor", ")", "treatment", "."], "event_mentions": [{"id": "15224368_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15224368_1_Ent0", "role": "Effect", "text": "Sweet 's syndrome", "start": 0, "end": 3}, {"entity_id": "15224368_1_Ent2", "role": "Treatment_Drug", "text": "sargramostim", "start": 5, "end": 6}, {"entity_id": "15224368_1_Ent1", "role": "Treatment", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "start": 5, "end": 15}]}], "entity_mentions": [{"id": "15224368_1_Ent0", "text": "Sweet 's syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15224368_1_Ent2", "text": "sargramostim", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15224368_1_Ent1", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "entity_type": "Entity", "start": 5, "end": 15}], "lang": "en"}
{"doc_id": "15235919_1", "wnd_id": "15235919_1_1", "text": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment .", "tokens": ["Sudden", "cardiac", "death", "due", "to", "hypersensitivity", "myocarditis", "during", "clozapine", "treatment", "."], "event_mentions": [{"id": "15235919_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "15235919_1_Ent0", "role": "Effect", "text": "Sudden cardiac death due to hypersensitivity myocarditis", "start": 0, "end": 7}, {"entity_id": "15235919_1_Ent1", "role": "Treatment", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "15235919_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15235919_1_Ent0", "text": "Sudden cardiac death due to hypersensitivity myocarditis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15235919_1_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15235919_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15235919_3", "wnd_id": "15235919_3_1", "text": "The case concerns the sudden death of a 29 - year - old male during clozapine therapy started 2 weeks before .", "tokens": ["The", "case", "concerns", "the", "sudden", "death", "of", "a", "29", "-", "year", "-", "old", "male", "during", "clozapine", "therapy", "started", "2", "weeks", "before", "."], "event_mentions": [{"id": "15235919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_3_Ent3", "role": "Effect", "text": "sudden death", "start": 4, "end": 6}, {"entity_id": "15235919_3_Ent0", "role": "Subject", "text": "a 29 - year - old male", "start": 7, "end": 14}, {"entity_id": "15235919_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 8, "end": 13}, {"entity_id": "15235919_3_Ent2", "role": "Subject_Population", "text": "male", "start": 13, "end": 14}, {"entity_id": "15235919_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks before", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "15235919_3_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15235919_3_Ent0", "text": "a 29 - year - old male", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15235919_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15235919_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15235919_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent6", "text": "2 weeks before", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "15286697_2", "wnd_id": "15286697_2_1", "text": "Pulmonary fibrosis is a severe complication associated with bis - chloronitrosourea ( BCNU ) therapy .", "tokens": ["Pulmonary", "fibrosis", "is", "a", "severe", "complication", "associated", "with", "bis", "-", "chloronitrosourea", "(", "BCNU", ")", "therapy", "."], "event_mentions": [{"id": "15286697_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15286697_2_Ent0", "role": "Effect", "text": "Pulmonary fibrosis is a severe complication", "start": 0, "end": 6}, {"entity_id": "15286697_2_Ent2", "role": "Treatment_Drug", "text": "bis - chloronitrosourea", "start": 8, "end": 11}, {"entity_id": "15286697_2_Ent1", "role": "Treatment", "text": "bis - chloronitrosourea ( BCNU ) therapy", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "15286697_2_Ent0", "text": "Pulmonary fibrosis is a severe complication", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15286697_2_Ent2", "text": "bis - chloronitrosourea", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15286697_2_Ent1", "text": "bis - chloronitrosourea ( BCNU ) therapy", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "15289139_3", "wnd_id": "15289139_3_1", "text": "We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma .", "tokens": ["We", "document", "the", "abrupt", "development", "of", "an", "extensive", "choroidal", "detachment", "after", "initiation", "of", "dorzolamide", "therapy", "in", "a", "surgically", "untreated", "eye", "with", "primary", "open", "-", "angle", "glaucoma", "."], "event_mentions": [{"id": "15289139_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 4, "end": 5}, "arguments": [{"entity_id": "15289139_3_Ent1", "role": "Effect", "text": "extensive choroidal detachment", "start": 7, "end": 10}, {"entity_id": "15289139_3_Ent3", "role": "Treatment_Drug", "text": "dorzolamide", "start": 13, "end": 14}, {"entity_id": "15289139_3_Ent2", "role": "Treatment", "text": "dorzolamide therapy", "start": 13, "end": 15}, {"entity_id": "15289139_3_Ent0", "role": "Subject", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}, {"entity_id": "15289139_3_Ent4", "role": "Treatment_Disorder", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}]}], "entity_mentions": [{"id": "15289139_3_Ent1", "text": "extensive choroidal detachment", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15289139_3_Ent3", "text": "dorzolamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15289139_3_Ent2", "text": "dorzolamide therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15289139_3_Ent0", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "15289139_3_Ent4", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}], "lang": "en"}
{"doc_id": "15304176_1", "wnd_id": "15304176_1_1", "text": "Lichen planus induced by hepatitis B vaccination : a new case and review of the literature .", "tokens": ["Lichen", "planus", "induced", "by", "hepatitis", "B", "vaccination", ":", "a", "new", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15304176_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15304176_1_Ent0", "role": "Effect", "text": "Lichen planus", "start": 0, "end": 2}, {"entity_id": "15304176_1_Ent1", "role": "Treatment", "text": "hepatitis B vaccination", "start": 4, "end": 7}, {"entity_id": "15304176_1_Ent2", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15304176_1_Ent0", "text": "Lichen planus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15304176_1_Ent1", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15304176_1_Ent2", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15331204_6", "wnd_id": "15331204_6_1", "text": "CONCLUSION : Therapy with indapamide may induce diabetes in essential hypertension patients .", "tokens": ["CONCLUSION", ":", "Therapy", "with", "indapamide", "may", "induce", "diabetes", "in", "essential", "hypertension", "patients", "."], "event_mentions": [{"id": "15331204_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "15331204_6_Ent2", "role": "Treatment", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent3", "role": "Treatment_Drug", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent1", "role": "Effect", "text": "diabetes", "start": 7, "end": 8}, {"entity_id": "15331204_6_Ent4", "role": "Treatment_Disorder", "text": "essential hypertension", "start": 9, "end": 11}, {"entity_id": "15331204_6_Ent0", "role": "Subject", "text": "essential hypertension patients", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15331204_6_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent3", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15331204_6_Ent4", "text": "essential hypertension", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15331204_6_Ent0", "text": "essential hypertension patients", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15359206_1", "wnd_id": "15359206_1_1", "text": "Easily reversible hypoxemia and hypotension induced by nimodipine .", "tokens": ["Easily", "reversible", "hypoxemia", "and", "hypotension", "induced", "by", "nimodipine", "."], "event_mentions": [{"id": "15359206_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15359206_1_Ent0", "role": "Effect", "text": "hypoxemia and hypotension", "start": 2, "end": 5}, {"entity_id": "15359206_1_Ent1", "role": "Treatment", "text": "nimodipine", "start": 7, "end": 8}, {"entity_id": "15359206_1_Ent2", "role": "Treatment_Drug", "text": "nimodipine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15359206_1_Ent0", "text": "hypoxemia and hypotension", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15359206_1_Ent1", "text": "nimodipine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15359206_1_Ent2", "text": "nimodipine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15359206_2", "wnd_id": "15359206_2_1", "text": "In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia , which was successfully treated with calcium gluconate .", "tokens": ["In", "this", "paper", "we", "report", "a", "case", "of", "nimodipine", "overdosage", "resulting", "in", "prolonged", "hypotension", "and", "hypoxemia", ",", "which", "was", "successfully", "treated", "with", "calcium", "gluconate", "."], "event_mentions": [{"id": "15359206_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "15359206_2_Ent3", "role": "Treatment_Drug", "text": "nimodipine", "start": 8, "end": 9}, {"entity_id": "15359206_2_Ent1", "role": "Treatment", "text": "nimodipine overdosage", "start": 8, "end": 10}, {"entity_id": "15359206_2_Ent2", "role": "Treatment_Dosage", "text": "overdosage", "start": 9, "end": 10}, {"entity_id": "15359206_2_Ent0", "role": "Effect", "text": "prolonged hypotension and hypoxemia", "start": 12, "end": 16}]}, {"id": "15359206_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15359206_2_Ent5", "role": "Treatment_Disorder", "text": "prolonged hypotension and hypoxemia", "start": 12, "end": 16}, {"entity_id": "15359206_2_Ent4", "role": "Treatment", "text": "calcium gluconate", "start": 22, "end": 24}, {"entity_id": "15359206_2_Ent6", "role": "Treatment_Drug", "text": "calcium gluconate", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "15359206_2_Ent3", "text": "nimodipine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15359206_2_Ent1", "text": "nimodipine overdosage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15359206_2_Ent2", "text": "overdosage", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15359206_2_Ent0", "text": "prolonged hypotension and hypoxemia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15359206_2_Ent5", "text": "prolonged hypotension and hypoxemia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15359206_2_Ent4", "text": "calcium gluconate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15359206_2_Ent6", "text": "calcium gluconate", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "15362597_1", "wnd_id": "15362597_1_1", "text": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction .", "tokens": ["Refractory", "hypoglycemia", "from", "ciprofloxacin", "and", "glyburide", "interaction", "."], "event_mentions": [{"id": "15362597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "15362597_1_Ent0", "role": "Effect", "text": "Refractory hypoglycemia", "start": 0, "end": 2}, {"entity_id": "15362597_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent1", "role": "Treatment", "text": "ciprofloxacin and glyburide interaction", "start": 3, "end": 7}, {"entity_id": "15362597_1_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 5, "end": 6}, {"entity_id": "15362597_1_Ent4", "role": "Combination_Drug", "text": "glyburide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15362597_1_Ent0", "text": "Refractory hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15362597_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent1", "text": "ciprofloxacin and glyburide interaction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15362597_1_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15362597_1_Ent4", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15368548_2", "wnd_id": "15368548_2_1", "text": "L - asparaginase - induced severe necrotizing pancreatitis successfully treated with percutaneous drainage .", "tokens": ["L", "-", "asparaginase", "-", "induced", "severe", "necrotizing", "pancreatitis", "successfully", "treated", "with", "percutaneous", "drainage", "."], "event_mentions": [{"id": "15368548_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_2_Ent3", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_2_Ent4", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_2_Ent2", "role": "Effect", "text": "severe necrotizing pancreatitis", "start": 5, "end": 8}]}, {"id": "15368548_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "15368548_2_Ent1", "role": "Treatment_Disorder", "text": "L - asparaginase - induced severe necrotizing pancreatitis", "start": 0, "end": 8}, {"entity_id": "15368548_2_Ent0", "role": "Treatment", "text": "percutaneous drainage", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15368548_2_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_2_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_2_Ent1", "text": "L - asparaginase - induced severe necrotizing pancreatitis", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15368548_2_Ent2", "text": "severe necrotizing pancreatitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15368548_2_Ent0", "text": "percutaneous drainage", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15373932_2", "wnd_id": "15373932_2_1", "text": "Fungal infection is a significant comorbidity in patients with diabetes mellitus , and ketoconazole , an antifungal agent , causes a number of drug interactions with coadministered drugs .", "tokens": ["Fungal", "infection", "is", "a", "significant", "comorbidity", "in", "patients", "with", "diabetes", "mellitus", ",", "and", "ketoconazole", ",", "an", "antifungal", "agent", ",", "causes", "a", "number", "of", "drug", "interactions", "with", "coadministered", "drugs", "."], "event_mentions": [{"id": "15373932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 19, "end": 20}, "arguments": [{"entity_id": "15373932_2_Ent5", "role": "Treatment_Disorder", "text": "Fungal infection", "start": 0, "end": 2}, {"entity_id": "15373932_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus", "start": 7, "end": 11}, {"entity_id": "15373932_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 9, "end": 11}, {"entity_id": "15373932_2_Ent3", "role": "Treatment", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent4", "role": "Treatment_Drug", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent2", "role": "Effect", "text": "a number of drug interactions with coadministered drugs", "start": 20, "end": 28}]}], "entity_mentions": [{"id": "15373932_2_Ent5", "text": "Fungal infection", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15373932_2_Ent0", "text": "patients with diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "15373932_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15373932_2_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent4", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent2", "text": "a number of drug interactions with coadministered drugs", "entity_type": "Entity", "start": 20, "end": 28}], "lang": "en"}
{"doc_id": "15379082_1", "wnd_id": "15379082_1_1", "text": "Disulfiram - induced fulminant hepatic failure in an active duty soldier .", "tokens": ["Disulfiram", "-", "induced", "fulminant", "hepatic", "failure", "in", "an", "active", "duty", "soldier", "."], "event_mentions": [{"id": "15379082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15379082_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}, {"entity_id": "15379082_1_Ent0", "role": "Subject", "text": "an active duty soldier", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "15379082_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15379082_1_Ent0", "text": "an active duty soldier", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "15454180_3", "wnd_id": "15454180_3_1", "text": "Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device .", "tokens": ["Sideroblastic", "anemia", "due", "to", "linezolid", "in", "a", "patient", "with", "a", "left", "ventricular", "assist", "device", "."], "event_mentions": [{"id": "15454180_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "15454180_3_Ent1", "role": "Effect", "text": "Sideroblastic anemia", "start": 0, "end": 2}, {"entity_id": "15454180_3_Ent2", "role": "Treatment", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent0", "role": "Subject", "text": "patient with a left ventricular assist device", "start": 7, "end": 14}, {"entity_id": "15454180_3_Ent4", "role": "Treatment_Disorder", "text": "left ventricular assist device", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "15454180_3_Ent1", "text": "Sideroblastic anemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15454180_3_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent0", "text": "patient with a left ventricular assist device", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15454180_3_Ent4", "text": "left ventricular assist device", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "15463865_1", "wnd_id": "15463865_1_1", "text": "Ciprofloxacin - induced renal insufficiency in cystic fibrosis .", "tokens": ["Ciprofloxacin", "-", "induced", "renal", "insufficiency", "in", "cystic", "fibrosis", "."], "event_mentions": [{"id": "15463865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15463865_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15463865_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15463865_1_Ent0", "role": "Effect", "text": "renal insufficiency", "start": 3, "end": 5}, {"entity_id": "15463865_1_Ent3", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15463865_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15463865_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15463865_1_Ent0", "text": "renal insufficiency", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15463865_1_Ent3", "text": "cystic fibrosis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15463865_5", "wnd_id": "15463865_5_1", "text": "Multiple mechanisms for ciprofloxacin - induced nephrotoxicity have been proposed .", "tokens": ["Multiple", "mechanisms", "for", "ciprofloxacin", "-", "induced", "nephrotoxicity", "have", "been", "proposed", "."], "event_mentions": [{"id": "15463865_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15463865_5_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15463865_5_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15463865_5_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15463865_5_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_5_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_5_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15468380_1", "wnd_id": "15468380_1_1", "text": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis .", "tokens": ["Sensory", "neuropathy", "revealing", "necrotizing", "vasculitis", "during", "infliximab", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "15468380_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "15468380_1_Ent0", "role": "Effect", "text": "Sensory neuropathy revealing necrotizing vasculitis", "start": 0, "end": 5}, {"entity_id": "15468380_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 6, "end": 7}, {"entity_id": "15468380_1_Ent1", "role": "Treatment", "text": "infliximab therapy", "start": 6, "end": 8}, {"entity_id": "15468380_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15468380_1_Ent0", "text": "Sensory neuropathy revealing necrotizing vasculitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15468380_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15468380_1_Ent1", "text": "infliximab therapy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15468380_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15479299_2", "wnd_id": "15479299_2_1", "text": "We report a case of severe anemia , which responded well to steroid therapy , in a patient receiving IL - 2 plus IFN - alpha for metastatic renal cell carcinoma .", "tokens": ["We", "report", "a", "case", "of", "severe", "anemia", ",", "which", "responded", "well", "to", "steroid", "therapy", ",", "in", "a", "patient", "receiving", "IL", "-", "2", "plus", "IFN", "-", "alpha", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "15479299_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 9, "end": 10}, "arguments": [{"entity_id": "15479299_2_Ent9", "role": "Treatment_Disorder", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent8", "role": "Treatment", "text": "steroid", "start": 12, "end": 13}, {"entity_id": "15479299_2_Ent10", "role": "Treatment_Drug", "text": "steroid", "start": 12, "end": 13}]}, {"id": "15479299_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "15479299_2_Ent1", "role": "Effect", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "15479299_2_Ent4", "role": "Treatment_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent7", "role": "Combination_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent2", "role": "Treatment", "text": "IL - 2 plus IFN - alpha", "start": 19, "end": 26}, {"entity_id": "15479299_2_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent6", "role": "Combination_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent3", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "15479299_2_Ent1", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent9", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent8", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent10", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15479299_2_Ent4", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent7", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent2", "text": "IL - 2 plus IFN - alpha", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15479299_2_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent3", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "15494638_1", "wnd_id": "15494638_1_1", "text": "Peripheral neuropathy associated with capecitabine .", "tokens": ["Peripheral", "neuropathy", "associated", "with", "capecitabine", "."], "event_mentions": [{"id": "15494638_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15494638_1_Ent0", "role": "Effect", "text": "Peripheral neuropathy", "start": 0, "end": 2}, {"entity_id": "15494638_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 4, "end": 5}, {"entity_id": "15494638_1_Ent1", "role": "Treatment", "text": "capecitabine .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "15494638_1_Ent0", "text": "Peripheral neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15494638_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15494638_1_Ent1", "text": "capecitabine .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "15504988_1", "wnd_id": "15504988_1_1", "text": "Severe hypo - alpha - lipoproteinemia during treatment with rosiglitazone .", "tokens": ["Severe", "hypo", "-", "alpha", "-", "lipoproteinemia", "during", "treatment", "with", "rosiglitazone", "."], "event_mentions": [{"id": "15504988_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "15504988_1_Ent0", "role": "Effect", "text": "hypo - alpha - lipoproteinemia", "start": 1, "end": 6}, {"entity_id": "15504988_1_Ent1", "role": "Treatment", "text": "rosiglitazone", "start": 9, "end": 10}, {"entity_id": "15504988_1_Ent2", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15504988_1_Ent0", "text": "hypo - alpha - lipoproteinemia", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15504988_1_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15504988_1_Ent2", "text": "rosiglitazone", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15522120_12", "wnd_id": "15522120_12_1", "text": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake .", "tokens": ["After", "approximately", "two", "weeks", "of", "sertraline", "treatment", "he", "noted", "an", "intense", "itching", "sensation", "in", "his", "scalp", "after", "eating", "a", "piece", "of", "chocolate", "cake", "."], "event_mentions": [{"id": "15522120_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 8, "end": 9}, "arguments": [{"entity_id": "15522120_12_Ent4", "role": "Treatment_Time_elapsed", "text": "two weeks", "start": 2, "end": 4}, {"entity_id": "15522120_12_Ent1", "role": "Treatment", "text": "two weeks of sertraline", "start": 2, "end": 6}, {"entity_id": "15522120_12_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 5, "end": 6}, {"entity_id": "15522120_12_Ent6", "role": "Combination_Drug", "text": "sertraline", "start": 5, "end": 6}, {"entity_id": "15522120_12_Ent0", "role": "Effect", "text": "intense itching sensation in his scalp", "start": 10, "end": 16}, {"entity_id": "15522120_12_Ent3", "role": "Treatment_Drug", "text": "chocolate", "start": 21, "end": 22}, {"entity_id": "15522120_12_Ent5", "role": "Combination_Drug", "text": "chocolate", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15522120_12_Ent4", "text": "two weeks", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15522120_12_Ent1", "text": "two weeks of sertraline", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "15522120_12_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_12_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_12_Ent0", "text": "intense itching sensation in his scalp", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "15522120_12_Ent3", "text": "chocolate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15522120_12_Ent5", "text": "chocolate", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15529178_1", "wnd_id": "15529178_1_1", "text": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy .", "tokens": ["Pulmonary", "lymphohistiocytic", "reactions", "temporally", "related", "to", "etanercept", "therapy", "."], "event_mentions": [{"id": "15529178_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 4, "end": 5}, "arguments": [{"entity_id": "15529178_1_Ent0", "role": "Effect", "text": "Pulmonary lymphohistiocytic reactions", "start": 0, "end": 3}, {"entity_id": "15529178_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 6, "end": 7}, {"entity_id": "15529178_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15529178_1_Ent0", "text": "Pulmonary lymphohistiocytic reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15529178_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15529178_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15533031_1", "wnd_id": "15533031_1_1", "text": "Paradoxical cerebral cortical hyperexcitability following flupirtine overdose .", "tokens": ["Paradoxical", "cerebral", "cortical", "hyperexcitability", "following", "flupirtine", "overdose", "."], "event_mentions": [{"id": "15533031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "15533031_1_Ent0", "role": "Effect", "text": "Paradoxical cerebral cortical hyperexcitability", "start": 0, "end": 4}, {"entity_id": "15533031_1_Ent2", "role": "Treatment_Drug", "text": "flupirtine", "start": 5, "end": 6}, {"entity_id": "15533031_1_Ent1", "role": "Treatment", "text": "flupirtine overdose", "start": 5, "end": 7}, {"entity_id": "15533031_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15533031_1_Ent0", "text": "Paradoxical cerebral cortical hyperexcitability", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15533031_1_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15533031_1_Ent1", "text": "flupirtine overdose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1557089_1", "wnd_id": "1557089_1_1", "text": "In a postoperative patient with pre - existent myasthenia gravis , oral verapamil caused a marked exacerbation in myasthenic weakness .", "tokens": ["In", "a", "postoperative", "patient", "with", "pre", "-", "existent", "myasthenia", "gravis", ",", "oral", "verapamil", "caused", "a", "marked", "exacerbation", "in", "myasthenic", "weakness", "."], "event_mentions": [{"id": "1557089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "1557089_1_Ent0", "role": "Subject", "text": "a postoperative patient with pre - existent myasthenia gravis", "start": 1, "end": 10}, {"entity_id": "1557089_1_Ent1", "role": "Subject_Disorder", "text": "pre - existent myasthenia gravis", "start": 5, "end": 10}, {"entity_id": "1557089_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "1557089_1_Ent3", "role": "Treatment", "text": "oral verapamil", "start": 11, "end": 13}, {"entity_id": "1557089_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 12, "end": 13}, {"entity_id": "1557089_1_Ent2", "role": "Effect", "text": "marked exacerbation in myasthenic weakness", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "1557089_1_Ent0", "text": "a postoperative patient with pre - existent myasthenia gravis", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "1557089_1_Ent1", "text": "pre - existent myasthenia gravis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "1557089_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1557089_1_Ent3", "text": "oral verapamil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "1557089_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1557089_1_Ent2", "text": "marked exacerbation in myasthenic weakness", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "15571949_1", "wnd_id": "15571949_1_1", "text": "In four patients , thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing busulfan .", "tokens": ["In", "four", "patients", ",", "thrombosis", "occurred", "2", "-", "45", "days", "after", "severe", "hepatic", "veno", "-", "occlusive", "disease", "(", "HVOD", ")", "secondary", "to", "intensive", "chemotherapy", "containing", "busulfan", "."], "event_mentions": [{"id": "15571949_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 20, "end": 21}, "arguments": [{"entity_id": "15571949_1_Ent1", "role": "Subject_Population", "text": "four", "start": 1, "end": 2}, {"entity_id": "15571949_1_Ent0", "role": "Subject", "text": "four patients", "start": 1, "end": 3}, {"entity_id": "15571949_1_Ent2", "role": "Effect", "text": "thrombosis occurred", "start": 4, "end": 6}, {"entity_id": "15571949_1_Ent5", "role": "Treatment_Time_elapsed", "text": "2 - 45 days after", "start": 6, "end": 11}, {"entity_id": "15571949_1_Ent3", "role": "Effect", "text": "severe hepatic veno - occlusive disease ( HVOD )", "start": 11, "end": 20}, {"entity_id": "15571949_1_Ent4", "role": "Treatment", "text": "intensive chemotherapy containing busulfan", "start": 22, "end": 26}, {"entity_id": "15571949_1_Ent6", "role": "Treatment_Drug", "text": "busulfan", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15571949_1_Ent1", "text": "four", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15571949_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15571949_1_Ent2", "text": "thrombosis occurred", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15571949_1_Ent5", "text": "2 - 45 days after", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15571949_1_Ent3", "text": "severe hepatic veno - occlusive disease ( HVOD )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15571949_1_Ent4", "text": "intensive chemotherapy containing busulfan", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "15571949_1_Ent6", "text": "busulfan", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15588385_2", "wnd_id": "15588385_2_1", "text": "After an extensive review of the literature , we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU - induced fulminant hepatitis .", "tokens": ["After", "an", "extensive", "review", "of", "the", "literature", ",", "we", "believe", "that", "this", "is", "the", "first", "communication", "of", "the", "successful", "use", "of", "amiodarone", "to", "control", "hyperthyroidism", "in", "a", "patient", "with", "PTU", "-", "induced", "fulminant", "hepatitis", "."], "event_mentions": [{"id": "15588385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "control", "start": 23, "end": 24}, "arguments": [{"entity_id": "15588385_2_Ent2", "role": "Treatment", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 24, "end": 25}, {"entity_id": "15588385_2_Ent0", "role": "Subject", "text": "a patient with PTU - induced fulminant hepatitis", "start": 26, "end": 34}, {"entity_id": "15588385_2_Ent1", "role": "Subject_Disorder", "text": "PTU - induced fulminant hepatitis", "start": 29, "end": 34}]}, {"id": "15588385_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 31, "end": 32}, "arguments": [{"entity_id": "15588385_2_Ent6", "role": "Treatment", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent7", "role": "Treatment_Drug", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent5", "role": "Effect", "text": "fulminant hepatitis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15588385_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15588385_2_Ent0", "text": "a patient with PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "15588385_2_Ent6", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent7", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent1", "text": "PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "15588385_2_Ent5", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "15588385_4", "wnd_id": "15588385_4_1", "text": "We present a 20 - year - old woman with Basedow - Graves ' disease who developed PTU - induced fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy .", "tokens": ["We", "present", "a", "20", "-", "year", "-", "old", "woman", "with", "Basedow", "-", "Graves", "'", "disease", "who", "developed", "PTU", "-", "induced", "fulminant", "hepatitis", ",", "which", "progressed", "to", "acute", "hepatic", "failure", "with", "grade", "III", "hepatic", "encephalopathy", "."], "event_mentions": [{"id": "15588385_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "15588385_4_Ent0", "role": "Subject", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "start": 2, "end": 15}, {"entity_id": "15588385_4_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 3, "end": 8}, {"entity_id": "15588385_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15588385_4_Ent5", "role": "Treatment_Disorder", "text": "Basedow - Graves ' disease", "start": 10, "end": 15}, {"entity_id": "15588385_4_Ent4", "role": "Treatment", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent6", "role": "Treatment_Drug", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent3", "role": "Effect", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "start": 20, "end": 34}]}], "entity_mentions": [{"id": "15588385_4_Ent0", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "15588385_4_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15588385_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15588385_4_Ent5", "text": "Basedow - Graves ' disease", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15588385_4_Ent4", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent6", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent3", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "entity_type": "Entity", "start": 20, "end": 34}], "lang": "en"}
{"doc_id": "15611427_2", "wnd_id": "15611427_2_1", "text": "Psoriasis triggered by toll - like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors .", "tokens": ["Psoriasis", "triggered", "by", "toll", "-", "like", "receptor", "7", "agonist", "imiquimod", "in", "the", "presence", "of", "dermal", "plasmacytoid", "dendritic", "cell", "precursors", "."], "event_mentions": [{"id": "15611427_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 1, "end": 2}, "arguments": [{"entity_id": "15611427_2_Ent0", "role": "Effect", "text": "Psoriasis", "start": 0, "end": 1}, {"entity_id": "15611427_2_Ent1", "role": "Treatment", "text": "imiquimod", "start": 9, "end": 10}, {"entity_id": "15611427_2_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 9, "end": 10}, {"entity_id": "15611427_2_Ent2", "role": "Treatment_Disorder", "text": "dermal plasmacytoid dendritic cell precursors", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "15611427_2_Ent0", "text": "Psoriasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15611427_2_Ent1", "text": "imiquimod", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15611427_2_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15611427_2_Ent2", "text": "dermal plasmacytoid dendritic cell precursors", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "15628319_1", "wnd_id": "15628319_1_1", "text": "Allergic side effects of AZA are rare , and reported allergic skin eruptions from AZA are very limited in Japan .", "tokens": ["Allergic", "side", "effects", "of", "AZA", "are", "rare", ",", "and", "reported", "allergic", "skin", "eruptions", "from", "AZA", "are", "very", "limited", "in", "Japan", "."], "event_mentions": [{"id": "15628319_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "15628319_1_Ent0", "role": "Effect", "text": "allergic skin eruptions", "start": 10, "end": 13}, {"entity_id": "15628319_1_Ent1", "role": "Treatment", "text": "AZA", "start": 14, "end": 15}, {"entity_id": "15628319_1_Ent2", "role": "Treatment_Drug", "text": "AZA", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15628319_1_Ent0", "text": "allergic skin eruptions", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15628319_1_Ent1", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15628319_1_Ent2", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15644988_2", "wnd_id": "15644988_2_1", "text": "Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy , respectively .", "tokens": ["Two", "of", "our", "patients", "developed", "TD", "after", "23", "months", "and", "34", "months", "of", "ziprasidone", "monotherapy", ",", "respectively", "."], "event_mentions": [{"id": "15644988_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15644988_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "15644988_2_Ent0", "role": "Subject", "text": "Two of our patients", "start": 0, "end": 4}, {"entity_id": "15644988_2_Ent2", "role": "Effect", "text": "TD", "start": 5, "end": 6}, {"entity_id": "15644988_2_Ent5", "role": "Treatment_Time_elapsed", "text": "23 months", "start": 7, "end": 9}, {"entity_id": "15644988_2_Ent6", "role": "Treatment_Time_elapsed", "text": "34 months", "start": 10, "end": 12}, {"entity_id": "15644988_2_Ent3", "role": "Treatment", "text": "ziprasidone", "start": 13, "end": 14}, {"entity_id": "15644988_2_Ent4", "role": "Treatment_Drug", "text": "ziprasidone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15644988_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15644988_2_Ent0", "text": "Two of our patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15644988_2_Ent2", "text": "TD", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15644988_2_Ent5", "text": "23 months", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15644988_2_Ent6", "text": "34 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15644988_2_Ent3", "text": "ziprasidone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15644988_2_Ent4", "text": "ziprasidone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15663666_1", "wnd_id": "15663666_1_1", "text": "Scrotal ulceration induced by all - trans retinoic acid in a patient with acute promyelocytic leukemia .", "tokens": ["Scrotal", "ulceration", "induced", "by", "all", "-", "trans", "retinoic", "acid", "in", "a", "patient", "with", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "15663666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15663666_1_Ent1", "role": "Effect", "text": "Scrotal ulceration", "start": 0, "end": 2}, {"entity_id": "15663666_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "15663666_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "15663666_1_Ent0", "role": "Subject", "text": "a patient with acute promyelocytic leukemia .", "start": 10, "end": 17}, {"entity_id": "15663666_1_Ent4", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15663666_1_Ent1", "text": "Scrotal ulceration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15663666_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15663666_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15663666_1_Ent0", "text": "a patient with acute promyelocytic leukemia .", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15663666_1_Ent4", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15681911_1", "wnd_id": "15681911_1_1", "text": "CONCLUSIONS : Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib .", "tokens": ["CONCLUSIONS", ":", "Symptoms", "and", "pathologic", "changes", "of", "colitis", "are", "associated", "with", "exposure", "to", "rofecoxib", "."], "event_mentions": [{"id": "15681911_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 9, "end": 11}, "arguments": [{"entity_id": "15681911_1_Ent0", "role": "Effect", "text": "Symptoms and pathologic changes of colitis", "start": 2, "end": 8}, {"entity_id": "15681911_1_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 11, "end": 12}, {"entity_id": "15681911_1_Ent1", "role": "Treatment", "text": "rofecoxib", "start": 13, "end": 14}, {"entity_id": "15681911_1_Ent2", "role": "Treatment_Drug", "text": "rofecoxib", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15681911_1_Ent0", "text": "Symptoms and pathologic changes of colitis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "15681911_1_Ent3", "text": "exposure", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15681911_1_Ent1", "text": "rofecoxib", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15681911_1_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15681911_2", "wnd_id": "15681911_2_1", "text": "OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib .", "tokens": ["OBJECTIVES", ":", "To", "describe", "clinical", "and", "pathologic", "findings", "in", "patients", "noted", "to", "develop", "lower", "gastrointestinal", "symptoms", "when", "exposed", "to", "rofecoxib", "."], "event_mentions": [{"id": "15681911_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "15681911_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "15681911_2_Ent1", "role": "Effect", "text": "lower gastrointestinal symptoms", "start": 13, "end": 16}, {"entity_id": "15681911_2_Ent2", "role": "Treatment", "text": "rofecoxib", "start": 19, "end": 20}, {"entity_id": "15681911_2_Ent3", "role": "Treatment_Drug", "text": "rofecoxib", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "15681911_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15681911_2_Ent1", "text": "lower gastrointestinal symptoms", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15681911_2_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15681911_2_Ent3", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "15681911_3", "wnd_id": "15681911_3_1", "text": "RESULTS : Three patients who developed symptoms of inflammatory bowel disease ( IBD ) during rofecoxib exposure are described along with pathology findings .", "tokens": ["RESULTS", ":", "Three", "patients", "who", "developed", "symptoms", "of", "inflammatory", "bowel", "disease", "(", "IBD", ")", "during", "rofecoxib", "exposure", "are", "described", "along", "with", "pathology", "findings", "."], "event_mentions": [{"id": "15681911_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "15681911_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 2, "end": 3}, {"entity_id": "15681911_3_Ent0", "role": "Subject", "text": "Three patients", "start": 2, "end": 4}, {"entity_id": "15681911_3_Ent2", "role": "Effect", "text": "symptoms of inflammatory bowel disease ( IBD )", "start": 6, "end": 14}, {"entity_id": "15681911_3_Ent4", "role": "Treatment_Drug", "text": "rofecoxib", "start": 15, "end": 16}, {"entity_id": "15681911_3_Ent3", "role": "Treatment", "text": "rofecoxib exposure", "start": 15, "end": 17}, {"entity_id": "15681911_3_Ent5", "role": "Treatment_Route", "text": "exposure", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15681911_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15681911_3_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15681911_3_Ent2", "text": "symptoms of inflammatory bowel disease ( IBD )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "15681911_3_Ent4", "text": "rofecoxib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15681911_3_Ent3", "text": "rofecoxib exposure", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15681911_3_Ent5", "text": "exposure", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15685264_2", "wnd_id": "15685264_2_1", "text": "OBJECTIVE : To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "Carbamazepine", "toxicity", "following", "the", "administration", "of", "Oxybutynin", "and", "Dantrolene", "."], "event_mentions": [{"id": "15685264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "15685264_2_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent6", "role": "Combination_Drug", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent0", "role": "Effect", "text": "Carbamazepine toxicity", "start": 7, "end": 9}, {"entity_id": "15685264_2_Ent3", "role": "Treatment_Drug", "text": "Oxybutynin", "start": 13, "end": 14}, {"entity_id": "15685264_2_Ent7", "role": "Combination_Drug", "text": "Oxybutynin", "start": 13, "end": 14}, {"entity_id": "15685264_2_Ent2", "role": "Treatment", "text": "Oxybutynin and Dantrolene", "start": 13, "end": 16}, {"entity_id": "15685264_2_Ent4", "role": "Treatment_Drug", "text": "Dantrolene", "start": 15, "end": 16}, {"entity_id": "15685264_2_Ent8", "role": "Combination_Drug", "text": "Dantrolene", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15685264_2_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent6", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent0", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15685264_2_Ent3", "text": "Oxybutynin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15685264_2_Ent7", "text": "Oxybutynin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15685264_2_Ent2", "text": "Oxybutynin and Dantrolene", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15685264_2_Ent4", "text": "Dantrolene", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15685264_2_Ent8", "text": "Dantrolene", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15694139_2", "wnd_id": "15694139_2_1", "text": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects .", "tokens": ["Thalidomide", "was", "withdrawn", "from", "world", "markets", "in", "1961", "following", "recognition", "of", "its", "teratogenic", "effects", "."], "event_mentions": [{"id": "15694139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "15694139_2_Ent1", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent2", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15694139_2_Ent1", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15719254_3", "wnd_id": "15719254_3_1", "text": "Retinoic acid may increase the risk of bone marrow transplant nephropathy .", "tokens": ["Retinoic", "acid", "may", "increase", "the", "risk", "of", "bone", "marrow", "transplant", "nephropathy", "."], "event_mentions": [{"id": "15719254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 3, "end": 4}, "arguments": [{"entity_id": "15719254_3_Ent1", "role": "Treatment", "text": "Retinoic acid", "start": 0, "end": 2}, {"entity_id": "15719254_3_Ent2", "role": "Treatment_Drug", "text": "Retinoic acid", "start": 0, "end": 2}, {"entity_id": "15719254_3_Ent0", "role": "Effect", "text": "bone marrow transplant nephropathy", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "15719254_3_Ent1", "text": "Retinoic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15719254_3_Ent2", "text": "Retinoic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15719254_3_Ent0", "text": "bone marrow transplant nephropathy", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "15719254_4", "wnd_id": "15719254_4_1", "text": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental .", "tokens": ["The", "occurrence", "of", "BMTN", "in", "two", "children", "treated", "with", "RA", "in", "our", "unit", "is", "unlikely", "to", "be", "coincidental", "."], "event_mentions": [{"id": "15719254_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "15719254_4_Ent3", "role": "Effect", "text": "BMTN", "start": 3, "end": 4}, {"entity_id": "15719254_4_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "15719254_4_Ent0", "role": "Subject", "text": "two children", "start": 5, "end": 7}, {"entity_id": "15719254_4_Ent2", "role": "Subject_Age", "text": "children", "start": 6, "end": 7}, {"entity_id": "15719254_4_Ent4", "role": "Treatment", "text": "RA", "start": 9, "end": 10}, {"entity_id": "15719254_4_Ent5", "role": "Treatment_Drug", "text": "RA", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15719254_4_Ent3", "text": "BMTN", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15719254_4_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15719254_4_Ent0", "text": "two children", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15719254_4_Ent2", "text": "children", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15719254_4_Ent4", "text": "RA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15719254_4_Ent5", "text": "RA", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15727358_1", "wnd_id": "15727358_1_1", "text": "He developed a late secondary infection in some sites treated with imiquimod .", "tokens": ["He", "developed", "a", "late", "secondary", "infection", "in", "some", "sites", "treated", "with", "imiquimod", "."], "event_mentions": [{"id": "15727358_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "15727358_1_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "15727358_1_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "15727358_1_Ent2", "role": "Effect", "text": "late secondary infection", "start": 3, "end": 6}, {"entity_id": "15727358_1_Ent3", "role": "Treatment", "text": "imiquimod", "start": 11, "end": 12}, {"entity_id": "15727358_1_Ent4", "role": "Treatment_Drug", "text": "imiquimod", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15727358_1_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15727358_1_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15727358_1_Ent2", "text": "late secondary infection", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15727358_1_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15727358_1_Ent4", "text": "imiquimod", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15735923_8", "wnd_id": "15735923_8_1", "text": "Considering the increasing use of TMZ , which is regarded as a drug with moderate toxicity , careful follow - up with routine blood testing is vital .", "tokens": ["Considering", "the", "increasing", "use", "of", "TMZ", ",", "which", "is", "regarded", "as", "a", "drug", "with", "moderate", "toxicity", ",", "careful", "follow", "-", "up", "with", "routine", "blood", "testing", "is", "vital", "."], "event_mentions": [{"id": "15735923_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 13, "end": 14}, "arguments": [{"entity_id": "15735923_8_Ent1", "role": "Treatment", "text": "TMZ", "start": 5, "end": 6}, {"entity_id": "15735923_8_Ent2", "role": "Treatment_Drug", "text": "TMZ", "start": 5, "end": 6}, {"entity_id": "15735923_8_Ent0", "role": "Effect", "text": "moderate toxicity", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "15735923_8_Ent1", "text": "TMZ", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15735923_8_Ent2", "text": "TMZ", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15735923_8_Ent0", "text": "moderate toxicity", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "15752306_2", "wnd_id": "15752306_2_1", "text": "We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma .", "tokens": ["We", "report", "two", "patients", "who", "developed", "intense", "livedo", "reticularis", "clearly", "related", "to", "the", "administration", "of", "interferon", "alpha", "2b", "as", "an", "adjuvant", "therapy", "for", "melanoma", "."], "event_mentions": [{"id": "15752306_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "15752306_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "15752306_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "15752306_2_Ent2", "role": "Effect", "text": "intense livedo reticularis", "start": 6, "end": 9}, {"entity_id": "15752306_2_Ent4", "role": "Treatment_Drug", "text": "interferon alpha 2b", "start": 15, "end": 18}, {"entity_id": "15752306_2_Ent3", "role": "Treatment", "text": "interferon alpha 2b as an adjuvant therapy for melanoma", "start": 15, "end": 24}, {"entity_id": "15752306_2_Ent5", "role": "Treatment_Disorder", "text": "melanoma", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15752306_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15752306_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15752306_2_Ent2", "text": "intense livedo reticularis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15752306_2_Ent4", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15752306_2_Ent3", "text": "interferon alpha 2b as an adjuvant therapy for melanoma", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "15752306_2_Ent5", "text": "melanoma", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15760792_1", "wnd_id": "15760792_1_1", "text": "CONCLUSION : This rare case of PTU - induced ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement .", "tokens": ["CONCLUSION", ":", "This", "rare", "case", "of", "PTU", "-", "induced", "ANCA", "-", "associated", "vasculitis", "manifested", "with", "ototoxicity", "in", "combination", "with", "systemic", "involvement", "."], "event_mentions": [{"id": "15760792_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "15760792_1_Ent1", "role": "Treatment", "text": "PTU", "start": 6, "end": 7}, {"entity_id": "15760792_1_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 6, "end": 7}, {"entity_id": "15760792_1_Ent0", "role": "Effect", "text": "ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement", "start": 9, "end": 21}]}], "entity_mentions": [{"id": "15760792_1_Ent1", "text": "PTU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15760792_1_Ent2", "text": "PTU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15760792_1_Ent0", "text": "ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement", "entity_type": "Entity", "start": 9, "end": 21}], "lang": "en"}
{"doc_id": "15770343_3", "wnd_id": "15770343_3_1", "text": "In addition , ethambutol rarely causes visual loss during the early period or when given at lower doses .", "tokens": ["In", "addition", ",", "ethambutol", "rarely", "causes", "visual", "loss", "during", "the", "early", "period", "or", "when", "given", "at", "lower", "doses", "."], "event_mentions": [{"id": "15770343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 5, "end": 6}, "arguments": [{"entity_id": "15770343_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "15770343_3_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "15770343_3_Ent0", "role": "Effect", "text": "visual loss", "start": 6, "end": 8}, {"entity_id": "15770343_3_Ent2", "role": "Treatment", "text": "during the early period or when given at lower doses", "start": 8, "end": 18}, {"entity_id": "15770343_3_Ent4", "role": "Treatment_Time_elapsed", "text": "early period", "start": 10, "end": 12}, {"entity_id": "15770343_3_Ent5", "role": "Treatment_Dosage", "text": "lower doses", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "15770343_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15770343_3_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15770343_3_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15770343_3_Ent2", "text": "during the early period or when given at lower doses", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "15770343_3_Ent4", "text": "early period", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15770343_3_Ent5", "text": "lower doses", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "15773973_1", "wnd_id": "15773973_1_1", "text": "Flucloxacillin - induced aplastic anaemia and liver failure .", "tokens": ["Flucloxacillin", "-", "induced", "aplastic", "anaemia", "and", "liver", "failure", "."], "event_mentions": [{"id": "15773973_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15773973_1_Ent1", "role": "Treatment", "text": "Flucloxacillin", "start": 0, "end": 1}, {"entity_id": "15773973_1_Ent2", "role": "Treatment_Drug", "text": "Flucloxacillin", "start": 0, "end": 1}, {"entity_id": "15773973_1_Ent0", "role": "Effect", "text": "aplastic anaemia and liver failure", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "15773973_1_Ent1", "text": "Flucloxacillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15773973_1_Ent2", "text": "Flucloxacillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15773973_1_Ent0", "text": "aplastic anaemia and liver failure", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "15785053_3", "wnd_id": "15785053_3_1", "text": "We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus .", "tokens": ["We", "report", "the", "first", "histopathologically", "documented", "case", "of", "oral", "mucosa", "pigmentation", "after", "OLP", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "15785053_3_Ent0", "role": "Effect", "text": "oral mucosa pigmentation", "start": 8, "end": 11}, {"entity_id": "15785053_3_Ent3", "role": "Treatment_Disorder", "text": "OLP", "start": 12, "end": 13}, {"entity_id": "15785053_3_Ent4", "role": "Treatment_Route", "text": "topical", "start": 15, "end": 16}, {"entity_id": "15785053_3_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 15, "end": 17}, {"entity_id": "15785053_3_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15785053_3_Ent0", "text": "oral mucosa pigmentation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15785053_3_Ent3", "text": "OLP", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15785053_3_Ent4", "text": "topical", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15785053_3_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15785053_3_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15806568_2", "wnd_id": "15806568_2_1", "text": "To date , there have been few reports of visual disturbances associated with BTX - B use .", "tokens": ["To", "date", ",", "there", "have", "been", "few", "reports", "of", "visual", "disturbances", "associated", "with", "BTX", "-", "B", "use", "."], "event_mentions": [{"id": "15806568_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15806568_2_Ent0", "role": "Effect", "text": "visual disturbances", "start": 9, "end": 11}, {"entity_id": "15806568_2_Ent1", "role": "Treatment", "text": "BTX - B", "start": 13, "end": 16}, {"entity_id": "15806568_2_Ent2", "role": "Treatment_Drug", "text": "BTX - B", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15806568_2_Ent0", "text": "visual disturbances", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15806568_2_Ent1", "text": "BTX - B", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15806568_2_Ent2", "text": "BTX - B", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15811174_1", "wnd_id": "15811174_1_1", "text": "A 74 - year - old hypercholestrerolaemic woman taking cerivastatin ( 0.15 mg / day ) for 22 days complained of general muscle weakness and muscle pain .", "tokens": ["A", "74", "-", "year", "-", "old", "hypercholestrerolaemic", "woman", "taking", "cerivastatin", "(", "0.15", "mg", "/", "day", ")", "for", "22", "days", "complained", "of", "general", "muscle", "weakness", "and", "muscle", "pain", "."], "event_mentions": [{"id": "15811174_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 19, "end": 20}, "arguments": [{"entity_id": "15811174_1_Ent0", "role": "Subject", "text": "A 74 - year - old hypercholestrerolaemic woman", "start": 0, "end": 8}, {"entity_id": "15811174_1_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "15811174_1_Ent8", "role": "Treatment_Disorder", "text": "hypercholestrerolaemic", "start": 6, "end": 7}, {"entity_id": "15811174_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "15811174_1_Ent5", "role": "Treatment_Drug", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_1_Ent4", "role": "Treatment", "text": "cerivastatin ( 0.15 mg / day )", "start": 9, "end": 16}, {"entity_id": "15811174_1_Ent6", "role": "Treatment_Dosage", "text": "0.15 mg / day", "start": 11, "end": 15}, {"entity_id": "15811174_1_Ent7", "role": "Treatment_Duration", "text": "22 days", "start": 17, "end": 19}, {"entity_id": "15811174_1_Ent3", "role": "Effect", "text": "general muscle weakness and muscle pain .", "start": 21, "end": 28}]}], "entity_mentions": [{"id": "15811174_1_Ent0", "text": "A 74 - year - old hypercholestrerolaemic woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15811174_1_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15811174_1_Ent8", "text": "hypercholestrerolaemic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15811174_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15811174_1_Ent5", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_1_Ent4", "text": "cerivastatin ( 0.15 mg / day )", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "15811174_1_Ent6", "text": "0.15 mg / day", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15811174_1_Ent7", "text": "22 days", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15811174_1_Ent3", "text": "general muscle weakness and muscle pain .", "entity_type": "Entity", "start": 21, "end": 28}], "lang": "en"}
{"doc_id": "15827071_10", "wnd_id": "15827071_10_1", "text": "The following day , the patient developed anxiety , panic attacks , tremors , tachycardia , and hypertension that persisted throughout linezolid treatment .", "tokens": ["The", "following", "day", ",", "the", "patient", "developed", "anxiety", ",", "panic", "attacks", ",", "tremors", ",", "tachycardia", ",", "and", "hypertension", "that", "persisted", "throughout", "linezolid", "treatment", "."], "event_mentions": [{"id": "15827071_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "15827071_10_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "15827071_10_Ent1", "role": "Effect", "text": "anxiety , panic attacks , tremors , tachycardia , and hypertension", "start": 7, "end": 18}, {"entity_id": "15827071_10_Ent2", "role": "Treatment", "text": "linezolid", "start": 21, "end": 22}, {"entity_id": "15827071_10_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15827071_10_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15827071_10_Ent1", "text": "anxiety , panic attacks , tremors , tachycardia , and hypertension", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "15827071_10_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15827071_10_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15827071_5", "wnd_id": "15827071_5_1", "text": "She displayed symptoms of ST 8 days after the introduction of linezolid .", "tokens": ["She", "displayed", "symptoms", "of", "ST", "8", "days", "after", "the", "introduction", "of", "linezolid", "."], "event_mentions": [{"id": "15827071_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "displayed", "start": 1, "end": 2}, "arguments": [{"entity_id": "15827071_5_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "15827071_5_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "15827071_5_Ent2", "role": "Effect", "text": "symptoms of ST", "start": 2, "end": 5}, {"entity_id": "15827071_5_Ent4", "role": "Treatment_Time_elapsed", "text": "8 days", "start": 5, "end": 7}, {"entity_id": "15827071_5_Ent3", "role": "Treatment", "text": "8 days after the introduction of linezolid", "start": 5, "end": 12}, {"entity_id": "15827071_5_Ent5", "role": "Treatment_Route", "text": "introduction", "start": 9, "end": 10}, {"entity_id": "15827071_5_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15827071_5_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15827071_5_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15827071_5_Ent2", "text": "symptoms of ST", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15827071_5_Ent4", "text": "8 days", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15827071_5_Ent3", "text": "8 days after the introduction of linezolid", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15827071_5_Ent5", "text": "introduction", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15827071_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15836666_1", "wnd_id": "15836666_1_1", "text": "Chronic fentanyl application induces adrenocortical insufficiency .", "tokens": ["Chronic", "fentanyl", "application", "induces", "adrenocortical", "insufficiency", "."], "event_mentions": [{"id": "15836666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 3, "end": 4}, "arguments": [{"entity_id": "15836666_1_Ent3", "role": "Treatment_Duration", "text": "Chronic", "start": 0, "end": 1}, {"entity_id": "15836666_1_Ent1", "role": "Treatment", "text": "Chronic fentanyl", "start": 0, "end": 2}, {"entity_id": "15836666_1_Ent2", "role": "Treatment_Drug", "text": "fentanyl", "start": 1, "end": 2}, {"entity_id": "15836666_1_Ent0", "role": "Effect", "text": "adrenocortical insufficiency", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "15836666_1_Ent3", "text": "Chronic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15836666_1_Ent1", "text": "Chronic fentanyl", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15836666_1_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15836666_1_Ent0", "text": "adrenocortical insufficiency", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1584367_1", "wnd_id": "1584367_1_1", "text": "Intraventricular vancomycin - induced cerebrospinal fluid eosinophilia : report of two patients .", "tokens": ["Intraventricular", "vancomycin", "-", "induced", "cerebrospinal", "fluid", "eosinophilia", ":", "report", "of", "two", "patients", "."], "event_mentions": [{"id": "1584367_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1584367_1_Ent4", "role": "Treatment_Route", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "1584367_1_Ent3", "role": "Treatment", "text": "Intraventricular vancomycin", "start": 0, "end": 2}, {"entity_id": "1584367_1_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "1584367_1_Ent2", "role": "Effect", "text": "cerebrospinal fluid eosinophilia", "start": 4, "end": 7}, {"entity_id": "1584367_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "1584367_1_Ent0", "role": "Subject", "text": "two patients .", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1584367_1_Ent4", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1584367_1_Ent3", "text": "Intraventricular vancomycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1584367_1_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1584367_1_Ent2", "text": "cerebrospinal fluid eosinophilia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1584367_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1584367_1_Ent0", "text": "two patients .", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15852680_2", "wnd_id": "15852680_2_1", "text": "We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer , in which the pneumonitis was successfully managed by steroid treatment .", "tokens": ["We", "report", "a", "case", "of", "interstitial", "pneumonitis", "induced", "by", "bicalutamide", "and/or", "leuprorelin", "acetate", "given", "as", "therapy", "for", "prostate", "cancer", ",", "in", "which", "the", "pneumonitis", "was", "successfully", "managed", "by", "steroid", "treatment", "."], "event_mentions": [{"id": "15852680_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "15852680_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15852680_2_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 5, "end": 7}, {"entity_id": "15852680_2_Ent4", "role": "Treatment_Drug", "text": "bicalutamide", "start": 9, "end": 10}, {"entity_id": "15852680_2_Ent6", "role": "Combination_Drug", "text": "bicalutamide", "start": 9, "end": 10}, {"entity_id": "15852680_2_Ent2", "role": "Treatment", "text": "bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer", "start": 9, "end": 19}, {"entity_id": "15852680_2_Ent5", "role": "Treatment_Drug", "text": "leuprorelin acetate", "start": 11, "end": 13}, {"entity_id": "15852680_2_Ent7", "role": "Combination_Drug", "text": "leuprorelin acetate", "start": 11, "end": 13}, {"entity_id": "15852680_2_Ent3", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15852680_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15852680_2_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15852680_2_Ent4", "text": "bicalutamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15852680_2_Ent6", "text": "bicalutamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15852680_2_Ent2", "text": "bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "15852680_2_Ent5", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15852680_2_Ent7", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15852680_2_Ent3", "text": "prostate cancer", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15857283_3", "wnd_id": "15857283_3_1", "text": "PURPOSE : The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin .", "tokens": ["PURPOSE", ":", "The", "aim", "of", "this", "study", "was", "to", "report", "on", "the", "possible", "development", "of", "corneal", "endothelial", "deposits", "resulting", "from", "the", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 18, "end": 19}, "arguments": [{"entity_id": "15857283_3_Ent0", "role": "Effect", "text": "corneal endothelial deposits", "start": 15, "end": 18}, {"entity_id": "15857283_3_Ent1", "role": "Treatment", "text": "rifabutin", "start": 23, "end": 24}, {"entity_id": "15857283_3_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15857283_3_Ent0", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15857283_3_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15857283_3_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15857283_4", "wnd_id": "15857283_4_1", "text": "RESULTS : All cases developed corneal endothelial deposits after previous use of rifabutin .", "tokens": ["RESULTS", ":", "All", "cases", "developed", "corneal", "endothelial", "deposits", "after", "previous", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15857283_4_Ent0", "role": "Subject", "text": "All cases", "start": 2, "end": 4}, {"entity_id": "15857283_4_Ent1", "role": "Effect", "text": "corneal endothelial deposits", "start": 5, "end": 8}, {"entity_id": "15857283_4_Ent2", "role": "Treatment", "text": "rifabutin", "start": 12, "end": 13}, {"entity_id": "15857283_4_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15857283_4_Ent0", "text": "All cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15857283_4_Ent1", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15857283_4_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15857283_4_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15863610_1", "wnd_id": "15863610_1_1", "text": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene .", "tokens": ["Malignant", "mixed", "mullerian", "tumor", "of", "the", "uterus", "in", "a", "patient", "taking", "raloxifene", "."], "event_mentions": [{"id": "15863610_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "15863610_1_Ent1", "role": "Effect", "text": "Malignant mixed mullerian tumor of the uterus", "start": 0, "end": 7}, {"entity_id": "15863610_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "15863610_1_Ent2", "role": "Treatment", "text": "raloxifene", "start": 11, "end": 12}, {"entity_id": "15863610_1_Ent3", "role": "Treatment_Drug", "text": "raloxifene", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15863610_1_Ent1", "text": "Malignant mixed mullerian tumor of the uterus", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15863610_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15863610_1_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15863610_1_Ent3", "text": "raloxifene", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1592841_1", "wnd_id": "1592841_1_1", "text": "Falling backward in two elderly patients taking bupropion .", "tokens": ["Falling", "backward", "in", "two", "elderly", "patients", "taking", "bupropion", "."], "event_mentions": [{"id": "1592841_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 6, "end": 7}, "arguments": [{"entity_id": "1592841_1_Ent3", "role": "Effect", "text": "Falling backward", "start": 0, "end": 2}, {"entity_id": "1592841_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "1592841_1_Ent0", "role": "Subject", "text": "two elderly patients", "start": 3, "end": 6}, {"entity_id": "1592841_1_Ent2", "role": "Subject_Age", "text": "elderly", "start": 4, "end": 5}, {"entity_id": "1592841_1_Ent4", "role": "Treatment", "text": "bupropion", "start": 7, "end": 8}, {"entity_id": "1592841_1_Ent5", "role": "Treatment_Drug", "text": "bupropion", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1592841_1_Ent3", "text": "Falling backward", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1592841_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1592841_1_Ent0", "text": "two elderly patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1592841_1_Ent2", "text": "elderly", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1592841_1_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1592841_1_Ent5", "text": "bupropion", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15944830_6", "wnd_id": "15944830_6_1", "text": "With the use of optical coherence tomography ( OCT ) , two patients with IFN - associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed .", "tokens": ["With", "the", "use", "of", "optical", "coherence", "tomography", "(", "OCT", ")", ",", "two", "patients", "with", "IFN", "-", "associated", "retinopathy", "who", "had", "developed", "macular", "edema", "and", "reduced", "visual", "acuity", "during", "the", "clinical", "course", "of", "IFN", "therapy", "were", "observed", "."], "event_mentions": [{"id": "15944830_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "15944830_6_Ent2", "role": "Treatment", "text": "IFN", "start": 14, "end": 15}, {"entity_id": "15944830_6_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 14, "end": 15}, {"entity_id": "15944830_6_Ent0", "role": "Effect", "text": "retinopathy", "start": 17, "end": 18}, {"entity_id": "15944830_6_Ent1", "role": "Effect", "text": "macular edema and reduced visual acuity", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "15944830_6_Ent2", "text": "IFN", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15944830_6_Ent3", "text": "IFN", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15944830_6_Ent0", "text": "retinopathy", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15944830_6_Ent1", "text": "macular edema and reduced visual acuity", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "16012330_1", "wnd_id": "16012330_1_1", "text": "Itraconazole - related increased vincristine neurotoxicity : case report and review of literature .", "tokens": ["Itraconazole", "-", "related", "increased", "vincristine", "neurotoxicity", ":", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "16012330_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16012330_1_Ent1", "role": "Treatment", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent2", "role": "Treatment_Drug", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent4", "role": "Combination_Drug", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent0", "role": "Effect", "text": "increased vincristine neurotoxicity", "start": 3, "end": 6}, {"entity_id": "16012330_1_Ent3", "role": "Treatment_Drug", "text": "vincristine", "start": 4, "end": 5}, {"entity_id": "16012330_1_Ent5", "role": "Combination_Drug", "text": "vincristine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16012330_1_Ent1", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent4", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent0", "text": "increased vincristine neurotoxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "16012330_1_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16012330_1_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16012330_5", "wnd_id": "16012330_5_1", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy .", "tokens": ["A", "3", "-", "year", "-", "old", "boy", "diagnosed", "with", "acute", "lymphoblastic", "leukemia", "received", "induction", "chemotherapy", "."], "event_mentions": [{"id": "16012330_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 12, "end": 13}, "arguments": [{"entity_id": "16012330_5_Ent0", "role": "Subject", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "start": 0, "end": 12}, {"entity_id": "16012330_5_Ent1", "role": "Subject_Age", "text": "3 - year - old", "start": 1, "end": 6}, {"entity_id": "16012330_5_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "16012330_5_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 9, "end": 12}, {"entity_id": "16012330_5_Ent3", "role": "Treatment", "text": "induction chemotherapy", "start": 13, "end": 15}, {"entity_id": "16012330_5_Ent5", "role": "Treatment_Route", "text": "induction chemotherapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16012330_5_Ent0", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16012330_5_Ent1", "text": "3 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16012330_5_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16012330_5_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16012330_5_Ent3", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16012330_5_Ent5", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16018164_1", "wnd_id": "16018164_1_1", "text": "CASE REPORT : We report a case of intracerebral hemorrhage occurring in a middle - aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year .", "tokens": ["CASE", "REPORT", ":", "We", "report", "a", "case", "of", "intracerebral", "hemorrhage", "occurring", "in", "a", "middle", "-", "aged", "man", "who", "suffered", "from", "chronic", "sinusitis", "and", "had", "been", "ingesting", "pseudoephedrine", "daily", "for", "one", "year", "."], "event_mentions": [{"id": "16018164_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 10, "end": 11}, "arguments": [{"entity_id": "16018164_1_Ent3", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_1_Ent1", "role": "Subject_Age", "text": "middle - aged", "start": 13, "end": 16}, {"entity_id": "16018164_1_Ent0", "role": "Subject", "text": "middle - aged man who suffered from chronic sinusitis", "start": 13, "end": 22}, {"entity_id": "16018164_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 16, "end": 17}, {"entity_id": "16018164_1_Ent9", "role": "Treatment_Disorder", "text": "chronic sinusitis", "start": 20, "end": 22}, {"entity_id": "16018164_1_Ent5", "role": "Treatment_Route", "text": "ingesting", "start": 25, "end": 26}, {"entity_id": "16018164_1_Ent4", "role": "Treatment", "text": "ingesting pseudoephedrine daily for one year", "start": 25, "end": 31}, {"entity_id": "16018164_1_Ent6", "role": "Treatment_Drug", "text": "pseudoephedrine", "start": 26, "end": 27}, {"entity_id": "16018164_1_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 27, "end": 28}, {"entity_id": "16018164_1_Ent8", "role": "Treatment_Duration", "text": "for one year", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "16018164_1_Ent3", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_1_Ent1", "text": "middle - aged", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "16018164_1_Ent0", "text": "middle - aged man who suffered from chronic sinusitis", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "16018164_1_Ent2", "text": "man", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16018164_1_Ent9", "text": "chronic sinusitis", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16018164_1_Ent5", "text": "ingesting", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16018164_1_Ent4", "text": "ingesting pseudoephedrine daily for one year", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "16018164_1_Ent6", "text": "pseudoephedrine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16018164_1_Ent7", "text": "daily", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16018164_1_Ent8", "text": "for one year", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "16018164_2", "wnd_id": "16018164_2_1", "text": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM .", "tokens": ["Only", "one", "report", "links", "phenylpropanolamine", "consumption", "to", "an", "intracerebral", "hemorrhage", "in", "a", "patient", "with", "an", "AVM", "."], "event_mentions": [{"id": "16018164_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "links", "start": 3, "end": 4}, "arguments": [{"entity_id": "16018164_2_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent2", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_2_Ent0", "role": "Subject", "text": "a patient with an AVM", "start": 11, "end": 16}, {"entity_id": "16018164_2_Ent1", "role": "Subject_Disorder", "text": "AVM", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_2_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent2", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_2_Ent0", "text": "a patient with an AVM", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16018164_2_Ent1", "text": "AVM", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16018164_3", "wnd_id": "16018164_3_1", "text": "Pseudoephedrine - induced hemorrhage associated with a cerebral vascular malformation .", "tokens": ["Pseudoephedrine", "-", "induced", "hemorrhage", "associated", "with", "a", "cerebral", "vascular", "malformation", "."], "event_mentions": [{"id": "16018164_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16018164_3_Ent1", "role": "Treatment", "text": "Pseudoephedrine", "start": 0, "end": 1}, {"entity_id": "16018164_3_Ent2", "role": "Treatment_Drug", "text": "Pseudoephedrine", "start": 0, "end": 1}, {"entity_id": "16018164_3_Ent0", "role": "Effect", "text": "hemorrhage associated with a cerebral vascular malformation", "start": 3, "end": 10}]}], "entity_mentions": [{"id": "16018164_3_Ent1", "text": "Pseudoephedrine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16018164_3_Ent2", "text": "Pseudoephedrine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16018164_3_Ent0", "text": "hemorrhage associated with a cerebral vascular malformation", "entity_type": "Entity", "start": 3, "end": 10}], "lang": "en"}
{"doc_id": "16029707_2", "wnd_id": "16029707_2_1", "text": "METHODS : A 79 - year - old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy .", "tokens": ["METHODS", ":", "A", "79", "-", "year", "-", "old", "woman", "being", "treated", "with", "imiquimod", "5", "days", "per", "week", "for", "a", "nodular", "basal", "cell", "developed", "a", "verrucous", "plaque", "over", "the", "treatment", "area", "after", "7", "weeks", "of", "therapy", "."], "event_mentions": [{"id": "16029707_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "16029707_2_Ent0", "role": "Subject", "text": "A 79 - year - old woman", "start": 2, "end": 9}, {"entity_id": "16029707_2_Ent1", "role": "Subject_Age", "text": "79 - year - old", "start": 3, "end": 8}, {"entity_id": "16029707_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "16029707_2_Ent7", "role": "Treatment_Drug", "text": "imiquimod", "start": 12, "end": 13}, {"entity_id": "16029707_2_Ent4", "role": "Treatment", "text": "imiquimod 5 days per week", "start": 12, "end": 17}, {"entity_id": "16029707_2_Ent8", "role": "Treatment_Freq", "text": "5 days per week", "start": 13, "end": 17}, {"entity_id": "16029707_2_Ent6", "role": "Treatment_Disorder", "text": "nodular basal cell", "start": 19, "end": 22}, {"entity_id": "16029707_2_Ent3", "role": "Effect", "text": "verrucous plaque", "start": 24, "end": 26}, {"entity_id": "16029707_2_Ent5", "role": "Treatment", "text": "after 7 weeks", "start": 30, "end": 33}, {"entity_id": "16029707_2_Ent9", "role": "Treatment_Time_elapsed", "text": "7 weeks", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "16029707_2_Ent0", "text": "A 79 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "16029707_2_Ent1", "text": "79 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16029707_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16029707_2_Ent7", "text": "imiquimod", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16029707_2_Ent4", "text": "imiquimod 5 days per week", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "16029707_2_Ent8", "text": "5 days per week", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16029707_2_Ent6", "text": "nodular basal cell", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16029707_2_Ent3", "text": "verrucous plaque", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "16029707_2_Ent5", "text": "after 7 weeks", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "16029707_2_Ent9", "text": "7 weeks", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "16044093_2", "wnd_id": "16044093_2_1", "text": "The case reported here is of a child given a large dose of intravenous iron sucrose ( 16 mg / kg ) over 3 hours , who subsequently developed features of systemic iron toxicity .", "tokens": ["The", "case", "reported", "here", "is", "of", "a", "child", "given", "a", "large", "dose", "of", "intravenous", "iron", "sucrose", "(", "16", "mg", "/", "kg", ")", "over", "3", "hours", ",", "who", "subsequently", "developed", "features", "of", "systemic", "iron", "toxicity", "."], "event_mentions": [{"id": "16044093_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "16044093_2_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "16044093_2_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "16044093_2_Ent3", "role": "Treatment", "text": "a large dose of intravenous iron sucrose", "start": 9, "end": 16}, {"entity_id": "16044093_2_Ent4", "role": "Treatment_Drug", "text": "iron sucrose", "start": 14, "end": 16}, {"entity_id": "16044093_2_Ent5", "role": "Treatment_Dosage", "text": "16 mg / kg", "start": 17, "end": 21}, {"entity_id": "16044093_2_Ent6", "role": "Treatment_Duration", "text": "3 hours", "start": 23, "end": 25}, {"entity_id": "16044093_2_Ent2", "role": "Effect", "text": "systemic iron toxicity", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "16044093_2_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16044093_2_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16044093_2_Ent3", "text": "a large dose of intravenous iron sucrose", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "16044093_2_Ent4", "text": "iron sucrose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16044093_2_Ent5", "text": "16 mg / kg", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "16044093_2_Ent6", "text": "3 hours", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16044093_2_Ent2", "text": "systemic iron toxicity", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "16062101_4", "wnd_id": "16062101_4_1", "text": "The authors think that although lamivudine is widely used and well tolerated , it can cause ADRs , which are reversible after drug withdrawal .", "tokens": ["The", "authors", "think", "that", "although", "lamivudine", "is", "widely", "used", "and", "well", "tolerated", ",", "it", "can", "cause", "ADRs", ",", "which", "are", "reversible", "after", "drug", "withdrawal", "."], "event_mentions": [{"id": "16062101_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "16062101_4_Ent1", "role": "Treatment", "text": "lamivudine", "start": 5, "end": 6}, {"entity_id": "16062101_4_Ent2", "role": "Treatment_Drug", "text": "lamivudine", "start": 5, "end": 6}, {"entity_id": "16062101_4_Ent0", "role": "Effect", "text": "ADRs", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16062101_4_Ent1", "text": "lamivudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16062101_4_Ent2", "text": "lamivudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16062101_4_Ent0", "text": "ADRs", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16092915_1", "wnd_id": "16092915_1_1", "text": "CONCLUSIONS : This observation of \" on - off \" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent .", "tokens": ["CONCLUSIONS", ":", "This", "observation", "of", "\"", "on", "-", "off", "\"", "risperidone", "treatment", "suggests", "that", "risperidone", "may", "have", "worsened", "both", "psychiatric", "and", "physical", "manifestations", "of", "the", "mitochondrial", "disorder", "in", "this", "adolescent", "."], "event_mentions": [{"id": "16092915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have worsened", "start": 16, "end": 18}, "arguments": [{"entity_id": "16092915_1_Ent4", "role": "Treatment", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent3", "role": "Effect", "text": "psychiatric and physical manifestations", "start": 19, "end": 23}, {"entity_id": "16092915_1_Ent2", "role": "Subject_Disorder", "text": "mitochondrial disorder", "start": 25, "end": 27}, {"entity_id": "16092915_1_Ent0", "role": "Subject", "text": "mitochondrial disorder in this adolescent", "start": 25, "end": 30}, {"entity_id": "16092915_1_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "16092915_1_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent3", "text": "psychiatric and physical manifestations", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "16092915_1_Ent2", "text": "mitochondrial disorder", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16092915_1_Ent0", "text": "mitochondrial disorder in this adolescent", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "16092915_1_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "16099004_3", "wnd_id": "16099004_3_1", "text": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use .", "tokens": ["We", "report", "recrudescence", "of", "imported", "Plasmodium", "falciparum", "malaria", "following", "quinine", "treatment", "in", "the", "context", "of", "concurrent", "phenytoin", "use", "."], "event_mentions": [{"id": "16099004_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "16099004_3_Ent0", "role": "Effect", "text": "Plasmodium falciparum malaria", "start": 5, "end": 8}, {"entity_id": "16099004_3_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 9, "end": 10}, {"entity_id": "16099004_3_Ent5", "role": "Combination_Drug", "text": "quinine", "start": 9, "end": 10}, {"entity_id": "16099004_3_Ent1", "role": "Treatment", "text": "quinine treatment in the context of concurrent phenytoin use", "start": 9, "end": 18}, {"entity_id": "16099004_3_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 16, "end": 17}, {"entity_id": "16099004_3_Ent4", "role": "Combination_Drug", "text": "phenytoin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16099004_3_Ent0", "text": "Plasmodium falciparum malaria", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16099004_3_Ent2", "text": "quinine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16099004_3_Ent5", "text": "quinine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16099004_3_Ent1", "text": "quinine treatment in the context of concurrent phenytoin use", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "16099004_3_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16099004_3_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16101941_1", "wnd_id": "16101941_1_1", "text": "Anaphylactic reaction and unrelated , subsequent , known side effects during therapy with thiethylperazine .", "tokens": ["Anaphylactic", "reaction", "and", "unrelated", ",", "subsequent", ",", "known", "side", "effects", "during", "therapy", "with", "thiethylperazine", "."], "event_mentions": [{"id": "16101941_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "16101941_1_Ent0", "role": "Effect", "text": "Anaphylactic reaction", "start": 0, "end": 2}, {"entity_id": "16101941_1_Ent1", "role": "Treatment", "text": "thiethylperazine", "start": 13, "end": 14}, {"entity_id": "16101941_1_Ent2", "role": "Treatment_Drug", "text": "thiethylperazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16101941_1_Ent0", "text": "Anaphylactic reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16101941_1_Ent1", "text": "thiethylperazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16101941_1_Ent2", "text": "thiethylperazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16101941_2", "wnd_id": "16101941_2_1", "text": "We report the first case presenting with successive anaphylactic reaction and extra - pyramidal syndrome after treatment with thiethylperazine maleate ( thiethylperazine ) .", "tokens": ["We", "report", "the", "first", "case", "presenting", "with", "successive", "anaphylactic", "reaction", "and", "extra", "-", "pyramidal", "syndrome", "after", "treatment", "with", "thiethylperazine", "maleate", "(", "thiethylperazine", ")", "."], "event_mentions": [{"id": "16101941_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "16101941_2_Ent0", "role": "Effect", "text": "successive anaphylactic reaction and extra - pyramidal syndrome", "start": 7, "end": 15}, {"entity_id": "16101941_2_Ent1", "role": "Treatment", "text": "treatment with thiethylperazine maleate ( thiethylperazine )", "start": 16, "end": 23}, {"entity_id": "16101941_2_Ent2", "role": "Treatment_Drug", "text": "thiethylperazine maleate", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16101941_2_Ent0", "text": "successive anaphylactic reaction and extra - pyramidal syndrome", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "16101941_2_Ent1", "text": "treatment with thiethylperazine maleate ( thiethylperazine )", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "16101941_2_Ent2", "text": "thiethylperazine maleate", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16109609_3", "wnd_id": "16109609_3_1", "text": "Physicians should be aware of the potential for developing a gemcitabine - induced radiation recall reaction resulting in hemodynamically significant pericardial effusion .", "tokens": ["Physicians", "should", "be", "aware", "of", "the", "potential", "for", "developing", "a", "gemcitabine", "-", "induced", "radiation", "recall", "reaction", "resulting", "in", "hemodynamically", "significant", "pericardial", "effusion", "."], "event_mentions": [{"id": "16109609_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16109609_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16109609_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16109609_3_Ent0", "role": "Effect", "text": "radiation recall reaction resulting in hemodynamically significant pericardial effusion", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "16109609_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16109609_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16109609_3_Ent0", "text": "radiation recall reaction resulting in hemodynamically significant pericardial effusion", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "16122280_3", "wnd_id": "16122280_3_1", "text": "Clinical experience in infectious patients has shown that oral telithromycin 800 mg once daily for 5 - 10 days is effective for the treatment of community - acquired upper and lower respiratory tract infections .", "tokens": ["Clinical", "experience", "in", "infectious", "patients", "has", "shown", "that", "oral", "telithromycin", "800", "mg", "once", "daily", "for", "5", "-", "10", "days", "is", "effective", "for", "the", "treatment", "of", "community", "-", "acquired", "upper", "and", "lower", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "16122280_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "16122280_3_Ent1", "role": "Subject_Disorder", "text": "infectious", "start": 3, "end": 4}, {"entity_id": "16122280_3_Ent0", "role": "Subject", "text": "infectious patients", "start": 3, "end": 5}, {"entity_id": "16122280_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "16122280_3_Ent2", "role": "Treatment", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "start": 8, "end": 19}, {"entity_id": "16122280_3_Ent3", "role": "Treatment_Drug", "text": "telithromycin", "start": 9, "end": 10}, {"entity_id": "16122280_3_Ent4", "role": "Treatment_Dosage", "text": "800 mg", "start": 10, "end": 12}, {"entity_id": "16122280_3_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 12, "end": 14}, {"entity_id": "16122280_3_Ent6", "role": "Treatment_Duration", "text": "5 - 10 days", "start": 15, "end": 19}, {"entity_id": "16122280_3_Ent7", "role": "Treatment_Disorder", "text": "community - acquired upper and lower respiratory tract infections", "start": 25, "end": 34}]}], "entity_mentions": [{"id": "16122280_3_Ent1", "text": "infectious", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16122280_3_Ent0", "text": "infectious patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16122280_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16122280_3_Ent2", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "16122280_3_Ent3", "text": "telithromycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16122280_3_Ent4", "text": "800 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16122280_3_Ent5", "text": "once daily", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16122280_3_Ent6", "text": "5 - 10 days", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16122280_3_Ent7", "text": "community - acquired upper and lower respiratory tract infections", "entity_type": "Entity", "start": 25, "end": 34}], "lang": "en"}
{"doc_id": "16132305_5", "wnd_id": "16132305_5_1", "text": "After discontinuing captopril and starting systemic steroids , her symptomatology rapidly improved , and her eosinophilia and radiographic abnormalities both resolved .", "tokens": ["After", "discontinuing", "captopril", "and", "starting", "systemic", "steroids", ",", "her", "symptomatology", "rapidly", "improved", ",", "and", "her", "eosinophilia", "and", "radiographic", "abnormalities", "both", "resolved", "."], "event_mentions": [{"id": "16132305_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 20, "end": 21}, "arguments": [{"entity_id": "16132305_5_Ent1", "role": "Treatment", "text": "discontinuing captopril and starting systemic steroids", "start": 1, "end": 7}, {"entity_id": "16132305_5_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "16132305_5_Ent3", "role": "Treatment_Drug", "text": "steroids", "start": 6, "end": 7}, {"entity_id": "16132305_5_Ent0", "role": "Effect", "text": "her eosinophilia and radiographic abnormalities both resolved", "start": 14, "end": 21}, {"entity_id": "16132305_5_Ent4", "role": "Treatment_Disorder", "text": "eosinophilia", "start": 15, "end": 16}, {"entity_id": "16132305_5_Ent5", "role": "Treatment_Disorder", "text": "radiographic abnormalities", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "16132305_5_Ent1", "text": "discontinuing captopril and starting systemic steroids", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16132305_5_Ent2", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16132305_5_Ent3", "text": "steroids", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_5_Ent0", "text": "her eosinophilia and radiographic abnormalities both resolved", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "16132305_5_Ent4", "text": "eosinophilia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16132305_5_Ent5", "text": "radiographic abnormalities", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "16146480_2", "wnd_id": "16146480_2_1", "text": "Since elevated cortisol levels in Cushing 's disease poses a threat for pancreatitis , there is a possibility that patients with Cushing 's disease might be more prone to acute pancreatitis following propofol administration .", "tokens": ["Since", "elevated", "cortisol", "levels", "in", "Cushing", "'s", "disease", "poses", "a", "threat", "for", "pancreatitis", ",", "there", "is", "a", "possibility", "that", "patients", "with", "Cushing", "'s", "disease", "might", "be", "more", "prone", "to", "acute", "pancreatitis", "following", "propofol", "administration", "."], "event_mentions": [{"id": "16146480_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 31, "end": 32}, "arguments": [{"entity_id": "16146480_2_Ent0", "role": "Subject", "text": "patients with Cushing 's disease", "start": 19, "end": 24}, {"entity_id": "16146480_2_Ent4", "role": "Treatment_Disorder", "text": "Cushing 's disease", "start": 21, "end": 24}, {"entity_id": "16146480_2_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 29, "end": 31}, {"entity_id": "16146480_2_Ent2", "role": "Treatment", "text": "propofol", "start": 32, "end": 33}, {"entity_id": "16146480_2_Ent3", "role": "Treatment_Drug", "text": "propofol", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "16146480_2_Ent0", "text": "patients with Cushing 's disease", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16146480_2_Ent4", "text": "Cushing 's disease", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "16146480_2_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16146480_2_Ent2", "text": "propofol", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16146480_2_Ent3", "text": "propofol", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "16181292_2", "wnd_id": "16181292_2_1", "text": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration .", "tokens": ["Severe", "loss", "of", "vision", "after", "removal", "of", "cataract", "caused", "by", "intravitreal", "triamcinolone", "in", "combination", "with", "photodynamic", "therapy", "for", "exudative", "age", "-", "related", "macular", "degeneration", "."], "event_mentions": [{"id": "16181292_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "16181292_2_Ent0", "role": "Effect", "text": "Severe loss of vision", "start": 0, "end": 4}, {"entity_id": "16181292_2_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone", "start": 10, "end": 12}, {"entity_id": "16181292_2_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent6", "role": "Combination_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent2", "role": "Treatment", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent4", "role": "Treatment_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent7", "role": "Combination_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent5", "role": "Treatment_Disorder", "text": "exudative age - related macular degeneration", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "16181292_2_Ent0", "text": "Severe loss of vision", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16181292_2_Ent1", "text": "intravitreal triamcinolone", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16181292_2_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent6", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent2", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent4", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent7", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent5", "text": "exudative age - related macular degeneration", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "16196187_3", "wnd_id": "16196187_3_1", "text": "We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously .", "tokens": ["We", "present", "a", "case", "of", "acute", "epinephrine", "toxicity", "resulting", "in", "acute", "myocardial", "ischemia", "in", "a", "young", "boy", "with", "combined", "variable", "immunodeficiency", "syndrome", "who", "developed", "severe", "allergic", "reaction", "to", "intravenous", "immunoglobulin", ",", "and", "was", "subsequently", "given", "epinephrine", "by", "mistake", "intravenously", "rather", "than", "subcutaneously", "."], "event_mentions": [{"id": "16196187_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 7, "end": 8}, "arguments": [{"entity_id": "16196187_3_Ent5", "role": "Treatment", "text": "acute epinephrine", "start": 5, "end": 7}, {"entity_id": "16196187_3_Ent7", "role": "Treatment_Drug", "text": "epinephrine", "start": 6, "end": 7}, {"entity_id": "16196187_3_Ent3", "role": "Effect", "text": "acute myocardial ischemia", "start": 10, "end": 13}, {"entity_id": "16196187_3_Ent0", "role": "Subject", "text": "a young boy with combined variable immunodeficiency syndrome", "start": 14, "end": 22}, {"entity_id": "16196187_3_Ent1", "role": "Subject_Age", "text": "young", "start": 15, "end": 16}, {"entity_id": "16196187_3_Ent2", "role": "Subject_Gender", "text": "boy", "start": 16, "end": 17}, {"entity_id": "16196187_3_Ent9", "role": "Treatment_Disorder", "text": "combined variable immunodeficiency syndrome", "start": 18, "end": 22}, {"entity_id": "16196187_3_Ent4", "role": "Effect", "text": "severe allergic reaction", "start": 24, "end": 27}, {"entity_id": "16196187_3_Ent11", "role": "Treatment_Route", "text": "intravenous", "start": 28, "end": 29}, {"entity_id": "16196187_3_Ent6", "role": "Treatment", "text": "intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously", "start": 28, "end": 42}, {"entity_id": "16196187_3_Ent8", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 29, "end": 30}, {"entity_id": "16196187_3_Ent10", "role": "Treatment_Route", "text": "intravenously", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "16196187_3_Ent5", "text": "acute epinephrine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16196187_3_Ent7", "text": "epinephrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16196187_3_Ent3", "text": "acute myocardial ischemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16196187_3_Ent0", "text": "a young boy with combined variable immunodeficiency syndrome", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "16196187_3_Ent1", "text": "young", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16196187_3_Ent2", "text": "boy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16196187_3_Ent9", "text": "combined variable immunodeficiency syndrome", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "16196187_3_Ent4", "text": "severe allergic reaction", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "16196187_3_Ent11", "text": "intravenous", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16196187_3_Ent6", "text": "intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously", "entity_type": "Entity", "start": 28, "end": 42}, {"id": "16196187_3_Ent8", "text": "immunoglobulin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "16196187_3_Ent10", "text": "intravenously", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "16200540_1", "wnd_id": "16200540_1_1", "text": "Polysomnographic and pharmacokinetic findings in levodopa - induced augmentation of restless legs syndrome .", "tokens": ["Polysomnographic", "and", "pharmacokinetic", "findings", "in", "levodopa", "-", "induced", "augmentation", "of", "restless", "legs", "syndrome", "."], "event_mentions": [{"id": "16200540_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16200540_1_Ent1", "role": "Treatment", "text": "levodopa", "start": 5, "end": 6}, {"entity_id": "16200540_1_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 5, "end": 6}, {"entity_id": "16200540_1_Ent0", "role": "Effect", "text": "augmentation of restless legs syndrome", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "16200540_1_Ent1", "text": "levodopa", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16200540_1_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16200540_1_Ent0", "text": "augmentation of restless legs syndrome", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "16200540_4", "wnd_id": "16200540_4_1", "text": "We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment .", "tokens": ["We", "describe", "a", "patient", "with", "idiopathic", "RLS", "who", "developed", "augmentation", "after", "8", "months", "of", "levodopa", "treatment", "."], "event_mentions": [{"id": "16200540_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16200540_4_Ent0", "role": "Subject", "text": "a patient with idiopathic RLS", "start": 2, "end": 7}, {"entity_id": "16200540_4_Ent3", "role": "Treatment_Disorder", "text": "idiopathic RLS", "start": 5, "end": 7}, {"entity_id": "16200540_4_Ent1", "role": "Effect", "text": "augmentation", "start": 9, "end": 10}, {"entity_id": "16200540_4_Ent2", "role": "Treatment", "text": "after 8 months of levodopa treatment", "start": 10, "end": 16}, {"entity_id": "16200540_4_Ent4", "role": "Treatment_Time_elapsed", "text": "8 months", "start": 11, "end": 13}, {"entity_id": "16200540_4_Ent5", "role": "Treatment_Drug", "text": "levodopa", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16200540_4_Ent0", "text": "a patient with idiopathic RLS", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16200540_4_Ent3", "text": "idiopathic RLS", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16200540_4_Ent1", "text": "augmentation", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16200540_4_Ent2", "text": "after 8 months of levodopa treatment", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "16200540_4_Ent4", "text": "8 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16200540_4_Ent5", "text": "levodopa", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16211208_2", "wnd_id": "16211208_2_1", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale .", "tokens": ["Marked", "QT", "prolongation", "and", "torsades", "de", "pointes", "secondary", "to", "acute", "ischemia", "in", "an", "elderly", "man", "taking", "dofetilide", "for", "atrial", "fibrillation", ":", "a", "cautionary", "tale", "."], "event_mentions": [{"id": "16211208_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 15, "end": 16}, "arguments": [{"entity_id": "16211208_2_Ent3", "role": "Effect", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "start": 0, "end": 11}, {"entity_id": "16211208_2_Ent0", "role": "Subject", "text": "an elderly man", "start": 12, "end": 15}, {"entity_id": "16211208_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "16211208_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "16211208_2_Ent4", "role": "Treatment", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent5", "role": "Treatment_Drug", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent6", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16211208_2_Ent3", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "16211208_2_Ent0", "text": "an elderly man", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16211208_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16211208_2_Ent2", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16211208_2_Ent4", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent5", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent6", "text": "atrial fibrillation", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16225183_7", "wnd_id": "16225183_7_1", "text": "SUBSEQUENT COURSE : The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment .", "tokens": ["SUBSEQUENT", "COURSE", ":", "The", "nephrosis", "resolved", "almost", "completely", "once", "the", "interferon", "was", "stopped", "and", "after", "immunosuppressive", "treatment", "."], "event_mentions": [{"id": "16225183_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "16225183_7_Ent3", "role": "Treatment_Disorder", "text": "nephrosis", "start": 4, "end": 5}, {"entity_id": "16225183_7_Ent1", "role": "Treatment_Drug", "text": "interferon", "start": 10, "end": 11}, {"entity_id": "16225183_7_Ent0", "role": "Treatment", "text": "interferon was stopped and after immunosuppressive treatment", "start": 10, "end": 17}, {"entity_id": "16225183_7_Ent2", "role": "Treatment_Drug", "text": "immunosuppressive", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16225183_7_Ent3", "text": "nephrosis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16225183_7_Ent1", "text": "interferon", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16225183_7_Ent0", "text": "interferon was stopped and after immunosuppressive treatment", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16225183_7_Ent2", "text": "immunosuppressive", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16239768_1", "wnd_id": "16239768_1_1", "text": "A 56 - year - old white woman with a diagnosis of reactive depression developed severe UI after a 30 days ' treatment with venlafaxine 75 mg / day .", "tokens": ["A", "56", "-", "year", "-", "old", "white", "woman", "with", "a", "diagnosis", "of", "reactive", "depression", "developed", "severe", "UI", "after", "a", "30", "days", "'", "treatment", "with", "venlafaxine", "75", "mg", "/", "day", "."], "event_mentions": [{"id": "16239768_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "16239768_1_Ent0", "role": "Subject", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "start": 0, "end": 14}, {"entity_id": "16239768_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "16239768_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "16239768_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16239768_1_Ent6", "role": "Treatment_Disorder", "text": "reactive depression", "start": 12, "end": 14}, {"entity_id": "16239768_1_Ent4", "role": "Effect", "text": "severe UI", "start": 15, "end": 17}, {"entity_id": "16239768_1_Ent7", "role": "Treatment_Time_elapsed", "text": "30 days", "start": 19, "end": 21}, {"entity_id": "16239768_1_Ent5", "role": "Treatment", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "start": 19, "end": 30}, {"entity_id": "16239768_1_Ent8", "role": "Treatment_Drug", "text": "venlafaxine", "start": 24, "end": 25}, {"entity_id": "16239768_1_Ent9", "role": "Treatment_Dosage", "text": "75 mg / day", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16239768_1_Ent0", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "16239768_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16239768_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16239768_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16239768_1_Ent6", "text": "reactive depression", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16239768_1_Ent4", "text": "severe UI", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16239768_1_Ent7", "text": "30 days", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16239768_1_Ent5", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "entity_type": "Entity", "start": 19, "end": 30}, {"id": "16239768_1_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16239768_1_Ent9", "text": "75 mg / day", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "1624172_2", "wnd_id": "1624172_2_1", "text": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "tokens": ["Sustained", "hypothyroidism", "induced", "by", "recombinant", "alpha", "interferon", "in", "patients", "with", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "1624172_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1624172_2_Ent1", "role": "Effect", "text": "Sustained hypothyroidism", "start": 0, "end": 2}, {"entity_id": "1624172_2_Ent2", "role": "Treatment", "text": "recombinant alpha interferon", "start": 4, "end": 7}, {"entity_id": "1624172_2_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 4, "end": 7}, {"entity_id": "1624172_2_Ent0", "role": "Subject", "text": "patients with chronic hepatitis C.", "start": 8, "end": 13}, {"entity_id": "1624172_2_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1624172_2_Ent1", "text": "Sustained hypothyroidism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_2_Ent2", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1624172_2_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1624172_2_Ent0", "text": "patients with chronic hepatitis C.", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "1624172_2_Ent3", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "16244351_1", "wnd_id": "16244351_1_1", "text": "Atrial fibrillation after vardenafil therapy .", "tokens": ["Atrial", "fibrillation", "after", "vardenafil", "therapy", "."], "event_mentions": [{"id": "16244351_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16244351_1_Ent0", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "16244351_1_Ent2", "role": "Treatment_Drug", "text": "vardenafil", "start": 3, "end": 4}, {"entity_id": "16244351_1_Ent1", "role": "Treatment", "text": "vardenafil therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16244351_1_Ent0", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16244351_1_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16244351_1_Ent1", "text": "vardenafil therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16268429_1", "wnd_id": "16268429_1_1", "text": "In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury .", "tokens": ["In", "this", "case", "senna", "was", "likely", "the", "cause", "of", "a", "subacute", "cholestatic", "hepatitis", "exemplifying", "again", "the", "potential", "role", "of", "herbal", "related", "liver", "injury", "."], "event_mentions": [{"id": "16268429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_1_Ent2", "role": "Treatment", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent0", "role": "Effect", "text": "a subacute cholestatic hepatitis", "start": 9, "end": 13}, {"entity_id": "16268429_1_Ent1", "role": "Effect", "text": "herbal related liver injury", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "16268429_1_Ent2", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent3", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent0", "text": "a subacute cholestatic hepatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16268429_1_Ent1", "text": "herbal related liver injury", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "16284443_2", "wnd_id": "16284443_2_1", "text": "Insulin - induced lipohypertrophy : report of a case with histopathology .", "tokens": ["Insulin", "-", "induced", "lipohypertrophy", ":", "report", "of", "a", "case", "with", "histopathology", "."], "event_mentions": [{"id": "16284443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16284443_2_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "16284443_2_Ent2", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "16284443_2_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16284443_2_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16284443_2_Ent2", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16284443_2_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16288069_4", "wnd_id": "16288069_4_1", "text": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin .", "tokens": ["The", "patient", "described", "feeling", "cold", "with", "worsening", "headache", "and", "chills", "approximately", "one", "hour", "after", "infusion", "of", "the", "first", "dose", "of", "penicillin", "."], "event_mentions": [{"id": "16288069_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "16288069_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "16288069_4_Ent1", "role": "Effect", "text": "feeling cold with worsening headache and chills", "start": 3, "end": 10}, {"entity_id": "16288069_4_Ent3", "role": "Treatment_Time_elapsed", "text": "one hour", "start": 11, "end": 13}, {"entity_id": "16288069_4_Ent2", "role": "Treatment", "text": "one hour after infusion of the first dose of penicillin", "start": 11, "end": 21}, {"entity_id": "16288069_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 14, "end": 15}, {"entity_id": "16288069_4_Ent5", "role": "Treatment_Drug", "text": "penicillin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "16288069_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16288069_4_Ent1", "text": "feeling cold with worsening headache and chills", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "16288069_4_Ent3", "text": "one hour", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16288069_4_Ent2", "text": "one hour after infusion of the first dose of penicillin", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "16288069_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16288069_4_Ent5", "text": "penicillin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "16313549_2", "wnd_id": "16313549_2_1", "text": "We report three cases of severe hypocalcaemia associated with i.v . bisphosphonate treatment in patients with multiple myeloma .", "tokens": ["We", "report", "three", "cases", "of", "severe", "hypocalcaemia", "associated", "with", "i.v", ".", "bisphosphonate", "treatment", "in", "patients", "with", "multiple", "myeloma", "."], "event_mentions": [{"id": "16313549_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16313549_2_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "16313549_2_Ent2", "role": "Effect", "text": "severe hypocalcaemia", "start": 5, "end": 7}, {"entity_id": "16313549_2_Ent6", "role": "Treatment_Route", "text": "i.v .", "start": 9, "end": 11}, {"entity_id": "16313549_2_Ent3", "role": "Treatment", "text": "i.v . bisphosphonate treatment", "start": 9, "end": 13}, {"entity_id": "16313549_2_Ent5", "role": "Treatment_Drug", "text": "bisphosphonate", "start": 11, "end": 12}, {"entity_id": "16313549_2_Ent0", "role": "Subject", "text": "patients with multiple myeloma", "start": 14, "end": 18}, {"entity_id": "16313549_2_Ent4", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16313549_2_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16313549_2_Ent2", "text": "severe hypocalcaemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16313549_2_Ent6", "text": "i.v .", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16313549_2_Ent3", "text": "i.v . bisphosphonate treatment", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16313549_2_Ent5", "text": "bisphosphonate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16313549_2_Ent0", "text": "patients with multiple myeloma", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16313549_2_Ent4", "text": "multiple myeloma", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16317298_3", "wnd_id": "16317298_3_1", "text": "Radiation recall from gemcitabine is rare , but can potentially arise in any site that has been previously irradiated .", "tokens": ["Radiation", "recall", "from", "gemcitabine", "is", "rare", ",", "but", "can", "potentially", "arise", "in", "any", "site", "that", "has", "been", "previously", "irradiated", "."], "event_mentions": [{"id": "16317298_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "16317298_3_Ent0", "role": "Effect", "text": "Radiation recall", "start": 0, "end": 2}, {"entity_id": "16317298_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 3, "end": 4}, {"entity_id": "16317298_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16317298_3_Ent0", "text": "Radiation recall", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16317298_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16317298_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16317298_4", "wnd_id": "16317298_4_1", "text": "Radiation recall related to gemcitabine has been reported in lung and breast cancer .", "tokens": ["Radiation", "recall", "related", "to", "gemcitabine", "has", "been", "reported", "in", "lung", "and", "breast", "cancer", "."], "event_mentions": [{"id": "16317298_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16317298_4_Ent0", "role": "Effect", "text": "Radiation recall", "start": 0, "end": 2}, {"entity_id": "16317298_4_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 4, "end": 5}, {"entity_id": "16317298_4_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 4, "end": 5}, {"entity_id": "16317298_4_Ent2", "role": "Treatment_Disorder", "text": "lung and breast cancer", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "16317298_4_Ent0", "text": "Radiation recall", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16317298_4_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16317298_4_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16317298_4_Ent2", "text": "lung and breast cancer", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "16317298_5", "wnd_id": "16317298_5_1", "text": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation - recall related to gemcitabine and review literature .", "tokens": ["We", "report", "a", "patient", "with", "inoperable", "pancreatic", "cancer", "who", "developed", "gastrointestinal", "bleeding", "secondary", "to", "radiation", "-", "recall", "related", "to", "gemcitabine", "and", "review", "literature", "."], "event_mentions": [{"id": "16317298_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "16317298_5_Ent0", "role": "Subject", "text": "a patient with inoperable pancreatic cancer", "start": 2, "end": 8}, {"entity_id": "16317298_5_Ent4", "role": "Treatment_Disorder", "text": "inoperable pancreatic cancer", "start": 5, "end": 8}, {"entity_id": "16317298_5_Ent1", "role": "Effect", "text": "gastrointestinal bleeding", "start": 10, "end": 12}, {"entity_id": "16317298_5_Ent2", "role": "Effect", "text": "radiation - recall", "start": 14, "end": 17}, {"entity_id": "16317298_5_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 19, "end": 20}, {"entity_id": "16317298_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16317298_5_Ent0", "text": "a patient with inoperable pancreatic cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16317298_5_Ent4", "text": "inoperable pancreatic cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16317298_5_Ent1", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16317298_5_Ent2", "text": "radiation - recall", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16317298_5_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16317298_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16326413_2", "wnd_id": "16326413_2_1", "text": "High - dose methotrexate - associated acute renal failure may be an avoidable complication .", "tokens": ["High", "-", "dose", "methotrexate", "-", "associated", "acute", "renal", "failure", "may", "be", "an", "avoidable", "complication", "."], "event_mentions": [{"id": "16326413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "16326413_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "16326413_2_Ent1", "role": "Treatment", "text": "High - dose methotrexate", "start": 0, "end": 4}, {"entity_id": "16326413_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "16326413_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16326413_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16326413_2_Ent1", "text": "High - dose methotrexate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16326413_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16326413_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16341621_1", "wnd_id": "16341621_1_1", "text": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence .", "tokens": ["Massive", "prolapse", "of", "the", "urethral", "mucosa", "following", "periurethral", "injection", "of", "calcium", "hydroxylapatite", "for", "stress", "urinary", "incontinence", "."], "event_mentions": [{"id": "16341621_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "16341621_1_Ent0", "role": "Effect", "text": "Massive prolapse of the urethral mucosa", "start": 0, "end": 6}, {"entity_id": "16341621_1_Ent3", "role": "Treatment_Route", "text": "periurethral injection", "start": 7, "end": 9}, {"entity_id": "16341621_1_Ent1", "role": "Treatment", "text": "periurethral injection of calcium hydroxylapatite", "start": 7, "end": 12}, {"entity_id": "16341621_1_Ent2", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 10, "end": 12}, {"entity_id": "16341621_1_Ent4", "role": "Treatment_Disorder", "text": "stress urinary incontinence", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16341621_1_Ent0", "text": "Massive prolapse of the urethral mucosa", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "16341621_1_Ent3", "text": "periurethral injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16341621_1_Ent1", "text": "periurethral injection of calcium hydroxylapatite", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16341621_1_Ent2", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16341621_1_Ent4", "text": "stress urinary incontinence", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16341621_2", "wnd_id": "16341621_2_1", "text": "The authors present a case report of a granulomatous reaction leading to urethral prolapse , 3 months after the transurethral injection of calcium hydroxylapatite .", "tokens": ["The", "authors", "present", "a", "case", "report", "of", "a", "granulomatous", "reaction", "leading", "to", "urethral", "prolapse", ",", "3", "months", "after", "the", "transurethral", "injection", "of", "calcium", "hydroxylapatite", "."], "event_mentions": [{"id": "16341621_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "16341621_2_Ent0", "role": "Subject", "text": "a case report", "start": 3, "end": 6}, {"entity_id": "16341621_2_Ent1", "role": "Effect", "text": "granulomatous reaction", "start": 8, "end": 10}, {"entity_id": "16341621_2_Ent2", "role": "Effect", "text": "urethral prolapse", "start": 12, "end": 14}, {"entity_id": "16341621_2_Ent4", "role": "Treatment_Time_elapsed", "text": "3 months", "start": 15, "end": 17}, {"entity_id": "16341621_2_Ent3", "role": "Treatment", "text": "3 months after the transurethral injection of calcium hydroxylapatite", "start": 15, "end": 24}, {"entity_id": "16341621_2_Ent5", "role": "Treatment_Route", "text": "transurethral injection", "start": 19, "end": 21}, {"entity_id": "16341621_2_Ent6", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "16341621_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "16341621_2_Ent1", "text": "granulomatous reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16341621_2_Ent2", "text": "urethral prolapse", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16341621_2_Ent4", "text": "3 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16341621_2_Ent3", "text": "3 months after the transurethral injection of calcium hydroxylapatite", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "16341621_2_Ent5", "text": "transurethral injection", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16341621_2_Ent6", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "16352777_3", "wnd_id": "16352777_3_1", "text": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis .", "tokens": ["Torsemide", "appears", "to", "also", "be", "a", "part", "of", "a", "long", "list", "of", "agents", "that", "can", "cause", "pancreatitis", "."], "event_mentions": [{"id": "16352777_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "16352777_3_Ent1", "role": "Treatment", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent2", "role": "Treatment_Drug", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16352777_3_Ent1", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent2", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16371793_11", "wnd_id": "16371793_11_1", "text": "CONCLUSIONS : Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy - resistant cystoid macular edema after penetrating keratoplasty .", "tokens": ["CONCLUSIONS", ":", "Intravitreal", "injection", "of", "triamcinolone", "acetonide", "may", "be", "an", "additional", "tool", "in", "the", "treatment", "of", "therapy", "-", "resistant", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "16371793_11_Ent1", "role": "Treatment_Route", "text": "Intravitreal injection", "start": 2, "end": 4}, {"entity_id": "16371793_11_Ent0", "role": "Treatment", "text": "Intravitreal injection of triamcinolone acetonide", "start": 2, "end": 7}, {"entity_id": "16371793_11_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 5, "end": 7}, {"entity_id": "16371793_11_Ent3", "role": "Treatment_Disorder", "text": "therapy - resistant cystoid macular edema", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "16371793_11_Ent1", "text": "Intravitreal injection", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16371793_11_Ent0", "text": "Intravitreal injection of triamcinolone acetonide", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16371793_11_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16371793_11_Ent3", "text": "therapy - resistant cystoid macular edema", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "16393774_3", "wnd_id": "16393774_3_1", "text": "Therapy with IFN - beta has rarely been associated with the development of autoimmune disorders .", "tokens": ["Therapy", "with", "IFN", "-", "beta", "has", "rarely", "been", "associated", "with", "the", "development", "of", "autoimmune", "disorders", "."], "event_mentions": [{"id": "16393774_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 11, "end": 12}, "arguments": [{"entity_id": "16393774_3_Ent1", "role": "Treatment", "text": "IFN - beta", "start": 2, "end": 5}, {"entity_id": "16393774_3_Ent2", "role": "Treatment_Drug", "text": "IFN - beta", "start": 2, "end": 5}, {"entity_id": "16393774_3_Ent0", "role": "Effect", "text": "autoimmune disorders", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16393774_3_Ent1", "text": "IFN - beta", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16393774_3_Ent2", "text": "IFN - beta", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16393774_3_Ent0", "text": "autoimmune disorders", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16393774_4", "wnd_id": "16393774_4_1", "text": "We present the cases of two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS ) who developed inflammatory musculoskeletal manifestations , following IFN - beta therapy .", "tokens": ["We", "present", "the", "cases", "of", "two", "female", "patients", "diagnosed", "with", "relapsing", "-", "remitting", "multiple", "sclerosis", "(", "RRMS", ")", "who", "developed", "inflammatory", "musculoskeletal", "manifestations", ",", "following", "IFN", "-", "beta", "therapy", "."], "event_mentions": [{"id": "16393774_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16393774_4_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "16393774_4_Ent0", "role": "Subject", "text": "two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS )", "start": 5, "end": 18}, {"entity_id": "16393774_4_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "16393774_4_Ent6", "role": "Treatment_Disorder", "text": "relapsing - remitting multiple sclerosis", "start": 10, "end": 15}, {"entity_id": "16393774_4_Ent3", "role": "Effect", "text": "inflammatory musculoskeletal manifestations", "start": 20, "end": 23}, {"entity_id": "16393774_4_Ent4", "role": "Treatment", "text": "IFN - beta", "start": 25, "end": 28}, {"entity_id": "16393774_4_Ent5", "role": "Treatment_Drug", "text": "IFN - beta", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "16393774_4_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16393774_4_Ent0", "text": "two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS )", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "16393774_4_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16393774_4_Ent6", "text": "relapsing - remitting multiple sclerosis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16393774_4_Ent3", "text": "inflammatory musculoskeletal manifestations", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "16393774_4_Ent4", "text": "IFN - beta", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "16393774_4_Ent5", "text": "IFN - beta", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "16396068_1", "wnd_id": "16396068_1_1", "text": "Trimethoprim - sulfamethoxazole - induced aseptic meningitis .", "tokens": ["Trimethoprim", "-", "sulfamethoxazole", "-", "induced", "aseptic", "meningitis", "."], "event_mentions": [{"id": "16396068_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16396068_1_Ent1", "role": "Treatment", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent2", "role": "Treatment_Drug", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent0", "role": "Effect", "text": "aseptic meningitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16396068_1_Ent1", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent2", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent0", "text": "aseptic meningitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16404563_4", "wnd_id": "16404563_4_1", "text": "Nocardia is an important opportunistic infectious agent in immunocompromised hosts , i.e. in patients taking corticosteroids .", "tokens": ["Nocardia", "is", "an", "important", "opportunistic", "infectious", "agent", "in", "immunocompromised", "hosts", ",", "i.e.", "in", "patients", "taking", "corticosteroids", "."], "event_mentions": [{"id": "16404563_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "infectious agent", "start": 5, "end": 7}, "arguments": [{"entity_id": "16404563_4_Ent2", "role": "Effect", "text": "Nocardia", "start": 0, "end": 1}, {"entity_id": "16404563_4_Ent1", "role": "Subject_Disorder", "text": "immunocompromised", "start": 8, "end": 9}, {"entity_id": "16404563_4_Ent0", "role": "Subject", "text": "immunocompromised hosts", "start": 8, "end": 10}, {"entity_id": "16404563_4_Ent3", "role": "Treatment", "text": "corticosteroids", "start": 15, "end": 16}, {"entity_id": "16404563_4_Ent4", "role": "Treatment_Drug", "text": "corticosteroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16404563_4_Ent2", "text": "Nocardia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16404563_4_Ent1", "text": "immunocompromised", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16404563_4_Ent0", "text": "immunocompromised hosts", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16404563_4_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16404563_4_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16404563_6", "wnd_id": "16404563_6_1", "text": "In this paper , we report a patient with primary anti - phospholipid syndrome treated by corticosteroid , who developed disseminated nocardiosis .", "tokens": ["In", "this", "paper", ",", "we", "report", "a", "patient", "with", "primary", "anti", "-", "phospholipid", "syndrome", "treated", "by", "corticosteroid", ",", "who", "developed", "disseminated", "nocardiosis", "."], "event_mentions": [{"id": "16404563_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16404563_6_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "16404563_6_Ent4", "role": "Treatment_Disorder", "text": "anti - phospholipid syndrome", "start": 10, "end": 14}, {"entity_id": "16404563_6_Ent2", "role": "Treatment", "text": "corticosteroid", "start": 16, "end": 17}, {"entity_id": "16404563_6_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 16, "end": 17}, {"entity_id": "16404563_6_Ent1", "role": "Effect", "text": "disseminated nocardiosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16404563_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16404563_6_Ent4", "text": "anti - phospholipid syndrome", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16404563_6_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16404563_6_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16404563_6_Ent1", "text": "disseminated nocardiosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16411025_1", "wnd_id": "16411025_1_1", "text": "DESIGN : We reviewed the medical records of four patients , who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX .", "tokens": ["DESIGN", ":", "We", "reviewed", "the", "medical", "records", "of", "four", "patients", ",", "who", "were", "seen", "by", "us", "between", "July", "2000", "and", "February", "2004", "for", "sudden", "onset", "of", "a", "central", "neurological", "syndrome", "within", "days", "of", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intrathecal", "start": 33, "end": 34}, "arguments": [{"entity_id": "16411025_1_Ent0", "role": "Subject", "text": "medical records of four patients", "start": 5, "end": 10}, {"entity_id": "16411025_1_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "16411025_1_Ent2", "role": "Effect", "text": "a central neurological syndrome", "start": 26, "end": 30}, {"entity_id": "16411025_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within days", "start": 30, "end": 32}, {"entity_id": "16411025_1_Ent3", "role": "Treatment", "text": "MTX", "start": 34, "end": 35}, {"entity_id": "16411025_1_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16411025_1_Ent0", "text": "medical records of four patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16411025_1_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16411025_1_Ent2", "text": "a central neurological syndrome", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "16411025_1_Ent5", "text": "within days", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "16411025_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16411025_1_Ent4", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16411025_2", "wnd_id": "16411025_2_1", "text": "Diffusion - weighted MRI correlates of subacute methotrexate - related neurotoxicity .", "tokens": ["Diffusion", "-", "weighted", "MRI", "correlates", "of", "subacute", "methotrexate", "-", "related", "neurotoxicity", "."], "event_mentions": [{"id": "16411025_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "16411025_2_Ent0", "role": "Effect", "text": "subacute", "start": 6, "end": 7}, {"entity_id": "16411025_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "16411025_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "16411025_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16411025_2_Ent0", "text": "subacute", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16411025_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16411025_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16411025_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16411025_3", "wnd_id": "16411025_3_1", "text": "OBJECTIVES : A delayed stroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( MTX ) for childhood leukemia .", "tokens": ["OBJECTIVES", ":", "A", "delayed", "stroke", "-", "like", "leukoencephalopathy", "has", "been", "observed", "in", "patients", "receiving", "methotrexate", "(", "MTX", ")", "for", "childhood", "leukemia", "."], "event_mentions": [{"id": "16411025_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "has been observed", "start": 8, "end": 11}, "arguments": [{"entity_id": "16411025_3_Ent3", "role": "Effect", "text": "delayed stroke - like leukoencephalopathy", "start": 3, "end": 8}, {"entity_id": "16411025_3_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "16411025_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "16411025_3_Ent4", "role": "Treatment", "text": "methotrexate ( MTX )", "start": 14, "end": 18}, {"entity_id": "16411025_3_Ent2", "role": "Subject_Age", "text": "childhood", "start": 19, "end": 20}, {"entity_id": "16411025_3_Ent1", "role": "Subject", "text": "childhood leukemia", "start": 19, "end": 21}, {"entity_id": "16411025_3_Ent6", "role": "Treatment_Disorder", "text": "childhood leukemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "16411025_3_Ent3", "text": "delayed stroke - like leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16411025_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16411025_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16411025_3_Ent4", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16411025_3_Ent2", "text": "childhood", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16411025_3_Ent1", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16411025_3_Ent6", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "16411025_4", "wnd_id": "16411025_4_1", "text": "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX .", "tokens": ["Our", "objective", "is", "to", "present", "a", "retrospective", "analysis", "of", "the", "DWI", "findings", "in", "four", "patients", "who", "suffered", "subacute", "neurotoxicity", "after", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "16411025_4_Ent1", "role": "Subject_Population", "text": "four", "start": 13, "end": 14}, {"entity_id": "16411025_4_Ent0", "role": "Subject", "text": "four patients", "start": 13, "end": 15}, {"entity_id": "16411025_4_Ent2", "role": "Effect", "text": "subacute neurotoxicity", "start": 17, "end": 19}, {"entity_id": "16411025_4_Ent3", "role": "Treatment", "text": "intrathecal MTX", "start": 20, "end": 22}, {"entity_id": "16411025_4_Ent4", "role": "Treatment_Drug", "text": "intrathecal MTX", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16411025_4_Ent1", "text": "four", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16411025_4_Ent0", "text": "four patients", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16411025_4_Ent2", "text": "subacute neurotoxicity", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16411025_4_Ent3", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16411025_4_Ent4", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16421117_1", "wnd_id": "16421117_1_1", "text": "CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the \" indirect \" pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop .", "tokens": ["CONCLUSION", ":", "The", "present", "findings", "suggest", "that", ":", "(", "i", ")", "amantadine", "probably", "exerts", "its", "anti", "-", "dyskinetic", "effect", "by", "acting", "on", "the", "\"", "indirect", "\"", "pathway", ";", "(", "ii", ")", "the", "pathophysiological", "mechanisms", "of", "subthalamotomy", "induced", "dyskinesias", "may", "differ", "from", "those", "involved", "in", "L", "-", "dopa", "induced", "dyskinesias", ";", "(", "iii", ")", "dyskinesias", "induced", "by", "STN", "surgery", "resolve", "spontaneously", "as", "compensatory", "mechanisms", "develop", "."], "event_mentions": [{"id": "16421117_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "exerts", "start": 13, "end": 14}, "arguments": [{"entity_id": "16421117_1_Ent1", "role": "Treatment", "text": "amantadine", "start": 11, "end": 12}, {"entity_id": "16421117_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 11, "end": 12}, {"entity_id": "16421117_1_Ent0", "role": "Effect", "text": "anti - dyskinetic effect", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "16421117_1_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16421117_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16421117_1_Ent0", "text": "anti - dyskinetic effect", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "16421117_2", "wnd_id": "16421117_2_1", "text": "Prior to surgery , levodopa induced dyskinesia had improved ( < or = 50 % ) under treatment with amantadine ( 400 mg / day , po ) in all three patients .", "tokens": ["Prior", "to", "surgery", ",", "levodopa", "induced", "dyskinesia", "had", "improved", "(", "<", "or", "=", "50", "%", ")", "under", "treatment", "with", "amantadine", "(", "400", "mg", "/", "day", ",", "po", ")", "in", "all", "three", "patients", "."], "event_mentions": [{"id": "16421117_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 8, "end": 9}, "arguments": [{"entity_id": "16421117_2_Ent2", "role": "Effect", "text": "levodopa induced dyskinesia", "start": 4, "end": 7}, {"entity_id": "16421117_2_Ent3", "role": "Treatment", "text": "treatment with amantadine ( 400 mg / day , po )", "start": 17, "end": 28}, {"entity_id": "16421117_2_Ent4", "role": "Treatment_Drug", "text": "amantadine", "start": 19, "end": 20}, {"entity_id": "16421117_2_Ent5", "role": "Treatment_Dosage", "text": "400 mg / day", "start": 21, "end": 25}, {"entity_id": "16421117_2_Ent0", "role": "Subject", "text": "all three patients", "start": 29, "end": 32}, {"entity_id": "16421117_2_Ent1", "role": "Subject_Population", "text": "three", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "16421117_2_Ent2", "text": "levodopa induced dyskinesia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16421117_2_Ent3", "text": "treatment with amantadine ( 400 mg / day , po )", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "16421117_2_Ent4", "text": "amantadine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16421117_2_Ent5", "text": "400 mg / day", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16421117_2_Ent0", "text": "all three patients", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "16421117_2_Ent1", "text": "three", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "1642627_1", "wnd_id": "1642627_1_1", "text": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam - induced eating disorder .", "tokens": ["A", "combination", "of", "behavioural", "and", "cognitive", "adverse", "effects", "is", "illustrated", "in", "this", "case", "report", "of", "a", "recurrent", "triazolam", "-", "induced", "eating", "disorder", "."], "event_mentions": [{"id": "1642627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "1642627_1_Ent1", "role": "Treatment", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent2", "role": "Treatment_Drug", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent0", "role": "Effect", "text": "eating disorder", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1642627_1_Ent1", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent2", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent0", "text": "eating disorder", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16432996_14", "wnd_id": "16432996_14_1", "text": "We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment , and diagnostic tests for this adverse effect should be performed during the follow - ups .", "tokens": ["We", "suggest", "that", "sarcoidosis", "may", "develop", "in", "chronic", "hepatitis", "C", "patients", "during", "interferon", "alpha", "and/or", "ribavirin", "treatment", ",", "and", "diagnostic", "tests", "for", "this", "adverse", "effect", "should", "be", "performed", "during", "the", "follow", "-", "ups", "."], "event_mentions": [{"id": "16432996_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 5, "end": 6}, "arguments": [{"entity_id": "16432996_14_Ent1", "role": "Effect", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "16432996_14_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 7, "end": 10}, {"entity_id": "16432996_14_Ent0", "role": "Subject", "text": "chronic hepatitis C patients", "start": 7, "end": 11}, {"entity_id": "16432996_14_Ent4", "role": "Treatment_Drug", "text": "interferon alpha", "start": 12, "end": 14}, {"entity_id": "16432996_14_Ent2", "role": "Treatment", "text": "interferon alpha and/or ribavirin", "start": 12, "end": 16}, {"entity_id": "16432996_14_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16432996_14_Ent1", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16432996_14_Ent3", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16432996_14_Ent0", "text": "chronic hepatitis C patients", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "16432996_14_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16432996_14_Ent2", "text": "interferon alpha and/or ribavirin", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "16432996_14_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16446228_2", "wnd_id": "16446228_2_1", "text": "Reversible sirolimus - associated pneumonitis after heart transplantation .", "tokens": ["Reversible", "sirolimus", "-", "associated", "pneumonitis", "after", "heart", "transplantation", "."], "event_mentions": [{"id": "16446228_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16446228_2_Ent1", "role": "Treatment", "text": "sirolimus", "start": 1, "end": 2}, {"entity_id": "16446228_2_Ent2", "role": "Treatment_Drug", "text": "sirolimus", "start": 1, "end": 2}, {"entity_id": "16446228_2_Ent0", "role": "Effect", "text": "pneumonitis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16446228_2_Ent1", "text": "sirolimus", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16446228_2_Ent2", "text": "sirolimus", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16446228_2_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16449538_2", "wnd_id": "16449538_2_1", "text": "CASE SUMMARIES : Two patients who received ifosfamide - containing chemotherapy developed NCSE .", "tokens": ["CASE", "SUMMARIES", ":", "Two", "patients", "who", "received", "ifosfamide", "-", "containing", "chemotherapy", "developed", "NCSE", "."], "event_mentions": [{"id": "16449538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16449538_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "16449538_2_Ent0", "role": "Subject", "text": "Two patients", "start": 3, "end": 5}, {"entity_id": "16449538_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "16449538_2_Ent3", "role": "Treatment", "text": "ifosfamide - containing chemotherapy", "start": 7, "end": 11}, {"entity_id": "16449538_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "16449538_2_Ent2", "role": "Effect", "text": "NCSE", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16449538_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16449538_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16449538_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16449538_2_Ent3", "text": "ifosfamide - containing chemotherapy", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "16449538_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16449538_2_Ent2", "text": "NCSE", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16449538_6", "wnd_id": "16449538_6_1", "text": "OBJECTIVE : To report 2 cases of nonconvulsive status epilepticus ( NCSE ) following infusion of ifosfamide .", "tokens": ["OBJECTIVE", ":", "To", "report", "2", "cases", "of", "nonconvulsive", "status", "epilepticus", "(", "NCSE", ")", "following", "infusion", "of", "ifosfamide", "."], "event_mentions": [{"id": "16449538_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "16449538_6_Ent0", "role": "Effect", "text": "nonconvulsive status epilepticus ( NCSE )", "start": 7, "end": 13}, {"entity_id": "16449538_6_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 14, "end": 15}, {"entity_id": "16449538_6_Ent1", "role": "Treatment", "text": "infusion of ifosfamide", "start": 14, "end": 17}, {"entity_id": "16449538_6_Ent3", "role": "Treatment_Drug", "text": "ifosfamide", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16449538_6_Ent0", "text": "nonconvulsive status epilepticus ( NCSE )", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "16449538_6_Ent2", "text": "infusion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16449538_6_Ent1", "text": "infusion of ifosfamide", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16449538_6_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16472339_1", "wnd_id": "16472339_1_1", "text": "Administration of sumatriptan in subarachnoid haemorrhage ( SAH ) patients , misdiagnosed as migraine patients , may induce symptomatic cerebral vasospasm with potentially dangerous consequences .", "tokens": ["Administration", "of", "sumatriptan", "in", "subarachnoid", "haemorrhage", "(", "SAH", ")", "patients", ",", "misdiagnosed", "as", "migraine", "patients", ",", "may", "induce", "symptomatic", "cerebral", "vasospasm", "with", "potentially", "dangerous", "consequences", "."], "event_mentions": [{"id": "16472339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 17, "end": 18}, "arguments": [{"entity_id": "16472339_1_Ent2", "role": "Treatment", "text": "sumatriptan", "start": 2, "end": 3}, {"entity_id": "16472339_1_Ent4", "role": "Treatment_Drug", "text": "sumatriptan", "start": 2, "end": 3}, {"entity_id": "16472339_1_Ent3", "role": "Treatment_Disorder", "text": "subarachnoid haemorrhage", "start": 4, "end": 6}, {"entity_id": "16472339_1_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "16472339_1_Ent1", "role": "Effect", "text": "symptomatic cerebral vasospasm", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16472339_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16472339_1_Ent4", "text": "sumatriptan", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16472339_1_Ent3", "text": "subarachnoid haemorrhage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16472339_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16472339_1_Ent1", "text": "symptomatic cerebral vasospasm", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16480245_1", "wnd_id": "16480245_1_1", "text": "METHOD : We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone , respectively .", "tokens": ["METHOD", ":", "We", "describe", "two", "patients", "who", "presented", "with", "diabetic", "ketoacidosis", "after", "treatment", "with", "quetiapine", "and", "risperidone", ",", "respectively", "."], "event_mentions": [{"id": "16480245_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "16480245_1_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "16480245_1_Ent0", "role": "Subject", "text": "two patients", "start": 4, "end": 6}, {"entity_id": "16480245_1_Ent2", "role": "Effect", "text": "diabetic ketoacidosis", "start": 9, "end": 11}, {"entity_id": "16480245_1_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 14, "end": 15}, {"entity_id": "16480245_1_Ent3", "role": "Treatment", "text": "quetiapine and risperidone", "start": 14, "end": 17}, {"entity_id": "16480245_1_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16480245_1_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16480245_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16480245_1_Ent2", "text": "diabetic ketoacidosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16480245_1_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16480245_1_Ent3", "text": "quetiapine and risperidone", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16480245_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16490518_4", "wnd_id": "16490518_4_1", "text": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid - induced glaucoma .", "tokens": ["This", "treatment", "has", "the", "potential", "to", "cause", "severe", "vision", "loss", "as", "a", "result", "of", "intractable", "corticosteroid", "-", "induced", "glaucoma", "."], "event_mentions": [{"id": "16490518_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "16490518_4_Ent0", "role": "Effect", "text": "severe vision loss", "start": 7, "end": 10}, {"entity_id": "16490518_4_Ent2", "role": "Treatment", "text": "corticosteroid", "start": 15, "end": 16}, {"entity_id": "16490518_4_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 15, "end": 16}, {"entity_id": "16490518_4_Ent1", "role": "Effect", "text": "glaucoma", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16490518_4_Ent0", "text": "severe vision loss", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16490518_4_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16490518_4_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16490518_4_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16507380_13", "wnd_id": "16507380_13_1", "text": "A possible drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN - induced hypertriglyceridemia .", "tokens": ["A", "possible", "drug", "-", "drug", "interaction", "between", "IFN", "alfa", "11", "MU", "TIW", "and", "gemfibrozil", "600", "mg", "BID", "was", "reported", "in", "a", "patient", "undergoing", "treatment", "for", "IFN", "-", "induced", "hypertriglyceridemia", "."], "event_mentions": [{"id": "16507380_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 18, "end": 19}, "arguments": [{"entity_id": "16507380_13_Ent2", "role": "Treatment", "text": "drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "start": 2, "end": 17}, {"entity_id": "16507380_13_Ent3", "role": "Treatment_Drug", "text": "IFN alfa", "start": 7, "end": 9}, {"entity_id": "16507380_13_Ent9", "role": "Combination_Drug", "text": "IFN alfa", "start": 7, "end": 9}, {"entity_id": "16507380_13_Ent6", "role": "Treatment_Dosage", "text": "11 MU", "start": 9, "end": 11}, {"entity_id": "16507380_13_Ent8", "role": "Treatment_Freq", "text": "TIW", "start": 11, "end": 12}, {"entity_id": "16507380_13_Ent4", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 13, "end": 14}, {"entity_id": "16507380_13_Ent10", "role": "Combination_Drug", "text": "gemfibrozil", "start": 13, "end": 14}, {"entity_id": "16507380_13_Ent5", "role": "Treatment_Dosage", "text": "600 mg", "start": 14, "end": 16}, {"entity_id": "16507380_13_Ent7", "role": "Treatment_Freq", "text": "BID", "start": 16, "end": 17}, {"entity_id": "16507380_13_Ent0", "role": "Subject", "text": "a patient", "start": 20, "end": 22}, {"entity_id": "16507380_13_Ent1", "role": "Effect", "text": "IFN - induced hypertriglyceridemia", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16507380_13_Ent2", "text": "drug - drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "entity_type": "Entity", "start": 2, "end": 17}, {"id": "16507380_13_Ent3", "text": "IFN alfa", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16507380_13_Ent9", "text": "IFN alfa", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16507380_13_Ent6", "text": "11 MU", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16507380_13_Ent8", "text": "TIW", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16507380_13_Ent4", "text": "gemfibrozil", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16507380_13_Ent10", "text": "gemfibrozil", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16507380_13_Ent5", "text": "600 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16507380_13_Ent7", "text": "BID", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16507380_13_Ent0", "text": "a patient", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16507380_13_Ent1", "text": "IFN - induced hypertriglyceridemia", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16511396_3", "wnd_id": "16511396_3_1", "text": "This case underscores problems in clinical management with sulfadiazine hypersensitivity , potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis .", "tokens": ["This", "case", "underscores", "problems", "in", "clinical", "management", "with", "sulfadiazine", "hypersensitivity", ",", "potential", "immunosuppression", "from", "corticosteroids", "and", "selection", "of", "medications", "for", "recurrences", "of", "toxoplasmic", "chorioretinitis", "."], "event_mentions": [{"id": "16511396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 9, "end": 10}, "arguments": [{"entity_id": "16511396_3_Ent1", "role": "Treatment", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent2", "role": "Treatment_Drug", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 9, "end": 10}]}, {"id": "16511396_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "16511396_3_Ent3", "role": "Effect", "text": "immunosuppression", "start": 12, "end": 13}, {"entity_id": "16511396_3_Ent4", "role": "Treatment", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "16511396_3_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16511396_3_Ent1", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent2", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16511396_3_Ent3", "text": "immunosuppression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16511396_3_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16511396_3_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16515630_1", "wnd_id": "16515630_1_1", "text": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer .", "tokens": ["Fatal", "lung", "fibrosis", "caused", "by", "paclitaxel", "toxicity", "has", "not", "been", "reported", "In", "this", "report", ",", "we", "describe", "the", "case", "of", "a", "62", "-", "year", "-", "old", "woman", "who", "received", "six", "cycles", "of", "paclitaxel", "and", "carboplatin", "as", "combination", "chemotherapy", "for", "advanced", "ovarian", "cancer", "."], "event_mentions": [{"id": "16515630_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 28, "end": 29}, "arguments": [{"entity_id": "16515630_1_Ent4", "role": "Effect", "text": "Fatal lung fibrosis", "start": 0, "end": 3}, {"entity_id": "16515630_1_Ent2", "role": "Subject_Age", "text": "62 - year - old", "start": 21, "end": 26}, {"entity_id": "16515630_1_Ent0", "role": "Subject", "text": "62 - year - old woman", "start": 21, "end": 27}, {"entity_id": "16515630_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 26, "end": 27}, {"entity_id": "16515630_1_Ent6", "role": "Treatment_Dosage", "text": "six cycles", "start": 29, "end": 31}, {"entity_id": "16515630_1_Ent5", "role": "Treatment", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "start": 29, "end": 38}, {"entity_id": "16515630_1_Ent7", "role": "Treatment_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent11", "role": "Combination_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent8", "role": "Treatment_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent12", "role": "Combination_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent10", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}, {"entity_id": "16515630_1_Ent1", "role": "Subject", "text": "advanced ovarian cancer", "start": 39, "end": 42}, {"entity_id": "16515630_1_Ent9", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16515630_1_Ent4", "text": "Fatal lung fibrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16515630_1_Ent2", "text": "62 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "16515630_1_Ent0", "text": "62 - year - old woman", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "16515630_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16515630_1_Ent6", "text": "six cycles", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16515630_1_Ent5", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "16515630_1_Ent7", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent11", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent8", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent12", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16515630_1_Ent1", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "16515630_1_Ent9", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16531969_1", "wnd_id": "16531969_1_1", "text": "Drug induced liver injury secondary to interferon - beta ( IFN - beta ) in multiple sclerosis .", "tokens": ["Drug", "induced", "liver", "injury", "secondary", "to", "interferon", "-", "beta", "(", "IFN", "-", "beta", ")", "in", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16531969_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "16531969_1_Ent0", "role": "Effect", "text": "liver injury", "start": 2, "end": 4}, {"entity_id": "16531969_1_Ent2", "role": "Treatment_Drug", "text": "interferon - beta", "start": 6, "end": 9}, {"entity_id": "16531969_1_Ent1", "role": "Treatment", "text": "interferon - beta ( IFN - beta )", "start": 6, "end": 14}, {"entity_id": "16531969_1_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16531969_1_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_1_Ent2", "text": "interferon - beta", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16531969_1_Ent1", "text": "interferon - beta ( IFN - beta )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16531969_1_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16540070_2", "wnd_id": "16540070_2_1", "text": "Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime .", "tokens": ["Allergy", "to", "cloxacillin", "with", "normal", "tolerance", "to", "amoxicillin", "and", "cefuroxime", "."], "event_mentions": [{"id": "16540070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16540070_2_Ent0", "role": "Effect", "text": "Allergy", "start": 0, "end": 1}, {"entity_id": "16540070_2_Ent1", "role": "Treatment", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent2", "role": "Treatment_Drug", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent3", "role": "Treatment_Drug", "text": "amoxicillin", "start": 7, "end": 8}, {"entity_id": "16540070_2_Ent4", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16540070_2_Ent0", "text": "Allergy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16540070_2_Ent1", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent3", "text": "amoxicillin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16540070_2_Ent4", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16573370_6", "wnd_id": "16573370_6_1", "text": "She had been prescribed two mood stabilizers and suffered from anticholinergic adverse effects and the movement disorder tardive dyskinesia ( TD ) .", "tokens": ["She", "had", "been", "prescribed", "two", "mood", "stabilizers", "and", "suffered", "from", "anticholinergic", "adverse", "effects", "and", "the", "movement", "disorder", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "16573370_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered from", "start": 8, "end": 10}, "arguments": [{"entity_id": "16573370_6_Ent1", "role": "Treatment", "text": "prescribed two mood stabilizers", "start": 3, "end": 7}, {"entity_id": "16573370_6_Ent2", "role": "Treatment_Drug", "text": "mood stabilizers", "start": 5, "end": 7}, {"entity_id": "16573370_6_Ent0", "role": "Effect", "text": "anticholinergic adverse effects and the movement disorder tardive dyskinesia ( TD )", "start": 10, "end": 22}]}], "entity_mentions": [{"id": "16573370_6_Ent1", "text": "prescribed two mood stabilizers", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16573370_6_Ent2", "text": "mood stabilizers", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16573370_6_Ent0", "text": "anticholinergic adverse effects and the movement disorder tardive dyskinesia ( TD )", "entity_type": "Entity", "start": 10, "end": 22}], "lang": "en"}
{"doc_id": "16580907_5", "wnd_id": "16580907_5_1", "text": "The plasma concentrations of both drugs were significantly increased during the coadministration , and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued , which suggested that the fainting was induced by the pharmacokinetic drug interaction .", "tokens": ["The", "plasma", "concentrations", "of", "both", "drugs", "were", "significantly", "increased", "during", "the", "coadministration", ",", "and", "the", "cetirizine", "concentration", "decreased", "on", "cessation", "of", "pilsicainide", "despite", "the", "fact", "that", "treatment", "with", "cetirizine", "was", "continued", ",", "which", "suggested", "that", "the", "fainting", "was", "induced", "by", "the", "pharmacokinetic", "drug", "interaction", "."], "event_mentions": [{"id": "16580907_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 38, "end": 39}, "arguments": [{"entity_id": "16580907_5_Ent1", "role": "Treatment", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent3", "role": "Treatment_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent5", "role": "Combination_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent2", "role": "Treatment", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent6", "role": "Combination_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent0", "role": "Effect", "text": "fainting", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16580907_5_Ent1", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent3", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent5", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent2", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent6", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent0", "text": "fainting", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16599252_1", "wnd_id": "16599252_1_1", "text": "Adverse reaction in a patient with aspirin - induced asthma treated with zafirlukast .", "tokens": ["Adverse", "reaction", "in", "a", "patient", "with", "aspirin", "-", "induced", "asthma", "treated", "with", "zafirlukast", "."], "event_mentions": [{"id": "16599252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16599252_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "16599252_1_Ent2", "role": "Treatment", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent6", "role": "Combination_Drug", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent1", "role": "Effect", "text": "asthma", "start": 9, "end": 10}, {"entity_id": "16599252_1_Ent4", "role": "Treatment_Drug", "text": "zafirlukast", "start": 12, "end": 13}, {"entity_id": "16599252_1_Ent5", "role": "Combination_Drug", "text": "zafirlukast", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16599252_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16599252_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent1", "text": "asthma", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16599252_1_Ent4", "text": "zafirlukast", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16599252_1_Ent5", "text": "zafirlukast", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16609346_3", "wnd_id": "16609346_3_1", "text": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug .", "tokens": ["We", "report", "4", "patients", "who", "developed", "symptoms", "of", "myasthenia", "gravis", "within", "2", "weeks", "of", "starting", "treatment", "with", "a", "statin", "drug", "."], "event_mentions": [{"id": "16609346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "16609346_3_Ent1", "role": "Subject_Population", "text": "4", "start": 2, "end": 3}, {"entity_id": "16609346_3_Ent0", "role": "Subject", "text": "4 patients", "start": 2, "end": 4}, {"entity_id": "16609346_3_Ent2", "role": "Effect", "text": "symptoms of myasthenia gravis", "start": 6, "end": 10}, {"entity_id": "16609346_3_Ent3", "role": "Treatment", "text": "within 2 weeks of starting treatment with a statin", "start": 10, "end": 19}, {"entity_id": "16609346_3_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 11, "end": 13}, {"entity_id": "16609346_3_Ent4", "role": "Treatment_Drug", "text": "statin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16609346_3_Ent1", "text": "4", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16609346_3_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16609346_3_Ent2", "text": "symptoms of myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16609346_3_Ent3", "text": "within 2 weeks of starting treatment with a statin", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "16609346_3_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16609346_3_Ent4", "text": "statin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "1661260_1", "wnd_id": "1661260_1_1", "text": "Reactivation of cytomegalovirus probably followed the treatment of Wegener 's granulomatosis with corticosteroids and azathioprine .", "tokens": ["Reactivation", "of", "cytomegalovirus", "probably", "followed", "the", "treatment", "of", "Wegener", "'s", "granulomatosis", "with", "corticosteroids", "and", "azathioprine", "."], "event_mentions": [{"id": "1661260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 4, "end": 5}, "arguments": [{"entity_id": "1661260_1_Ent0", "role": "Effect", "text": "Reactivation of cytomegalovirus", "start": 0, "end": 3}, {"entity_id": "1661260_1_Ent2", "role": "Treatment_Disorder", "text": "Wegener 's granulomatosis", "start": 8, "end": 11}, {"entity_id": "1661260_1_Ent3", "role": "Treatment_Drug", "text": "corticosteroids", "start": 12, "end": 13}, {"entity_id": "1661260_1_Ent5", "role": "Combination_Drug", "text": "corticosteroids", "start": 12, "end": 13}, {"entity_id": "1661260_1_Ent1", "role": "Treatment", "text": "corticosteroids and azathioprine", "start": 12, "end": 15}, {"entity_id": "1661260_1_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 14, "end": 15}, {"entity_id": "1661260_1_Ent6", "role": "Combination_Drug", "text": "azathioprine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "1661260_1_Ent0", "text": "Reactivation of cytomegalovirus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1661260_1_Ent2", "text": "Wegener 's granulomatosis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "1661260_1_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1661260_1_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1661260_1_Ent1", "text": "corticosteroids and azathioprine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1661260_1_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1661260_1_Ent6", "text": "azathioprine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16615675_1", "wnd_id": "16615675_1_1", "text": "After excluding other causes of long QT syndrome , the HCQ was suspected as the cause of her ventricular tachycardia .", "tokens": ["After", "excluding", "other", "causes", "of", "long", "QT", "syndrome", ",", "the", "HCQ", "was", "suspected", "as", "the", "cause", "of", "her", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "16615675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 12, "end": 13}, "arguments": [{"entity_id": "16615675_1_Ent3", "role": "Treatment", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent4", "role": "Treatment_Drug", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent0", "role": "Subject", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent1", "role": "Subject_Gender", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent2", "role": "Effect", "text": "ventricular tachycardia", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16615675_1_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent4", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent0", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent1", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent2", "text": "ventricular tachycardia", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16620273_2", "wnd_id": "16620273_2_1", "text": "Severe acidosis in patients taking metformin -- rapid reversal and survival despite high APACHE score .", "tokens": ["Severe", "acidosis", "in", "patients", "taking", "metformin", "--", "rapid", "reversal", "and", "survival", "despite", "high", "APACHE", "score", "."], "event_mentions": [{"id": "16620273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 4, "end": 5}, "arguments": [{"entity_id": "16620273_2_Ent1", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "16620273_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "16620273_2_Ent2", "role": "Treatment", "text": "metformin", "start": 5, "end": 6}, {"entity_id": "16620273_2_Ent3", "role": "Treatment_Drug", "text": "metformin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16620273_2_Ent1", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16620273_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16620273_2_Ent2", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16620273_2_Ent3", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16632429_1", "wnd_id": "16632429_1_1", "text": "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency , and simulating a progression of the tumor .", "tokens": ["We", "report", "the", "case", "of", "a", "lung", "cancer", "patient", "with", "bronquiloalveolar", "carcinoma", "(", "BAC", ")", "presenting", "with", "BOOP", "after", "chemotherapy", "with", "docetaxel", "and", "gemcitabine", "producing", "severe", "respiratory", "insufficiency", ",", "and", "simulating", "a", "progression", "of", "the", "tumor", "."], "event_mentions": [{"id": "16632429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "16632429_1_Ent4", "role": "Treatment_Disorder", "text": "lung cancer", "start": 6, "end": 8}, {"entity_id": "16632429_1_Ent0", "role": "Subject", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "start": 6, "end": 15}, {"entity_id": "16632429_1_Ent5", "role": "Treatment_Disorder", "text": "bronquiloalveolar carcinoma ( BAC )", "start": 10, "end": 15}, {"entity_id": "16632429_1_Ent2", "role": "Effect", "text": "BOOP", "start": 17, "end": 18}, {"entity_id": "16632429_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "16632429_1_Ent3", "role": "Treatment", "text": "chemotherapy with docetaxel and gemcitabine", "start": 19, "end": 24}, {"entity_id": "16632429_1_Ent6", "role": "Treatment_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent9", "role": "Combination_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent7", "role": "Treatment_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent10", "role": "Combination_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent1", "role": "Effect", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "start": 24, "end": 36}]}], "entity_mentions": [{"id": "16632429_1_Ent4", "text": "lung cancer", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16632429_1_Ent0", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "16632429_1_Ent5", "text": "bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16632429_1_Ent2", "text": "BOOP", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16632429_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16632429_1_Ent3", "text": "chemotherapy with docetaxel and gemcitabine", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16632429_1_Ent6", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent9", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent7", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent10", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent1", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "entity_type": "Entity", "start": 24, "end": 36}], "lang": "en"}
{"doc_id": "16637972_2", "wnd_id": "16637972_2_1", "text": "An unusual presentation of spontaneous sub - conjunctival haematoma in a patient receiving warfarin .", "tokens": ["An", "unusual", "presentation", "of", "spontaneous", "sub", "-", "conjunctival", "haematoma", "in", "a", "patient", "receiving", "warfarin", "."], "event_mentions": [{"id": "16637972_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "16637972_2_Ent1", "role": "Effect", "text": "spontaneous sub - conjunctival haematoma", "start": 4, "end": 9}, {"entity_id": "16637972_2_Ent0", "role": "Subject", "text": "a patient", "start": 10, "end": 12}, {"entity_id": "16637972_2_Ent2", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "16637972_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16637972_2_Ent1", "text": "spontaneous sub - conjunctival haematoma", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16637972_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16637972_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16637972_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16641839_5", "wnd_id": "16641839_5_1", "text": "We report the case of a 27 - year - old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration .", "tokens": ["We", "report", "the", "case", "of", "a", "27", "-", "year", "-", "old", "Indian", "woman", "who", "developed", "maculopapular", "rash", "and", "angioedema", "secondary", "to", "carbamazepine", "administration", "."], "event_mentions": [{"id": "16641839_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "16641839_5_Ent0", "role": "Subject", "text": "a 27 - year - old Indian woman", "start": 5, "end": 13}, {"entity_id": "16641839_5_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "16641839_5_Ent2", "role": "Subject_Race", "text": "Indian", "start": 11, "end": 12}, {"entity_id": "16641839_5_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "16641839_5_Ent4", "role": "Effect", "text": "maculopapular rash and angioedema", "start": 15, "end": 19}, {"entity_id": "16641839_5_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 21, "end": 22}, {"entity_id": "16641839_5_Ent5", "role": "Treatment", "text": "carbamazepine administration", "start": 21, "end": 23}, {"entity_id": "16641839_5_Ent7", "role": "Treatment_Route", "text": "administration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16641839_5_Ent0", "text": "a 27 - year - old Indian woman", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "16641839_5_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16641839_5_Ent2", "text": "Indian", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16641839_5_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_5_Ent4", "text": "maculopapular rash and angioedema", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16641839_5_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16641839_5_Ent5", "text": "carbamazepine administration", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16641839_5_Ent7", "text": "administration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16649344_2", "wnd_id": "16649344_2_1", "text": "Current immunosuppressive therapies are effective but can be associated with significant adverse reactions .", "tokens": ["Current", "immunosuppressive", "therapies", "are", "effective", "but", "can", "be", "associated", "with", "significant", "adverse", "reactions", "."], "event_mentions": [{"id": "16649344_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16649344_2_Ent1", "role": "Treatment", "text": "Current immunosuppressive therapies", "start": 0, "end": 3}, {"entity_id": "16649344_2_Ent2", "role": "Treatment_Drug", "text": "immunosuppressive", "start": 1, "end": 2}, {"entity_id": "16649344_2_Ent0", "role": "Effect", "text": "significant adverse reactions .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "16649344_2_Ent1", "text": "Current immunosuppressive therapies", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16649344_2_Ent2", "text": "immunosuppressive", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16649344_2_Ent0", "text": "significant adverse reactions .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "16649344_3", "wnd_id": "16649344_3_1", "text": "Sirolimus works differently from the immunosuppressants currently available , and except for increased lipid levels , the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus .", "tokens": ["Sirolimus", "works", "differently", "from", "the", "immunosuppressants", "currently", "available", ",", "and", "except", "for", "increased", "lipid", "levels", ",", "the", "adverse", "reaction", "profile", "of", "sirolimus", "does", "not", "appear", "to", "overlap", "to", "any", "great", "extent", "with", "that", "associated", "with", "cyclosporine", "or", "tacrolimus", "."], "event_mentions": [{"id": "16649344_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "16649344_3_Ent2", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16649344_3_Ent1", "role": "Treatment", "text": "Sirolimus works differently from the immunosuppressants currently available", "start": 0, "end": 8}, {"entity_id": "16649344_3_Ent3", "role": "Treatment_Drug", "text": "immunosuppressants", "start": 5, "end": 6}, {"entity_id": "16649344_3_Ent0", "role": "Effect", "text": "increased lipid levels", "start": 12, "end": 15}, {"entity_id": "16649344_3_Ent4", "role": "Treatment_Drug", "text": "sirolimus", "start": 21, "end": 22}, {"entity_id": "16649344_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "16649344_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "16649344_3_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16649344_3_Ent1", "text": "Sirolimus works differently from the immunosuppressants currently available", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16649344_3_Ent3", "text": "immunosuppressants", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16649344_3_Ent0", "text": "increased lipid levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16649344_3_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16649344_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16649344_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "16682062_2", "wnd_id": "16682062_2_1", "text": "To our knowledge , this is the first case of ivermectin - induced severe liver disease published in the literature .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "ivermectin", "-", "induced", "severe", "liver", "disease", "published", "in", "the", "literature", "."], "event_mentions": [{"id": "16682062_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16682062_2_Ent1", "role": "Treatment", "text": "ivermectin", "start": 10, "end": 11}, {"entity_id": "16682062_2_Ent2", "role": "Treatment_Drug", "text": "ivermectin", "start": 10, "end": 11}, {"entity_id": "16682062_2_Ent0", "role": "Effect", "text": "severe liver disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16682062_2_Ent1", "text": "ivermectin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16682062_2_Ent2", "text": "ivermectin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16682062_2_Ent0", "text": "severe liver disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16685007_5", "wnd_id": "16685007_5_1", "text": "Adult and adolescent patients ( > or = 12 years old ; n = 141 ) with severe , persistent , oral steroid ( prednisone) - dependent asthma .", "tokens": ["Adult", "and", "adolescent", "patients", "(", ">", "or", "=", "12", "years", "old", ";", "n", "=", "141", ")", "with", "severe", ",", "persistent", ",", "oral", "steroid", "(", "prednisone)", "-", "dependent", "asthma", "."], "event_mentions": [{"id": "16685007_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "dependent", "start": 26, "end": 27}, "arguments": [{"entity_id": "16685007_5_Ent1", "role": "Subject_Age", "text": "Adult and adolescent", "start": 0, "end": 3}, {"entity_id": "16685007_5_Ent0", "role": "Subject", "text": "Adult and adolescent patients", "start": 0, "end": 4}, {"entity_id": "16685007_5_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "16685007_5_Ent3", "role": "Treatment", "text": "oral steroid ( prednisone)", "start": 21, "end": 25}, {"entity_id": "16685007_5_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 22, "end": 23}, {"entity_id": "16685007_5_Ent6", "role": "Treatment_Drug", "text": "prednisone)", "start": 24, "end": 25}, {"entity_id": "16685007_5_Ent2", "role": "Effect", "text": "asthma", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16685007_5_Ent1", "text": "Adult and adolescent", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16685007_5_Ent0", "text": "Adult and adolescent patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16685007_5_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16685007_5_Ent3", "text": "oral steroid ( prednisone)", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16685007_5_Ent5", "text": "steroid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16685007_5_Ent6", "text": "prednisone)", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16685007_5_Ent2", "text": "asthma", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16685112_1", "wnd_id": "16685112_1_1", "text": "CASE REPORT : We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy , five months after completing chemoradiation for locally advanced pancreatic cancer .", "tokens": ["CASE", "REPORT", ":", "We", "hereby", "report", "a", "case", "of", "radiation", "recall", "dermatitis", "and", "myositis", "occurring", "on", "gemcitabine", "monotherapy", ",", "five", "months", "after", "completing", "chemoradiation", "for", "locally", "advanced", "pancreatic", "cancer", "."], "event_mentions": [{"id": "16685112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 14, "end": 15}, "arguments": [{"entity_id": "16685112_1_Ent0", "role": "Effect", "text": "radiation recall dermatitis and myositis", "start": 9, "end": 14}, {"entity_id": "16685112_1_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 16, "end": 17}, {"entity_id": "16685112_1_Ent1", "role": "Treatment", "text": "gemcitabine monotherapy , five months after completing chemoradiation", "start": 16, "end": 24}, {"entity_id": "16685112_1_Ent4", "role": "Treatment_Time_elapsed", "text": "five months after", "start": 19, "end": 22}, {"entity_id": "16685112_1_Ent3", "role": "Treatment_Disorder", "text": "locally advanced pancreatic cancer", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16685112_1_Ent0", "text": "radiation recall dermatitis and myositis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "16685112_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16685112_1_Ent1", "text": "gemcitabine monotherapy , five months after completing chemoradiation", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "16685112_1_Ent4", "text": "five months after", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16685112_1_Ent3", "text": "locally advanced pancreatic cancer", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16697705_1", "wnd_id": "16697705_1_1", "text": "Acute coronary syndrome induced by capecitabine therapy .", "tokens": ["Acute", "coronary", "syndrome", "induced", "by", "capecitabine", "therapy", "."], "event_mentions": [{"id": "16697705_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "16697705_1_Ent0", "role": "Effect", "text": "Acute coronary syndrome", "start": 0, "end": 3}, {"entity_id": "16697705_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 5, "end": 6}, {"entity_id": "16697705_1_Ent1", "role": "Treatment", "text": "capecitabine therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16697705_1_Ent0", "text": "Acute coronary syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16697705_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16697705_1_Ent1", "text": "capecitabine therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16728538_4", "wnd_id": "16728538_4_1", "text": "We report on a patient with acromegaly who developed severe drug - induced hepatitis during combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist pegvisomant .", "tokens": ["We", "report", "on", "a", "patient", "with", "acromegaly", "who", "developed", "severe", "drug", "-", "induced", "hepatitis", "during", "combined", "treatment", "with", "the", "long", "-", "acting", "somatostatin", "-", "analog", "octreotide", "and", "the", "GH", "receptor", "antagonist", "pegvisomant", "."], "event_mentions": [{"id": "16728538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16728538_4_Ent0", "role": "Subject", "text": "a patient with acromegaly", "start": 3, "end": 7}, {"entity_id": "16728538_4_Ent4", "role": "Treatment_Disorder", "text": "acromegaly", "start": 6, "end": 7}, {"entity_id": "16728538_4_Ent1", "role": "Effect", "text": "hepatitis", "start": 13, "end": 14}, {"entity_id": "16728538_4_Ent2", "role": "Treatment", "text": "long - acting somatostatin - analog octreotide", "start": 19, "end": 26}, {"entity_id": "16728538_4_Ent6", "role": "Treatment_Drug", "text": "octreotide", "start": 25, "end": 26}, {"entity_id": "16728538_4_Ent8", "role": "Combination_Drug", "text": "octreotide", "start": 25, "end": 26}, {"entity_id": "16728538_4_Ent3", "role": "Treatment", "text": "GH receptor antagonist pegvisomant", "start": 28, "end": 32}, {"entity_id": "16728538_4_Ent5", "role": "Treatment_Drug", "text": "pegvisomant", "start": 31, "end": 32}, {"entity_id": "16728538_4_Ent7", "role": "Combination_Drug", "text": "pegvisomant", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "16728538_4_Ent0", "text": "a patient with acromegaly", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16728538_4_Ent4", "text": "acromegaly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16728538_4_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16728538_4_Ent2", "text": "long - acting somatostatin - analog octreotide", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "16728538_4_Ent6", "text": "octreotide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16728538_4_Ent8", "text": "octreotide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16728538_4_Ent3", "text": "GH receptor antagonist pegvisomant", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "16728538_4_Ent5", "text": "pegvisomant", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "16728538_4_Ent7", "text": "pegvisomant", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "16765687_2", "wnd_id": "16765687_2_1", "text": "Rapid resolution of topiramate - induced angle - closure glaucoma with methylprednisolone and mannitol .", "tokens": ["Rapid", "resolution", "of", "topiramate", "-", "induced", "angle", "-", "closure", "glaucoma", "with", "methylprednisolone", "and", "mannitol", "."], "event_mentions": [{"id": "16765687_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 1, "end": 2}, "arguments": [{"entity_id": "16765687_2_Ent1", "role": "Treatment_Disorder", "text": "topiramate - induced angle - closure glaucoma", "start": 3, "end": 10}, {"entity_id": "16765687_2_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 11, "end": 12}, {"entity_id": "16765687_2_Ent4", "role": "Combination_Drug", "text": "methylprednisolone", "start": 11, "end": 12}, {"entity_id": "16765687_2_Ent0", "role": "Treatment", "text": "methylprednisolone and mannitol", "start": 11, "end": 14}, {"entity_id": "16765687_2_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 13, "end": 14}, {"entity_id": "16765687_2_Ent5", "role": "Combination_Drug", "text": "mannitol", "start": 13, "end": 14}]}, {"id": "16765687_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16765687_2_Ent7", "role": "Treatment", "text": "topiramate", "start": 3, "end": 4}, {"entity_id": "16765687_2_Ent8", "role": "Treatment_Drug", "text": "topiramate", "start": 3, "end": 4}, {"entity_id": "16765687_2_Ent6", "role": "Effect", "text": "angle - closure glaucoma", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "16765687_2_Ent7", "text": "topiramate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16765687_2_Ent8", "text": "topiramate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16765687_2_Ent1", "text": "topiramate - induced angle - closure glaucoma", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "16765687_2_Ent6", "text": "angle - closure glaucoma", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16765687_2_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16765687_2_Ent4", "text": "methylprednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16765687_2_Ent0", "text": "methylprednisolone and mannitol", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16765687_2_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16765687_2_Ent5", "text": "mannitol", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16767537_1", "wnd_id": "16767537_1_1", "text": "Spontaneous splenic infarction associated with sumatriptan use .", "tokens": ["Spontaneous", "splenic", "infarction", "associated", "with", "sumatriptan", "use", "."], "event_mentions": [{"id": "16767537_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16767537_1_Ent0", "role": "Effect", "text": "Spontaneous splenic infarction", "start": 0, "end": 3}, {"entity_id": "16767537_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 5, "end": 6}, {"entity_id": "16767537_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16767537_1_Ent0", "text": "Spontaneous splenic infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16767537_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16767537_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16843118_2", "wnd_id": "16843118_2_1", "text": "Morphine , an opium alkaloid , frequently causes side effects such as hyperhidrosis and facial flushing , but serious cutaneous adverse drug reactions are seldom observed .", "tokens": ["Morphine", ",", "an", "opium", "alkaloid", ",", "frequently", "causes", "side", "effects", "such", "as", "hyperhidrosis", "and", "facial", "flushing", ",", "but", "serious", "cutaneous", "adverse", "drug", "reactions", "are", "seldom", "observed", "."], "event_mentions": [{"id": "16843118_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 7, "end": 8}, "arguments": [{"entity_id": "16843118_2_Ent2", "role": "Treatment", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent3", "role": "Treatment_Drug", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent0", "role": "Effect", "text": "hyperhidrosis", "start": 12, "end": 13}, {"entity_id": "16843118_2_Ent1", "role": "Effect", "text": "facial flushing", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "16843118_2_Ent2", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent3", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent0", "text": "hyperhidrosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16843118_2_Ent1", "text": "facial flushing", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "16882109_2", "wnd_id": "16882109_2_1", "text": "Factors that suggested an association between the severe angioedematous reaction and BP topical application include the strong reaction to BP in the patch - test , the temporal relationship , the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations .", "tokens": ["Factors", "that", "suggested", "an", "association", "between", "the", "severe", "angioedematous", "reaction", "and", "BP", "topical", "application", "include", "the", "strong", "reaction", "to", "BP", "in", "the", "patch", "-", "test", ",", "the", "temporal", "relationship", ",", "the", "complete", "resolution", "of", "symptoms", "after", "the", "drug", "was", "withdrawn", "and", "the", "absence", "of", "other", "identified", "explanations", "."], "event_mentions": [{"id": "16882109_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 4, "end": 5}, "arguments": [{"entity_id": "16882109_2_Ent0", "role": "Effect", "text": "severe angioedematous reaction", "start": 7, "end": 10}, {"entity_id": "16882109_2_Ent1", "role": "Treatment", "text": "BP topical application", "start": 11, "end": 14}, {"entity_id": "16882109_2_Ent2", "role": "Treatment_Drug", "text": "BP topical application", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16882109_2_Ent0", "text": "severe angioedematous reaction", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16882109_2_Ent1", "text": "BP topical application", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16882109_2_Ent2", "text": "BP topical application", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16882112_1", "wnd_id": "16882112_1_1", "text": "Lithium and venlafaxine interaction : a case of serotonin syndrome .", "tokens": ["Lithium", "and", "venlafaxine", "interaction", ":", "a", "case", "of", "serotonin", "syndrome", "."], "event_mentions": [{"id": "16882112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 6, "end": 7}, "arguments": [{"entity_id": "16882112_1_Ent2", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent4", "role": "Combination_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent1", "role": "Treatment", "text": "Lithium and venlafaxine interaction", "start": 0, "end": 4}, {"entity_id": "16882112_1_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent5", "role": "Combination_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16882112_1_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent4", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent1", "text": "Lithium and venlafaxine interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16882112_1_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16882112_2", "wnd_id": "16882112_2_1", "text": "Serotonin syndrome , which occurs as a result of enhanced serotonin concentration in the central nervous system , is a well - known adverse effect of serotonin - active medications .", "tokens": ["Serotonin", "syndrome", ",", "which", "occurs", "as", "a", "result", "of", "enhanced", "serotonin", "concentration", "in", "the", "central", "nervous", "system", ",", "is", "a", "well", "-", "known", "adverse", "effect", "of", "serotonin", "-", "active", "medications", "."], "event_mentions": [{"id": "16882112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 4, "end": 5}, "arguments": [{"entity_id": "16882112_2_Ent0", "role": "Effect", "text": "Serotonin syndrome ,", "start": 0, "end": 3}, {"entity_id": "16882112_2_Ent1", "role": "Treatment", "text": "serotonin - active medications", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "16882112_2_Ent0", "text": "Serotonin syndrome ,", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16882112_2_Ent1", "text": "serotonin - active medications", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "16882112_4", "wnd_id": "16882112_4_1", "text": "We report a case of the serotonin syndrome during treatment with lithium and venlafaxine , an antidepressant with a dual selective re - uptake inhibition mechanism , and review the literature for similar cases .", "tokens": ["We", "report", "a", "case", "of", "the", "serotonin", "syndrome", "during", "treatment", "with", "lithium", "and", "venlafaxine", ",", "an", "antidepressant", "with", "a", "dual", "selective", "re", "-", "uptake", "inhibition", "mechanism", ",", "and", "review", "the", "literature", "for", "similar", "cases", "."], "event_mentions": [{"id": "16882112_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "16882112_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16882112_4_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "16882112_4_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "16882112_4_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "16882112_4_Ent2", "role": "Treatment", "text": "lithium and venlafaxine", "start": 11, "end": 14}, {"entity_id": "16882112_4_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 13, "end": 14}, {"entity_id": "16882112_4_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16882112_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16882112_4_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16882112_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16882112_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16882112_4_Ent2", "text": "lithium and venlafaxine", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16882112_4_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16882112_4_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16901609_1", "wnd_id": "16901609_1_1", "text": "Anaphylaxis to intrathecal diamorphine .", "tokens": ["Anaphylaxis", "to", "intrathecal", "diamorphine", "."], "event_mentions": [{"id": "16901609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16901609_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "16901609_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "16901609_1_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 2, "end": 4}, {"entity_id": "16901609_1_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16901609_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16901609_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16901609_1_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16901609_1_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16901609_2", "wnd_id": "16901609_2_1", "text": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "intrathecal", "diamorphine", "causing", "anaphylaxis", "."], "event_mentions": [{"id": "16901609_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 10, "end": 11}, "arguments": [{"entity_id": "16901609_2_Ent3", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "16901609_2_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 8, "end": 10}, {"entity_id": "16901609_2_Ent2", "role": "Treatment_Drug", "text": "diamorphine", "start": 9, "end": 10}, {"entity_id": "16901609_2_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16901609_2_Ent3", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16901609_2_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16901609_2_Ent2", "text": "diamorphine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16901609_2_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16914372_1", "wnd_id": "16914372_1_1", "text": "We highlight two instances of systemic allergic reaction , and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use .", "tokens": ["We", "highlight", "two", "instances", "of", "systemic", "allergic", "reaction", ",", "and", "discuss", "the", "potential", "side", "effects", "of", "local", "aprotinin", "injections", "in", "the", "orthopaedic", "setting", "as", "well", "as", "the", "evidence", "base", "for", "its", "use", "."], "event_mentions": [{"id": "16914372_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 15, "end": 16}, "arguments": [{"entity_id": "16914372_1_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "16914372_1_Ent0", "role": "Subject", "text": "two instances", "start": 2, "end": 4}, {"entity_id": "16914372_1_Ent2", "role": "Effect", "text": "systemic allergic reaction", "start": 5, "end": 8}, {"entity_id": "16914372_1_Ent3", "role": "Effect", "text": "potential side effects", "start": 12, "end": 15}, {"entity_id": "16914372_1_Ent4", "role": "Treatment", "text": "aprotinin", "start": 17, "end": 18}, {"entity_id": "16914372_1_Ent5", "role": "Treatment_Drug", "text": "aprotinin", "start": 17, "end": 18}, {"entity_id": "16914372_1_Ent6", "role": "Treatment_Route", "text": "injections", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16914372_1_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16914372_1_Ent0", "text": "two instances", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16914372_1_Ent2", "text": "systemic allergic reaction", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16914372_1_Ent3", "text": "potential side effects", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16914372_1_Ent4", "text": "aprotinin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16914372_1_Ent5", "text": "aprotinin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16914372_1_Ent6", "text": "injections", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16960880_3", "wnd_id": "16960880_3_1", "text": "Native arterial thrombosis , though recognized as a severe complication of thrombin injection , has not been well described in the literature .", "tokens": ["Native", "arterial", "thrombosis", ",", "though", "recognized", "as", "a", "severe", "complication", "of", "thrombin", "injection", ",", "has", "not", "been", "well", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "16960880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "16960880_3_Ent0", "role": "Effect", "text": "Native arterial thrombosis", "start": 0, "end": 3}, {"entity_id": "16960880_3_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 11, "end": 12}, {"entity_id": "16960880_3_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 11, "end": 13}, {"entity_id": "16960880_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16960880_3_Ent0", "text": "Native arterial thrombosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16960880_3_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16960880_3_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16960880_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16968538_1", "wnd_id": "16968538_1_1", "text": "Hemolytic uremic syndrome following the infusion of oxaliplatin : case report .", "tokens": ["Hemolytic", "uremic", "syndrome", "following", "the", "infusion", "of", "oxaliplatin", ":", "case", "report", "."], "event_mentions": [{"id": "16968538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "16968538_1_Ent0", "role": "Effect", "text": "Hemolytic uremic syndrome", "start": 0, "end": 3}, {"entity_id": "16968538_1_Ent1", "role": "Treatment", "text": "oxaliplatin", "start": 7, "end": 8}, {"entity_id": "16968538_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16968538_1_Ent0", "text": "Hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16968538_1_Ent1", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16968538_1_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16968538_3", "wnd_id": "16968538_3_1", "text": "A small number of oxaliplatin - related hemolytic and/or thrombocytopenic reactions have been reported .", "tokens": ["A", "small", "number", "of", "oxaliplatin", "-", "related", "hemolytic", "and/or", "thrombocytopenic", "reactions", "have", "been", "reported", "."], "event_mentions": [{"id": "16968538_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "16968538_3_Ent1", "role": "Treatment", "text": "oxaliplatin", "start": 4, "end": 5}, {"entity_id": "16968538_3_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 4, "end": 5}, {"entity_id": "16968538_3_Ent0", "role": "Effect", "text": "hemolytic and/or thrombocytopenic reactions", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "16968538_3_Ent1", "text": "oxaliplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16968538_3_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16968538_3_Ent0", "text": "hemolytic and/or thrombocytopenic reactions", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "17009081_1", "wnd_id": "17009081_1_1", "text": "A 43 - year - old woman with multiple sclerosis ( MS ) had nephrotic syndrome 21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration ) .", "tokens": ["A", "43", "-", "year", "-", "old", "woman", "with", "multiple", "sclerosis", "(", "MS", ")", "had", "nephrotic", "syndrome", "21", "months", "after", "starting", "treatment", "with", "interferon", "(", "IFN)", "-", "beta", "-", "1b", "(", "subcutaneous", "administration", ")", "."], "event_mentions": [{"id": "17009081_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 13, "end": 14}, "arguments": [{"entity_id": "17009081_1_Ent0", "role": "Subject", "text": "A 43 - year - old woman with multiple sclerosis ( MS )", "start": 0, "end": 13}, {"entity_id": "17009081_1_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 1, "end": 6}, {"entity_id": "17009081_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "17009081_1_Ent5", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 8, "end": 10}, {"entity_id": "17009081_1_Ent3", "role": "Effect", "text": "nephrotic syndrome", "start": 14, "end": 16}, {"entity_id": "17009081_1_Ent7", "role": "Treatment_Time_elapsed", "text": "21 months", "start": 16, "end": 18}, {"entity_id": "17009081_1_Ent4", "role": "Treatment", "text": "21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration )", "start": 16, "end": 33}, {"entity_id": "17009081_1_Ent6", "role": "Treatment_Drug", "text": "interferon ( IFN) - beta - 1b", "start": 22, "end": 29}]}], "entity_mentions": [{"id": "17009081_1_Ent0", "text": "A 43 - year - old woman with multiple sclerosis ( MS )", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "17009081_1_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17009081_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17009081_1_Ent5", "text": "multiple sclerosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17009081_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17009081_1_Ent7", "text": "21 months", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17009081_1_Ent4", "text": "21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration )", "entity_type": "Entity", "start": 16, "end": 33}, {"id": "17009081_1_Ent6", "text": "interferon ( IFN) - beta - 1b", "entity_type": "Entity", "start": 22, "end": 29}], "lang": "en"}
{"doc_id": "17016002_3", "wnd_id": "17016002_3_1", "text": "Therefore , we concluded that this patient 's pulmonary disease was caused by calcium stearate , an additive for an antihistaminic drug .", "tokens": ["Therefore", ",", "we", "concluded", "that", "this", "patient", "'s", "pulmonary", "disease", "was", "caused", "by", "calcium", "stearate", ",", "an", "additive", "for", "an", "antihistaminic", "drug", "."], "event_mentions": [{"id": "17016002_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "17016002_3_Ent0", "role": "Subject", "text": "this patient 's", "start": 5, "end": 8}, {"entity_id": "17016002_3_Ent1", "role": "Effect", "text": "pulmonary disease", "start": 8, "end": 10}, {"entity_id": "17016002_3_Ent2", "role": "Treatment", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent4", "role": "Treatment_Drug", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent3", "role": "Treatment", "text": "an additive for an antihistaminic drug", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17016002_3_Ent0", "text": "this patient 's", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17016002_3_Ent1", "text": "pulmonary disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17016002_3_Ent2", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent4", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent3", "text": "an additive for an antihistaminic drug", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "17034541_1", "wnd_id": "17034541_1_1", "text": "Late lethal hepatitis B virus reactivation after rituximab treatment of low - grade cutaneous B - cell lymphoma .", "tokens": ["Late", "lethal", "hepatitis", "B", "virus", "reactivation", "after", "rituximab", "treatment", "of", "low", "-", "grade", "cutaneous", "B", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "17034541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "17034541_1_Ent0", "role": "Effect", "text": "Late lethal hepatitis B virus reactivation", "start": 0, "end": 6}, {"entity_id": "17034541_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent2", "role": "Treatment_Disorder", "text": "low - grade cutaneous B - cell lymphoma", "start": 10, "end": 18}]}], "entity_mentions": [{"id": "17034541_1_Ent0", "text": "Late lethal hepatitis B virus reactivation", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17034541_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent2", "text": "low - grade cutaneous B - cell lymphoma", "entity_type": "Entity", "start": 10, "end": 18}], "lang": "en"}
{"doc_id": "1703754_1", "wnd_id": "1703754_1_1", "text": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine .", "tokens": ["This", "is", "a", "case", "report", "of", "fatal", "cryptococcal", "meningitis", "in", "a", "child", "with", "systemic", "lupus", "erythematosus", "being", "treated", "with", "prednisolone", "and", "azathioprine", "."], "event_mentions": [{"id": "1703754_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "1703754_1_Ent2", "role": "Effect", "text": "fatal cryptococcal meningitis", "start": 6, "end": 9}, {"entity_id": "1703754_1_Ent0", "role": "Subject", "text": "a child with systemic lupus erythematosus", "start": 10, "end": 16}, {"entity_id": "1703754_1_Ent1", "role": "Subject_Age", "text": "child", "start": 11, "end": 12}, {"entity_id": "1703754_1_Ent4", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus", "start": 13, "end": 16}, {"entity_id": "1703754_1_Ent5", "role": "Treatment_Drug", "text": "prednisolone", "start": 19, "end": 20}, {"entity_id": "1703754_1_Ent7", "role": "Combination_Drug", "text": "prednisolone", "start": 19, "end": 20}, {"entity_id": "1703754_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 19, "end": 22}, {"entity_id": "1703754_1_Ent6", "role": "Treatment_Drug", "text": "azathioprine", "start": 21, "end": 22}, {"entity_id": "1703754_1_Ent8", "role": "Combination_Drug", "text": "azathioprine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1703754_1_Ent2", "text": "fatal cryptococcal meningitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1703754_1_Ent0", "text": "a child with systemic lupus erythematosus", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "1703754_1_Ent1", "text": "child", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1703754_1_Ent4", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "1703754_1_Ent5", "text": "prednisolone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1703754_1_Ent7", "text": "prednisolone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1703754_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "1703754_1_Ent6", "text": "azathioprine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1703754_1_Ent8", "text": "azathioprine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17039658_2", "wnd_id": "17039658_2_1", "text": "This eruption appears to be a distinct cutaneous toxicity of PLD .", "tokens": ["This", "eruption", "appears", "to", "be", "a", "distinct", "cutaneous", "toxicity", "of", "PLD", "."], "event_mentions": [{"id": "17039658_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "17039658_2_Ent0", "role": "Effect", "text": "eruption", "start": 1, "end": 2}, {"entity_id": "17039658_2_Ent1", "role": "Effect", "text": "distinct cutaneous toxicity", "start": 6, "end": 9}, {"entity_id": "17039658_2_Ent2", "role": "Treatment", "text": "PLD", "start": 10, "end": 11}, {"entity_id": "17039658_2_Ent3", "role": "Treatment_Drug", "text": "PLD", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17039658_2_Ent0", "text": "eruption", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17039658_2_Ent1", "text": "distinct cutaneous toxicity", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17039658_2_Ent2", "text": "PLD", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17039658_2_Ent3", "text": "PLD", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17060191_5", "wnd_id": "17060191_5_1", "text": "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure .", "tokens": ["This", "selective", "closure", "of", "the", "ductus", "arteriosus", "suggests", "that", "the", "affected", "twin", "was", "predisposed", "to", "hypoxia", "and", "thus", "was", "more", "susceptible", "to", "ductal", "closure", "in", "response", "to", "indomethacin", "exposure", "."], "event_mentions": [{"id": "17060191_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 25, "end": 26}, "arguments": [{"entity_id": "17060191_5_Ent0", "role": "Effect", "text": "ductal closure", "start": 22, "end": 24}, {"entity_id": "17060191_5_Ent2", "role": "Treatment_Drug", "text": "indomethacin", "start": 27, "end": 28}, {"entity_id": "17060191_5_Ent1", "role": "Treatment", "text": "indomethacin exposure", "start": 27, "end": 29}, {"entity_id": "17060191_5_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17060191_5_Ent0", "text": "ductal closure", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17060191_5_Ent2", "text": "indomethacin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17060191_5_Ent1", "text": "indomethacin exposure", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "17060191_5_Ent3", "text": "exposure", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17083890_5", "wnd_id": "17083890_5_1", "text": "During administration of chemotherapy , the patient progressively developed a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin .", "tokens": ["During", "administration", "of", "chemotherapy", ",", "the", "patient", "progressively", "developed", "a", "complex", "association", "of", "Beau", "'s", "lines", ",", "transverse", "melanonychia", ",", "Muehrcke", "'s", "lines", ",", "and", "diffuse", "hyperpigmentation", "of", "the", "skin", "."], "event_mentions": [{"id": "17083890_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "17083890_5_Ent2", "role": "Treatment", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "17083890_5_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "17083890_5_Ent0", "role": "Subject", "text": "patient", "start": 6, "end": 7}, {"entity_id": "17083890_5_Ent1", "role": "Effect", "text": "a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin", "start": 9, "end": 30}]}], "entity_mentions": [{"id": "17083890_5_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17083890_5_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17083890_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17083890_5_Ent1", "text": "a complex association of Beau 's lines , transverse melanonychia , Muehrcke 's lines , and diffuse hyperpigmentation of the skin", "entity_type": "Entity", "start": 9, "end": 30}], "lang": "en"}
{"doc_id": "17083890_7", "wnd_id": "17083890_7_1", "text": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments .", "tokens": ["This", "complex", "pattern", "of", "nail", "and", "skin", "changes", "is", "accounted", "by", "synergy", "or", "an", "additive", "effect", "of", "chemotherapy", "agents", "on", "cellular", "proliferation", "of", "nail", "compartments", "."], "event_mentions": [{"id": "17083890_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "synergy or an additive effect", "start": 11, "end": 16}, "arguments": [{"entity_id": "17083890_7_Ent0", "role": "Effect", "text": "complex pattern of nail and skin changes", "start": 1, "end": 8}, {"entity_id": "17083890_7_Ent1", "role": "Treatment", "text": "chemotherapy agents", "start": 17, "end": 19}, {"entity_id": "17083890_7_Ent2", "role": "Treatment_Drug", "text": "chemotherapy agents", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "17083890_7_Ent0", "text": "complex pattern of nail and skin changes", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "17083890_7_Ent1", "text": "chemotherapy agents", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17083890_7_Ent2", "text": "chemotherapy agents", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "17122225_2", "wnd_id": "17122225_2_1", "text": "Serotonin syndrome is a potentially lethal adverse drug reaction that may occur in patients taking proserotoninergic medications .", "tokens": ["Serotonin", "syndrome", "is", "a", "potentially", "lethal", "adverse", "drug", "reaction", "that", "may", "occur", "in", "patients", "taking", "proserotoninergic", "medications", "."], "event_mentions": [{"id": "17122225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 11, "end": 12}, "arguments": [{"entity_id": "17122225_2_Ent1", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_2_Ent4", "role": "Treatment_Disorder", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}, {"entity_id": "17122225_2_Ent3", "role": "Treatment_Drug", "text": "proserotoninergic", "start": 15, "end": 16}, {"entity_id": "17122225_2_Ent2", "role": "Treatment", "text": "proserotoninergic medications", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17122225_2_Ent1", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_2_Ent4", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_2_Ent3", "text": "proserotoninergic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_2_Ent2", "text": "proserotoninergic medications", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17123120_1", "wnd_id": "17123120_1_1", "text": "Tacrolimus - induced HUS : an unusual cause of acute renal failure in nephrotic syndrome .", "tokens": ["Tacrolimus", "-", "induced", "HUS", ":", "an", "unusual", "cause", "of", "acute", "renal", "failure", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17123120_1_Ent1", "role": "Treatment", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent0", "role": "Effect", "text": "HUS", "start": 3, "end": 4}, {"entity_id": "17123120_1_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_1_Ent1", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent0", "text": "HUS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17123120_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17123120_2", "wnd_id": "17123120_2_1", "text": "Thus , tacrolimus - induced HUS is a rare cause of ARF in nephrotic syndrome .", "tokens": ["Thus", ",", "tacrolimus", "-", "induced", "HUS", "is", "a", "rare", "cause", "of", "ARF", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17123120_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent0", "role": "Effect", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "17123120_2_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17123120_2_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17133571_2", "wnd_id": "17133571_2_1", "text": "We describe a detailed case of fulminant hepatitis induced by nevirapine ( Viramune ) and treated by liver transplantation .", "tokens": ["We", "describe", "a", "detailed", "case", "of", "fulminant", "hepatitis", "induced", "by", "nevirapine", "(", "Viramune", ")", "and", "treated", "by", "liver", "transplantation", "."], "event_mentions": [{"id": "17133571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17133571_2_Ent0", "role": "Effect", "text": "fulminant hepatitis", "start": 6, "end": 8}, {"entity_id": "17133571_2_Ent1", "role": "Treatment", "text": "nevirapine", "start": 10, "end": 11}, {"entity_id": "17133571_2_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17133571_2_Ent0", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17133571_2_Ent1", "text": "nevirapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17133571_2_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17167851_2", "wnd_id": "17167851_2_1", "text": "Three male patients aged 78 - 83 years are presented , in whom severe hepatotoxic reactions emerged after CPA administration .", "tokens": ["Three", "male", "patients", "aged", "78", "-", "83", "years", "are", "presented", ",", "in", "whom", "severe", "hepatotoxic", "reactions", "emerged", "after", "CPA", "administration", "."], "event_mentions": [{"id": "17167851_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "17167851_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "17167851_2_Ent0", "role": "Subject", "text": "Three male patients aged 78 - 83 years", "start": 0, "end": 8}, {"entity_id": "17167851_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "17167851_2_Ent3", "role": "Subject_Age", "text": "78 - 83 years", "start": 4, "end": 8}, {"entity_id": "17167851_2_Ent4", "role": "Effect", "text": "severe hepatotoxic reactions", "start": 13, "end": 16}, {"entity_id": "17167851_2_Ent5", "role": "Treatment", "text": "CPA", "start": 18, "end": 19}, {"entity_id": "17167851_2_Ent6", "role": "Treatment_Drug", "text": "CPA", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17167851_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17167851_2_Ent0", "text": "Three male patients aged 78 - 83 years", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17167851_2_Ent2", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17167851_2_Ent3", "text": "78 - 83 years", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17167851_2_Ent4", "text": "severe hepatotoxic reactions", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17167851_2_Ent5", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17167851_2_Ent6", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17182354_1", "wnd_id": "17182354_1_1", "text": "However , an association of Ritalin with glaucoma has been reported .", "tokens": ["However", ",", "an", "association", "of", "Ritalin", "with", "glaucoma", "has", "been", "reported", "."], "event_mentions": [{"id": "17182354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 3, "end": 4}, "arguments": [{"entity_id": "17182354_1_Ent1", "role": "Treatment", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_1_Ent2", "role": "Treatment_Drug", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_1_Ent0", "role": "Effect", "text": "glaucoma", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17182354_1_Ent1", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_1_Ent2", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_1_Ent0", "text": "glaucoma", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17182354_2", "wnd_id": "17182354_2_1", "text": "Large dose of methylphenidate may cause cataract and glaucoma .", "tokens": ["Large", "dose", "of", "methylphenidate", "may", "cause", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "17182354_2_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "17182354_2_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "17182354_4", "wnd_id": "17182354_4_1", "text": "We report a case of Ritalin - associated cataract and glaucoma .", "tokens": ["We", "report", "a", "case", "of", "Ritalin", "-", "associated", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17182354_4_Ent1", "role": "Treatment", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_4_Ent2", "role": "Treatment_Drug", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_4_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "17182354_4_Ent1", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_4_Ent2", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_4_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "17188061_2", "wnd_id": "17188061_2_1", "text": "PURPOSE : To describe transient structured visual hallucinations in a patient with vascular age - related macular degeneration ( AMD ) , following an intravitreal Avastin - injection .", "tokens": ["PURPOSE", ":", "To", "describe", "transient", "structured", "visual", "hallucinations", "in", "a", "patient", "with", "vascular", "age", "-", "related", "macular", "degeneration", "(", "AMD", ")", ",", "following", "an", "intravitreal", "Avastin", "-", "injection", "."], "event_mentions": [{"id": "17188061_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 22, "end": 23}, "arguments": [{"entity_id": "17188061_2_Ent1", "role": "Effect", "text": "transient structured visual hallucinations", "start": 4, "end": 8}, {"entity_id": "17188061_2_Ent0", "role": "Subject", "text": "a patient with vascular age - related macular degeneration ( AMD )", "start": 9, "end": 21}, {"entity_id": "17188061_2_Ent3", "role": "Treatment_Disorder", "text": "vascular age - related macular degeneration ( AMD )", "start": 12, "end": 21}, {"entity_id": "17188061_2_Ent2", "role": "Treatment", "text": "an intravitreal Avastin - injection", "start": 23, "end": 28}, {"entity_id": "17188061_2_Ent5", "role": "Treatment_Route", "text": "intravitreal", "start": 24, "end": 25}, {"entity_id": "17188061_2_Ent4", "role": "Treatment_Drug", "text": "Avastin", "start": 25, "end": 26}, {"entity_id": "17188061_2_Ent6", "role": "Treatment_Route", "text": "injection", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "17188061_2_Ent1", "text": "transient structured visual hallucinations", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17188061_2_Ent0", "text": "a patient with vascular age - related macular degeneration ( AMD )", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "17188061_2_Ent3", "text": "vascular age - related macular degeneration ( AMD )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "17188061_2_Ent2", "text": "an intravitreal Avastin - injection", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "17188061_2_Ent5", "text": "intravitreal", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17188061_2_Ent4", "text": "Avastin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17188061_2_Ent6", "text": "injection", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "17189581_16", "wnd_id": "17189581_16_1", "text": "Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine .", "tokens": ["Serotonin", "syndrome", "developed", "in", "a", "patient", "taking", "concurrent", "linezolid", "and", "fluoxetine", "."], "event_mentions": [{"id": "17189581_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "17189581_16_Ent1", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17189581_16_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "17189581_16_Ent2", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 7, "end": 11}, {"entity_id": "17189581_16_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent5", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 10, "end": 11}, {"entity_id": "17189581_16_Ent6", "role": "Combination_Drug", "text": "fluoxetine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17189581_16_Ent1", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17189581_16_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17189581_16_Ent2", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "17189581_16_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent5", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17189581_16_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17189581_3", "wnd_id": "17189581_3_1", "text": "A 23 - year - old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia .", "tokens": ["A", "23", "-", "year", "-", "old", "white", "male", "patient", "was", "originally", "admitted", "to", "receive", "intravenous", "chemotherapy", "for", "acute", "myelogenous", "leukemia", "."], "event_mentions": [{"id": "17189581_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 13, "end": 14}, "arguments": [{"entity_id": "17189581_3_Ent0", "role": "Subject", "text": "A 23 - year - old white male patient", "start": 0, "end": 9}, {"entity_id": "17189581_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 1, "end": 6}, {"entity_id": "17189581_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "17189581_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "17189581_3_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "17189581_3_Ent4", "role": "Treatment", "text": "intravenous chemotherapy", "start": 14, "end": 16}, {"entity_id": "17189581_3_Ent5", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "17189581_3_Ent6", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "17189581_3_Ent0", "text": "A 23 - year - old white male patient", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17189581_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17189581_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17189581_3_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17189581_3_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17189581_3_Ent4", "text": "intravenous chemotherapy", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17189581_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17189581_3_Ent6", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "17228132_2", "wnd_id": "17228132_2_1", "text": "CONTEXT : Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor ( EGFR ) inhibitors .", "tokens": ["CONTEXT", ":", "Acute", "drug", "induced", "hepatitis", "has", "not", "been", "commonly", "associated", "with", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitors", "."], "event_mentions": [{"id": "17228132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "17228132_2_Ent0", "role": "Effect", "text": "Acute drug induced hepatitis", "start": 2, "end": 6}, {"entity_id": "17228132_2_Ent2", "role": "Treatment_Drug", "text": "epidermal growth factor receptor", "start": 12, "end": 16}, {"entity_id": "17228132_2_Ent1", "role": "Treatment", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "start": 12, "end": 20}, {"entity_id": "17228132_2_Ent3", "role": "Treatment_Drug", "text": "inhibitors", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17228132_2_Ent0", "text": "Acute drug induced hepatitis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "17228132_2_Ent2", "text": "epidermal growth factor receptor", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17228132_2_Ent1", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "17228132_2_Ent3", "text": "inhibitors", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "1722991_1", "wnd_id": "1722991_1_1", "text": "Usefulness of antiplatelet drugs in the management of heparin - associated thrombocytopenia and thrombosis .", "tokens": ["Usefulness", "of", "antiplatelet", "drugs", "in", "the", "management", "of", "heparin", "-", "associated", "thrombocytopenia", "and", "thrombosis", "."], "event_mentions": [{"id": "1722991_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Usefulness", "start": 0, "end": 1}, "arguments": [{"entity_id": "1722991_1_Ent3", "role": "Treatment", "text": "antiplatelet drugs", "start": 2, "end": 4}, {"entity_id": "1722991_1_Ent5", "role": "Treatment_Drug", "text": "antiplatelet drugs", "start": 2, "end": 4}, {"entity_id": "1722991_1_Ent4", "role": "Treatment_Disorder", "text": "heparin - associated thrombocytopenia and thrombosis", "start": 8, "end": 14}]}, {"id": "1722991_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "1722991_1_Ent1", "role": "Treatment", "text": "heparin", "start": 8, "end": 9}, {"entity_id": "1722991_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 8, "end": 9}, {"entity_id": "1722991_1_Ent0", "role": "Effect", "text": "thrombocytopenia and thrombosis", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "1722991_1_Ent3", "text": "antiplatelet drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_1_Ent5", "text": "antiplatelet drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_1_Ent1", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_1_Ent4", "text": "heparin - associated thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1722991_1_Ent0", "text": "thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "1722991_6", "wnd_id": "1722991_6_1", "text": "In the two cases , a combination of iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin - induced platelet aggregation .", "tokens": ["In", "the", "two", "cases", ",", "a", "combination", "of", "iloprost", ",", "a", "stable", "prostacyclin", "analogue", "(", "1", "to", "2", "ng", "/", "kg", "/", "mn", ")", "with", "aspirin", "and", "dipyridamole", "was", "shown", "to", "inhibit", "ex", "vivo", "the", "heparin", "-", "induced", "platelet", "aggregation", "."], "event_mentions": [{"id": "1722991_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit ex vivo", "start": 31, "end": 34}, "arguments": [{"entity_id": "1722991_6_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "1722991_6_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "1722991_6_Ent5", "role": "Treatment_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent8", "role": "Combination_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent2", "role": "Treatment", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "start": 8, "end": 28}, {"entity_id": "1722991_6_Ent4", "role": "Treatment_Dosage", "text": "1 to 2 ng / kg / mn", "start": 15, "end": 23}, {"entity_id": "1722991_6_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent9", "role": "Combination_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent7", "role": "Treatment_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent10", "role": "Combination_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent3", "role": "Treatment_Disorder", "text": "heparin - induced platelet aggregation", "start": 35, "end": 40}]}, {"id": "1722991_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "1722991_6_Ent12", "role": "Treatment", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent13", "role": "Treatment_Drug", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent11", "role": "Effect", "text": "platelet aggregation", "start": 38, "end": 40}]}], "entity_mentions": [{"id": "1722991_6_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1722991_6_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_6_Ent5", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent8", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent2", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "entity_type": "Entity", "start": 8, "end": 28}, {"id": "1722991_6_Ent4", "text": "1 to 2 ng / kg / mn", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "1722991_6_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent9", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent7", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent10", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent12", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent13", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent3", "text": "heparin - induced platelet aggregation", "entity_type": "Entity", "start": 35, "end": 40}, {"id": "1722991_6_Ent11", "text": "platelet aggregation", "entity_type": "Entity", "start": 38, "end": 40}], "lang": "en"}
{"doc_id": "17260498_2", "wnd_id": "17260498_2_1", "text": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms .", "tokens": ["Taxanes", "are", "widely", "used", "chemotherapeutic", "agents", "with", "the", "potential", "to", "induce", "pulmonary", "injury", "through", "a", "variety", "of", "mechanisms", "."], "event_mentions": [{"id": "17260498_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 10, "end": 11}, "arguments": [{"entity_id": "17260498_2_Ent1", "role": "Treatment", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent2", "role": "Treatment_Drug", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent0", "role": "Effect", "text": "pulmonary injury", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "17260498_2_Ent1", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent2", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent0", "text": "pulmonary injury", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "17260498_4", "wnd_id": "17260498_4_1", "text": "The case is presented of a 72 - year - old man with hormone - refractory prostate cancer and weekly administration of 30 mg / m2 docetaxel who developed subacute interstitial pneumonitis - related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high - dose corticosteroid treatment .", "tokens": ["The", "case", "is", "presented", "of", "a", "72", "-", "year", "-", "old", "man", "with", "hormone", "-", "refractory", "prostate", "cancer", "and", "weekly", "administration", "of", "30", "mg", "/", "m2", "docetaxel", "who", "developed", "subacute", "interstitial", "pneumonitis", "-", "related", "pulmonary", "fibrosis", "after", "seven", "doses", "and", "died", "despite", "mechanical", "ventilation", "and", "high", "-", "dose", "corticosteroid", "treatment", "."], "event_mentions": [{"id": "17260498_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "17260498_4_Ent0", "role": "Subject", "text": "a 72 - year - old man with hormone - refractory prostate cancer", "start": 5, "end": 18}, {"entity_id": "17260498_4_Ent1", "role": "Subject_Age", "text": "72 - year - old", "start": 6, "end": 11}, {"entity_id": "17260498_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "17260498_4_Ent15", "role": "Treatment_Disorder", "text": "hormone - refractory prostate cancer", "start": 13, "end": 18}, {"entity_id": "17260498_4_Ent8", "role": "Treatment_Freq", "text": "weekly", "start": 19, "end": 20}, {"entity_id": "17260498_4_Ent5", "role": "Treatment", "text": "weekly administration of 30 mg / m2 docetaxel", "start": 19, "end": 27}, {"entity_id": "17260498_4_Ent9", "role": "Treatment_Route", "text": "administration", "start": 20, "end": 21}, {"entity_id": "17260498_4_Ent10", "role": "Treatment_Dosage", "text": "30 mg / m2", "start": 22, "end": 26}, {"entity_id": "17260498_4_Ent13", "role": "Treatment_Drug", "text": "docetaxel", "start": 26, "end": 27}, {"entity_id": "17260498_4_Ent3", "role": "Effect", "text": "subacute interstitial pneumonitis - related pulmonary fibrosis", "start": 29, "end": 36}, {"entity_id": "17260498_4_Ent6", "role": "Treatment", "text": "seven doses", "start": 37, "end": 39}, {"entity_id": "17260498_4_Ent11", "role": "Treatment_Dosage", "text": "seven doses", "start": 37, "end": 39}, {"entity_id": "17260498_4_Ent4", "role": "Effect", "text": "and died", "start": 39, "end": 41}, {"entity_id": "17260498_4_Ent7", "role": "Treatment", "text": "despite mechanical ventilation and high - dose corticosteroid treatment", "start": 41, "end": 50}, {"entity_id": "17260498_4_Ent12", "role": "Treatment_Dosage", "text": "high - dose", "start": 45, "end": 48}, {"entity_id": "17260498_4_Ent14", "role": "Treatment_Drug", "text": "corticosteroid", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "17260498_4_Ent0", "text": "a 72 - year - old man with hormone - refractory prostate cancer", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "17260498_4_Ent1", "text": "72 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17260498_4_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17260498_4_Ent15", "text": "hormone - refractory prostate cancer", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17260498_4_Ent8", "text": "weekly", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17260498_4_Ent5", "text": "weekly administration of 30 mg / m2 docetaxel", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "17260498_4_Ent9", "text": "administration", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17260498_4_Ent10", "text": "30 mg / m2", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17260498_4_Ent13", "text": "docetaxel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17260498_4_Ent3", "text": "subacute interstitial pneumonitis - related pulmonary fibrosis", "entity_type": "Entity", "start": 29, "end": 36}, {"id": "17260498_4_Ent6", "text": "seven doses", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "17260498_4_Ent11", "text": "seven doses", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "17260498_4_Ent4", "text": "and died", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "17260498_4_Ent7", "text": "despite mechanical ventilation and high - dose corticosteroid treatment", "entity_type": "Entity", "start": 41, "end": 50}, {"id": "17260498_4_Ent12", "text": "high - dose", "entity_type": "Entity", "start": 45, "end": 48}, {"id": "17260498_4_Ent14", "text": "corticosteroid", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "17266059_3", "wnd_id": "17266059_3_1", "text": "We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim - sulfamethoxazole therapy ( Bactrim , Septra ) in a Jehovah 's Witness patient .", "tokens": ["We", "report", "a", "case", "of", "Thrombotic", "Thrombocytopenic", "Purpura", "occurring", "as", "an", "allergic", "response", "to", "trimethoprim", "-", "sulfamethoxazole", "therapy", "(", "Bactrim", ",", "Septra", ")", "in", "a", "Jehovah", "'s", "Witness", "patient", "."], "event_mentions": [{"id": "17266059_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 13, "end": 14}, "arguments": [{"entity_id": "17266059_3_Ent1", "role": "Effect", "text": "Thrombotic Thrombocytopenic Purpura", "start": 5, "end": 8}, {"entity_id": "17266059_3_Ent2", "role": "Effect", "text": "allergic response", "start": 11, "end": 13}, {"entity_id": "17266059_3_Ent4", "role": "Treatment_Drug", "text": "trimethoprim", "start": 14, "end": 15}, {"entity_id": "17266059_3_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 14, "end": 15}, {"entity_id": "17266059_3_Ent3", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 14, "end": 17}, {"entity_id": "17266059_3_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 16, "end": 17}, {"entity_id": "17266059_3_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 16, "end": 17}, {"entity_id": "17266059_3_Ent0", "role": "Subject", "text": "Jehovah 's Witness patient", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "17266059_3_Ent1", "text": "Thrombotic Thrombocytopenic Purpura", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_3_Ent2", "text": "allergic response", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17266059_3_Ent4", "text": "trimethoprim", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17266059_3_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17266059_3_Ent3", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "17266059_3_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17266059_3_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17266059_3_Ent0", "text": "Jehovah 's Witness patient", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "17275666_6", "wnd_id": "17275666_6_1", "text": "This report describes a case of paradoxical , intravenous valproic acid - induced seizure exacerbation in a child with juvenile absence epilepsy , documented by video - electroencephalography .", "tokens": ["This", "report", "describes", "a", "case", "of", "paradoxical", ",", "intravenous", "valproic", "acid", "-", "induced", "seizure", "exacerbation", "in", "a", "child", "with", "juvenile", "absence", "epilepsy", ",", "documented", "by", "video", "-", "electroencephalography", "."], "event_mentions": [{"id": "17275666_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "17275666_6_Ent3", "role": "Treatment", "text": "intravenous valproic acid", "start": 8, "end": 11}, {"entity_id": "17275666_6_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 9, "end": 11}, {"entity_id": "17275666_6_Ent2", "role": "Effect", "text": "seizure exacerbation", "start": 13, "end": 15}, {"entity_id": "17275666_6_Ent0", "role": "Subject", "text": "a child with juvenile absence epilepsy", "start": 16, "end": 22}, {"entity_id": "17275666_6_Ent1", "role": "Subject_Age", "text": "child", "start": 17, "end": 18}, {"entity_id": "17275666_6_Ent6", "role": "Treatment_Disorder", "text": "juvenile absence epilepsy", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "17275666_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17275666_6_Ent3", "text": "intravenous valproic acid", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17275666_6_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17275666_6_Ent2", "text": "seizure exacerbation", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17275666_6_Ent0", "text": "a child with juvenile absence epilepsy", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "17275666_6_Ent1", "text": "child", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17275666_6_Ent6", "text": "juvenile absence epilepsy", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "17285101_2", "wnd_id": "17285101_2_1", "text": "The authors presented a case of pulmonary hypertension during lithium therapy , while she has been on lithium for 6 years .", "tokens": ["The", "authors", "presented", "a", "case", "of", "pulmonary", "hypertension", "during", "lithium", "therapy", ",", "while", "she", "has", "been", "on", "lithium", "for", "6", "years", "."], "event_mentions": [{"id": "17285101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "17285101_2_Ent2", "role": "Effect", "text": "pulmonary hypertension", "start": 6, "end": 8}, {"entity_id": "17285101_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17285101_2_Ent3", "role": "Treatment", "text": "lithium therapy", "start": 9, "end": 11}, {"entity_id": "17285101_2_Ent0", "role": "Subject", "text": "she", "start": 13, "end": 14}, {"entity_id": "17285101_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 13, "end": 14}, {"entity_id": "17285101_2_Ent5", "role": "Treatment_Duration", "text": "6 years", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "17285101_2_Ent2", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17285101_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17285101_2_Ent3", "text": "lithium therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17285101_2_Ent0", "text": "she", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17285101_2_Ent1", "text": "she", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17285101_2_Ent5", "text": "6 years", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "17316160_3", "wnd_id": "17316160_3_1", "text": "Combination antimicrobial regimens ( e.g. , linezolid with rifampin ) aimed at improving bacterial eradication and preventing resistance are often used ; however , most data supporting this treatment strategy are not from randomized controlled trials .", "tokens": ["Combination", "antimicrobial", "regimens", "(", "e.g.", ",", "linezolid", "with", "rifampin", ")", "aimed", "at", "improving", "bacterial", "eradication", "and", "preventing", "resistance", "are", "often", "used", ";", "however", ",", "most", "data", "supporting", "this", "treatment", "strategy", "are", "not", "from", "randomized", "controlled", "trials", "."], "event_mentions": [{"id": "17316160_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "aimed", "start": 10, "end": 11}, "arguments": [{"entity_id": "17316160_3_Ent1", "role": "Treatment", "text": "Combination antimicrobial regimens ( e.g. , linezolid with rifampin )", "start": 0, "end": 10}, {"entity_id": "17316160_3_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "17316160_3_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "17316160_3_Ent3", "role": "Treatment_Drug", "text": "rifampin", "start": 8, "end": 9}, {"entity_id": "17316160_3_Ent5", "role": "Combination_Drug", "text": "rifampin", "start": 8, "end": 9}, {"entity_id": "17316160_3_Ent0", "role": "Effect", "text": "improving bacterial eradication and preventing resistance", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "17316160_3_Ent1", "text": "Combination antimicrobial regimens ( e.g. , linezolid with rifampin )", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "17316160_3_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17316160_3_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17316160_3_Ent3", "text": "rifampin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17316160_3_Ent5", "text": "rifampin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17316160_3_Ent0", "text": "improving bacterial eradication and preventing resistance", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "17324248_2", "wnd_id": "17324248_2_1", "text": "CONCLUSIONS : The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran .", "tokens": ["CONCLUSIONS", ":", "The", "piloerection", "observed", "after", "the", "replacement", "of", "fluvoxamine", "with", "milnacipran", "in", "this", "patient", "appears", "to", "have", "been", "due", "to", "an", "increase", "in", "the", "alpha(1)", "-", "adrenoceptor", "occupancy", "by", "endogenous", "norepinephrine", "induced", "by", "milnacipran", "."], "event_mentions": [{"id": "17324248_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 4, "end": 5}, "arguments": [{"entity_id": "17324248_2_Ent4", "role": "Effect", "text": "piloerection", "start": 3, "end": 4}, {"entity_id": "17324248_2_Ent5", "role": "Treatment", "text": "milnacipran", "start": 11, "end": 12}, {"entity_id": "17324248_2_Ent6", "role": "Treatment_Drug", "text": "milnacipran", "start": 11, "end": 12}, {"entity_id": "17324248_2_Ent3", "role": "Subject", "text": "this patient", "start": 13, "end": 15}]}, {"id": "17324248_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 32, "end": 33}, "arguments": [{"entity_id": "17324248_2_Ent0", "role": "Effect", "text": "an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine", "start": 21, "end": 32}, {"entity_id": "17324248_2_Ent1", "role": "Treatment", "text": "milnacipran", "start": 34, "end": 35}, {"entity_id": "17324248_2_Ent2", "role": "Treatment_Drug", "text": "milnacipran", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "17324248_2_Ent4", "text": "piloerection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17324248_2_Ent5", "text": "milnacipran", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17324248_2_Ent6", "text": "milnacipran", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17324248_2_Ent3", "text": "this patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17324248_2_Ent0", "text": "an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine", "entity_type": "Entity", "start": 21, "end": 32}, {"id": "17324248_2_Ent1", "text": "milnacipran", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17324248_2_Ent2", "text": "milnacipran", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "17329303_3", "wnd_id": "17329303_3_1", "text": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate .", "tokens": ["This", "report", "is", "about", "three", "cases", "of", "children", "who", "developed", "severe", "adverse", "reactions", "during", "switching", "from", "risperidone", "to", "methylphenidate", "."], "event_mentions": [{"id": "17329303_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "17329303_3_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "17329303_3_Ent0", "role": "Subject", "text": "three cases of children", "start": 4, "end": 8}, {"entity_id": "17329303_3_Ent2", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "17329303_3_Ent3", "role": "Effect", "text": "adverse reactions", "start": 11, "end": 13}, {"entity_id": "17329303_3_Ent4", "role": "Treatment", "text": "during switching from risperidone to methylphenidate", "start": 13, "end": 19}, {"entity_id": "17329303_3_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 16, "end": 17}, {"entity_id": "17329303_3_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17329303_3_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17329303_3_Ent0", "text": "three cases of children", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_3_Ent2", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_3_Ent3", "text": "adverse reactions", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17329303_3_Ent4", "text": "during switching from risperidone to methylphenidate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "17329303_3_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17329303_3_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17329303_5", "wnd_id": "17329303_5_1", "text": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment .", "tokens": ["He", "developed", "severe", "hyperactivity", "and", "agitation", "on", "taking", "methylphenidate", "after", "the", "discontinuation", "of", "risperidone", "treatment", "."], "event_mentions": [{"id": "17329303_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "17329303_5_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "17329303_5_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "17329303_5_Ent2", "role": "Effect", "text": "hyperactivity and agitation", "start": 3, "end": 6}, {"entity_id": "17329303_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "17329303_5_Ent3", "role": "Treatment", "text": "methylphenidate after the discontinuation of risperidone", "start": 8, "end": 14}, {"entity_id": "17329303_5_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17329303_5_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17329303_5_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17329303_5_Ent2", "text": "hyperactivity and agitation", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17329303_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17329303_5_Ent3", "text": "methylphenidate after the discontinuation of risperidone", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17329303_5_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17329303_6", "wnd_id": "17329303_6_1", "text": "The second patient was a girl of 6 , already on risperidone for ADHD and borderline intellectual functioning when referred .", "tokens": ["The", "second", "patient", "was", "a", "girl", "of", "6", ",", "already", "on", "risperidone", "for", "ADHD", "and", "borderline", "intellectual", "functioning", "when", "referred", "."], "event_mentions": [{"id": "17329303_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "on", "start": 10, "end": 11}, "arguments": [{"entity_id": "17329303_6_Ent0", "role": "Subject", "text": "a girl of 6", "start": 4, "end": 8}, {"entity_id": "17329303_6_Ent1", "role": "Subject_Gender", "text": "girl", "start": 5, "end": 6}, {"entity_id": "17329303_6_Ent2", "role": "Subject_Age", "text": "6", "start": 7, "end": 8}, {"entity_id": "17329303_6_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent5", "role": "Treatment_Disorder", "text": "ADHD", "start": 13, "end": 14}, {"entity_id": "17329303_6_Ent6", "role": "Treatment_Disorder", "text": "borderline intellectual functioning", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "17329303_6_Ent0", "text": "a girl of 6", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_6_Ent1", "text": "girl", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17329303_6_Ent2", "text": "6", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent5", "text": "ADHD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17329303_6_Ent6", "text": "borderline intellectual functioning", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "17352036_1", "wnd_id": "17352036_1_1", "text": "Adverse effects of amiodarone including pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases are well understood .", "tokens": ["Adverse", "effects", "of", "amiodarone", "including", "pulmonary", "toxicity", ",", "hepatotoxicity", ",", "aggravation", "of", "arrhythmia", ",", "and", "thyroid", "diseases", "are", "well", "understood", "."], "event_mentions": [{"id": "17352036_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "including", "start": 4, "end": 5}, "arguments": [{"entity_id": "17352036_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "17352036_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "17352036_1_Ent0", "role": "Effect", "text": "pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases", "start": 5, "end": 17}]}], "entity_mentions": [{"id": "17352036_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17352036_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17352036_1_Ent0", "text": "pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases", "entity_type": "Entity", "start": 5, "end": 17}], "lang": "en"}
{"doc_id": "17364199_2", "wnd_id": "17364199_2_1", "text": "BACKGROUND : Etanercept is a tumor necrosis factor ( TNF ) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis .", "tokens": ["BACKGROUND", ":", "Etanercept", "is", "a", "tumor", "necrosis", "factor", "(", "TNF", ")", "inhibitor", "that", "has", "been", "licensed", "in", "the", "United", "States", "for", "the", "treatment", "of", "adult", "and", "juvenile", "rheumatoid", "arthritis", "as", "well", "as", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "17364199_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "licensed", "start": 15, "end": 16}, "arguments": [{"entity_id": "17364199_2_Ent3", "role": "Treatment", "text": "Etanercept", "start": 2, "end": 3}, {"entity_id": "17364199_2_Ent5", "role": "Treatment_Drug", "text": "Etanercept", "start": 2, "end": 3}, {"entity_id": "17364199_2_Ent4", "role": "Treatment", "text": "a tumor necrosis factor ( TNF ) inhibitor", "start": 4, "end": 12}, {"entity_id": "17364199_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 24, "end": 25}, {"entity_id": "17364199_2_Ent6", "role": "Treatment_Disorder", "text": "adult and juvenile rheumatoid arthritis", "start": 24, "end": 29}, {"entity_id": "17364199_2_Ent0", "role": "Subject", "text": "adult and juvenile rheumatoid arthritis as well as psoriatic arthritis", "start": 24, "end": 34}, {"entity_id": "17364199_2_Ent2", "role": "Subject_Age", "text": "juvenile", "start": 26, "end": 27}, {"entity_id": "17364199_2_Ent7", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "17364199_2_Ent3", "text": "Etanercept", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17364199_2_Ent5", "text": "Etanercept", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17364199_2_Ent4", "text": "a tumor necrosis factor ( TNF ) inhibitor", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "17364199_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17364199_2_Ent6", "text": "adult and juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "17364199_2_Ent0", "text": "adult and juvenile rheumatoid arthritis as well as psoriatic arthritis", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "17364199_2_Ent2", "text": "juvenile", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17364199_2_Ent7", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "17383767_1", "wnd_id": "17383767_1_1", "text": "Significant drug interaction : phenytoin toxicity due to erlotinib .", "tokens": ["Significant", "drug", "interaction", ":", "phenytoin", "toxicity", "due", "to", "erlotinib", "."], "event_mentions": [{"id": "17383767_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "17383767_1_Ent0", "role": "Effect", "text": "phenytoin toxicity", "start": 4, "end": 6}, {"entity_id": "17383767_1_Ent1", "role": "Treatment", "text": "erlotinib", "start": 8, "end": 9}, {"entity_id": "17383767_1_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17383767_1_Ent0", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17383767_1_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17383767_1_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17387702_1", "wnd_id": "17387702_1_1", "text": "Renal failure after high - dose methotrexate in a child homozygous for MTHFR C677 T polymorphism .", "tokens": ["Renal", "failure", "after", "high", "-", "dose", "methotrexate", "in", "a", "child", "homozygous", "for", "MTHFR", "C677", "T", "polymorphism", "."], "event_mentions": [{"id": "17387702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17387702_1_Ent3", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "17387702_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "17387702_1_Ent4", "role": "Treatment", "text": "high - dose methotrexate", "start": 3, "end": 7}, {"entity_id": "17387702_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "17387702_1_Ent0", "role": "Subject", "text": "a child homozygous for MTHFR C677 T polymorphism", "start": 8, "end": 16}, {"entity_id": "17387702_1_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "17387702_1_Ent2", "role": "Subject_Disorder", "text": "homozygous for MTHFR C677 T polymorphism", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "17387702_1_Ent3", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17387702_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17387702_1_Ent4", "text": "high - dose methotrexate", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "17387702_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17387702_1_Ent0", "text": "a child homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "17387702_1_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17387702_1_Ent2", "text": "homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "17404582_1", "wnd_id": "17404582_1_1", "text": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past .", "tokens": ["Docetaxel", "induced", "Meibomian", "duct", "inflammation", "and", "blockage", "is", "the", "likely", "cause", "of", "this", "presentation", "in", "a", "patient", "with", "no", "history", "of", "eyelid", "masses", "in", "the", "past", "."], "event_mentions": [{"id": "17404582_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "17404582_1_Ent2", "role": "Treatment", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent3", "role": "Treatment_Drug", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent1", "role": "Effect", "text": "Meibomian duct inflammation and blockage", "start": 2, "end": 7}, {"entity_id": "17404582_1_Ent0", "role": "Subject", "text": "a patient with no history of eyelid masses in the past", "start": 15, "end": 26}]}], "entity_mentions": [{"id": "17404582_1_Ent2", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent3", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent1", "text": "Meibomian duct inflammation and blockage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "17404582_1_Ent0", "text": "a patient with no history of eyelid masses in the past", "entity_type": "Entity", "start": 15, "end": 26}], "lang": "en"}
{"doc_id": "17404582_2", "wnd_id": "17404582_2_1", "text": "Docetaxel - induced Meibomian duct inflammation and blockage leading to chalazion formation .", "tokens": ["Docetaxel", "-", "induced", "Meibomian", "duct", "inflammation", "and", "blockage", "leading", "to", "chalazion", "formation", "."], "event_mentions": [{"id": "17404582_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17404582_2_Ent1", "role": "Treatment", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_2_Ent2", "role": "Treatment_Drug", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_2_Ent0", "role": "Effect", "text": "Meibomian duct inflammation and blockage leading to chalazion formation", "start": 3, "end": 12}]}], "entity_mentions": [{"id": "17404582_2_Ent1", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_2_Ent2", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_2_Ent0", "text": "Meibomian duct inflammation and blockage leading to chalazion formation", "entity_type": "Entity", "start": 3, "end": 12}], "lang": "en"}
{"doc_id": "17420198_10", "wnd_id": "17420198_10_1", "text": "Facial , tongue , and arm movements were first reported approximately five weeks after the initiation of aripiprazole .", "tokens": ["Facial", ",", "tongue", ",", "and", "arm", "movements", "were", "first", "reported", "approximately", "five", "weeks", "after", "the", "initiation", "of", "aripiprazole", "."], "event_mentions": [{"id": "17420198_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "17420198_10_Ent0", "role": "Effect", "text": "Facial , tongue , and arm movements", "start": 0, "end": 7}, {"entity_id": "17420198_10_Ent2", "role": "Treatment_Time_elapsed", "text": "five weeks", "start": 11, "end": 13}, {"entity_id": "17420198_10_Ent1", "role": "Treatment", "text": "initiation of aripiprazole", "start": 15, "end": 18}, {"entity_id": "17420198_10_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17420198_10_Ent0", "text": "Facial , tongue , and arm movements", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17420198_10_Ent2", "text": "five weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17420198_10_Ent1", "text": "initiation of aripiprazole", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17420198_10_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17420198_17", "wnd_id": "17420198_17_1", "text": "The patient 's movements resolved following diphenhydramine administration .", "tokens": ["The", "patient", "'s", "movements", "resolved", "following", "diphenhydramine", "administration", "."], "event_mentions": [{"id": "17420198_17_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 4, "end": 5}, "arguments": [{"entity_id": "17420198_17_Ent2", "role": "Treatment_Disorder", "text": "movements", "start": 3, "end": 4}, {"entity_id": "17420198_17_Ent0", "role": "Treatment", "text": "diphenhydramine", "start": 6, "end": 7}, {"entity_id": "17420198_17_Ent1", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17420198_17_Ent2", "text": "movements", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17420198_17_Ent0", "text": "diphenhydramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17420198_17_Ent1", "text": "diphenhydramine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17420198_2", "wnd_id": "17420198_2_1", "text": "A case of extrapyramidal symptoms ( EPS ) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented .", "tokens": ["A", "case", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "following", "administration", "of", "aripiprazole", "to", "a", "man", "with", "developmental", "disabilities", "who", "had", "never", "received", "antipsychotic", "medications", "and", "had", "no", "history", "of", "movement", "disorders", "is", "presented", "."], "event_mentions": [{"id": "17420198_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17420198_2_Ent3", "role": "Effect", "text": "extrapyramidal symptoms ( EPS )", "start": 3, "end": 8}, {"entity_id": "17420198_2_Ent4", "role": "Treatment", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent5", "role": "Treatment_Drug", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent0", "role": "Subject", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "start": 13, "end": 33}, {"entity_id": "17420198_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "17420198_2_Ent2", "role": "Subject_Disorder", "text": "developmental disabilities", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "17420198_2_Ent3", "text": "extrapyramidal symptoms ( EPS )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17420198_2_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent5", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent0", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "entity_type": "Entity", "start": 13, "end": 33}, {"id": "17420198_2_Ent1", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17420198_2_Ent2", "text": "developmental disabilities", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "17420198_8", "wnd_id": "17420198_8_1", "text": "Baclofen and oxazepam were prescribed secondary to right - sided hemiparesis contractures .", "tokens": ["Baclofen", "and", "oxazepam", "were", "prescribed", "secondary", "to", "right", "-", "sided", "hemiparesis", "contractures", "."], "event_mentions": [{"id": "17420198_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 4, "end": 5}, "arguments": [{"entity_id": "17420198_8_Ent1", "role": "Treatment", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent3", "role": "Treatment_Drug", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent6", "role": "Combination_Drug", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent0", "role": "Treatment", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent4", "role": "Treatment_Drug", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent5", "role": "Combination_Drug", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent2", "role": "Treatment_Disorder", "text": "right - sided hemiparesis contractures", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17420198_8_Ent1", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent3", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent6", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent0", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent4", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent5", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent2", "text": "right - sided hemiparesis contractures", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17426073_1", "wnd_id": "17426073_1_1", "text": "CONCLUSIONS : For all patients with vancomycin - induced neutropenia , possible cross - reactivity of teicoplanin should be monitored .", "tokens": ["CONCLUSIONS", ":", "For", "all", "patients", "with", "vancomycin", "-", "induced", "neutropenia", ",", "possible", "cross", "-", "reactivity", "of", "teicoplanin", "should", "be", "monitored", "."], "event_mentions": [{"id": "17426073_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17426073_1_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "17426073_1_Ent2", "role": "Treatment", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent6", "role": "Combination_Drug", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent1", "role": "Effect", "text": "neutropenia", "start": 9, "end": 10}, {"entity_id": "17426073_1_Ent4", "role": "Treatment_Drug", "text": "teicoplanin", "start": 16, "end": 17}, {"entity_id": "17426073_1_Ent5", "role": "Combination_Drug", "text": "teicoplanin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17426073_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17426073_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent6", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17426073_1_Ent4", "text": "teicoplanin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17426073_1_Ent5", "text": "teicoplanin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17438184_3", "wnd_id": "17438184_3_1", "text": "OBSERVATIONS : A 48 - year - old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and ribavirin for chronic hepatitis C infection .", "tokens": ["OBSERVATIONS", ":", "A", "48", "-", "year", "-", "old", "woman", "presented", "with", "disfiguring", "facial", "edema", "10", "weeks", "after", "she", "began", "antiviral", "therapy", "with", "peginterferon", "alfa", "-", "2a", "and", "ribavirin", "for", "chronic", "hepatitis", "C", "infection", "."], "event_mentions": [{"id": "17438184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "17438184_3_Ent0", "role": "Subject", "text": "A 48 - year - old woman", "start": 2, "end": 9}, {"entity_id": "17438184_3_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 3, "end": 8}, {"entity_id": "17438184_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "17438184_3_Ent3", "role": "Effect", "text": "disfiguring facial edema", "start": 11, "end": 14}, {"entity_id": "17438184_3_Ent4", "role": "Treatment", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent7", "role": "Treatment_Time_elapsed", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent5", "role": "Treatment", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "start": 19, "end": 28}, {"entity_id": "17438184_3_Ent8", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent10", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent9", "role": "Treatment_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent11", "role": "Combination_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent6", "role": "Treatment_Disorder", "text": "chronic hepatitis C infection", "start": 29, "end": 33}]}], "entity_mentions": [{"id": "17438184_3_Ent0", "text": "A 48 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "17438184_3_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17438184_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17438184_3_Ent3", "text": "disfiguring facial edema", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17438184_3_Ent4", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent7", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent5", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "17438184_3_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent10", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent9", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent11", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent6", "text": "chronic hepatitis C infection", "entity_type": "Entity", "start": 29, "end": 33}], "lang": "en"}
{"doc_id": "17444802_2", "wnd_id": "17444802_2_1", "text": "AIMS : The aim of this study was to report on the effectiveness and tumor side effects of topical interferon ( INF ) alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure .", "tokens": ["AIMS", ":", "The", "aim", "of", "this", "study", "was", "to", "report", "on", "the", "effectiveness", "and", "tumor", "side", "effects", "of", "topical", "interferon", "(", "INF", ")", "alpha", "2", "-", "beta", "in", "a", "case", "of", "conjunctiva", "-", "cornea", "intraepithelial", "neoplasia", "(", "CIN", ")", "of", "a", "patient", "that", "rejected", "any", "surgical", "procedure", "."], "event_mentions": [{"id": "17444802_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 15, "end": 17}, "arguments": [{"entity_id": "17444802_2_Ent1", "role": "Effect", "text": "tumor side effects", "start": 14, "end": 17}, {"entity_id": "17444802_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 18, "end": 19}, {"entity_id": "17444802_2_Ent2", "role": "Treatment", "text": "topical interferon ( INF ) alpha 2 - beta", "start": 18, "end": 27}, {"entity_id": "17444802_2_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 19, "end": 20}, {"entity_id": "17444802_2_Ent5", "role": "Treatment_Drug", "text": "alpha 2 - beta", "start": 23, "end": 27}, {"entity_id": "17444802_2_Ent6", "role": "Treatment_Disorder", "text": "conjunctiva - cornea intraepithelial neoplasia", "start": 31, "end": 36}, {"entity_id": "17444802_2_Ent0", "role": "Subject", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "start": 31, "end": 47}]}], "entity_mentions": [{"id": "17444802_2_Ent1", "text": "tumor side effects", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "17444802_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17444802_2_Ent2", "text": "topical interferon ( INF ) alpha 2 - beta", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "17444802_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17444802_2_Ent5", "text": "alpha 2 - beta", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "17444802_2_Ent6", "text": "conjunctiva - cornea intraepithelial neoplasia", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "17444802_2_Ent0", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "entity_type": "Entity", "start": 31, "end": 47}], "lang": "en"}
{"doc_id": "17458405_1", "wnd_id": "17458405_1_1", "text": "Ezetimibe - induced acute pancreatitis .", "tokens": ["Ezetimibe", "-", "induced", "acute", "pancreatitis", "."], "event_mentions": [{"id": "17458405_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17458405_1_Ent1", "role": "Treatment", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent2", "role": "Treatment_Drug", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17458405_1_Ent1", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent2", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17473920_1", "wnd_id": "17473920_1_1", "text": "Pharmacokinetics of methadone in human - immunodeficiency - virus - infected patients receiving nevirapine once daily .", "tokens": ["Pharmacokinetics", "of", "methadone", "in", "human", "-", "immunodeficiency", "-", "virus", "-", "infected", "patients", "receiving", "nevirapine", "once", "daily", "."], "event_mentions": [{"id": "17473920_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 12, "end": 13}, "arguments": [{"entity_id": "17473920_1_Ent1", "role": "Treatment", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent6", "role": "Treatment_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent8", "role": "Combination_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent3", "role": "Treatment_Disorder", "text": "human - immunodeficiency - virus", "start": 4, "end": 9}, {"entity_id": "17473920_1_Ent0", "role": "Subject", "text": "human - immunodeficiency - virus - infected patients", "start": 4, "end": 12}, {"entity_id": "17473920_1_Ent5", "role": "Treatment_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent7", "role": "Combination_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent2", "role": "Treatment", "text": "nevirapine once daily", "start": 13, "end": 16}, {"entity_id": "17473920_1_Ent4", "role": "Treatment_Freq", "text": "once daily", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "17473920_1_Ent1", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent6", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent8", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent3", "text": "human - immunodeficiency - virus", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17473920_1_Ent0", "text": "human - immunodeficiency - virus - infected patients", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "17473920_1_Ent5", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent7", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent2", "text": "nevirapine once daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17473920_1_Ent4", "text": "once daily", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1747495_1", "wnd_id": "1747495_1_1", "text": "Hepatic damage after danazol treatment .", "tokens": ["Hepatic", "damage", "after", "danazol", "treatment", "."], "event_mentions": [{"id": "1747495_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "1747495_1_Ent0", "role": "Effect", "text": "Hepatic damage", "start": 0, "end": 2}, {"entity_id": "1747495_1_Ent1", "role": "Treatment", "text": "danazol", "start": 3, "end": 4}, {"entity_id": "1747495_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "1747495_1_Ent0", "text": "Hepatic damage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1747495_1_Ent1", "text": "danazol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1747495_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17505739_1", "wnd_id": "17505739_1_1", "text": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient .", "tokens": ["Intravitreal", "triamcinolone", "may", "have", "had", "an", "influence", "on", "the", "exacerbation", "of", "retinochoroiditis", "in", "the", "posterior", "pole", "of", "the", "patient", "."], "event_mentions": [{"id": "17505739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "influence", "start": 6, "end": 7}, "arguments": [{"entity_id": "17505739_1_Ent4", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "17505739_1_Ent2", "role": "Treatment", "text": "Intravitreal triamcinolone", "start": 0, "end": 2}, {"entity_id": "17505739_1_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 1, "end": 2}, {"entity_id": "17505739_1_Ent1", "role": "Effect", "text": "exacerbation of retinochoroiditis in the posterior pole", "start": 9, "end": 16}, {"entity_id": "17505739_1_Ent0", "role": "Subject", "text": "the patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "17505739_1_Ent4", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17505739_1_Ent2", "text": "Intravitreal triamcinolone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17505739_1_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17505739_1_Ent1", "text": "exacerbation of retinochoroiditis in the posterior pole", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17505739_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "17509184_1", "wnd_id": "17509184_1_1", "text": "A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol , and symptoms fully resolved with cessation .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "advanced", "HIV", "infection", "and", "Mycobacterium", "avium", "complex", "infection", "experienced", "rapid", "cognitive", "decline", "after", "commencement", "of", "ethambutol", ",", "and", "symptoms", "fully", "resolved", "with", "cessation", "."], "event_mentions": [{"id": "17509184_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17509184_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "17509184_1_Ent0", "role": "Subject", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "start": 1, "end": 16}, {"entity_id": "17509184_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17509184_1_Ent8", "role": "Treatment_Disorder", "text": "HIV infection", "start": 9, "end": 11}, {"entity_id": "17509184_1_Ent7", "role": "Treatment_Disorder", "text": "Mycobacterium avium complex infection", "start": 12, "end": 16}, {"entity_id": "17509184_1_Ent3", "role": "Effect", "text": "rapid cognitive decline", "start": 17, "end": 20}, {"entity_id": "17509184_1_Ent4", "role": "Treatment", "text": "commencement of ethambutol", "start": 21, "end": 24}, {"entity_id": "17509184_1_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 23, "end": 24}, {"entity_id": "17509184_1_Ent6", "role": "Treatment_Disorder", "text": "ethambutol", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17509184_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17509184_1_Ent0", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "17509184_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17509184_1_Ent8", "text": "HIV infection", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17509184_1_Ent7", "text": "Mycobacterium avium complex infection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17509184_1_Ent3", "text": "rapid cognitive decline", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17509184_1_Ent4", "text": "commencement of ethambutol", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "17509184_1_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17509184_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "1751354_2", "wnd_id": "1751354_2_1", "text": "Recombinant human interferon - alpha has been used in the treatment of several cancers , but there have been several reports that it may exacerbate psoriasis or trigger off its onset .", "tokens": ["Recombinant", "human", "interferon", "-", "alpha", "has", "been", "used", "in", "the", "treatment", "of", "several", "cancers", ",", "but", "there", "have", "been", "several", "reports", "that", "it", "may", "exacerbate", "psoriasis", "or", "trigger", "off", "its", "onset", "."], "event_mentions": [{"id": "1751354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 27, "end": 28}, "arguments": [{"entity_id": "1751354_2_Ent1", "role": "Treatment", "text": "Recombinant human interferon - alpha", "start": 0, "end": 5}, {"entity_id": "1751354_2_Ent2", "role": "Treatment_Drug", "text": "Recombinant human interferon - alpha", "start": 0, "end": 5}, {"entity_id": "1751354_2_Ent3", "role": "Treatment_Disorder", "text": "cancers", "start": 13, "end": 14}, {"entity_id": "1751354_2_Ent0", "role": "Effect", "text": "exacerbate psoriasis", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "1751354_2_Ent1", "text": "Recombinant human interferon - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1751354_2_Ent2", "text": "Recombinant human interferon - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1751354_2_Ent3", "text": "cancers", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1751354_2_Ent0", "text": "exacerbate psoriasis", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "17522786_1", "wnd_id": "17522786_1_1", "text": "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( VPA ) intoxication .", "tokens": ["INTRODUCTION", ":", "We", "describe", "the", "neurointensive", "care", "(", "NIC", ")", "management", "of", "a", "patient", "with", "severe", "cerebral", "swelling", "and", "raised", "intracranial", "pressure", "(", "ICP", ")", "after", "severe", "sodium", "valproic", "acid", "(", "VPA", ")", "intoxication", "."], "event_mentions": [{"id": "17522786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "17522786_1_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "17522786_1_Ent1", "role": "Effect", "text": "severe cerebral swelling and raised intracranial pressure ( ICP )", "start": 15, "end": 25}, {"entity_id": "17522786_1_Ent4", "role": "Treatment_Drug", "text": "sodium valproic acid", "start": 27, "end": 30}, {"entity_id": "17522786_1_Ent3", "role": "Treatment", "text": "sodium valproic acid ( VPA )", "start": 27, "end": 33}, {"entity_id": "17522786_1_Ent2", "role": "Effect", "text": "intoxication", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "17522786_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17522786_1_Ent1", "text": "severe cerebral swelling and raised intracranial pressure ( ICP )", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "17522786_1_Ent4", "text": "sodium valproic acid", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "17522786_1_Ent3", "text": "sodium valproic acid ( VPA )", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "17522786_1_Ent2", "text": "intoxication", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "17526968_3", "wnd_id": "17526968_3_1", "text": "We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin .", "tokens": ["We", "report", "a", "child", "with", "yolk", "sac", "tumor", "who", "developed", "localized", "pigmentation", "after", "the", "first", "course", "of", "chemotherapy", "regimen", "that", "included", "cisplatin", ",", "etoposide", "and", "bleomycin", "."], "event_mentions": [{"id": "17526968_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17526968_3_Ent0", "role": "Subject", "text": "a child with yolk sac tumor", "start": 2, "end": 8}, {"entity_id": "17526968_3_Ent1", "role": "Subject_Age", "text": "child", "start": 3, "end": 4}, {"entity_id": "17526968_3_Ent8", "role": "Treatment_Disorder", "text": "yolk sac tumor", "start": 5, "end": 8}, {"entity_id": "17526968_3_Ent2", "role": "Effect", "text": "localized pigmentation", "start": 10, "end": 12}, {"entity_id": "17526968_3_Ent4", "role": "Treatment_Duration", "text": "the first course", "start": 13, "end": 16}, {"entity_id": "17526968_3_Ent3", "role": "Treatment", "text": "the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin", "start": 13, "end": 26}, {"entity_id": "17526968_3_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "17526968_3_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "17526968_3_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 23, "end": 24}, {"entity_id": "17526968_3_Ent10", "role": "Combination_Drug", "text": "etoposide", "start": 23, "end": 24}, {"entity_id": "17526968_3_Ent7", "role": "Treatment_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "17526968_3_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17526968_3_Ent0", "text": "a child with yolk sac tumor", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17526968_3_Ent1", "text": "child", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17526968_3_Ent8", "text": "yolk sac tumor", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17526968_3_Ent2", "text": "localized pigmentation", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17526968_3_Ent4", "text": "the first course", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17526968_3_Ent3", "text": "the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "17526968_3_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17526968_3_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17526968_3_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_3_Ent10", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_3_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17526968_3_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "17526968_4", "wnd_id": "17526968_4_1", "text": "The hyperpigmentation was diffuse scattered , flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin .", "tokens": ["The", "hyperpigmentation", "was", "diffuse", "scattered", ",", "flagellate", "like", "and", "linear", "streaking", "which", "was", "thought", "to", "be", "mainly", "related", "to", "the", "skin", "toxicity", "of", "bleomycin", "."], "event_mentions": [{"id": "17526968_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 21, "end": 22}, "arguments": [{"entity_id": "17526968_4_Ent0", "role": "Effect", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "start": 1, "end": 11}, {"entity_id": "17526968_4_Ent1", "role": "Treatment", "text": "bleomycin", "start": 23, "end": 24}, {"entity_id": "17526968_4_Ent2", "role": "Treatment_Drug", "text": "bleomycin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17526968_4_Ent0", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "17526968_4_Ent1", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_4_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17536204_4", "wnd_id": "17536204_4_1", "text": "CCBs should be considered in the treatment of 5 - FU or capecitabine - induced headaches .", "tokens": ["CCBs", "should", "be", "considered", "in", "the", "treatment", "of", "5", "-", "FU", "or", "capecitabine", "-", "induced", "headaches", "."], "event_mentions": [{"id": "17536204_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "17536204_4_Ent0", "role": "Treatment", "text": "CCBs", "start": 0, "end": 1}, {"entity_id": "17536204_4_Ent1", "role": "Treatment_Drug", "text": "CCBs", "start": 0, "end": 1}, {"entity_id": "17536204_4_Ent2", "role": "Treatment_Disorder", "text": "headaches", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17536204_4_Ent0", "text": "CCBs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_4_Ent1", "text": "CCBs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_4_Ent2", "text": "headaches", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "17547624_1", "wnd_id": "17547624_1_1", "text": "Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff - Parkinson - White syndrome .", "tokens": ["Brugada", "type", "electrocardiographic", "changes", "induced", "by", "concomitant", "use", "of", "lithium", "and", "propafenone", "in", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "."], "event_mentions": [{"id": "17547624_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17547624_1_Ent1", "role": "Effect", "text": "Brugada type electrocardiographic changes", "start": 0, "end": 4}, {"entity_id": "17547624_1_Ent2", "role": "Treatment", "text": "concomitant use of lithium and propafenone", "start": 6, "end": 12}, {"entity_id": "17547624_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent0", "role": "Subject", "text": "patient with Wolff - Parkinson - White syndrome", "start": 13, "end": 21}, {"entity_id": "17547624_1_Ent3", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "17547624_1_Ent1", "text": "Brugada type electrocardiographic changes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17547624_1_Ent2", "text": "concomitant use of lithium and propafenone", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "17547624_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent0", "text": "patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "17547624_1_Ent3", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "17556909_2", "wnd_id": "17556909_2_1", "text": "Paralytic ileus in patients undergoing bortezomib treatment has been reported , although a definite attribution to bortezomib administration has not been established .", "tokens": ["Paralytic", "ileus", "in", "patients", "undergoing", "bortezomib", "treatment", "has", "been", "reported", ",", "although", "a", "definite", "attribution", "to", "bortezomib", "administration", "has", "not", "been", "established", "."], "event_mentions": [{"id": "17556909_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "17556909_2_Ent1", "role": "Effect", "text": "Paralytic ileus", "start": 0, "end": 2}, {"entity_id": "17556909_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "17556909_2_Ent3", "role": "Treatment_Drug", "text": "bortezomib", "start": 5, "end": 6}, {"entity_id": "17556909_2_Ent2", "role": "Treatment", "text": "bortezomib treatment", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17556909_2_Ent1", "text": "Paralytic ileus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17556909_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_2_Ent3", "text": "bortezomib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17556909_2_Ent2", "text": "bortezomib treatment", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "1759924_2", "wnd_id": "1759924_2_1", "text": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous metoclopramide .", "tokens": ["We", "report", "a", "case", "of", "fulminant", "neuroleptic", "malignant", "syndrome", "in", "a", "man", "aged", "70", "developing", "within", "12", "hours", "of", "starting", "six", "-", "hourly", "intravenous", "metoclopramide", "."], "event_mentions": [{"id": "1759924_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 14, "end": 15}, "arguments": [{"entity_id": "1759924_2_Ent3", "role": "Effect", "text": "fulminant neuroleptic malignant syndrome", "start": 5, "end": 9}, {"entity_id": "1759924_2_Ent0", "role": "Subject", "text": "a man aged 70", "start": 10, "end": 14}, {"entity_id": "1759924_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "1759924_2_Ent2", "role": "Subject_Age", "text": "aged 70", "start": 12, "end": 14}, {"entity_id": "1759924_2_Ent5", "role": "Treatment_Time_elapsed", "text": "within 12 hours", "start": 15, "end": 18}, {"entity_id": "1759924_2_Ent8", "role": "Treatment_Freq", "text": "six - hourly", "start": 20, "end": 23}, {"entity_id": "1759924_2_Ent4", "role": "Treatment", "text": "six - hourly intravenous metoclopramide", "start": 20, "end": 25}, {"entity_id": "1759924_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 23, "end": 24}, {"entity_id": "1759924_2_Ent7", "role": "Treatment_Drug", "text": "metoclopramide", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1759924_2_Ent3", "text": "fulminant neuroleptic malignant syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "1759924_2_Ent0", "text": "a man aged 70", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "1759924_2_Ent1", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1759924_2_Ent2", "text": "aged 70", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1759924_2_Ent5", "text": "within 12 hours", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "1759924_2_Ent8", "text": "six - hourly", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "1759924_2_Ent4", "text": "six - hourly intravenous metoclopramide", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "1759924_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1759924_2_Ent7", "text": "metoclopramide", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17624096_1", "wnd_id": "17624096_1_1", "text": "5 - Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer -- case report .", "tokens": ["5", "-", "Fluorouracil", "cardiotoxicity", "complicating", "treatment", "of", "stage", "IIB", "cervical", "cancer", "--", "case", "report", "."], "event_mentions": [{"id": "17624096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "17624096_1_Ent1", "role": "Treatment", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent2", "role": "Treatment_Drug", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 3, "end": 4}, {"entity_id": "17624096_1_Ent3", "role": "Treatment_Disorder", "text": "cervical cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17624096_1_Ent1", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent2", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17624096_1_Ent3", "text": "cervical cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17627694_1", "wnd_id": "17627694_1_1", "text": "CONCLUSION : Acetic acid is corrosive and may cause vagina bleeding .", "tokens": ["CONCLUSION", ":", "Acetic", "acid", "is", "corrosive", "and", "may", "cause", "vagina", "bleeding", "."], "event_mentions": [{"id": "17627694_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "17627694_1_Ent1", "role": "Treatment", "text": "Acetic acid", "start": 2, "end": 4}, {"entity_id": "17627694_1_Ent2", "role": "Treatment_Drug", "text": "Acetic acid", "start": 2, "end": 4}, {"entity_id": "17627694_1_Ent0", "role": "Effect", "text": "vagina bleeding", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17627694_1_Ent1", "text": "Acetic acid", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17627694_1_Ent2", "text": "Acetic acid", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17627694_1_Ent0", "text": "vagina bleeding", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17655376_2", "wnd_id": "17655376_2_1", "text": "Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris ; however , the oral formulation is known to cause dose - dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen 's disease .", "tokens": ["Oral", "dapsone", "has", "been", "available", "for", "over", "60", "years", "and", "has", "been", "used", "to", "treat", "severe", "acne", "vulgaris", ";", "however", ",", "the", "oral", "formulation", "is", "known", "to", "cause", "dose", "-", "dependent", "haematological", "reactions", "and", "is", "currently", "indicated", "only", "for", "diseases", "such", "as", "dermatitis", "herpetiformis", "and", "Hansen", "'s", "disease", "."], "event_mentions": [{"id": "17655376_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 27, "end": 28}, "arguments": [{"entity_id": "17655376_2_Ent3", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "17655376_2_Ent1", "role": "Treatment", "text": "Oral dapsone", "start": 0, "end": 2}, {"entity_id": "17655376_2_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "17655376_2_Ent0", "role": "Effect", "text": "dose - dependent haematological reactions", "start": 28, "end": 33}, {"entity_id": "17655376_2_Ent4", "role": "Treatment_Disorder", "text": "dermatitis herpetiformis", "start": 42, "end": 44}, {"entity_id": "17655376_2_Ent5", "role": "Treatment_Disorder", "text": "Hansen 's disease", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "17655376_2_Ent3", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655376_2_Ent1", "text": "Oral dapsone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17655376_2_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17655376_2_Ent0", "text": "dose - dependent haematological reactions", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "17655376_2_Ent4", "text": "dermatitis herpetiformis", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "17655376_2_Ent5", "text": "Hansen 's disease", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "17655517_8", "wnd_id": "17655517_8_1", "text": "Linezolid should be discontinued immediately in patients experiencing these adverse effects .", "tokens": ["Linezolid", "should", "be", "discontinued", "immediately", "in", "patients", "experiencing", "these", "adverse", "effects", "."], "event_mentions": [{"id": "17655517_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 3, "end": 4}, "arguments": [{"entity_id": "17655517_8_Ent2", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent3", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "17655517_8_Ent1", "role": "Effect", "text": "adverse effects", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17655517_8_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent3", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17655517_8_Ent1", "text": "adverse effects", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17667887_8", "wnd_id": "17667887_8_1", "text": "In both cases , we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic .", "tokens": ["In", "both", "cases", ",", "we", "believe", "that", "serotonin", "syndrome", "was", "produced", "by", "a", "combination", "of", "an", "antidepressant", "and", "an", "atypical", "antipsychotic", "."], "event_mentions": [{"id": "17667887_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17667887_8_Ent0", "role": "Subject", "text": "In both cases", "start": 0, "end": 3}, {"entity_id": "17667887_8_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "17667887_8_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}, {"entity_id": "17667887_8_Ent3", "role": "Treatment", "text": "a combination of an antidepressant and an atypical antipsychotic", "start": 12, "end": 21}, {"entity_id": "17667887_8_Ent4", "role": "Treatment_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent6", "role": "Combination_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent5", "role": "Treatment_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}, {"entity_id": "17667887_8_Ent7", "role": "Combination_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "17667887_8_Ent0", "text": "In both cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17667887_8_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17667887_8_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17667887_8_Ent3", "text": "a combination of an antidepressant and an atypical antipsychotic", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "17667887_8_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent6", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent5", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "17667887_8_Ent7", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "17671884_7", "wnd_id": "17671884_7_1", "text": "One previous study of four transplant patients whose immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin noted anemia in 13 % of them .", "tokens": ["One", "previous", "study", "of", "four", "transplant", "patients", "whose", "immediate", "post", "-", "transplantation", "immunosuppression", "utilized", "corticosteroids", ",", "cyclosporine", ",", "MMF", ",", "and", "anti", "-", "T", "-", "lymphocyte", "globulin", "noted", "anemia", "in", "13", "%", "of", "them", "."], "event_mentions": [{"id": "17671884_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 27, "end": 28}, "arguments": [{"entity_id": "17671884_7_Ent1", "role": "Subject_Population", "text": "four", "start": 4, "end": 5}, {"entity_id": "17671884_7_Ent0", "role": "Subject", "text": "four transplant patients", "start": 4, "end": 7}, {"entity_id": "17671884_7_Ent2", "role": "Subject_Disorder", "text": "transplant", "start": 5, "end": 6}, {"entity_id": "17671884_7_Ent4", "role": "Treatment", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "start": 8, "end": 27}, {"entity_id": "17671884_7_Ent9", "role": "Treatment_Disorder", "text": "post - transplantation immunosuppression", "start": 9, "end": 13}, {"entity_id": "17671884_7_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent10", "role": "Combination_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent6", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent7", "role": "Treatment_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent12", "role": "Combination_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent8", "role": "Treatment_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent13", "role": "Combination_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent3", "role": "Effect", "text": "anemia", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17671884_7_Ent1", "text": "four", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17671884_7_Ent0", "text": "four transplant patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17671884_7_Ent2", "text": "transplant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17671884_7_Ent4", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 8, "end": 27}, {"id": "17671884_7_Ent9", "text": "post - transplantation immunosuppression", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "17671884_7_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent10", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent7", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent12", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent8", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent13", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent3", "text": "anemia", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17675030_3", "wnd_id": "17675030_3_1", "text": "Oxcarbazepine - associated angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both ) is a rare but potentially life - threatening reaction for which early recognition and management are vital .", "tokens": ["Oxcarbazepine", "-", "associated", "angioedema", "manifested", "by", "swelling", "of", "the", "face", ",", "eyes", ",", "lips", ",", "or", "tongue", "or", "difficulty", "swallowing", "or", "breathing", "(", "or", "both", ")", "is", "a", "rare", "but", "potentially", "life", "-", "threatening", "reaction", "for", "which", "early", "recognition", "and", "management", "are", "vital", "."], "event_mentions": [{"id": "17675030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17675030_3_Ent1", "role": "Treatment", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "17675030_3_Ent2", "role": "Treatment_Drug", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "17675030_3_Ent0", "role": "Effect", "text": "angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both )", "start": 3, "end": 26}]}], "entity_mentions": [{"id": "17675030_3_Ent1", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17675030_3_Ent2", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17675030_3_Ent0", "text": "angioedema manifested by swelling of the face , eyes , lips , or tongue or difficulty swallowing or breathing ( or both )", "entity_type": "Entity", "start": 3, "end": 26}], "lang": "en"}
{"doc_id": "17697264_1", "wnd_id": "17697264_1_1", "text": "Here we describe another case of VOD occurring after LT , but in which the causative role was played by azathioprine .", "tokens": ["Here", "we", "describe", "another", "case", "of", "VOD", "occurring", "after", "LT", ",", "but", "in", "which", "the", "causative", "role", "was", "played", "by", "azathioprine", "."], "event_mentions": [{"id": "17697264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "17697264_1_Ent0", "role": "Effect", "text": "VOD", "start": 6, "end": 7}, {"entity_id": "17697264_1_Ent1", "role": "Treatment", "text": "azathioprine", "start": 20, "end": 21}, {"entity_id": "17697264_1_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17697264_1_Ent0", "text": "VOD", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17697264_1_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17697264_1_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17725438_1", "wnd_id": "17725438_1_1", "text": "Here , we report a case of RFP - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Here", ",", "we", "report", "a", "case", "of", "RFP", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "17725438_1_Ent1", "role": "Treatment", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent2", "role": "Treatment_Drug", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "17725438_1_Ent1", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent2", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "1775411_2", "wnd_id": "1775411_2_1", "text": "Pulmonary fibrosis associated with nabumetone .", "tokens": ["Pulmonary", "fibrosis", "associated", "with", "nabumetone", "."], "event_mentions": [{"id": "1775411_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1775411_2_Ent0", "role": "Effect", "text": "Pulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "1775411_2_Ent1", "role": "Treatment", "text": "nabumetone", "start": 4, "end": 5}, {"entity_id": "1775411_2_Ent2", "role": "Treatment_Drug", "text": "nabumetone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1775411_2_Ent0", "text": "Pulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1775411_2_Ent1", "text": "nabumetone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1775411_2_Ent2", "text": "nabumetone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17763133_3", "wnd_id": "17763133_3_1", "text": "Simvastatin - induced rhabdomyolysis following cyclosporine treatment for uveitis .", "tokens": ["Simvastatin", "-", "induced", "rhabdomyolysis", "following", "cyclosporine", "treatment", "for", "uveitis", "."], "event_mentions": [{"id": "17763133_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17763133_3_Ent2", "role": "Treatment", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent7", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}, {"entity_id": "17763133_3_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "17763133_3_Ent6", "role": "Combination_Drug", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "17763133_3_Ent1", "role": "Treatment", "text": "cyclosporine treatment", "start": 5, "end": 7}, {"entity_id": "17763133_3_Ent5", "role": "Treatment_Disorder", "text": "uveitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17763133_3_Ent2", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent7", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17763133_3_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17763133_3_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17763133_3_Ent1", "text": "cyclosporine treatment", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17763133_3_Ent5", "text": "uveitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17852449_6", "wnd_id": "17852449_6_1", "text": "Review of all reported cases of the use of ATRA in pregnancy revealed no serious adverse outcomes or congenital anomalies although only very few cases had exposure in the first trimester .", "tokens": ["Review", "of", "all", "reported", "cases", "of", "the", "use", "of", "ATRA", "in", "pregnancy", "revealed", "no", "serious", "adverse", "outcomes", "or", "congenital", "anomalies", "although", "only", "very", "few", "cases", "had", "exposure", "in", "the", "first", "trimester", "."], "event_mentions": [{"id": "17852449_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revealed", "start": 12, "end": 13}, "arguments": [{"entity_id": "17852449_6_Ent3", "role": "Treatment", "text": "ATRA", "start": 9, "end": 10}, {"entity_id": "17852449_6_Ent4", "role": "Treatment_Drug", "text": "ATRA", "start": 9, "end": 10}, {"entity_id": "17852449_6_Ent0", "role": "Subject", "text": "in pregnancy", "start": 10, "end": 12}, {"entity_id": "17852449_6_Ent1", "role": "Subject_Disorder", "text": "pregnancy", "start": 11, "end": 12}, {"entity_id": "17852449_6_Ent2", "role": "Effect", "text": "adverse outcomes or congenital anomalies", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "17852449_6_Ent3", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17852449_6_Ent4", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17852449_6_Ent0", "text": "in pregnancy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17852449_6_Ent1", "text": "pregnancy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17852449_6_Ent2", "text": "adverse outcomes or congenital anomalies", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "17873198_1", "wnd_id": "17873198_1_1", "text": "Interstitial lung disease ( ILD ) related to therapy with the drug gefitinib has been well reported .", "tokens": ["Interstitial", "lung", "disease", "(", "ILD", ")", "related", "to", "therapy", "with", "the", "drug", "gefitinib", "has", "been", "well", "reported", "."], "event_mentions": [{"id": "17873198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "17873198_1_Ent0", "role": "Effect", "text": "Interstitial lung disease ( ILD )", "start": 0, "end": 6}, {"entity_id": "17873198_1_Ent1", "role": "Treatment", "text": "therapy with the drug gefitinib", "start": 8, "end": 13}, {"entity_id": "17873198_1_Ent2", "role": "Treatment_Drug", "text": "gefitinib", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17873198_1_Ent0", "text": "Interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17873198_1_Ent1", "text": "therapy with the drug gefitinib", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17873198_1_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17931455_1", "wnd_id": "17931455_1_1", "text": "CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy .", "tokens": ["CASE", "REPORT", ":", "A", "six", "-", "year", "-", "old", "boy", "with", "transfusion", "-", "dependent", "beta", "-", "thalassaemia", "developed", "a", "unilateral", "hearing", "loss", "shortly", "after", "commencing", "desferrioxamine", "therapy", "."], "event_mentions": [{"id": "17931455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "17931455_1_Ent0", "role": "Subject", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "start": 3, "end": 17}, {"entity_id": "17931455_1_Ent1", "role": "Subject_Age", "text": "six - year - old", "start": 4, "end": 9}, {"entity_id": "17931455_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 9, "end": 10}, {"entity_id": "17931455_1_Ent5", "role": "Treatment_Disorder", "text": "transfusion - dependent beta - thalassaemia", "start": 11, "end": 17}, {"entity_id": "17931455_1_Ent3", "role": "Effect", "text": "a unilateral hearing loss", "start": 18, "end": 22}, {"entity_id": "17931455_1_Ent6", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 22, "end": 24}, {"entity_id": "17931455_1_Ent4", "role": "Treatment", "text": "commencing desferrioxamine therapy", "start": 24, "end": 27}, {"entity_id": "17931455_1_Ent7", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17931455_1_Ent0", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 3, "end": 17}, {"id": "17931455_1_Ent1", "text": "six - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17931455_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17931455_1_Ent5", "text": "transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "17931455_1_Ent3", "text": "a unilateral hearing loss", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "17931455_1_Ent6", "text": "shortly after", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17931455_1_Ent4", "text": "commencing desferrioxamine therapy", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17931455_1_Ent7", "text": "desferrioxamine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "17952482_3", "wnd_id": "17952482_3_1", "text": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine .", "tokens": ["This", "case", "illustrates", "that", "the", "hemophagocytic", "syndrome", "associated", "with", "reactivation", "of", "EBV", "can", "occur", "as", "part", "of", "drug", "hypersensitivity", "reactions", "in", "RA", "patients", "taking", "sulfasalazine", "."], "event_mentions": [{"id": "17952482_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 13, "end": 14}, "arguments": [{"entity_id": "17952482_3_Ent0", "role": "Effect", "text": "the hemophagocytic syndrome associated with reactivation of EBV", "start": 4, "end": 12}, {"entity_id": "17952482_3_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 24, "end": 25}, {"entity_id": "17952482_3_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17952482_3_Ent0", "text": "the hemophagocytic syndrome associated with reactivation of EBV", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "17952482_3_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17952482_3_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17955169_2", "wnd_id": "17955169_2_1", "text": "Uncontrolled headache induced by oxcarbazepine .", "tokens": ["Uncontrolled", "headache", "induced", "by", "oxcarbazepine", "."], "event_mentions": [{"id": "17955169_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17955169_2_Ent0", "role": "Effect", "text": "Uncontrolled headache", "start": 0, "end": 2}, {"entity_id": "17955169_2_Ent1", "role": "Treatment", "text": "oxcarbazepine", "start": 4, "end": 5}, {"entity_id": "17955169_2_Ent2", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "17955169_2_Ent0", "text": "Uncontrolled headache", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17955169_2_Ent1", "text": "oxcarbazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17955169_2_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17959575_12", "wnd_id": "17959575_12_1", "text": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion .", "tokens": ["On", "March", "13", "the", "patient", "was", "again", "admitted", "for", "worsening", "CHF", "and", "was", "started", "on", "continuous", "dobutamine", "infusion", "."], "event_mentions": [{"id": "17959575_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "started on", "start": 13, "end": 15}, "arguments": [{"entity_id": "17959575_12_Ent0", "role": "Subject", "text": "the patient was again admitted for worsening CHF", "start": 3, "end": 11}, {"entity_id": "17959575_12_Ent4", "role": "Treatment_Freq", "text": "continuous", "start": 15, "end": 16}, {"entity_id": "17959575_12_Ent1", "role": "Treatment", "text": "continuous dobutamine infusion", "start": 15, "end": 18}, {"entity_id": "17959575_12_Ent2", "role": "Treatment_Drug", "text": "dobutamine", "start": 16, "end": 17}, {"entity_id": "17959575_12_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17959575_12_Ent0", "text": "the patient was again admitted for worsening CHF", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "17959575_12_Ent4", "text": "continuous", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17959575_12_Ent1", "text": "continuous dobutamine infusion", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17959575_12_Ent2", "text": "dobutamine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17959575_12_Ent3", "text": "infusion", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17965530_1", "wnd_id": "17965530_1_1", "text": "Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare .", "tokens": ["Reports", "of", "colonic", "perforation", "as", "a", "result", "of", "the", "administration", "of", "calcium", "polystyrene", "sulfonate", "and", "sorbitol", "are", "rare", "."], "event_mentions": [{"id": "17965530_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 6, "end": 7}, "arguments": [{"entity_id": "17965530_1_Ent0", "role": "Effect", "text": "colonic perforation", "start": 2, "end": 4}, {"entity_id": "17965530_1_Ent5", "role": "Treatment_Route", "text": "the administration", "start": 8, "end": 10}, {"entity_id": "17965530_1_Ent1", "role": "Treatment", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent3", "role": "Treatment_Drug", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent6", "role": "Combination_Drug", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent2", "role": "Treatment", "text": "sorbitol", "start": 15, "end": 16}, {"entity_id": "17965530_1_Ent4", "role": "Treatment_Drug", "text": "sorbitol", "start": 15, "end": 16}, {"entity_id": "17965530_1_Ent7", "role": "Combination_Drug", "text": "sorbitol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17965530_1_Ent0", "text": "colonic perforation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17965530_1_Ent5", "text": "the administration", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17965530_1_Ent1", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent3", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent6", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent2", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17965530_1_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17965530_1_Ent7", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18020545_2", "wnd_id": "18020545_2_1", "text": "Tardive oculogyric crisis during treatment with clozapine : report of three cases .", "tokens": ["Tardive", "oculogyric", "crisis", "during", "treatment", "with", "clozapine", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "18020545_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 5, "end": 6}, "arguments": [{"entity_id": "18020545_2_Ent2", "role": "Effect", "text": "Tardive oculogyric crisis", "start": 0, "end": 3}, {"entity_id": "18020545_2_Ent3", "role": "Treatment", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "18020545_2_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "18020545_2_Ent1", "role": "Subject_Population", "text": "three", "start": 10, "end": 11}, {"entity_id": "18020545_2_Ent0", "role": "Subject", "text": "three cases", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18020545_2_Ent2", "text": "Tardive oculogyric crisis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18020545_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18020545_2_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18020545_2_Ent1", "text": "three", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18020545_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18067642_1", "wnd_id": "18067642_1_1", "text": "Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case , it is reasonable to presume that this histopathology is associated with amiodarone - induced hypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder .", "tokens": ["Although", "it", "is", "difficult", "to", "be", "certain", "of", "the", "direct", "link", "of", "amiodarone", "on", "the", "basis", "of", "a", "single", "case", ",", "it", "is", "reasonable", "to", "presume", "that", "this", "histopathology", "is", "associated", "with", "amiodarone", "-", "induced", "hypothyroidism", "and", "that", "involution", "changes", "represent", "the", "hypofunctional", "status", "of", "this", "drug", "-", "induced", "disorder", "."], "event_mentions": [{"id": "18067642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 34, "end": 35}, "arguments": [{"entity_id": "18067642_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "18067642_1_Ent0", "role": "Subject", "text": "a single case", "start": 17, "end": 20}, {"entity_id": "18067642_1_Ent1", "role": "Subject_Population", "text": "single", "start": 18, "end": 19}, {"entity_id": "18067642_1_Ent3", "role": "Treatment", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "18067642_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18067642_1_Ent0", "text": "a single case", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18067642_1_Ent1", "text": "single", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18067642_1_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "18076602_1", "wnd_id": "18076602_1_1", "text": "Amphotericin B - induced cutaneous leucocytoclastic vasculitis : case report .", "tokens": ["Amphotericin", "B", "-", "induced", "cutaneous", "leucocytoclastic", "vasculitis", ":", "case", "report", "."], "event_mentions": [{"id": "18076602_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18076602_1_Ent1", "role": "Treatment", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "18076602_1_Ent2", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "18076602_1_Ent0", "role": "Effect", "text": "cutaneous leucocytoclastic vasculitis", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "18076602_1_Ent1", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18076602_1_Ent2", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18076602_1_Ent0", "text": "cutaneous leucocytoclastic vasculitis", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18094347_7", "wnd_id": "18094347_7_1", "text": "Pathogenesis of methotrexate - induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate - induced cutaneous vasculitis in collagen vascular disease .", "tokens": ["Pathogenesis", "of", "methotrexate", "-", "induced", "papular", "eruption", "in", "psoriasis", "may", "involve", "immune", "mechanisms", "other", "than", "those", "of", "methotrexate", "-", "induced", "cutaneous", "vasculitis", "in", "collagen", "vascular", "disease", "."], "event_mentions": [{"id": "18094347_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18094347_7_Ent2", "role": "Treatment", "text": "methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_7_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_7_Ent0", "role": "Effect", "text": "papular eruption in psoriasis", "start": 5, "end": 9}, {"entity_id": "18094347_7_Ent1", "role": "Effect", "text": "cutaneous vasculitis in collagen vascular disease", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18094347_7_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_7_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_7_Ent0", "text": "papular eruption in psoriasis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18094347_7_Ent1", "text": "cutaneous vasculitis in collagen vascular disease", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18166746_1", "wnd_id": "18166746_1_1", "text": "[ Serotonin syndrome following methylene blue infusion during parathyroidectomy : a case report and literature review ] .", "tokens": ["[", "Serotonin", "syndrome", "following", "methylene", "blue", "infusion", "during", "parathyroidectomy", ":", "a", "case", "report", "and", "literature", "review", "]", "."], "event_mentions": [{"id": "18166746_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "18166746_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "18166746_1_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 4, "end": 6}, {"entity_id": "18166746_1_Ent1", "role": "Treatment", "text": "methylene blue infusion during parathyroidectomy", "start": 4, "end": 9}, {"entity_id": "18166746_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18166746_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "18166746_1_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18166746_1_Ent1", "text": "methylene blue infusion during parathyroidectomy", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18166746_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18166746_7", "wnd_id": "18166746_7_1", "text": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome .", "tokens": ["An", "interaction", "between", "methylene", "blue", "and", "serotonergic", "agents", "may", "give", "rise", "to", "the", "serotonin", "syndrome", "."], "event_mentions": [{"id": "18166746_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "rise", "start": 10, "end": 11}, "arguments": [{"entity_id": "18166746_7_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 3, "end": 5}, {"entity_id": "18166746_7_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 3, "end": 5}, {"entity_id": "18166746_7_Ent1", "role": "Treatment", "text": "methylene blue and serotonergic agents", "start": 3, "end": 8}, {"entity_id": "18166746_7_Ent3", "role": "Treatment_Drug", "text": "serotonergic agents", "start": 6, "end": 8}, {"entity_id": "18166746_7_Ent4", "role": "Combination_Drug", "text": "serotonergic agents", "start": 6, "end": 8}, {"entity_id": "18166746_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "18166746_7_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18166746_7_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18166746_7_Ent1", "text": "methylene blue and serotonergic agents", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18166746_7_Ent3", "text": "serotonergic agents", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18166746_7_Ent4", "text": "serotonergic agents", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18166746_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "18171260_5", "wnd_id": "18171260_5_1", "text": "We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27 - year - old man with acute leukemia .", "tokens": ["We", "describe", "serotonin", "syndrome", "after", "concomitant", "use", "of", "linezolid", "and", "meperidine", "in", "a", "27", "-", "year", "-", "old", "man", "with", "acute", "leukemia", "."], "event_mentions": [{"id": "18171260_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18171260_5_Ent4", "role": "Effect", "text": "serotonin syndrome", "start": 2, "end": 4}, {"entity_id": "18171260_5_Ent5", "role": "Treatment", "text": "concomitant use of linezolid and meperidine", "start": 5, "end": 11}, {"entity_id": "18171260_5_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent8", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent7", "role": "Treatment_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent9", "role": "Combination_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent0", "role": "Subject", "text": "a 27 - year - old man with acute leukemia", "start": 12, "end": 22}, {"entity_id": "18171260_5_Ent2", "role": "Subject_Age", "text": "27 - year - old", "start": 13, "end": 18}, {"entity_id": "18171260_5_Ent3", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "18171260_5_Ent1", "role": "Subject_Disorder", "text": "acute leukemia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "18171260_5_Ent4", "text": "serotonin syndrome", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18171260_5_Ent5", "text": "concomitant use of linezolid and meperidine", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "18171260_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent8", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent7", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent9", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent0", "text": "a 27 - year - old man with acute leukemia", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18171260_5_Ent2", "text": "27 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "18171260_5_Ent3", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18171260_5_Ent1", "text": "acute leukemia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "18203308_2", "wnd_id": "18203308_2_1", "text": "New onset of Crohn 's disease during treatment of active ankylosing spondylitis with etanercept .", "tokens": ["New", "onset", "of", "Crohn", "'s", "disease", "during", "treatment", "of", "active", "ankylosing", "spondylitis", "with", "etanercept", "."], "event_mentions": [{"id": "18203308_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "18203308_2_Ent0", "role": "Effect", "text": "New onset of Crohn 's disease", "start": 0, "end": 6}, {"entity_id": "18203308_2_Ent3", "role": "Treatment_Disorder", "text": "active ankylosing spondylitis", "start": 9, "end": 12}, {"entity_id": "18203308_2_Ent1", "role": "Treatment", "text": "etanercept", "start": 13, "end": 14}, {"entity_id": "18203308_2_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18203308_2_Ent0", "text": "New onset of Crohn 's disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18203308_2_Ent3", "text": "active ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18203308_2_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18203308_2_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18262450_14", "wnd_id": "18262450_14_1", "text": "This study provides the first evidence that co - administration of prolonged - release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy .", "tokens": ["This", "study", "provides", "the", "first", "evidence", "that", "co", "-", "administration", "of", "prolonged", "-", "release", "oxycodone", "and", "existing", "gabapentin", "therapy", "has", "a", "clinically", "meaningful", "effect", "in", "painful", "diabetic", "neuropathy", "."], "event_mentions": [{"id": "18262450_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has", "start": 19, "end": 20}, "arguments": [{"entity_id": "18262450_14_Ent1", "role": "Treatment", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "start": 7, "end": 19}, {"entity_id": "18262450_14_Ent3", "role": "Treatment_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent5", "role": "Combination_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent0", "role": "Effect", "text": "clinically meaningful effect", "start": 21, "end": 24}, {"entity_id": "18262450_14_Ent2", "role": "Treatment_Disorder", "text": "painful diabetic neuropathy", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "18262450_14_Ent1", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "18262450_14_Ent3", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent0", "text": "clinically meaningful effect", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18262450_14_Ent2", "text": "painful diabetic neuropathy", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "18262450_7", "wnd_id": "18262450_7_1", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin , had oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks .", "tokens": ["Three", "hundred", "and", "thirty", "eight", "patients", "with", "moderate", "to", "severe", "painful", "diabetic", "neuropathy", "despite", "receiving", "their", "maximum", "tolerated", "dose", "of", "gabapentin", ",", "had", "oral", "prolonged", "-", "release", "oxycodone", "or", "placebo", "tablets", "added", "to", "their", "therapy", "for", "up", "to", "12", "weeks", "."], "event_mentions": [{"id": "18262450_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "18262450_7_Ent1", "role": "Subject_Population", "text": "Three hundred and thirty eight", "start": 0, "end": 5}, {"entity_id": "18262450_7_Ent0", "role": "Subject", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy", "start": 0, "end": 13}, {"entity_id": "18262450_7_Ent11", "role": "Treatment_Disorder", "text": "painful diabetic neuropathy", "start": 10, "end": 13}, {"entity_id": "18262450_7_Ent7", "role": "Treatment_Dosage", "text": "maximum tolerated dose", "start": 16, "end": 19}, {"entity_id": "18262450_7_Ent2", "role": "Treatment", "text": "gabapentin", "start": 20, "end": 21}, {"entity_id": "18262450_7_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 20, "end": 21}, {"entity_id": "18262450_7_Ent8", "role": "Treatment_Route", "text": "oral", "start": 23, "end": 24}, {"entity_id": "18262450_7_Ent3", "role": "Treatment", "text": "oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks", "start": 23, "end": 40}, {"entity_id": "18262450_7_Ent5", "role": "Treatment_Drug", "text": "prolonged - release oxycodone", "start": 24, "end": 28}, {"entity_id": "18262450_7_Ent6", "role": "Treatment_Drug", "text": "placebo", "start": 29, "end": 30}, {"entity_id": "18262450_7_Ent9", "role": "Treatment_Route", "text": "tablets", "start": 30, "end": 31}, {"entity_id": "18262450_7_Ent10", "role": "Treatment_Time_elapsed", "text": "for up to 12 weeks", "start": 35, "end": 40}]}], "entity_mentions": [{"id": "18262450_7_Ent1", "text": "Three hundred and thirty eight", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18262450_7_Ent0", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "18262450_7_Ent11", "text": "painful diabetic neuropathy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18262450_7_Ent7", "text": "maximum tolerated dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18262450_7_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18262450_7_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18262450_7_Ent8", "text": "oral", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18262450_7_Ent3", "text": "oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks", "entity_type": "Entity", "start": 23, "end": 40}, {"id": "18262450_7_Ent5", "text": "prolonged - release oxycodone", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "18262450_7_Ent6", "text": "placebo", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18262450_7_Ent9", "text": "tablets", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "18262450_7_Ent10", "text": "for up to 12 weeks", "entity_type": "Entity", "start": 35, "end": 40}], "lang": "en"}
{"doc_id": "18294121_1", "wnd_id": "18294121_1_1", "text": "According to the Naranjo adverse drug reaction probability scale , the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable ( score of 6 ) .", "tokens": ["According", "to", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "the", "likelihood", "that", "temozolomide", "was", "responsible", "for", "the", "adverse", "drug", "reaction", "of", "fever", "was", "probable", "(", "score", "of", "6", ")", "."], "event_mentions": [{"id": "18294121_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse drug reaction", "start": 18, "end": 21}, "arguments": [{"entity_id": "18294121_1_Ent1", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent0", "role": "Effect", "text": "fever", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18294121_1_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18294121_3", "wnd_id": "18294121_3_1", "text": "Due to the severity of the rash , temozolomide was permanently discontinued .", "tokens": ["Due", "to", "the", "severity", "of", "the", "rash", ",", "temozolomide", "was", "permanently", "discontinued", "."], "event_mentions": [{"id": "18294121_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Due", "start": 0, "end": 1}, "arguments": [{"entity_id": "18294121_3_Ent0", "role": "Effect", "text": "rash", "start": 6, "end": 7}, {"entity_id": "18294121_3_Ent1", "role": "Treatment", "text": "temozolomide", "start": 8, "end": 9}, {"entity_id": "18294121_3_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18294121_3_Ent0", "text": "rash", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18294121_3_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18294121_3_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1829999_1", "wnd_id": "1829999_1_1", "text": "Exfoliative dermatitis secondary to tobramycin sulfate .", "tokens": ["Exfoliative", "dermatitis", "secondary", "to", "tobramycin", "sulfate", "."], "event_mentions": [{"id": "1829999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "1829999_1_Ent0", "role": "Effect", "text": "Exfoliative dermatitis", "start": 0, "end": 2}, {"entity_id": "1829999_1_Ent2", "role": "Treatment_Drug", "text": "tobramycin sulfate", "start": 4, "end": 6}, {"entity_id": "1829999_1_Ent1", "role": "Treatment", "text": "tobramycin sulfate .", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "1829999_1_Ent0", "text": "Exfoliative dermatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1829999_1_Ent2", "text": "tobramycin sulfate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1829999_1_Ent1", "text": "tobramycin sulfate .", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18315788_1", "wnd_id": "18315788_1_1", "text": "Phenytoin toxicity : an easily missed cause of cerebellar syndrome .", "tokens": ["Phenytoin", "toxicity", ":", "an", "easily", "missed", "cause", "of", "cerebellar", "syndrome", "."], "event_mentions": [{"id": "18315788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "18315788_1_Ent1", "role": "Treatment", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent0", "role": "Effect", "text": "cerebellar syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "18315788_1_Ent1", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent0", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "18343993_3", "wnd_id": "18343993_3_1", "text": "Life - threatening interstitial lung disease associated with trastuzumab : case report .", "tokens": ["Life", "-", "threatening", "interstitial", "lung", "disease", "associated", "with", "trastuzumab", ":", "case", "report", "."], "event_mentions": [{"id": "18343993_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "18343993_3_Ent1", "role": "Effect", "text": "Life - threatening interstitial lung disease", "start": 0, "end": 6}, {"entity_id": "18343993_3_Ent2", "role": "Treatment", "text": "trastuzumab", "start": 8, "end": 9}, {"entity_id": "18343993_3_Ent3", "role": "Treatment_Drug", "text": "trastuzumab", "start": 8, "end": 9}, {"entity_id": "18343993_3_Ent0", "role": "Subject", "text": "case", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18343993_3_Ent1", "text": "Life - threatening interstitial lung disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18343993_3_Ent2", "text": "trastuzumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18343993_3_Ent3", "text": "trastuzumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18343993_3_Ent0", "text": "case", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "1834424_1", "wnd_id": "1834424_1_1", "text": "A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ) .", "tokens": ["A", "30", "-", "year", "-", "old", "pharmacist", "suffered", "from", "acute", "allergic", "contact", "dermatitis", "due", "to", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "(", "NBD", "-", "Cl", ")", "."], "event_mentions": [{"id": "1834424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 7, "end": 8}, "arguments": [{"entity_id": "1834424_1_Ent0", "role": "Subject", "text": "A 30 - year - old pharmacist", "start": 0, "end": 7}, {"entity_id": "1834424_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 1, "end": 6}, {"entity_id": "1834424_1_Ent2", "role": "Effect", "text": "acute allergic contact dermatitis", "start": 9, "end": 13}, {"entity_id": "1834424_1_Ent4", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 15, "end": 22}, {"entity_id": "1834424_1_Ent3", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "1834424_1_Ent0", "text": "A 30 - year - old pharmacist", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1834424_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1834424_1_Ent2", "text": "acute allergic contact dermatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1834424_1_Ent4", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1834424_1_Ent3", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "18344455_2", "wnd_id": "18344455_2_1", "text": "It is rare to develop simultaneous toxicities while on anticonvulsants .", "tokens": ["It", "is", "rare", "to", "develop", "simultaneous", "toxicities", "while", "on", "anticonvulsants", "."], "event_mentions": [{"id": "18344455_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 4, "end": 5}, "arguments": [{"entity_id": "18344455_2_Ent0", "role": "Effect", "text": "toxicities", "start": 6, "end": 7}, {"entity_id": "18344455_2_Ent1", "role": "Treatment", "text": "anticonvulsants", "start": 9, "end": 10}, {"entity_id": "18344455_2_Ent2", "role": "Treatment_Drug", "text": "anticonvulsants", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18344455_2_Ent0", "text": "toxicities", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18344455_2_Ent1", "text": "anticonvulsants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18344455_2_Ent2", "text": "anticonvulsants", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18344455_3", "wnd_id": "18344455_3_1", "text": "This article presents a 3(1/2) - year - old child on valproic acid , lamotrigine , and phenytoin who developed simultaneous hepatotoxicity and bone marrow toxicity during a parainfluenza virus type 3 infection .", "tokens": ["This", "article", "presents", "a", "3(1/2)", "-", "year", "-", "old", "child", "on", "valproic", "acid", ",", "lamotrigine", ",", "and", "phenytoin", "who", "developed", "simultaneous", "hepatotoxicity", "and", "bone", "marrow", "toxicity", "during", "a", "parainfluenza", "virus", "type", "3", "infection", "."], "event_mentions": [{"id": "18344455_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "18344455_3_Ent0", "role": "Subject", "text": "a 3(1/2) - year - old child", "start": 3, "end": 10}, {"entity_id": "18344455_3_Ent1", "role": "Subject_Age", "text": "3(1/2) - year - old", "start": 4, "end": 9}, {"entity_id": "18344455_3_Ent2", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "18344455_3_Ent5", "role": "Treatment_Drug", "text": "valproic acid", "start": 11, "end": 13}, {"entity_id": "18344455_3_Ent10", "role": "Combination_Drug", "text": "valproic acid", "start": 11, "end": 13}, {"entity_id": "18344455_3_Ent4", "role": "Treatment", "text": "valproic acid , lamotrigine , and phenytoin", "start": 11, "end": 18}, {"entity_id": "18344455_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "18344455_3_Ent9", "role": "Combination_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "18344455_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 17, "end": 18}, {"entity_id": "18344455_3_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 17, "end": 18}, {"entity_id": "18344455_3_Ent3", "role": "Effect", "text": "simultaneous hepatotoxicity and bone marrow toxicity", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18344455_3_Ent0", "text": "a 3(1/2) - year - old child", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18344455_3_Ent1", "text": "3(1/2) - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18344455_3_Ent2", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18344455_3_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18344455_3_Ent10", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18344455_3_Ent4", "text": "valproic acid , lamotrigine , and phenytoin", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "18344455_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18344455_3_Ent9", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18344455_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18344455_3_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18344455_3_Ent3", "text": "simultaneous hepatotoxicity and bone marrow toxicity", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18344455_5", "wnd_id": "18344455_5_1", "text": "This article discusses the possibility that simultaneous use of valproic acid , lamotrigine , and phenytoin could give this combination of toxicities and that concurrent viral infection may increase this risk .", "tokens": ["This", "article", "discusses", "the", "possibility", "that", "simultaneous", "use", "of", "valproic", "acid", ",", "lamotrigine", ",", "and", "phenytoin", "could", "give", "this", "combination", "of", "toxicities", "and", "that", "concurrent", "viral", "infection", "may", "increase", "this", "risk", "."], "event_mentions": [{"id": "18344455_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "give", "start": 17, "end": 18}, "arguments": [{"entity_id": "18344455_5_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 9, "end": 11}, {"entity_id": "18344455_5_Ent6", "role": "Combination_Drug", "text": "valproic acid", "start": 9, "end": 11}, {"entity_id": "18344455_5_Ent2", "role": "Treatment", "text": "valproic acid , lamotrigine , and phenytoin", "start": 9, "end": 16}, {"entity_id": "18344455_5_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 12, "end": 13}, {"entity_id": "18344455_5_Ent7", "role": "Combination_Drug", "text": "lamotrigine", "start": 12, "end": 13}, {"entity_id": "18344455_5_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 15, "end": 16}, {"entity_id": "18344455_5_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 15, "end": 16}, {"entity_id": "18344455_5_Ent0", "role": "Effect", "text": "toxicities", "start": 21, "end": 22}, {"entity_id": "18344455_5_Ent1", "role": "Effect", "text": "concurrent viral infection", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "18344455_5_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18344455_5_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18344455_5_Ent2", "text": "valproic acid , lamotrigine , and phenytoin", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "18344455_5_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18344455_5_Ent7", "text": "lamotrigine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18344455_5_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18344455_5_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18344455_5_Ent0", "text": "toxicities", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18344455_5_Ent1", "text": "concurrent viral infection", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "18344734_2", "wnd_id": "18344734_2_1", "text": "We report the case of a woman who developed photo - onycholysis on multiple nails after uptake of olanzapine .", "tokens": ["We", "report", "the", "case", "of", "a", "woman", "who", "developed", "photo", "-", "onycholysis", "on", "multiple", "nails", "after", "uptake", "of", "olanzapine", "."], "event_mentions": [{"id": "18344734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "18344734_2_Ent0", "role": "Subject", "text": "a woman", "start": 5, "end": 7}, {"entity_id": "18344734_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "18344734_2_Ent2", "role": "Effect", "text": "photo - onycholysis on multiple nails", "start": 9, "end": 15}, {"entity_id": "18344734_2_Ent5", "role": "Treatment_Time_elapsed", "text": "after uptake", "start": 15, "end": 17}, {"entity_id": "18344734_2_Ent3", "role": "Treatment", "text": "uptake of olanzapine", "start": 16, "end": 19}, {"entity_id": "18344734_2_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18344734_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18344734_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18344734_2_Ent2", "text": "photo - onycholysis on multiple nails", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "18344734_2_Ent5", "text": "after uptake", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18344734_2_Ent3", "text": "uptake of olanzapine", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18344734_2_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18362995_3", "wnd_id": "18362995_3_1", "text": "Up to four percent of patients treated with imatinib may develop hepatotoxicity , which usually resolves with discontinuation of the drug .", "tokens": ["Up", "to", "four", "percent", "of", "patients", "treated", "with", "imatinib", "may", "develop", "hepatotoxicity", ",", "which", "usually", "resolves", "with", "discontinuation", "of", "the", "drug", "."], "event_mentions": [{"id": "18362995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 10, "end": 11}, "arguments": [{"entity_id": "18362995_3_Ent1", "role": "Subject_Population", "text": "Up to four percent", "start": 0, "end": 4}, {"entity_id": "18362995_3_Ent0", "role": "Subject", "text": "Up to four percent of patients", "start": 0, "end": 6}, {"entity_id": "18362995_3_Ent3", "role": "Treatment", "text": "imatinib", "start": 8, "end": 9}, {"entity_id": "18362995_3_Ent4", "role": "Treatment_Drug", "text": "imatinib", "start": 8, "end": 9}, {"entity_id": "18362995_3_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18362995_3_Ent1", "text": "Up to four percent", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18362995_3_Ent0", "text": "Up to four percent of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18362995_3_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_3_Ent4", "text": "imatinib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_3_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18364401_1", "wnd_id": "18364401_1_1", "text": "CONCLUSIONS : Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "treating", "elderly", "patients", "with", "olanzapine", "should", "be", "aware", "of", "the", "potential", "for", "rapidly", "developing", "hyperglycemia", "and", "monitor", "such", "patients", "accordingly", "."], "event_mentions": [{"id": "18364401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "18364401_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 4, "end": 5}, {"entity_id": "18364401_1_Ent0", "role": "Subject", "text": "elderly patients", "start": 4, "end": 6}, {"entity_id": "18364401_1_Ent3", "role": "Treatment", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "18364401_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "18364401_1_Ent2", "role": "Effect", "text": "rapidly developing hyperglycemia", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "18364401_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18364401_1_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18364401_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18364401_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18364401_1_Ent2", "text": "rapidly developing hyperglycemia", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "18364401_4", "wnd_id": "18364401_4_1", "text": "Subsequently , he developed hyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2.5 mg twice daily .", "tokens": ["Subsequently", ",", "he", "developed", "hyperglycemia", "(", "fasting", "blood", "glucose", "138", "mg", "/", "dL", ")", "that", "resolved", "when", "olanzapine", "was", "stopped", "and", "recurred", "(", "fasting", "blood", "glucose", "150", "mg", "/", "dL", ")", "after", "2", "days", "of", "rechallenge", "with", "olanzapine", "2.5", "mg", "twice", "daily", "."], "event_mentions": [{"id": "18364401_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 15, "end": 16}, "arguments": [{"entity_id": "18364401_4_Ent1", "role": "Treatment_Disorder", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "start": 4, "end": 14}, {"entity_id": "18364401_4_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 17, "end": 18}, {"entity_id": "18364401_4_Ent0", "role": "Treatment", "text": "olanzapine was stopped", "start": 17, "end": 20}]}, {"id": "18364401_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 31, "end": 32}, "arguments": [{"entity_id": "18364401_4_Ent3", "role": "Effect", "text": "hyperglycemia", "start": 4, "end": 5}, {"entity_id": "18364401_4_Ent4", "role": "Effect", "text": "recurred ( fasting blood glucose 150 mg / dL )", "start": 21, "end": 31}, {"entity_id": "18364401_4_Ent6", "role": "Treatment_Time_elapsed", "text": "2 days", "start": 32, "end": 34}, {"entity_id": "18364401_4_Ent5", "role": "Treatment", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "start": 32, "end": 42}, {"entity_id": "18364401_4_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 37, "end": 38}, {"entity_id": "18364401_4_Ent8", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 38, "end": 40}, {"entity_id": "18364401_4_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 40, "end": 42}]}], "entity_mentions": [{"id": "18364401_4_Ent3", "text": "hyperglycemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18364401_4_Ent1", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "18364401_4_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18364401_4_Ent0", "text": "olanzapine was stopped", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18364401_4_Ent4", "text": "recurred ( fasting blood glucose 150 mg / dL )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "18364401_4_Ent6", "text": "2 days", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18364401_4_Ent5", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "entity_type": "Entity", "start": 32, "end": 42}, {"id": "18364401_4_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18364401_4_Ent8", "text": "2.5 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18364401_4_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 40, "end": 42}], "lang": "en"}
{"doc_id": "18379937_1", "wnd_id": "18379937_1_1", "text": "Bilateral anterior uveitis associated with clomiphene citrate .", "tokens": ["Bilateral", "anterior", "uveitis", "associated", "with", "clomiphene", "citrate", "."], "event_mentions": [{"id": "18379937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "18379937_1_Ent0", "role": "Effect", "text": "Bilateral anterior uveitis", "start": 0, "end": 3}, {"entity_id": "18379937_1_Ent1", "role": "Treatment", "text": "clomiphene citrate", "start": 5, "end": 7}, {"entity_id": "18379937_1_Ent2", "role": "Treatment_Drug", "text": "clomiphene citrate", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18379937_1_Ent0", "text": "Bilateral anterior uveitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18379937_1_Ent1", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18379937_1_Ent2", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18421192_2", "wnd_id": "18421192_2_1", "text": "The clinical course suggested that recombinant alpha - 2b peginterferon plus ribavirin provoked type 1 diabetes mellitus , therefore , in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment .", "tokens": ["The", "clinical", "course", "suggested", "that", "recombinant", "alpha", "-", "2b", "peginterferon", "plus", "ribavirin", "provoked", "type", "1", "diabetes", "mellitus", ",", "therefore", ",", "in", "patients", "who", "are", "candidates", "for", "interferon", "therapy", "the", "presence", "of", "pancreatic", "autoantibodies", "and", "the", "fasting", "plasma", "glucose", "level", "should", "be", "investigated", "before", "and", "during", "treatment", "."], "event_mentions": [{"id": "18421192_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 12, "end": 13}, "arguments": [{"entity_id": "18421192_2_Ent2", "role": "Treatment_Drug", "text": "recombinant alpha - 2b peginterferon", "start": 5, "end": 10}, {"entity_id": "18421192_2_Ent5", "role": "Combination_Drug", "text": "recombinant alpha - 2b peginterferon", "start": 5, "end": 10}, {"entity_id": "18421192_2_Ent1", "role": "Treatment", "text": "recombinant alpha - 2b peginterferon plus ribavirin", "start": 5, "end": 12}, {"entity_id": "18421192_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_2_Ent4", "role": "Combination_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_2_Ent0", "role": "Effect", "text": "type 1 diabetes mellitus", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "18421192_2_Ent2", "text": "recombinant alpha - 2b peginterferon", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18421192_2_Ent5", "text": "recombinant alpha - 2b peginterferon", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18421192_2_Ent1", "text": "recombinant alpha - 2b peginterferon plus ribavirin", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "18421192_2_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_2_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_2_Ent0", "text": "type 1 diabetes mellitus", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "18425523_4", "wnd_id": "18425523_4_1", "text": "Persisent ocular hypertension following intravitreal ranibizumab .", "tokens": ["Persisent", "ocular", "hypertension", "following", "intravitreal", "ranibizumab", "."], "event_mentions": [{"id": "18425523_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "18425523_4_Ent0", "role": "Effect", "text": "Persisent ocular hypertension", "start": 0, "end": 3}, {"entity_id": "18425523_4_Ent1", "role": "Treatment", "text": "intravitreal ranibizumab", "start": 4, "end": 6}, {"entity_id": "18425523_4_Ent2", "role": "Treatment_Drug", "text": "ranibizumab", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "18425523_4_Ent0", "text": "Persisent ocular hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18425523_4_Ent1", "text": "intravitreal ranibizumab", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18425523_4_Ent2", "text": "ranibizumab", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "18446030_2", "wnd_id": "18446030_2_1", "text": "We report a 45 - year - old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab .", "tokens": ["We", "report", "a", "45", "-", "year", "-", "old", "psoriasis", "patient", "who", "developed", "eruptive", "mollusca", "contagiosa", "during", "an", "antipsoriatic", "treatment", "with", "efalizumab", "."], "event_mentions": [{"id": "18446030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "18446030_2_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 3, "end": 8}, {"entity_id": "18446030_2_Ent0", "role": "Subject", "text": "45 - year - old psoriasis patient", "start": 3, "end": 10}, {"entity_id": "18446030_2_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 8, "end": 9}, {"entity_id": "18446030_2_Ent2", "role": "Effect", "text": "eruptive mollusca contagiosa", "start": 12, "end": 15}, {"entity_id": "18446030_2_Ent3", "role": "Treatment", "text": "antipsoriatic treatment with efalizumab", "start": 17, "end": 21}, {"entity_id": "18446030_2_Ent5", "role": "Treatment_Drug", "text": "efalizumab", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18446030_2_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18446030_2_Ent0", "text": "45 - year - old psoriasis patient", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18446030_2_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18446030_2_Ent2", "text": "eruptive mollusca contagiosa", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18446030_2_Ent3", "text": "antipsoriatic treatment with efalizumab", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18446030_2_Ent5", "text": "efalizumab", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18487000_1", "wnd_id": "18487000_1_1", "text": "Severe symptomatic hyponatremia during sibutramine therapy : a case report .", "tokens": ["Severe", "symptomatic", "hyponatremia", "during", "sibutramine", "therapy", ":", "a", "case", "report", "."], "event_mentions": [{"id": "18487000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "18487000_1_Ent0", "role": "Effect", "text": "Severe symptomatic hyponatremia", "start": 0, "end": 3}, {"entity_id": "18487000_1_Ent1", "role": "Treatment", "text": "sibutramine", "start": 4, "end": 5}, {"entity_id": "18487000_1_Ent2", "role": "Treatment_Drug", "text": "sibutramine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18487000_1_Ent0", "text": "Severe symptomatic hyponatremia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18487000_1_Ent1", "text": "sibutramine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18487000_1_Ent2", "text": "sibutramine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18492617_2", "wnd_id": "18492617_2_1", "text": "Pregabalin - induced cortical negative myoclonus in a patient with neuropathic pain .", "tokens": ["Pregabalin", "-", "induced", "cortical", "negative", "myoclonus", "in", "a", "patient", "with", "neuropathic", "pain", "."], "event_mentions": [{"id": "18492617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18492617_2_Ent2", "role": "Treatment", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "18492617_2_Ent4", "role": "Treatment_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "18492617_2_Ent1", "role": "Effect", "text": "cortical negative myoclonus", "start": 3, "end": 6}, {"entity_id": "18492617_2_Ent0", "role": "Subject", "text": "a patient with neuropathic pain", "start": 7, "end": 12}, {"entity_id": "18492617_2_Ent3", "role": "Treatment_Disorder", "text": "neuropathic pain", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18492617_2_Ent2", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18492617_2_Ent4", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18492617_2_Ent1", "text": "cortical negative myoclonus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18492617_2_Ent0", "text": "a patient with neuropathic pain", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18492617_2_Ent3", "text": "neuropathic pain", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "1849334_2", "wnd_id": "1849334_2_1", "text": "We report on 7 patients ( 2 women , 5 men ) with chronic renal failure , who developed under a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day ) fatal neuromyeloencephalopathy .", "tokens": ["We", "report", "on", "7", "patients", "(", "2", "women", ",", "5", "men", ")", "with", "chronic", "renal", "failure", ",", "who", "developed", "under", "a", "high", "dosage", "of", "the", "new", "diuretic", "muzolimine", "(", "range", "240", "to", "1440", "mg", "per", "day", ")", "fatal", "neuromyeloencephalopathy", "."], "event_mentions": [{"id": "1849334_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "1849334_2_Ent2", "role": "Subject_Population", "text": "7", "start": 3, "end": 4}, {"entity_id": "1849334_2_Ent0", "role": "Subject", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "start": 3, "end": 16}, {"entity_id": "1849334_2_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 13, "end": 16}, {"entity_id": "1849334_2_Ent4", "role": "Treatment", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "start": 20, "end": 37}, {"entity_id": "1849334_2_Ent5", "role": "Treatment_Drug", "text": "diuretic muzolimine", "start": 26, "end": 28}, {"entity_id": "1849334_2_Ent7", "role": "Treatment_Dosage", "text": "range 240 to 1440 mg", "start": 29, "end": 34}, {"entity_id": "1849334_2_Ent6", "role": "Treatment_Freq", "text": "per day", "start": 34, "end": 36}, {"entity_id": "1849334_2_Ent3", "role": "Effect", "text": "fatal neuromyeloencephalopathy", "start": 37, "end": 39}]}], "entity_mentions": [{"id": "1849334_2_Ent2", "text": "7", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1849334_2_Ent0", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "1849334_2_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "1849334_2_Ent4", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "entity_type": "Entity", "start": 20, "end": 37}, {"id": "1849334_2_Ent5", "text": "diuretic muzolimine", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1849334_2_Ent7", "text": "range 240 to 1440 mg", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "1849334_2_Ent6", "text": "per day", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "1849334_2_Ent3", "text": "fatal neuromyeloencephalopathy", "entity_type": "Entity", "start": 37, "end": 39}], "lang": "en"}
{"doc_id": "18505911_13", "wnd_id": "18505911_13_1", "text": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance .", "tokens": ["This", "case", "report", "and", "several", "others", "point", "toward", "azathioprine", "as", "a", "clinically", "significant", "inducer", "of", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducer", "start": 13, "end": 14}, "arguments": [{"entity_id": "18505911_13_Ent1", "role": "Treatment", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent3", "role": "Treatment_Drug", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 15, "end": 16}, {"entity_id": "18505911_13_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18505911_13_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18505911_13_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18505911_2", "wnd_id": "18505911_2_1", "text": "To describe a case of azathioprine - induced warfarin resistance , present a literature review on warfarin - azathioprine interactions , and provide recommendations on appropriate management of this clinically significant interaction .", "tokens": ["To", "describe", "a", "case", "of", "azathioprine", "-", "induced", "warfarin", "resistance", ",", "present", "a", "literature", "review", "on", "warfarin", "-", "azathioprine", "interactions", ",", "and", "provide", "recommendations", "on", "appropriate", "management", "of", "this", "clinically", "significant", "interaction", "."], "event_mentions": [{"id": "18505911_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "18505911_2_Ent1", "role": "Treatment", "text": "azathioprine", "start": 5, "end": 6}, {"entity_id": "18505911_2_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 5, "end": 6}, {"entity_id": "18505911_2_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "18505911_2_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18505911_2_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18505911_2_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "18515982_1", "wnd_id": "18515982_1_1", "text": "Anastrozole - associated sclerosing glomerulonephritis in a patient with breast cancer .", "tokens": ["Anastrozole", "-", "associated", "sclerosing", "glomerulonephritis", "in", "a", "patient", "with", "breast", "cancer", "."], "event_mentions": [{"id": "18515982_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "18515982_1_Ent2", "role": "Treatment", "text": "Anastrozole", "start": 0, "end": 1}, {"entity_id": "18515982_1_Ent3", "role": "Treatment_Drug", "text": "Anastrozole", "start": 0, "end": 1}, {"entity_id": "18515982_1_Ent1", "role": "Effect", "text": "sclerosing glomerulonephritis", "start": 3, "end": 5}, {"entity_id": "18515982_1_Ent0", "role": "Subject", "text": "a patient with breast cancer .", "start": 6, "end": 12}, {"entity_id": "18515982_1_Ent4", "role": "Treatment_Disorder", "text": "breast cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "18515982_1_Ent2", "text": "Anastrozole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18515982_1_Ent3", "text": "Anastrozole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18515982_1_Ent1", "text": "sclerosing glomerulonephritis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18515982_1_Ent0", "text": "a patient with breast cancer .", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18515982_1_Ent4", "text": "breast cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "18515982_2", "wnd_id": "18515982_2_1", "text": "CONCLUSIONS : Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis .", "tokens": ["CONCLUSIONS", ":", "Anastrozole", "may", "be", "the", "causative", "factor", "in", "patients", "with", "sclerosing", "glomerulonephritis", "."], "event_mentions": [{"id": "18515982_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causative", "start": 6, "end": 7}, "arguments": [{"entity_id": "18515982_2_Ent2", "role": "Treatment", "text": "Anastrozole", "start": 2, "end": 3}, {"entity_id": "18515982_2_Ent3", "role": "Treatment_Drug", "text": "Anastrozole", "start": 2, "end": 3}, {"entity_id": "18515982_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "18515982_2_Ent1", "role": "Effect", "text": "sclerosing glomerulonephritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18515982_2_Ent2", "text": "Anastrozole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18515982_2_Ent3", "text": "Anastrozole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18515982_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18515982_2_Ent1", "text": "sclerosing glomerulonephritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18523232_1", "wnd_id": "18523232_1_1", "text": "CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk ) for onychomycosis .", "tokens": ["CASE", "SUMMARY", ":", "A", "61", "-", "year", "-", "old", "woman", "with", "no", "apparent", "risk", "factors", "for", "liver", "injury", "developed", "acute", "hepatitis", "one", "week", "after", "the", "final", "dose", "of", "a", "long", "-", "term", "course", "of", "pulse", "itraconazole", "therapy", "(", "200", "mg", "orally", "twice", "daily", ",", "1", "wk", "on", ",", "3", "wk", "off", ",", "for", "24", "wk", ")", "for", "onychomycosis", "."], "event_mentions": [{"id": "18523232_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "18523232_1_Ent0", "role": "Subject", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "start": 3, "end": 18}, {"entity_id": "18523232_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "18523232_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "18523232_1_Ent3", "role": "Effect", "text": "acute hepatitis", "start": 19, "end": 21}, {"entity_id": "18523232_1_Ent4", "role": "Treatment", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "start": 29, "end": 56}, {"entity_id": "18523232_1_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 35, "end": 36}, {"entity_id": "18523232_1_Ent7", "role": "Treatment_Dosage", "text": "200 mg", "start": 38, "end": 40}, {"entity_id": "18523232_1_Ent8", "role": "Treatment_Route", "text": "orally", "start": 40, "end": 41}, {"entity_id": "18523232_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 41, "end": 43}, {"entity_id": "18523232_1_Ent5", "role": "Treatment_Disorder", "text": "onychomycosis", "start": 57, "end": 58}]}], "entity_mentions": [{"id": "18523232_1_Ent0", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "18523232_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18523232_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18523232_1_Ent3", "text": "acute hepatitis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "18523232_1_Ent4", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "entity_type": "Entity", "start": 29, "end": 56}, {"id": "18523232_1_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18523232_1_Ent7", "text": "200 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18523232_1_Ent8", "text": "orally", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "18523232_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 41, "end": 43}, {"id": "18523232_1_Ent5", "text": "onychomycosis", "entity_type": "Entity", "start": 57, "end": 58}], "lang": "en"}
{"doc_id": "18556970_1", "wnd_id": "18556970_1_1", "text": "Anaphylactic reaction to recombinant insulin - like growth factor - I.", "tokens": ["Anaphylactic", "reaction", "to", "recombinant", "insulin", "-", "like", "growth", "factor", "-", "I."], "event_mentions": [{"id": "18556970_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "18556970_1_Ent0", "role": "Effect", "text": "Anaphylactic reaction", "start": 0, "end": 2}, {"entity_id": "18556970_1_Ent1", "role": "Treatment", "text": "recombinant insulin - like growth factor - I.", "start": 3, "end": 11}, {"entity_id": "18556970_1_Ent2", "role": "Treatment_Drug", "text": "recombinant insulin - like growth factor - I.", "start": 3, "end": 11}]}], "entity_mentions": [{"id": "18556970_1_Ent0", "text": "Anaphylactic reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18556970_1_Ent1", "text": "recombinant insulin - like growth factor - I.", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18556970_1_Ent2", "text": "recombinant insulin - like growth factor - I.", "entity_type": "Entity", "start": 3, "end": 11}], "lang": "en"}
{"doc_id": "18562412_1", "wnd_id": "18562412_1_1", "text": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS .", "tokens": ["Increasing", "the", "olanzapine", "dosage", "severely", "aggravated", "the", "symptoms", "of", "RLS", "."], "event_mentions": [{"id": "18562412_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravated", "start": 5, "end": 6}, "arguments": [{"entity_id": "18562412_1_Ent1", "role": "Treatment", "text": "Increasing the olanzapine dosage", "start": 0, "end": 4}, {"entity_id": "18562412_1_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 2, "end": 3}, {"entity_id": "18562412_1_Ent0", "role": "Effect", "text": "symptoms of RLS", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "18562412_1_Ent1", "text": "Increasing the olanzapine dosage", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18562412_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18562412_1_Ent0", "text": "symptoms of RLS", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "18562412_5", "wnd_id": "18562412_5_1", "text": "The second patient exhibited sudden PLMS following olanzapine injection .", "tokens": ["The", "second", "patient", "exhibited", "sudden", "PLMS", "following", "olanzapine", "injection", "."], "event_mentions": [{"id": "18562412_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "18562412_5_Ent0", "role": "Subject", "text": "The second patient", "start": 0, "end": 3}, {"entity_id": "18562412_5_Ent1", "role": "Effect", "text": "sudden PLMS", "start": 4, "end": 6}, {"entity_id": "18562412_5_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "18562412_5_Ent2", "role": "Treatment", "text": "olanzapine injection", "start": 7, "end": 9}, {"entity_id": "18562412_5_Ent4", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18562412_5_Ent0", "text": "The second patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_5_Ent1", "text": "sudden PLMS", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18562412_5_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18562412_5_Ent2", "text": "olanzapine injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18562412_5_Ent4", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18569796_1", "wnd_id": "18569796_1_1", "text": "CONCLUSION : Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis .", "tokens": ["CONCLUSION", ":", "Alendronate", "led", "to", "nodular", "scleritis", "and", "rechallenge", "caused", "recurrence", "of", "scleritis", "."], "event_mentions": [{"id": "18569796_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led to", "start": 3, "end": 5}, "arguments": [{"entity_id": "18569796_1_Ent1", "role": "Treatment", "text": "Alendronate", "start": 2, "end": 3}, {"entity_id": "18569796_1_Ent2", "role": "Treatment_Drug", "text": "Alendronate", "start": 2, "end": 3}, {"entity_id": "18569796_1_Ent0", "role": "Effect", "text": "nodular scleritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18569796_1_Ent1", "text": "Alendronate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18569796_1_Ent2", "text": "Alendronate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18569796_1_Ent0", "text": "nodular scleritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18580694_1", "wnd_id": "18580694_1_1", "text": "In addition , there is a report on prolonged ECT seizure related to ciprofloxacin , which has an epileptogenic property with a similar action to beta - lactam antibiotics .", "tokens": ["In", "addition", ",", "there", "is", "a", "report", "on", "prolonged", "ECT", "seizure", "related", "to", "ciprofloxacin", ",", "which", "has", "an", "epileptogenic", "property", "with", "a", "similar", "action", "to", "beta", "-", "lactam", "antibiotics", "."], "event_mentions": [{"id": "18580694_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "18580694_1_Ent0", "role": "Effect", "text": "prolonged ECT seizure", "start": 8, "end": 11}, {"entity_id": "18580694_1_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "18580694_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18580694_1_Ent0", "text": "prolonged ECT seizure", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18580694_1_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18580694_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18585545_3", "wnd_id": "18585545_3_1", "text": "Here , we describe levofloxacin - induced delirium with psychotic features in a relatively young , otherwise healthy female .", "tokens": ["Here", ",", "we", "describe", "levofloxacin", "-", "induced", "delirium", "with", "psychotic", "features", "in", "a", "relatively", "young", ",", "otherwise", "healthy", "female", "."], "event_mentions": [{"id": "18585545_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "18585545_3_Ent2", "role": "Treatment", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent3", "role": "Treatment_Drug", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent1", "role": "Effect", "text": "delirium with psychotic features", "start": 7, "end": 11}, {"entity_id": "18585545_3_Ent0", "role": "Subject", "text": "relatively young , otherwise healthy female", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "18585545_3_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent1", "text": "delirium with psychotic features", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "18585545_3_Ent0", "text": "relatively young , otherwise healthy female", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "18609153_1", "wnd_id": "18609153_1_1", "text": "Terlipressin - induced ventricular arrhythmia .", "tokens": ["Terlipressin", "-", "induced", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "18609153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18609153_1_Ent1", "role": "Treatment", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent2", "role": "Treatment_Drug", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent0", "role": "Effect", "text": "ventricular arrhythmia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18609153_1_Ent1", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent2", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent0", "text": "ventricular arrhythmia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18609153_2", "wnd_id": "18609153_2_1", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding , a 50 - year - old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes .", "tokens": ["During", "intravenous", "treatment", "with", "terlipressin", "for", "recurrent", "gastrointestinal", "(", "GI", ")", "bleeding", ",", "a", "50", "-", "year", "-", "old", "male", "with", "no", "history", "of", "heart", "disease", "developed", "a", "newly", "prolonged", "QT", "interval", "and", "torsade", "de", "pointes", "."], "event_mentions": [{"id": "18609153_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 26, "end": 27}, "arguments": [{"entity_id": "18609153_2_Ent4", "role": "Treatment", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding", "start": 0, "end": 12}, {"entity_id": "18609153_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 1, "end": 2}, {"entity_id": "18609153_2_Ent6", "role": "Treatment_Drug", "text": "terlipressin", "start": 4, "end": 5}, {"entity_id": "18609153_2_Ent7", "role": "Treatment_Disorder", "text": "recurrent gastrointestinal", "start": 6, "end": 8}, {"entity_id": "18609153_2_Ent0", "role": "Subject", "text": "a 50 - year - old male with no history of heart disease", "start": 13, "end": 26}, {"entity_id": "18609153_2_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 14, "end": 19}, {"entity_id": "18609153_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 19, "end": 20}, {"entity_id": "18609153_2_Ent3", "role": "Effect", "text": "a newly prolonged QT interval and torsade de pointes", "start": 27, "end": 36}]}], "entity_mentions": [{"id": "18609153_2_Ent4", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "18609153_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18609153_2_Ent6", "text": "terlipressin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18609153_2_Ent7", "text": "recurrent gastrointestinal", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18609153_2_Ent0", "text": "a 50 - year - old male with no history of heart disease", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "18609153_2_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "18609153_2_Ent2", "text": "male", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18609153_2_Ent3", "text": "a newly prolonged QT interval and torsade de pointes", "entity_type": "Entity", "start": 27, "end": 36}], "lang": "en"}
{"doc_id": "18622319_2", "wnd_id": "18622319_2_1", "text": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies .", "tokens": ["Otolaryngologists", "should", "be", "made", "aware", "of", "a", "newer", "cause", "of", "nasal", "septal", "perforations", "resulting", "from", "the", "more", "recent", "antiangiogenic", "therapy", "used", "to", "treat", "malignancies", "."], "event_mentions": [{"id": "18622319_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 13, "end": 14}, "arguments": [{"entity_id": "18622319_2_Ent0", "role": "Effect", "text": "nasal septal perforations", "start": 10, "end": 13}, {"entity_id": "18622319_2_Ent1", "role": "Treatment", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent2", "role": "Treatment_Drug", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent3", "role": "Treatment_Disorder", "text": "malignancies", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18622319_2_Ent0", "text": "nasal septal perforations", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18622319_2_Ent1", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent2", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent3", "text": "malignancies", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18628507_4", "wnd_id": "18628507_4_1", "text": "To our knowledge , this is the first report of an angio - oedema associated with VRC .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "an", "angio", "-", "oedema", "associated", "with", "VRC", "."], "event_mentions": [{"id": "18628507_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "18628507_4_Ent0", "role": "Effect", "text": "angio - oedema", "start": 11, "end": 14}, {"entity_id": "18628507_4_Ent1", "role": "Treatment", "text": "VRC", "start": 16, "end": 17}, {"entity_id": "18628507_4_Ent2", "role": "Treatment_Drug", "text": "VRC", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18628507_4_Ent0", "text": "angio - oedema", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18628507_4_Ent1", "text": "VRC", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18628507_4_Ent2", "text": "VRC", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18648015_2", "wnd_id": "18648015_2_1", "text": "CONCLUSIONS : Cefazolin was a probable cause of this patient 's leukopenia .", "tokens": ["CONCLUSIONS", ":", "Cefazolin", "was", "a", "probable", "cause", "of", "this", "patient", "'s", "leukopenia", "."], "event_mentions": [{"id": "18648015_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "18648015_2_Ent2", "role": "Treatment", "text": "Cefazolin", "start": 2, "end": 3}, {"entity_id": "18648015_2_Ent3", "role": "Treatment_Drug", "text": "Cefazolin", "start": 2, "end": 3}, {"entity_id": "18648015_2_Ent0", "role": "Subject", "text": "patient", "start": 9, "end": 10}, {"entity_id": "18648015_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18648015_2_Ent2", "text": "Cefazolin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18648015_2_Ent3", "text": "Cefazolin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18648015_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18648015_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18648015_3", "wnd_id": "18648015_3_1", "text": "OBJECTIVE : To describe a case of cefazolin - induced leukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "cefazolin", "-", "induced", "leukopenia", "in", "a", "critically", "ill", "patient", "who", "developed", "this", "adverse", "reaction", "upon", "rechallenge", "with", "cefoxitin", "."], "event_mentions": [{"id": "18648015_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18648015_3_Ent3", "role": "Treatment", "text": "cefazolin", "start": 7, "end": 8}, {"entity_id": "18648015_3_Ent4", "role": "Treatment_Drug", "text": "cefazolin", "start": 7, "end": 8}, {"entity_id": "18648015_3_Ent2", "role": "Effect", "text": "leukopenia", "start": 10, "end": 11}, {"entity_id": "18648015_3_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 12, "end": 16}, {"entity_id": "18648015_3_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "18648015_3_Ent3", "text": "cefazolin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18648015_3_Ent4", "text": "cefazolin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18648015_3_Ent2", "text": "leukopenia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18648015_3_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18648015_3_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "18665833_1", "wnd_id": "18665833_1_1", "text": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency .", "tokens": ["Stuttering", "priapism", "complicating", "warfarin", "therapy", "in", "a", "patient", "with", "protein", "C", "deficiency", "."], "event_mentions": [{"id": "18665833_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "18665833_1_Ent1", "role": "Effect", "text": "Stuttering priapism", "start": 0, "end": 2}, {"entity_id": "18665833_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent0", "role": "Subject", "text": "a patient with protein C deficiency", "start": 6, "end": 12}, {"entity_id": "18665833_1_Ent3", "role": "Treatment_Disorder", "text": "protein C deficiency", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18665833_1_Ent1", "text": "Stuttering priapism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18665833_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent0", "text": "a patient with protein C deficiency", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18665833_1_Ent3", "text": "protein C deficiency", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "18675768_15", "wnd_id": "18675768_15_1", "text": "CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["CONCLUSIONS", ":", "This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 17, "end": 18}, "arguments": [{"entity_id": "18675768_15_Ent1", "role": "Treatment", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent2", "role": "Treatment", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent0", "role": "Effect", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "18675768_15_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent0", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "18675768_6", "wnd_id": "18675768_6_1", "text": "Three months after starting citalopram , she experienced episodes of chest tightness and dizziness .", "tokens": ["Three", "months", "after", "starting", "citalopram", ",", "she", "experienced", "episodes", "of", "chest", "tightness", "and", "dizziness", "."], "event_mentions": [{"id": "18675768_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 7, "end": 8}, "arguments": [{"entity_id": "18675768_6_Ent5", "role": "Treatment_Time_elapsed", "text": "Three months", "start": 0, "end": 2}, {"entity_id": "18675768_6_Ent3", "role": "Treatment", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "18675768_6_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "18675768_6_Ent0", "role": "Subject", "text": "she", "start": 6, "end": 7}, {"entity_id": "18675768_6_Ent1", "role": "Subject_Gender", "text": "she", "start": 6, "end": 7}, {"entity_id": "18675768_6_Ent2", "role": "Effect", "text": "chest tightness and dizziness", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "18675768_6_Ent5", "text": "Three months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18675768_6_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18675768_6_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18675768_6_Ent0", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_6_Ent1", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_6_Ent2", "text": "chest tightness and dizziness", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "18676387_3", "wnd_id": "18676387_3_1", "text": "Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting .", "tokens": ["Serotonin", "toxicity", "precipitated", "by", "fentanyl", "is", "unusual", "and", "has", "not", "previously", "been", "described", "in", "combination", "with", "SSRIs", "in", "the", "perioperative", "setting", "."], "event_mentions": [{"id": "18676387_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 2, "end": 3}, "arguments": [{"entity_id": "18676387_3_Ent0", "role": "Effect", "text": "Serotonin toxicity", "start": 0, "end": 2}, {"entity_id": "18676387_3_Ent1", "role": "Treatment", "text": "fentanyl", "start": 4, "end": 5}, {"entity_id": "18676387_3_Ent2", "role": "Treatment_Drug", "text": "fentanyl", "start": 4, "end": 5}, {"entity_id": "18676387_3_Ent4", "role": "Combination_Drug", "text": "fentanyl", "start": 4, "end": 5}, {"entity_id": "18676387_3_Ent3", "role": "Treatment_Drug", "text": "SSRIs", "start": 16, "end": 17}, {"entity_id": "18676387_3_Ent5", "role": "Combination_Drug", "text": "SSRIs", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18676387_3_Ent0", "text": "Serotonin toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18676387_3_Ent1", "text": "fentanyl", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18676387_3_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18676387_3_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18676387_3_Ent3", "text": "SSRIs", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18676387_3_Ent5", "text": "SSRIs", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18682542_2", "wnd_id": "18682542_2_1", "text": "DISCUSSION : To our knowledge , this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin , tobramycin , and piperacillin / tazobactam .", "tokens": ["DISCUSSION", ":", "To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "report", "illustrating", "neuralgic", "amyotrophy", "triggered", "by", "exposure", "to", "the", "antibiotics", "vancomycin", ",", "tobramycin", ",", "and", "piperacillin", "/", "tazobactam", "."], "event_mentions": [{"id": "18682542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 15, "end": 16}, "arguments": [{"entity_id": "18682542_2_Ent0", "role": "Effect", "text": "neuralgic amyotrophy", "start": 13, "end": 15}, {"entity_id": "18682542_2_Ent1", "role": "Treatment", "text": "antibiotics vancomycin , tobramycin , and piperacillin / tazobactam", "start": 20, "end": 29}, {"entity_id": "18682542_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 21, "end": 22}, {"entity_id": "18682542_2_Ent6", "role": "Combination_Drug", "text": "vancomycin", "start": 21, "end": 22}, {"entity_id": "18682542_2_Ent3", "role": "Treatment_Drug", "text": "tobramycin", "start": 23, "end": 24}, {"entity_id": "18682542_2_Ent7", "role": "Combination_Drug", "text": "tobramycin", "start": 23, "end": 24}, {"entity_id": "18682542_2_Ent4", "role": "Treatment_Drug", "text": "piperacillin", "start": 26, "end": 27}, {"entity_id": "18682542_2_Ent8", "role": "Combination_Drug", "text": "piperacillin", "start": 26, "end": 27}, {"entity_id": "18682542_2_Ent5", "role": "Treatment_Drug", "text": "tazobactam", "start": 28, "end": 29}, {"entity_id": "18682542_2_Ent9", "role": "Combination_Drug", "text": "tazobactam", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18682542_2_Ent0", "text": "neuralgic amyotrophy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "18682542_2_Ent1", "text": "antibiotics vancomycin , tobramycin , and piperacillin / tazobactam", "entity_type": "Entity", "start": 20, "end": 29}, {"id": "18682542_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18682542_2_Ent6", "text": "vancomycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18682542_2_Ent3", "text": "tobramycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18682542_2_Ent7", "text": "tobramycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18682542_2_Ent4", "text": "piperacillin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18682542_2_Ent8", "text": "piperacillin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18682542_2_Ent5", "text": "tazobactam", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "18682542_2_Ent9", "text": "tazobactam", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18691992_5", "wnd_id": "18691992_5_1", "text": "Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject .", "tokens": ["Hydroxyurea", "associated", "with", "concomitant", "occurrence", "of", "diffuse", "longitudinal", "melanonychia", "and", "multiple", "squamous", "cell", "carcinomas", "in", "an", "elderly", "subject", "."], "event_mentions": [{"id": "18691992_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "18691992_5_Ent3", "role": "Treatment", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "18691992_5_Ent4", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "18691992_5_Ent2", "role": "Effect", "text": "concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas", "start": 3, "end": 14}, {"entity_id": "18691992_5_Ent0", "role": "Subject", "text": "an elderly subject", "start": 15, "end": 18}, {"entity_id": "18691992_5_Ent1", "role": "Subject_Age", "text": "elderly", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18691992_5_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18691992_5_Ent4", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18691992_5_Ent2", "text": "concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "18691992_5_Ent0", "text": "an elderly subject", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "18691992_5_Ent1", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18707772_1", "wnd_id": "18707772_1_1", "text": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel .", "tokens": ["A", "64", "year", "old", "woman", "with", "previous", "history", "of", "coronary", "stenting", "five", "days", "before", "was", "admitted", "in", "our", "institution", "for", "intracranial", "bleeding", "while", "receiving", "aspirin", "and", "clopidogrel", "."], "event_mentions": [{"id": "18707772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "18707772_1_Ent0", "role": "Subject", "text": "A 64 year old woman with previous history of coronary stenting", "start": 0, "end": 11}, {"entity_id": "18707772_1_Ent1", "role": "Subject_Age", "text": "64 year old", "start": 1, "end": 4}, {"entity_id": "18707772_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "18707772_1_Ent8", "role": "Treatment_Disorder", "text": "coronary stenting", "start": 9, "end": 11}, {"entity_id": "18707772_1_Ent9", "role": "Treatment_Time_elapsed", "text": "five days", "start": 11, "end": 13}, {"entity_id": "18707772_1_Ent4", "role": "Treatment", "text": "five days before", "start": 11, "end": 14}, {"entity_id": "18707772_1_Ent3", "role": "Effect", "text": "intracranial bleeding", "start": 20, "end": 22}, {"entity_id": "18707772_1_Ent7", "role": "Treatment_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent10", "role": "Combination_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent5", "role": "Treatment", "text": "aspirin and clopidogrel", "start": 24, "end": 27}, {"entity_id": "18707772_1_Ent6", "role": "Treatment_Drug", "text": "clopidogrel", "start": 26, "end": 27}, {"entity_id": "18707772_1_Ent11", "role": "Combination_Drug", "text": "clopidogrel", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18707772_1_Ent0", "text": "A 64 year old woman with previous history of coronary stenting", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18707772_1_Ent1", "text": "64 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18707772_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18707772_1_Ent8", "text": "coronary stenting", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18707772_1_Ent9", "text": "five days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18707772_1_Ent4", "text": "five days before", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18707772_1_Ent3", "text": "intracranial bleeding", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "18707772_1_Ent7", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent10", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent5", "text": "aspirin and clopidogrel", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18707772_1_Ent6", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18707772_1_Ent11", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18717612_1", "wnd_id": "18717612_1_1", "text": "Ceftriaxone - induced fixed drug eruption : first report .", "tokens": ["Ceftriaxone", "-", "induced", "fixed", "drug", "eruption", ":", "first", "report", "."], "event_mentions": [{"id": "18717612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18717612_1_Ent1", "role": "Treatment", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent2", "role": "Treatment_Drug", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "18717612_1_Ent1", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent2", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "18721173_3", "wnd_id": "18721173_3_1", "text": "OBJECTIVE : This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure .", "tokens": ["OBJECTIVE", ":", "This", "case", "report", "outlines", "a", "significant", "type", "of", "morbidity", "due", "to", "continued", "use", "of", "gabapentin", "during", "an", "episode", "of", "acute", "renal", "failure", "."], "event_mentions": [{"id": "18721173_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "18721173_3_Ent0", "role": "Subject", "text": "This case", "start": 2, "end": 4}, {"entity_id": "18721173_3_Ent1", "role": "Effect", "text": "a significant type of morbidity", "start": 6, "end": 11}, {"entity_id": "18721173_3_Ent2", "role": "Treatment", "text": "gabapentin", "start": 16, "end": 17}, {"entity_id": "18721173_3_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18721173_3_Ent0", "text": "This case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18721173_3_Ent1", "text": "a significant type of morbidity", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18721173_3_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18721173_3_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18751717_1", "wnd_id": "18751717_1_1", "text": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection .", "tokens": ["Acute", "syphilitic", "posterior", "placoid", "chorioretinitis", "following", "intravitreal", "triamcinolone", "acetonide", "injection", "."], "event_mentions": [{"id": "18751717_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "18751717_1_Ent0", "role": "Effect", "text": "Acute syphilitic posterior placoid chorioretinitis", "start": 0, "end": 5}, {"entity_id": "18751717_1_Ent2", "role": "Treatment_Route", "text": "intravitreal", "start": 6, "end": 7}, {"entity_id": "18751717_1_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone acetonide injection", "start": 6, "end": 10}, {"entity_id": "18751717_1_Ent4", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 7, "end": 9}, {"entity_id": "18751717_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18751717_1_Ent0", "text": "Acute syphilitic posterior placoid chorioretinitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18751717_1_Ent2", "text": "intravitreal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18751717_1_Ent1", "text": "intravitreal triamcinolone acetonide injection", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18751717_1_Ent4", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18751717_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18751717_4", "wnd_id": "18751717_4_1", "text": "RESULTS : Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection .", "tokens": ["RESULTS", ":", "Two", "patients", "with", "ocular", "inflammation", "of", "unknown", "origin", "developed", "severe", "chorioretinitis", "after", "IVTA", "injection", "."], "event_mentions": [{"id": "18751717_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "18751717_4_Ent2", "role": "Subject_Population", "text": "Two", "start": 2, "end": 3}, {"entity_id": "18751717_4_Ent0", "role": "Subject", "text": "Two patients with ocular inflammation", "start": 2, "end": 7}, {"entity_id": "18751717_4_Ent1", "role": "Subject_Disorder", "text": "ocular inflammation", "start": 5, "end": 7}, {"entity_id": "18751717_4_Ent3", "role": "Effect", "text": "severe chorioretinitis", "start": 11, "end": 13}, {"entity_id": "18751717_4_Ent5", "role": "Treatment_Drug", "text": "IVTA", "start": 14, "end": 15}, {"entity_id": "18751717_4_Ent4", "role": "Treatment", "text": "IVTA injection", "start": 14, "end": 16}, {"entity_id": "18751717_4_Ent6", "role": "Treatment_Route", "text": "injection", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18751717_4_Ent2", "text": "Two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18751717_4_Ent0", "text": "Two patients with ocular inflammation", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18751717_4_Ent1", "text": "ocular inflammation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18751717_4_Ent3", "text": "severe chorioretinitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18751717_4_Ent5", "text": "IVTA", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18751717_4_Ent4", "text": "IVTA injection", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18751717_4_Ent6", "text": "injection", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18755414_6", "wnd_id": "18755414_6_1", "text": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin , we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma .", "tokens": ["Although", "it", "is", "difficult", "to", "solely", "attribute", "intratumoral", "hemorrhage", "to", "aspirin", ",", "we", "have", "to", "be", "careful", "when", "prescribing", "aspirin", "for", "patients", "who", "have", "asymptomatic", "meningioma", "."], "event_mentions": [{"id": "18755414_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attribute", "start": 6, "end": 7}, "arguments": [{"entity_id": "18755414_6_Ent1", "role": "Effect", "text": "intratumoral hemorrhage", "start": 7, "end": 9}, {"entity_id": "18755414_6_Ent2", "role": "Treatment", "text": "aspirin", "start": 10, "end": 11}, {"entity_id": "18755414_6_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 10, "end": 11}, {"entity_id": "18755414_6_Ent0", "role": "Subject", "text": "patients who have asymptomatic meningioma", "start": 21, "end": 26}, {"entity_id": "18755414_6_Ent4", "role": "Treatment_Disorder", "text": "asymptomatic meningioma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "18755414_6_Ent1", "text": "intratumoral hemorrhage", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18755414_6_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18755414_6_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18755414_6_Ent0", "text": "patients who have asymptomatic meningioma", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "18755414_6_Ent4", "text": "asymptomatic meningioma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "18784429_2", "wnd_id": "18784429_2_1", "text": "CONCLUSIONS : Life - threatening adrenal suppression , requiring hydrocortisone supplementation and intensive therapy , was observed and successfully treated in a newborn , whose mother had received high - dose methylprednisolone in late pregnancy .", "tokens": ["CONCLUSIONS", ":", "Life", "-", "threatening", "adrenal", "suppression", ",", "requiring", "hydrocortisone", "supplementation", "and", "intensive", "therapy", ",", "was", "observed", "and", "successfully", "treated", "in", "a", "newborn", ",", "whose", "mother", "had", "received", "high", "-", "dose", "methylprednisolone", "in", "late", "pregnancy", "."], "event_mentions": [{"id": "18784429_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "requiring", "start": 8, "end": 9}, "arguments": [{"entity_id": "18784429_2_Ent4", "role": "Treatment_Drug", "text": "hydrocortisone", "start": 9, "end": 10}, {"entity_id": "18784429_2_Ent3", "role": "Treatment", "text": "hydrocortisone supplementation and intensive therapy", "start": 9, "end": 14}, {"entity_id": "18784429_2_Ent2", "role": "Effect", "text": "successfully treated", "start": 18, "end": 20}, {"entity_id": "18784429_2_Ent0", "role": "Subject", "text": "a newborn , whose mother had received high - dose methylprednisolone in late pregnancy", "start": 21, "end": 35}, {"entity_id": "18784429_2_Ent1", "role": "Subject_Age", "text": "newborn", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18784429_2_Ent4", "text": "hydrocortisone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18784429_2_Ent3", "text": "hydrocortisone supplementation and intensive therapy", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "18784429_2_Ent2", "text": "successfully treated", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18784429_2_Ent0", "text": "a newborn , whose mother had received high - dose methylprednisolone in late pregnancy", "entity_type": "Entity", "start": 21, "end": 35}, {"id": "18784429_2_Ent1", "text": "newborn", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18795_2", "wnd_id": "18795_2_1", "text": "Asthma and urticaria during disodium cromoglycate treatment .", "tokens": ["Asthma", "and", "urticaria", "during", "disodium", "cromoglycate", "treatment", "."], "event_mentions": [{"id": "18795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "18795_2_Ent0", "role": "Effect", "text": "Asthma and urticaria", "start": 0, "end": 3}, {"entity_id": "18795_2_Ent2", "role": "Treatment_Drug", "text": "disodium cromoglycate", "start": 4, "end": 6}, {"entity_id": "18795_2_Ent1", "role": "Treatment", "text": "disodium cromoglycate treatment", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "18795_2_Ent0", "text": "Asthma and urticaria", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18795_2_Ent2", "text": "disodium cromoglycate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18795_2_Ent1", "text": "disodium cromoglycate treatment", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18795_3", "wnd_id": "18795_3_1", "text": "When DSCG was withdrawn , urticaria vanished and the child remained symptom - free .", "tokens": ["When", "DSCG", "was", "withdrawn", ",", "urticaria", "vanished", "and", "the", "child", "remained", "symptom", "-", "free", "."], "event_mentions": [{"id": "18795_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "remained", "start": 10, "end": 11}, "arguments": [{"entity_id": "18795_3_Ent5", "role": "Treatment_Drug", "text": "DSCG", "start": 1, "end": 2}, {"entity_id": "18795_3_Ent4", "role": "Treatment", "text": "DSCG was withdrawn", "start": 1, "end": 4}, {"entity_id": "18795_3_Ent2", "role": "Effect", "text": "urticaria vanished", "start": 5, "end": 7}, {"entity_id": "18795_3_Ent0", "role": "Subject", "text": "the child", "start": 8, "end": 10}, {"entity_id": "18795_3_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "18795_3_Ent3", "role": "Effect", "text": "symptom - free", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "18795_3_Ent5", "text": "DSCG", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18795_3_Ent4", "text": "DSCG was withdrawn", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18795_3_Ent2", "text": "urticaria vanished", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18795_3_Ent0", "text": "the child", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18795_3_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18795_3_Ent3", "text": "symptom - free", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "1879988_3", "wnd_id": "1879988_3_1", "text": "After the first oral dose of propranolol , syncope developed together with atrioventricular block .", "tokens": ["After", "the", "first", "oral", "dose", "of", "propranolol", ",", "syncope", "developed", "together", "with", "atrioventricular", "block", "."], "event_mentions": [{"id": "1879988_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "1879988_3_Ent3", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "1879988_3_Ent2", "role": "Treatment", "text": "oral dose of propranolol", "start": 3, "end": 7}, {"entity_id": "1879988_3_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "1879988_3_Ent0", "role": "Effect", "text": "syncope", "start": 8, "end": 9}, {"entity_id": "1879988_3_Ent1", "role": "Effect", "text": "atrioventricular block", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1879988_3_Ent3", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1879988_3_Ent2", "text": "oral dose of propranolol", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "1879988_3_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1879988_3_Ent0", "text": "syncope", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1879988_3_Ent1", "text": "atrioventricular block", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "18801826_3", "wnd_id": "18801826_3_1", "text": "We report a case of a 35 - year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode .", "tokens": ["We", "report", "a", "case", "of", "a", "35", "-", "year", "old", "female", "who", "developed", "new", "onset", "type", "II", "diabetes", "mellitus", "with", "hyperosmolar", "hyperglycaemic", "coma", "and", "acute", "renal", "failure", "following", "treatment", "with", "a", "SGA", "for", "a", "first", "manic", "episode", "."], "event_mentions": [{"id": "18801826_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18801826_3_Ent1", "role": "Subject_Age", "text": "35 - year old", "start": 6, "end": 10}, {"entity_id": "18801826_3_Ent0", "role": "Subject", "text": "35 - year old female", "start": 6, "end": 11}, {"entity_id": "18801826_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 10, "end": 11}, {"entity_id": "18801826_3_Ent3", "role": "Effect", "text": "type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure", "start": 15, "end": 27}, {"entity_id": "18801826_3_Ent4", "role": "Treatment", "text": "treatment with a SGA", "start": 28, "end": 32}, {"entity_id": "18801826_3_Ent5", "role": "Treatment_Drug", "text": "SGA", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18801826_3_Ent1", "text": "35 - year old", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18801826_3_Ent0", "text": "35 - year old female", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18801826_3_Ent2", "text": "female", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18801826_3_Ent3", "text": "type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "18801826_3_Ent4", "text": "treatment with a SGA", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "18801826_3_Ent5", "text": "SGA", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18821094_1", "wnd_id": "18821094_1_1", "text": "Oxcarbazepine - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ) .", "tokens": ["Oxcarbazepine", "-", "induced", "Drug", "Reaction", "with", "Eosinophilia", "and", "Systemic", "Symptoms", "(", "DRESS", ")", "."], "event_mentions": [{"id": "18821094_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18821094_1_Ent1", "role": "Treatment", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "18821094_1_Ent2", "role": "Treatment_Drug", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "18821094_1_Ent0", "role": "Effect", "text": "Eosinophilia and Systemic Symptoms ( DRESS )", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "18821094_1_Ent1", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18821094_1_Ent2", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18821094_1_Ent0", "text": "Eosinophilia and Systemic Symptoms ( DRESS )", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "18821094_2", "wnd_id": "18821094_2_1", "text": "This is an image and brief case report of a 13 - year - old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine .", "tokens": ["This", "is", "an", "image", "and", "brief", "case", "report", "of", "a", "13", "-", "year", "-", "old", "boy", "who", "presented", "with", "severe", "rash", "and", "systemic", "symptoms", "after", "starting", "oxcarbazepine", "."], "event_mentions": [{"id": "18821094_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "18821094_2_Ent0", "role": "Subject", "text": "a 13 - year - old boy", "start": 9, "end": 16}, {"entity_id": "18821094_2_Ent1", "role": "Subject_Age", "text": "13 - year - old", "start": 10, "end": 15}, {"entity_id": "18821094_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 15, "end": 16}, {"entity_id": "18821094_2_Ent3", "role": "Effect", "text": "severe rash and systemic symptoms", "start": 19, "end": 24}, {"entity_id": "18821094_2_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 26, "end": 27}, {"entity_id": "18821094_2_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18821094_2_Ent0", "text": "a 13 - year - old boy", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "18821094_2_Ent1", "text": "13 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "18821094_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18821094_2_Ent3", "text": "severe rash and systemic symptoms", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "18821094_2_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18821094_2_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18837734_2", "wnd_id": "18837734_2_1", "text": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81 - year - old - man and to discuss the pathogenetic role of Demodex folliculorum mites , found in the present patient , using skin scraping .", "tokens": ["The", "aim", "of", "this", "paper", "is", "to", "report", "the", "case", "of", "rosaceiform", "eruption", "induced", "by", "erlotinib", "in", "an", "81", "-", "year", "-", "old", "-", "man", "and", "to", "discuss", "the", "pathogenetic", "role", "of", "Demodex", "folliculorum", "mites", ",", "found", "in", "the", "present", "patient", ",", "using", "skin", "scraping", "."], "event_mentions": [{"id": "18837734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "18837734_2_Ent3", "role": "Effect", "text": "rosaceiform eruption", "start": 11, "end": 13}, {"entity_id": "18837734_2_Ent5", "role": "Treatment", "text": "erlotinib", "start": 15, "end": 16}, {"entity_id": "18837734_2_Ent7", "role": "Treatment_Drug", "text": "erlotinib", "start": 15, "end": 16}, {"entity_id": "18837734_2_Ent0", "role": "Subject", "text": "an 81 - year - old - man", "start": 17, "end": 25}, {"entity_id": "18837734_2_Ent2", "role": "Subject_Age", "text": "81 - year - old", "start": 18, "end": 23}, {"entity_id": "18837734_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 24, "end": 25}, {"entity_id": "18837734_2_Ent4", "role": "Effect", "text": "Demodex folliculorum mites", "start": 32, "end": 35}, {"entity_id": "18837734_2_Ent6", "role": "Treatment", "text": "skin scraping", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "18837734_2_Ent3", "text": "rosaceiform eruption", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18837734_2_Ent5", "text": "erlotinib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18837734_2_Ent7", "text": "erlotinib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18837734_2_Ent0", "text": "an 81 - year - old - man", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "18837734_2_Ent2", "text": "81 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18837734_2_Ent1", "text": "man", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18837734_2_Ent4", "text": "Demodex folliculorum mites", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "18837734_2_Ent6", "text": "skin scraping", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "18855892_3", "wnd_id": "18855892_3_1", "text": "In patients with methotrexate - induced anaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression .", "tokens": ["In", "patients", "with", "methotrexate", "-", "induced", "anaphylaxis", ",", "discontinuation", "of", "treatment", "may", "increase", "the", "risk", "of", "death", "due", "to", "cancer", "progression", "."], "event_mentions": [{"id": "18855892_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18855892_3_Ent5", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent4", "role": "Effect", "text": "anaphylaxis", "start": 6, "end": 7}]}, {"id": "18855892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 8, "end": 9}, "arguments": [{"entity_id": "18855892_3_Ent0", "role": "Subject", "text": "In patients with methotrexate - induced anaphylaxis", "start": 0, "end": 7}, {"entity_id": "18855892_3_Ent3", "role": "Treatment_Disorder", "text": "methotrexate - induced anaphylaxis", "start": 3, "end": 7}, {"entity_id": "18855892_3_Ent2", "role": "Treatment", "text": "treatment", "start": 10, "end": 11}, {"entity_id": "18855892_3_Ent1", "role": "Effect", "text": "death due to cancer progression", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "18855892_3_Ent0", "text": "In patients with methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18855892_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent3", "text": "methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18855892_3_Ent4", "text": "anaphylaxis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18855892_3_Ent2", "text": "treatment", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18855892_3_Ent1", "text": "death due to cancer progression", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "189279_1", "wnd_id": "189279_1_1", "text": "A case of congestive heart failure in a child with Wilms ' tumor treated Adriamycin is presented and discussed .", "tokens": ["A", "case", "of", "congestive", "heart", "failure", "in", "a", "child", "with", "Wilms", "'", "tumor", "treated", "Adriamycin", "is", "presented", "and", "discussed", "."], "event_mentions": [{"id": "189279_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "189279_1_Ent2", "role": "Effect", "text": "congestive heart failure", "start": 3, "end": 6}, {"entity_id": "189279_1_Ent0", "role": "Subject", "text": "a child with Wilms ' tumor", "start": 7, "end": 13}, {"entity_id": "189279_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "189279_1_Ent5", "role": "Treatment_Disorder", "text": "Wilms ' tumor", "start": 10, "end": 13}, {"entity_id": "189279_1_Ent3", "role": "Treatment", "text": "Adriamycin", "start": 14, "end": 15}, {"entity_id": "189279_1_Ent4", "role": "Treatment_Drug", "text": "Adriamycin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "189279_1_Ent2", "text": "congestive heart failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "189279_1_Ent0", "text": "a child with Wilms ' tumor", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "189279_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "189279_1_Ent5", "text": "Wilms ' tumor", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "189279_1_Ent3", "text": "Adriamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "189279_1_Ent4", "text": "Adriamycin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1893404_1", "wnd_id": "1893404_1_1", "text": "Carbamazepine - induced Diabetes mellitus .", "tokens": ["Carbamazepine", "-", "induced", "Diabetes", "mellitus", "."], "event_mentions": [{"id": "1893404_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1893404_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1893404_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1893404_1_Ent0", "role": "Effect", "text": "Diabetes mellitus", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1893404_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1893404_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1893404_1_Ent0", "text": "Diabetes mellitus", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18983414_1", "wnd_id": "18983414_1_1", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus .", "tokens": ["Four", "months", "after", "receiving", "an", "orthotopic", "liver", "transplant", ",", "a", "51", "-", "year", "-", "old", "man", "was", "admitted", "for", "progressive", "liver", "failure", "and", "severe", "hepatocellular", "necrosis", "thought", "to", "be", "due", "to", "tacrolimus", "."], "event_mentions": [{"id": "18983414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 29, "end": 31}, "arguments": [{"entity_id": "18983414_1_Ent5", "role": "Treatment_Time_elapsed", "text": "Four months", "start": 0, "end": 2}, {"entity_id": "18983414_1_Ent0", "role": "Subject", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man", "start": 0, "end": 16}, {"entity_id": "18983414_1_Ent1", "role": "Subject_Age", "text": "a 51 - year - old", "start": 9, "end": 15}, {"entity_id": "18983414_1_Ent2", "role": "Effect", "text": "progressive liver failure and severe hepatocellular necrosis", "start": 19, "end": 26}, {"entity_id": "18983414_1_Ent3", "role": "Treatment", "text": "tacrolimus", "start": 31, "end": 32}, {"entity_id": "18983414_1_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18983414_1_Ent5", "text": "Four months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18983414_1_Ent0", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "18983414_1_Ent1", "text": "a 51 - year - old", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "18983414_1_Ent2", "text": "progressive liver failure and severe hepatocellular necrosis", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "18983414_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "18983414_1_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19003750_1", "wnd_id": "19003750_1_1", "text": "A 22 - year - old drug - abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg .", "tokens": ["A", "22", "-", "year", "-", "old", "drug", "-", "abuser", "injected", "flunitrazepam", "tablets", "dissolved", "in", "tap", "water", "into", "her", "left", "femoral", "artery", "and", "presented", "with", "clinical", "signs", "of", "acute", "ischaemia", "of", "the", "left", "leg", "."], "event_mentions": [{"id": "19003750_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 22, "end": 23}, "arguments": [{"entity_id": "19003750_1_Ent0", "role": "Subject", "text": "A 22 - year - old drug - abuser", "start": 0, "end": 9}, {"entity_id": "19003750_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "19003750_1_Ent2", "role": "Subject_Disorder", "text": "drug - abuser", "start": 6, "end": 9}, {"entity_id": "19003750_1_Ent6", "role": "Treatment_Route", "text": "injected", "start": 9, "end": 10}, {"entity_id": "19003750_1_Ent4", "role": "Treatment", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "start": 9, "end": 21}, {"entity_id": "19003750_1_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "19003750_1_Ent7", "role": "Treatment_Route", "text": "tablets dissolved in tap water", "start": 11, "end": 16}, {"entity_id": "19003750_1_Ent3", "role": "Effect", "text": "acute ischaemia of the left leg", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "19003750_1_Ent0", "text": "A 22 - year - old drug - abuser", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "19003750_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19003750_1_Ent2", "text": "drug - abuser", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19003750_1_Ent6", "text": "injected", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19003750_1_Ent4", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "19003750_1_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_1_Ent7", "text": "tablets dissolved in tap water", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19003750_1_Ent3", "text": "acute ischaemia of the left leg", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "19017039_1", "wnd_id": "19017039_1_1", "text": "A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described .", "tokens": ["A", "17", "-", "year", "-", "old", "boy", "with", "refractory", "psoriatic", "arthritis", "and", "alpha", "-", "1", "antitrypsin", "deficiency", "who", "developed", "a", "syringotropic", "hypersensitivity", "reaction", "after", "9", "months", "of", "therapy", "with", "infliximab", "and", "leflunomide", "is", "described", "."], "event_mentions": [{"id": "19017039_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19017039_1_Ent0", "role": "Subject", "text": "A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency", "start": 0, "end": 17}, {"entity_id": "19017039_1_Ent1", "role": "Subject_Age", "text": "17 - year - old", "start": 1, "end": 6}, {"entity_id": "19017039_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "19017039_1_Ent6", "role": "Treatment_Disorder", "text": "refractory psoriatic arthritis", "start": 8, "end": 11}, {"entity_id": "19017039_1_Ent3", "role": "Subject_Disorder", "text": "alpha - 1 antitrypsin deficiency", "start": 12, "end": 17}, {"entity_id": "19017039_1_Ent4", "role": "Effect", "text": "syringotropic hypersensitivity reaction", "start": 20, "end": 23}, {"entity_id": "19017039_1_Ent9", "role": "Treatment_Duration", "text": "9 months", "start": 24, "end": 26}, {"entity_id": "19017039_1_Ent5", "role": "Treatment", "text": "9 months of therapy with infliximab and leflunomide", "start": 24, "end": 32}, {"entity_id": "19017039_1_Ent7", "role": "Treatment_Drug", "text": "infliximab", "start": 29, "end": 30}, {"entity_id": "19017039_1_Ent10", "role": "Combination_Drug", "text": "infliximab", "start": 29, "end": 30}, {"entity_id": "19017039_1_Ent8", "role": "Treatment_Drug", "text": "leflunomide", "start": 31, "end": 32}, {"entity_id": "19017039_1_Ent11", "role": "Combination_Drug", "text": "leflunomide", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19017039_1_Ent0", "text": "A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency", "entity_type": "Entity", "start": 0, "end": 17}, {"id": "19017039_1_Ent1", "text": "17 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19017039_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19017039_1_Ent6", "text": "refractory psoriatic arthritis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19017039_1_Ent3", "text": "alpha - 1 antitrypsin deficiency", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19017039_1_Ent4", "text": "syringotropic hypersensitivity reaction", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "19017039_1_Ent9", "text": "9 months", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "19017039_1_Ent5", "text": "9 months of therapy with infliximab and leflunomide", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "19017039_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "19017039_1_Ent10", "text": "infliximab", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "19017039_1_Ent8", "text": "leflunomide", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "19017039_1_Ent11", "text": "leflunomide", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19039026_2", "wnd_id": "19039026_2_1", "text": "We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer .", "tokens": ["We", "report", "the", "first", "biopsy", "confirmed", "occurrence", "of", "acute", "interstitial", "nephritis", "in", "a", "patient", "receiving", "treatment", "with", "Sunitinib", "for", "metastatic", "renal", "cell", "cancer", "."], "event_mentions": [{"id": "19039026_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 6, "end": 7}, "arguments": [{"entity_id": "19039026_2_Ent1", "role": "Effect", "text": "acute interstitial nephritis", "start": 8, "end": 11}, {"entity_id": "19039026_2_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "19039026_2_Ent2", "role": "Treatment", "text": "Sunitinib", "start": 17, "end": 18}, {"entity_id": "19039026_2_Ent4", "role": "Treatment_Drug", "text": "Sunitinib", "start": 17, "end": 18}, {"entity_id": "19039026_2_Ent3", "role": "Treatment_Disorder", "text": "metastatic renal cell cancer", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19039026_2_Ent1", "text": "acute interstitial nephritis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19039026_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19039026_2_Ent2", "text": "Sunitinib", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19039026_2_Ent4", "text": "Sunitinib", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19039026_2_Ent3", "text": "metastatic renal cell cancer", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19058340_1", "wnd_id": "19058340_1_1", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten - month treatment of methotrexate .", "tokens": ["A", "52", "year", "-", "old", "male", "patient", "diagnosed", "of", "ankylosing", "spondylitis", "presented", "with", "an", "iron", "deficiency", "anemia", "after", "a", "ten", "-", "month", "treatment", "of", "methotrexate", "."], "event_mentions": [{"id": "19058340_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 11, "end": 12}, "arguments": [{"entity_id": "19058340_1_Ent0", "role": "Subject", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "start": 0, "end": 11}, {"entity_id": "19058340_1_Ent1", "role": "Subject_Age", "text": "52 year - old", "start": 1, "end": 5}, {"entity_id": "19058340_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "19058340_1_Ent7", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}, {"entity_id": "19058340_1_Ent3", "role": "Effect", "text": "an iron deficiency anemia", "start": 13, "end": 17}, {"entity_id": "19058340_1_Ent4", "role": "Treatment", "text": "a ten - month treatment of methotrexate", "start": 18, "end": 25}, {"entity_id": "19058340_1_Ent5", "role": "Treatment_Time_elapsed", "text": "ten - month", "start": 19, "end": 22}, {"entity_id": "19058340_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19058340_1_Ent0", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "19058340_1_Ent1", "text": "52 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19058340_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19058340_1_Ent7", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19058340_1_Ent3", "text": "an iron deficiency anemia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "19058340_1_Ent4", "text": "a ten - month treatment of methotrexate", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "19058340_1_Ent5", "text": "ten - month", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19058340_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19116715_2", "wnd_id": "19116715_2_1", "text": "METHODS : A retrospective report of the first case of gemcitabine - related HUS , in a patient with metastatic pancreatic adenocarcinoma , treated with a variety of standard therapies in addition to rituximab is presented .", "tokens": ["METHODS", ":", "A", "retrospective", "report", "of", "the", "first", "case", "of", "gemcitabine", "-", "related", "HUS", ",", "in", "a", "patient", "with", "metastatic", "pancreatic", "adenocarcinoma", ",", "treated", "with", "a", "variety", "of", "standard", "therapies", "in", "addition", "to", "rituximab", "is", "presented", "."], "event_mentions": [{"id": "19116715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "19116715_2_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "19116715_2_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "19116715_2_Ent1", "role": "Effect", "text": "HUS", "start": 13, "end": 14}, {"entity_id": "19116715_2_Ent0", "role": "Subject", "text": "a patient with metastatic pancreatic adenocarcinoma", "start": 16, "end": 22}, {"entity_id": "19116715_2_Ent4", "role": "Treatment_Disorder", "text": "metastatic pancreatic adenocarcinoma ,", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19116715_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19116715_2_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19116715_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19116715_2_Ent0", "text": "a patient with metastatic pancreatic adenocarcinoma", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "19116715_2_Ent4", "text": "metastatic pancreatic adenocarcinoma ,", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19122478_1", "wnd_id": "19122478_1_1", "text": "Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia .", "tokens": ["Drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "after", "chlorambucil", "treatment", "in", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "19122478_1_Ent0", "role": "Effect", "text": "Drug rash with eosinophilia and systemic symptoms", "start": 0, "end": 7}, {"entity_id": "19122478_1_Ent1", "role": "Treatment", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19122478_1_Ent0", "text": "Drug rash with eosinophilia and systemic symptoms", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19122478_1_Ent1", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent3", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19145124_3", "wnd_id": "19145124_3_1", "text": "Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium - intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage .", "tokens": ["Two", "patients", "who", "developed", "decreased", "visual", "acuity", "after", "several", "months", "of", "ethambutol", "treatment", "for", "Mycobacterium", "avium", "-", "intracellulare", "infection", "had", "bitemporal", "visual", "field", "defects", "that", "suggested", "optic", "chiasm", "damage", "."], "event_mentions": [{"id": "19145124_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "19145124_3_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "19145124_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "19145124_3_Ent3", "role": "Effect", "text": "decreased visual acuity", "start": 4, "end": 7}, {"entity_id": "19145124_3_Ent6", "role": "Treatment", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "19145124_3_Ent8", "role": "Treatment_Drug", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "19145124_3_Ent1", "role": "Subject", "text": "Mycobacterium avium - intracellulare infection", "start": 14, "end": 19}, {"entity_id": "19145124_3_Ent7", "role": "Treatment_Disorder", "text": "Mycobacterium avium - intracellulare infection", "start": 14, "end": 19}, {"entity_id": "19145124_3_Ent4", "role": "Effect", "text": "bitemporal visual field defects", "start": 20, "end": 24}, {"entity_id": "19145124_3_Ent5", "role": "Effect", "text": "optic chiasm damage", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "19145124_3_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19145124_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19145124_3_Ent3", "text": "decreased visual acuity", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19145124_3_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19145124_3_Ent8", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19145124_3_Ent1", "text": "Mycobacterium avium - intracellulare infection", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19145124_3_Ent7", "text": "Mycobacterium avium - intracellulare infection", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19145124_3_Ent4", "text": "bitemporal visual field defects", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "19145124_3_Ent5", "text": "optic chiasm damage", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "19183077_3", "wnd_id": "19183077_3_1", "text": "We report two cases of tenofovir ( TDF) - associated nephrotoxicity in perinatally HIV - infected adolescents .", "tokens": ["We", "report", "two", "cases", "of", "tenofovir", "(", "TDF)", "-", "associated", "nephrotoxicity", "in", "perinatally", "HIV", "-", "infected", "adolescents", "."], "event_mentions": [{"id": "19183077_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19183077_3_Ent4", "role": "Treatment_Drug", "text": "tenofovir", "start": 5, "end": 6}, {"entity_id": "19183077_3_Ent3", "role": "Treatment", "text": "tenofovir ( TDF)", "start": 5, "end": 8}, {"entity_id": "19183077_3_Ent2", "role": "Effect", "text": "nephrotoxicity", "start": 10, "end": 11}, {"entity_id": "19183077_3_Ent0", "role": "Subject", "text": "perinatally HIV - infected adolescents", "start": 12, "end": 17}, {"entity_id": "19183077_3_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 13, "end": 14}, {"entity_id": "19183077_3_Ent1", "role": "Subject_Age", "text": "adolescents", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19183077_3_Ent4", "text": "tenofovir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19183077_3_Ent3", "text": "tenofovir ( TDF)", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "19183077_3_Ent2", "text": "nephrotoxicity", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19183077_3_Ent0", "text": "perinatally HIV - infected adolescents", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19183077_3_Ent5", "text": "HIV", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19183077_3_Ent1", "text": "adolescents", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1918672_1", "wnd_id": "1918672_1_1", "text": "In this case , discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment plan helped resolve a patient 's ulcers .", "tokens": ["In", "this", "case", ",", "discontinuing", "piroxicam", ",", "a", "nonsteroidal", "anti", "-", "inflammatory", "drug", ",", "and", "starting", "a", "palliative", "treatment", "plan", "helped", "resolve", "a", "patient", "'s", "ulcers", "."], "event_mentions": [{"id": "1918672_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolve", "start": 21, "end": 22}, "arguments": [{"entity_id": "1918672_1_Ent1", "role": "Treatment", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "start": 4, "end": 19}, {"entity_id": "1918672_1_Ent3", "role": "Treatment_Drug", "text": "piroxicam", "start": 5, "end": 6}, {"entity_id": "1918672_1_Ent0", "role": "Subject", "text": "a patient 's", "start": 22, "end": 25}, {"entity_id": "1918672_1_Ent2", "role": "Treatment_Disorder", "text": "ulcers", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1918672_1_Ent1", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "entity_type": "Entity", "start": 4, "end": 19}, {"id": "1918672_1_Ent3", "text": "piroxicam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1918672_1_Ent0", "text": "a patient 's", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "1918672_1_Ent2", "text": "ulcers", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19203515_1", "wnd_id": "19203515_1_1", "text": "Acute renal failure following intravenous immunoglobulin therapy in a HIV - infected patient .", "tokens": ["Acute", "renal", "failure", "following", "intravenous", "immunoglobulin", "therapy", "in", "a", "HIV", "-", "infected", "patient", "."], "event_mentions": [{"id": "19203515_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19203515_1_Ent2", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "19203515_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 4, "end": 5}, {"entity_id": "19203515_1_Ent3", "role": "Treatment", "text": "intravenous immunoglobulin therapy", "start": 4, "end": 7}, {"entity_id": "19203515_1_Ent4", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 5, "end": 6}, {"entity_id": "19203515_1_Ent0", "role": "Subject", "text": "a HIV - infected patient", "start": 8, "end": 13}, {"entity_id": "19203515_1_Ent1", "role": "Subject_Disorder", "text": "HIV", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19203515_1_Ent2", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19203515_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_1_Ent3", "text": "intravenous immunoglobulin therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19203515_1_Ent4", "text": "immunoglobulin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19203515_1_Ent0", "text": "a HIV - infected patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "19203515_1_Ent1", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19217693_2", "wnd_id": "19217693_2_1", "text": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis .", "tokens": ["Persistent", "hypoglycemia", "in", "a", "patient", "with", "diabetes", "taking", "etanercept", "for", "the", "treatment", "of", "psoriasis", "."], "event_mentions": [{"id": "19217693_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 7, "end": 8}, "arguments": [{"entity_id": "19217693_2_Ent2", "role": "Effect", "text": "Persistent hypoglycemia", "start": 0, "end": 2}, {"entity_id": "19217693_2_Ent0", "role": "Subject", "text": "a patient with diabetes", "start": 3, "end": 7}, {"entity_id": "19217693_2_Ent1", "role": "Subject_Disorder", "text": "diabetes", "start": 6, "end": 7}, {"entity_id": "19217693_2_Ent3", "role": "Treatment", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent5", "role": "Treatment_Disorder", "text": "psoriasis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19217693_2_Ent2", "text": "Persistent hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19217693_2_Ent0", "text": "a patient with diabetes", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "19217693_2_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19217693_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent5", "text": "psoriasis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19224802_6", "wnd_id": "19224802_6_1", "text": "glycopyrrolate ( 5.0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure .", "tokens": ["glycopyrrolate", "(", "5.0", "microg", "/", "kg", ")", "not", "only", "resulting", "in", "resolution", "of", "bradycardia", "but", "also", "resulting", "in", "an", "exaggerated", "increase", "of", "arterial", "blood", "pressure", "."], "event_mentions": [{"id": "19224802_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 9, "end": 10}, "arguments": [{"entity_id": "19224802_6_Ent3", "role": "Treatment_Drug", "text": "glycopyrrolate", "start": 0, "end": 1}, {"entity_id": "19224802_6_Ent2", "role": "Treatment", "text": "glycopyrrolate ( 5.0 microg / kg )", "start": 0, "end": 7}, {"entity_id": "19224802_6_Ent4", "role": "Treatment_Dosage", "text": "5.0 microg / kg", "start": 2, "end": 6}, {"entity_id": "19224802_6_Ent0", "role": "Effect", "text": "resolution of bradycardia", "start": 11, "end": 14}, {"entity_id": "19224802_6_Ent1", "role": "Effect", "text": "an exaggerated increase of arterial blood pressure", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "19224802_6_Ent3", "text": "glycopyrrolate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_6_Ent2", "text": "glycopyrrolate ( 5.0 microg / kg )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19224802_6_Ent4", "text": "5.0 microg / kg", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19224802_6_Ent0", "text": "resolution of bradycardia", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19224802_6_Ent1", "text": "an exaggerated increase of arterial blood pressure", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "19249953_1", "wnd_id": "19249953_1_1", "text": "Rhabdomyolysis caused by a potential sitagliptin - lovastatin interaction .", "tokens": ["Rhabdomyolysis", "caused", "by", "a", "potential", "sitagliptin", "-", "lovastatin", "interaction", "."], "event_mentions": [{"id": "19249953_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "19249953_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "19249953_1_Ent1", "role": "Treatment", "text": "potential sitagliptin - lovastatin interaction", "start": 4, "end": 9}, {"entity_id": "19249953_1_Ent2", "role": "Treatment_Drug", "text": "sitagliptin", "start": 5, "end": 6}, {"entity_id": "19249953_1_Ent5", "role": "Combination_Drug", "text": "sitagliptin", "start": 5, "end": 6}, {"entity_id": "19249953_1_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 7, "end": 8}, {"entity_id": "19249953_1_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19249953_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19249953_1_Ent1", "text": "potential sitagliptin - lovastatin interaction", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "19249953_1_Ent2", "text": "sitagliptin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19249953_1_Ent5", "text": "sitagliptin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19249953_1_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19249953_1_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19249953_6", "wnd_id": "19249953_6_1", "text": "Because the patient had been taking lovastatin for the past 12 years , the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated .", "tokens": ["Because", "the", "patient", "had", "been", "taking", "lovastatin", "for", "the", "past", "12", "years", ",", "the", "possibility", "that", "the", "rhabdomyolysis", "may", "have", "been", "caused", "by", "a", "drug", "interaction", "between", "lovastatin", "and", "a", "concomitant", "drug", "was", "evaluated", "."], "event_mentions": [{"id": "19249953_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 21, "end": 22}, "arguments": [{"entity_id": "19249953_6_Ent0", "role": "Subject", "text": "the patient", "start": 1, "end": 3}, {"entity_id": "19249953_6_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 6, "end": 7}, {"entity_id": "19249953_6_Ent5", "role": "Treatment_Duration", "text": "12 years", "start": 10, "end": 12}, {"entity_id": "19249953_6_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 17, "end": 18}, {"entity_id": "19249953_6_Ent2", "role": "Treatment", "text": "lovastatin", "start": 27, "end": 28}, {"entity_id": "19249953_6_Ent4", "role": "Treatment_Drug", "text": "lovastatin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "19249953_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19249953_6_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19249953_6_Ent5", "text": "12 years", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19249953_6_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_6_Ent2", "text": "lovastatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19249953_6_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "19260037_5", "wnd_id": "19260037_5_1", "text": "We recommend that a TMA in association with quinine be consistently referred to as quinine - associated thrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP .", "tokens": ["We", "recommend", "that", "a", "TMA", "in", "association", "with", "quinine", "be", "consistently", "referred", "to", "as", "quinine", "-", "associated", "thrombotic", "microangiopathy", "(", "quinine", "-", "TMA", ")", "to", "better", "distinguish", "this", "entity", "from", "idiopathic", "TTP", "."], "event_mentions": [{"id": "19260037_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "19260037_5_Ent1", "role": "Treatment", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent0", "role": "Effect", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "19260037_5_Ent1", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent2", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent0", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "19281746_1", "wnd_id": "19281746_1_1", "text": "Aliskiren - associated acute renal failure with hyperkalemia .", "tokens": ["Aliskiren", "-", "associated", "acute", "renal", "failure", "with", "hyperkalemia", "."], "event_mentions": [{"id": "19281746_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19281746_1_Ent1", "role": "Treatment", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent2", "role": "Treatment_Drug", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "19281746_1_Ent1", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent2", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "19296063_3", "wnd_id": "19296063_3_1", "text": "We report the case of a 17 - year - old male who developed chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction following a single dose of methylphenidate .", "tokens": ["We", "report", "the", "case", "of", "a", "17", "-", "year", "-", "old", "male", "who", "developed", "chest", "pain", ",", "elevated", "cardiac", "biomarkers", ",", "and", "acute", "left", "ventricular", "dysfunction", "following", "a", "single", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "19296063_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 26, "end": 27}, "arguments": [{"entity_id": "19296063_3_Ent0", "role": "Subject", "text": "a 17 - year - old male", "start": 5, "end": 12}, {"entity_id": "19296063_3_Ent2", "role": "Subject_Age", "text": "17 - year - old", "start": 6, "end": 11}, {"entity_id": "19296063_3_Ent1", "role": "Subject_Gender", "text": "male", "start": 11, "end": 12}, {"entity_id": "19296063_3_Ent3", "role": "Effect", "text": "chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction", "start": 14, "end": 26}, {"entity_id": "19296063_3_Ent5", "role": "Treatment_Dosage", "text": "a single dose", "start": 27, "end": 30}, {"entity_id": "19296063_3_Ent4", "role": "Treatment", "text": "a single dose of methylphenidate", "start": 27, "end": 32}, {"entity_id": "19296063_3_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19296063_3_Ent0", "text": "a 17 - year - old male", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19296063_3_Ent2", "text": "17 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19296063_3_Ent1", "text": "male", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19296063_3_Ent3", "text": "chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction", "entity_type": "Entity", "start": 14, "end": 26}, {"id": "19296063_3_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "19296063_3_Ent4", "text": "a single dose of methylphenidate", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "19296063_3_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19299370_4", "wnd_id": "19299370_4_1", "text": "PURPOSE : A case of probable enoxaparin - induced hepatotoxicity is described .", "tokens": ["PURPOSE", ":", "A", "case", "of", "probable", "enoxaparin", "-", "induced", "hepatotoxicity", "is", "described", "."], "event_mentions": [{"id": "19299370_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19299370_4_Ent1", "role": "Treatment", "text": "enoxaparin", "start": 6, "end": 7}, {"entity_id": "19299370_4_Ent2", "role": "Treatment_Drug", "text": "enoxaparin", "start": 6, "end": 7}, {"entity_id": "19299370_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19299370_4_Ent1", "text": "enoxaparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19299370_4_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19299370_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19331262_4", "wnd_id": "19331262_4_1", "text": "This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome .", "tokens": ["This", "report", "describes", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "due", "to", "risperidone", "in", "a", "child", "with", "Joubert", "syndrome", "."], "event_mentions": [{"id": "19331262_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "19331262_4_Ent2", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 6, "end": 9}, {"entity_id": "19331262_4_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent0", "role": "Subject", "text": "a child with Joubert syndrome", "start": 13, "end": 18}, {"entity_id": "19331262_4_Ent1", "role": "Subject_Age", "text": "child", "start": 14, "end": 15}, {"entity_id": "19331262_4_Ent4", "role": "Treatment_Disorder", "text": "Joubert syndrome", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19331262_4_Ent2", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19331262_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent0", "text": "a child with Joubert syndrome", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19331262_4_Ent1", "text": "child", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19331262_4_Ent4", "text": "Joubert syndrome", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "19357764_1", "wnd_id": "19357764_1_1", "text": "CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute , Kampala , Uganda .", "tokens": ["CASE", "REPORT", ":", "We", "describe", "here", "a", "case", "of", "a", "60", "year", "old", "female", "that", "experienced", "a", "relapse", "of", "symptomatic", "hyperlactatemia", "after", "being", "switched", "from", "stavudine", "to", "zidovudine", "and", "how", "the", "case", "was", "managed", "at", "the", "Infectious", "Diseases", "Institute", ",", "Kampala", ",", "Uganda", "."], "event_mentions": [{"id": "19357764_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "19357764_1_Ent0", "role": "Subject", "text": "a case of a 60 year old female", "start": 6, "end": 14}, {"entity_id": "19357764_1_Ent1", "role": "Subject_Age", "text": "60 year old", "start": 10, "end": 13}, {"entity_id": "19357764_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 13, "end": 14}, {"entity_id": "19357764_1_Ent3", "role": "Effect", "text": "relapse of symptomatic hyperlactatemia", "start": 17, "end": 21}, {"entity_id": "19357764_1_Ent4", "role": "Treatment", "text": "switched from stavudine to zidovudine", "start": 23, "end": 28}, {"entity_id": "19357764_1_Ent5", "role": "Treatment_Drug", "text": "stavudine", "start": 25, "end": 26}, {"entity_id": "19357764_1_Ent6", "role": "Treatment_Drug", "text": "zidovudine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "19357764_1_Ent0", "text": "a case of a 60 year old female", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "19357764_1_Ent1", "text": "60 year old", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "19357764_1_Ent2", "text": "female", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19357764_1_Ent3", "text": "relapse of symptomatic hyperlactatemia", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "19357764_1_Ent4", "text": "switched from stavudine to zidovudine", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "19357764_1_Ent5", "text": "stavudine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19357764_1_Ent6", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "19363904_1", "wnd_id": "19363904_1_1", "text": "Anaphylactic reaction to bacitracin ointment .", "tokens": ["Anaphylactic", "reaction", "to", "bacitracin", "ointment", "."], "event_mentions": [{"id": "19363904_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 1, "end": 2}, "arguments": [{"entity_id": "19363904_1_Ent0", "role": "Effect", "text": "Anaphylactic", "start": 0, "end": 1}, {"entity_id": "19363904_1_Ent2", "role": "Treatment_Drug", "text": "bacitracin", "start": 3, "end": 4}, {"entity_id": "19363904_1_Ent1", "role": "Treatment", "text": "bacitracin ointment", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19363904_1_Ent0", "text": "Anaphylactic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19363904_1_Ent2", "text": "bacitracin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19363904_1_Ent1", "text": "bacitracin ointment", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19365885_2", "wnd_id": "19365885_2_1", "text": "Hypoglycemia induced by long - acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor .", "tokens": ["Hypoglycemia", "induced", "by", "long", "-", "acting", "somatostatin", "analogues", "in", "a", "patient", "with", "nonfunctional", "neuroendocrine", "tumor", "."], "event_mentions": [{"id": "19365885_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19365885_2_Ent1", "role": "Effect", "text": "Hypoglycemia", "start": 0, "end": 1}, {"entity_id": "19365885_2_Ent2", "role": "Treatment", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent4", "role": "Treatment_Drug", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent0", "role": "Subject", "text": "a patient with nonfunctional neuroendocrine tumor", "start": 9, "end": 15}, {"entity_id": "19365885_2_Ent3", "role": "Treatment_Disorder", "text": "nonfunctional neuroendocrine tumor", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "19365885_2_Ent1", "text": "Hypoglycemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19365885_2_Ent2", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent4", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent0", "text": "a patient with nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19365885_2_Ent3", "text": "nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "19423476_1", "wnd_id": "19423476_1_1", "text": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab : case report and review of the literature .", "tokens": ["Cryptococcus", "neoformans", "fatal", "sepsis", "in", "a", "chronic", "lymphocytic", "leukemia", "patient", "treated", "with", "alemtuzumab", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "19423476_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "19423476_1_Ent1", "role": "Effect", "text": "Cryptococcus neoformans fatal sepsis", "start": 0, "end": 4}, {"entity_id": "19423476_1_Ent0", "role": "Subject", "text": "a chronic lymphocytic leukemia patient", "start": 5, "end": 10}, {"entity_id": "19423476_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 6, "end": 9}, {"entity_id": "19423476_1_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 12, "end": 13}, {"entity_id": "19423476_1_Ent4", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19423476_1_Ent1", "text": "Cryptococcus neoformans fatal sepsis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19423476_1_Ent0", "text": "a chronic lymphocytic leukemia patient", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19423476_1_Ent3", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19423476_1_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19423476_1_Ent4", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19423476_4", "wnd_id": "19423476_4_1", "text": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab .", "tokens": ["We", "report", "a", "case", "of", "fatal", "C.", "neoformans", "fungemia", "in", "a", "neutropenic", "patient", "with", "a", "history", "of", "chronic", "lymphocytic", "leukemia", "treated", "with", "alemtuzumab", "."], "event_mentions": [{"id": "19423476_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 20, "end": 22}, "arguments": [{"entity_id": "19423476_4_Ent1", "role": "Effect", "text": "fatal C. neoformans fungemia", "start": 5, "end": 9}, {"entity_id": "19423476_4_Ent0", "role": "Subject", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "start": 10, "end": 20}, {"entity_id": "19423476_4_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 17, "end": 20}, {"entity_id": "19423476_4_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 22, "end": 23}, {"entity_id": "19423476_4_Ent3", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423476_4_Ent1", "text": "fatal C. neoformans fungemia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19423476_4_Ent0", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "19423476_4_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "19423476_4_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19423476_4_Ent3", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19423476_6", "wnd_id": "19423476_6_1", "text": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed .", "tokens": ["The", "international", "literature", "regarding", "opportunistic", "infections", "after", "immunosuppressive", "therapy", "with", "alemtuzumab", "with", "particular", "attention", "on", "fungal", "infections", "has", "also", "been", "reviewed", "."], "event_mentions": [{"id": "19423476_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "19423476_6_Ent0", "role": "Effect", "text": "opportunistic infections", "start": 4, "end": 6}, {"entity_id": "19423476_6_Ent1", "role": "Treatment", "text": "immunosuppressive therapy with alemtuzumab", "start": 7, "end": 11}, {"entity_id": "19423476_6_Ent2", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19423476_6_Ent0", "text": "opportunistic infections", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19423476_6_Ent1", "text": "immunosuppressive therapy with alemtuzumab", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "19423476_6_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19423610_1", "wnd_id": "19423610_1_1", "text": "Risk of severe serotonin toxicity following co - administration of methylene blue and serotonin reuptake inhibitors : an update on a case report of post - operative delirium .", "tokens": ["Risk", "of", "severe", "serotonin", "toxicity", "following", "co", "-", "administration", "of", "methylene", "blue", "and", "serotonin", "reuptake", "inhibitors", ":", "an", "update", "on", "a", "case", "report", "of", "post", "-", "operative", "delirium", "."], "event_mentions": [{"id": "19423610_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "19423610_1_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 3, "end": 5}, {"entity_id": "19423610_1_Ent2", "role": "Treatment", "text": "co - administration of methylene blue and serotonin reuptake inhibitors", "start": 6, "end": 16}, {"entity_id": "19423610_1_Ent3", "role": "Treatment_Drug", "text": "methylene blue", "start": 10, "end": 12}, {"entity_id": "19423610_1_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 10, "end": 12}, {"entity_id": "19423610_1_Ent4", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 13, "end": 16}, {"entity_id": "19423610_1_Ent6", "role": "Combination_Drug", "text": "serotonin reuptake inhibitors", "start": 13, "end": 16}, {"entity_id": "19423610_1_Ent1", "role": "Effect", "text": "post - operative delirium", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "19423610_1_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19423610_1_Ent2", "text": "co - administration of methylene blue and serotonin reuptake inhibitors", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "19423610_1_Ent3", "text": "methylene blue", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19423610_1_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19423610_1_Ent4", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19423610_1_Ent6", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19423610_1_Ent1", "text": "post - operative delirium", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "19434733_1", "wnd_id": "19434733_1_1", "text": "Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis .", "tokens": ["Secondary", "acute", "myeloid", "leukemia", "after", "etoposide", "therapy", "for", "haemophagocytic", "lymphohistiocytosis", "."], "event_mentions": [{"id": "19434733_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "19434733_1_Ent0", "role": "Effect", "text": "Secondary acute myeloid leukemia", "start": 0, "end": 4}, {"entity_id": "19434733_1_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_1_Ent1", "role": "Treatment", "text": "etoposide therapy", "start": 5, "end": 7}, {"entity_id": "19434733_1_Ent3", "role": "Treatment_Disorder", "text": "haemophagocytic lymphohistiocytosis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19434733_1_Ent0", "text": "Secondary acute myeloid leukemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19434733_1_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_1_Ent1", "text": "etoposide therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19434733_1_Ent3", "text": "haemophagocytic lymphohistiocytosis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19499966_5", "wnd_id": "19499966_5_1", "text": "The more common grade 3 or 4 adverse effects of sunitinib include hypertension , fatigue , hand - foot syndrome , elevated lipase and lymphopenia .", "tokens": ["The", "more", "common", "grade", "3", "or", "4", "adverse", "effects", "of", "sunitinib", "include", "hypertension", ",", "fatigue", ",", "hand", "-", "foot", "syndrome", ",", "elevated", "lipase", "and", "lymphopenia", "."], "event_mentions": [{"id": "19499966_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 7, "end": 9}, "arguments": [{"entity_id": "19499966_5_Ent1", "role": "Treatment", "text": "sunitinib", "start": 10, "end": 11}, {"entity_id": "19499966_5_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 10, "end": 11}, {"entity_id": "19499966_5_Ent0", "role": "Effect", "text": "hypertension , fatigue , hand - foot syndrome , elevated lipase and lymphopenia", "start": 12, "end": 25}]}], "entity_mentions": [{"id": "19499966_5_Ent1", "text": "sunitinib", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19499966_5_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19499966_5_Ent0", "text": "hypertension , fatigue , hand - foot syndrome , elevated lipase and lymphopenia", "entity_type": "Entity", "start": 12, "end": 25}], "lang": "en"}
{"doc_id": "19520277_2", "wnd_id": "19520277_2_1", "text": "The case of a 4 - year - old girl with valproate - induced stupor and electroencephalographic pattern of increased fast activity is reported .", "tokens": ["The", "case", "of", "a", "4", "-", "year", "-", "old", "girl", "with", "valproate", "-", "induced", "stupor", "and", "electroencephalographic", "pattern", "of", "increased", "fast", "activity", "is", "reported", "."], "event_mentions": [{"id": "19520277_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "19520277_2_Ent0", "role": "Subject", "text": "a 4 - year - old girl", "start": 3, "end": 10}, {"entity_id": "19520277_2_Ent1", "role": "Subject_Age", "text": "4 - year - old", "start": 4, "end": 9}, {"entity_id": "19520277_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 9, "end": 10}, {"entity_id": "19520277_2_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_2_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_2_Ent3", "role": "Effect", "text": "stupor and electroencephalographic pattern of increased fast activity", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "19520277_2_Ent0", "text": "a 4 - year - old girl", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "19520277_2_Ent1", "text": "4 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "19520277_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19520277_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_2_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_2_Ent3", "text": "stupor and electroencephalographic pattern of increased fast activity", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "19531695_13", "wnd_id": "19531695_13_1", "text": "Supratherapeutic flecainide plasma concentrations may cause delirium .", "tokens": ["Supratherapeutic", "flecainide", "plasma", "concentrations", "may", "cause", "delirium", "."], "event_mentions": [{"id": "19531695_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "19531695_13_Ent1", "role": "Treatment", "text": "Supratherapeutic flecainide plasma concentrations", "start": 0, "end": 4}, {"entity_id": "19531695_13_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 1, "end": 2}, {"entity_id": "19531695_13_Ent0", "role": "Effect", "text": "delirium", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "19531695_13_Ent1", "text": "Supratherapeutic flecainide plasma concentrations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19531695_13_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_13_Ent0", "text": "delirium", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "19531696_2", "wnd_id": "19531696_2_1", "text": "To report a probable interaction between warfarin and marijuana smoking , resulting in increased international normalized ratio ( INR ) values and bleeding complications .", "tokens": ["To", "report", "a", "probable", "interaction", "between", "warfarin", "and", "marijuana", "smoking", ",", "resulting", "in", "increased", "international", "normalized", "ratio", "(", "INR", ")", "values", "and", "bleeding", "complications", "."], "event_mentions": [{"id": "19531696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531696_2_Ent1", "role": "Treatment", "text": "interaction between warfarin and marijuana smoking", "start": 4, "end": 10}, {"entity_id": "19531696_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent3", "role": "Treatment_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent6", "role": "Combination_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent4", "role": "Treatment_Route", "text": "smoking", "start": 9, "end": 10}, {"entity_id": "19531696_2_Ent0", "role": "Effect", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "start": 13, "end": 24}]}], "entity_mentions": [{"id": "19531696_2_Ent1", "text": "interaction between warfarin and marijuana smoking", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "19531696_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent3", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent6", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent4", "text": "smoking", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531696_2_Ent0", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "entity_type": "Entity", "start": 13, "end": 24}], "lang": "en"}
{"doc_id": "19537383_4", "wnd_id": "19537383_4_1", "text": "This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy .", "tokens": ["This", "article", "presents", "a", "case", "of", "an", "atypical", "localized", "cutaneous", "eruption", "with", "an", "unusual", "course", "and", "protracted", "resolution", "time", "associated", "with", "sorafenib", "therapy", "."], "event_mentions": [{"id": "19537383_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 19, "end": 21}, "arguments": [{"entity_id": "19537383_4_Ent0", "role": "Effect", "text": "an atypical localized cutaneous eruption with an unusual course and protracted resolution time", "start": 6, "end": 19}, {"entity_id": "19537383_4_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 21, "end": 22}, {"entity_id": "19537383_4_Ent1", "role": "Treatment", "text": "sorafenib therapy", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19537383_4_Ent0", "text": "an atypical localized cutaneous eruption with an unusual course and protracted resolution time", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "19537383_4_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19537383_4_Ent1", "text": "sorafenib therapy", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "1954704_2", "wnd_id": "1954704_2_1", "text": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer .", "tokens": ["We", "report", "a", "case", "of", "biopsy", "proven", "myositis", "whose", "symptoms", "began", "within", "10", "days", "of", "receiving", "leuprolide", "acetate", "therapy", "for", "prostate", "cancer", "."], "event_mentions": [{"id": "1954704_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptoms began", "start": 9, "end": 11}, "arguments": [{"entity_id": "1954704_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1954704_2_Ent1", "role": "Effect", "text": "myositis", "start": 7, "end": 8}, {"entity_id": "1954704_2_Ent2", "role": "Treatment", "text": "within 10 days of receiving leuprolide acetate therapy", "start": 11, "end": 19}, {"entity_id": "1954704_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 12, "end": 14}, {"entity_id": "1954704_2_Ent3", "role": "Treatment_Drug", "text": "leuprolide acetate", "start": 16, "end": 18}, {"entity_id": "1954704_2_Ent5", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1954704_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1954704_2_Ent1", "text": "myositis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1954704_2_Ent2", "text": "within 10 days of receiving leuprolide acetate therapy", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "1954704_2_Ent4", "text": "10 days", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1954704_2_Ent3", "text": "leuprolide acetate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "1954704_2_Ent5", "text": "prostate cancer", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "19555801_1", "wnd_id": "19555801_1_1", "text": "Aripiprazole - induced hiccups : a case report .", "tokens": ["Aripiprazole", "-", "induced", "hiccups", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19555801_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19555801_1_Ent1", "role": "Treatment", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "19555801_1_Ent2", "role": "Treatment_Drug", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "19555801_1_Ent0", "role": "Effect", "text": "hiccups", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "19555801_1_Ent1", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19555801_1_Ent2", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19555801_1_Ent0", "text": "hiccups", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "19567656_1", "wnd_id": "19567656_1_1", "text": "CONCLUSIONS : This patient 's rhabdomyolysis was probably induced by sertraline therapy .", "tokens": ["CONCLUSIONS", ":", "This", "patient", "'s", "rhabdomyolysis", "was", "probably", "induced", "by", "sertraline", "therapy", "."], "event_mentions": [{"id": "19567656_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19567656_1_Ent0", "role": "Subject", "text": "This patient", "start": 2, "end": 4}, {"entity_id": "19567656_1_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "19567656_1_Ent2", "role": "Treatment", "text": "sertraline", "start": 10, "end": 11}, {"entity_id": "19567656_1_Ent3", "role": "Treatment_Drug", "text": "sertraline", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19567656_1_Ent0", "text": "This patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19567656_1_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19567656_1_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_1_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19687711_3", "wnd_id": "19687711_3_1", "text": "Although the association between SJS / TEN and the sulfonamide class of antibiotics is well established , the increasing prevalence of CA - MRSA has left practitioners with limited regimens to effectively treat skin and soft tissue infections ( SSTIs ) in the outpatient setting .", "tokens": ["Although", "the", "association", "between", "SJS", "/", "TEN", "and", "the", "sulfonamide", "class", "of", "antibiotics", "is", "well", "established", ",", "the", "increasing", "prevalence", "of", "CA", "-", "MRSA", "has", "left", "practitioners", "with", "limited", "regimens", "to", "effectively", "treat", "skin", "and", "soft", "tissue", "infections", "(", "SSTIs", ")", "in", "the", "outpatient", "setting", "."], "event_mentions": [{"id": "19687711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_3_Ent2", "role": "Effect", "text": "SJS / TEN", "start": 4, "end": 7}, {"entity_id": "19687711_3_Ent3", "role": "Treatment", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent4", "role": "Treatment_Drug", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent0", "role": "Subject", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent1", "role": "Subject_Disorder", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent5", "role": "Treatment_Disorder", "text": "skin and soft tissue infections ( SSTIs )", "start": 33, "end": 41}]}], "entity_mentions": [{"id": "19687711_3_Ent2", "text": "SJS / TEN", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19687711_3_Ent3", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent4", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent0", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent1", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent5", "text": "skin and soft tissue infections ( SSTIs )", "entity_type": "Entity", "start": 33, "end": 41}], "lang": "en"}
{"doc_id": "19687711_6", "wnd_id": "19687711_6_1", "text": "The potential development of SJS / TEN , a severe life - threatening illness , emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs .", "tokens": ["The", "potential", "development", "of", "SJS", "/", "TEN", ",", "a", "severe", "life", "-", "threatening", "illness", ",", "emphasizes", "the", "need", "for", "judicious", "use", "of", "TMP", "-", "Sx", "and", "close", "monitoring", "and", "follow", "-", "up", "for", "patients", "who", "were", "given", "TMP", "-", "Sx", "for", "SSTIs", "."], "event_mentions": [{"id": "19687711_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_6_Ent1", "role": "Effect", "text": "SJS / TEN , a severe life - threatening illness", "start": 4, "end": 14}, {"entity_id": "19687711_6_Ent0", "role": "Subject", "text": "patients", "start": 33, "end": 34}, {"entity_id": "19687711_6_Ent4", "role": "Treatment_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent6", "role": "Combination_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent2", "role": "Treatment", "text": "TMP - Sx", "start": 37, "end": 40}, {"entity_id": "19687711_6_Ent5", "role": "Treatment_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent7", "role": "Combination_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent3", "role": "Treatment_Disorder", "text": "SSTIs", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "19687711_6_Ent1", "text": "SJS / TEN , a severe life - threatening illness", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "19687711_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19687711_6_Ent4", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent6", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent2", "text": "TMP - Sx", "entity_type": "Entity", "start": 37, "end": 40}, {"id": "19687711_6_Ent5", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent7", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent3", "text": "SSTIs", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "19690222_1", "wnd_id": "19690222_1_1", "text": "CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH .", "tokens": ["CONCLUSIONS", ":", "Spontaneous", "hemothorax", "is", "a", "rare", "phenomenon", "in", "conjunction", "with", "LMWH", "but", "should", "be", "considered", "in", "cases", "of", "acute", "respiratory", "distress", "following", "commencement", "of", "LMWH", "."], "event_mentions": [{"id": "19690222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 15, "end": 16}, "arguments": [{"entity_id": "19690222_1_Ent0", "role": "Effect", "text": "Spontaneous hemothorax", "start": 2, "end": 4}, {"entity_id": "19690222_1_Ent2", "role": "Treatment", "text": "LMWH", "start": 11, "end": 12}, {"entity_id": "19690222_1_Ent3", "role": "Treatment_Drug", "text": "LMWH", "start": 11, "end": 12}, {"entity_id": "19690222_1_Ent1", "role": "Effect", "text": "acute respiratory distress", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19690222_1_Ent0", "text": "Spontaneous hemothorax", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19690222_1_Ent2", "text": "LMWH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19690222_1_Ent3", "text": "LMWH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19690222_1_Ent1", "text": "acute respiratory distress", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19707032_1", "wnd_id": "19707032_1_1", "text": "Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery .", "tokens": ["Acute", "ocular", "ischemic", "change", "may", "be", "associated", "with", "intravitreal", "injection", "of", "bevacizumab", "in", "patients", "with", "vascular", "compromised", "diabetic", "retinopathy", "and/or", "underlying", "stenosis", "of", "the", "carotid", "artery", "."], "event_mentions": [{"id": "19707032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "19707032_1_Ent3", "role": "Effect", "text": "Acute ocular ischemic change", "start": 0, "end": 4}, {"entity_id": "19707032_1_Ent6", "role": "Treatment_Dosage", "text": "intravitreal injection", "start": 8, "end": 10}, {"entity_id": "19707032_1_Ent4", "role": "Treatment", "text": "intravitreal injection of bevacizumab", "start": 8, "end": 12}, {"entity_id": "19707032_1_Ent5", "role": "Treatment_Drug", "text": "bevacizumab", "start": 11, "end": 12}, {"entity_id": "19707032_1_Ent0", "role": "Subject", "text": "patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery", "start": 13, "end": 26}, {"entity_id": "19707032_1_Ent1", "role": "Subject_Disorder", "text": "vascular compromised diabetic retinopathy", "start": 15, "end": 19}, {"entity_id": "19707032_1_Ent2", "role": "Subject_Disorder", "text": "underlying stenosis of the carotid artery", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "19707032_1_Ent3", "text": "Acute ocular ischemic change", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19707032_1_Ent6", "text": "intravitreal injection", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "19707032_1_Ent4", "text": "intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "19707032_1_Ent5", "text": "bevacizumab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19707032_1_Ent0", "text": "patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "19707032_1_Ent1", "text": "vascular compromised diabetic retinopathy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19707032_1_Ent2", "text": "underlying stenosis of the carotid artery", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "19745701_3", "wnd_id": "19745701_3_1", "text": "She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by MTX administration .", "tokens": ["She", "was", "diagnosed", "with", "Epstein", "-", "Barr", "virus", "-", "associated", "polymorphic", "lymphoproliferative", "disorder", "(", "LPD", ")", "due", "to", "immunodeficiency", "caused", "by", "MTX", "administration", "."], "event_mentions": [{"id": "19745701_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 16, "end": 17}, "arguments": [{"entity_id": "19745701_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent2", "role": "Effect", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "start": 4, "end": 16}, {"entity_id": "19745701_3_Ent3", "role": "Treatment", "text": "immunodeficiency caused by MTX administration", "start": 18, "end": 23}, {"entity_id": "19745701_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19745701_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent2", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "19745701_3_Ent3", "text": "immunodeficiency caused by MTX administration", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "19745701_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19754002_4", "wnd_id": "19754002_4_1", "text": "The allergic reaction started to develop after co - administration of pravastatin .", "tokens": ["The", "allergic", "reaction", "started", "to", "develop", "after", "co", "-", "administration", "of", "pravastatin", "."], "event_mentions": [{"id": "19754002_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 5, "end": 6}, "arguments": [{"entity_id": "19754002_4_Ent0", "role": "Effect", "text": "allergic reaction", "start": 1, "end": 3}, {"entity_id": "19754002_4_Ent1", "role": "Treatment", "text": "co - administration of pravastatin", "start": 7, "end": 12}, {"entity_id": "19754002_4_Ent2", "role": "Treatment_Drug", "text": "pravastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19754002_4_Ent0", "text": "allergic reaction", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19754002_4_Ent1", "text": "co - administration of pravastatin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19754002_4_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19775485_2", "wnd_id": "19775485_2_1", "text": "We report here a case of cardiovascular and neurological depression induced by oxymetalzoline in a toddler .", "tokens": ["We", "report", "here", "a", "case", "of", "cardiovascular", "and", "neurological", "depression", "induced", "by", "oxymetalzoline", "in", "a", "toddler", "."], "event_mentions": [{"id": "19775485_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19775485_2_Ent2", "role": "Effect", "text": "cardiovascular and neurological depression", "start": 6, "end": 10}, {"entity_id": "19775485_2_Ent3", "role": "Treatment", "text": "oxymetalzoline", "start": 12, "end": 13}, {"entity_id": "19775485_2_Ent4", "role": "Treatment_Drug", "text": "oxymetalzoline", "start": 12, "end": 13}, {"entity_id": "19775485_2_Ent0", "role": "Subject", "text": "a toddler", "start": 14, "end": 16}, {"entity_id": "19775485_2_Ent1", "role": "Subject_Age", "text": "toddler", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "19775485_2_Ent2", "text": "cardiovascular and neurological depression", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19775485_2_Ent3", "text": "oxymetalzoline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19775485_2_Ent4", "text": "oxymetalzoline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19775485_2_Ent0", "text": "a toddler", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19775485_2_Ent1", "text": "toddler", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1977935_6", "wnd_id": "1977935_6_1", "text": "We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose .", "tokens": ["We", "believe", "that", "a", "drug", "interaction", "between", "terfenadine", "and", "ketoconazole", "resulted", "in", "the", "elevated", "terfenadine", "levels", "in", "plasma", "and", "in", "the", "cardiotoxicity", "previously", "seen", "only", "in", "cases", "of", "terfenadine", "overdose", "."], "event_mentions": [{"id": "1977935_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 10, "end": 11}, "arguments": [{"entity_id": "1977935_6_Ent1", "role": "Treatment", "text": "a drug interaction between terfenadine and ketoconazole", "start": 3, "end": 10}, {"entity_id": "1977935_6_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_6_Ent4", "role": "Combination_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_6_Ent3", "role": "Treatment_Drug", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "1977935_6_Ent5", "role": "Combination_Drug", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "1977935_6_Ent0", "role": "Effect", "text": "the elevated terfenadine levels in plasma and in the cardiotoxicity", "start": 12, "end": 22}]}], "entity_mentions": [{"id": "1977935_6_Ent1", "text": "a drug interaction between terfenadine and ketoconazole", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "1977935_6_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_6_Ent4", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_6_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1977935_6_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1977935_6_Ent0", "text": "the elevated terfenadine levels in plasma and in the cardiotoxicity", "entity_type": "Entity", "start": 12, "end": 22}], "lang": "en"}
{"doc_id": "19782276_10", "wnd_id": "19782276_10_1", "text": "Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs .", "tokens": ["Concomitant", "administration", "of", "cytarabine", "might", "have", "affected", "his", "liver", "function", "and", "there", "might", "have", "been", "interaction", "between", "the", "drugs", "."], "event_mentions": [{"id": "19782276_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "affected", "start": 6, "end": 7}, "arguments": [{"entity_id": "19782276_10_Ent1", "role": "Treatment", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent0", "role": "Effect", "text": "liver function", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19782276_10_Ent1", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent0", "text": "liver function", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19789166_1", "wnd_id": "19789166_1_1", "text": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels , restoring most of them to normal , we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin .", "tokens": ["Given", "that", "discontinuation", "of", "nitrofurantoin", "and", "introduction", "of", "methylprednisolon", "therapy", "significantly", "lowered", "liver", "enzyme", "levels", ",", "restoring", "most", "of", "them", "to", "normal", ",", "we", "concluded", "that", "this", "was", "probably", "the", "case", "of", "toxic", "liver", "damage", "caused", "by", "nitrofurantoin", "."], "event_mentions": [{"id": "19789166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 35, "end": 36}, "arguments": [{"entity_id": "19789166_1_Ent0", "role": "Effect", "text": "toxic liver damage", "start": 32, "end": 35}, {"entity_id": "19789166_1_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 37, "end": 38}, {"entity_id": "19789166_1_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "19789166_1_Ent0", "text": "toxic liver damage", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "19789166_1_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19789166_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "19798640_1", "wnd_id": "19798640_1_1", "text": "A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( PCNSL ) after having received 21 doses of natalizumab monotherapy .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "relapsing", "-", "remitting", "multiple", "sclerosis", "(", "MS", ")", "developed", "primary", "central", "nervous", "system", "lymphoma", "(", "PCNSL", ")", "after", "having", "received", "21", "doses", "of", "natalizumab", "monotherapy", "."], "event_mentions": [{"id": "19798640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "19798640_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "19798640_1_Ent0", "role": "Subject", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "start": 1, "end": 16}, {"entity_id": "19798640_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19798640_1_Ent5", "role": "Treatment_Disorder", "text": "relapsing - remitting multiple sclerosis ( MS )", "start": 8, "end": 16}, {"entity_id": "19798640_1_Ent3", "role": "Effect", "text": "primary central nervous system lymphoma ( PCNSL )", "start": 17, "end": 25}, {"entity_id": "19798640_1_Ent6", "role": "Treatment_Dosage", "text": "21 doses", "start": 28, "end": 30}, {"entity_id": "19798640_1_Ent4", "role": "Treatment", "text": "21 doses of natalizumab monotherapy", "start": 28, "end": 33}, {"entity_id": "19798640_1_Ent7", "role": "Treatment_Drug", "text": "natalizumab", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19798640_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19798640_1_Ent0", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "19798640_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19798640_1_Ent5", "text": "relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "19798640_1_Ent3", "text": "primary central nervous system lymphoma ( PCNSL )", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "19798640_1_Ent6", "text": "21 doses", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "19798640_1_Ent4", "text": "21 doses of natalizumab monotherapy", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "19798640_1_Ent7", "text": "natalizumab", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19798640_2", "wnd_id": "19798640_2_1", "text": "Primary central nervous system lymphoma in a patient treated with natalizumab .", "tokens": ["Primary", "central", "nervous", "system", "lymphoma", "in", "a", "patient", "treated", "with", "natalizumab", "."], "event_mentions": [{"id": "19798640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "19798640_2_Ent1", "role": "Effect", "text": "Primary central nervous system lymphoma", "start": 0, "end": 5}, {"entity_id": "19798640_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "19798640_2_Ent2", "role": "Treatment", "text": "natalizumab", "start": 10, "end": 11}, {"entity_id": "19798640_2_Ent3", "role": "Treatment_Drug", "text": "natalizumab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19798640_2_Ent1", "text": "Primary central nervous system lymphoma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19798640_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19798640_2_Ent2", "text": "natalizumab", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19798640_2_Ent3", "text": "natalizumab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19826099_1", "wnd_id": "19826099_1_1", "text": "OBJECTIVE : To report a case of severe apnea in an infant exposed to lamotrigine through breast - feeding .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "severe", "apnea", "in", "an", "infant", "exposed", "to", "lamotrigine", "through", "breast", "-", "feeding", "."], "event_mentions": [{"id": "19826099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "19826099_1_Ent2", "role": "Effect", "text": "severe apnea", "start": 7, "end": 9}, {"entity_id": "19826099_1_Ent0", "role": "Subject", "text": "an infant", "start": 10, "end": 12}, {"entity_id": "19826099_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "19826099_1_Ent3", "role": "Treatment", "text": "exposed to lamotrigine through breast - feeding", "start": 12, "end": 19}, {"entity_id": "19826099_1_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "19826099_1_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "19826099_1_Ent2", "text": "severe apnea", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19826099_1_Ent0", "text": "an infant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19826099_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19826099_1_Ent3", "text": "exposed to lamotrigine through breast - feeding", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19826099_1_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19826099_1_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "19844714_1", "wnd_id": "19844714_1_1", "text": "RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin - based regimen , developed a platinum hypersensitivity .", "tokens": ["RESULTS", ":", "One", "case", "of", "recurrent", "primary", "peritoneal", "carcinoma", "previously", "treated", "with", "a", "carboplatin", "-", "based", "regimen", ",", "developed", "a", "platinum", "hypersensitivity", "."], "event_mentions": [{"id": "19844714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19844714_1_Ent3", "role": "Treatment_Disorder", "text": "recurrent primary peritoneal carcinoma", "start": 5, "end": 9}, {"entity_id": "19844714_1_Ent1", "role": "Treatment", "text": "a carboplatin - based regimen", "start": 12, "end": 17}, {"entity_id": "19844714_1_Ent2", "role": "Treatment_Drug", "text": "carboplatin", "start": 13, "end": 14}, {"entity_id": "19844714_1_Ent0", "role": "Effect", "text": "a platinum hypersensitivity", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19844714_1_Ent3", "text": "recurrent primary peritoneal carcinoma", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19844714_1_Ent1", "text": "a carboplatin - based regimen", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19844714_1_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19844714_1_Ent0", "text": "a platinum hypersensitivity", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19857154_4", "wnd_id": "19857154_4_1", "text": "We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir - boosted atazanavir .", "tokens": ["We", "describe", "two", "patients", "who", "experienced", "serious", "quetiapine", "adverse", "effects", "potentially", "mediated", "through", "an", "interaction", "with", "ritonavir", "-", "boosted", "atazanavir", "."], "event_mentions": [{"id": "19857154_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "19857154_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "19857154_4_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "19857154_4_Ent2", "role": "Effect", "text": "serious quetiapine adverse effects", "start": 6, "end": 10}, {"entity_id": "19857154_4_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent6", "role": "Combination_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent3", "role": "Treatment", "text": "ritonavir - boosted atazanavir", "start": 16, "end": 20}, {"entity_id": "19857154_4_Ent5", "role": "Treatment_Drug", "text": "atazanavir", "start": 19, "end": 20}, {"entity_id": "19857154_4_Ent7", "role": "Combination_Drug", "text": "atazanavir", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19857154_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19857154_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19857154_4_Ent2", "text": "serious quetiapine adverse effects", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19857154_4_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent3", "text": "ritonavir - boosted atazanavir", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "19857154_4_Ent5", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19857154_4_Ent7", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19875411_1", "wnd_id": "19875411_1_1", "text": "One week after the initial - dose of adalimumab ( 160 mg ) , which was initiated due to an acute exacerbation of Crohn 's disease , the patient developed a fulminant cardiomyopathy .", "tokens": ["One", "week", "after", "the", "initial", "-", "dose", "of", "adalimumab", "(", "160", "mg", ")", ",", "which", "was", "initiated", "due", "to", "an", "acute", "exacerbation", "of", "Crohn", "'s", "disease", ",", "the", "patient", "developed", "a", "fulminant", "cardiomyopathy", "."], "event_mentions": [{"id": "19875411_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "19875411_1_Ent6", "role": "Treatment_Time_elapsed", "text": "One week", "start": 0, "end": 2}, {"entity_id": "19875411_1_Ent2", "role": "Treatment", "text": "One week after the initial - dose of adalimumab ( 160 mg )", "start": 0, "end": 13}, {"entity_id": "19875411_1_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 8, "end": 9}, {"entity_id": "19875411_1_Ent5", "role": "Treatment_Dosage", "text": "160 mg", "start": 10, "end": 12}, {"entity_id": "19875411_1_Ent0", "role": "Subject", "text": "an acute exacerbation of Crohn 's disease , the patient", "start": 19, "end": 29}, {"entity_id": "19875411_1_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 23, "end": 26}, {"entity_id": "19875411_1_Ent1", "role": "Effect", "text": "fulminant cardiomyopathy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "19875411_1_Ent6", "text": "One week", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19875411_1_Ent2", "text": "One week after the initial - dose of adalimumab ( 160 mg )", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "19875411_1_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19875411_1_Ent5", "text": "160 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19875411_1_Ent0", "text": "an acute exacerbation of Crohn 's disease , the patient", "entity_type": "Entity", "start": 19, "end": 29}, {"id": "19875411_1_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19875411_1_Ent1", "text": "fulminant cardiomyopathy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "19884751_3", "wnd_id": "19884751_3_1", "text": "We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria .", "tokens": ["We", "discuss", "a", "patient", "who", "developed", "severe", "renal", "tubular", "dysfunction", "secondary", "to", "short", "-", "term", "therapy", "with", "Amikacin", ",", "resulting", "in", "refractory", "hypokalemia", ",", "hypocalcemia", ",", "hypomagnesemia", ",", "metabolic", "alkalosis", ",", "and", "polyuria", "."], "event_mentions": [{"id": "19884751_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "19884751_3_Ent0", "role": "Effect", "text": "severe renal tubular dysfunction", "start": 6, "end": 10}, {"entity_id": "19884751_3_Ent4", "role": "Treatment_Duration", "text": "short - term", "start": 12, "end": 15}, {"entity_id": "19884751_3_Ent2", "role": "Treatment", "text": "short - term therapy with Amikacin", "start": 12, "end": 18}, {"entity_id": "19884751_3_Ent3", "role": "Treatment_Drug", "text": "Amikacin", "start": 17, "end": 18}, {"entity_id": "19884751_3_Ent1", "role": "Effect", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "19884751_3_Ent0", "text": "severe renal tubular dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19884751_3_Ent4", "text": "short - term", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "19884751_3_Ent2", "text": "short - term therapy with Amikacin", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19884751_3_Ent3", "text": "Amikacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19884751_3_Ent1", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "19892516_1", "wnd_id": "19892516_1_1", "text": "Ciprofloxacin - induced hemorrhagic vasculitis .", "tokens": ["Ciprofloxacin", "-", "induced", "hemorrhagic", "vasculitis", "."], "event_mentions": [{"id": "19892516_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19892516_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "19892516_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "19892516_1_Ent0", "role": "Effect", "text": "hemorrhagic vasculitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19892516_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19892516_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19892516_1_Ent0", "text": "hemorrhagic vasculitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19934385_2", "wnd_id": "19934385_2_1", "text": "To report the results of therapeutic drug monitoring of lopinavir / ritonavir and itraconazole concentrations in an HIV - infected male who was treated for histoplasmosis .", "tokens": ["To", "report", "the", "results", "of", "therapeutic", "drug", "monitoring", "of", "lopinavir", "/", "ritonavir", "and", "itraconazole", "concentrations", "in", "an", "HIV", "-", "infected", "male", "who", "was", "treated", "for", "histoplasmosis", "."], "event_mentions": [{"id": "19934385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 23, "end": 24}, "arguments": [{"entity_id": "19934385_2_Ent7", "role": "Treatment_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent8", "role": "Combination_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent2", "role": "Treatment", "text": "lopinavir / ritonavir and itraconazole concentrations", "start": 9, "end": 15}, {"entity_id": "19934385_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent5", "role": "Treatment_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent10", "role": "Combination_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent0", "role": "Subject", "text": "an HIV - infected male", "start": 16, "end": 21}, {"entity_id": "19934385_2_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 17, "end": 18}, {"entity_id": "19934385_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 20, "end": 21}, {"entity_id": "19934385_2_Ent3", "role": "Treatment_Disorder", "text": "histoplasmosis", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19934385_2_Ent7", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent8", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent2", "text": "lopinavir / ritonavir and itraconazole concentrations", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19934385_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent10", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent0", "text": "an HIV - infected male", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19934385_2_Ent4", "text": "HIV", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_2_Ent1", "text": "male", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19934385_2_Ent3", "text": "histoplasmosis", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19949685_1", "wnd_id": "19949685_1_1", "text": "Colonic mucosal necrosis following administration of calcium polystryrene sulfonate ( Kalimate ) in a uremic patient .", "tokens": ["Colonic", "mucosal", "necrosis", "following", "administration", "of", "calcium", "polystryrene", "sulfonate", "(", "Kalimate", ")", "in", "a", "uremic", "patient", "."], "event_mentions": [{"id": "19949685_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 4, "end": 5}, "arguments": [{"entity_id": "19949685_1_Ent1", "role": "Effect", "text": "Colonic mucosal necrosis", "start": 0, "end": 3}, {"entity_id": "19949685_1_Ent3", "role": "Treatment_Drug", "text": "calcium polystryrene sulfonate", "start": 6, "end": 9}, {"entity_id": "19949685_1_Ent2", "role": "Treatment", "text": "calcium polystryrene sulfonate ( Kalimate )", "start": 6, "end": 12}, {"entity_id": "19949685_1_Ent4", "role": "Treatment_Disorder", "text": "uremic", "start": 14, "end": 15}, {"entity_id": "19949685_1_Ent0", "role": "Subject", "text": "uremic patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19949685_1_Ent1", "text": "Colonic mucosal necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19949685_1_Ent3", "text": "calcium polystryrene sulfonate", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_1_Ent2", "text": "calcium polystryrene sulfonate ( Kalimate )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "19949685_1_Ent4", "text": "uremic", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19949685_1_Ent0", "text": "uremic patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19949685_4", "wnd_id": "19949685_4_1", "text": "We report a rare case of colonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol in a 34 - yr - old man .", "tokens": ["We", "report", "a", "rare", "case", "of", "colonic", "mucosal", "necrosis", "following", "Kalimate", "(", "calcium", "polystryrene", "sulfonate", ")", ",", "an", "analogue", "of", "Kayexalate", "without", "sorbitol", "in", "a", "34", "-", "yr", "-", "old", "man", "."], "event_mentions": [{"id": "19949685_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "19949685_4_Ent3", "role": "Effect", "text": "colonic mucosal necrosis", "start": 6, "end": 9}, {"entity_id": "19949685_4_Ent5", "role": "Treatment_Drug", "text": "Kalimate", "start": 10, "end": 11}, {"entity_id": "19949685_4_Ent4", "role": "Treatment", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "start": 10, "end": 23}, {"entity_id": "19949685_4_Ent6", "role": "Treatment_Drug", "text": "( calcium polystryrene sulfonate )", "start": 11, "end": 16}, {"entity_id": "19949685_4_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 20, "end": 21}, {"entity_id": "19949685_4_Ent0", "role": "Subject", "text": "a 34 - yr - old man", "start": 24, "end": 31}, {"entity_id": "19949685_4_Ent1", "role": "Subject_Age", "text": "34 - yr - old", "start": 25, "end": 30}, {"entity_id": "19949685_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19949685_4_Ent3", "text": "colonic mucosal necrosis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_4_Ent5", "text": "Kalimate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19949685_4_Ent4", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "19949685_4_Ent6", "text": "( calcium polystryrene sulfonate )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19949685_4_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19949685_4_Ent0", "text": "a 34 - yr - old man", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "19949685_4_Ent1", "text": "34 - yr - old", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "19949685_4_Ent2", "text": "man", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19995222_1", "wnd_id": "19995222_1_1", "text": "Clozapine - induced tardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug .", "tokens": ["Clozapine", "-", "induced", "tardive", "dyskinesia", "in", "schizophrenic", "patients", "taking", "clozapine", "as", "a", "first", "-", "line", "antipsychotic", "drug", "."], "event_mentions": [{"id": "19995222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19995222_1_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent3", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 3, "end": 5}, {"entity_id": "19995222_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 6, "end": 7}, {"entity_id": "19995222_1_Ent0", "role": "Subject", "text": "schizophrenic patients", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "19995222_1_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19995222_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_1_Ent0", "text": "schizophrenic patients", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "19995690_4", "wnd_id": "19995690_4_1", "text": "We report a case of a 34 - year - old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen .", "tokens": ["We", "report", "a", "case", "of", "a", "34", "-", "year", "-", "old", "man", "on", "carbamazepine", "for", "complex", "partial", "seizures", "who", "developed", "acute", "liver", "and", "renal", "failure", "on", "less", "than", "2.5", "grams", "a", "day", "of", "acetaminophen", "."], "event_mentions": [{"id": "19995690_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 12, "end": 13}, "arguments": [{"entity_id": "19995690_4_Ent0", "role": "Subject", "text": "a 34 - year - old man", "start": 5, "end": 12}, {"entity_id": "19995690_4_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 6, "end": 11}, {"entity_id": "19995690_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "19995690_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent12", "role": "Combination_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent8", "role": "Treatment_Disorder", "text": "complex partial seizures", "start": 15, "end": 18}, {"entity_id": "19995690_4_Ent3", "role": "Effect", "text": "acute liver and renal failure", "start": 20, "end": 25}, {"entity_id": "19995690_4_Ent9", "role": "Treatment_Dosage", "text": "less than 2.5 grams", "start": 26, "end": 30}, {"entity_id": "19995690_4_Ent5", "role": "Treatment", "text": "less than 2.5 grams a day of acetaminophen", "start": 26, "end": 34}, {"entity_id": "19995690_4_Ent10", "role": "Treatment_Freq", "text": "a day", "start": 30, "end": 32}, {"entity_id": "19995690_4_Ent7", "role": "Treatment_Drug", "text": "acetaminophen", "start": 33, "end": 34}, {"entity_id": "19995690_4_Ent11", "role": "Combination_Drug", "text": "acetaminophen", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "19995690_4_Ent0", "text": "a 34 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19995690_4_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19995690_4_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19995690_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent12", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent8", "text": "complex partial seizures", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19995690_4_Ent3", "text": "acute liver and renal failure", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "19995690_4_Ent9", "text": "less than 2.5 grams", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "19995690_4_Ent5", "text": "less than 2.5 grams a day of acetaminophen", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "19995690_4_Ent10", "text": "a day", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19995690_4_Ent7", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19995690_4_Ent11", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "20009973_2", "wnd_id": "20009973_2_1", "text": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis , synovitis , and possible vasculitis , after receiving all - trans retinoic acid therapy .", "tokens": ["Here", "we", "report", "a", "patient", "with", "newly", "diagnosed", "acute", "promyelocytic", "leukemia", "who", "developed", "acute", "focal", "myositis", ",", "synovitis", ",", "and", "possible", "vasculitis", ",", "after", "receiving", "all", "-", "trans", "retinoic", "acid", "therapy", "."], "event_mentions": [{"id": "20009973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "20009973_2_Ent0", "role": "Subject", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "start": 3, "end": 11}, {"entity_id": "20009973_2_Ent3", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 8, "end": 11}, {"entity_id": "20009973_2_Ent1", "role": "Effect", "text": "acute focal myositis , synovitis , and possible vasculitis", "start": 13, "end": 22}, {"entity_id": "20009973_2_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 25, "end": 30}, {"entity_id": "20009973_2_Ent4", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "20009973_2_Ent0", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "20009973_2_Ent3", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20009973_2_Ent1", "text": "acute focal myositis , synovitis , and possible vasculitis", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "20009973_2_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "20009973_2_Ent4", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "20038831_3", "wnd_id": "20038831_3_1", "text": "Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin .", "tokens": ["Prick", "tests", "and", "intradermal", "tests", "with", "a", "series", "of", "dilutions", "of", "carboplatin", "and", "cisplatin", "were", "performed", "on", "three", "patients", "who", "had", "exhibited", "medium", "and", "severe", "hypersensitivity", "reactions", "to", "carboplatin", "."], "event_mentions": [{"id": "20038831_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 21, "end": 22}, "arguments": [{"entity_id": "20038831_3_Ent0", "role": "Subject", "text": "three patients", "start": 17, "end": 19}, {"entity_id": "20038831_3_Ent1", "role": "Effect", "text": "medium and severe hypersensitivity reactions", "start": 22, "end": 27}, {"entity_id": "20038831_3_Ent2", "role": "Treatment", "text": "carboplatin", "start": 28, "end": 29}, {"entity_id": "20038831_3_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "20038831_3_Ent0", "text": "three patients", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "20038831_3_Ent1", "text": "medium and severe hypersensitivity reactions", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "20038831_3_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "20038831_3_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "20065266_1", "wnd_id": "20065266_1_1", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole .", "tokens": ["Aseptic", "meningitis", ",", "hemolytic", "anemia", ",", "hepatitis", ",", "and", "orthostatic", "hypotension", "in", "a", "patient", "treated", "with", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "20065266_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "20065266_1_Ent1", "role": "Effect", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension", "start": 0, "end": 11}, {"entity_id": "20065266_1_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "20065266_1_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "20065266_1_Ent5", "role": "Combination_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "20065266_1_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 16, "end": 19}, {"entity_id": "20065266_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}, {"entity_id": "20065266_1_Ent6", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20065266_1_Ent1", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "20065266_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "20065266_1_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20065266_1_Ent5", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20065266_1_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "20065266_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20065266_1_Ent6", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2006943_1", "wnd_id": "2006943_1_1", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block ) during ritodrine therapy for preterm labor .", "tokens": ["Type", "I", "second", "-", "degree", "AV", "block", "(", "Mobitz", "type", "I", ",", "Wenckebach", "AV", "block", ")", "during", "ritodrine", "therapy", "for", "preterm", "labor", "."], "event_mentions": [{"id": "2006943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 16, "end": 17}, "arguments": [{"entity_id": "2006943_1_Ent0", "role": "Effect", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "start": 0, "end": 16}, {"entity_id": "2006943_1_Ent1", "role": "Treatment", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent3", "role": "Treatment_Drug", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent2", "role": "Treatment_Disorder", "text": "preterm labor", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2006943_1_Ent0", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "2006943_1_Ent1", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent3", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent2", "text": "preterm labor", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "2006943_2", "wnd_id": "2006943_2_1", "text": "A patient , while on intravenous ritodrine therapy for preterm labor , experienced an episode of acute chest pain .", "tokens": ["A", "patient", ",", "while", "on", "intravenous", "ritodrine", "therapy", "for", "preterm", "labor", ",", "experienced", "an", "episode", "of", "acute", "chest", "pain", "."], "event_mentions": [{"id": "2006943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 4, "end": 5}, "arguments": [{"entity_id": "2006943_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "2006943_2_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "2006943_2_Ent2", "role": "Treatment", "text": "intravenous ritodrine therapy", "start": 5, "end": 8}, {"entity_id": "2006943_2_Ent4", "role": "Treatment_Drug", "text": "ritodrine", "start": 6, "end": 7}, {"entity_id": "2006943_2_Ent1", "role": "Effect", "text": "an episode of acute chest pain", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "2006943_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2006943_2_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2006943_2_Ent2", "text": "intravenous ritodrine therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2006943_2_Ent4", "text": "ritodrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2006943_2_Ent1", "text": "an episode of acute chest pain", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "2011096_1", "wnd_id": "2011096_1_1", "text": "Bulbar and pseudobulbar palsy complicating therapy with high - dose cytosine arabinoside in children with leukemia .", "tokens": ["Bulbar", "and", "pseudobulbar", "palsy", "complicating", "therapy", "with", "high", "-", "dose", "cytosine", "arabinoside", "in", "children", "with", "leukemia", "."], "event_mentions": [{"id": "2011096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "2011096_1_Ent2", "role": "Effect", "text": "Bulbar and pseudobulbar palsy", "start": 0, "end": 4}, {"entity_id": "2011096_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2011096_1_Ent3", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 7, "end": 12}, {"entity_id": "2011096_1_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 10, "end": 12}, {"entity_id": "2011096_1_Ent1", "role": "Subject_Age", "text": "children", "start": 13, "end": 14}, {"entity_id": "2011096_1_Ent0", "role": "Subject", "text": "children with leukemia", "start": 13, "end": 16}, {"entity_id": "2011096_1_Ent6", "role": "Treatment_Disorder", "text": "leukemia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2011096_1_Ent2", "text": "Bulbar and pseudobulbar palsy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2011096_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2011096_1_Ent3", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2011096_1_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2011096_1_Ent1", "text": "children", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2011096_1_Ent0", "text": "children with leukemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "2011096_1_Ent6", "text": "leukemia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20126479_1", "wnd_id": "20126479_1_1", "text": "CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss .", "tokens": ["CONCLUSIONS", ":", "SD", "-", "OCT", "and", "AO", "detected", "abnormalities", "that", "correlate", "topographically", "with", "visual", "field", "loss", "from", "hydroxychloroquine", "toxicity", "as", "demonstrated", "by", "HVF", "10", "-", "2", "and", "may", "be", "useful", "in", "the", "detection", "of", "subclinical", "abnormalities", "that", "precede", "symptoms", "or", "objective", "visual", "field", "loss", "."], "event_mentions": [{"id": "20126479_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 16, "end": 17}, "arguments": [{"entity_id": "20126479_1_Ent0", "role": "Effect", "text": "visual field loss", "start": 13, "end": 16}, {"entity_id": "20126479_1_Ent1", "role": "Treatment", "text": "hydroxychloroquine", "start": 17, "end": 18}, {"entity_id": "20126479_1_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "20126479_1_Ent0", "text": "visual field loss", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "20126479_1_Ent1", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20126479_1_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2012922_2", "wnd_id": "2012922_2_1", "text": "Trazodone - induced transient hypomanic symptoms and their management .", "tokens": ["Trazodone", "-", "induced", "transient", "hypomanic", "symptoms", "and", "their", "management", "."], "event_mentions": [{"id": "2012922_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2012922_2_Ent1", "role": "Treatment", "text": "Trazodone", "start": 0, "end": 1}, {"entity_id": "2012922_2_Ent2", "role": "Treatment_Drug", "text": "Trazodone", "start": 0, "end": 1}, {"entity_id": "2012922_2_Ent0", "role": "Effect", "text": "transient hypomanic symptoms", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "2012922_2_Ent1", "text": "Trazodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2012922_2_Ent2", "text": "Trazodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2012922_2_Ent0", "text": "transient hypomanic symptoms", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "20130478_2", "wnd_id": "20130478_2_1", "text": "Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis .", "tokens": ["Reversible", "heart", "failure", "in", "a", "patient", "receiving", "etanercept", "for", "ankylosing", "spondylitis", "."], "event_mentions": [{"id": "20130478_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "20130478_2_Ent1", "role": "Effect", "text": "Reversible heart failure", "start": 0, "end": 3}, {"entity_id": "20130478_2_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "20130478_2_Ent2", "role": "Treatment", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent4", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "20130478_2_Ent1", "text": "Reversible heart failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20130478_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "20130478_2_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent4", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "20171144_1", "wnd_id": "20171144_1_1", "text": "Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence ) .", "tokens": ["Common", "adverse", "events", "(", "frequency", "10", "%", ")", "of", "lacosamide", "doses", "up", "to", "600", "mg", "/", "day", "include", "nonspecific", "central", "nervous", "system", "effects", "(", "e.g.", ",", "dizziness", ",", "ataxia", ",", "diplopia", ",", "and", "somnolence", ")", "."], "event_mentions": [{"id": "20171144_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "include", "start": 17, "end": 18}, "arguments": [{"entity_id": "20171144_1_Ent2", "role": "Treatment_Drug", "text": "lacosamide", "start": 9, "end": 10}, {"entity_id": "20171144_1_Ent1", "role": "Treatment", "text": "lacosamide doses up to 600 mg / day", "start": 9, "end": 17}, {"entity_id": "20171144_1_Ent3", "role": "Treatment_Dosage", "text": "600 mg / day", "start": 13, "end": 17}, {"entity_id": "20171144_1_Ent0", "role": "Effect", "text": "nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence )", "start": 18, "end": 35}]}], "entity_mentions": [{"id": "20171144_1_Ent2", "text": "lacosamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20171144_1_Ent1", "text": "lacosamide doses up to 600 mg / day", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "20171144_1_Ent3", "text": "600 mg / day", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "20171144_1_Ent0", "text": "nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence )", "entity_type": "Entity", "start": 18, "end": 35}], "lang": "en"}
{"doc_id": "20178709_1", "wnd_id": "20178709_1_1", "text": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy .", "tokens": ["A", "case", "of", "aseptic", "pleuropericarditis", "in", "a", "patient", "with", "chronic", "plaque", "psoriasis", "under", "methotrexate", "therapy", "."], "event_mentions": [{"id": "20178709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20178709_1_Ent1", "role": "Effect", "text": "aseptic pleuropericarditis", "start": 3, "end": 5}, {"entity_id": "20178709_1_Ent0", "role": "Subject", "text": "a patient with chronic plaque psoriasis", "start": 6, "end": 12}, {"entity_id": "20178709_1_Ent4", "role": "Treatment_Disorder", "text": "chronic plaque psoriasis", "start": 9, "end": 12}, {"entity_id": "20178709_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "20178709_1_Ent2", "role": "Treatment", "text": "methotrexate therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "20178709_1_Ent1", "text": "aseptic pleuropericarditis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20178709_1_Ent0", "text": "a patient with chronic plaque psoriasis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "20178709_1_Ent4", "text": "chronic plaque psoriasis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20178709_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20178709_1_Ent2", "text": "methotrexate therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "20180933_2", "wnd_id": "20180933_2_1", "text": "Artemether - lumefantrine ( AL ) is first - line treatment for uncomplicated malaria in many African countries .", "tokens": ["Artemether", "-", "lumefantrine", "(", "AL", ")", "is", "first", "-", "line", "treatment", "for", "uncomplicated", "malaria", "in", "many", "African", "countries", "."], "event_mentions": [{"id": "20180933_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "first - line treatment", "start": 7, "end": 11}, "arguments": [{"entity_id": "20180933_2_Ent2", "role": "Treatment_Drug", "text": "Artemether - lumefantrine", "start": 0, "end": 3}, {"entity_id": "20180933_2_Ent0", "role": "Treatment", "text": "Artemether - lumefantrine ( AL )", "start": 0, "end": 6}, {"entity_id": "20180933_2_Ent1", "role": "Treatment_Disorder", "text": "uncomplicated malaria", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "20180933_2_Ent2", "text": "Artemether - lumefantrine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20180933_2_Ent0", "text": "Artemether - lumefantrine ( AL )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "20180933_2_Ent1", "text": "uncomplicated malaria", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "20234160_3", "wnd_id": "20234160_3_1", "text": "We report a case of a 23 - year - old man who developed a vancomycin - induced anaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection .", "tokens": ["We", "report", "a", "case", "of", "a", "23", "-", "year", "-", "old", "man", "who", "developed", "a", "vancomycin", "-", "induced", "anaphylactic", "reaction", "in", "the", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infection", "."], "event_mentions": [{"id": "20234160_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "20234160_3_Ent0", "role": "Subject", "text": "a 23 - year - old man", "start": 5, "end": 12}, {"entity_id": "20234160_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 6, "end": 11}, {"entity_id": "20234160_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20234160_3_Ent3", "role": "Effect", "text": "a vancomycin - induced anaphylactic reaction", "start": 14, "end": 20}, {"entity_id": "20234160_3_Ent4", "role": "Treatment", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent6", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infection", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "20234160_3_Ent0", "text": "a 23 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "20234160_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20234160_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20234160_3_Ent3", "text": "a vancomycin - induced anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20234160_3_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent6", "text": "methicillin - resistant Staphylococcus aureus infection", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "20298401_7", "wnd_id": "20298401_7_1", "text": "Six days after taking erlotinib , a chest radiograph showed rapid progression of reticular infiltration in both lung fields .", "tokens": ["Six", "days", "after", "taking", "erlotinib", ",", "a", "chest", "radiograph", "showed", "rapid", "progression", "of", "reticular", "infiltration", "in", "both", "lung", "fields", "."], "event_mentions": [{"id": "20298401_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "20298401_7_Ent1", "role": "Treatment", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent3", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent2", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent0", "role": "Effect", "text": "rapid progression of reticular infiltration in both lung fields", "start": 10, "end": 19}]}], "entity_mentions": [{"id": "20298401_7_Ent1", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent3", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent0", "text": "rapid progression of reticular infiltration in both lung fields", "entity_type": "Entity", "start": 10, "end": 19}], "lang": "en"}
{"doc_id": "20338114_2", "wnd_id": "20338114_2_1", "text": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine .", "tokens": ["The", "other", "patient", "developed", "transient", "intraoperative", "hypertension", "immediately", "after", "inadvertent", "submucosal", "injection", "of", "concentrated", "epinephrine", "."], "event_mentions": [{"id": "20338114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "20338114_2_Ent0", "role": "Subject", "text": "The other patient", "start": 0, "end": 3}, {"entity_id": "20338114_2_Ent1", "role": "Effect", "text": "transient intraoperative hypertension immediately", "start": 4, "end": 8}, {"entity_id": "20338114_2_Ent2", "role": "Treatment", "text": "inadvertent submucosal injection of concentrated epinephrine", "start": 9, "end": 15}, {"entity_id": "20338114_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 11, "end": 12}, {"entity_id": "20338114_2_Ent3", "role": "Treatment_Drug", "text": "epinephrine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "20338114_2_Ent0", "text": "The other patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20338114_2_Ent1", "text": "transient intraoperative hypertension immediately", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "20338114_2_Ent2", "text": "inadvertent submucosal injection of concentrated epinephrine", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "20338114_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20338114_2_Ent3", "text": "epinephrine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "20456080_1", "wnd_id": "20456080_1_1", "text": "Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone .", "tokens": ["Triamcinolone", "acetonide", "induced", "secondary", "adrenal", "insufficiency", "related", "to", "impaired", "CYP3A4", "metabolism", "by", "coadministration", "of", "nefazodone", "."], "event_mentions": [{"id": "20456080_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "20456080_1_Ent1", "role": "Treatment", "text": "Triamcinolone acetonide", "start": 0, "end": 2}, {"entity_id": "20456080_1_Ent3", "role": "Treatment_Drug", "text": "Triamcinolone acetonide", "start": 0, "end": 2}, {"entity_id": "20456080_1_Ent6", "role": "Combination_Drug", "text": "Triamcinolone acetonide", "start": 0, "end": 2}, {"entity_id": "20456080_1_Ent0", "role": "Effect", "text": "secondary adrenal insufficiency", "start": 3, "end": 6}, {"entity_id": "20456080_1_Ent2", "role": "Treatment", "text": "coadministration of nefazodone", "start": 12, "end": 15}, {"entity_id": "20456080_1_Ent4", "role": "Treatment_Drug", "text": "nefazodone", "start": 14, "end": 15}, {"entity_id": "20456080_1_Ent5", "role": "Combination_Drug", "text": "nefazodone", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "20456080_1_Ent1", "text": "Triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20456080_1_Ent3", "text": "Triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20456080_1_Ent6", "text": "Triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20456080_1_Ent0", "text": "secondary adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20456080_1_Ent2", "text": "coadministration of nefazodone", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "20456080_1_Ent4", "text": "nefazodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20456080_1_Ent5", "text": "nefazodone", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "20465622_2", "wnd_id": "20465622_2_1", "text": "BACKGROUND : Aphthous stomatitis , a common mucocutaneous disorder , is a well accepted complication of sirolimus therapy .", "tokens": ["BACKGROUND", ":", "Aphthous", "stomatitis", ",", "a", "common", "mucocutaneous", "disorder", ",", "is", "a", "well", "accepted", "complication", "of", "sirolimus", "therapy", "."], "event_mentions": [{"id": "20465622_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 14, "end": 15}, "arguments": [{"entity_id": "20465622_2_Ent0", "role": "Effect", "text": "Aphthous stomatitis", "start": 2, "end": 4}, {"entity_id": "20465622_2_Ent1", "role": "Treatment", "text": "sirolimus", "start": 16, "end": 17}, {"entity_id": "20465622_2_Ent2", "role": "Treatment_Drug", "text": "sirolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "20465622_2_Ent0", "text": "Aphthous stomatitis", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "20465622_2_Ent1", "text": "sirolimus", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20465622_2_Ent2", "text": "sirolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "2051906_2", "wnd_id": "2051906_2_1", "text": "It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .", "tokens": ["It", "is", "believed", "that", "this", "is", "the", "first", "reported", "case", "of", "reversible", "azathioprine", "-", "induced", "cholestasis", "associated", "with", "histological", "evidence", "of", "bile", "duct", "injury", "."], "event_mentions": [{"id": "2051906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "2051906_2_Ent1", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent0", "role": "Effect", "text": "cholestasis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2051906_2_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent0", "text": "cholestasis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20628041_2", "wnd_id": "20628041_2_1", "text": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant - like syndrome ( NMLS ) in a polytrauma patient with Parkinson 's disease ( PD ) .", "tokens": ["To", "describe", "a", "probable", "interaction", "between", "enteral", "feeds", "and", "levodopa", "leading", "to", "neuroleptic", "malignant", "-", "like", "syndrome", "(", "NMLS", ")", "in", "a", "polytrauma", "patient", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "."], "event_mentions": [{"id": "20628041_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "20628041_2_Ent3", "role": "Treatment", "text": "interaction between enteral feeds and levodopa", "start": 4, "end": 10}, {"entity_id": "20628041_2_Ent5", "role": "Treatment_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent7", "role": "Combination_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent8", "role": "Combination_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent2", "role": "Effect", "text": "neuroleptic malignant - like syndrome ( NMLS )", "start": 12, "end": 20}, {"entity_id": "20628041_2_Ent0", "role": "Subject", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "start": 21, "end": 31}, {"entity_id": "20628041_2_Ent1", "role": "Subject_Disorder", "text": "polytrauma", "start": 22, "end": 23}, {"entity_id": "20628041_2_Ent6", "role": "Treatment_Disorder", "text": "Parkinson 's disease ( PD )", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "20628041_2_Ent3", "text": "interaction between enteral feeds and levodopa", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "20628041_2_Ent5", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent7", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent8", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent2", "text": "neuroleptic malignant - like syndrome ( NMLS )", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "20628041_2_Ent0", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "20628041_2_Ent1", "text": "polytrauma", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20628041_2_Ent6", "text": "Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "20628041_5", "wnd_id": "20628041_5_1", "text": "His PD medications ( pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily ) were administered via nasogastric tube .", "tokens": ["His", "PD", "medications", "(", "pramipexole", ",", "entacapone", ",", "and", "immediate", "-", "release", "levodopa", "/", "carbidopa", "100", "mg/25", "mg", ",", "1.5", "tablets", "4", "times", "daily", ")", "were", "administered", "via", "nasogastric", "tube", "."], "event_mentions": [{"id": "20628041_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 26, "end": 27}, "arguments": [{"entity_id": "20628041_5_Ent1", "role": "Subject_Gender", "text": "His", "start": 0, "end": 1}, {"entity_id": "20628041_5_Ent0", "role": "Subject", "text": "His PD", "start": 0, "end": 2}, {"entity_id": "20628041_5_Ent4", "role": "Treatment_Disorder", "text": "PD", "start": 1, "end": 2}, {"entity_id": "20628041_5_Ent5", "role": "Treatment_Drug", "text": "pramipexole", "start": 4, "end": 5}, {"entity_id": "20628041_5_Ent14", "role": "Combination_Drug", "text": "pramipexole", "start": 4, "end": 5}, {"entity_id": "20628041_5_Ent2", "role": "Treatment", "text": "pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily", "start": 4, "end": 24}, {"entity_id": "20628041_5_Ent6", "role": "Treatment_Drug", "text": "entacapone", "start": 6, "end": 7}, {"entity_id": "20628041_5_Ent15", "role": "Combination_Drug", "text": "entacapone", "start": 6, "end": 7}, {"entity_id": "20628041_5_Ent7", "role": "Treatment_Drug", "text": "levodopa", "start": 12, "end": 13}, {"entity_id": "20628041_5_Ent16", "role": "Combination_Drug", "text": "levodopa", "start": 12, "end": 13}, {"entity_id": "20628041_5_Ent8", "role": "Treatment_Drug", "text": "carbidopa", "start": 14, "end": 15}, {"entity_id": "20628041_5_Ent17", "role": "Combination_Drug", "text": "carbidopa", "start": 14, "end": 15}, {"entity_id": "20628041_5_Ent9", "role": "Treatment_Dosage", "text": "100 mg/25", "start": 15, "end": 17}, {"entity_id": "20628041_5_Ent10", "role": "Treatment_Dosage", "text": "mg/25 mg", "start": 16, "end": 18}, {"entity_id": "20628041_5_Ent11", "role": "Treatment_Dosage", "text": "1.5 tablets", "start": 19, "end": 21}, {"entity_id": "20628041_5_Ent12", "role": "Treatment_Freq", "text": "4 times daily", "start": 21, "end": 24}, {"entity_id": "20628041_5_Ent3", "role": "Treatment", "text": "via nasogastric tube", "start": 27, "end": 30}, {"entity_id": "20628041_5_Ent13", "role": "Treatment_Route", "text": "nasogastric tube", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "20628041_5_Ent1", "text": "His", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20628041_5_Ent0", "text": "His PD", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20628041_5_Ent4", "text": "PD", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20628041_5_Ent5", "text": "pramipexole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20628041_5_Ent14", "text": "pramipexole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20628041_5_Ent2", "text": "pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily", "entity_type": "Entity", "start": 4, "end": 24}, {"id": "20628041_5_Ent6", "text": "entacapone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20628041_5_Ent15", "text": "entacapone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20628041_5_Ent7", "text": "levodopa", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20628041_5_Ent16", "text": "levodopa", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20628041_5_Ent8", "text": "carbidopa", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20628041_5_Ent17", "text": "carbidopa", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20628041_5_Ent9", "text": "100 mg/25", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "20628041_5_Ent10", "text": "mg/25 mg", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "20628041_5_Ent11", "text": "1.5 tablets", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "20628041_5_Ent12", "text": "4 times daily", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "20628041_5_Ent3", "text": "via nasogastric tube", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20628041_5_Ent13", "text": "nasogastric tube", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "2063999_2", "wnd_id": "2063999_2_1", "text": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate ( HOPA ) .", "tokens": ["We", "report", "a", "girl", "with", "the", "Rett", "syndrome", "who", "had", "acute", "encephalopathy", "probably", "induced", "by", "calcium", "hopantenate", "(", "HOPA", ")", "."], "event_mentions": [{"id": "2063999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "2063999_2_Ent0", "role": "Subject", "text": "a girl", "start": 2, "end": 4}, {"entity_id": "2063999_2_Ent1", "role": "Subject_Gender", "text": "girl", "start": 3, "end": 4}, {"entity_id": "2063999_2_Ent2", "role": "Effect", "text": "Rett syndrome", "start": 6, "end": 8}, {"entity_id": "2063999_2_Ent3", "role": "Effect", "text": "acute encephalopathy", "start": 10, "end": 12}, {"entity_id": "2063999_2_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 15, "end": 17}, {"entity_id": "2063999_2_Ent4", "role": "Treatment", "text": "calcium hopantenate ( HOPA )", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "2063999_2_Ent0", "text": "a girl", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2063999_2_Ent1", "text": "girl", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2063999_2_Ent2", "text": "Rett syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2063999_2_Ent3", "text": "acute encephalopathy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2063999_2_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2063999_2_Ent4", "text": "calcium hopantenate ( HOPA )", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "2076372_1", "wnd_id": "2076372_1_1", "text": "Persistent light reactivity from systemic quinine .", "tokens": ["Persistent", "light", "reactivity", "from", "systemic", "quinine", "."], "event_mentions": [{"id": "2076372_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 3, "end": 4}, "arguments": [{"entity_id": "2076372_1_Ent0", "role": "Effect", "text": "Persistent light reactivity", "start": 0, "end": 3}, {"entity_id": "2076372_1_Ent1", "role": "Treatment", "text": "systemic quinine", "start": 4, "end": 6}, {"entity_id": "2076372_1_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2076372_1_Ent0", "text": "Persistent light reactivity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2076372_1_Ent1", "text": "systemic quinine", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2076372_1_Ent2", "text": "quinine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "20925534_1", "wnd_id": "20925534_1_1", "text": "Clopidogrel with or without omeprazole in coronary artery disease .", "tokens": ["Clopidogrel", "with", "or", "without", "omeprazole", "in", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "20925534_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_1_Ent2", "role": "Treatment_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent4", "role": "Treatment_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent5", "role": "Combination_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent0", "role": "Treatment", "text": "Clopidogrel with or without omeprazole", "start": 0, "end": 5}, {"entity_id": "20925534_1_Ent3", "role": "Treatment_Drug", "text": "omeprazole", "start": 4, "end": 5}, {"entity_id": "20925534_1_Ent6", "role": "Combination_Drug", "text": "omeprazole", "start": 4, "end": 5}, {"entity_id": "20925534_1_Ent1", "role": "Treatment_Disorder", "text": "coronary artery disease", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "20925534_1_Ent2", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent4", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent5", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent0", "text": "Clopidogrel with or without omeprazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "20925534_1_Ent3", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20925534_1_Ent6", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20925534_1_Ent1", "text": "coronary artery disease", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "2104570_4", "wnd_id": "2104570_4_1", "text": "Intravesical chemotherapy may be associated with a risk of secondary malignancy .", "tokens": ["Intravesical", "chemotherapy", "may", "be", "associated", "with", "a", "risk", "of", "secondary", "malignancy", "."], "event_mentions": [{"id": "2104570_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "2104570_4_Ent2", "role": "Treatment_Route", "text": "Intravesical", "start": 0, "end": 1}, {"entity_id": "2104570_4_Ent1", "role": "Treatment", "text": "Intravesical chemotherapy", "start": 0, "end": 2}, {"entity_id": "2104570_4_Ent3", "role": "Treatment_Drug", "text": "chemotherapy", "start": 1, "end": 2}, {"entity_id": "2104570_4_Ent0", "role": "Effect", "text": "secondary malignancy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "2104570_4_Ent2", "text": "Intravesical", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2104570_4_Ent1", "text": "Intravesical chemotherapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2104570_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2104570_4_Ent0", "text": "secondary malignancy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "21350204_2", "wnd_id": "21350204_2_1", "text": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator , even in those with an international normalized ratio < 1.7 .", "tokens": ["Concern", "exists", "that", "preadmission", "warfarin", "use", "may", "be", "associated", "with", "an", "increased", "risk", "of", "intracerebral", "hemorrhage", "in", "patients", "with", "ischemic", "stroke", "receiving", "intravenous", "tissue", "plasminogen", "activator", ",", "even", "in", "those", "with", "an", "international", "normalized", "ratio", "<", "1.7", "."], "event_mentions": [{"id": "21350204_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "21350204_2_Ent3", "role": "Treatment", "text": "preadmission warfarin", "start": 3, "end": 5}, {"entity_id": "21350204_2_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21350204_2_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21350204_2_Ent1", "role": "Effect", "text": "increased risk of intracerebral hemorrhage", "start": 11, "end": 16}, {"entity_id": "21350204_2_Ent0", "role": "Subject", "text": "patients with ischemic stroke", "start": 17, "end": 21}, {"entity_id": "21350204_2_Ent4", "role": "Treatment_Disorder", "text": "ischemic stroke", "start": 19, "end": 21}, {"entity_id": "21350204_2_Ent2", "role": "Treatment", "text": "receiving intravenous tissue plasminogen activator", "start": 21, "end": 26}, {"entity_id": "21350204_2_Ent6", "role": "Treatment_Drug", "text": "intravenous tissue plasminogen activator", "start": 22, "end": 26}, {"entity_id": "21350204_2_Ent8", "role": "Combination_Drug", "text": "intravenous tissue plasminogen activator", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "21350204_2_Ent3", "text": "preadmission warfarin", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21350204_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21350204_2_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21350204_2_Ent1", "text": "increased risk of intracerebral hemorrhage", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "21350204_2_Ent0", "text": "patients with ischemic stroke", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "21350204_2_Ent4", "text": "ischemic stroke", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "21350204_2_Ent2", "text": "receiving intravenous tissue plasminogen activator", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "21350204_2_Ent6", "text": "intravenous tissue plasminogen activator", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "21350204_2_Ent8", "text": "intravenous tissue plasminogen activator", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "21448111_5", "wnd_id": "21448111_5_1", "text": "During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time , which is very difficult to determine in everyday clinical practice .", "tokens": ["During", "the", "second", "hospitalization", "it", "is", "possible", "that", "antipsychotic", "treatment", "combined", "with", "an", "antidepressant", "caused", "akathisia", "or", "there", "were", "symptoms", "of", "agitated", "depression", "and", "akathisia", "present", "at", "the", "same", "time", ",", "which", "is", "very", "difficult", "to", "determine", "in", "everyday", "clinical", "practice", "."], "event_mentions": [{"id": "21448111_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "21448111_5_Ent2", "role": "Treatment_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent5", "role": "Combination_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent1", "role": "Treatment", "text": "antipsychotic treatment combined with an antidepressant", "start": 8, "end": 14}, {"entity_id": "21448111_5_Ent3", "role": "Treatment_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent4", "role": "Combination_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent0", "role": "Effect", "text": "akathisia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "21448111_5_Ent2", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent5", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent1", "text": "antipsychotic treatment combined with an antidepressant", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "21448111_5_Ent3", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "21512888_4", "wnd_id": "21512888_4_1", "text": "Valproic acid also displaces warfarin from the protein binding sites resulting in significant INR changes but this type of drug interaction is less well known .", "tokens": ["Valproic", "acid", "also", "displaces", "warfarin", "from", "the", "protein", "binding", "sites", "resulting", "in", "significant", "INR", "changes", "but", "this", "type", "of", "drug", "interaction", "is", "less", "well", "known", "."], "event_mentions": [{"id": "21512888_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "21512888_4_Ent2", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "21512888_4_Ent4", "role": "Combination_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "21512888_4_Ent1", "role": "Treatment", "text": "Valproic acid also displaces warfarin from the protein binding sites", "start": 0, "end": 10}, {"entity_id": "21512888_4_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21512888_4_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21512888_4_Ent0", "role": "Effect", "text": "significant INR changes", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "21512888_4_Ent2", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21512888_4_Ent4", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21512888_4_Ent1", "text": "Valproic acid also displaces warfarin from the protein binding sites", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "21512888_4_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21512888_4_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21512888_4_Ent0", "text": "significant INR changes", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "2154663_2", "wnd_id": "2154663_2_1", "text": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient .", "tokens": ["Concomitant", "irradiation", "apparently", "enhanced", "the", "skin", "toxicity", "of", "aminoglutethimide", "or", "possibly", "aminoglutethimide", "had", "a", "radiosensitizing", "role", "in", "this", "patient", "."], "event_mentions": [{"id": "2154663_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2154663_2_Ent2", "role": "Treatment", "text": "Concomitant irradiation", "start": 0, "end": 2}, {"entity_id": "2154663_2_Ent5", "role": "Treatment_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent6", "role": "Combination_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent1", "role": "Effect", "text": "skin toxicity", "start": 5, "end": 7}, {"entity_id": "2154663_2_Ent3", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent7", "role": "Combination_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent0", "role": "Subject", "text": "this patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2154663_2_Ent2", "text": "Concomitant irradiation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2154663_2_Ent5", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent6", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent1", "text": "skin toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2154663_2_Ent3", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent7", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent0", "text": "this patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "21658326_3", "wnd_id": "21658326_3_1", "text": "While mild to moderate application site reactions ( ASRs ) are a well - known and common phenomenon associated with imiquimod , the potential of TNF - alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized .", "tokens": ["While", "mild", "to", "moderate", "application", "site", "reactions", "(", "ASRs", ")", "are", "a", "well", "-", "known", "and", "common", "phenomenon", "associated", "with", "imiquimod", ",", "the", "potential", "of", "TNF", "-", "alpha", "blockers", "to", "elicit", "cutaneous", "inflammatory", "reactions", "has", "only", "recently", "been", "recognized", "."], "event_mentions": [{"id": "21658326_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "21658326_3_Ent3", "role": "Effect", "text": "application site reactions ( ASRs )", "start": 4, "end": 10}, {"entity_id": "21658326_3_Ent4", "role": "Treatment", "text": "imiquimod", "start": 20, "end": 21}, {"entity_id": "21658326_3_Ent5", "role": "Treatment_Drug", "text": "imiquimod", "start": 20, "end": 21}]}, {"id": "21658326_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elicit", "start": 30, "end": 31}, "arguments": [{"entity_id": "21658326_3_Ent1", "role": "Treatment", "text": "TNF - alpha blockers", "start": 25, "end": 29}, {"entity_id": "21658326_3_Ent2", "role": "Treatment_Drug", "text": "TNF - alpha blockers", "start": 25, "end": 29}, {"entity_id": "21658326_3_Ent0", "role": "Effect", "text": "cutaneous inflammatory reactions", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "21658326_3_Ent3", "text": "application site reactions ( ASRs )", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "21658326_3_Ent4", "text": "imiquimod", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_3_Ent5", "text": "imiquimod", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_3_Ent1", "text": "TNF - alpha blockers", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "21658326_3_Ent2", "text": "TNF - alpha blockers", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "21658326_3_Ent0", "text": "cutaneous inflammatory reactions", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "21712512_1", "wnd_id": "21712512_1_1", "text": "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis - related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor .", "tokens": ["Rapid", "onset", "of", "iatrogenic", "adrenal", "insufficiency", "in", "a", "patient", "with", "cystic", "fibrosis", "-", "related", "liver", "disease", "treated", "with", "inhaled", "corticosteroids", "and", "a", "moderate", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 1, "end": 2}, "arguments": [{"entity_id": "21712512_1_Ent2", "role": "Effect", "text": "iatrogenic adrenal insufficiency", "start": 3, "end": 6}, {"entity_id": "21712512_1_Ent0", "role": "Subject", "text": "a patient with cystic fibrosis - related liver disease", "start": 7, "end": 16}, {"entity_id": "21712512_1_Ent1", "role": "Subject_Disorder", "text": "cystic fibrosis - related liver disease", "start": 10, "end": 16}, {"entity_id": "21712512_1_Ent4", "role": "Treatment_Drug", "text": "inhaled corticosteroids", "start": 18, "end": 20}, {"entity_id": "21712512_1_Ent6", "role": "Combination_Drug", "text": "inhaled corticosteroids", "start": 18, "end": 20}, {"entity_id": "21712512_1_Ent3", "role": "Treatment", "text": "inhaled corticosteroids and a moderate CYP3A4 inhibitor", "start": 18, "end": 25}, {"entity_id": "21712512_1_Ent5", "role": "Treatment_Drug", "text": "CYP3A4 inhibitor .", "start": 23, "end": 26}, {"entity_id": "21712512_1_Ent7", "role": "Combination_Drug", "text": "CYP3A4 inhibitor .", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "21712512_1_Ent2", "text": "iatrogenic adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "21712512_1_Ent0", "text": "a patient with cystic fibrosis - related liver disease", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "21712512_1_Ent1", "text": "cystic fibrosis - related liver disease", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "21712512_1_Ent4", "text": "inhaled corticosteroids", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "21712512_1_Ent6", "text": "inhaled corticosteroids", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "21712512_1_Ent3", "text": "inhaled corticosteroids and a moderate CYP3A4 inhibitor", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "21712512_1_Ent5", "text": "CYP3A4 inhibitor .", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "21712512_1_Ent7", "text": "CYP3A4 inhibitor .", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "21712512_11", "wnd_id": "21712512_11_1", "text": "This case highlights rapid onset of adrenal insufficiency in a patient with CF - related liver disease treated briefly with a moderate CYP3A4 inhibitor .", "tokens": ["This", "case", "highlights", "rapid", "onset", "of", "adrenal", "insufficiency", "in", "a", "patient", "with", "CF", "-", "related", "liver", "disease", "treated", "briefly", "with", "a", "moderate", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 4, "end": 5}, "arguments": [{"entity_id": "21712512_11_Ent1", "role": "Effect", "text": "rapid onset of adrenal insufficiency", "start": 3, "end": 8}, {"entity_id": "21712512_11_Ent0", "role": "Subject", "text": "a patient with CF - related liver disease", "start": 9, "end": 17}, {"entity_id": "21712512_11_Ent4", "role": "Treatment_Disorder", "text": "CF - related liver disease", "start": 12, "end": 17}, {"entity_id": "21712512_11_Ent2", "role": "Treatment", "text": "briefly with a moderate CYP3A4 inhibitor", "start": 18, "end": 24}, {"entity_id": "21712512_11_Ent3", "role": "Treatment_Drug", "text": "CYP3A4 inhibitor", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "21712512_11_Ent1", "text": "rapid onset of adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "21712512_11_Ent0", "text": "a patient with CF - related liver disease", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "21712512_11_Ent4", "text": "CF - related liver disease", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "21712512_11_Ent2", "text": "briefly with a moderate CYP3A4 inhibitor", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "21712512_11_Ent3", "text": "CYP3A4 inhibitor", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "21712512_5", "wnd_id": "21712512_5_1", "text": "Seven weeks after the initiation of inhaled fluticasone , she developed vaginal candidiasis and was prescribed fluconazole 100 mg / day , a CYP3A4 inhibitor .", "tokens": ["Seven", "weeks", "after", "the", "initiation", "of", "inhaled", "fluticasone", ",", "she", "developed", "vaginal", "candidiasis", "and", "was", "prescribed", "fluconazole", "100", "mg", "/", "day", ",", "a", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "21712512_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Seven weeks", "start": 0, "end": 2}, {"entity_id": "21712512_5_Ent1", "role": "Treatment", "text": "Seven weeks after the initiation of inhaled fluticasone", "start": 0, "end": 8}, {"entity_id": "21712512_5_Ent2", "role": "Treatment_Route", "text": "inhaled", "start": 6, "end": 7}, {"entity_id": "21712512_5_Ent3", "role": "Treatment_Drug", "text": "fluticasone", "start": 7, "end": 8}, {"entity_id": "21712512_5_Ent0", "role": "Effect", "text": "vaginal candidiasis", "start": 11, "end": 13}]}, {"id": "21712512_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 15, "end": 16}, "arguments": [{"entity_id": "21712512_5_Ent6", "role": "Treatment_Disorder", "text": "vaginal candidiasis", "start": 11, "end": 13}, {"entity_id": "21712512_5_Ent7", "role": "Treatment_Drug", "text": "fluconazole", "start": 16, "end": 17}, {"entity_id": "21712512_5_Ent5", "role": "Treatment", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "start": 16, "end": 25}, {"entity_id": "21712512_5_Ent8", "role": "Treatment_Dosage", "text": "100 mg / day", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "21712512_5_Ent4", "text": "Seven weeks", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21712512_5_Ent1", "text": "Seven weeks after the initiation of inhaled fluticasone", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "21712512_5_Ent2", "text": "inhaled", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21712512_5_Ent3", "text": "fluticasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21712512_5_Ent0", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent6", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent7", "text": "fluconazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21712512_5_Ent5", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "21712512_5_Ent8", "text": "100 mg / day", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "21751692_3", "wnd_id": "21751692_3_1", "text": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy .", "tokens": ["We", "retrospectively", "reviewed", "the", "records", "of", "7", "pediatric", "oncology", "patients", "who", "received", "low", "-", "dose", "ketamine", "in", "conjunction", "with", "propofol", "for", "total", "intravenous", "anesthesia", "(", "TIVA", ")", "repeatedly", "for", "radiation", "therapy", "."], "event_mentions": [{"id": "21751692_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "21751692_3_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_3_Ent0", "role": "Subject", "text": "7 pediatric oncology patients", "start": 6, "end": 10}, {"entity_id": "21751692_3_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 7, "end": 8}, {"entity_id": "21751692_3_Ent7", "role": "Treatment_Disorder", "text": "oncology", "start": 8, "end": 9}, {"entity_id": "21751692_3_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 12, "end": 15}, {"entity_id": "21751692_3_Ent3", "role": "Treatment", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "start": 12, "end": 31}, {"entity_id": "21751692_3_Ent5", "role": "Treatment_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent9", "role": "Combination_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent4", "role": "Treatment_Drug", "text": "propofol", "start": 19, "end": 20}, {"entity_id": "21751692_3_Ent8", "role": "Combination_Drug", "text": "propofol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "21751692_3_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_3_Ent0", "text": "7 pediatric oncology patients", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "21751692_3_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751692_3_Ent7", "text": "oncology", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21751692_3_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "21751692_3_Ent3", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "entity_type": "Entity", "start": 12, "end": 31}, {"id": "21751692_3_Ent5", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent9", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent4", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "21751692_3_Ent8", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "21881031_11", "wnd_id": "21881031_11_1", "text": "Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations .", "tokens": ["Cisplatin", "was", "the", "common", "drug", "in", "the", "cases", "presented", "and", "therefore", "could", "be", "related", "to", "the", "INR", "elevations", "."], "event_mentions": [{"id": "21881031_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "21881031_11_Ent2", "role": "Treatment", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent3", "role": "Treatment_Drug", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent0", "role": "Subject", "text": "the cases", "start": 6, "end": 8}, {"entity_id": "21881031_11_Ent1", "role": "Effect", "text": "INR elevations", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "21881031_11_Ent2", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent3", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent0", "text": "the cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21881031_11_Ent1", "text": "INR elevations", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "22010004_3", "wnd_id": "22010004_3_1", "text": "A 69 - year - old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk ) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week .", "tokens": ["A", "69", "-", "year", "-", "old", "white", "female", "whose", "anticoagulation", "treatment", "had", "been", "stable", "for", "18", "months", "with", "warfarin", "2.5", "mg", "daily", "(", "17.5", "mg", "/", "wk", ")", "presented", "to", "an", "anticoagulation", "clinic", "with", "a", "critically", "elevated", "INR", "of", "greater", "than", "12.3", "after", "a", "dose", "increase", "in", "extended", "-", "release", "niacin", "(", "Niaspan", ")", "from", "500", "mg", "to", "1000", "mg", "daily", "the", "previous", "week", "."], "event_mentions": [{"id": "22010004_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 42, "end": 43}, "arguments": [{"entity_id": "22010004_3_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 1, "end": 6}, {"entity_id": "22010004_3_Ent0", "role": "Subject", "text": "69 - year - old white female", "start": 1, "end": 8}, {"entity_id": "22010004_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "22010004_3_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "22010004_3_Ent5", "role": "Treatment", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "start": 9, "end": 28}, {"entity_id": "22010004_3_Ent8", "role": "Treatment_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent14", "role": "Combination_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent10", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 19, "end": 21}, {"entity_id": "22010004_3_Ent12", "role": "Treatment_Freq", "text": "daily", "start": 21, "end": 22}, {"entity_id": "22010004_3_Ent4", "role": "Effect", "text": "elevated INR of greater than 12.3", "start": 36, "end": 42}, {"entity_id": "22010004_3_Ent6", "role": "Treatment", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "start": 44, "end": 64}, {"entity_id": "22010004_3_Ent7", "role": "Treatment_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent13", "role": "Combination_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent9", "role": "Treatment_Dosage", "text": "1000 mg", "start": 58, "end": 60}, {"entity_id": "22010004_3_Ent11", "role": "Treatment_Freq", "text": "daily", "start": 60, "end": 61}]}], "entity_mentions": [{"id": "22010004_3_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "22010004_3_Ent0", "text": "69 - year - old white female", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "22010004_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_3_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_3_Ent5", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "entity_type": "Entity", "start": 9, "end": 28}, {"id": "22010004_3_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent14", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent10", "text": "2.5 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22010004_3_Ent12", "text": "daily", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "22010004_3_Ent4", "text": "elevated INR of greater than 12.3", "entity_type": "Entity", "start": 36, "end": 42}, {"id": "22010004_3_Ent6", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "entity_type": "Entity", "start": 44, "end": 64}, {"id": "22010004_3_Ent7", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent13", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent9", "text": "1000 mg", "entity_type": "Entity", "start": 58, "end": 60}, {"id": "22010004_3_Ent11", "text": "daily", "entity_type": "Entity", "start": 60, "end": 61}], "lang": "en"}
{"doc_id": "22047557_8", "wnd_id": "22047557_8_1", "text": "Subjects receiving ivacaftor were 55 % less likely to have a pulmonary exacerbation than were patients receiving placebo , through week 48 ( P<0.001 ) .", "tokens": ["Subjects", "receiving", "ivacaftor", "were", "55", "%", "less", "likely", "to", "have", "a", "pulmonary", "exacerbation", "than", "were", "patients", "receiving", "placebo", ",", "through", "week", "48", "(", "P<0.001", ")", "."], "event_mentions": [{"id": "22047557_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 1, "end": 2}, "arguments": [{"entity_id": "22047557_8_Ent0", "role": "Treatment", "text": "ivacaftor", "start": 2, "end": 3}, {"entity_id": "22047557_8_Ent2", "role": "Treatment_Drug", "text": "ivacaftor", "start": 2, "end": 3}, {"entity_id": "22047557_8_Ent1", "role": "Treatment_Disorder", "text": "pulmonary exacerbation", "start": 11, "end": 13}]}, {"id": "22047557_8_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 1, "end": 2}, "arguments": [{"entity_id": "22047557_8_Ent3", "role": "Treatment", "text": "placebo", "start": 17, "end": 18}, {"entity_id": "22047557_8_Ent4", "role": "Treatment_Drug", "text": "placebo", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "22047557_8_Ent0", "text": "ivacaftor", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "22047557_8_Ent2", "text": "ivacaftor", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "22047557_8_Ent1", "text": "pulmonary exacerbation", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "22047557_8_Ent3", "text": "placebo", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22047557_8_Ent4", "text": "placebo", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2234880_2", "wnd_id": "2234880_2_1", "text": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug - induced gingival hyperplasia .", "tokens": ["Nitrendipine", "is", "an", "experimental", "calcium", "channel", "blocking", "agent", "that", "also", "appears", "to", "cause", "the", "side", "effect", "of", "drug", "-", "induced", "gingival", "hyperplasia", "."], "event_mentions": [{"id": "2234880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "2234880_2_Ent2", "role": "Treatment_Drug", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_2_Ent1", "role": "Treatment", "text": "Nitrendipine is an experimental calcium channel blocking agent", "start": 0, "end": 8}, {"entity_id": "2234880_2_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2234880_2_Ent2", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_2_Ent1", "text": "Nitrendipine is an experimental calcium channel blocking agent", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "2234880_2_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "22677303_11", "wnd_id": "22677303_11_1", "text": "According to the Drug Interaction Probability Scale , a causal relationship between the warfarin - cloxacillin interaction and increased INR value was rated \" probable \" .", "tokens": ["According", "to", "the", "Drug", "Interaction", "Probability", "Scale", ",", "a", "causal", "relationship", "between", "the", "warfarin", "-", "cloxacillin", "interaction", "and", "increased", "INR", "value", "was", "rated", "\"", "probable", "\"", "."], "event_mentions": [{"id": "22677303_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 10, "end": 11}, "arguments": [{"entity_id": "22677303_11_Ent1", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent2", "role": "Treatment", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent4", "role": "Treatment_Drug", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent6", "role": "Combination_Drug", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent0", "role": "Effect", "text": "increased INR value", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "22677303_11_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent4", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent6", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent0", "text": "increased INR value", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "22735246_1", "wnd_id": "22735246_1_1", "text": "Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor .", "tokens": ["Fatal", "serotonin", "syndrome", "precipitated", "by", "oxcarbazepine", "in", "a", "patient", "using", "an", "selective", "serotonin", "reuptake", "inhibitor", "."], "event_mentions": [{"id": "22735246_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 3, "end": 4}, "arguments": [{"entity_id": "22735246_1_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "22735246_1_Ent2", "role": "Treatment", "text": "oxcarbazepine", "start": 5, "end": 6}, {"entity_id": "22735246_1_Ent3", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 5, "end": 6}, {"entity_id": "22735246_1_Ent0", "role": "Subject", "text": "a patient", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "22735246_1_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22735246_1_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22735246_1_Ent3", "text": "oxcarbazepine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22735246_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2276822_1", "wnd_id": "2276822_1_1", "text": "Because of a hypersensitivity reaction , initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin .", "tokens": ["Because", "of", "a", "hypersensitivity", "reaction", ",", "initial", "therapy", "with", "penicillin", "G", "and", "gentamicin", "was", "stopped", "and", "substituted", "with", "cefazolin", "."], "event_mentions": [{"id": "2276822_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "2276822_1_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 3, "end": 5}, {"entity_id": "2276822_1_Ent1", "role": "Treatment", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent3", "role": "Treatment_Drug", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent6", "role": "Combination_Drug", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent2", "role": "Treatment", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent4", "role": "Treatment_Drug", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent7", "role": "Combination_Drug", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent5", "role": "Treatment_Drug", "text": "cefazolin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2276822_1_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2276822_1_Ent1", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent3", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent6", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent2", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent4", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent7", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent5", "text": "cefazolin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "22791547_4", "wnd_id": "22791547_4_1", "text": "Orofacial dyskinesia appeared 5 hours after methylphenidate administration , persisted for 10 hours , and had completely resolved within 2 days .", "tokens": ["Orofacial", "dyskinesia", "appeared", "5", "hours", "after", "methylphenidate", "administration", ",", "persisted", "for", "10", "hours", ",", "and", "had", "completely", "resolved", "within", "2", "days", "."], "event_mentions": [{"id": "22791547_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 2, "end": 3}, "arguments": [{"entity_id": "22791547_4_Ent0", "role": "Effect", "text": "Orofacial dyskinesia", "start": 0, "end": 2}, {"entity_id": "22791547_4_Ent3", "role": "Treatment_Time_elapsed", "text": "5 hours after", "start": 3, "end": 6}, {"entity_id": "22791547_4_Ent1", "role": "Treatment", "text": "5 hours after methylphenidate", "start": 3, "end": 7}, {"entity_id": "22791547_4_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "22791547_4_Ent0", "text": "Orofacial dyskinesia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "22791547_4_Ent3", "text": "5 hours after", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "22791547_4_Ent1", "text": "5 hours after methylphenidate", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "22791547_4_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "22791547_5", "wnd_id": "22791547_5_1", "text": "Although limb dyskinesia after methylphenidate is a commonly reported side effect , to the authors ' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate .", "tokens": ["Although", "limb", "dyskinesia", "after", "methylphenidate", "is", "a", "commonly", "reported", "side", "effect", ",", "to", "the", "authors", "'", "knowledge", "this", "is", "only", "the", "second", "reported", "case", "to", "develop", "both", "orofacial", "and", "limb", "dyskinesia", "in", "the", "acute", "period", "after", "the", "first", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "22791547_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "22791547_5_Ent3", "role": "Treatment_Drug", "text": "methylphenidate", "start": 4, "end": 5}, {"entity_id": "22791547_5_Ent0", "role": "Subject", "text": "the second reported case", "start": 20, "end": 24}, {"entity_id": "22791547_5_Ent1", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 27, "end": 31}, {"entity_id": "22791547_5_Ent2", "role": "Treatment", "text": "methylphenidate", "start": 40, "end": 41}, {"entity_id": "22791547_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "22791547_5_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22791547_5_Ent0", "text": "the second reported case", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22791547_5_Ent1", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "22791547_5_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "22791547_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "2305654_2", "wnd_id": "2305654_2_1", "text": "We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening pseudo - obstruction of the colon , a variant of adynamic ileus , while being treated with intravenous nimodipine .", "tokens": ["We", "report", "on", "a", "patient", "with", "subarachnoid", "haemorrhage", "who", "developed", "an", "acute", "life", "-", "threatening", "pseudo", "-", "obstruction", "of", "the", "colon", ",", "a", "variant", "of", "adynamic", "ileus", ",", "while", "being", "treated", "with", "intravenous", "nimodipine", "."], "event_mentions": [{"id": "2305654_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "2305654_2_Ent0", "role": "Subject", "text": "patient with subarachnoid haemorrhage", "start": 4, "end": 8}, {"entity_id": "2305654_2_Ent3", "role": "Treatment_Disorder", "text": "subarachnoid haemorrhage", "start": 6, "end": 8}, {"entity_id": "2305654_2_Ent1", "role": "Effect", "text": "pseudo - obstruction of the colon", "start": 15, "end": 21}, {"entity_id": "2305654_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 32, "end": 33}, {"entity_id": "2305654_2_Ent2", "role": "Treatment", "text": "intravenous nimodipine", "start": 32, "end": 34}, {"entity_id": "2305654_2_Ent4", "role": "Treatment_Drug", "text": "nimodipine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "2305654_2_Ent0", "text": "patient with subarachnoid haemorrhage", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2305654_2_Ent3", "text": "subarachnoid haemorrhage", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2305654_2_Ent1", "text": "pseudo - obstruction of the colon", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "2305654_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "2305654_2_Ent2", "text": "intravenous nimodipine", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "2305654_2_Ent4", "text": "nimodipine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "2309833_3", "wnd_id": "2309833_3_1", "text": "Insulin - dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis .", "tokens": ["Insulin", "-", "dependent", "diabetes", "mellitus", "developed", "in", "a", "young", "woman", "8", "weeks", "after", "the", "initiation", "of", "danazol", "for", "treatment", "of", "pelvic", "endometriosis", "."], "event_mentions": [{"id": "2309833_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "2309833_3_Ent3", "role": "Effect", "text": "Insulin - dependent diabetes mellitus", "start": 0, "end": 5}, {"entity_id": "2309833_3_Ent0", "role": "Subject", "text": "a young woman", "start": 7, "end": 10}, {"entity_id": "2309833_3_Ent1", "role": "Subject_Age", "text": "young", "start": 8, "end": 9}, {"entity_id": "2309833_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "2309833_3_Ent6", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 10, "end": 12}, {"entity_id": "2309833_3_Ent4", "role": "Treatment", "text": "8 weeks after the initiation of danazol", "start": 10, "end": 17}, {"entity_id": "2309833_3_Ent7", "role": "Treatment_Drug", "text": "danazol", "start": 16, "end": 17}, {"entity_id": "2309833_3_Ent5", "role": "Treatment_Disorder", "text": "pelvic endometriosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2309833_3_Ent3", "text": "Insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2309833_3_Ent0", "text": "a young woman", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2309833_3_Ent1", "text": "young", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2309833_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2309833_3_Ent6", "text": "8 weeks", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2309833_3_Ent4", "text": "8 weeks after the initiation of danazol", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "2309833_3_Ent7", "text": "danazol", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "2309833_3_Ent5", "text": "pelvic endometriosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "23115227_6", "wnd_id": "23115227_6_1", "text": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 ) , with a mean international normalized ratio ( INR ) of 2.8 ( 95 % CI 2.5 to 3.1 ) .", "tokens": ["The", "mean", "weekly", "warfarin", "dose", "while", "the", "patient", "was", "receiving", "emtricitabine", "monotherapy", "was", "13.3", "mg", "(", "95", "%", "CI", "12.7", "to", "13.8", ")", ",", "with", "a", "mean", "international", "normalized", "ratio", "(", "INR", ")", "of", "2.8", "(", "95", "%", "CI", "2.5", "to", "3.1", ")", "."], "event_mentions": [{"id": "23115227_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "23115227_6_Ent1", "role": "Treatment", "text": "The mean weekly warfarin dose", "start": 0, "end": 5}, {"entity_id": "23115227_6_Ent3", "role": "Treatment_Freq", "text": "weekly", "start": 2, "end": 3}, {"entity_id": "23115227_6_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "23115227_6_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "23115227_6_Ent5", "role": "Treatment_Drug", "text": "emtricitabine", "start": 10, "end": 11}, {"entity_id": "23115227_6_Ent2", "role": "Treatment", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "start": 10, "end": 23}, {"entity_id": "23115227_6_Ent6", "role": "Treatment_Dosage", "text": "13.3 mg", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "23115227_6_Ent1", "text": "The mean weekly warfarin dose", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23115227_6_Ent3", "text": "weekly", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "23115227_6_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "23115227_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23115227_6_Ent5", "text": "emtricitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23115227_6_Ent2", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "23115227_6_Ent6", "text": "13.3 mg", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "2320800_7", "wnd_id": "2320800_7_1", "text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .", "tokens": ["We", "strongly", "suspect", "that", "this", "lethal", "anuria", "was", "mainly", "due", "to", "ifosfamide", ",", "occurring", "in", "a", "patient", "having", "received", "previous", "cisplatin", "chemotherapy", "and", "with", "poor", "kidney", "perfusion", "due", "to", "transient", "hypotension", "."], "event_mentions": [{"id": "2320800_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 13, "end": 14}, "arguments": [{"entity_id": "2320800_7_Ent2", "role": "Effect", "text": "lethal anuria", "start": 5, "end": 7}, {"entity_id": "2320800_7_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent7", "role": "Combination_Drug", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent0", "role": "Subject", "text": "a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension", "start": 15, "end": 31}, {"entity_id": "2320800_7_Ent4", "role": "Treatment", "text": "having received previous cisplatin chemotherapy", "start": 17, "end": 22}, {"entity_id": "2320800_7_Ent6", "role": "Treatment_Drug", "text": "cisplatin", "start": 20, "end": 21}, {"entity_id": "2320800_7_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 20, "end": 21}, {"entity_id": "2320800_7_Ent1", "role": "Subject_Disorder", "text": "poor kidney perfusion", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "2320800_7_Ent2", "text": "lethal anuria", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2320800_7_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent7", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent0", "text": "a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension", "entity_type": "Entity", "start": 15, "end": 31}, {"id": "2320800_7_Ent4", "text": "having received previous cisplatin chemotherapy", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "2320800_7_Ent6", "text": "cisplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "2320800_7_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "2320800_7_Ent1", "text": "poor kidney perfusion", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "2327115_1", "wnd_id": "2327115_1_1", "text": "Ciprofloxacin is one drug that has been reported to cause interstitial nephritis .", "tokens": ["Ciprofloxacin", "is", "one", "drug", "that", "has", "been", "reported", "to", "cause", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2327115_4", "wnd_id": "2327115_4_1", "text": "This article describes a patient with suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["This", "article", "describes", "a", "patient", "with", "suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_4_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "2327115_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent1", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2327115_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent1", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "23552010_2", "wnd_id": "23552010_2_1", "text": "This is a case report involving a patient who was treated with topical 5 - FU cream and subsequently developed a severe case of angioedema .", "tokens": ["This", "is", "a", "case", "report", "involving", "a", "patient", "who", "was", "treated", "with", "topical", "5", "-", "FU", "cream", "and", "subsequently", "developed", "a", "severe", "case", "of", "angioedema", "."], "event_mentions": [{"id": "23552010_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "23552010_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "23552010_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 12, "end": 13}, {"entity_id": "23552010_2_Ent2", "role": "Treatment", "text": "topical 5 - FU cream", "start": 12, "end": 17}, {"entity_id": "23552010_2_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 13, "end": 16}, {"entity_id": "23552010_2_Ent1", "role": "Effect", "text": "a severe case of angioedema", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "23552010_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23552010_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "23552010_2_Ent2", "text": "topical 5 - FU cream", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23552010_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "23552010_2_Ent1", "text": "a severe case of angioedema", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "23624139_1", "wnd_id": "23624139_1_1", "text": "Severe water intoxication secondary to the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin : a case report and review of the literature .", "tokens": ["Severe", "water", "intoxication", "secondary", "to", "the", "concomitant", "intake", "of", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "and", "desmopressin", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "23624139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 3, "end": 5}, "arguments": [{"entity_id": "23624139_1_Ent0", "role": "Effect", "text": "Severe water intoxication", "start": 0, "end": 3}, {"entity_id": "23624139_1_Ent1", "role": "Treatment", "text": "the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin", "start": 5, "end": 18}, {"entity_id": "23624139_1_Ent2", "role": "Treatment_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 9, "end": 16}, {"entity_id": "23624139_1_Ent4", "role": "Combination_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 9, "end": 16}, {"entity_id": "23624139_1_Ent3", "role": "Treatment_Drug", "text": "desmopressin", "start": 17, "end": 18}, {"entity_id": "23624139_1_Ent5", "role": "Combination_Drug", "text": "desmopressin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "23624139_1_Ent0", "text": "Severe water intoxication", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "23624139_1_Ent1", "text": "the concomitant intake of non - steroidal anti - inflammatory drugs and desmopressin", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "23624139_1_Ent2", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "23624139_1_Ent4", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "23624139_1_Ent3", "text": "desmopressin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23624139_1_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "23774436_1", "wnd_id": "23774436_1_1", "text": "Evaluation of initial and steady - state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations .", "tokens": ["Evaluation", "of", "initial", "and", "steady", "-", "state", "gatifloxacin", "pharmacokinetics", "and", "dose", "in", "pulmonary", "tuberculosis", "patients", "by", "using", "monte", "carlo", "simulations", "."], "event_mentions": [{"id": "23774436_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "23774436_1_Ent1", "role": "Treatment", "text": "gatifloxacin", "start": 7, "end": 8}, {"entity_id": "23774436_1_Ent3", "role": "Treatment_Drug", "text": "gatifloxacin", "start": 7, "end": 8}, {"entity_id": "23774436_1_Ent2", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 12, "end": 14}, {"entity_id": "23774436_1_Ent0", "role": "Subject", "text": "pulmonary tuberculosis patients", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "23774436_1_Ent1", "text": "gatifloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "23774436_1_Ent3", "text": "gatifloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "23774436_1_Ent2", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "23774436_1_Ent0", "text": "pulmonary tuberculosis patients", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "23868369_4", "wnd_id": "23868369_4_1", "text": "She presented to clinic with nausea and anorexia within a few days of addition of ciprofloxacin to her current regimen of medications , which included digoxin .", "tokens": ["She", "presented", "to", "clinic", "with", "nausea", "and", "anorexia", "within", "a", "few", "days", "of", "addition", "of", "ciprofloxacin", "to", "her", "current", "regimen", "of", "medications", ",", "which", "included", "digoxin", "."], "event_mentions": [{"id": "23868369_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 1, "end": 2}, "arguments": [{"entity_id": "23868369_4_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "23868369_4_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "23868369_4_Ent2", "role": "Effect", "text": "nausea and anorexia", "start": 5, "end": 8}, {"entity_id": "23868369_4_Ent4", "role": "Treatment_Time_elapsed", "text": "within a few days", "start": 8, "end": 12}, {"entity_id": "23868369_4_Ent3", "role": "Treatment", "text": "addition of ciprofloxacin to her current regimen of medications , which included digoxin", "start": 13, "end": 26}, {"entity_id": "23868369_4_Ent5", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 15, "end": 16}, {"entity_id": "23868369_4_Ent7", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 15, "end": 16}, {"entity_id": "23868369_4_Ent6", "role": "Treatment_Drug", "text": "digoxin", "start": 25, "end": 26}, {"entity_id": "23868369_4_Ent8", "role": "Combination_Drug", "text": "digoxin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "23868369_4_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "23868369_4_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "23868369_4_Ent2", "text": "nausea and anorexia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "23868369_4_Ent4", "text": "within a few days", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "23868369_4_Ent3", "text": "addition of ciprofloxacin to her current regimen of medications , which included digoxin", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "23868369_4_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23868369_4_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23868369_4_Ent6", "text": "digoxin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "23868369_4_Ent8", "text": "digoxin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "2394154_2", "wnd_id": "2394154_2_1", "text": "Following the institution of intravenous therapy with acyclovir , the patient developed fever , hemoptysis , and a pleural friction rub .", "tokens": ["Following", "the", "institution", "of", "intravenous", "therapy", "with", "acyclovir", ",", "the", "patient", "developed", "fever", ",", "hemoptysis", ",", "and", "a", "pleural", "friction", "rub", "."], "event_mentions": [{"id": "2394154_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2394154_2_Ent2", "role": "Treatment", "text": "acyclovir", "start": 7, "end": 8}, {"entity_id": "2394154_2_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 7, "end": 8}, {"entity_id": "2394154_2_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "2394154_2_Ent1", "role": "Effect", "text": "fever , hemoptysis , and a pleural friction rub", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "2394154_2_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2394154_2_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2394154_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2394154_2_Ent1", "text": "fever , hemoptysis , and a pleural friction rub", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "2394154_4", "wnd_id": "2394154_4_1", "text": "To our knowledge , the syndrome of fever , pulmonary infiltrates , and pleural effusion following use of acyclovir has not been previously reported .", "tokens": ["To", "our", "knowledge", ",", "the", "syndrome", "of", "fever", ",", "pulmonary", "infiltrates", ",", "and", "pleural", "effusion", "following", "use", "of", "acyclovir", "has", "not", "been", "previously", "reported", "."], "event_mentions": [{"id": "2394154_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "2394154_4_Ent0", "role": "Effect", "text": "fever , pulmonary infiltrates , and pleural effusion", "start": 7, "end": 15}, {"entity_id": "2394154_4_Ent1", "role": "Treatment", "text": "acyclovir", "start": 18, "end": 19}, {"entity_id": "2394154_4_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2394154_4_Ent0", "text": "fever , pulmonary infiltrates , and pleural effusion", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "2394154_4_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2394154_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2406680_3", "wnd_id": "2406680_3_1", "text": "The case of a 29 - year - old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented .", "tokens": ["The", "case", "of", "a", "29", "-", "year", "-", "old", "man", "suffering", "from", "falciparum", "malaria", "disease", "who", "got", "a", "reversible", "hearing", "loss", "from", "quinine", "therapy", "is", "presented", "."], "event_mentions": [{"id": "2406680_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "got", "start": 16, "end": 17}, "arguments": [{"entity_id": "2406680_3_Ent0", "role": "Subject", "text": "a 29 - year - old man suffering from falciparum malaria disease", "start": 3, "end": 15}, {"entity_id": "2406680_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "2406680_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "2406680_3_Ent5", "role": "Treatment_Disorder", "text": "falciparum malaria disease", "start": 12, "end": 15}, {"entity_id": "2406680_3_Ent3", "role": "Effect", "text": "reversible hearing loss", "start": 18, "end": 21}, {"entity_id": "2406680_3_Ent4", "role": "Treatment", "text": "quinine", "start": 22, "end": 23}, {"entity_id": "2406680_3_Ent6", "role": "Treatment_Drug", "text": "quinine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "2406680_3_Ent0", "text": "a 29 - year - old man suffering from falciparum malaria disease", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "2406680_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2406680_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2406680_3_Ent5", "text": "falciparum malaria disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "2406680_3_Ent3", "text": "reversible hearing loss", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "2406680_3_Ent4", "text": "quinine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2406680_3_Ent6", "text": "quinine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "2417800_2", "wnd_id": "2417800_2_1", "text": "Autopsy findings were consistent with bleomycin and oxygen - induced pulmonary damage .", "tokens": ["Autopsy", "findings", "were", "consistent", "with", "bleomycin", "and", "oxygen", "-", "induced", "pulmonary", "damage", "."], "event_mentions": [{"id": "2417800_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2417800_2_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "2417800_2_Ent5", "role": "Combination_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "2417800_2_Ent1", "role": "Treatment", "text": "bleomycin and oxygen", "start": 5, "end": 8}, {"entity_id": "2417800_2_Ent2", "role": "Treatment_Drug", "text": "oxygen", "start": 7, "end": 8}, {"entity_id": "2417800_2_Ent4", "role": "Combination_Drug", "text": "oxygen", "start": 7, "end": 8}, {"entity_id": "2417800_2_Ent0", "role": "Effect", "text": "pulmonary damage", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2417800_2_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2417800_2_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2417800_2_Ent1", "text": "bleomycin and oxygen", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2417800_2_Ent2", "text": "oxygen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2417800_2_Ent4", "text": "oxygen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2417800_2_Ent0", "text": "pulmonary damage", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "24318743_15", "wnd_id": "24318743_15_1", "text": "In addition , single - agent weekly AUC2 - carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC .", "tokens": ["In", "addition", ",", "single", "-", "agent", "weekly", "AUC2", "-", "carboplatin", "appeared", "to", "be", "inactive", "by", "response", "criteria", "in", "a", "homogenously", "defined", "population", "of", "PROC", "."], "event_mentions": [{"id": "24318743_15_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inactive", "start": 13, "end": 14}, "arguments": [{"entity_id": "24318743_15_Ent1", "role": "Treatment", "text": "single - agent weekly AUC2 - carboplatin", "start": 3, "end": 10}, {"entity_id": "24318743_15_Ent3", "role": "Treatment_Freq", "text": "weekly", "start": 6, "end": 7}, {"entity_id": "24318743_15_Ent4", "role": "Treatment_Drug", "text": "AUC2 - carboplatin", "start": 7, "end": 10}, {"entity_id": "24318743_15_Ent0", "role": "Subject", "text": "a homogenously defined population of PROC", "start": 18, "end": 24}, {"entity_id": "24318743_15_Ent2", "role": "Treatment_Disorder", "text": "PROC", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "24318743_15_Ent1", "text": "single - agent weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "24318743_15_Ent3", "text": "weekly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "24318743_15_Ent4", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24318743_15_Ent0", "text": "a homogenously defined population of PROC", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "24318743_15_Ent2", "text": "PROC", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "24429012_2", "wnd_id": "24429012_2_1", "text": "A case report of a sharp rise in International Normalized Ratio ( INR ) values during a patient 's concomitant use of warfarin and the antineoplastic agent vismodegib is presented .", "tokens": ["A", "case", "report", "of", "a", "sharp", "rise", "in", "International", "Normalized", "Ratio", "(", "INR", ")", "values", "during", "a", "patient", "'s", "concomitant", "use", "of", "warfarin", "and", "the", "antineoplastic", "agent", "vismodegib", "is", "presented", "."], "event_mentions": [{"id": "24429012_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "24429012_2_Ent1", "role": "Effect", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "start": 4, "end": 15}, {"entity_id": "24429012_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "24429012_2_Ent2", "role": "Treatment", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "start": 19, "end": 28}, {"entity_id": "24429012_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 27, "end": 28}, {"entity_id": "24429012_2_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24429012_2_Ent1", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "24429012_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "24429012_2_Ent2", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "24429012_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24429012_2_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "2452936_1", "wnd_id": "2452936_1_1", "text": "Life - threatening hyponatremia caused by vinblastine .", "tokens": ["Life", "-", "threatening", "hyponatremia", "caused", "by", "vinblastine", "."], "event_mentions": [{"id": "2452936_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "2452936_1_Ent0", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}, {"entity_id": "2452936_1_Ent1", "role": "Treatment", "text": "vinblastine", "start": 6, "end": 7}, {"entity_id": "2452936_1_Ent2", "role": "Treatment_Drug", "text": "vinblastine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2452936_1_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2452936_1_Ent1", "text": "vinblastine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2452936_1_Ent2", "text": "vinblastine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "2452936_2", "wnd_id": "2452936_2_1", "text": "The most likely cause of such hyponatremic episode is vinblastine .", "tokens": ["The", "most", "likely", "cause", "of", "such", "hyponatremic", "episode", "is", "vinblastine", "."], "event_mentions": [{"id": "2452936_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 8, "end": 9}, "arguments": [{"entity_id": "2452936_2_Ent0", "role": "Effect", "text": "hyponatremic episode", "start": 6, "end": 8}, {"entity_id": "2452936_2_Ent1", "role": "Treatment", "text": "vinblastine", "start": 9, "end": 10}, {"entity_id": "2452936_2_Ent2", "role": "Treatment_Drug", "text": "vinblastine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2452936_2_Ent0", "text": "hyponatremic episode", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2452936_2_Ent1", "text": "vinblastine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2452936_2_Ent2", "text": "vinblastine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2461837_1", "wnd_id": "2461837_1_1", "text": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin , this is , to our knowledge , the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients .", "tokens": ["Although", "this", "type", "of", "hyperpigmentation", "has", "been", "previously", "seen", "in", "patients", "with", "cancer", "who", "are", "receiving", "bleomycin", ",", "this", "is", ",", "to", "our", "knowledge", ",", "the", "first", "reported", "case", "of", "bleomycin", "-", "induced", "hyperpigmentation", "in", "an", "AIDS", "patient", "and", "should", "be", "added", "to", "the", "growing", "list", "of", "cutaneous", "eruptions", "seen", "in", "these", "patients", "."], "event_mentions": [{"id": "2461837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 32, "end": 33}, "arguments": [{"entity_id": "2461837_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 30, "end": 31}, {"entity_id": "2461837_1_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 30, "end": 31}, {"entity_id": "2461837_1_Ent1", "role": "Effect", "text": "hyperpigmentation", "start": 33, "end": 34}, {"entity_id": "2461837_1_Ent0", "role": "Subject", "text": "an AIDS patient", "start": 35, "end": 38}, {"entity_id": "2461837_1_Ent4", "role": "Treatment_Disorder", "text": "AIDS", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "2461837_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "2461837_1_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "2461837_1_Ent1", "text": "hyperpigmentation", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "2461837_1_Ent0", "text": "an AIDS patient", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2461837_1_Ent4", "text": "AIDS", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "2461837_2", "wnd_id": "2461837_2_1", "text": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ) .", "tokens": ["We", "report", "a", "case", "of", "hyperpigmentation", "due", "to", "bleomycin", "treatment", "in", "a", "patient", "with", "acquired", "immune", "deficiency", "syndrome", "(", "AIDS", ")", "."], "event_mentions": [{"id": "2461837_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "2461837_2_Ent1", "role": "Effect", "text": "hyperpigmentation", "start": 5, "end": 6}, {"entity_id": "2461837_2_Ent2", "role": "Treatment", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent0", "role": "Subject", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "start": 11, "end": 21}, {"entity_id": "2461837_2_Ent4", "role": "Treatment_Disorder", "text": "acquired immune deficiency syndrome", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2461837_2_Ent1", "text": "hyperpigmentation", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2461837_2_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent0", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "2461837_2_Ent4", "text": "acquired immune deficiency syndrome", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "24927617_5", "wnd_id": "24927617_5_1", "text": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug - drug interaction was suspected .", "tokens": ["At", "admission", "simvastatin", "and", "all", "antiviral", "drugs", "were", "discontinued", "because", "toxicity", "due", "to", "a", "drug", "-", "drug", "interaction", "was", "suspected", "."], "event_mentions": [{"id": "24927617_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 11, "end": 12}, "arguments": [{"entity_id": "24927617_5_Ent2", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "24927617_5_Ent1", "role": "Treatment", "text": "simvastatin and all antiviral drugs", "start": 2, "end": 7}, {"entity_id": "24927617_5_Ent0", "role": "Effect", "text": "toxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "24927617_5_Ent2", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24927617_5_Ent1", "text": "simvastatin and all antiviral drugs", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "24927617_5_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "2532694_2", "wnd_id": "2532694_2_1", "text": "Dapsone - induced erythroderma with Beau 's lines .", "tokens": ["Dapsone", "-", "induced", "erythroderma", "with", "Beau", "'s", "lines", "."], "event_mentions": [{"id": "2532694_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2532694_2_Ent1", "role": "Treatment", "text": "Dapsone", "start": 0, "end": 1}, {"entity_id": "2532694_2_Ent2", "role": "Treatment_Drug", "text": "Dapsone", "start": 0, "end": 1}, {"entity_id": "2532694_2_Ent0", "role": "Effect", "text": "erythroderma with Beau 's lines", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "2532694_2_Ent1", "text": "Dapsone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2532694_2_Ent2", "text": "Dapsone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2532694_2_Ent0", "text": "erythroderma with Beau 's lines", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "25407257_1", "wnd_id": "25407257_1_1", "text": "First case report of suspected onset of convulsive seizures due to co - administration of valproic acid and tebipenem .", "tokens": ["First", "case", "report", "of", "suspected", "onset", "of", "convulsive", "seizures", "due", "to", "co", "-", "administration", "of", "valproic", "acid", "and", "tebipenem", "."], "event_mentions": [{"id": "25407257_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 9, "end": 10}, "arguments": [{"entity_id": "25407257_1_Ent0", "role": "Effect", "text": "convulsive seizures", "start": 7, "end": 9}, {"entity_id": "25407257_1_Ent1", "role": "Treatment", "text": "co - administration of valproic acid and tebipenem", "start": 11, "end": 19}, {"entity_id": "25407257_1_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent4", "role": "Combination_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent3", "role": "Treatment_Drug", "text": "tebipenem", "start": 18, "end": 19}, {"entity_id": "25407257_1_Ent5", "role": "Combination_Drug", "text": "tebipenem", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "25407257_1_Ent0", "text": "convulsive seizures", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "25407257_1_Ent1", "text": "co - administration of valproic acid and tebipenem", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "25407257_1_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent3", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "25407257_1_Ent5", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "25538343_1", "wnd_id": "25538343_1_1", "text": "Duloxetine - induced hyponatremia in an elderly patient treated with thiazide diuretics .", "tokens": ["Duloxetine", "-", "induced", "hyponatremia", "in", "an", "elderly", "patient", "treated", "with", "thiazide", "diuretics", "."], "event_mentions": [{"id": "25538343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "25538343_1_Ent3", "role": "Treatment", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent4", "role": "Treatment_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent7", "role": "Combination_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent2", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}, {"entity_id": "25538343_1_Ent0", "role": "Subject", "text": "an elderly patient treated with thiazide diuretics", "start": 5, "end": 12}, {"entity_id": "25538343_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "25538343_1_Ent5", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}, {"entity_id": "25538343_1_Ent6", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "25538343_1_Ent3", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent4", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent7", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25538343_1_Ent0", "text": "an elderly patient treated with thiazide diuretics", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "25538343_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25538343_1_Ent5", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "25538343_1_Ent6", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "25540831_4", "wnd_id": "25540831_4_1", "text": "We report a typical case of transient serotonin syndrome secondary to tramadol - Citalopram combination .", "tokens": ["We", "report", "a", "typical", "case", "of", "transient", "serotonin", "syndrome", "secondary", "to", "tramadol", "-", "Citalopram", "combination", "."], "event_mentions": [{"id": "25540831_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "25540831_4_Ent0", "role": "Subject", "text": "a typical case", "start": 2, "end": 5}, {"entity_id": "25540831_4_Ent1", "role": "Effect", "text": "transient serotonin syndrome", "start": 6, "end": 9}, {"entity_id": "25540831_4_Ent3", "role": "Treatment_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent5", "role": "Combination_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent2", "role": "Treatment", "text": "tramadol - Citalopram combination", "start": 11, "end": 15}, {"entity_id": "25540831_4_Ent4", "role": "Treatment_Drug", "text": "Citalopram", "start": 13, "end": 14}, {"entity_id": "25540831_4_Ent6", "role": "Combination_Drug", "text": "Citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "25540831_4_Ent0", "text": "a typical case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "25540831_4_Ent1", "text": "transient serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "25540831_4_Ent3", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent5", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent2", "text": "tramadol - Citalopram combination", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "25540831_4_Ent4", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25540831_4_Ent6", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "25540831_8", "wnd_id": "25540831_8_1", "text": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome .", "tokens": ["Clinicians", "should", "also", "be", "aware", "of", "the", "possibility", "of", "serotonin", "syndrome", "when", "encountering", "a", "patient", "taking", "serotonergic", "drugs", "who", "presents", "with", "characteristic", "symptoms", "of", "serotonin", "syndrome", "."], "event_mentions": [{"id": "25540831_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 15, "end": 16}, "arguments": [{"entity_id": "25540831_8_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 9, "end": 11}, {"entity_id": "25540831_8_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}, {"entity_id": "25540831_8_Ent2", "role": "Treatment", "text": "serotonergic drugs", "start": 16, "end": 18}, {"entity_id": "25540831_8_Ent3", "role": "Treatment_Drug", "text": "serotonergic drugs", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "25540831_8_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "25540831_8_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "25540831_8_Ent2", "text": "serotonergic drugs", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "25540831_8_Ent3", "text": "serotonergic drugs", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "2554727_2", "wnd_id": "2554727_2_1", "text": "High - dose cytosine arabinoside may benefit patients with refractory acute leukemia .", "tokens": ["High", "-", "dose", "cytosine", "arabinoside", "may", "benefit", "patients", "with", "refractory", "acute", "leukemia", "."], "event_mentions": [{"id": "2554727_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "benefit", "start": 6, "end": 7}, "arguments": [{"entity_id": "2554727_2_Ent3", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "2554727_2_Ent1", "role": "Treatment", "text": "High - dose cytosine arabinoside", "start": 0, "end": 5}, {"entity_id": "2554727_2_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 3, "end": 5}, {"entity_id": "2554727_2_Ent0", "role": "Subject", "text": "patients with refractory acute leukemia", "start": 7, "end": 12}, {"entity_id": "2554727_2_Ent2", "role": "Treatment_Disorder", "text": "refractory acute leukemia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2554727_2_Ent3", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2554727_2_Ent1", "text": "High - dose cytosine arabinoside", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2554727_2_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2554727_2_Ent0", "text": "patients with refractory acute leukemia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2554727_2_Ent2", "text": "refractory acute leukemia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "2554727_4", "wnd_id": "2554727_4_1", "text": "We describe a patient with acute leukemia who developed Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose cytosine arabinoside .", "tokens": ["We", "describe", "a", "patient", "with", "acute", "leukemia", "who", "developed", "Horner", "'s", "syndrome", "and", "a", "severe", "demyelinating", "peripheral", "neuropathy", "leading", "to", "death", "after", "receiving", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_4_Ent0", "role": "Subject", "text": "a patient with acute leukemia", "start": 2, "end": 7}, {"entity_id": "2554727_4_Ent3", "role": "Treatment_Disorder", "text": "acute leukemia", "start": 5, "end": 7}, {"entity_id": "2554727_4_Ent1", "role": "Effect", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "start": 9, "end": 21}, {"entity_id": "2554727_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 23, "end": 26}, {"entity_id": "2554727_4_Ent2", "role": "Treatment", "text": "high - dose cytosine arabinoside .", "start": 23, "end": 29}, {"entity_id": "2554727_4_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "2554727_4_Ent0", "text": "a patient with acute leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2554727_4_Ent3", "text": "acute leukemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2554727_4_Ent1", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "2554727_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "2554727_4_Ent2", "text": "high - dose cytosine arabinoside .", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2554727_4_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "2568058_1", "wnd_id": "2568058_1_1", "text": "Nail - changes induced by penicillamine .", "tokens": ["Nail", "-", "changes", "induced", "by", "penicillamine", "."], "event_mentions": [{"id": "2568058_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2568058_1_Ent0", "role": "Effect", "text": "Nail - changes", "start": 0, "end": 3}, {"entity_id": "2568058_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 5, "end": 6}, {"entity_id": "2568058_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2568058_1_Ent0", "text": "Nail - changes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2568058_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2568058_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2586773_1", "wnd_id": "2586773_1_1", "text": "Ibuprofen - induced meningitis : detection of intrathecal IgG synthesis and immune complexes .", "tokens": ["Ibuprofen", "-", "induced", "meningitis", ":", "detection", "of", "intrathecal", "IgG", "synthesis", "and", "immune", "complexes", "."], "event_mentions": [{"id": "2586773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2586773_1_Ent1", "role": "Treatment", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2586773_1_Ent2", "role": "Treatment_Drug", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2586773_1_Ent0", "role": "Effect", "text": "meningitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2586773_1_Ent1", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2586773_1_Ent2", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2586773_1_Ent0", "text": "meningitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2595431_1", "wnd_id": "2595431_1_1", "text": "Metoclopramide - induced parkinsonism is not rare , and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity .", "tokens": ["Metoclopramide", "-", "induced", "parkinsonism", "is", "not", "rare", ",", "and", "appropriate", "dose", "reduction", "in", "patients", "with", "renal", "failure", "will", "help", "reduce", "the", "incidence", "of", "this", "morbidity", "."], "event_mentions": [{"id": "2595431_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2595431_1_Ent3", "role": "Treatment", "text": "Metoclopramide", "start": 0, "end": 1}, {"entity_id": "2595431_1_Ent4", "role": "Treatment_Drug", "text": "Metoclopramide", "start": 0, "end": 1}, {"entity_id": "2595431_1_Ent2", "role": "Effect", "text": "parkinsonism", "start": 3, "end": 4}, {"entity_id": "2595431_1_Ent0", "role": "Subject", "text": "patients with renal failure", "start": 13, "end": 17}, {"entity_id": "2595431_1_Ent1", "role": "Subject_Disorder", "text": "renal failure", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "2595431_1_Ent3", "text": "Metoclopramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2595431_1_Ent4", "text": "Metoclopramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2595431_1_Ent2", "text": "parkinsonism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2595431_1_Ent0", "text": "patients with renal failure", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "2595431_1_Ent1", "text": "renal failure", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "25957434_3", "wnd_id": "25957434_3_1", "text": "We report a case of bullous eruption , one month after starting nicardipine and lercanidipine .", "tokens": ["We", "report", "a", "case", "of", "bullous", "eruption", ",", "one", "month", "after", "starting", "nicardipine", "and", "lercanidipine", "."], "event_mentions": [{"id": "25957434_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "25957434_3_Ent0", "role": "Effect", "text": "bullous eruption ,", "start": 5, "end": 8}, {"entity_id": "25957434_3_Ent2", "role": "Treatment_Time_elapsed", "text": "one month", "start": 8, "end": 10}, {"entity_id": "25957434_3_Ent1", "role": "Treatment", "text": "starting nicardipine and lercanidipine .", "start": 11, "end": 16}, {"entity_id": "25957434_3_Ent3", "role": "Treatment_Drug", "text": "nicardipine", "start": 12, "end": 13}, {"entity_id": "25957434_3_Ent5", "role": "Combination_Drug", "text": "nicardipine", "start": 12, "end": 13}, {"entity_id": "25957434_3_Ent4", "role": "Treatment_Drug", "text": "lercanidipine", "start": 14, "end": 15}, {"entity_id": "25957434_3_Ent6", "role": "Combination_Drug", "text": "lercanidipine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "25957434_3_Ent0", "text": "bullous eruption ,", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "25957434_3_Ent2", "text": "one month", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "25957434_3_Ent1", "text": "starting nicardipine and lercanidipine .", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "25957434_3_Ent3", "text": "nicardipine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25957434_3_Ent5", "text": "nicardipine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25957434_3_Ent4", "text": "lercanidipine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25957434_3_Ent6", "text": "lercanidipine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "2616440_2", "wnd_id": "2616440_2_1", "text": "We report the case of a patient with multiple myeloma who developed acute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "multiple", "myeloma", "who", "developed", "acute", "life", "-", "threatening", "water", "intoxication", "following", "treatment", "with", "oral", "indomethacin", "and", "low", "dose", "intravenous", "cyclophosphamide", "."], "event_mentions": [{"id": "2616440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2616440_2_Ent0", "role": "Subject", "text": "a patient with multiple myeloma", "start": 5, "end": 10}, {"entity_id": "2616440_2_Ent3", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 8, "end": 10}, {"entity_id": "2616440_2_Ent1", "role": "Effect", "text": "acute life - threatening water intoxication", "start": 12, "end": 18}, {"entity_id": "2616440_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "2616440_2_Ent2", "role": "Treatment", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "start": 21, "end": 28}, {"entity_id": "2616440_2_Ent6", "role": "Treatment_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent9", "role": "Combination_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent8", "role": "Treatment_Dosage", "text": "low dose", "start": 24, "end": 26}, {"entity_id": "2616440_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 26, "end": 27}, {"entity_id": "2616440_2_Ent7", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "2616440_2_Ent10", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "2616440_2_Ent0", "text": "a patient with multiple myeloma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "2616440_2_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2616440_2_Ent1", "text": "acute life - threatening water intoxication", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2616440_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2616440_2_Ent2", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "2616440_2_Ent6", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent9", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent8", "text": "low dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "2616440_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "2616440_2_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "2616440_2_Ent10", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "2690546_2", "wnd_id": "2690546_2_1", "text": "Amiodarone induced torsades de pointe .", "tokens": ["Amiodarone", "induced", "torsades", "de", "pointe", "."], "event_mentions": [{"id": "2690546_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "2690546_2_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2690546_2_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2690546_2_Ent0", "role": "Effect", "text": "torsades de pointe", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "2690546_2_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2690546_2_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2690546_2_Ent0", "text": "torsades de pointe", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "2719905_1", "wnd_id": "2719905_1_1", "text": "Long lasting respiratory depression induced by morphine - 6 - glucuronide ?", "tokens": ["Long", "lasting", "respiratory", "depression", "induced", "by", "morphine", "-", "6", "-", "glucuronide", "?"], "event_mentions": [{"id": "2719905_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2719905_1_Ent0", "role": "Effect", "text": "Long lasting respiratory depression", "start": 0, "end": 4}, {"entity_id": "2719905_1_Ent1", "role": "Treatment", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}, {"entity_id": "2719905_1_Ent2", "role": "Treatment_Drug", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}]}], "entity_mentions": [{"id": "2719905_1_Ent0", "text": "Long lasting respiratory depression", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2719905_1_Ent1", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "2719905_1_Ent2", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}], "lang": "en"}
{"doc_id": "2738729_1", "wnd_id": "2738729_1_1", "text": "We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy .", "tokens": ["We", "present", "the", "first", "case", "of", "WES", "in", "an", "infant", "born", "to", "a", "mother", "taking", "haloperidol", "during", "her", "pregnancy", "."], "event_mentions": [{"id": "2738729_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 4, "end": 5}, "arguments": [{"entity_id": "2738729_1_Ent2", "role": "Effect", "text": "WES", "start": 6, "end": 7}, {"entity_id": "2738729_1_Ent0", "role": "Subject", "text": "an infant born to a mother", "start": 8, "end": 14}, {"entity_id": "2738729_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 9, "end": 10}, {"entity_id": "2738729_1_Ent3", "role": "Treatment", "text": "haloperidol", "start": 15, "end": 16}, {"entity_id": "2738729_1_Ent4", "role": "Treatment_Drug", "text": "haloperidol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2738729_1_Ent2", "text": "WES", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2738729_1_Ent0", "text": "an infant born to a mother", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "2738729_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2738729_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2738729_1_Ent4", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2803154_3", "wnd_id": "2803154_3_1", "text": "The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium - effectuated neurotoxicity ( SILENT ) while being treated with lithium for a manic episode .", "tokens": ["The", "authors", "describe", "a", "patient", "with", "hemiparesis", "who", "developed", "the", "syndrome", "of", "irreversible", "lithium", "-", "effectuated", "neurotoxicity", "(", "SILENT", ")", "while", "being", "treated", "with", "lithium", "for", "a", "manic", "episode", "."], "event_mentions": [{"id": "2803154_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "2803154_3_Ent0", "role": "Subject", "text": "a patient with hemiparesis", "start": 3, "end": 7}, {"entity_id": "2803154_3_Ent1", "role": "Subject_Disorder", "text": "hemiparesis", "start": 6, "end": 7}, {"entity_id": "2803154_3_Ent2", "role": "Effect", "text": "irreversible lithium - effectuated neurotoxicity ( SILENT )", "start": 12, "end": 20}, {"entity_id": "2803154_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 24, "end": 25}, {"entity_id": "2803154_3_Ent3", "role": "Treatment", "text": "lithium for a manic episode", "start": 24, "end": 29}, {"entity_id": "2803154_3_Ent5", "role": "Treatment_Disorder", "text": "manic episode", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "2803154_3_Ent0", "text": "a patient with hemiparesis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "2803154_3_Ent1", "text": "hemiparesis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2803154_3_Ent2", "text": "irreversible lithium - effectuated neurotoxicity ( SILENT )", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "2803154_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "2803154_3_Ent3", "text": "lithium for a manic episode", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "2803154_3_Ent5", "text": "manic episode", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "282937_3", "wnd_id": "282937_3_1", "text": "Paraplegia following prophylactic intrathecal cytosine arabinoside ( Ara - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2/d for 5 consecutive days .", "tokens": ["Paraplegia", "following", "prophylactic", "intrathecal", "cytosine", "arabinoside", "(", "Ara", "-", "C", ")", "is", "described", "in", "a", "patient", "with", "acute", "myelogenous", "leukemia", "in", "remission", "who", "received", "doses", "of", "100", "mg", "/", "m2/d", "for", "5", "consecutive", "days", "."], "event_mentions": [{"id": "282937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "282937_3_Ent1", "role": "Effect", "text": "Paraplegia", "start": 0, "end": 1}, {"entity_id": "282937_3_Ent2", "role": "Treatment", "text": "prophylactic intrathecal cytosine arabinoside ( Ara - C )", "start": 2, "end": 11}, {"entity_id": "282937_3_Ent5", "role": "Treatment_Route", "text": "intrathecal", "start": 3, "end": 4}, {"entity_id": "282937_3_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 4, "end": 6}, {"entity_id": "282937_3_Ent0", "role": "Subject", "text": "a patient with acute myelogenous leukemia in remission", "start": 14, "end": 22}, {"entity_id": "282937_3_Ent6", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia in remission", "start": 17, "end": 22}, {"entity_id": "282937_3_Ent3", "role": "Treatment", "text": "doses of 100 mg / m2/d for 5 consecutive days", "start": 24, "end": 34}, {"entity_id": "282937_3_Ent7", "role": "Treatment_Dosage", "text": "100 mg / m2/d", "start": 26, "end": 30}, {"entity_id": "282937_3_Ent8", "role": "Treatment_Duration", "text": "5 consecutive days", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "282937_3_Ent1", "text": "Paraplegia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "282937_3_Ent2", "text": "prophylactic intrathecal cytosine arabinoside ( Ara - C )", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "282937_3_Ent5", "text": "intrathecal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "282937_3_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "282937_3_Ent0", "text": "a patient with acute myelogenous leukemia in remission", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "282937_3_Ent6", "text": "acute myelogenous leukemia in remission", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "282937_3_Ent3", "text": "doses of 100 mg / m2/d for 5 consecutive days", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "282937_3_Ent7", "text": "100 mg / m2/d", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "282937_3_Ent8", "text": "5 consecutive days", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "2863342_2", "wnd_id": "2863342_2_1", "text": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine .", "tokens": ["We", "discuss", "a", "variety", "of", "bronchopulmonary", "complications", "of", "IBD", "and", "their", "association", "with", "sulfasalazine", "."], "event_mentions": [{"id": "2863342_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 11, "end": 12}, "arguments": [{"entity_id": "2863342_2_Ent0", "role": "Effect", "text": "a variety of bronchopulmonary complications of IBD", "start": 2, "end": 9}, {"entity_id": "2863342_2_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 13, "end": 14}, {"entity_id": "2863342_2_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2863342_2_Ent0", "text": "a variety of bronchopulmonary complications of IBD", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "2863342_2_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2863342_2_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2894766_1", "wnd_id": "2894766_1_1", "text": "It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .", "tokens": ["It", "is", "suggested", "that", "the", "patient", "had", "sulfasalazine", "-", "induced", "lupus", ",", "which", "manifested", "with", "serositis", "and", "pulmonary", "parenchymal", "involvement", "in", "the", "absence", "of", "joint", "symptoms", "."], "event_mentions": [{"id": "2894766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2894766_1_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent0", "role": "Effect", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "2894766_1_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent0", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "2894766_3", "wnd_id": "2894766_3_1", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .", "tokens": ["Pneumonitis", ",", "bilateral", "pleural", "effusions", ",", "echocardiographic", "evidence", "of", "cardiac", "tamponade", ",", "and", "positive", "autoantibodies", "developed", "in", "a", "43", "-", "year", "-", "old", "man", ",", "who", "was", "receiving", "long", "-", "term", "sulfasalazine", "therapy", "for", "chronic", "ulcerative", "colitis", "."], "event_mentions": [{"id": "2894766_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2894766_3_Ent3", "role": "Effect", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "start": 0, "end": 15}, {"entity_id": "2894766_3_Ent0", "role": "Subject", "text": "a 43 - year - old man", "start": 17, "end": 24}, {"entity_id": "2894766_3_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 18, "end": 23}, {"entity_id": "2894766_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}, {"entity_id": "2894766_3_Ent4", "role": "Treatment", "text": "long - term sulfasalazine", "start": 28, "end": 32}, {"entity_id": "2894766_3_Ent6", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 31, "end": 32}, {"entity_id": "2894766_3_Ent5", "role": "Treatment_Disorder", "text": "chronic ulcerative colitis", "start": 34, "end": 37}]}], "entity_mentions": [{"id": "2894766_3_Ent3", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2894766_3_Ent0", "text": "a 43 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "2894766_3_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "2894766_3_Ent2", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2894766_3_Ent4", "text": "long - term sulfasalazine", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "2894766_3_Ent6", "text": "sulfasalazine", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2894766_3_Ent5", "text": "chronic ulcerative colitis", "entity_type": "Entity", "start": 34, "end": 37}], "lang": "en"}
{"doc_id": "2935070_1", "wnd_id": "2935070_1_1", "text": "Ampicillin - induced interstitial nephritis with generalised exfoliative dermatitis .", "tokens": ["Ampicillin", "-", "induced", "interstitial", "nephritis", "with", "generalised", "exfoliative", "dermatitis", "."], "event_mentions": [{"id": "2935070_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2935070_1_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "2935070_1_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "2935070_1_Ent0", "role": "Effect", "text": "interstitial nephritis with generalised exfoliative dermatitis", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "2935070_1_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2935070_1_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2935070_1_Ent0", "text": "interstitial nephritis with generalised exfoliative dermatitis", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "2940999_1", "wnd_id": "2940999_1_1", "text": "Abnormal retinal function associated with isotretinoin therapy for acne .", "tokens": ["Abnormal", "retinal", "function", "associated", "with", "isotretinoin", "therapy", "for", "acne", "."], "event_mentions": [{"id": "2940999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2940999_1_Ent0", "role": "Effect", "text": "Abnormal retinal function", "start": 0, "end": 3}, {"entity_id": "2940999_1_Ent1", "role": "Treatment", "text": "isotretinoin", "start": 5, "end": 6}, {"entity_id": "2940999_1_Ent3", "role": "Treatment_Drug", "text": "isotretinoin", "start": 5, "end": 6}, {"entity_id": "2940999_1_Ent2", "role": "Treatment_Disorder", "text": "acne", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2940999_1_Ent0", "text": "Abnormal retinal function", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2940999_1_Ent1", "text": "isotretinoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2940999_1_Ent3", "text": "isotretinoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2940999_1_Ent2", "text": "acne", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2943526_1", "wnd_id": "2943526_1_1", "text": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "tokens": ["Neurologic", "toxicity", "associated", "with", "hepatic", "artery", "infusion", "HAI", "of", "FUdR."], "event_mentions": [{"id": "2943526_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "2943526_1_Ent0", "role": "Effect", "text": "Neurologic toxicity", "start": 0, "end": 2}, {"entity_id": "2943526_1_Ent3", "role": "Treatment_Route", "text": "hepatic artery infusion", "start": 4, "end": 7}, {"entity_id": "2943526_1_Ent1", "role": "Treatment", "text": "hepatic artery infusion HAI of FUdR.", "start": 4, "end": 10}, {"entity_id": "2943526_1_Ent2", "role": "Treatment_Drug", "text": "FUdR.", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2943526_1_Ent0", "text": "Neurologic toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2943526_1_Ent3", "text": "hepatic artery infusion", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2943526_1_Ent1", "text": "hepatic artery infusion HAI of FUdR.", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "2943526_1_Ent2", "text": "FUdR.", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2979256_3", "wnd_id": "2979256_3_1", "text": "Nifedipine may induce , or aggravate , pre - existing , gastro - oesophageal reflux .", "tokens": ["Nifedipine", "may", "induce", ",", "or", "aggravate", ",", "pre", "-", "existing", ",", "gastro", "-", "oesophageal", "reflux", "."], "event_mentions": [{"id": "2979256_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce , or aggravate", "start": 2, "end": 6}, "arguments": [{"entity_id": "2979256_3_Ent1", "role": "Treatment", "text": "Nifedipine", "start": 0, "end": 1}, {"entity_id": "2979256_3_Ent2", "role": "Treatment_Drug", "text": "Nifedipine", "start": 0, "end": 1}, {"entity_id": "2979256_3_Ent0", "role": "Effect", "text": "gastro - oesophageal reflux", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "2979256_3_Ent1", "text": "Nifedipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2979256_3_Ent2", "text": "Nifedipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2979256_3_Ent0", "text": "gastro - oesophageal reflux", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "3084231_1", "wnd_id": "3084231_1_1", "text": "Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced hyperammonemia .", "tokens": ["Possible", "pathophysiological", "mechanisms", "which", "may", "have", "been", "operative", "in", "this", "case", "include", ":", "a", "direct", "central", "nervous", "system", "(", "CNS", ")", "toxic", "effect", "of", "valproic", "acid", ";", "a", "paradoxical", "epileptogenic", "effect", "secondary", "to", "the", "drug", ";", "and", "an", "indirect", "CNS", "toxic", "effect", "mediated", "through", "valproic", "acid", "-", "induced", "hyperammonemia", "."], "event_mentions": [{"id": "3084231_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 47, "end": 48}, "arguments": [{"entity_id": "3084231_1_Ent0", "role": "Effect", "text": "a direct central nervous system ( CNS ) toxic effect", "start": 13, "end": 23}, {"entity_id": "3084231_1_Ent3", "role": "Treatment", "text": "valproic acid", "start": 24, "end": 26}, {"entity_id": "3084231_1_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 24, "end": 26}, {"entity_id": "3084231_1_Ent1", "role": "Effect", "text": "a paradoxical epileptogenic effect", "start": 27, "end": 31}, {"entity_id": "3084231_1_Ent2", "role": "Effect", "text": "hyperammonemia", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "3084231_1_Ent0", "text": "a direct central nervous system ( CNS ) toxic effect", "entity_type": "Entity", "start": 13, "end": 23}, {"id": "3084231_1_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "3084231_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "3084231_1_Ent1", "text": "a paradoxical epileptogenic effect", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "3084231_1_Ent2", "text": "hyperammonemia", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "3084231_2", "wnd_id": "3084231_2_1", "text": "Reversible valproic acid - induced dementia : a case report .", "tokens": ["Reversible", "valproic", "acid", "-", "induced", "dementia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "3084231_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3084231_2_Ent1", "role": "Treatment", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent0", "role": "Effect", "text": "dementia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3084231_2_Ent1", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent0", "text": "dementia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3101617_2", "wnd_id": "3101617_2_1", "text": "When co - trimoxazole was stopped the red cell aplasia resolved .", "tokens": ["When", "co", "-", "trimoxazole", "was", "stopped", "the", "red", "cell", "aplasia", "resolved", "."], "event_mentions": [{"id": "3101617_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopped", "start": 5, "end": 6}, "arguments": [{"entity_id": "3101617_2_Ent1", "role": "Treatment", "text": "co - trimoxazole", "start": 1, "end": 4}, {"entity_id": "3101617_2_Ent2", "role": "Treatment_Drug", "text": "co - trimoxazole", "start": 1, "end": 4}, {"entity_id": "3101617_2_Ent0", "role": "Effect", "text": "red cell aplasia resolved", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "3101617_2_Ent1", "text": "co - trimoxazole", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "3101617_2_Ent2", "text": "co - trimoxazole", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "3101617_2_Ent0", "text": "red cell aplasia resolved", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "3136101_2", "wnd_id": "3136101_2_1", "text": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms .", "tokens": ["Two", "infants", "developed", "hyperkalemia", "shortly", "after", "cessation", "of", "prolonged", "ACTH", "therapy", "for", "infantile", "spasms", "."], "event_mentions": [{"id": "3136101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "3136101_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3136101_2_Ent0", "role": "Subject", "text": "Two infants", "start": 0, "end": 2}, {"entity_id": "3136101_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 1, "end": 2}, {"entity_id": "3136101_2_Ent3", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}, {"entity_id": "3136101_2_Ent6", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 4, "end": 6}, {"entity_id": "3136101_2_Ent4", "role": "Treatment", "text": "shortly after cessation of prolonged ACTH therapy", "start": 4, "end": 11}, {"entity_id": "3136101_2_Ent7", "role": "Treatment_Dosage", "text": "cessation", "start": 6, "end": 7}, {"entity_id": "3136101_2_Ent8", "role": "Treatment_Drug", "text": "ACTH", "start": 9, "end": 10}, {"entity_id": "3136101_2_Ent5", "role": "Treatment_Disorder", "text": "infantile spasms", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3136101_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3136101_2_Ent0", "text": "Two infants", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3136101_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3136101_2_Ent3", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3136101_2_Ent6", "text": "shortly after", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3136101_2_Ent4", "text": "shortly after cessation of prolonged ACTH therapy", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "3136101_2_Ent7", "text": "cessation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3136101_2_Ent8", "text": "ACTH", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3136101_2_Ent5", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3143551_4", "wnd_id": "3143551_4_1", "text": "Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine , lynestrenol and sodium valproate .", "tokens": ["Four", "weeks", "earlier", "she", "had", "developed", "hepatopathy", "during", "a", "regimen", "of", "carbamazepine", ",", "lynestrenol", "and", "sodium", "valproate", "."], "event_mentions": [{"id": "3143551_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "3143551_4_Ent0", "role": "Subject", "text": "she", "start": 3, "end": 4}, {"entity_id": "3143551_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 3, "end": 4}, {"entity_id": "3143551_4_Ent2", "role": "Effect", "text": "hepatopathy", "start": 6, "end": 7}, {"entity_id": "3143551_4_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 11, "end": 12}, {"entity_id": "3143551_4_Ent3", "role": "Treatment", "text": "carbamazepine , lynestrenol and sodium valproate", "start": 11, "end": 17}, {"entity_id": "3143551_4_Ent5", "role": "Treatment_Drug", "text": "lynestrenol", "start": 13, "end": 14}, {"entity_id": "3143551_4_Ent6", "role": "Treatment_Drug", "text": "sodium valproate", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "3143551_4_Ent0", "text": "she", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3143551_4_Ent1", "text": "she", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3143551_4_Ent2", "text": "hepatopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3143551_4_Ent3", "text": "carbamazepine , lynestrenol and sodium valproate", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "3143551_4_Ent5", "text": "lynestrenol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3143551_4_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "3156465_3", "wnd_id": "3156465_3_1", "text": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts .", "tokens": ["We", "report", "an", "additional", "case", "of", "isotretinoin", "teratogenicity", "in", "which", "the", "patient", "had", "agenesis", "of", "the", "cerebellar", "vermis", ",", "multiple", "leptomeningeal", "neuroglial", "heterotopias", ",", "hydrocephalus", ",", "and", "abnormalities", "of", "the", "corticospinal", "tracts", "."], "event_mentions": [{"id": "3156465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "teratogenicity", "start": 7, "end": 8}, "arguments": [{"entity_id": "3156465_3_Ent2", "role": "Treatment", "text": "isotretinoin", "start": 6, "end": 7}, {"entity_id": "3156465_3_Ent3", "role": "Treatment_Drug", "text": "isotretinoin", "start": 6, "end": 7}, {"entity_id": "3156465_3_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "3156465_3_Ent1", "role": "Effect", "text": "agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts", "start": 13, "end": 32}]}], "entity_mentions": [{"id": "3156465_3_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3156465_3_Ent3", "text": "isotretinoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3156465_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3156465_3_Ent1", "text": "agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts", "entity_type": "Entity", "start": 13, "end": 32}], "lang": "en"}
{"doc_id": "3159106_3", "wnd_id": "3159106_3_1", "text": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction .", "tokens": ["The", "allopurinol", "hypersensitivity", "syndrome", "is", "a", "rare", "adverse", "drug", "reaction", "."], "event_mentions": [{"id": "3159106_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 7, "end": 8}, "arguments": [{"entity_id": "3159106_3_Ent1", "role": "Treatment", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent2", "role": "Treatment_Drug", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "3159106_3_Ent1", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent2", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "3301251_3", "wnd_id": "3301251_3_1", "text": "Salicylate - induced hepatotoxicity is reviewed .", "tokens": ["Salicylate", "-", "induced", "hepatotoxicity", "is", "reviewed", "."], "event_mentions": [{"id": "3301251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3301251_3_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent2", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3301251_3_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent2", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3346128_1", "wnd_id": "3346128_1_1", "text": "A 43 - year - old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate .", "tokens": ["A", "43", "-", "year", "-", "old", "white", "man", "developed", "a", "shallow", "erosion", "of", "a", "psoriatic", "plaque", "after", "chronic", "administration", "of", "methotrexate", "."], "event_mentions": [{"id": "3346128_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "3346128_1_Ent0", "role": "Subject", "text": "A 43 - year - old white man", "start": 0, "end": 8}, {"entity_id": "3346128_1_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 1, "end": 6}, {"entity_id": "3346128_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "3346128_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "3346128_1_Ent4", "role": "Effect", "text": "shallow erosion of a psoriatic plaque", "start": 10, "end": 16}, {"entity_id": "3346128_1_Ent7", "role": "Treatment_Disorder", "text": "psoriatic plaque", "start": 14, "end": 16}, {"entity_id": "3346128_1_Ent8", "role": "Treatment_Duration", "text": "chronic", "start": 17, "end": 18}, {"entity_id": "3346128_1_Ent5", "role": "Treatment", "text": "chronic administration of methotrexate", "start": 17, "end": 21}, {"entity_id": "3346128_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3346128_1_Ent0", "text": "A 43 - year - old white man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3346128_1_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3346128_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3346128_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3346128_1_Ent4", "text": "shallow erosion of a psoriatic plaque", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3346128_1_Ent7", "text": "psoriatic plaque", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3346128_1_Ent8", "text": "chronic", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "3346128_1_Ent5", "text": "chronic administration of methotrexate", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "3346128_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3430507_1", "wnd_id": "3430507_1_1", "text": "D - penicillamine induced crescentic glomerulonephritis : report and review of the literature .", "tokens": ["D", "-", "penicillamine", "induced", "crescentic", "glomerulonephritis", ":", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "3430507_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3430507_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent0", "role": "Effect", "text": "crescentic glomerulonephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3430507_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent0", "text": "crescentic glomerulonephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3430507_4", "wnd_id": "3430507_4_1", "text": "The 9 other reported cases of D - penicillamine induced rapidly progressive glomerulonephritis have been reviewed .", "tokens": ["The", "9", "other", "reported", "cases", "of", "D", "-", "penicillamine", "induced", "rapidly", "progressive", "glomerulonephritis", "have", "been", "reviewed", "."], "event_mentions": [{"id": "3430507_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "3430507_4_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 6, "end": 9}, {"entity_id": "3430507_4_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 6, "end": 9}, {"entity_id": "3430507_4_Ent0", "role": "Effect", "text": "rapidly progressive glomerulonephritis", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "3430507_4_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3430507_4_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3430507_4_Ent0", "text": "rapidly progressive glomerulonephritis", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "3470173_2", "wnd_id": "3470173_2_1", "text": "Cytarabine - induced cerebellar syndrome : case report and literature review .", "tokens": ["Cytarabine", "-", "induced", "cerebellar", "syndrome", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "3470173_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3470173_2_Ent1", "role": "Treatment", "text": "Cytarabine", "start": 0, "end": 1}, {"entity_id": "3470173_2_Ent2", "role": "Treatment_Drug", "text": "Cytarabine", "start": 0, "end": 1}, {"entity_id": "3470173_2_Ent0", "role": "Effect", "text": "cerebellar syndrome", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "3470173_2_Ent1", "text": "Cytarabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3470173_2_Ent2", "text": "Cytarabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3470173_2_Ent0", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3493797_1", "wnd_id": "3493797_1_1", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs , developed a B - cell lymphoma of the lip following 4 1/2 years of treatment with razoxane .", "tokens": ["A", "woman", "with", "a", "20", "-", "year", "history", "of", "acral", "pustular", "psoriasis", "of", "Hallopeau", "and", "recurrent", "pustular", "lesions", "of", "the", "forearms", "and", "lower", "legs", ",", "developed", "a", "B", "-", "cell", "lymphoma", "of", "the", "lip", "following", "4", "1/2", "years", "of", "treatment", "with", "razoxane", "."], "event_mentions": [{"id": "3493797_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "3493797_1_Ent0", "role": "Subject", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "start": 0, "end": 24}, {"entity_id": "3493797_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "3493797_1_Ent6", "role": "Treatment_Disorder", "text": "acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "start": 9, "end": 24}, {"entity_id": "3493797_1_Ent2", "role": "Effect", "text": "a B - cell lymphoma of the lip", "start": 26, "end": 34}, {"entity_id": "3493797_1_Ent4", "role": "Treatment_Duration", "text": "following 4 1/2 years", "start": 34, "end": 38}, {"entity_id": "3493797_1_Ent3", "role": "Treatment", "text": "4 1/2 years of treatment with razoxane", "start": 35, "end": 42}, {"entity_id": "3493797_1_Ent5", "role": "Treatment_Drug", "text": "razoxane", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "3493797_1_Ent0", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "entity_type": "Entity", "start": 0, "end": 24}, {"id": "3493797_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3493797_1_Ent6", "text": "acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "entity_type": "Entity", "start": 9, "end": 24}, {"id": "3493797_1_Ent2", "text": "a B - cell lymphoma of the lip", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "3493797_1_Ent4", "text": "following 4 1/2 years", "entity_type": "Entity", "start": 34, "end": 38}, {"id": "3493797_1_Ent3", "text": "4 1/2 years of treatment with razoxane", "entity_type": "Entity", "start": 35, "end": 42}, {"id": "3493797_1_Ent5", "text": "razoxane", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "3549808_1", "wnd_id": "3549808_1_1", "text": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction .", "tokens": ["One", "of", "the", "subjects", "who", "was", "using", "extemporaneous", "topical", "minoxidil", "had", "hypertension", "and", "arteriosclerotic", "disease", "and", "the", "other", "died", "of", "a", "myocardial", "infarction", "."], "event_mentions": [{"id": "3549808_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 10, "end": 11}, "arguments": [{"entity_id": "3549808_1_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "3549808_1_Ent0", "role": "Subject", "text": "One of the subjects", "start": 0, "end": 4}, {"entity_id": "3549808_1_Ent3", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent5", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent2", "role": "Effect", "text": "hypertension and arteriosclerotic disease", "start": 11, "end": 15}]}, {"id": "3549808_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 18, "end": 19}, "arguments": [{"entity_id": "3549808_1_Ent8", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent9", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent10", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent6", "role": "Subject", "text": "the other", "start": 16, "end": 18}, {"entity_id": "3549808_1_Ent7", "role": "Effect", "text": "died of a myocardial infarction", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "3549808_1_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3549808_1_Ent0", "text": "One of the subjects", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3549808_1_Ent3", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent8", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent9", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent5", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent10", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent2", "text": "hypertension and arteriosclerotic disease", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "3549808_1_Ent6", "text": "the other", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3549808_1_Ent7", "text": "died of a myocardial infarction", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "3569037_4", "wnd_id": "3569037_4_1", "text": "We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate .", "tokens": ["We", "present", "a", "case", "report", "of", "a", "patient", "with", "typhoid", "fever", "who", "experienced", "a", "hypersensitivity", "reaction", "subsequent", "to", "the", "infusion", "of", "chloramphenicol", "sodium", "succinate", "."], "event_mentions": [{"id": "3569037_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "subsequent to", "start": 16, "end": 18}, "arguments": [{"entity_id": "3569037_4_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_4_Ent3", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}, {"entity_id": "3569037_4_Ent1", "role": "Effect", "text": "hypersensitivity reaction", "start": 14, "end": 16}, {"entity_id": "3569037_4_Ent2", "role": "Treatment", "text": "the infusion of chloramphenicol sodium succinate", "start": 18, "end": 24}, {"entity_id": "3569037_4_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "3569037_4_Ent4", "role": "Treatment_Drug", "text": "chloramphenicol sodium succinate", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "3569037_4_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_4_Ent3", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3569037_4_Ent1", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3569037_4_Ent2", "text": "the infusion of chloramphenicol sodium succinate", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "3569037_4_Ent5", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3569037_4_Ent4", "text": "chloramphenicol sodium succinate", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "3579660_3", "wnd_id": "3579660_3_1", "text": "We describe a patient with Wilson 's disease who presented with neurologic disease , was treated with D - penicillamine , and suffered sudden neurologic deterioration coincident with therapy .", "tokens": ["We", "describe", "a", "patient", "with", "Wilson", "'s", "disease", "who", "presented", "with", "neurologic", "disease", ",", "was", "treated", "with", "D", "-", "penicillamine", ",", "and", "suffered", "sudden", "neurologic", "deterioration", "coincident", "with", "therapy", "."], "event_mentions": [{"id": "3579660_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 22, "end": 23}, "arguments": [{"entity_id": "3579660_3_Ent0", "role": "Subject", "text": "a patient with Wilson 's disease who presented with neurologic disease", "start": 2, "end": 13}, {"entity_id": "3579660_3_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 5, "end": 8}, {"entity_id": "3579660_3_Ent1", "role": "Subject_Disorder", "text": "neurologic disease", "start": 11, "end": 13}, {"entity_id": "3579660_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent2", "role": "Effect", "text": "sudden neurologic deterioration", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "3579660_3_Ent0", "text": "a patient with Wilson 's disease who presented with neurologic disease", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "3579660_3_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3579660_3_Ent1", "text": "neurologic disease", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3579660_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent2", "text": "sudden neurologic deterioration", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "3586163_2", "wnd_id": "3586163_2_1", "text": "Upper tract urothelial malignancy after cyclophosphamide therapy : a case report and literature review .", "tokens": ["Upper", "tract", "urothelial", "malignancy", "after", "cyclophosphamide", "therapy", ":", "a", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "3586163_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3586163_2_Ent0", "role": "Effect", "text": "Upper tract urothelial malignancy", "start": 0, "end": 4}, {"entity_id": "3586163_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 5, "end": 6}, {"entity_id": "3586163_2_Ent1", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "3586163_2_Ent0", "text": "Upper tract urothelial malignancy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3586163_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3586163_2_Ent1", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "3609047_3", "wnd_id": "3609047_3_1", "text": "We report a case of torsade de pointes following a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 ) administered after short intravenous loading for prevention of paroxysmal atrial flutter .", "tokens": ["We", "report", "a", "case", "of", "torsade", "de", "pointes", "following", "a", "single", "oral", "dose", "of", "amiodarone", "(", "1400", "mg", "or", "30", "mg", "kg", "-", "1", ")", "administered", "after", "short", "intravenous", "loading", "for", "prevention", "of", "paroxysmal", "atrial", "flutter", "."], "event_mentions": [{"id": "3609047_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "3609047_3_Ent0", "role": "Effect", "text": "torsade de pointes", "start": 5, "end": 8}, {"entity_id": "3609047_3_Ent1", "role": "Treatment", "text": "a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 )", "start": 9, "end": 25}, {"entity_id": "3609047_3_Ent2", "role": "Treatment_Dosage", "text": "single oral dose", "start": 10, "end": 13}, {"entity_id": "3609047_3_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3609047_3_Ent3", "role": "Treatment_Dosage", "text": "1400 mg", "start": 16, "end": 18}, {"entity_id": "3609047_3_Ent4", "role": "Treatment_Dosage", "text": "30 mg kg - 1", "start": 19, "end": 24}, {"entity_id": "3609047_3_Ent6", "role": "Treatment_Disorder", "text": "prevention of paroxysmal atrial flutter", "start": 31, "end": 36}]}], "entity_mentions": [{"id": "3609047_3_Ent0", "text": "torsade de pointes", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3609047_3_Ent1", "text": "a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 )", "entity_type": "Entity", "start": 9, "end": 25}, {"id": "3609047_3_Ent2", "text": "single oral dose", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3609047_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3609047_3_Ent3", "text": "1400 mg", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3609047_3_Ent4", "text": "30 mg kg - 1", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "3609047_3_Ent6", "text": "prevention of paroxysmal atrial flutter", "entity_type": "Entity", "start": 31, "end": 36}], "lang": "en"}
{"doc_id": "3628148_1", "wnd_id": "3628148_1_1", "text": "Rupture of a cerebral aneurysm associated with nifedipine treatment .", "tokens": ["Rupture", "of", "a", "cerebral", "aneurysm", "associated", "with", "nifedipine", "treatment", "."], "event_mentions": [{"id": "3628148_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "3628148_1_Ent0", "role": "Effect", "text": "Rupture of a cerebral aneurysm", "start": 0, "end": 5}, {"entity_id": "3628148_1_Ent1", "role": "Treatment", "text": "nifedipine", "start": 7, "end": 8}, {"entity_id": "3628148_1_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3628148_1_Ent0", "text": "Rupture of a cerebral aneurysm", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "3628148_1_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3628148_1_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3628148_2", "wnd_id": "3628148_2_1", "text": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment .", "tokens": ["We", "describe", "rupture", "of", "a", "cerebral", "arterial", "aneurysm", "in", "a", "32", "year", "old", "hypertensive", "woman", "following", "the", "introduction", "of", "nifedipine", "treatment", "."], "event_mentions": [{"id": "3628148_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "3628148_2_Ent3", "role": "Effect", "text": "rupture of a cerebral arterial aneurysm", "start": 2, "end": 8}, {"entity_id": "3628148_2_Ent0", "role": "Subject", "text": "a 32 year old hypertensive woman", "start": 9, "end": 15}, {"entity_id": "3628148_2_Ent1", "role": "Subject_Age", "text": "32 year old", "start": 10, "end": 13}, {"entity_id": "3628148_2_Ent5", "role": "Treatment_Disorder", "text": "hypertensive", "start": 13, "end": 14}, {"entity_id": "3628148_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 14, "end": 15}, {"entity_id": "3628148_2_Ent6", "role": "Treatment_Drug", "text": "nifedipine", "start": 19, "end": 20}, {"entity_id": "3628148_2_Ent4", "role": "Treatment", "text": "nifedipine treatment", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3628148_2_Ent3", "text": "rupture of a cerebral arterial aneurysm", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "3628148_2_Ent0", "text": "a 32 year old hypertensive woman", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "3628148_2_Ent1", "text": "32 year old", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3628148_2_Ent5", "text": "hypertensive", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3628148_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3628148_2_Ent6", "text": "nifedipine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3628148_2_Ent4", "text": "nifedipine treatment", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3677571_1", "wnd_id": "3677571_1_1", "text": "Phenytoin - induced hypersensitivity reactions .", "tokens": ["Phenytoin", "-", "induced", "hypersensitivity", "reactions", "."], "event_mentions": [{"id": "3677571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3677571_1_Ent1", "role": "Treatment", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "3677571_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "3677571_1_Ent0", "role": "Effect", "text": "hypersensitivity reactions .", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3677571_1_Ent1", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_1_Ent0", "text": "hypersensitivity reactions .", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3708949_1", "wnd_id": "3708949_1_1", "text": "After therapy with parenteral amiodarone ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy .", "tokens": ["After", "therapy", "with", "parenteral", "amiodarone", "(", "2300", "mg", "in", "3", "days", ")", "and", "other", "measures", ",", "signs", "of", "congestive", "heart", "failure", "disappeared", ";", "subsequently", "the", "patient", "developed", "jaundice", ",", "marked", "increase", "in", "serum", "transaminase", "levels", "and", "fall", "in", "prothrombin", "time", ",", "and", "histologic", "changes", "of", "severe", "centrilobular", "necrosis", "were", "observed", "in", "hepatic", "biopsy", "."], "event_mentions": [{"id": "3708949_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "3708949_1_Ent3", "role": "Treatment_Route", "text": "parenteral", "start": 3, "end": 4}, {"entity_id": "3708949_1_Ent1", "role": "Treatment", "text": "parenteral amiodarone ( 2300 mg in 3 days ) and other measures", "start": 3, "end": 15}, {"entity_id": "3708949_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "3708949_1_Ent4", "role": "Treatment_Dosage", "text": "2300 mg in 3 days", "start": 6, "end": 11}, {"entity_id": "3708949_1_Ent5", "role": "Treatment_Disorder", "text": "congestive heart failure", "start": 18, "end": 21}, {"entity_id": "3708949_1_Ent0", "role": "Effect", "text": "jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy", "start": 27, "end": 53}]}], "entity_mentions": [{"id": "3708949_1_Ent3", "text": "parenteral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3708949_1_Ent1", "text": "parenteral amiodarone ( 2300 mg in 3 days ) and other measures", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "3708949_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3708949_1_Ent4", "text": "2300 mg in 3 days", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3708949_1_Ent5", "text": "congestive heart failure", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "3708949_1_Ent0", "text": "jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy", "entity_type": "Entity", "start": 27, "end": 53}], "lang": "en"}
{"doc_id": "3732375_1", "wnd_id": "3732375_1_1", "text": "Theophylline intoxication following viloxazine induced decrease in clearance .", "tokens": ["Theophylline", "intoxication", "following", "viloxazine", "induced", "decrease", "in", "clearance", "."], "event_mentions": [{"id": "3732375_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3732375_1_Ent3", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent5", "role": "Combination_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent0", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "3732375_1_Ent1", "role": "Treatment", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent2", "role": "Treatment_Drug", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3732375_1_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent5", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent0", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3732375_1_Ent1", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent2", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3763264_1", "wnd_id": "3763264_1_1", "text": "Graft versus host - like illness in a child with phenobarbital hypersensitivity .", "tokens": ["Graft", "versus", "host", "-", "like", "illness", "in", "a", "child", "with", "phenobarbital", "hypersensitivity", "."], "event_mentions": [{"id": "3763264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 11, "end": 12}, "arguments": [{"entity_id": "3763264_1_Ent2", "role": "Effect", "text": "Graft versus host - like illness", "start": 0, "end": 6}, {"entity_id": "3763264_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "3763264_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "3763264_1_Ent4", "role": "Treatment", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent3", "role": "Effect", "text": "hypersensitivity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3763264_1_Ent2", "text": "Graft versus host - like illness", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "3763264_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3763264_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3763264_1_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent3", "text": "hypersensitivity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3804181_1", "wnd_id": "3804181_1_1", "text": "Methimazole - associated cholestatic liver injury : case report and brief literature review .", "tokens": ["Methimazole", "-", "associated", "cholestatic", "liver", "injury", ":", "case", "report", "and", "brief", "literature", "review", "."], "event_mentions": [{"id": "3804181_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "3804181_1_Ent1", "role": "Treatment", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "3804181_1_Ent2", "role": "Treatment_Drug", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "3804181_1_Ent0", "role": "Effect", "text": "cholestatic liver injury", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3804181_1_Ent1", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3804181_1_Ent2", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3804181_1_Ent0", "text": "cholestatic liver injury", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3815268_2", "wnd_id": "3815268_2_1", "text": "The possible role of interferon beta in the pathogenesis of sarcoidosis in this patient is discussed .", "tokens": ["The", "possible", "role", "of", "interferon", "beta", "in", "the", "pathogenesis", "of", "sarcoidosis", "in", "this", "patient", "is", "discussed", "."], "event_mentions": [{"id": "3815268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "role", "start": 2, "end": 3}, "arguments": [{"entity_id": "3815268_2_Ent2", "role": "Treatment", "text": "interferon beta", "start": 4, "end": 6}, {"entity_id": "3815268_2_Ent3", "role": "Treatment_Drug", "text": "interferon beta", "start": 4, "end": 6}, {"entity_id": "3815268_2_Ent1", "role": "Effect", "text": "sarcoidosis", "start": 10, "end": 11}, {"entity_id": "3815268_2_Ent0", "role": "Subject", "text": "this patient", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3815268_2_Ent2", "text": "interferon beta", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3815268_2_Ent3", "text": "interferon beta", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3815268_2_Ent1", "text": "sarcoidosis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3815268_2_Ent0", "text": "this patient", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3824704_1", "wnd_id": "3824704_1_1", "text": "Fatal outcome of intravesical formalin instillation , with changes mimicking renal tuberculosis .", "tokens": ["Fatal", "outcome", "of", "intravesical", "formalin", "instillation", ",", "with", "changes", "mimicking", "renal", "tuberculosis", "."], "event_mentions": [{"id": "3824704_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "3824704_1_Ent1", "role": "Effect", "text": "Fatal outcome", "start": 0, "end": 2}, {"entity_id": "3824704_1_Ent4", "role": "Treatment_Route", "text": "intravesical", "start": 3, "end": 4}, {"entity_id": "3824704_1_Ent2", "role": "Treatment", "text": "intravesical formalin instillation", "start": 3, "end": 6}, {"entity_id": "3824704_1_Ent3", "role": "Treatment_Drug", "text": "formalin", "start": 4, "end": 5}, {"entity_id": "3824704_1_Ent5", "role": "Treatment_Route", "text": "instillation", "start": 5, "end": 6}, {"entity_id": "3824704_1_Ent0", "role": "Effect", "text": "with changes mimicking renal tuberculosis", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "3824704_1_Ent1", "text": "Fatal outcome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3824704_1_Ent4", "text": "intravesical", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3824704_1_Ent2", "text": "intravesical formalin instillation", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3824704_1_Ent3", "text": "formalin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3824704_1_Ent5", "text": "instillation", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3824704_1_Ent0", "text": "with changes mimicking renal tuberculosis", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "3873709_1", "wnd_id": "3873709_1_1", "text": "Antibiotic - associated colitis ( pseudomembranous colitis ) developed in four patients with spinal cord injury and taking oral trimethoprim - sulfamethoxazole .", "tokens": ["Antibiotic", "-", "associated", "colitis", "(", "pseudomembranous", "colitis", ")", "developed", "in", "four", "patients", "with", "spinal", "cord", "injury", "and", "taking", "oral", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "3873709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "3873709_1_Ent2", "role": "Effect", "text": "Antibiotic - associated colitis ( pseudomembranous colitis )", "start": 0, "end": 8}, {"entity_id": "3873709_1_Ent1", "role": "Subject_Population", "text": "four", "start": 10, "end": 11}, {"entity_id": "3873709_1_Ent0", "role": "Subject", "text": "four patients with spinal cord injury", "start": 10, "end": 16}, {"entity_id": "3873709_1_Ent7", "role": "Treatment_Disorder", "text": "spinal cord injury", "start": 13, "end": 16}, {"entity_id": "3873709_1_Ent6", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "3873709_1_Ent3", "role": "Treatment", "text": "oral trimethoprim - sulfamethoxazole", "start": 18, "end": 22}, {"entity_id": "3873709_1_Ent5", "role": "Treatment_Drug", "text": "trimethoprim", "start": 19, "end": 20}, {"entity_id": "3873709_1_Ent8", "role": "Combination_Drug", "text": "trimethoprim", "start": 19, "end": 20}, {"entity_id": "3873709_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 21, "end": 22}, {"entity_id": "3873709_1_Ent9", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "3873709_1_Ent2", "text": "Antibiotic - associated colitis ( pseudomembranous colitis )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3873709_1_Ent1", "text": "four", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3873709_1_Ent0", "text": "four patients with spinal cord injury", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3873709_1_Ent7", "text": "spinal cord injury", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3873709_1_Ent6", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3873709_1_Ent3", "text": "oral trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "3873709_1_Ent5", "text": "trimethoprim", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3873709_1_Ent8", "text": "trimethoprim", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3873709_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3873709_1_Ent9", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "3878320_1", "wnd_id": "3878320_1_1", "text": "A lethal complication of peripheral vein vasopressin infusion .", "tokens": ["A", "lethal", "complication", "of", "peripheral", "vein", "vasopressin", "infusion", "."], "event_mentions": [{"id": "3878320_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 2, "end": 3}, "arguments": [{"entity_id": "3878320_1_Ent0", "role": "Effect", "text": "complication", "start": 2, "end": 3}, {"entity_id": "3878320_1_Ent2", "role": "Treatment_Route", "text": "peripheral vein", "start": 4, "end": 6}, {"entity_id": "3878320_1_Ent1", "role": "Treatment", "text": "peripheral vein vasopressin infusion", "start": 4, "end": 8}, {"entity_id": "3878320_1_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3878320_1_Ent0", "text": "complication", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3878320_1_Ent2", "text": "peripheral vein", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3878320_1_Ent1", "text": "peripheral vein vasopressin infusion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3878320_1_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3947272_2", "wnd_id": "3947272_2_1", "text": "Ampicillin may aggravate clinical and experimental myasthenia gravis .", "tokens": ["Ampicillin", "may", "aggravate", "clinical", "and", "experimental", "myasthenia", "gravis", "."], "event_mentions": [{"id": "3947272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravate", "start": 2, "end": 3}, "arguments": [{"entity_id": "3947272_2_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent0", "role": "Effect", "text": "myasthenia gravis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "3947272_2_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent0", "text": "myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3964363_2", "wnd_id": "3964363_2_1", "text": "Esophageal spasm following propranolol overdose relieved by glucagon .", "tokens": ["Esophageal", "spasm", "following", "propranolol", "overdose", "relieved", "by", "glucagon", "."], "event_mentions": [{"id": "3964363_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3964363_2_Ent0", "role": "Effect", "text": "Esophageal spasm", "start": 0, "end": 2}, {"entity_id": "3964363_2_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 3, "end": 4}, {"entity_id": "3964363_2_Ent1", "role": "Treatment", "text": "propranolol overdose", "start": 3, "end": 5}, {"entity_id": "3964363_2_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3964363_2_Ent0", "text": "Esophageal spasm", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3964363_2_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3964363_2_Ent1", "text": "propranolol overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3964363_2_Ent3", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3982906_3", "wnd_id": "3982906_3_1", "text": "The risk of cardiac decompensation in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of verapamil .", "tokens": ["The", "risk", "of", "cardiac", "decompensation", "in", "infants", "with", "supraventricular", "tachycardia", "and", "congestive", "cardiac", "failure", "should", "be", "kept", "in", "mind", "prior", "to", "administration", "of", "verapamil", "."], "event_mentions": [{"id": "3982906_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 1, "end": 2}, "arguments": [{"entity_id": "3982906_3_Ent3", "role": "Effect", "text": "cardiac decompensation", "start": 3, "end": 5}, {"entity_id": "3982906_3_Ent2", "role": "Subject_Age", "text": "infants", "start": 6, "end": 7}, {"entity_id": "3982906_3_Ent0", "role": "Subject", "text": "infants with supraventricular tachycardia and congestive cardiac failure", "start": 6, "end": 14}, {"entity_id": "3982906_3_Ent6", "role": "Treatment_Disorder", "text": "supraventricular tachycardia", "start": 8, "end": 10}, {"entity_id": "3982906_3_Ent1", "role": "Subject_Disorder", "text": "congestive cardiac failure", "start": 11, "end": 14}, {"entity_id": "3982906_3_Ent4", "role": "Treatment", "text": "verapamil", "start": 23, "end": 24}, {"entity_id": "3982906_3_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "3982906_3_Ent3", "text": "cardiac decompensation", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3982906_3_Ent2", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3982906_3_Ent0", "text": "infants with supraventricular tachycardia and congestive cardiac failure", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "3982906_3_Ent6", "text": "supraventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3982906_3_Ent1", "text": "congestive cardiac failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "3982906_3_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3982906_3_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "3997294_1", "wnd_id": "3997294_1_1", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .", "tokens": ["Pneumonitis", "with", "pleural", "and", "pericardial", "effusion", "and", "neuropathy", "during", "amiodarone", "therapy", "."], "event_mentions": [{"id": "3997294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "3997294_1_Ent0", "role": "Effect", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "start": 0, "end": 8}, {"entity_id": "3997294_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 9, "end": 10}, {"entity_id": "3997294_1_Ent1", "role": "Treatment", "text": "amiodarone therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3997294_1_Ent0", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3997294_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3997294_1_Ent1", "text": "amiodarone therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "4014301_4", "wnd_id": "4014301_4_1", "text": "This report describes the first case of insulin - induced cardiac failure in a patient without underlying heart disease .", "tokens": ["This", "report", "describes", "the", "first", "case", "of", "insulin", "-", "induced", "cardiac", "failure", "in", "a", "patient", "without", "underlying", "heart", "disease", "."], "event_mentions": [{"id": "4014301_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "4014301_4_Ent2", "role": "Treatment", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent1", "role": "Effect", "text": "cardiac failure", "start": 10, "end": 12}, {"entity_id": "4014301_4_Ent0", "role": "Subject", "text": "a patient without underlying heart disease", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "4014301_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent1", "text": "cardiac failure", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4014301_4_Ent0", "text": "a patient without underlying heart disease", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "4025011_2", "wnd_id": "4025011_2_1", "text": "Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described .", "tokens": ["Two", "patients", "with", "osteomyelitis", "who", "developed", "reversible", "cholestatic", "jaundice", "during", "treatment", "with", "oxacillin", "derivatives", "are", "described", "."], "event_mentions": [{"id": "4025011_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "4025011_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "4025011_2_Ent0", "role": "Subject", "text": "Two patients with osteomyelitis", "start": 0, "end": 4}, {"entity_id": "4025011_2_Ent4", "role": "Treatment_Disorder", "text": "osteomyelitis", "start": 3, "end": 4}, {"entity_id": "4025011_2_Ent2", "role": "Effect", "text": "reversible cholestatic jaundice", "start": 6, "end": 9}, {"entity_id": "4025011_2_Ent3", "role": "Treatment", "text": "oxacillin", "start": 12, "end": 13}, {"entity_id": "4025011_2_Ent5", "role": "Treatment_Drug", "text": "oxacillin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "4025011_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4025011_2_Ent0", "text": "Two patients with osteomyelitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "4025011_2_Ent4", "text": "osteomyelitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4025011_2_Ent2", "text": "reversible cholestatic jaundice", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "4025011_2_Ent3", "text": "oxacillin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "4025011_2_Ent5", "text": "oxacillin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "4031907_1", "wnd_id": "4031907_1_1", "text": "In all the patients , pellagra symptoms appeared during isoniazid therapy .", "tokens": ["In", "all", "the", "patients", ",", "pellagra", "symptoms", "appeared", "during", "isoniazid", "therapy", "."], "event_mentions": [{"id": "4031907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 7, "end": 8}, "arguments": [{"entity_id": "4031907_1_Ent0", "role": "Subject", "text": "all the patients", "start": 1, "end": 4}, {"entity_id": "4031907_1_Ent1", "role": "Effect", "text": "pellagra symptoms", "start": 5, "end": 7}, {"entity_id": "4031907_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "4031907_1_Ent2", "role": "Treatment", "text": "isoniazid therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "4031907_1_Ent0", "text": "all the patients", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4031907_1_Ent1", "text": "pellagra symptoms", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "4031907_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4031907_1_Ent2", "text": "isoniazid therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "4036917_2", "wnd_id": "4036917_2_1", "text": "Reye syndrome ( RS ) is believed to occur infrequently among children receiving long - term aspirin therapy .", "tokens": ["Reye", "syndrome", "(", "RS", ")", "is", "believed", "to", "occur", "infrequently", "among", "children", "receiving", "long", "-", "term", "aspirin", "therapy", "."], "event_mentions": [{"id": "4036917_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 8, "end": 9}, "arguments": [{"entity_id": "4036917_2_Ent2", "role": "Effect", "text": "Reye syndrome ( RS )", "start": 0, "end": 5}, {"entity_id": "4036917_2_Ent0", "role": "Subject", "text": "children", "start": 11, "end": 12}, {"entity_id": "4036917_2_Ent1", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}, {"entity_id": "4036917_2_Ent3", "role": "Treatment", "text": "long - term aspirin", "start": 13, "end": 17}, {"entity_id": "4036917_2_Ent4", "role": "Treatment_Drug", "text": "aspirin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "4036917_2_Ent2", "text": "Reye syndrome ( RS )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "4036917_2_Ent0", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_2_Ent1", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_2_Ent3", "text": "long - term aspirin", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "4036917_2_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "4082283_2", "wnd_id": "4082283_2_1", "text": "Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis , usually occurring well into the course of therapy .", "tokens": ["Renal", "failure", "is", "a", "rare", "complication", "associated", "with", "the", "use", "of", "rifampicin", "for", "the", "treatment", "of", "tuberculosis", ",", "usually", "occurring", "well", "into", "the", "course", "of", "therapy", "."], "event_mentions": [{"id": "4082283_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "4082283_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "4082283_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "4082283_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "4082283_2_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "4082283_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4082283_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4082283_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4082283_2_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "4095247_2", "wnd_id": "4095247_2_1", "text": "Subsequent in vivo / vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine , probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems .", "tokens": ["Subsequent", "in", "vivo", "/", "vitro", "studies", "clearly", "demonstrated", "that", "the", "neurological", "effects", "were", "due", "to", "a", "synergistic", "action", "of", "desferrioxamine", "and", "prochlorperazine", ",", "probably", "resulting", "in", "exceptional", "fluxes", "of", "intra", "/", "extra", "cellular", "iron", "/", "copper", "disturbing", "noradrenergic", "and", "serotonergic", "systems", "."], "event_mentions": [{"id": "4095247_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "4095247_2_Ent0", "role": "Effect", "text": "neurological effects", "start": 10, "end": 12}, {"entity_id": "4095247_2_Ent2", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 19, "end": 20}, {"entity_id": "4095247_2_Ent4", "role": "Combination_Drug", "text": "desferrioxamine", "start": 19, "end": 20}, {"entity_id": "4095247_2_Ent1", "role": "Treatment", "text": "desferrioxamine and prochlorperazine", "start": 19, "end": 22}, {"entity_id": "4095247_2_Ent3", "role": "Treatment_Drug", "text": "prochlorperazine", "start": 21, "end": 22}, {"entity_id": "4095247_2_Ent5", "role": "Combination_Drug", "text": "prochlorperazine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "4095247_2_Ent0", "text": "neurological effects", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4095247_2_Ent2", "text": "desferrioxamine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "4095247_2_Ent4", "text": "desferrioxamine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "4095247_2_Ent1", "text": "desferrioxamine and prochlorperazine", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "4095247_2_Ent3", "text": "prochlorperazine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "4095247_2_Ent5", "text": "prochlorperazine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "4095247_3", "wnd_id": "4095247_3_1", "text": "Two of these patients , who also received the anti - emetic prochlorperazine , lost consciousness for 48 - 72 h and then fully recovered .", "tokens": ["Two", "of", "these", "patients", ",", "who", "also", "received", "the", "anti", "-", "emetic", "prochlorperazine", ",", "lost", "consciousness", "for", "48", "-", "72", "h", "and", "then", "fully", "recovered", "."], "event_mentions": [{"id": "4095247_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lost", "start": 14, "end": 15}, "arguments": [{"entity_id": "4095247_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "4095247_3_Ent0", "role": "Subject", "text": "Two of these patients", "start": 0, "end": 4}, {"entity_id": "4095247_3_Ent3", "role": "Treatment", "text": "anti - emetic prochlorperazine", "start": 9, "end": 13}, {"entity_id": "4095247_3_Ent4", "role": "Treatment_Drug", "text": "prochlorperazine", "start": 12, "end": 13}, {"entity_id": "4095247_3_Ent2", "role": "Effect", "text": "lost consciousness for 48 - 72 h and then fully recovered", "start": 14, "end": 25}]}], "entity_mentions": [{"id": "4095247_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4095247_3_Ent0", "text": "Two of these patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "4095247_3_Ent3", "text": "anti - emetic prochlorperazine", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "4095247_3_Ent4", "text": "prochlorperazine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "4095247_3_Ent2", "text": "lost consciousness for 48 - 72 h and then fully recovered", "entity_type": "Entity", "start": 14, "end": 25}], "lang": "en"}
{"doc_id": "412488_2", "wnd_id": "412488_2_1", "text": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis .", "tokens": ["Three", "patients", "developed", "proteinuria", "following", "gold", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "412488_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "412488_2_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "412488_2_Ent2", "role": "Effect", "text": "proteinuria", "start": 3, "end": 4}, {"entity_id": "412488_2_Ent3", "role": "Treatment", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent5", "role": "Treatment_Drug", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "412488_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "412488_2_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "412488_2_Ent2", "text": "proteinuria", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "412488_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent5", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "424824_1", "wnd_id": "424824_1_1", "text": "Conversely , diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms .", "tokens": ["Conversely", ",", "diffuse", "interstitial", "pulmonary", "fibrosis", "should", "be", "considered", "in", "the", "differential", "diagnosis", "of", "patients", "receiving", "methotrexate", "who", "develop", "bilateral", "pulmonary", "infiltrates", "seen", "on", "chest", "roentgenograms", "."], "event_mentions": [{"id": "424824_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 18, "end": 19}, "arguments": [{"entity_id": "424824_1_Ent1", "role": "Effect", "text": "diffuse interstitial pulmonary fibrosis", "start": 2, "end": 6}, {"entity_id": "424824_1_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "424824_1_Ent3", "role": "Treatment", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "424824_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "424824_1_Ent2", "role": "Effect", "text": "bilateral pulmonary infiltrates", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "424824_1_Ent1", "text": "diffuse interstitial pulmonary fibrosis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "424824_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "424824_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "424824_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "424824_1_Ent2", "text": "bilateral pulmonary infiltrates", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "440873_4", "wnd_id": "440873_4_1", "text": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use .", "tokens": ["We", "have", "cared", "for", "three", "children", "in", "whom", "four", "episodes", "of", "dystonia", "proceeding", "to", "opisthotonus", "occurred", "in", "association", "with", "carbamazepine", "use", "."], "event_mentions": [{"id": "440873_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 15, "end": 16}, "arguments": [{"entity_id": "440873_4_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "440873_4_Ent0", "role": "Subject", "text": "three children", "start": 4, "end": 6}, {"entity_id": "440873_4_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "440873_4_Ent3", "role": "Effect", "text": "four episodes of dystonia proceeding to opisthotonus", "start": 8, "end": 15}, {"entity_id": "440873_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 19, "end": 20}, {"entity_id": "440873_4_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "440873_4_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "440873_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "440873_4_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "440873_4_Ent3", "text": "four episodes of dystonia proceeding to opisthotonus", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "440873_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "440873_4_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "458006_1", "wnd_id": "458006_1_1", "text": "Squamous - cell carcinoma arising in a basal - cell epithelioma treated with 5 - fluorouracil .", "tokens": ["Squamous", "-", "cell", "carcinoma", "arising", "in", "a", "basal", "-", "cell", "epithelioma", "treated", "with", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "458006_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "458006_1_Ent0", "role": "Effect", "text": "Squamous - cell carcinoma arising", "start": 0, "end": 5}, {"entity_id": "458006_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 13, "end": 16}, {"entity_id": "458006_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "458006_1_Ent0", "text": "Squamous - cell carcinoma arising", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "458006_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "458006_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "573779_3", "wnd_id": "573779_3_1", "text": "A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant , amoxapine .", "tokens": ["A", "young", "woman", "developed", "galactorrhea", "during", "treatment", "with", "a", "new", "dibenzoxazepine", "antidepressant", ",", "amoxapine", "."], "event_mentions": [{"id": "573779_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "573779_3_Ent0", "role": "Subject", "text": "A young woman", "start": 0, "end": 3}, {"entity_id": "573779_3_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "573779_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "573779_3_Ent3", "role": "Effect", "text": "galactorrhea", "start": 4, "end": 5}, {"entity_id": "573779_3_Ent4", "role": "Treatment", "text": "during treatment with a new dibenzoxazepine antidepressant , amoxapine", "start": 5, "end": 14}, {"entity_id": "573779_3_Ent5", "role": "Treatment_Drug", "text": "amoxapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "573779_3_Ent0", "text": "A young woman", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "573779_3_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "573779_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "573779_3_Ent3", "text": "galactorrhea", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "573779_3_Ent4", "text": "during treatment with a new dibenzoxazepine antidepressant , amoxapine", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "573779_3_Ent5", "text": "amoxapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6093724_1", "wnd_id": "6093724_1_1", "text": "A healthy , 30 - year - old man , exposed to sulindac on two separate occasions , had an incapacitating isolated idential sensory neuropathy .", "tokens": ["A", "healthy", ",", "30", "-", "year", "-", "old", "man", ",", "exposed", "to", "sulindac", "on", "two", "separate", "occasions", ",", "had", "an", "incapacitating", "isolated", "idential", "sensory", "neuropathy", "."], "event_mentions": [{"id": "6093724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 10, "end": 11}, "arguments": [{"entity_id": "6093724_1_Ent0", "role": "Subject", "text": "A healthy , 30 - year - old man", "start": 0, "end": 9}, {"entity_id": "6093724_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 3, "end": 8}, {"entity_id": "6093724_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "6093724_1_Ent4", "role": "Treatment", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent5", "role": "Treatment_Drug", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent3", "role": "Effect", "text": "incapacitating isolated idential sensory neuropathy", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "6093724_1_Ent0", "text": "A healthy , 30 - year - old man", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6093724_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6093724_1_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6093724_1_Ent4", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent5", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent3", "text": "incapacitating isolated idential sensory neuropathy", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "6113770_1", "wnd_id": "6113770_1_1", "text": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia .", "tokens": ["The", "authors", "describe", "a", "case", "of", "combined", "lithium", "and", "haloperidol", "toxicity", "characterized", "by", "hyperpyrexia", ",", "severe", "rigidity", ",", "mutism", ",", "and", "development", "of", "irreversible", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "6113770_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 10, "end": 11}, "arguments": [{"entity_id": "6113770_1_Ent1", "role": "Treatment", "text": "combined lithium and haloperidol", "start": 6, "end": 10}, {"entity_id": "6113770_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "6113770_1_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "6113770_1_Ent3", "role": "Treatment_Drug", "text": "haloperidol", "start": 9, "end": 10}, {"entity_id": "6113770_1_Ent5", "role": "Combination_Drug", "text": "haloperidol", "start": 9, "end": 10}, {"entity_id": "6113770_1_Ent0", "role": "Effect", "text": "hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "6113770_1_Ent1", "text": "combined lithium and haloperidol", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "6113770_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6113770_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6113770_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6113770_1_Ent5", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6113770_1_Ent0", "text": "hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "6113770_2", "wnd_id": "6113770_2_1", "text": "The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines , primarily thioridazine .", "tokens": ["The", "authors", "postulate", "that", "two", "types", "of", "combined", "lithium", "-", "neuroleptic", "toxicity", "occur", ":", "a", "neuroleptic", "malignant", "extrapyramidal", "syndrome", "and", "a", "lithium", "toxicity", "that", "occurs", "in", "combination", "with", "phenothiazines", ",", "primarily", "thioridazine", "."], "event_mentions": [{"id": "6113770_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 12, "end": 13}, "arguments": [{"entity_id": "6113770_2_Ent1", "role": "Treatment", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "6113770_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "6113770_2_Ent0", "role": "Effect", "text": "neuroleptic toxicity", "start": 10, "end": 12}]}, {"id": "6113770_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 24, "end": 25}, "arguments": [{"entity_id": "6113770_2_Ent3", "role": "Effect", "text": "a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity", "start": 14, "end": 23}, {"entity_id": "6113770_2_Ent4", "role": "Treatment", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent5", "role": "Treatment", "text": "in combination with phenothiazines , primarily thioridazine", "start": 25, "end": 32}, {"entity_id": "6113770_2_Ent7", "role": "Treatment_Drug", "text": "phenothiazines", "start": 28, "end": 29}, {"entity_id": "6113770_2_Ent9", "role": "Combination_Drug", "text": "phenothiazines", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "6113770_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6113770_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6113770_2_Ent0", "text": "neuroleptic toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "6113770_2_Ent3", "text": "a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "6113770_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent6", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent5", "text": "in combination with phenothiazines , primarily thioridazine", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "6113770_2_Ent7", "text": "phenothiazines", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6113770_2_Ent9", "text": "phenothiazines", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "6142995_2", "wnd_id": "6142995_2_1", "text": "Sister chromatid exchanges ( SCEs ) , a sensitive measure of chromosome damage , were counted in peripheral - blood lymphocytes from 10 patients with Behcet 's syndrome receiving chlorambucil .", "tokens": ["Sister", "chromatid", "exchanges", "(", "SCEs", ")", ",", "a", "sensitive", "measure", "of", "chromosome", "damage", ",", "were", "counted", "in", "peripheral", "-", "blood", "lymphocytes", "from", "10", "patients", "with", "Behcet", "'s", "syndrome", "receiving", "chlorambucil", "."], "event_mentions": [{"id": "6142995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 28, "end": 29}, "arguments": [{"entity_id": "6142995_2_Ent2", "role": "Effect", "text": "chromosome damage", "start": 11, "end": 13}, {"entity_id": "6142995_2_Ent1", "role": "Subject_Population", "text": "10", "start": 22, "end": 23}, {"entity_id": "6142995_2_Ent0", "role": "Subject", "text": "10 patients with Behcet 's syndrome", "start": 22, "end": 28}, {"entity_id": "6142995_2_Ent4", "role": "Treatment_Disorder", "text": "Behcet 's syndrome", "start": 25, "end": 28}, {"entity_id": "6142995_2_Ent3", "role": "Treatment", "text": "chlorambucil", "start": 29, "end": 30}, {"entity_id": "6142995_2_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6142995_2_Ent2", "text": "chromosome damage", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6142995_2_Ent1", "text": "10", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6142995_2_Ent0", "text": "10 patients with Behcet 's syndrome", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "6142995_2_Ent4", "text": "Behcet 's syndrome", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6142995_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6142995_2_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6159523_3", "wnd_id": "6159523_3_1", "text": "Investigations suggested that the dextrose , rather than any additives , was responsible for the reaction .", "tokens": ["Investigations", "suggested", "that", "the", "dextrose", ",", "rather", "than", "any", "additives", ",", "was", "responsible", "for", "the", "reaction", "."], "event_mentions": [{"id": "6159523_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 12, "end": 13}, "arguments": [{"entity_id": "6159523_3_Ent1", "role": "Treatment", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent2", "role": "Treatment_Drug", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent0", "role": "Effect", "text": "the reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "6159523_3_Ent1", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent2", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent0", "text": "the reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6159523_7", "wnd_id": "6159523_7_1", "text": "Preliminary results suggest that the higher concentrations of dextrose induce increased histamine release from blood cells , and that this phenomenon is more marked in diabetic , and particularly diabetic - allergic , individuals .", "tokens": ["Preliminary", "results", "suggest", "that", "the", "higher", "concentrations", "of", "dextrose", "induce", "increased", "histamine", "release", "from", "blood", "cells", ",", "and", "that", "this", "phenomenon", "is", "more", "marked", "in", "diabetic", ",", "and", "particularly", "diabetic", "-", "allergic", ",", "individuals", "."], "event_mentions": [{"id": "6159523_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 9, "end": 10}, "arguments": [{"entity_id": "6159523_7_Ent6", "role": "Treatment_Dosage", "text": "higher concentrations", "start": 5, "end": 7}, {"entity_id": "6159523_7_Ent4", "role": "Treatment", "text": "higher concentrations of dextrose", "start": 5, "end": 9}, {"entity_id": "6159523_7_Ent5", "role": "Treatment_Drug", "text": "dextrose", "start": 8, "end": 9}, {"entity_id": "6159523_7_Ent3", "role": "Effect", "text": "increased histamine release from blood cells", "start": 10, "end": 16}, {"entity_id": "6159523_7_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 25, "end": 26}, {"entity_id": "6159523_7_Ent0", "role": "Subject", "text": "diabetic , and particularly diabetic - allergic , individuals", "start": 25, "end": 34}, {"entity_id": "6159523_7_Ent2", "role": "Subject_Disorder", "text": "diabetic - allergic", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "6159523_7_Ent6", "text": "higher concentrations", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6159523_7_Ent4", "text": "higher concentrations of dextrose", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "6159523_7_Ent5", "text": "dextrose", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6159523_7_Ent3", "text": "increased histamine release from blood cells", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "6159523_7_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6159523_7_Ent0", "text": "diabetic , and particularly diabetic - allergic , individuals", "entity_type": "Entity", "start": 25, "end": 34}, {"id": "6159523_7_Ent2", "text": "diabetic - allergic", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "6221046_2", "wnd_id": "6221046_2_1", "text": "Multiple complications of propylthiouracil treatment : granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization .", "tokens": ["Multiple", "complications", "of", "propylthiouracil", "treatment", ":", "granulocytopenia", ",", "eosinophilia", ",", "skin", "reaction", "and", "hepatitis", "with", "lymphocyte", "sensitization", "."], "event_mentions": [{"id": "6221046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 1, "end": 2}, "arguments": [{"entity_id": "6221046_2_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "6221046_2_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "6221046_2_Ent0", "role": "Effect", "text": "granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization", "start": 6, "end": 17}]}], "entity_mentions": [{"id": "6221046_2_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6221046_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6221046_2_Ent0", "text": "granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization", "entity_type": "Entity", "start": 6, "end": 17}], "lang": "en"}
{"doc_id": "6233326_2", "wnd_id": "6233326_2_1", "text": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D - penicillamine for about 1 year .", "tokens": ["Optic", "neuropathy", "developed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "who", "had", "been", "receiving", "D", "-", "penicillamine", "for", "about", "1", "year", "."], "event_mentions": [{"id": "6233326_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6233326_2_Ent1", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "6233326_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 4, "end": 9}, {"entity_id": "6233326_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "6233326_2_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "6233326_2_Ent2", "role": "Treatment", "text": "D - penicillamine for about 1 year", "start": 13, "end": 20}, {"entity_id": "6233326_2_Ent5", "role": "Treatment_Duration", "text": "1 year", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "6233326_2_Ent1", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6233326_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "6233326_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6233326_2_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "6233326_2_Ent2", "text": "D - penicillamine for about 1 year", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "6233326_2_Ent5", "text": "1 year", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "6236730_3", "wnd_id": "6236730_3_1", "text": "Transient acute myopia resulting from isotretinoin ( accutane ) therapy .", "tokens": ["Transient", "acute", "myopia", "resulting", "from", "isotretinoin", "(", "accutane", ")", "therapy", "."], "event_mentions": [{"id": "6236730_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "6236730_3_Ent0", "role": "Effect", "text": "Transient acute myopia", "start": 0, "end": 3}, {"entity_id": "6236730_3_Ent2", "role": "Treatment_Drug", "text": "isotretinoin", "start": 5, "end": 6}, {"entity_id": "6236730_3_Ent1", "role": "Treatment", "text": "isotretinoin ( accutane ) therapy", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "6236730_3_Ent0", "text": "Transient acute myopia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6236730_3_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6236730_3_Ent1", "text": "isotretinoin ( accutane ) therapy", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "6311654_6", "wnd_id": "6311654_6_1", "text": "It is concluded that ' cerebral atrophy ' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion , and in as low a dose as possible .", "tokens": ["It", "is", "concluded", "that", "'", "cerebral", "atrophy", "'", "on", "CT", "scans", "may", "represent", "an", "accumulative", "effect", "of", "ACTH", "and", "that", "ACTH", "should", "be", "given", "with", "the", "utmost", "discretion", ",", "and", "in", "as", "low", "a", "dose", "as", "possible", "."], "event_mentions": [{"id": "6311654_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "represent", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_6_Ent0", "role": "Effect", "text": "cerebral atrophy", "start": 5, "end": 7}, {"entity_id": "6311654_6_Ent1", "role": "Treatment", "text": "ACTH", "start": 17, "end": 18}, {"entity_id": "6311654_6_Ent2", "role": "Treatment_Drug", "text": "ACTH", "start": 17, "end": 18}, {"entity_id": "6311654_6_Ent3", "role": "Treatment_Drug", "text": "ACTH", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "6311654_6_Ent0", "text": "cerebral atrophy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6311654_6_Ent1", "text": "ACTH", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "6311654_6_Ent2", "text": "ACTH", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "6311654_6_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6344831_2", "wnd_id": "6344831_2_1", "text": "In a patient with severe renovascular hypertension , nonoliguric acute renal failure developed after she received captopril treatment .", "tokens": ["In", "a", "patient", "with", "severe", "renovascular", "hypertension", ",", "nonoliguric", "acute", "renal", "failure", "developed", "after", "she", "received", "captopril", "treatment", "."], "event_mentions": [{"id": "6344831_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "6344831_2_Ent0", "role": "Subject", "text": "a patient with severe renovascular hypertension", "start": 1, "end": 7}, {"entity_id": "6344831_2_Ent4", "role": "Treatment_Disorder", "text": "renovascular hypertension", "start": 5, "end": 7}, {"entity_id": "6344831_2_Ent2", "role": "Effect", "text": "nonoliguric acute renal failure", "start": 8, "end": 12}, {"entity_id": "6344831_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "6344831_2_Ent3", "role": "Treatment", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "6344831_2_Ent5", "role": "Treatment_Drug", "text": "captopril", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "6344831_2_Ent0", "text": "a patient with severe renovascular hypertension", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "6344831_2_Ent4", "text": "renovascular hypertension", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6344831_2_Ent2", "text": "nonoliguric acute renal failure", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "6344831_2_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6344831_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6344831_2_Ent5", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "6353252_1", "wnd_id": "6353252_1_1", "text": "Captopril - induced acute reversible renal failure .", "tokens": ["Captopril", "-", "induced", "acute", "reversible", "renal", "failure", "."], "event_mentions": [{"id": "6353252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6353252_1_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent0", "role": "Effect", "text": "acute reversible renal failure", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "6353252_1_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent0", "text": "acute reversible renal failure", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "6353252_2", "wnd_id": "6353252_2_1", "text": "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril - induced acute renal failure .", "tokens": ["The", "5", "patients", "had", "severe", "renovascular", "disease", "which", "might", "thus", "represent", "a", "significant", "risk", "factor", "in", "the", "development", "of", "captopril", "-", "induced", "acute", "renal", "failure", "."], "event_mentions": [{"id": "6353252_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "6353252_2_Ent0", "role": "Subject", "text": "The 5 patients had severe renovascular disease", "start": 0, "end": 7}, {"entity_id": "6353252_2_Ent1", "role": "Subject_Population", "text": "5", "start": 1, "end": 2}, {"entity_id": "6353252_2_Ent2", "role": "Subject_Disorder", "text": "renovascular disease", "start": 5, "end": 7}, {"entity_id": "6353252_2_Ent4", "role": "Treatment", "text": "captopril", "start": 19, "end": 20}, {"entity_id": "6353252_2_Ent5", "role": "Treatment_Drug", "text": "captopril", "start": 19, "end": 20}, {"entity_id": "6353252_2_Ent3", "role": "Effect", "text": "acute renal failure", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "6353252_2_Ent0", "text": "The 5 patients had severe renovascular disease", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6353252_2_Ent1", "text": "5", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6353252_2_Ent2", "text": "renovascular disease", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6353252_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6353252_2_Ent5", "text": "captopril", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6353252_2_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "640344_2", "wnd_id": "640344_2_1", "text": "Severe histological osteomalacia developed in a woman with Crohn 's disease 2 years after ileal resection and the start of cholestyramine therapy .", "tokens": ["Severe", "histological", "osteomalacia", "developed", "in", "a", "woman", "with", "Crohn", "'s", "disease", "2", "years", "after", "ileal", "resection", "and", "the", "start", "of", "cholestyramine", "therapy", "."], "event_mentions": [{"id": "640344_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "640344_2_Ent2", "role": "Effect", "text": "histological osteomalacia", "start": 1, "end": 3}, {"entity_id": "640344_2_Ent0", "role": "Subject", "text": "a woman with Crohn 's disease", "start": 5, "end": 11}, {"entity_id": "640344_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "640344_2_Ent6", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}, {"entity_id": "640344_2_Ent3", "role": "Treatment", "text": "2 years after ileal resection and the start of cholestyramine", "start": 11, "end": 21}, {"entity_id": "640344_2_Ent5", "role": "Treatment_Time_elapsed", "text": "start", "start": 18, "end": 19}, {"entity_id": "640344_2_Ent4", "role": "Treatment_Drug", "text": "cholestyramine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "640344_2_Ent2", "text": "histological osteomalacia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "640344_2_Ent0", "text": "a woman with Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "640344_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "640344_2_Ent6", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "640344_2_Ent3", "text": "2 years after ileal resection and the start of cholestyramine", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "640344_2_Ent5", "text": "start", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "640344_2_Ent4", "text": "cholestyramine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6414095_3", "wnd_id": "6414095_3_1", "text": "A 52 - year - old Black woman on phenytoin therapy for post - traumatic epilepsy developed transient hemiparesis contralateral to the injury .", "tokens": ["A", "52", "-", "year", "-", "old", "Black", "woman", "on", "phenytoin", "therapy", "for", "post", "-", "traumatic", "epilepsy", "developed", "transient", "hemiparesis", "contralateral", "to", "the", "injury", "."], "event_mentions": [{"id": "6414095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "6414095_3_Ent0", "role": "Subject", "text": "A 52 - year - old Black woman", "start": 0, "end": 8}, {"entity_id": "6414095_3_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6414095_3_Ent2", "role": "Subject_Race", "text": "Black", "start": 6, "end": 7}, {"entity_id": "6414095_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "6414095_3_Ent5", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent6", "role": "Treatment_Disorder", "text": "post - traumatic epilepsy", "start": 12, "end": 16}, {"entity_id": "6414095_3_Ent4", "role": "Effect", "text": "transient hemiparesis contralateral to the injury", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "6414095_3_Ent0", "text": "A 52 - year - old Black woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6414095_3_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6414095_3_Ent2", "text": "Black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6414095_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6414095_3_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent6", "text": "post - traumatic epilepsy", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6414095_3_Ent4", "text": "transient hemiparesis contralateral to the injury", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "6416845_1", "wnd_id": "6416845_1_1", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "tokens": ["A", "7", "-", "year", "-", "old", "boy", "developed", "a", "severe", "unilateral", "grand", "mal", "seizure", "at", "the", "age", "of", "5", "years", "(", "phenobarbitone", "therapy", ")", ";", "1.5", "years", "later", "valproate", "(", "2", "-", "propylpentanoic", "acid", ",", "VPA", ")", "was", "added", "to", "the", "therapy", "."], "event_mentions": [{"id": "6416845_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 41, "end": 42}, "arguments": [{"entity_id": "6416845_1_Ent0", "role": "Subject", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure", "start": 0, "end": 14}, {"entity_id": "6416845_1_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 1, "end": 6}, {"entity_id": "6416845_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "6416845_1_Ent3", "role": "Subject_Disorder", "text": "a severe unilateral grand mal seizure", "start": 8, "end": 14}, {"entity_id": "6416845_1_Ent4", "role": "Treatment", "text": "at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "start": 14, "end": 43}, {"entity_id": "6416845_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbitone", "start": 21, "end": 22}, {"entity_id": "6416845_1_Ent9", "role": "Combination_Drug", "text": "phenobarbitone", "start": 21, "end": 22}, {"entity_id": "6416845_1_Ent7", "role": "Treatment_Time_elapsed", "text": "1.5 years later", "start": 25, "end": 28}, {"entity_id": "6416845_1_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 28, "end": 29}, {"entity_id": "6416845_1_Ent8", "role": "Combination_Drug", "text": "valproate", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "6416845_1_Ent0", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "6416845_1_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6416845_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6416845_1_Ent3", "text": "a severe unilateral grand mal seizure", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "6416845_1_Ent4", "text": "at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "entity_type": "Entity", "start": 14, "end": 43}, {"id": "6416845_1_Ent5", "text": "phenobarbitone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6416845_1_Ent9", "text": "phenobarbitone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6416845_1_Ent7", "text": "1.5 years later", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6416845_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6416845_1_Ent8", "text": "valproate", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "6427463_1", "wnd_id": "6427463_1_1", "text": "Stroke - like syndrome after gold sodium thiomalate induced vasomotor reaction .", "tokens": ["Stroke", "-", "like", "syndrome", "after", "gold", "sodium", "thiomalate", "induced", "vasomotor", "reaction", "."], "event_mentions": [{"id": "6427463_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "6427463_1_Ent1", "role": "Effect", "text": "Stroke - like syndrome", "start": 0, "end": 4}, {"entity_id": "6427463_1_Ent2", "role": "Treatment", "text": "gold sodium thiomalate", "start": 5, "end": 8}, {"entity_id": "6427463_1_Ent3", "role": "Treatment_Drug", "text": "gold sodium thiomalate", "start": 5, "end": 8}, {"entity_id": "6427463_1_Ent0", "role": "Effect", "text": "vasomotor reaction", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "6427463_1_Ent1", "text": "Stroke - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6427463_1_Ent2", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6427463_1_Ent3", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6427463_1_Ent0", "text": "vasomotor reaction", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "6440806_1", "wnd_id": "6440806_1_1", "text": "A 52 - year - old , white female developed low - grade fever , cough , and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis .", "tokens": ["A", "52", "-", "year", "-", "old", ",", "white", "female", "developed", "low", "-", "grade", "fever", ",", "cough", ",", "and", "dyspnea", "after", "8", "weeks", "treatment", "with", "sodium", "aurothiomalate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6440806_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6440806_1_Ent0", "role": "Subject", "text": "A 52 - year - old", "start": 0, "end": 6}, {"entity_id": "6440806_1_Ent2", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6440806_1_Ent3", "role": "Subject_Race", "text": "white", "start": 7, "end": 8}, {"entity_id": "6440806_1_Ent1", "role": "Subject", "text": "white female", "start": 7, "end": 9}, {"entity_id": "6440806_1_Ent4", "role": "Subject_Gender", "text": "female", "start": 8, "end": 9}, {"entity_id": "6440806_1_Ent5", "role": "Effect", "text": "low - grade fever , cough , and dyspnea", "start": 10, "end": 19}, {"entity_id": "6440806_1_Ent7", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 20, "end": 22}, {"entity_id": "6440806_1_Ent6", "role": "Treatment", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent8", "role": "Treatment_Drug", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent9", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "6440806_1_Ent0", "text": "A 52 - year - old", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6440806_1_Ent2", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6440806_1_Ent3", "text": "white", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6440806_1_Ent1", "text": "white female", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6440806_1_Ent4", "text": "female", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6440806_1_Ent5", "text": "low - grade fever , cough , and dyspnea", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "6440806_1_Ent7", "text": "8 weeks", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "6440806_1_Ent6", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent8", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent9", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "647693_1", "wnd_id": "647693_1_1", "text": "Four patients receiving high - dose tamoxifen for greater than 1 year have demonstrated similar retinal changes .", "tokens": ["Four", "patients", "receiving", "high", "-", "dose", "tamoxifen", "for", "greater", "than", "1", "year", "have", "demonstrated", "similar", "retinal", "changes", "."], "event_mentions": [{"id": "647693_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "647693_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "647693_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "647693_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "647693_1_Ent3", "role": "Treatment", "text": "high - dose tamoxifen for greater than 1 year", "start": 3, "end": 12}, {"entity_id": "647693_1_Ent6", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "647693_1_Ent4", "role": "Treatment_Duration", "text": "1 year", "start": 10, "end": 12}, {"entity_id": "647693_1_Ent2", "role": "Effect", "text": "retinal changes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "647693_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "647693_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "647693_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "647693_1_Ent3", "text": "high - dose tamoxifen for greater than 1 year", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "647693_1_Ent6", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "647693_1_Ent4", "text": "1 year", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "647693_1_Ent2", "text": "retinal changes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6498095_1", "wnd_id": "6498095_1_1", "text": "After the patient discontinued rifampicin , the skin lesions cleared completely within 5 weeks without any systemic medication .", "tokens": ["After", "the", "patient", "discontinued", "rifampicin", ",", "the", "skin", "lesions", "cleared", "completely", "within", "5", "weeks", "without", "any", "systemic", "medication", "."], "event_mentions": [{"id": "6498095_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "6498095_1_Ent1", "role": "Treatment", "text": "patient discontinued rifampicin", "start": 2, "end": 5}, {"entity_id": "6498095_1_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 4, "end": 5}, {"entity_id": "6498095_1_Ent3", "role": "Treatment_Disorder", "text": "skin lesions", "start": 7, "end": 9}, {"entity_id": "6498095_1_Ent0", "role": "Effect", "text": "skin lesions cleared completely within 5 weeks", "start": 7, "end": 14}, {"entity_id": "6498095_1_Ent4", "role": "Treatment_Time_elapsed", "text": "within 5 weeks", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "6498095_1_Ent1", "text": "patient discontinued rifampicin", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "6498095_1_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6498095_1_Ent3", "text": "skin lesions", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6498095_1_Ent0", "text": "skin lesions cleared completely within 5 weeks", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "6498095_1_Ent4", "text": "within 5 weeks", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "6519218_1", "wnd_id": "6519218_1_1", "text": "In a 61 - year - old man receiving chronic low - dosage amiodarone an interstitial pneumopathy was observed .", "tokens": ["In", "a", "61", "-", "year", "-", "old", "man", "receiving", "chronic", "low", "-", "dosage", "amiodarone", "an", "interstitial", "pneumopathy", "was", "observed", "."], "event_mentions": [{"id": "6519218_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6519218_1_Ent0", "role": "Subject", "text": "a 61 - year - old man", "start": 1, "end": 8}, {"entity_id": "6519218_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 2, "end": 7}, {"entity_id": "6519218_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "6519218_1_Ent4", "role": "Treatment", "text": "chronic low - dosage amiodarone", "start": 9, "end": 14}, {"entity_id": "6519218_1_Ent6", "role": "Treatment_Dosage", "text": "low - dosage", "start": 10, "end": 13}, {"entity_id": "6519218_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "6519218_1_Ent3", "role": "Effect", "text": "interstitial pneumopathy", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "6519218_1_Ent0", "text": "a 61 - year - old man", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "6519218_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "6519218_1_Ent2", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6519218_1_Ent4", "text": "chronic low - dosage amiodarone", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "6519218_1_Ent6", "text": "low - dosage", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6519218_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6519218_1_Ent3", "text": "interstitial pneumopathy", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6536282_3", "wnd_id": "6536282_3_1", "text": "Organometals also compromise the limbic system and result in deficits in learning and memory .", "tokens": ["Organometals", "also", "compromise", "the", "limbic", "system", "and", "result", "in", "deficits", "in", "learning", "and", "memory", "."], "event_mentions": [{"id": "6536282_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 7, "end": 8}, "arguments": [{"entity_id": "6536282_3_Ent2", "role": "Treatment", "text": "Organometals", "start": 0, "end": 1}, {"entity_id": "6536282_3_Ent3", "role": "Treatment_Drug", "text": "Organometals", "start": 0, "end": 1}, {"entity_id": "6536282_3_Ent0", "role": "Effect", "text": "compromise the limbic system", "start": 2, "end": 6}, {"entity_id": "6536282_3_Ent1", "role": "Effect", "text": "deficits in learning and memory", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "6536282_3_Ent2", "text": "Organometals", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6536282_3_Ent3", "text": "Organometals", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6536282_3_Ent0", "text": "compromise the limbic system", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "6536282_3_Ent1", "text": "deficits in learning and memory", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "6540393_2", "wnd_id": "6540393_2_1", "text": "Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis .", "tokens": ["Anaphylactoid", "reaction", "to", "methylprednisolone", "pulsed", "therapy", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "6540393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "6540393_2_Ent0", "role": "Effect", "text": "Anaphylactoid reaction", "start": 0, "end": 2}, {"entity_id": "6540393_2_Ent3", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 3, "end": 4}, {"entity_id": "6540393_2_Ent1", "role": "Treatment", "text": "methylprednisolone pulsed therapy", "start": 3, "end": 6}, {"entity_id": "6540393_2_Ent2", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6540393_2_Ent0", "text": "Anaphylactoid reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6540393_2_Ent3", "text": "methylprednisolone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6540393_2_Ent1", "text": "methylprednisolone pulsed therapy", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6540393_2_Ent2", "text": "multiple sclerosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6572542_1", "wnd_id": "6572542_1_1", "text": "Although lung specimens were lacking from these three patients , it is suggested that the pulmonary toxicity of CCNU may be dose - related .", "tokens": ["Although", "lung", "specimens", "were", "lacking", "from", "these", "three", "patients", ",", "it", "is", "suggested", "that", "the", "pulmonary", "toxicity", "of", "CCNU", "may", "be", "dose", "-", "related", "."], "event_mentions": [{"id": "6572542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 23, "end": 24}, "arguments": [{"entity_id": "6572542_1_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "6572542_1_Ent0", "role": "Subject", "text": "three patients", "start": 7, "end": 9}, {"entity_id": "6572542_1_Ent2", "role": "Effect", "text": "pulmonary toxicity", "start": 15, "end": 17}, {"entity_id": "6572542_1_Ent3", "role": "Treatment", "text": "CCNU", "start": 18, "end": 19}, {"entity_id": "6572542_1_Ent4", "role": "Treatment_Drug", "text": "CCNU", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "6572542_1_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6572542_1_Ent0", "text": "three patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6572542_1_Ent2", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6572542_1_Ent3", "text": "CCNU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6572542_1_Ent4", "text": "CCNU", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "6610943_1", "wnd_id": "6610943_1_1", "text": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion .", "tokens": ["Myoglobinuria", "and", "acute", "renal", "failure", "associated", "with", "intravenous", "vasopressin", "infusion", "."], "event_mentions": [{"id": "6610943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6610943_1_Ent0", "role": "Effect", "text": "Myoglobinuria and acute renal failure", "start": 0, "end": 5}, {"entity_id": "6610943_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "6610943_1_Ent1", "role": "Treatment", "text": "intravenous vasopressin infusion", "start": 7, "end": 10}, {"entity_id": "6610943_1_Ent4", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "6610943_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6610943_1_Ent0", "text": "Myoglobinuria and acute renal failure", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6610943_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6610943_1_Ent1", "text": "intravenous vasopressin infusion", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6610943_1_Ent4", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6610943_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6614033_1", "wnd_id": "6614033_1_1", "text": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity .", "tokens": ["A", "major", "limitation", "in", "the", "use", "of", "amphotericin", "B", "is", "its", "potential", "to", "cause", "nephrotoxicity", "."], "event_mentions": [{"id": "6614033_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "6614033_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6614033_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6628806_2", "wnd_id": "6628806_2_1", "text": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis .", "tokens": ["Toxic", "hepatitis", "due", "to", "combination", "therapy", "with", "methotrexate", "and", "etretinate", "in", "psoriasis", "."], "event_mentions": [{"id": "6628806_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "6628806_2_Ent0", "role": "Effect", "text": "Toxic hepatitis", "start": 0, "end": 2}, {"entity_id": "6628806_2_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "6628806_2_Ent5", "role": "Combination_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "6628806_2_Ent1", "role": "Treatment", "text": "methotrexate and etretinate", "start": 7, "end": 10}, {"entity_id": "6628806_2_Ent3", "role": "Treatment_Drug", "text": "etretinate", "start": 9, "end": 10}, {"entity_id": "6628806_2_Ent6", "role": "Combination_Drug", "text": "etretinate", "start": 9, "end": 10}, {"entity_id": "6628806_2_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6628806_2_Ent0", "text": "Toxic hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6628806_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6628806_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6628806_2_Ent1", "text": "methotrexate and etretinate", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6628806_2_Ent3", "text": "etretinate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6628806_2_Ent6", "text": "etretinate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6628806_2_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "665845_1", "wnd_id": "665845_1_1", "text": "A case history of a 15 - year - old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented .", "tokens": ["A", "case", "history", "of", "a", "15", "-", "year", "-", "old", "boy", "who", "developed", "incapacitating", "tardive", "dyskinesia", "that", "resolved", "during", "treatment", "with", "deanol", "is", "presented", "."], "event_mentions": [{"id": "665845_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 17, "end": 18}, "arguments": [{"entity_id": "665845_1_Ent0", "role": "Subject", "text": "a 15 - year - old boy", "start": 4, "end": 11}, {"entity_id": "665845_1_Ent1", "role": "Subject_Age", "text": "15 - year - old", "start": 5, "end": 10}, {"entity_id": "665845_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 10, "end": 11}, {"entity_id": "665845_1_Ent3", "role": "Effect", "text": "incapacitating tardive dyskinesia", "start": 13, "end": 16}, {"entity_id": "665845_1_Ent4", "role": "Treatment", "text": "deanol", "start": 21, "end": 22}, {"entity_id": "665845_1_Ent5", "role": "Treatment_Drug", "text": "deanol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "665845_1_Ent0", "text": "a 15 - year - old boy", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "665845_1_Ent1", "text": "15 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "665845_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "665845_1_Ent3", "text": "incapacitating tardive dyskinesia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "665845_1_Ent4", "text": "deanol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "665845_1_Ent5", "text": "deanol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "667809_2", "wnd_id": "667809_2_1", "text": "Fatal pulmonary fibrosis following 1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy .", "tokens": ["Fatal", "pulmonary", "fibrosis", "following", "1,3", "-", "bis(2", "-", "chloroethyl)", "-", "1", "-", "nitrosourea", "(", "BCNU", ")", "therapy", "."], "event_mentions": [{"id": "667809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "667809_2_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 1, "end": 3}, {"entity_id": "667809_2_Ent2", "role": "Treatment_Drug", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU )", "start": 4, "end": 16}, {"entity_id": "667809_2_Ent1", "role": "Treatment", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy", "start": 4, "end": 17}]}], "entity_mentions": [{"id": "667809_2_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "667809_2_Ent2", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU )", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "667809_2_Ent1", "text": "1,3 - bis(2 - chloroethyl) - 1 - nitrosourea ( BCNU ) therapy", "entity_type": "Entity", "start": 4, "end": 17}], "lang": "en"}
{"doc_id": "6683487_2", "wnd_id": "6683487_2_1", "text": "Thrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1/2 months of treatment with penicillamine .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "(", "TTP", ")", "developed", "in", "a", "patient", "with", "seropositive", "rheumatoid", "arthritis", "(", "RA", ")", "after", "2", "1/2", "months", "of", "treatment", "with", "penicillamine", "."], "event_mentions": [{"id": "6683487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "6683487_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "start": 0, "end": 6}, {"entity_id": "6683487_2_Ent0", "role": "Subject", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "start": 8, "end": 17}, {"entity_id": "6683487_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "6683487_2_Ent5", "role": "Treatment_Duration", "text": "2 1/2 months", "start": 18, "end": 21}, {"entity_id": "6683487_2_Ent2", "role": "Treatment", "text": "2 1/2 months of treatment with penicillamine", "start": 18, "end": 25}, {"entity_id": "6683487_2_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "6683487_2_Ent1", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6683487_2_Ent0", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "6683487_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6683487_2_Ent5", "text": "2 1/2 months", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "6683487_2_Ent2", "text": "2 1/2 months of treatment with penicillamine", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "6683487_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "6683487_4", "wnd_id": "6683487_4_1", "text": "To our knowledge , no prior cases of penicillamine - induced TTP in RA have been reported .", "tokens": ["To", "our", "knowledge", ",", "no", "prior", "cases", "of", "penicillamine", "-", "induced", "TTP", "in", "RA", "have", "been", "reported", "."], "event_mentions": [{"id": "6683487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "6683487_4_Ent1", "role": "Treatment", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent0", "role": "Effect", "text": "TTP", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6683487_4_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent0", "text": "TTP", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6693840_1", "wnd_id": "6693840_1_1", "text": "A 61 year - old male patient developed gynecomastia after starting theophylline .", "tokens": ["A", "61", "year", "-", "old", "male", "patient", "developed", "gynecomastia", "after", "starting", "theophylline", "."], "event_mentions": [{"id": "6693840_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_1_Ent0", "role": "Subject", "text": "A 61 year - old male patient", "start": 0, "end": 7}, {"entity_id": "6693840_1_Ent1", "role": "Subject_Age", "text": "61 year - old", "start": 1, "end": 5}, {"entity_id": "6693840_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "6693840_1_Ent3", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_1_Ent4", "role": "Treatment", "text": "theophylline", "start": 11, "end": 12}, {"entity_id": "6693840_1_Ent5", "role": "Treatment_Drug", "text": "theophylline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6693840_1_Ent0", "text": "A 61 year - old male patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6693840_1_Ent1", "text": "61 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6693840_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_1_Ent3", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_1_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6693840_1_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6697887_1", "wnd_id": "6697887_1_1", "text": "Parenteral - verapamil - induced sustained hypotension .", "tokens": ["Parenteral", "-", "verapamil", "-", "induced", "sustained", "hypotension", "."], "event_mentions": [{"id": "6697887_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6697887_1_Ent2", "role": "Treatment_Route", "text": "Parenteral", "start": 0, "end": 1}, {"entity_id": "6697887_1_Ent1", "role": "Treatment", "text": "Parenteral - verapamil", "start": 0, "end": 3}, {"entity_id": "6697887_1_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 2, "end": 3}, {"entity_id": "6697887_1_Ent0", "role": "Effect", "text": "sustained hypotension", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "6697887_1_Ent2", "text": "Parenteral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6697887_1_Ent1", "text": "Parenteral - verapamil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6697887_1_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6697887_1_Ent0", "text": "sustained hypotension", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "6731466_2", "wnd_id": "6731466_2_1", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache .", "tokens": ["Anaphylactoid", "shock", ",", "disseminated", "intravascular", "coagulation", ",", "and", "anuric", "renal", "failure", "requiring", "dialysis", "occurred", "in", "a", "patient", "receiving", "zomepirac", "sodium", "for", "toothache", "."], "event_mentions": [{"id": "6731466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "6731466_2_Ent2", "role": "Effect", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "start": 0, "end": 13}, {"entity_id": "6731466_2_Ent0", "role": "Subject", "text": "a patient", "start": 15, "end": 17}, {"entity_id": "6731466_2_Ent3", "role": "Treatment", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent4", "role": "Treatment_Drug", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent1", "role": "Subject", "text": "toothache", "start": 21, "end": 22}, {"entity_id": "6731466_2_Ent5", "role": "Treatment_Disorder", "text": "toothache", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6731466_2_Ent2", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "6731466_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6731466_2_Ent3", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent4", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent1", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6731466_2_Ent5", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6733633_2", "wnd_id": "6733633_2_1", "text": "Cimetidine is a rare cause of drug - induced fever .", "tokens": ["Cimetidine", "is", "a", "rare", "cause", "of", "drug", "-", "induced", "fever", "."], "event_mentions": [{"id": "6733633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "6733633_2_Ent1", "role": "Treatment", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent2", "role": "Treatment_Drug", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent0", "role": "Effect", "text": "fever", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6733633_2_Ent1", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent2", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6738830_2", "wnd_id": "6738830_2_1", "text": "Unique behavioral change with cinepazide in parkinsonism .", "tokens": ["Unique", "behavioral", "change", "with", "cinepazide", "in", "parkinsonism", "."], "event_mentions": [{"id": "6738830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6738830_2_Ent0", "role": "Effect", "text": "Unique behavioral change", "start": 0, "end": 3}, {"entity_id": "6738830_2_Ent1", "role": "Treatment", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent3", "role": "Treatment_Drug", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent2", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6738830_2_Ent0", "text": "Unique behavioral change", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6738830_2_Ent1", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent3", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent2", "text": "parkinsonism", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6830388_1", "wnd_id": "6830388_1_1", "text": "Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning .", "tokens": ["Since", "early", "symptoms", "of", "the", "toxic", "effects", "of", "theophylline", "can", "mimic", "peptic", "ulcer", "disease", ",", "cimetidine", "might", "be", "prescribed", "for", "the", "gastrointestinal", "symptoms", "with", "subsequent", "worsening", "of", "theophylline", "poisoning", "."], "event_mentions": [{"id": "6830388_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6830388_1_Ent0", "role": "Treatment", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal symptoms", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "6830388_1_Ent0", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent1", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "6854698_1", "wnd_id": "6854698_1_1", "text": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction .", "tokens": ["When", "tuberculosis", "patients", "on", "isoniazid", "eat", "certain", "varieties", "of", "fish", "they", "may", "develop", "a", "histamine", "reaction", "."], "event_mentions": [{"id": "6854698_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "6854698_1_Ent4", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 1, "end": 2}, {"entity_id": "6854698_1_Ent0", "role": "Subject", "text": "tuberculosis patients", "start": 1, "end": 3}, {"entity_id": "6854698_1_Ent2", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "6854698_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "6854698_1_Ent1", "role": "Effect", "text": "histamine reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "6854698_1_Ent4", "text": "tuberculosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6854698_1_Ent0", "text": "tuberculosis patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6854698_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6854698_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6854698_1_Ent1", "text": "histamine reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6860059_1", "wnd_id": "6860059_1_1", "text": "Fulminant hepatitis associated with disulfiram .", "tokens": ["Fulminant", "hepatitis", "associated", "with", "disulfiram", "."], "event_mentions": [{"id": "6860059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6860059_1_Ent0", "role": "Effect", "text": "Fulminant hepatitis", "start": 0, "end": 2}, {"entity_id": "6860059_1_Ent1", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6860059_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6860059_1_Ent0", "text": "Fulminant hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6860059_1_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6860059_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6958210_2", "wnd_id": "6958210_2_1", "text": "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis .", "tokens": ["Systemic", "lupus", "erythematosus", "during", "penicillamine", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6958210_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "6958210_2_Ent0", "role": "Effect", "text": "Systemic lupus erythematosus", "start": 0, "end": 3}, {"entity_id": "6958210_2_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6958210_2_Ent1", "role": "Treatment", "text": "penicillamine therapy", "start": 4, "end": 6}, {"entity_id": "6958210_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "6958210_2_Ent0", "text": "Systemic lupus erythematosus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6958210_2_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6958210_2_Ent1", "text": "penicillamine therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6958210_2_Ent3", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "6998294_1", "wnd_id": "6998294_1_1", "text": "Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy .", "tokens": ["Clinicians", "should", "be", "aware", "of", "fasting", "hypoglycemia", "as", "an", "unusual", "but", "potentially", "serious", "complication", "of", "disopyramide", "therapy", "."], "event_mentions": [{"id": "6998294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "6998294_1_Ent0", "role": "Effect", "text": "fasting hypoglycemia", "start": 5, "end": 7}, {"entity_id": "6998294_1_Ent1", "role": "Treatment", "text": "disopyramide", "start": 15, "end": 16}, {"entity_id": "6998294_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6998294_1_Ent0", "text": "fasting hypoglycemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6998294_1_Ent1", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6998294_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7139589_2", "wnd_id": "7139589_2_1", "text": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L - asparaginase .", "tokens": ["Delayed", "pseudocyst", "of", "the", "pancreas", "can", "be", "a", "complication", "of", "intramuscular", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "can", "start": 5, "end": 6}, "arguments": [{"entity_id": "7139589_2_Ent0", "role": "Effect", "text": "Delayed pseudocyst of the pancreas", "start": 0, "end": 5}, {"entity_id": "7139589_2_Ent3", "role": "Treatment_Route", "text": "intramuscular", "start": 10, "end": 11}, {"entity_id": "7139589_2_Ent1", "role": "Treatment", "text": "intramuscular L - asparaginase", "start": 10, "end": 14}, {"entity_id": "7139589_2_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7139589_2_Ent0", "text": "Delayed pseudocyst of the pancreas", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7139589_2_Ent3", "text": "intramuscular", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7139589_2_Ent1", "text": "intramuscular L - asparaginase", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7139589_2_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7139589_3", "wnd_id": "7139589_3_1", "text": "L - asparaginase - induced pancreatitis has been reported during or closely following administration of the drug .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "has", "been", "reported", "during", "or", "closely", "following", "administration", "of", "the", "drug", "."], "event_mentions": [{"id": "7139589_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7139589_3_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7139589_3_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7151655_1", "wnd_id": "7151655_1_1", "text": "In one patient , treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later .", "tokens": ["In", "one", "patient", ",", "treatment", "with", "DCA", "was", "associated", "with", "a", "decrease", "in", "blood", "lactate", "levels", "from", "11.2", "mM", "before", "treatment", "to", "0.8", "mM", "16", "h", "later", "."], "event_mentions": [{"id": "7151655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "7151655_1_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "7151655_1_Ent0", "role": "Subject", "text": "one patient", "start": 1, "end": 3}, {"entity_id": "7151655_1_Ent3", "role": "Treatment", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent4", "role": "Treatment_Drug", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent2", "role": "Effect", "text": "decrease in blood lactate levels", "start": 11, "end": 16}, {"entity_id": "7151655_1_Ent5", "role": "Treatment_Time_elapsed", "text": "16 h later", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "7151655_1_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7151655_1_Ent0", "text": "one patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "7151655_1_Ent3", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent4", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent2", "text": "decrease in blood lactate levels", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7151655_1_Ent5", "text": "16 h later", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "717931_1", "wnd_id": "717931_1_1", "text": "Life - threatening hyperkalemia induced by arginine .", "tokens": ["Life", "-", "threatening", "hyperkalemia", "induced", "by", "arginine", "."], "event_mentions": [{"id": "717931_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "717931_1_Ent0", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}, {"entity_id": "717931_1_Ent1", "role": "Treatment", "text": "arginine", "start": 6, "end": 7}, {"entity_id": "717931_1_Ent2", "role": "Treatment_Drug", "text": "arginine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "717931_1_Ent0", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "717931_1_Ent1", "text": "arginine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "717931_1_Ent2", "text": "arginine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "717931_2", "wnd_id": "717931_2_1", "text": "Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency .", "tokens": ["Marked", "hyperkalemia", "was", "observed", "during", "and", "immediately", "after", "an", "infusion", "of", "arginine", "monohydrochloride", "in", "two", "patients", "with", "severe", "hepatic", "disease", "and", "moderate", "renal", "insufficiency", "."], "event_mentions": [{"id": "717931_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "717931_2_Ent3", "role": "Effect", "text": "Marked hyperkalemia", "start": 0, "end": 2}, {"entity_id": "717931_2_Ent4", "role": "Treatment", "text": "during and immediately after an infusion of arginine monohydrochloride", "start": 4, "end": 13}, {"entity_id": "717931_2_Ent7", "role": "Treatment_Time_elapsed", "text": "immediately", "start": 6, "end": 7}, {"entity_id": "717931_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}, {"entity_id": "717931_2_Ent5", "role": "Treatment_Drug", "text": "arginine monohydrochloride", "start": 11, "end": 13}, {"entity_id": "717931_2_Ent1", "role": "Subject_Population", "text": "two", "start": 14, "end": 15}, {"entity_id": "717931_2_Ent0", "role": "Subject", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "start": 14, "end": 24}, {"entity_id": "717931_2_Ent8", "role": "Treatment_Disorder", "text": "hepatic disease", "start": 18, "end": 20}, {"entity_id": "717931_2_Ent2", "role": "Subject_Disorder", "text": "moderate renal insufficiency", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "717931_2_Ent3", "text": "Marked hyperkalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "717931_2_Ent4", "text": "during and immediately after an infusion of arginine monohydrochloride", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "717931_2_Ent7", "text": "immediately", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "717931_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "717931_2_Ent5", "text": "arginine monohydrochloride", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "717931_2_Ent1", "text": "two", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "717931_2_Ent0", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "717931_2_Ent8", "text": "hepatic disease", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "717931_2_Ent2", "text": "moderate renal insufficiency", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "7226916_1", "wnd_id": "7226916_1_1", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( CHB ) following administration of disopyramide phosphate ( Norpace ) .", "tokens": ["A", "57", "-", "year", "-", "old", "woman", "with", "right", "bundle", "branch", "block", "+", "LPH", "and", "ventricular", "premature", "contractions", "developed", "complete", "heart", "block", "(", "CHB", ")", "following", "administration", "of", "disopyramide", "phosphate", "(", "Norpace", ")", "."], "event_mentions": [{"id": "7226916_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "7226916_1_Ent0", "role": "Subject", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions", "start": 0, "end": 18}, {"entity_id": "7226916_1_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "7226916_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "7226916_1_Ent3", "role": "Subject_Disorder", "text": "right bundle branch block + LPH", "start": 8, "end": 14}, {"entity_id": "7226916_1_Ent4", "role": "Subject_Disorder", "text": "ventricular premature contractions", "start": 15, "end": 18}, {"entity_id": "7226916_1_Ent5", "role": "Effect", "text": "complete heart block ( CHB )", "start": 19, "end": 25}, {"entity_id": "7226916_1_Ent7", "role": "Treatment_Drug", "text": "disopyramide phosphate", "start": 28, "end": 30}, {"entity_id": "7226916_1_Ent6", "role": "Treatment", "text": "disopyramide phosphate ( Norpace )", "start": 28, "end": 33}]}], "entity_mentions": [{"id": "7226916_1_Ent0", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "7226916_1_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7226916_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7226916_1_Ent3", "text": "right bundle branch block + LPH", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "7226916_1_Ent4", "text": "ventricular premature contractions", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "7226916_1_Ent5", "text": "complete heart block ( CHB )", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "7226916_1_Ent7", "text": "disopyramide phosphate", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "7226916_1_Ent6", "text": "disopyramide phosphate ( Norpace )", "entity_type": "Entity", "start": 28, "end": 33}], "lang": "en"}
{"doc_id": "7226916_2", "wnd_id": "7226916_2_1", "text": "Disopyramide - induced heart block .", "tokens": ["Disopyramide", "-", "induced", "heart", "block", "."], "event_mentions": [{"id": "7226916_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7226916_2_Ent1", "role": "Treatment", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent0", "role": "Effect", "text": "heart block", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "7226916_2_Ent1", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent0", "text": "heart block", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "7249424_3", "wnd_id": "7249424_3_1", "text": "Two patients on long - term lithium therapy developed the nephrotic syndrome .", "tokens": ["Two", "patients", "on", "long", "-", "term", "lithium", "therapy", "developed", "the", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "7249424_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "7249424_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7249424_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7249424_3_Ent3", "role": "Treatment", "text": "long - term lithium therapy", "start": 3, "end": 8}, {"entity_id": "7249424_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7249424_3_Ent2", "role": "Effect", "text": "nephrotic syndrome", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7249424_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7249424_3_Ent3", "text": "long - term lithium therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7249424_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7249424_3_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7258204_1", "wnd_id": "7258204_1_1", "text": "A 67 - year - old man developed diarrhea shortly after a 10 - day course of oral ampicillin .", "tokens": ["A", "67", "-", "year", "-", "old", "man", "developed", "diarrhea", "shortly", "after", "a", "10", "-", "day", "course", "of", "oral", "ampicillin", "."], "event_mentions": [{"id": "7258204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7258204_1_Ent0", "role": "Subject", "text": "A 67 - year - old man", "start": 0, "end": 7}, {"entity_id": "7258204_1_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "7258204_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "7258204_1_Ent3", "role": "Effect", "text": "diarrhea", "start": 8, "end": 9}, {"entity_id": "7258204_1_Ent4", "role": "Treatment", "text": "a 10 - day course of oral ampicillin", "start": 11, "end": 19}, {"entity_id": "7258204_1_Ent5", "role": "Treatment_Duration", "text": "10 - day", "start": 12, "end": 15}, {"entity_id": "7258204_1_Ent7", "role": "Treatment_Route", "text": "oral", "start": 17, "end": 18}, {"entity_id": "7258204_1_Ent6", "role": "Treatment_Drug", "text": "ampicillin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7258204_1_Ent0", "text": "A 67 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7258204_1_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7258204_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7258204_1_Ent3", "text": "diarrhea", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7258204_1_Ent4", "text": "a 10 - day course of oral ampicillin", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "7258204_1_Ent5", "text": "10 - day", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "7258204_1_Ent7", "text": "oral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7258204_1_Ent6", "text": "ampicillin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7272895_1", "wnd_id": "7272895_1_1", "text": "A 73 - year - old woman with non - Hodgkin 's lymphoma had two episodes of severe , bilateral , sensori - neural hearing loss after vincristine therapy .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "with", "non", "-", "Hodgkin", "'s", "lymphoma", "had", "two", "episodes", "of", "severe", ",", "bilateral", ",", "sensori", "-", "neural", "hearing", "loss", "after", "vincristine", "therapy", "."], "event_mentions": [{"id": "7272895_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 26, "end": 27}, "arguments": [{"entity_id": "7272895_1_Ent0", "role": "Subject", "text": "A 73 - year - old woman with non - Hodgkin 's lymphoma", "start": 0, "end": 13}, {"entity_id": "7272895_1_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "7272895_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "7272895_1_Ent6", "role": "Treatment_Disorder", "text": "non - Hodgkin 's lymphoma", "start": 8, "end": 13}, {"entity_id": "7272895_1_Ent3", "role": "Effect", "text": "two episodes of severe , bilateral , sensori - neural hearing loss", "start": 14, "end": 26}, {"entity_id": "7272895_1_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 27, "end": 28}, {"entity_id": "7272895_1_Ent4", "role": "Treatment", "text": "vincristine therapy", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "7272895_1_Ent0", "text": "A 73 - year - old woman with non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "7272895_1_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7272895_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7272895_1_Ent6", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "7272895_1_Ent3", "text": "two episodes of severe , bilateral , sensori - neural hearing loss", "entity_type": "Entity", "start": 14, "end": 26}, {"id": "7272895_1_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7272895_1_Ent4", "text": "vincristine therapy", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "7272895_3", "wnd_id": "7272895_3_1", "text": "Bilateral acoustic ( VIII ) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity .", "tokens": ["Bilateral", "acoustic", "(", "VIII", ")", "nerve", "palsy", "in", "this", "patient", "was", "most", "likely", "a", "manifestation", "of", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "7272895_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "most likely", "start": 11, "end": 13}, "arguments": [{"entity_id": "7272895_3_Ent1", "role": "Effect", "text": "Bilateral acoustic ( VIII ) nerve palsy", "start": 0, "end": 7}, {"entity_id": "7272895_3_Ent0", "role": "Subject", "text": "this patient", "start": 8, "end": 10}, {"entity_id": "7272895_3_Ent3", "role": "Treatment", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "7272895_3_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "7272895_3_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "7272895_3_Ent1", "text": "Bilateral acoustic ( VIII ) nerve palsy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7272895_3_Ent0", "text": "this patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7272895_3_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7272895_3_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7272895_3_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7351000_4", "wnd_id": "7351000_4_1", "text": "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan .", "tokens": ["The", "probability", "of", "developing", "acute", "leukemia", "in", "this", "study", "was", "not", "significantly", "correlated", "to", "the", "total", "cumulative", "dosage", "of", "Treosulfan", "."], "event_mentions": [{"id": "7351000_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 3, "end": 4}, "arguments": [{"entity_id": "7351000_4_Ent0", "role": "Effect", "text": "acute leukemia", "start": 4, "end": 6}, {"entity_id": "7351000_4_Ent1", "role": "Treatment", "text": "the total cumulative dosage of Treosulfan", "start": 14, "end": 20}, {"entity_id": "7351000_4_Ent2", "role": "Treatment_Drug", "text": "Treosulfan", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7351000_4_Ent0", "text": "acute leukemia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7351000_4_Ent1", "text": "the total cumulative dosage of Treosulfan", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7351000_4_Ent2", "text": "Treosulfan", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7355327_3", "wnd_id": "7355327_3_1", "text": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy , the bronchospasm was believed to be caused by propranolol .", "tokens": ["Since", "the", "bronchospasm", "was", "relieved", "with", "discontinuation", "of", "propranolol", "and", "supportive", "bronchodilator", "therapy", ",", "the", "bronchospasm", "was", "believed", "to", "be", "caused", "by", "propranolol", "."], "event_mentions": [{"id": "7355327_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 20, "end": 21}, "arguments": [{"entity_id": "7355327_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "7355327_3_Ent0", "role": "Effect", "text": "bronchospasm", "start": 15, "end": 16}, {"entity_id": "7355327_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "7355327_3_Ent3", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7355327_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7355327_3_Ent0", "text": "bronchospasm", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7355327_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7355327_3_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7362333_1", "wnd_id": "7362333_1_1", "text": "Propranolol : an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass .", "tokens": ["Propranolol", ":", "an", "unrecognized", "cause", "of", "central", "nervous", "system", "dysfunction", "in", "patients", "undergoing", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "7362333_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7362333_1_Ent3", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent4", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent2", "role": "Effect", "text": "central nervous system dysfunction", "start": 6, "end": 10}, {"entity_id": "7362333_1_Ent0", "role": "Subject", "text": "patients undergoing cardiopulmonary bypass", "start": 11, "end": 15}, {"entity_id": "7362333_1_Ent1", "role": "Subject_Disorder", "text": "cardiopulmonary bypass", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7362333_1_Ent3", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent4", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent2", "text": "central nervous system dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7362333_1_Ent0", "text": "patients undergoing cardiopulmonary bypass", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7362333_1_Ent1", "text": "cardiopulmonary bypass", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7369302_2", "wnd_id": "7369302_2_1", "text": "A transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials in quinine toxicity , to our knowledge , have not been previously reported .", "tokens": ["A", "transient", "tonic", "pupillary", "response", ",", "denervation", "supersensitivity", ",", "and", "abnormal", "visual", "-", "evoked", "potentials", "in", "quinine", "toxicity", ",", "to", "our", "knowledge", ",", "have", "not", "been", "previously", "reported", "."], "event_mentions": [{"id": "7369302_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 27, "end": 28}, "arguments": [{"entity_id": "7369302_2_Ent0", "role": "Effect", "text": "transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials", "start": 1, "end": 15}, {"entity_id": "7369302_2_Ent1", "role": "Treatment", "text": "quinine", "start": 16, "end": 17}, {"entity_id": "7369302_2_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7369302_2_Ent0", "text": "transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "7369302_2_Ent1", "text": "quinine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7369302_2_Ent2", "text": "quinine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7379406_1", "wnd_id": "7379406_1_1", "text": "Niflumic acid - induced skeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis ?", "tokens": ["Niflumic", "acid", "-", "induced", "skeletal", "fluorosis", ":", "iatrogenic", "disease", "or", "therapeutic", "perspective", "for", "osteoporosis", "?"], "event_mentions": [{"id": "7379406_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7379406_1_Ent1", "role": "Treatment", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent2", "role": "Treatment_Drug", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent0", "role": "Effect", "text": "skeletal fluorosis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7379406_1_Ent1", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent2", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent0", "text": "skeletal fluorosis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7393795_1", "wnd_id": "7393795_1_1", "text": "A 62 - year - old Indian with diabetic nephropathy controlled with metformin , developed miliary tuberculosis for which he was treated with rifampicin , isoniazid and ethambutol .", "tokens": ["A", "62", "-", "year", "-", "old", "Indian", "with", "diabetic", "nephropathy", "controlled", "with", "metformin", ",", "developed", "miliary", "tuberculosis", "for", "which", "he", "was", "treated", "with", "rifampicin", ",", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "7393795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "7393795_1_Ent0", "role": "Subject", "text": "A 62 - year - old Indian with diabetic nephropathy", "start": 0, "end": 10}, {"entity_id": "7393795_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "7393795_1_Ent2", "role": "Subject_Race", "text": "Indian", "start": 6, "end": 7}, {"entity_id": "7393795_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic nephropathy", "start": 8, "end": 10}, {"entity_id": "7393795_1_Ent4", "role": "Treatment", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent6", "role": "Treatment_Drug", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent3", "role": "Effect", "text": "miliary tuberculosis", "start": 15, "end": 17}]}, {"id": "7393795_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "7393795_1_Ent8", "role": "Treatment_Disorder", "text": "miliary tuberculosis", "start": 15, "end": 17}, {"entity_id": "7393795_1_Ent10", "role": "Treatment_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent14", "role": "Combination_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent7", "role": "Treatment", "text": "rifampicin , isoniazid and ethambutol", "start": 23, "end": 28}, {"entity_id": "7393795_1_Ent11", "role": "Treatment_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent13", "role": "Combination_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent9", "role": "Treatment_Drug", "text": "ethambutol", "start": 27, "end": 28}, {"entity_id": "7393795_1_Ent12", "role": "Combination_Drug", "text": "ethambutol", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7393795_1_Ent0", "text": "A 62 - year - old Indian with diabetic nephropathy", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "7393795_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7393795_1_Ent2", "text": "Indian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7393795_1_Ent5", "text": "diabetic nephropathy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7393795_1_Ent4", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent6", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent3", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent8", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent10", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent14", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent7", "text": "rifampicin , isoniazid and ethambutol", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "7393795_1_Ent11", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent13", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent9", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7393795_1_Ent12", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7416268_1", "wnd_id": "7416268_1_1", "text": "Disulfiram encephalopathy as a cause of the catatonia syndrome .", "tokens": ["Disulfiram", "encephalopathy", "as", "a", "cause", "of", "the", "catatonia", "syndrome", "."], "event_mentions": [{"id": "7416268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7416268_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent1", "role": "Effect", "text": "encephalopathy", "start": 1, "end": 2}, {"entity_id": "7416268_1_Ent0", "role": "Effect", "text": "catatonia syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7416268_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent1", "text": "encephalopathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7416268_1_Ent0", "text": "catatonia syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7420580_2", "wnd_id": "7420580_2_1", "text": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine .", "tokens": ["We", "report", "on", "a", "patient", "with", "an", "embryonal", "teratocarcinoma", "of", "the", "testicle", "who", "had", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "after", "receiving", "a", "high", "dose", "of", "vinblastine", "."], "event_mentions": [{"id": "7420580_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 13, "end": 14}, "arguments": [{"entity_id": "7420580_2_Ent0", "role": "Subject", "text": "a patient with an embryonal teratocarcinoma of the testicle", "start": 3, "end": 12}, {"entity_id": "7420580_2_Ent5", "role": "Treatment_Disorder", "text": "embryonal teratocarcinoma of the testicle", "start": 7, "end": 12}, {"entity_id": "7420580_2_Ent1", "role": "Effect", "text": "syndrome of inappropriate secretion of antidiuretic hormone", "start": 15, "end": 22}, {"entity_id": "7420580_2_Ent2", "role": "Treatment", "text": "a high dose of vinblastine", "start": 24, "end": 29}, {"entity_id": "7420580_2_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 25, "end": 27}, {"entity_id": "7420580_2_Ent4", "role": "Treatment_Drug", "text": "vinblastine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7420580_2_Ent0", "text": "a patient with an embryonal teratocarcinoma of the testicle", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "7420580_2_Ent5", "text": "embryonal teratocarcinoma of the testicle", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7420580_2_Ent1", "text": "syndrome of inappropriate secretion of antidiuretic hormone", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "7420580_2_Ent2", "text": "a high dose of vinblastine", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "7420580_2_Ent3", "text": "high dose", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "7420580_2_Ent4", "text": "vinblastine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7468565_1", "wnd_id": "7468565_1_1", "text": "Barbiturate - induced submassive hepatic necrosis .", "tokens": ["Barbiturate", "-", "induced", "submassive", "hepatic", "necrosis", "."], "event_mentions": [{"id": "7468565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7468565_1_Ent1", "role": "Treatment", "text": "Barbiturate", "start": 0, "end": 1}, {"entity_id": "7468565_1_Ent2", "role": "Treatment_Drug", "text": "Barbiturate", "start": 0, "end": 1}, {"entity_id": "7468565_1_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "7468565_1_Ent1", "text": "Barbiturate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7468565_1_Ent2", "text": "Barbiturate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7468565_1_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7468565_3", "wnd_id": "7468565_3_1", "text": "A case of barbiturate - induced submassive hepatic necrosis is presented and the literature is reviewed .", "tokens": ["A", "case", "of", "barbiturate", "-", "induced", "submassive", "hepatic", "necrosis", "is", "presented", "and", "the", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "7468565_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7468565_3_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "7468565_3_Ent2", "role": "Treatment", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent3", "role": "Treatment_Drug", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent1", "role": "Effect", "text": "submassive hepatic necrosis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7468565_3_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7468565_3_Ent2", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent3", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent1", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7474364_2", "wnd_id": "7474364_2_1", "text": "Sustained - release procainamide - induced reversible granulocytopenia after myocardial infarction .", "tokens": ["Sustained", "-", "release", "procainamide", "-", "induced", "reversible", "granulocytopenia", "after", "myocardial", "infarction", "."], "event_mentions": [{"id": "7474364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7474364_2_Ent1", "role": "Treatment", "text": "Sustained - release procainamide", "start": 0, "end": 4}, {"entity_id": "7474364_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 3, "end": 4}, {"entity_id": "7474364_2_Ent0", "role": "Effect", "text": "reversible granulocytopenia", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "7474364_2_Ent1", "text": "Sustained - release procainamide", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7474364_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7474364_2_Ent0", "text": "reversible granulocytopenia", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "7474364_3", "wnd_id": "7474364_3_1", "text": "The frequency and relationship of granulocytopenia caused by sustained - release procainamide in patients with tachyarrhythmias are briefly discussed , and prior reported cases are reviewed .", "tokens": ["The", "frequency", "and", "relationship", "of", "granulocytopenia", "caused", "by", "sustained", "-", "release", "procainamide", "in", "patients", "with", "tachyarrhythmias", "are", "briefly", "discussed", ",", "and", "prior", "reported", "cases", "are", "reviewed", "."], "event_mentions": [{"id": "7474364_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "7474364_3_Ent1", "role": "Effect", "text": "granulocytopenia", "start": 5, "end": 6}, {"entity_id": "7474364_3_Ent2", "role": "Treatment", "text": "procainamide", "start": 11, "end": 12}, {"entity_id": "7474364_3_Ent3", "role": "Treatment_Drug", "text": "procainamide", "start": 11, "end": 12}, {"entity_id": "7474364_3_Ent0", "role": "Subject", "text": "patients with tachyarrhythmias", "start": 13, "end": 16}, {"entity_id": "7474364_3_Ent4", "role": "Treatment_Disorder", "text": "tachyarrhythmias", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7474364_3_Ent1", "text": "granulocytopenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7474364_3_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7474364_3_Ent3", "text": "procainamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7474364_3_Ent0", "text": "patients with tachyarrhythmias", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "7474364_3_Ent4", "text": "tachyarrhythmias", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "748238_2", "wnd_id": "748238_2_1", "text": "The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported .", "tokens": ["The", "development", "of", "an", "IgG", "lambda", "-", "type", "monoclonal", "gammopathy", "and", "subsequent", "multiple", "myeloma", "in", "an", "epilepsy", "patient", "on", "diphenylhydantoin", "(", "DILANTIN", ")", "therapy", "for", "20", "years", "is", "reported", "."], "event_mentions": [{"id": "748238_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "748238_2_Ent1", "role": "Effect", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "start": 3, "end": 14}, {"entity_id": "748238_2_Ent0", "role": "Subject", "text": "an epilepsy patient", "start": 15, "end": 18}, {"entity_id": "748238_2_Ent3", "role": "Treatment_Disorder", "text": "epilepsy", "start": 16, "end": 17}, {"entity_id": "748238_2_Ent4", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 19, "end": 20}, {"entity_id": "748238_2_Ent2", "role": "Treatment", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "start": 19, "end": 27}, {"entity_id": "748238_2_Ent5", "role": "Treatment_Duration", "text": "for 20 years", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "748238_2_Ent1", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "748238_2_Ent0", "text": "an epilepsy patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "748238_2_Ent3", "text": "epilepsy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "748238_2_Ent4", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "748238_2_Ent2", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "748238_2_Ent5", "text": "for 20 years", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7496198_9", "wnd_id": "7496198_9_1", "text": "Among the risk factors studied , two appear to increase the risk of ARE : the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients .", "tokens": ["Among", "the", "risk", "factors", "studied", ",", "two", "appear", "to", "increase", "the", "risk", "of", "ARE", ":", "the", "prescription", "of", "thiabendazole", "to", "treat", "strongyloidiasis", "during", "the", "melarsoprol", "cure", "and", "the", "bad", "general", "clinical", "conditions", "of", "patients", "."], "event_mentions": [{"id": "7496198_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear to", "start": 7, "end": 9}, "arguments": [{"entity_id": "7496198_9_Ent0", "role": "Effect", "text": "increase the risk of ARE", "start": 9, "end": 14}, {"entity_id": "7496198_9_Ent1", "role": "Treatment", "text": "prescription of thiabendazole", "start": 16, "end": 19}, {"entity_id": "7496198_9_Ent3", "role": "Treatment_Drug", "text": "thiabendazole", "start": 18, "end": 19}, {"entity_id": "7496198_9_Ent5", "role": "Treatment_Disorder", "text": "strongyloidiasis", "start": 21, "end": 22}, {"entity_id": "7496198_9_Ent2", "role": "Treatment", "text": "during the melarsoprol cure", "start": 22, "end": 26}, {"entity_id": "7496198_9_Ent4", "role": "Treatment_Drug", "text": "melarsoprol", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "7496198_9_Ent0", "text": "increase the risk of ARE", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "7496198_9_Ent1", "text": "prescription of thiabendazole", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7496198_9_Ent3", "text": "thiabendazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7496198_9_Ent5", "text": "strongyloidiasis", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7496198_9_Ent2", "text": "during the melarsoprol cure", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "7496198_9_Ent4", "text": "melarsoprol", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "7538828_1", "wnd_id": "7538828_1_1", "text": "Bone marrow aplasia and severe skin rash after a single low dose of methotrexate .", "tokens": ["Bone", "marrow", "aplasia", "and", "severe", "skin", "rash", "after", "a", "single", "low", "dose", "of", "methotrexate", "."], "event_mentions": [{"id": "7538828_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "7538828_1_Ent0", "role": "Effect", "text": "Bone marrow aplasia and severe skin rash", "start": 0, "end": 7}, {"entity_id": "7538828_1_Ent1", "role": "Treatment", "text": "a single low dose of methotrexate", "start": 8, "end": 14}, {"entity_id": "7538828_1_Ent3", "role": "Treatment_Dosage", "text": "single low dose", "start": 9, "end": 12}, {"entity_id": "7538828_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7538828_1_Ent0", "text": "Bone marrow aplasia and severe skin rash", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7538828_1_Ent1", "text": "a single low dose of methotrexate", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "7538828_1_Ent3", "text": "single low dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "7538828_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7594371_3", "wnd_id": "7594371_3_1", "text": "We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID - induced ototoxicity could result in adverse otologic consequences .", "tokens": ["We", "recommend", "the", "cautious", "use", "of", "ketorolac", "in", "patients", "with", "underlying", "illnesses", "where", "NSAID", "-", "induced", "ototoxicity", "could", "result", "in", "adverse", "otologic", "consequences", "."], "event_mentions": [{"id": "7594371_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "where", "start": 12, "end": 13}, "arguments": [{"entity_id": "7594371_3_Ent3", "role": "Treatment", "text": "ketorolac", "start": 6, "end": 7}, {"entity_id": "7594371_3_Ent4", "role": "Treatment_Drug", "text": "ketorolac", "start": 6, "end": 7}, {"entity_id": "7594371_3_Ent0", "role": "Subject", "text": "patients with underlying illnesses", "start": 8, "end": 12}, {"entity_id": "7594371_3_Ent1", "role": "Subject_Disorder", "text": "underlying illnesses", "start": 10, "end": 12}, {"entity_id": "7594371_3_Ent2", "role": "Effect", "text": "NSAID - induced ototoxicity could result in adverse otologic consequences", "start": 13, "end": 23}]}], "entity_mentions": [{"id": "7594371_3_Ent3", "text": "ketorolac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7594371_3_Ent4", "text": "ketorolac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7594371_3_Ent0", "text": "patients with underlying illnesses", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7594371_3_Ent1", "text": "underlying illnesses", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7594371_3_Ent2", "text": "NSAID - induced ototoxicity could result in adverse otologic consequences", "entity_type": "Entity", "start": 13, "end": 23}], "lang": "en"}
{"doc_id": "7606071_4", "wnd_id": "7606071_4_1", "text": "DISCUSSION : Anaphylactoid reactions have been described previously with cisplatin administration .", "tokens": ["DISCUSSION", ":", "Anaphylactoid", "reactions", "have", "been", "described", "previously", "with", "cisplatin", "administration", "."], "event_mentions": [{"id": "7606071_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "7606071_4_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 2, "end": 4}, {"entity_id": "7606071_4_Ent1", "role": "Treatment", "text": "cisplatin", "start": 9, "end": 10}, {"entity_id": "7606071_4_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7606071_4_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7606071_4_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7606071_4_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7632529_1", "wnd_id": "7632529_1_1", "text": "A 9 - year - old boy developed acute renal failure following intravenous acyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis .", "tokens": ["A", "9", "-", "year", "-", "old", "boy", "developed", "acute", "renal", "failure", "following", "intravenous", "acyclovir", "(", "30", "mg", "/", "kg", "per", "day", ")", "administered", "for", "6", "days", "to", "treat", "herpetic", "encephalitis", "."], "event_mentions": [{"id": "7632529_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7632529_1_Ent0", "role": "Subject", "text": "A 9 - year - old boy", "start": 0, "end": 7}, {"entity_id": "7632529_1_Ent1", "role": "Subject_Age", "text": "9 - year - old", "start": 1, "end": 6}, {"entity_id": "7632529_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "7632529_1_Ent3", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}, {"entity_id": "7632529_1_Ent4", "role": "Treatment", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent6", "role": "Treatment_Drug", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent7", "role": "Treatment_Dosage", "text": "30 mg / kg", "start": 15, "end": 19}, {"entity_id": "7632529_1_Ent8", "role": "Treatment_Freq", "text": "per day", "start": 19, "end": 21}, {"entity_id": "7632529_1_Ent9", "role": "Treatment_Duration", "text": "6 days", "start": 24, "end": 26}, {"entity_id": "7632529_1_Ent5", "role": "Treatment_Disorder", "text": "herpetic encephalitis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "7632529_1_Ent0", "text": "A 9 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7632529_1_Ent1", "text": "9 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7632529_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7632529_1_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7632529_1_Ent4", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent6", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent7", "text": "30 mg / kg", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "7632529_1_Ent8", "text": "per day", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "7632529_1_Ent9", "text": "6 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7632529_1_Ent5", "text": "herpetic encephalitis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "7653281_8", "wnd_id": "7653281_8_1", "text": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde ; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage .", "tokens": ["These", "results", "suggest", "that", "the", "hepatoxicity", "of", "ethanol", "in", "alcoholic", "beverages", "is", "enhanced", "by", "interaction", "with", "its", "congeners", "and", "acetaldehyde", ";", "they", "also", "suggest", "that", "alcoholic", "beverages", "are", "not", "equivalent", "in", "their", "potential", "to", "cause", "liver", "damage", "."], "event_mentions": [{"id": "7653281_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 12, "end": 13}, "arguments": [{"entity_id": "7653281_8_Ent0", "role": "Effect", "text": "hepatoxicity", "start": 5, "end": 6}, {"entity_id": "7653281_8_Ent1", "role": "Treatment", "text": "alcoholic", "start": 9, "end": 10}, {"entity_id": "7653281_8_Ent2", "role": "Treatment_Drug", "text": "alcoholic", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7653281_8_Ent0", "text": "hepatoxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7653281_8_Ent1", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7653281_8_Ent2", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7655130_1", "wnd_id": "7655130_1_1", "text": "CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .", "tokens": ["CASE", "SUMMARIES", ":", "Two", "patients", "with", "stable", "hypothyroidism", "experienced", "symptoms", "of", "hypothyroidism", "with", "increased", "serum", "thyroid", "-", "stimulating", "hormone", "(", "TSH", ")", "concentrations", "after", "switching", "from", "1", "levothyroxine", "product", "to", "another", "."], "event_mentions": [{"id": "7655130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "7655130_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "7655130_1_Ent0", "role": "Subject", "text": "Two patients with stable hypothyroidism", "start": 3, "end": 8}, {"entity_id": "7655130_1_Ent4", "role": "Treatment_Disorder", "text": "stable hypothyroidism", "start": 6, "end": 8}, {"entity_id": "7655130_1_Ent2", "role": "Effect", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "start": 11, "end": 19}, {"entity_id": "7655130_1_Ent3", "role": "Treatment", "text": "switching from 1 levothyroxine product to another", "start": 24, "end": 31}, {"entity_id": "7655130_1_Ent5", "role": "Treatment_Drug", "text": "levothyroxine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7655130_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7655130_1_Ent0", "text": "Two patients with stable hypothyroidism", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7655130_1_Ent4", "text": "stable hypothyroidism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7655130_1_Ent2", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "7655130_1_Ent3", "text": "switching from 1 levothyroxine product to another", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "7655130_1_Ent5", "text": "levothyroxine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7663030_2", "wnd_id": "7663030_2_1", "text": "OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "probable", "case", "of", "transient", "global", "amnesia", "caused", "by", "propafenone", "."], "event_mentions": [{"id": "7663030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "7663030_2_Ent0", "role": "Effect", "text": "transient global amnesia", "start": 8, "end": 11}, {"entity_id": "7663030_2_Ent1", "role": "Treatment", "text": "propafenone", "start": 13, "end": 14}, {"entity_id": "7663030_2_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7663030_2_Ent0", "text": "transient global amnesia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7663030_2_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7663030_2_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7668127_5", "wnd_id": "7668127_5_1", "text": "This observation questions the suitability of aspirin as prophylaxis for vascular disease in patients with meningiomas .", "tokens": ["This", "observation", "questions", "the", "suitability", "of", "aspirin", "as", "prophylaxis", "for", "vascular", "disease", "in", "patients", "with", "meningiomas", "."], "event_mentions": [{"id": "7668127_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 8, "end": 9}, "arguments": [{"entity_id": "7668127_5_Ent2", "role": "Treatment", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "7668127_5_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "7668127_5_Ent4", "role": "Treatment_Disorder", "text": "vascular disease", "start": 10, "end": 12}, {"entity_id": "7668127_5_Ent0", "role": "Subject", "text": "patients with meningiomas", "start": 13, "end": 16}, {"entity_id": "7668127_5_Ent1", "role": "Subject_Disorder", "text": "meningiomas", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7668127_5_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7668127_5_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7668127_5_Ent4", "text": "vascular disease", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7668127_5_Ent0", "text": "patients with meningiomas", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "7668127_5_Ent1", "text": "meningiomas", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7673653_3", "wnd_id": "7673653_3_1", "text": "However , the occurrence and management of akathisia induced by fluvoxamine have not been described .", "tokens": ["However", ",", "the", "occurrence", "and", "management", "of", "akathisia", "induced", "by", "fluvoxamine", "have", "not", "been", "described", "."], "event_mentions": [{"id": "7673653_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "7673653_3_Ent0", "role": "Effect", "text": "akathisia", "start": 7, "end": 8}, {"entity_id": "7673653_3_Ent1", "role": "Treatment", "text": "fluvoxamine", "start": 10, "end": 11}, {"entity_id": "7673653_3_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7673653_3_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7673653_3_Ent1", "text": "fluvoxamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7673653_3_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7696938_1", "wnd_id": "7696938_1_1", "text": "Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .", "tokens": ["Arrhythmias", "and", "cardiac", "arrest", "have", "been", "reported", "during", "amphotericin", "B", "administration", "but", "no", "effective", "technique", "has", "been", "described", "to", "prevent", "them", "."], "event_mentions": [{"id": "7696938_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "7696938_1_Ent0", "role": "Effect", "text": "Arrhythmias and cardiac arrest", "start": 0, "end": 4}, {"entity_id": "7696938_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 8, "end": 10}, {"entity_id": "7696938_1_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "7696938_1_Ent0", "text": "Arrhythmias and cardiac arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7696938_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7696938_1_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "7696938_2", "wnd_id": "7696938_2_1", "text": "Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .", "tokens": ["Correction", "of", "serum", "electrolyte", "imbalance", "prevents", "cardiac", "arrhythmia", "during", "amphotericin", "B", "administration", "."], "event_mentions": [{"id": "7696938_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "7696938_2_Ent0", "role": "Effect", "text": "cardiac arrhythmia", "start": 6, "end": 8}, {"entity_id": "7696938_2_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "7696938_2_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "7696938_2_Ent0", "text": "cardiac arrhythmia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7696938_2_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7696938_2_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7718983_4", "wnd_id": "7718983_4_1", "text": "This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .", "tokens": ["This", "case", "showed", "sequential", "manifestation", "from", "transient", "thyrotoxicosis", "to", "the", "appearance", "of", "TSH", "-", "receptor", "autoantibodies", ",", "and", "then", "the", "occurrence", "of", "Graves", "'", "hyperthyroidism", "during", "IFN", "therapy", "."], "event_mentions": [{"id": "7718983_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 20, "end": 21}, "arguments": [{"entity_id": "7718983_4_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "7718983_4_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 22, "end": 25}, {"entity_id": "7718983_4_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 26, "end": 27}, {"entity_id": "7718983_4_Ent2", "role": "Treatment", "text": "IFN therapy", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "7718983_4_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7718983_4_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7718983_4_Ent3", "text": "IFN", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7718983_4_Ent2", "text": "IFN therapy", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "7724306_6", "wnd_id": "7724306_6_1", "text": "Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .", "tokens": ["Parenteral", "pyridoxine", ",", "the", "specific", "antidote", "for", "INH", "-", "induced", "refractory", "seizures", ",", "should", "be", "readily", "available", "in", "every", "emergency", "department", "in", "the", "areas", "similarly", "experiencing", "increasing", "trends", "of", "TB", "."], "event_mentions": [{"id": "7724306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "7724306_6_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent0", "role": "Effect", "text": "refractory seizures", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7724306_6_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent0", "text": "refractory seizures", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7752014_1", "wnd_id": "7752014_1_1", "text": "Furosemide - associated fever .", "tokens": ["Furosemide", "-", "associated", "fever", "."], "event_mentions": [{"id": "7752014_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7752014_1_Ent1", "role": "Treatment", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent2", "role": "Treatment_Drug", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "7752014_1_Ent1", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent2", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "7761316_2", "wnd_id": "7761316_2_1", "text": "Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .", "tokens": ["Recognition", "of", "a", "potential", "drug", "-", "induced", "Fanconi", "syndrome", "is", "important", "when", "managing", "pediatric", "oncology", "patients", "previously", "treated", "with", "ifosfamide", "."], "event_mentions": [{"id": "7761316_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "7761316_2_Ent2", "role": "Effect", "text": "drug - induced Fanconi syndrome", "start": 4, "end": 9}, {"entity_id": "7761316_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 13, "end": 14}, {"entity_id": "7761316_2_Ent0", "role": "Subject", "text": "pediatric oncology patients", "start": 13, "end": 16}, {"entity_id": "7761316_2_Ent4", "role": "Treatment_Disorder", "text": "oncology", "start": 14, "end": 15}, {"entity_id": "7761316_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 19, "end": 20}, {"entity_id": "7761316_2_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7761316_2_Ent2", "text": "drug - induced Fanconi syndrome", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "7761316_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7761316_2_Ent0", "text": "pediatric oncology patients", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "7761316_2_Ent4", "text": "oncology", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7761316_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7761316_2_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7776854_2", "wnd_id": "7776854_2_1", "text": "Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .", "tokens": ["Severe", "hepatotoxicity", "related", "to", "benzarone", ":", "a", "report", "of", "three", "cases", "with", "two", "fatalities", "."], "event_mentions": [{"id": "7776854_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "7776854_2_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 1, "end": 2}, {"entity_id": "7776854_2_Ent3", "role": "Treatment", "text": "benzarone", "start": 4, "end": 5}, {"entity_id": "7776854_2_Ent4", "role": "Treatment_Drug", "text": "benzarone", "start": 4, "end": 5}, {"entity_id": "7776854_2_Ent1", "role": "Subject_Population", "text": "three", "start": 9, "end": 10}, {"entity_id": "7776854_2_Ent0", "role": "Subject", "text": "three cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7776854_2_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7776854_2_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7776854_2_Ent4", "text": "benzarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7776854_2_Ent1", "text": "three", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7776854_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7781845_1", "wnd_id": "7781845_1_1", "text": "Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .", "tokens": ["Mefloquine", "-", "associated", "hypoglycaemia", "in", "a", "cachectic", "AIDS", "patient", "."], "event_mentions": [{"id": "7781845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7781845_1_Ent3", "role": "Treatment", "text": "Mefloquine", "start": 0, "end": 1}, {"entity_id": "7781845_1_Ent4", "role": "Treatment_Drug", "text": "Mefloquine", "start": 0, "end": 1}, {"entity_id": "7781845_1_Ent2", "role": "Effect", "text": "hypoglycaemia", "start": 3, "end": 4}, {"entity_id": "7781845_1_Ent1", "role": "Subject_Disorder", "text": "cachectic AIDS", "start": 6, "end": 8}, {"entity_id": "7781845_1_Ent0", "role": "Subject", "text": "cachectic AIDS patient", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7781845_1_Ent3", "text": "Mefloquine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_1_Ent4", "text": "Mefloquine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_1_Ent2", "text": "hypoglycaemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7781845_1_Ent1", "text": "cachectic AIDS", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7781845_1_Ent0", "text": "cachectic AIDS patient", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7781845_10", "wnd_id": "7781845_10_1", "text": "Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .", "tokens": ["Mechanisms", "and", "triggering", "factors", "of", "hypoglycaemia", "induced", "by", "mefloquine", "and", "some", "other", "anti", "-", "malarial", "quinine", "analogues", "are", "discussed", "."], "event_mentions": [{"id": "7781845_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "7781845_10_Ent0", "role": "Effect", "text": "hypoglycaemia", "start": 5, "end": 6}, {"entity_id": "7781845_10_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 8, "end": 9}, {"entity_id": "7781845_10_Ent4", "role": "Combination_Drug", "text": "mefloquine", "start": 8, "end": 9}, {"entity_id": "7781845_10_Ent1", "role": "Treatment", "text": "mefloquine and some other anti - malarial quinine analogues", "start": 8, "end": 17}, {"entity_id": "7781845_10_Ent3", "role": "Treatment_Drug", "text": "quinine analogues", "start": 15, "end": 17}, {"entity_id": "7781845_10_Ent5", "role": "Combination_Drug", "text": "quinine analogues", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "7781845_10_Ent0", "text": "hypoglycaemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7781845_10_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7781845_10_Ent4", "text": "mefloquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7781845_10_Ent1", "text": "mefloquine and some other anti - malarial quinine analogues", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "7781845_10_Ent3", "text": "quinine analogues", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7781845_10_Ent5", "text": "quinine analogues", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "7781845_4", "wnd_id": "7781845_4_1", "text": "In particular , this adverse effect has never been described with mefloquine ( Lariam ) .", "tokens": ["In", "particular", ",", "this", "adverse", "effect", "has", "never", "been", "described", "with", "mefloquine", "(", "Lariam", ")", "."], "event_mentions": [{"id": "7781845_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 9, "end": 10}, "arguments": [{"entity_id": "7781845_4_Ent0", "role": "Effect", "text": "adverse effect", "start": 4, "end": 6}, {"entity_id": "7781845_4_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 11, "end": 12}, {"entity_id": "7781845_4_Ent1", "role": "Treatment", "text": "mefloquine ( Lariam )", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "7781845_4_Ent0", "text": "adverse effect", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7781845_4_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7781845_4_Ent1", "text": "mefloquine ( Lariam )", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "7865488_1", "wnd_id": "7865488_1_1", "text": "A case of noncardiogenic pulmonary edema by ethanolamine oleate .", "tokens": ["A", "case", "of", "noncardiogenic", "pulmonary", "edema", "by", "ethanolamine", "oleate", "."], "event_mentions": [{"id": "7865488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 6, "end": 7}, "arguments": [{"entity_id": "7865488_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "7865488_1_Ent1", "role": "Effect", "text": "noncardiogenic pulmonary edema", "start": 3, "end": 6}, {"entity_id": "7865488_1_Ent2", "role": "Treatment", "text": "ethanolamine oleate", "start": 7, "end": 9}, {"entity_id": "7865488_1_Ent3", "role": "Treatment_Drug", "text": "ethanolamine oleate", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7865488_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7865488_1_Ent1", "text": "noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7865488_1_Ent2", "text": "ethanolamine oleate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7865488_1_Ent3", "text": "ethanolamine oleate", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "788666_1", "wnd_id": "788666_1_1", "text": "Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .", "tokens": ["Five", "patients", "are", "described", "in", "whom", "only", "gentamicin", "sulfate", "appeared", "responsible", "for", "acute", "renal", "failure", "."], "event_mentions": [{"id": "788666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 10, "end": 11}, "arguments": [{"entity_id": "788666_1_Ent1", "role": "Subject_Population", "text": "Five", "start": 0, "end": 1}, {"entity_id": "788666_1_Ent0", "role": "Subject", "text": "Five patients", "start": 0, "end": 2}, {"entity_id": "788666_1_Ent3", "role": "Treatment", "text": "gentamicin sulfate", "start": 7, "end": 9}, {"entity_id": "788666_1_Ent4", "role": "Treatment_Drug", "text": "gentamicin sulfate", "start": 7, "end": 9}, {"entity_id": "788666_1_Ent2", "role": "Effect", "text": "acute renal failure", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "788666_1_Ent1", "text": "Five", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_1_Ent0", "text": "Five patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "788666_1_Ent3", "text": "gentamicin sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "788666_1_Ent4", "text": "gentamicin sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "788666_1_Ent2", "text": "acute renal failure", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "7889679_1", "wnd_id": "7889679_1_1", "text": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .", "tokens": ["We", "report", "a", "case", "of", "generalized", "cutaneous", "sclerosis", "associated", "with", "muscle", "and", "oesophageal", "involvement", "in", "a", "patient", "exposed", "to", "herbicides", "containing", "bromocil", ",", "diuron", "and", "aminotriazole", "."], "event_mentions": [{"id": "7889679_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed to", "start": 17, "end": 19}, "arguments": [{"entity_id": "7889679_1_Ent0", "role": "Effect", "text": "generalized cutaneous sclerosis associated with muscle and oesophageal involvement", "start": 5, "end": 14}, {"entity_id": "7889679_1_Ent1", "role": "Treatment", "text": "herbicides containing bromocil , diuron and aminotriazole", "start": 19, "end": 26}, {"entity_id": "7889679_1_Ent2", "role": "Treatment_Drug", "text": "bromocil", "start": 21, "end": 22}, {"entity_id": "7889679_1_Ent6", "role": "Combination_Drug", "text": "bromocil", "start": 21, "end": 22}, {"entity_id": "7889679_1_Ent3", "role": "Treatment_Drug", "text": "diuron", "start": 23, "end": 24}, {"entity_id": "7889679_1_Ent5", "role": "Combination_Drug", "text": "diuron", "start": 23, "end": 24}, {"entity_id": "7889679_1_Ent4", "role": "Treatment_Drug", "text": "aminotriazole", "start": 25, "end": 26}, {"entity_id": "7889679_1_Ent7", "role": "Combination_Drug", "text": "aminotriazole", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "7889679_1_Ent0", "text": "generalized cutaneous sclerosis associated with muscle and oesophageal involvement", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "7889679_1_Ent1", "text": "herbicides containing bromocil , diuron and aminotriazole", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "7889679_1_Ent2", "text": "bromocil", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7889679_1_Ent6", "text": "bromocil", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7889679_1_Ent3", "text": "diuron", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7889679_1_Ent5", "text": "diuron", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7889679_1_Ent4", "text": "aminotriazole", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7889679_1_Ent7", "text": "aminotriazole", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "7893301_2", "wnd_id": "7893301_2_1", "text": "Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .", "tokens": ["Hypokalemia", "after", "normal", "doses", "of", "neubulized", "albuterol", "(", "salbutamol", ")", "."], "event_mentions": [{"id": "7893301_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "7893301_2_Ent0", "role": "Effect", "text": "Hypokalemia", "start": 0, "end": 1}, {"entity_id": "7893301_2_Ent4", "role": "Treatment_Dosage", "text": "normal doses", "start": 2, "end": 4}, {"entity_id": "7893301_2_Ent1", "role": "Treatment", "text": "normal doses of neubulized albuterol ( salbutamol )", "start": 2, "end": 10}, {"entity_id": "7893301_2_Ent2", "role": "Treatment_Drug", "text": "albuterol", "start": 6, "end": 7}, {"entity_id": "7893301_2_Ent3", "role": "Treatment_Drug", "text": "salbutamol", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7893301_2_Ent0", "text": "Hypokalemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7893301_2_Ent4", "text": "normal doses", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7893301_2_Ent1", "text": "normal doses of neubulized albuterol ( salbutamol )", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "7893301_2_Ent2", "text": "albuterol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7893301_2_Ent3", "text": "salbutamol", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7900744_3", "wnd_id": "7900744_3_1", "text": "High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .", "tokens": ["High", "-", "dose", "intravenous", "mannitol", "infusion", "in", "various", "clinical", "settings", "may", "result", "in", "acute", "renal", "failure", "(", "ARF", ")", "."], "event_mentions": [{"id": "7900744_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 11, "end": 12}, "arguments": [{"entity_id": "7900744_3_Ent5", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "7900744_3_Ent1", "role": "Treatment", "text": "High - dose intravenous mannitol infusion", "start": 0, "end": 6}, {"entity_id": "7900744_3_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "7900744_3_Ent2", "role": "Treatment_Drug", "text": "mannitol", "start": 4, "end": 5}, {"entity_id": "7900744_3_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 5, "end": 6}, {"entity_id": "7900744_3_Ent0", "role": "Effect", "text": "acute renal failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "7900744_3_Ent5", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7900744_3_Ent1", "text": "High - dose intravenous mannitol infusion", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7900744_3_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_3_Ent2", "text": "mannitol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7900744_3_Ent4", "text": "infusion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7900744_3_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "7900744_4", "wnd_id": "7900744_4_1", "text": "Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .", "tokens": ["Mannitol", "-", "induced", "ARF", "responds", "promptly", "to", "hemodialysis", "with", "rapid", "resolution", "of", "anuria", "and", "recovery", "of", "renal", "failure", "."], "event_mentions": [{"id": "7900744_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7900744_4_Ent3", "role": "Treatment", "text": "Mannitol", "start": 0, "end": 1}, {"entity_id": "7900744_4_Ent4", "role": "Treatment_Drug", "text": "Mannitol", "start": 0, "end": 1}, {"entity_id": "7900744_4_Ent0", "role": "Effect", "text": "ARF", "start": 3, "end": 4}, {"entity_id": "7900744_4_Ent1", "role": "Effect", "text": "anuria", "start": 12, "end": 13}, {"entity_id": "7900744_4_Ent2", "role": "Effect", "text": "renal failure", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "7900744_4_Ent3", "text": "Mannitol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_4_Ent4", "text": "Mannitol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_4_Ent0", "text": "ARF", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_4_Ent1", "text": "anuria", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7900744_4_Ent2", "text": "renal failure", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "7907218_1", "wnd_id": "7907218_1_1", "text": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .", "tokens": ["Two", "patients", "with", "extrapyramidal", "side", "effects", "after", "the", "use", "of", "fluphenazine", "decanoate", "were", "evaluated", "by", "means", "of", "IBZM", "-", "SPECT", "."], "event_mentions": [{"id": "7907218_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "7907218_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7907218_1_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7907218_1_Ent2", "role": "Effect", "text": "extrapyramidal side effects", "start": 3, "end": 6}, {"entity_id": "7907218_1_Ent3", "role": "Treatment", "text": "fluphenazine decanoate", "start": 10, "end": 12}, {"entity_id": "7907218_1_Ent4", "role": "Treatment_Drug", "text": "fluphenazine decanoate", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7907218_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7907218_1_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7907218_1_Ent2", "text": "extrapyramidal side effects", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7907218_1_Ent3", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7907218_1_Ent4", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7919557_3", "wnd_id": "7919557_3_1", "text": "OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "chronic", ",", "nonproductive", "cough", "secondary", "to", "the", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "quinapril", ",", "with", "complete", "resolution", "after", "switching", "to", "another", "ACE", "inhibitor", ",", "fosinopril", "."], "event_mentions": [{"id": "7919557_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 26, "end": 27}, "arguments": [{"entity_id": "7919557_3_Ent0", "role": "Effect", "text": "chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril", "start": 7, "end": 23}, {"entity_id": "7919557_3_Ent1", "role": "Treatment", "text": "switching to another ACE inhibitor , fosinopril", "start": 28, "end": 35}, {"entity_id": "7919557_3_Ent2", "role": "Treatment_Drug", "text": "fosinopril", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "7919557_3_Ent0", "text": "chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril", "entity_type": "Entity", "start": 7, "end": 23}, {"id": "7919557_3_Ent1", "text": "switching to another ACE inhibitor , fosinopril", "entity_type": "Entity", "start": 28, "end": 35}, {"id": "7919557_3_Ent2", "text": "fosinopril", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "7919557_5", "wnd_id": "7919557_5_1", "text": "We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .", "tokens": ["We", "report", "a", "case", "of", "cough", "following", "the", "administration", "of", "quinapril", ",", "with", "complete", "resolution", "after", "changing", "to", "the", "alternative", "ACE", "inhibitor", "fosinopril", "in", "a", "patient", "with", "essential", "hypertension", "."], "event_mentions": [{"id": "7919557_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "7919557_5_Ent1", "role": "Effect", "text": "cough", "start": 5, "end": 6}, {"entity_id": "7919557_5_Ent2", "role": "Treatment", "text": "the administration of quinapril", "start": 7, "end": 11}, {"entity_id": "7919557_5_Ent3", "role": "Treatment_Drug", "text": "quinapril", "start": 10, "end": 11}, {"entity_id": "7919557_5_Ent0", "role": "Subject", "text": "patient with essential hypertension", "start": 25, "end": 29}, {"entity_id": "7919557_5_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7919557_5_Ent1", "text": "cough", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7919557_5_Ent2", "text": "the administration of quinapril", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "7919557_5_Ent3", "text": "quinapril", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7919557_5_Ent0", "text": "patient with essential hypertension", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7919557_5_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7946029_1", "wnd_id": "7946029_1_1", "text": "Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .", "tokens": ["Basilar", "invagination", "and", "mid", "-", "line", "skeletal", "abnormalities", "due", "to", "in", "utero", "exposure", "to", "phenytoin", "."], "event_mentions": [{"id": "7946029_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "7946029_1_Ent0", "role": "Effect", "text": "Basilar invagination and mid - line skeletal abnormalities", "start": 0, "end": 8}, {"entity_id": "7946029_1_Ent1", "role": "Treatment", "text": "utero exposure to phenytoin", "start": 11, "end": 15}, {"entity_id": "7946029_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "7946029_1_Ent0", "text": "Basilar invagination and mid - line skeletal abnormalities", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "7946029_1_Ent1", "text": "utero exposure to phenytoin", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7946029_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "7973922_1", "wnd_id": "7973922_1_1", "text": "Acyclovir neurotoxicity : clinical experience and review of the literature .", "tokens": ["Acyclovir", "neurotoxicity", ":", "clinical", "experience", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7973922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experience", "start": 4, "end": 5}, "arguments": [{"entity_id": "7973922_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "7973922_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "7978578_1", "wnd_id": "7978578_1_1", "text": "Response of a promethazine - induced coma to flumazenil .", "tokens": ["Response", "of", "a", "promethazine", "-", "induced", "coma", "to", "flumazenil", "."], "event_mentions": [{"id": "7978578_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Response", "start": 0, "end": 1}, "arguments": [{"entity_id": "7978578_1_Ent4", "role": "Treatment_Disorder", "text": "promethazine - induced coma", "start": 3, "end": 7}, {"entity_id": "7978578_1_Ent3", "role": "Treatment", "text": "flumazenil", "start": 8, "end": 9}, {"entity_id": "7978578_1_Ent5", "role": "Treatment_Drug", "text": "flumazenil", "start": 8, "end": 9}]}, {"id": "7978578_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7978578_1_Ent1", "role": "Treatment", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent2", "role": "Treatment_Drug", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent0", "role": "Effect", "text": "coma", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7978578_1_Ent1", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent2", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent4", "text": "promethazine - induced coma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7978578_1_Ent0", "text": "coma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7978578_1_Ent3", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7978578_1_Ent5", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7978578_2", "wnd_id": "7978578_2_1", "text": "We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "patient", "in", "a", "promethazine", "-", "induced", "coma", "responding", "to", "treatment", "with", "flumazenil", "."], "event_mentions": [{"id": "7978578_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responding to", "start": 14, "end": 16}, "arguments": [{"entity_id": "7978578_2_Ent0", "role": "Subject", "text": "a patient in a promethazine - induced coma", "start": 6, "end": 14}, {"entity_id": "7978578_2_Ent3", "role": "Treatment_Drug", "text": "promethazine", "start": 10, "end": 11}, {"entity_id": "7978578_2_Ent4", "role": "Treatment_Disorder", "text": "coma", "start": 13, "end": 14}, {"entity_id": "7978578_2_Ent1", "role": "Treatment", "text": "treatment with flumazenil", "start": 16, "end": 19}, {"entity_id": "7978578_2_Ent2", "role": "Treatment_Drug", "text": "flumazenil", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7978578_2_Ent0", "text": "a patient in a promethazine - induced coma", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7978578_2_Ent3", "text": "promethazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7978578_2_Ent4", "text": "coma", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7978578_2_Ent1", "text": "treatment with flumazenil", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7978578_2_Ent2", "text": "flumazenil", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8002140_2", "wnd_id": "8002140_2_1", "text": "Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .", "tokens": ["Contact", "dermatitis", "due", "to", "budesonide", ":", "report", "of", "five", "cases", "and", "review", "of", "the", "Japanese", "literature", "."], "event_mentions": [{"id": "8002140_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8002140_2_Ent0", "role": "Effect", "text": "Contact dermatitis", "start": 0, "end": 2}, {"entity_id": "8002140_2_Ent1", "role": "Treatment", "text": "budesonide", "start": 4, "end": 5}, {"entity_id": "8002140_2_Ent2", "role": "Treatment_Drug", "text": "budesonide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8002140_2_Ent0", "text": "Contact dermatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8002140_2_Ent1", "text": "budesonide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8002140_2_Ent2", "text": "budesonide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8007037_1", "wnd_id": "8007037_1_1", "text": "Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .", "tokens": ["Although", "other", "nitrites", "induce", "methemoglobinemia", ",", "exposure", "to", "methyl", "nitrite", "during", "phenylpropanolamine", "production", "appears", "to", "be", "a", "new", "cause", "of", "occupational", "methemoglobinemia", "."], "event_mentions": [{"id": "8007037_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 18, "end": 19}, "arguments": [{"entity_id": "8007037_1_Ent1", "role": "Treatment", "text": "methyl nitrite", "start": 8, "end": 10}, {"entity_id": "8007037_1_Ent2", "role": "Treatment_Drug", "text": "methyl nitrite", "start": 8, "end": 10}, {"entity_id": "8007037_1_Ent0", "role": "Effect", "text": "occupational methemoglobinemia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8007037_1_Ent1", "text": "methyl nitrite", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8007037_1_Ent2", "text": "methyl nitrite", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8007037_1_Ent0", "text": "occupational methemoglobinemia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8013261_1", "wnd_id": "8013261_1_1", "text": "During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .", "tokens": ["During", "and", "after", "IFN", "therapy", "we", "should", "consider", "the", "possibility", "of", "occurrence", "of", "IDDM", "as", "well", "as", "other", "autoimmune", "diseases", "and", "observe", "the", "clinical", "course", "carefully", "."], "event_mentions": [{"id": "8013261_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 11, "end": 12}, "arguments": [{"entity_id": "8013261_1_Ent3", "role": "Treatment_Time_elapsed", "text": "During and after", "start": 0, "end": 3}, {"entity_id": "8013261_1_Ent1", "role": "Treatment", "text": "IFN therapy", "start": 3, "end": 5}, {"entity_id": "8013261_1_Ent2", "role": "Treatment_Drug", "text": "IFN therapy", "start": 3, "end": 5}, {"entity_id": "8013261_1_Ent0", "role": "Effect", "text": "IDDM as well as other autoimmune diseases", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "8013261_1_Ent3", "text": "During and after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8013261_1_Ent1", "text": "IFN therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8013261_1_Ent2", "text": "IFN therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8013261_1_Ent0", "text": "IDDM as well as other autoimmune diseases", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "8034807_1", "wnd_id": "8034807_1_1", "text": "The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .", "tokens": ["The", "use", "of", "methotrexate", "(", "MTX", ")", "has", "been", "contraindicated", "for", "treatment", "of", "severe", "psoriasis", "in", "HIV", "infection", "on", "the", "basis", "of", "six", "previously", "reported", "cases", "in", "which", "MTX", "appeared", "to", "potentiate", "opportunistic", "infections", "and", "accelerate", "HIV", "disease", "."], "event_mentions": [{"id": "8034807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 35, "end": 36}, "arguments": [{"entity_id": "8034807_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate ( MTX )", "start": 3, "end": 7}, {"entity_id": "8034807_1_Ent1", "role": "Treatment", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent0", "role": "Effect", "text": "HIV disease", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "8034807_1_Ent2", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8034807_1_Ent1", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent0", "text": "HIV disease", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "8053440_2", "wnd_id": "8053440_2_1", "text": "One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .", "tokens": ["One", "patient", "who", "received", "clindamycin", "had", "liver", "biopsy", "findings", "of", "marked", "cholestasis", ",", "portal", "inflammation", ",", "bile", "duct", "injury", "and", "bile", "duct", "paucity", "(", "ductopenia", ")", "."], "event_mentions": [{"id": "8053440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "8053440_2_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "8053440_2_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "8053440_2_Ent3", "role": "Treatment", "text": "clindamycin", "start": 4, "end": 5}, {"entity_id": "8053440_2_Ent4", "role": "Treatment_Drug", "text": "clindamycin", "start": 4, "end": 5}, {"entity_id": "8053440_2_Ent2", "role": "Effect", "text": "marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia )", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "8053440_2_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8053440_2_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8053440_2_Ent3", "text": "clindamycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8053440_2_Ent4", "text": "clindamycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8053440_2_Ent2", "text": "marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia )", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "8053440_4", "wnd_id": "8053440_4_1", "text": "This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .", "tokens": ["This", "is", "the", "first", "description", ",", "to", "our", "knowledge", ",", "of", "ductopenia", "apparently", "caused", "by", "clindamycin", "."], "event_mentions": [{"id": "8053440_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "8053440_4_Ent0", "role": "Effect", "text": "ductopenia", "start": 11, "end": 12}, {"entity_id": "8053440_4_Ent1", "role": "Treatment", "text": "clindamycin", "start": 15, "end": 16}, {"entity_id": "8053440_4_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8053440_4_Ent0", "text": "ductopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8053440_4_Ent1", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8053440_4_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8053440_5", "wnd_id": "8053440_5_1", "text": "Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .", "tokens": ["Three", "years", "later", ",", "treatment", "with", "ampicillin", "caused", "another", "episode", "of", "cholestatic", "hepatitis", "with", "cholestasis", "and", "duct", "paucity", "on", "rebiopsy", "."], "event_mentions": [{"id": "8053440_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "8053440_5_Ent3", "role": "Treatment_Time_elapsed", "text": "Three years later", "start": 0, "end": 3}, {"entity_id": "8053440_5_Ent1", "role": "Treatment", "text": "ampicillin", "start": 6, "end": 7}, {"entity_id": "8053440_5_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 6, "end": 7}, {"entity_id": "8053440_5_Ent0", "role": "Effect", "text": "cholestatic hepatitis with cholestasis and duct paucity on rebiopsy", "start": 11, "end": 20}]}], "entity_mentions": [{"id": "8053440_5_Ent3", "text": "Three years later", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8053440_5_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8053440_5_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8053440_5_Ent0", "text": "cholestatic hepatitis with cholestasis and duct paucity on rebiopsy", "entity_type": "Entity", "start": 11, "end": 20}], "lang": "en"}
{"doc_id": "8098286_3", "wnd_id": "8098286_3_1", "text": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "hypersensitivity", "pneumonitis", "during", "treatment", "with", "the", "beta", "-", "blocker", ",", "celiprolol", "."], "event_mentions": [{"id": "8098286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "8098286_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "8098286_3_Ent1", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 7, "end": 9}, {"entity_id": "8098286_3_Ent2", "role": "Treatment", "text": "celiprolol", "start": 17, "end": 18}, {"entity_id": "8098286_3_Ent3", "role": "Treatment_Drug", "text": "celiprolol", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8098286_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8098286_3_Ent1", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8098286_3_Ent2", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8098286_3_Ent3", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8124920_2", "wnd_id": "8124920_2_1", "text": "In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .", "tokens": ["In", "a", "patient", "suffering", "from", "rheumatoid", "arthritis", ",", "we", "report", "the", "first", "simultaneous", "occurrence", "of", "two", "side", "effects", "of", "low", "-", "dose", "methotrexate", ":", "an", "acute", "megaloblastic", "anaemia", "and", "a", "pneumonitis", "."], "event_mentions": [{"id": "8124920_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "an", "start": 24, "end": 25}, "arguments": [{"entity_id": "8124920_2_Ent0", "role": "Subject", "text": "patient suffering from rheumatoid arthritis", "start": 2, "end": 7}, {"entity_id": "8124920_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}, {"entity_id": "8124920_2_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 19, "end": 22}, {"entity_id": "8124920_2_Ent2", "role": "Treatment", "text": "low - dose methotrexate", "start": 19, "end": 23}, {"entity_id": "8124920_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8124920_2_Ent1", "role": "Effect", "text": "acute megaloblastic anaemia and a pneumonitis", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "8124920_2_Ent0", "text": "patient suffering from rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8124920_2_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8124920_2_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "8124920_2_Ent2", "text": "low - dose methotrexate", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "8124920_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8124920_2_Ent1", "text": "acute megaloblastic anaemia and a pneumonitis", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "8149366_2", "wnd_id": "8149366_2_1", "text": "We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .", "tokens": ["We", "report", "on", "three", "observations", "of", "parkinsonian", "patients", "with", "levo", "-", "dopa", "-", "induced", "diphasic", "dyskinesias", ",", "who", "received", "subcutaneous", "apomorphine", "to", "reduce", "the", "duration", "of", "abnormal", "movements", "."], "event_mentions": [{"id": "8149366_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "8149366_2_Ent1", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent0", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent3", "role": "Treatment", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent4", "role": "Treatment_Drug", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent2", "role": "Effect", "text": "diphasic dyskinesias", "start": 14, "end": 16}]}, {"id": "8149366_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduce", "start": 22, "end": 23}, "arguments": [{"entity_id": "8149366_2_Ent6", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent5", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent9", "role": "Treatment_Route", "text": "subcutaneous", "start": 19, "end": 20}, {"entity_id": "8149366_2_Ent7", "role": "Treatment", "text": "subcutaneous apomorphine", "start": 19, "end": 21}, {"entity_id": "8149366_2_Ent10", "role": "Treatment_Drug", "text": "apomorphine", "start": 20, "end": 21}, {"entity_id": "8149366_2_Ent8", "role": "Treatment_Disorder", "text": "abnormal movements", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "8149366_2_Ent1", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent6", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent0", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent5", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent3", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent4", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent2", "text": "diphasic dyskinesias", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8149366_2_Ent9", "text": "subcutaneous", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8149366_2_Ent7", "text": "subcutaneous apomorphine", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "8149366_2_Ent10", "text": "apomorphine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8149366_2_Ent8", "text": "abnormal movements", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "8151270_2", "wnd_id": "8151270_2_1", "text": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .", "tokens": ["This", "prompted", "us", "to", "suspect", "that", "ddI", "might", "be", "responsible", "for", "fulminant", "hepatitis", "in", "all", "three", "AIDS", "patients", "."], "event_mentions": [{"id": "8151270_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be responsible for", "start": 8, "end": 11}, "arguments": [{"entity_id": "8151270_2_Ent3", "role": "Treatment", "text": "ddI", "start": 6, "end": 7}, {"entity_id": "8151270_2_Ent5", "role": "Treatment_Drug", "text": "ddI", "start": 6, "end": 7}, {"entity_id": "8151270_2_Ent2", "role": "Effect", "text": "fulminant hepatitis", "start": 11, "end": 13}, {"entity_id": "8151270_2_Ent1", "role": "Subject_Population", "text": "three", "start": 15, "end": 16}, {"entity_id": "8151270_2_Ent0", "role": "Subject", "text": "three AIDS patients", "start": 15, "end": 18}, {"entity_id": "8151270_2_Ent4", "role": "Treatment_Disorder", "text": "AIDS", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8151270_2_Ent3", "text": "ddI", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8151270_2_Ent5", "text": "ddI", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8151270_2_Ent2", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8151270_2_Ent1", "text": "three", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8151270_2_Ent0", "text": "three AIDS patients", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8151270_2_Ent4", "text": "AIDS", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "8157823_1", "wnd_id": "8157823_1_1", "text": "Generalized argyria after habitual use of AgNO3 .", "tokens": ["Generalized", "argyria", "after", "habitual", "use", "of", "AgNO3", "."], "event_mentions": [{"id": "8157823_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "8157823_1_Ent0", "role": "Effect", "text": "Generalized argyria", "start": 0, "end": 2}, {"entity_id": "8157823_1_Ent1", "role": "Treatment", "text": "habitual use of AgNO3", "start": 3, "end": 7}, {"entity_id": "8157823_1_Ent2", "role": "Treatment_Drug", "text": "AgNO3", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8157823_1_Ent0", "text": "Generalized argyria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8157823_1_Ent1", "text": "habitual use of AgNO3", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8157823_1_Ent2", "text": "AgNO3", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8175330_2", "wnd_id": "8175330_2_1", "text": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .", "tokens": ["We", "present", "findings", "from", "three", "patients", "who", "experienced", "a", "psoriasiform", "eruption", "apparently", "due", "to", "the", "antiepileptic", "agents", "sodium", "valproate", "and", "carbamazepine", "."], "event_mentions": [{"id": "8175330_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "8175330_2_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8175330_2_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8175330_2_Ent2", "role": "Effect", "text": "psoriasiform eruption", "start": 9, "end": 11}, {"entity_id": "8175330_2_Ent3", "role": "Treatment", "text": "antiepileptic agents sodium valproate and carbamazepine", "start": 15, "end": 21}, {"entity_id": "8175330_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent6", "role": "Combination_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "8175330_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8175330_2_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8175330_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8175330_2_Ent2", "text": "psoriasiform eruption", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8175330_2_Ent3", "text": "antiepileptic agents sodium valproate and carbamazepine", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8175330_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8175330_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8192712_3", "wnd_id": "8192712_3_1", "text": "Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .", "tokens": ["Hyperammonemia", "secondary", "to", "valproic", "acid", "as", "a", "cause", "of", "lethargy", "in", "a", "postictal", "patient", "."], "event_mentions": [{"id": "8192712_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "8192712_3_Ent1", "role": "Effect", "text": "Hyperammonemia", "start": 0, "end": 1}, {"entity_id": "8192712_3_Ent2", "role": "Treatment", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent0", "role": "Subject", "text": "a postictal patient", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "8192712_3_Ent1", "text": "Hyperammonemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8192712_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent0", "text": "a postictal patient", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "8222875_3", "wnd_id": "8222875_3_1", "text": "Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .", "tokens": ["Pulmonary", "hemorrhage", "is", "an", "uncommon", "feature", "in", "the", "HUS", ",", "and", "seems", "to", "appear", "especially", "in", "the", "HUS", "associated", "with", "MMC", "therapy", "."], "event_mentions": [{"id": "8222875_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_3_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_3_Ent1", "role": "Treatment", "text": "MMC", "start": 20, "end": 21}, {"entity_id": "8222875_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8222875_3_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8222875_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8244201_2", "wnd_id": "8244201_2_1", "text": "Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .", "tokens": ["Hyperkalaemia", "with", "renal", "tubular", "dysfunction", "by", "oral", "therapy", "of", "sulfamethoxazole", "-", "trimethoprim", "(", "co", "-", "trimoxazole", ")", "is", "described", "in", "2", "elderly", "Japanese", "patients", "with", "lymphoid", "malignancy", ",", "who", "developed", "Pneumocystis", "carinii", "pneumonia", "and", "improved", "."], "event_mentions": [{"id": "8244201_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 18, "end": 19}, "arguments": [{"entity_id": "8244201_2_Ent5", "role": "Effect", "text": "Hyperkalaemia with renal tubular dysfunction", "start": 0, "end": 5}, {"entity_id": "8244201_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 6, "end": 7}, {"entity_id": "8244201_2_Ent6", "role": "Treatment", "text": "oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole )", "start": 6, "end": 17}, {"entity_id": "8244201_2_Ent8", "role": "Treatment_Drug", "text": "sulfamethoxazole - trimethoprim", "start": 9, "end": 12}, {"entity_id": "8244201_2_Ent1", "role": "Subject_Population", "text": "2", "start": 20, "end": 21}, {"entity_id": "8244201_2_Ent0", "role": "Subject", "text": "2 elderly Japanese patients with lymphoid malignancy", "start": 20, "end": 27}, {"entity_id": "8244201_2_Ent2", "role": "Subject_Age", "text": "elderly", "start": 21, "end": 22}, {"entity_id": "8244201_2_Ent3", "role": "Subject_Race", "text": "Japanese", "start": 22, "end": 23}, {"entity_id": "8244201_2_Ent4", "role": "Subject_Disorder", "text": "lymphoid malignancy", "start": 25, "end": 27}, {"entity_id": "8244201_2_Ent9", "role": "Treatment_Disorder", "text": "Pneumocystis carinii pneumonia", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "8244201_2_Ent5", "text": "Hyperkalaemia with renal tubular dysfunction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8244201_2_Ent6", "text": "oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole )", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "8244201_2_Ent8", "text": "sulfamethoxazole - trimethoprim", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8244201_2_Ent1", "text": "2", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8244201_2_Ent0", "text": "2 elderly Japanese patients with lymphoid malignancy", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "8244201_2_Ent2", "text": "elderly", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8244201_2_Ent3", "text": "Japanese", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8244201_2_Ent4", "text": "lymphoid malignancy", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_2_Ent9", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "8253700_1", "wnd_id": "8253700_1_1", "text": "BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .", "tokens": ["BACKGROUND", ":", "Fluoxetine", ",", "a", "highly", "specific", "serotonin", "reuptake", "inhibitor", ",", "has", "been", "reported", "to", "cause", "sexual", "dysfunction", "in", "a", "minority", "of", "patients", "."], "event_mentions": [{"id": "8253700_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "8253700_1_Ent2", "role": "Treatment", "text": "Fluoxetine", "start": 2, "end": 3}, {"entity_id": "8253700_1_Ent3", "role": "Treatment_Drug", "text": "Fluoxetine", "start": 2, "end": 3}, {"entity_id": "8253700_1_Ent1", "role": "Effect", "text": "sexual dysfunction", "start": 16, "end": 18}, {"entity_id": "8253700_1_Ent0", "role": "Subject", "text": "minority of patients", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8253700_1_Ent2", "text": "Fluoxetine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8253700_1_Ent3", "text": "Fluoxetine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8253700_1_Ent1", "text": "sexual dysfunction", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8253700_1_Ent0", "text": "minority of patients", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8276031_1", "wnd_id": "8276031_1_1", "text": "Imidazoline intoxication in children .", "tokens": ["Imidazoline", "intoxication", "in", "children", "."], "event_mentions": [{"id": "8276031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 1, "end": 2}, "arguments": [{"entity_id": "8276031_1_Ent3", "role": "Treatment", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_1_Ent4", "role": "Treatment_Drug", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_1_Ent2", "role": "Effect", "text": "Imidazoline intoxication", "start": 0, "end": 2}, {"entity_id": "8276031_1_Ent0", "role": "Subject", "text": "children", "start": 3, "end": 4}, {"entity_id": "8276031_1_Ent1", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8276031_1_Ent3", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_1_Ent4", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_1_Ent2", "text": "Imidazoline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8276031_1_Ent0", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8276031_1_Ent1", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8276031_6", "wnd_id": "8276031_6_1", "text": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .", "tokens": ["Imidazoline", "intoxication", "due", "to", "overdose", "or", "accidental", "ingestion", "but", "also", "after", "normal", "therapeutic", "usage", "is", "frequent", "in", "children", "."], "event_mentions": [{"id": "8276031_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8276031_6_Ent3", "role": "Treatment", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_6_Ent2", "role": "Effect", "text": "intoxication", "start": 1, "end": 2}, {"entity_id": "8276031_6_Ent6", "role": "Treatment_Dosage", "text": "overdose or accidental", "start": 4, "end": 7}, {"entity_id": "8276031_6_Ent4", "role": "Treatment", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "start": 4, "end": 14}, {"entity_id": "8276031_6_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 7, "end": 8}, {"entity_id": "8276031_6_Ent7", "role": "Treatment_Dosage", "text": "but also after normal therapeutic usage", "start": 8, "end": 14}, {"entity_id": "8276031_6_Ent0", "role": "Subject", "text": "children", "start": 17, "end": 18}, {"entity_id": "8276031_6_Ent1", "role": "Subject_Age", "text": "children", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8276031_6_Ent3", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_6_Ent2", "text": "intoxication", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8276031_6_Ent6", "text": "overdose or accidental", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8276031_6_Ent4", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "8276031_6_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8276031_6_Ent7", "text": "but also after normal therapeutic usage", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8276031_6_Ent0", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8276031_6_Ent1", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8305778_3", "wnd_id": "8305778_3_1", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "history", "of", "congestive", "heart", "failure", "and", "coronary", "artery", "disease", "began", "taking", "amiodarone", "to", "suppress", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "8305778_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "suppress", "start": 22, "end": 23}, "arguments": [{"entity_id": "8305778_3_Ent0", "role": "Subject", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "start": 0, "end": 18}, {"entity_id": "8305778_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8305778_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8305778_3_Ent3", "role": "Subject_Disorder", "text": "congestive heart failure", "start": 11, "end": 14}, {"entity_id": "8305778_3_Ent4", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 15, "end": 18}, {"entity_id": "8305778_3_Ent5", "role": "Treatment", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent7", "role": "Treatment_Disorder", "text": "sustained ventricular tachycardia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "8305778_3_Ent0", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "8305778_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8305778_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8305778_3_Ent3", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8305778_3_Ent4", "text": "coronary artery disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8305778_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent7", "text": "sustained ventricular tachycardia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "8305778_6", "wnd_id": "8305778_6_1", "text": "Amiodarone is a Class III antiarrhythmic with an adverse - effect profile involving many different organ systems .", "tokens": ["Amiodarone", "is", "a", "Class", "III", "antiarrhythmic", "with", "an", "adverse", "-", "effect", "profile", "involving", "many", "different", "organ", "systems", "."], "event_mentions": [{"id": "8305778_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse - effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "8305778_6_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "8305778_6_Ent0", "role": "Effect", "text": "an adverse - effect profile involving many different organ systems", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "8305778_6_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8305778_6_Ent0", "text": "an adverse - effect profile involving many different organ systems", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "8305778_9", "wnd_id": "8305778_9_1", "text": "Hypothyroidism , occurring in up to 11 percent of patients treated with amiodarone , can also alter drug metabolism and sensitize the central nervous system , thus increasing the potential for toxicity .", "tokens": ["Hypothyroidism", ",", "occurring", "in", "up", "to", "11", "percent", "of", "patients", "treated", "with", "amiodarone", ",", "can", "also", "alter", "drug", "metabolism", "and", "sensitize", "the", "central", "nervous", "system", ",", "thus", "increasing", "the", "potential", "for", "toxicity", "."], "event_mentions": [{"id": "8305778_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 2, "end": 3}, "arguments": [{"entity_id": "8305778_9_Ent2", "role": "Effect", "text": "Hypothyroidism", "start": 0, "end": 1}, {"entity_id": "8305778_9_Ent1", "role": "Subject_Population", "text": "11 percent", "start": 6, "end": 8}, {"entity_id": "8305778_9_Ent0", "role": "Subject", "text": "11 percent of patients", "start": 6, "end": 10}, {"entity_id": "8305778_9_Ent3", "role": "Treatment", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "8305778_9_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8305778_9_Ent2", "text": "Hypothyroidism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8305778_9_Ent1", "text": "11 percent", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8305778_9_Ent0", "text": "11 percent of patients", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8305778_9_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8305778_9_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8313300_7", "wnd_id": "8313300_7_1", "text": "Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .", "tokens": ["Lithium", "therapy", "was", "discontinued", "because", "of", "poor", "compliance", "to", "the", "medication", "and", "intolerable", "polyuria", "."], "event_mentions": [{"id": "8313300_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 4, "end": 5}, "arguments": [{"entity_id": "8313300_7_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8313300_7_Ent0", "role": "Effect", "text": "polyuria", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8313300_7_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8313300_7_Ent0", "text": "polyuria", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8316494_1", "wnd_id": "8316494_1_1", "text": "Severe abdominal pain in low dosage clofazimine .", "tokens": ["Severe", "abdominal", "pain", "in", "low", "dosage", "clofazimine", "."], "event_mentions": [{"id": "8316494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "8316494_1_Ent0", "role": "Effect", "text": "abdominal pain", "start": 1, "end": 3}, {"entity_id": "8316494_1_Ent3", "role": "Treatment_Dosage", "text": "low dosage", "start": 4, "end": 6}, {"entity_id": "8316494_1_Ent1", "role": "Treatment", "text": "low dosage clofazimine", "start": 4, "end": 7}, {"entity_id": "8316494_1_Ent2", "role": "Treatment_Drug", "text": "clofazimine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8316494_1_Ent0", "text": "abdominal pain", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8316494_1_Ent3", "text": "low dosage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8316494_1_Ent1", "text": "low dosage clofazimine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8316494_1_Ent2", "text": "clofazimine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8329789_7", "wnd_id": "8329789_7_1", "text": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 ( the only survivor ) .", "tokens": ["Hydrocortisone", "prophylaxis", "and", "verapamil", "therapy", "were", "the", "primary", "therapies", "used", "in", "patient", "1", "(", "the", "only", "survivor", ")", "."], "event_mentions": [{"id": "8329789_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapies", "start": 8, "end": 9}, "arguments": [{"entity_id": "8329789_7_Ent2", "role": "Treatment_Drug", "text": "Hydrocortisone", "start": 0, "end": 1}, {"entity_id": "8329789_7_Ent1", "role": "Treatment", "text": "Hydrocortisone prophylaxis and verapamil therapy", "start": 0, "end": 5}, {"entity_id": "8329789_7_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "8329789_7_Ent0", "role": "Subject", "text": "patient 1 ( the only survivor )", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "8329789_7_Ent2", "text": "Hydrocortisone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8329789_7_Ent1", "text": "Hydrocortisone prophylaxis and verapamil therapy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8329789_7_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8329789_7_Ent0", "text": "patient 1 ( the only survivor )", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "8360712_1", "wnd_id": "8360712_1_1", "text": "A case is reported of a 40 year old woman treated with intraventricular IL - 2 for leptomeningeal disease who developed progressive cognitive dysfunction .", "tokens": ["A", "case", "is", "reported", "of", "a", "40", "year", "old", "woman", "treated", "with", "intraventricular", "IL", "-", "2", "for", "leptomeningeal", "disease", "who", "developed", "progressive", "cognitive", "dysfunction", "."], "event_mentions": [{"id": "8360712_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8360712_1_Ent0", "role": "Subject", "text": "a 40 year old woman", "start": 5, "end": 10}, {"entity_id": "8360712_1_Ent1", "role": "Subject_Age", "text": "40 year old", "start": 6, "end": 9}, {"entity_id": "8360712_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "8360712_1_Ent7", "role": "Treatment_Route", "text": "intraventricular", "start": 12, "end": 13}, {"entity_id": "8360712_1_Ent4", "role": "Treatment", "text": "intraventricular IL - 2", "start": 12, "end": 16}, {"entity_id": "8360712_1_Ent6", "role": "Treatment_Drug", "text": "IL - 2", "start": 13, "end": 16}, {"entity_id": "8360712_1_Ent5", "role": "Treatment_Disorder", "text": "leptomeningeal disease", "start": 17, "end": 19}, {"entity_id": "8360712_1_Ent3", "role": "Effect", "text": "progressive cognitive dysfunction", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "8360712_1_Ent0", "text": "a 40 year old woman", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8360712_1_Ent1", "text": "40 year old", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8360712_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8360712_1_Ent7", "text": "intraventricular", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8360712_1_Ent4", "text": "intraventricular IL - 2", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "8360712_1_Ent6", "text": "IL - 2", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8360712_1_Ent5", "text": "leptomeningeal disease", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8360712_1_Ent3", "text": "progressive cognitive dysfunction", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "8375752_1", "wnd_id": "8375752_1_1", "text": "Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : \" the retinoic acid syndrome \" .", "tokens": ["Although", "retinoic", "acid", "is", "well", "tolerated", "by", "the", "majority", "of", "patients", "with", "this", "disease", ",", "a", "potentially", "fatal", "complication", "of", "this", "kind", "of", "treatment", "has", "been", "reported", ":", "\"", "the", "retinoic", "acid", "syndrome", "\"", "."], "event_mentions": [{"id": "8375752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 18, "end": 19}, "arguments": [{"entity_id": "8375752_1_Ent1", "role": "Treatment", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent2", "role": "Treatment_Drug", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent0", "role": "Effect", "text": "fatal complication", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "8375752_1_Ent1", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent2", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent0", "text": "fatal complication", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8384030_1", "wnd_id": "8384030_1_1", "text": "CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .", "tokens": ["CONCLUSIONS", ":", "It", "is", "probable", "that", "foscarnet", "contributed", "to", "the", "electrolyte", "disorders", "and", "symptomatology", "in", "this", "patient", "."], "event_mentions": [{"id": "8384030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8384030_1_Ent2", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent1", "role": "Effect", "text": "electrolyte disorders and symptomatology", "start": 10, "end": 14}, {"entity_id": "8384030_1_Ent0", "role": "Subject", "text": "this patient", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8384030_1_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent1", "text": "electrolyte disorders and symptomatology", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8384030_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8384030_2", "wnd_id": "8384030_2_1", "text": "DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .", "tokens": ["DISCUSSION", ":", "Electrolyte", "disorders", "associated", "with", "foscarnet", "are", "reviewed", "."], "event_mentions": [{"id": "8384030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "8384030_2_Ent0", "role": "Effect", "text": "Electrolyte disorders", "start": 2, "end": 4}, {"entity_id": "8384030_2_Ent1", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8384030_2_Ent0", "text": "Electrolyte disorders", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8384030_2_Ent1", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8396491_1", "wnd_id": "8396491_1_1", "text": "Interference with the cortisol axis by the microtubule antagonist , CPH82 .", "tokens": ["Interference", "with", "the", "cortisol", "axis", "by", "the", "microtubule", "antagonist", ",", "CPH82", "."], "event_mentions": [{"id": "8396491_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8396491_1_Ent0", "role": "Effect", "text": "Interference with the cortisol axis", "start": 0, "end": 5}, {"entity_id": "8396491_1_Ent1", "role": "Treatment", "text": "CPH82", "start": 10, "end": 11}, {"entity_id": "8396491_1_Ent2", "role": "Treatment_Drug", "text": "CPH82", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8396491_1_Ent0", "text": "Interference with the cortisol axis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8396491_1_Ent1", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8396491_1_Ent2", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8404753_9", "wnd_id": "8404753_9_1", "text": "These cases demonstrate that CBZ can induce simple motor tics in children .", "tokens": ["These", "cases", "demonstrate", "that", "CBZ", "can", "induce", "simple", "motor", "tics", "in", "children", "."], "event_mentions": [{"id": "8404753_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "8404753_9_Ent3", "role": "Treatment", "text": "CBZ", "start": 4, "end": 5}, {"entity_id": "8404753_9_Ent4", "role": "Treatment_Drug", "text": "CBZ", "start": 4, "end": 5}, {"entity_id": "8404753_9_Ent2", "role": "Effect", "text": "simple motor tics", "start": 7, "end": 10}, {"entity_id": "8404753_9_Ent0", "role": "Subject", "text": "children", "start": 11, "end": 12}, {"entity_id": "8404753_9_Ent1", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8404753_9_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8404753_9_Ent4", "text": "CBZ", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8404753_9_Ent2", "text": "simple motor tics", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8404753_9_Ent0", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8404753_9_Ent1", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8438851_4", "wnd_id": "8438851_4_1", "text": "These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .", "tokens": ["These", "multiple", "overlapping", "factors", "probably", "lead", "to", "rhabdomyolysis", "in", "a", "minority", "of", "patients", "receiving", "vasopressin", "infusion", "."], "event_mentions": [{"id": "8438851_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 5, "end": 6}, "arguments": [{"entity_id": "8438851_4_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 7, "end": 8}, {"entity_id": "8438851_4_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "8438851_4_Ent2", "role": "Treatment", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8438851_4_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8438851_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8438851_4_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "847572_3", "wnd_id": "847572_3_1", "text": "Two fatal cases of poisoning by paracetamol are described .", "tokens": ["Two", "fatal", "cases", "of", "poisoning", "by", "paracetamol", "are", "described", "."], "event_mentions": [{"id": "847572_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "847572_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "847572_3_Ent0", "role": "Subject", "text": "Two fatal cases", "start": 0, "end": 3}, {"entity_id": "847572_3_Ent2", "role": "Effect", "text": "poisoning", "start": 4, "end": 5}, {"entity_id": "847572_3_Ent3", "role": "Treatment", "text": "paracetamol", "start": 6, "end": 7}, {"entity_id": "847572_3_Ent4", "role": "Treatment_Drug", "text": "paracetamol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "847572_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "847572_3_Ent0", "text": "Two fatal cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "847572_3_Ent2", "text": "poisoning", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "847572_3_Ent3", "text": "paracetamol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "847572_3_Ent4", "text": "paracetamol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8485005_1", "wnd_id": "8485005_1_1", "text": "Complete regression of iatrogenic Kaposi 's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis .", "tokens": ["Complete", "regression", "of", "iatrogenic", "Kaposi", "'s", "sarcoma", "due", "to", "corticosteroid", "treatment", "in", "a", "patient", "with", "tubercular", "pericarditis", "."], "event_mentions": [{"id": "8485005_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "regression", "start": 1, "end": 2}, "arguments": [{"entity_id": "8485005_1_Ent3", "role": "Treatment_Disorder", "text": "Kaposi 's sarcoma", "start": 4, "end": 7}, {"entity_id": "8485005_1_Ent2", "role": "Treatment", "text": "corticosteroid", "start": 9, "end": 10}, {"entity_id": "8485005_1_Ent4", "role": "Treatment_Drug", "text": "corticosteroid", "start": 9, "end": 10}, {"entity_id": "8485005_1_Ent0", "role": "Subject", "text": "a patient with tubercular pericarditis", "start": 12, "end": 17}, {"entity_id": "8485005_1_Ent1", "role": "Subject_Disorder", "text": "tubercular pericarditis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8485005_1_Ent3", "text": "Kaposi 's sarcoma", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8485005_1_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8485005_1_Ent4", "text": "corticosteroid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8485005_1_Ent0", "text": "a patient with tubercular pericarditis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8485005_1_Ent1", "text": "tubercular pericarditis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8485005_3", "wnd_id": "8485005_3_1", "text": "We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "Kaposi", "'s", "sarcoma", "(", "KS", ")", "on", "the", "sole", "of", "the", "right", "foot", "in", "a", "71", "-", "year", "-", "old", "man", ",", "treated", "for", "6", "months", "with", "corticosteroid", "therapy", "(", "prednisolone", "25", "mg", "/", "day", ")", "for", "pericardial", "effusion", "."], "event_mentions": [{"id": "8485005_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8485005_3_Ent0", "role": "Subject", "text": "a case of", "start": 2, "end": 5}, {"entity_id": "8485005_3_Ent5", "role": "Effect", "text": "Kaposi 's sarcoma ( KS )", "start": 8, "end": 14}, {"entity_id": "8485005_3_Ent1", "role": "Subject", "text": "a 71 - year - old man", "start": 22, "end": 29}, {"entity_id": "8485005_3_Ent3", "role": "Subject_Age", "text": "71 - year - old", "start": 23, "end": 28}, {"entity_id": "8485005_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 28, "end": 29}, {"entity_id": "8485005_3_Ent7", "role": "Treatment_Duration", "text": "6 months", "start": 32, "end": 34}, {"entity_id": "8485005_3_Ent6", "role": "Treatment", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "start": 32, "end": 44}, {"entity_id": "8485005_3_Ent9", "role": "Treatment_Drug", "text": "prednisolone", "start": 38, "end": 39}, {"entity_id": "8485005_3_Ent8", "role": "Treatment_Dosage", "text": "25 mg / day", "start": 39, "end": 43}, {"entity_id": "8485005_3_Ent2", "role": "Subject", "text": "for pericardial effusion", "start": 44, "end": 47}, {"entity_id": "8485005_3_Ent10", "role": "Treatment_Disorder", "text": "pericardial effusion", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "8485005_3_Ent0", "text": "a case of", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8485005_3_Ent5", "text": "Kaposi 's sarcoma ( KS )", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8485005_3_Ent1", "text": "a 71 - year - old man", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8485005_3_Ent3", "text": "71 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8485005_3_Ent4", "text": "man", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8485005_3_Ent7", "text": "6 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8485005_3_Ent6", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "entity_type": "Entity", "start": 32, "end": 44}, {"id": "8485005_3_Ent9", "text": "prednisolone", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "8485005_3_Ent8", "text": "25 mg / day", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "8485005_3_Ent2", "text": "for pericardial effusion", "entity_type": "Entity", "start": 44, "end": 47}, {"id": "8485005_3_Ent10", "text": "pericardial effusion", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "8503421_1", "wnd_id": "8503421_1_1", "text": "Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .", "tokens": ["Although", "there", "is", "one", "case", "report", "of", "cholesterol", "crystal", "embolization", "following", "t", "-", "PA", "therapy", "with", "only", "extrarenal", "manifestations", "(", "N", "Engl", "J", "Med", "321:1270", ",", "1989", ")", ",", "this", "is", "the", "first", "reported", "case", "of", "atheroembolic", "acute", "renal", "failure", "following", "t", "-", "PA", "therapy", "."], "event_mentions": [{"id": "8503421_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "8503421_1_Ent3", "role": "Effect", "text": "cholesterol crystal embolization", "start": 7, "end": 10}, {"entity_id": "8503421_1_Ent5", "role": "Treatment", "text": "t - PA", "start": 11, "end": 14}, {"entity_id": "8503421_1_Ent6", "role": "Treatment_Drug", "text": "t - PA", "start": 11, "end": 14}, {"entity_id": "8503421_1_Ent4", "role": "Effect", "text": "with only extrarenal manifestations", "start": 15, "end": 19}]}, {"id": "8503421_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 40, "end": 41}, "arguments": [{"entity_id": "8503421_1_Ent0", "role": "Effect", "text": "atheroembolic acute renal failure", "start": 36, "end": 40}, {"entity_id": "8503421_1_Ent2", "role": "Treatment_Drug", "text": "t - PA", "start": 41, "end": 44}, {"entity_id": "8503421_1_Ent1", "role": "Treatment", "text": "t - PA therapy", "start": 41, "end": 45}]}], "entity_mentions": [{"id": "8503421_1_Ent3", "text": "cholesterol crystal embolization", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8503421_1_Ent5", "text": "t - PA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8503421_1_Ent6", "text": "t - PA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8503421_1_Ent4", "text": "with only extrarenal manifestations", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "8503421_1_Ent0", "text": "atheroembolic acute renal failure", "entity_type": "Entity", "start": 36, "end": 40}, {"id": "8503421_1_Ent2", "text": "t - PA", "entity_type": "Entity", "start": 41, "end": 44}, {"id": "8503421_1_Ent1", "text": "t - PA therapy", "entity_type": "Entity", "start": 41, "end": 45}], "lang": "en"}
{"doc_id": "8503421_3", "wnd_id": "8503421_3_1", "text": "We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .", "tokens": ["We", "report", "the", "occurrence", "of", "renal", "failure", "due", "to", "cholesterol", "crystal", "embolization", "following", "thrombolytic", "therapy", "with", "intravenous", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "(", "t", "-", "PA", ")", "."], "event_mentions": [{"id": "8503421_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 3, "end": 4}, "arguments": [{"entity_id": "8503421_3_Ent0", "role": "Effect", "text": "renal failure due to cholesterol crystal embolization", "start": 5, "end": 12}, {"entity_id": "8503421_3_Ent1", "role": "Treatment", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "start": 13, "end": 28}, {"entity_id": "8503421_3_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 16, "end": 17}, {"entity_id": "8503421_3_Ent3", "role": "Treatment_Drug", "text": "recombinant tissue - type plasminogen activator", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "8503421_3_Ent0", "text": "renal failure due to cholesterol crystal embolization", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8503421_3_Ent1", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "entity_type": "Entity", "start": 13, "end": 28}, {"id": "8503421_3_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8503421_3_Ent3", "text": "recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "8530331_7", "wnd_id": "8530331_7_1", "text": "Only one patient , the youngest , did well on risperidone therapy .", "tokens": ["Only", "one", "patient", ",", "the", "youngest", ",", "did", "well", "on", "risperidone", "therapy", "."], "event_mentions": [{"id": "8530331_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "did well", "start": 7, "end": 9}, "arguments": [{"entity_id": "8530331_7_Ent0", "role": "Subject", "text": "the youngest", "start": 4, "end": 6}, {"entity_id": "8530331_7_Ent1", "role": "Treatment", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "8530331_7_Ent2", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8530331_7_Ent0", "text": "the youngest", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8530331_7_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8530331_7_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8551001_1", "wnd_id": "8551001_1_1", "text": "Azathioprine can cause severe myelosuppression .", "tokens": ["Azathioprine", "can", "cause", "severe", "myelosuppression", "."], "event_mentions": [{"id": "8551001_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "8551001_1_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_1_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_1_Ent0", "role": "Effect", "text": "severe myelosuppression", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8551001_1_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_1_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_1_Ent0", "text": "severe myelosuppression", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8589490_1", "wnd_id": "8589490_1_1", "text": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma .", "tokens": ["Supravenous", "hyperpigmentation", "in", "association", "with", "CHOP", "chemotherapy", "of", "a", "CD30", "(", "Ki", "-", "1)", "-", "positive", "anaplastic", "large", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "8589490_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 3, "end": 4}, "arguments": [{"entity_id": "8589490_1_Ent0", "role": "Effect", "text": "Supravenous hyperpigmentation", "start": 0, "end": 2}, {"entity_id": "8589490_1_Ent3", "role": "Treatment_Drug", "text": "CHOP", "start": 5, "end": 6}, {"entity_id": "8589490_1_Ent1", "role": "Treatment", "text": "CHOP chemotherapy", "start": 5, "end": 7}, {"entity_id": "8589490_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "8589490_1_Ent2", "role": "Treatment_Disorder", "text": "a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma", "start": 8, "end": 21}]}], "entity_mentions": [{"id": "8589490_1_Ent0", "text": "Supravenous hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8589490_1_Ent3", "text": "CHOP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8589490_1_Ent1", "text": "CHOP chemotherapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8589490_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8589490_1_Ent2", "text": "a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma", "entity_type": "Entity", "start": 8, "end": 21}], "lang": "en"}
{"doc_id": "8597009_1", "wnd_id": "8597009_1_1", "text": "Phenytoin toxicity due to concomitant antituberculosis therapy .", "tokens": ["Phenytoin", "toxicity", "due", "to", "concomitant", "antituberculosis", "therapy", "."], "event_mentions": [{"id": "8597009_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8597009_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "8597009_1_Ent5", "role": "Combination_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "8597009_1_Ent0", "role": "Effect", "text": "Phenytoin toxicity", "start": 0, "end": 2}, {"entity_id": "8597009_1_Ent1", "role": "Treatment", "text": "concomitant antituberculosis therapy .", "start": 4, "end": 8}, {"entity_id": "8597009_1_Ent3", "role": "Treatment_Drug", "text": "antituberculosis", "start": 5, "end": 6}, {"entity_id": "8597009_1_Ent4", "role": "Combination_Drug", "text": "antituberculosis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8597009_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8597009_1_Ent5", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8597009_1_Ent0", "text": "Phenytoin toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_1_Ent1", "text": "concomitant antituberculosis therapy .", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8597009_1_Ent3", "text": "antituberculosis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8597009_1_Ent4", "text": "antituberculosis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8597009_2", "wnd_id": "8597009_2_1", "text": "Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .", "tokens": ["Seventy", "-", "four", "per", "cent", "of", "patients", "with", "epileptogenic", "disorders", "seen", "at", "the", "Emergency", "Unit", "at", "Groote", "Schuur", "Hospital", "were", "on", "phenytoin", "and", "11.6", "%", "of", "these", "had", "blood", "levels", "in", "the", "toxic", "range", "."], "event_mentions": [{"id": "8597009_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 27, "end": 28}, "arguments": [{"entity_id": "8597009_2_Ent2", "role": "Subject_Population", "text": "Seventy - four per cent", "start": 0, "end": 5}, {"entity_id": "8597009_2_Ent0", "role": "Subject", "text": "Seventy - four per cent of patients with epileptogenic disorders", "start": 0, "end": 10}, {"entity_id": "8597009_2_Ent7", "role": "Treatment_Disorder", "text": "epileptogenic", "start": 8, "end": 9}, {"entity_id": "8597009_2_Ent5", "role": "Treatment", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent6", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent3", "role": "Subject_Population", "text": "11.6 %", "start": 23, "end": 25}, {"entity_id": "8597009_2_Ent1", "role": "Subject", "text": "11.6 % of these", "start": 23, "end": 27}, {"entity_id": "8597009_2_Ent4", "role": "Effect", "text": "blood levels in the toxic range", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "8597009_2_Ent2", "text": "Seventy - four per cent", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8597009_2_Ent0", "text": "Seventy - four per cent of patients with epileptogenic disorders", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "8597009_2_Ent7", "text": "epileptogenic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent6", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent3", "text": "11.6 %", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "8597009_2_Ent1", "text": "11.6 % of these", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "8597009_2_Ent4", "text": "blood levels in the toxic range", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "8597009_4", "wnd_id": "8597009_4_1", "text": "The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .", "tokens": ["The", "wide", "use", "of", "phenytoin", "during", "the", "recent", "tuberculosis", "epidemic", "makes", "it", "imperative", "to", "suspect", "this", "drug", "interaction", "in", "patients", "exhibiting", "clinical", "features", "that", "might", "be", "related", "to", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "8597009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspect", "start": 14, "end": 15}, "arguments": [{"entity_id": "8597009_4_Ent2", "role": "Treatment", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent3", "role": "Treatment_Duration", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "8597009_4_Ent0", "role": "Subject", "text": "patients", "start": 19, "end": 20}, {"entity_id": "8597009_4_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8597009_4_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8597009_4_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8604715_2", "wnd_id": "8604715_2_1", "text": "No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .", "tokens": ["No", "cases", "of", "renal", "acidosis", ",", "and", "only", "one", "case", "of", "nephrogenic", "diabetes", "insipidus", ",", "has", "been", "previously", "reported", "as", "a", "complication", "of", "foscarnet", "treatment", "."], "event_mentions": [{"id": "8604715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 18, "end": 19}, "arguments": [{"entity_id": "8604715_2_Ent0", "role": "Effect", "text": "nephrogenic diabetes insipidus", "start": 11, "end": 14}, {"entity_id": "8604715_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 23, "end": 24}, {"entity_id": "8604715_2_Ent1", "role": "Treatment", "text": "foscarnet treatment", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8604715_2_Ent0", "text": "nephrogenic diabetes insipidus", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8604715_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8604715_2_Ent1", "text": "foscarnet treatment", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8604715_3", "wnd_id": "8604715_3_1", "text": "Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .", "tokens": ["Our", "patient", "developed", "both", "nephrogenic", "diabetes", "insipidus", "and", "renal", "tubular", "acidosis", "with", "a", "temporal", "pattern", "that", "demonstrated", "a", "link", "between", "foscarnet", "therapy", "and", "these", "abnormalities", "."], "event_mentions": [{"id": "8604715_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "8604715_3_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "8604715_3_Ent1", "role": "Effect", "text": "nephrogenic diabetes insipidus and renal tubular acidosis", "start": 4, "end": 11}, {"entity_id": "8604715_3_Ent2", "role": "Treatment", "text": "foscarnet", "start": 20, "end": 21}, {"entity_id": "8604715_3_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8604715_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8604715_3_Ent1", "text": "nephrogenic diabetes insipidus and renal tubular acidosis", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "8604715_3_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8604715_3_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8610807_3", "wnd_id": "8610807_3_1", "text": "PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of tissue plasminogen activator .", "tokens": ["PURPOSE", ":", "To", "determine", "the", "cause", "of", "spontaneous", "choroidal", "hemorrhage", "in", "a", "67", "-", "year", "-", "old", "man", "after", "a", "myocardial", "infarction", "and", "administration", "of", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "8610807_3_Ent3", "role": "Effect", "text": "spontaneous choroidal hemorrhage", "start": 7, "end": 10}, {"entity_id": "8610807_3_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 12, "end": 17}, {"entity_id": "8610807_3_Ent0", "role": "Subject", "text": "67 - year - old man after a myocardial infarction", "start": 12, "end": 22}, {"entity_id": "8610807_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 17, "end": 18}, {"entity_id": "8610807_3_Ent5", "role": "Treatment_Disorder", "text": "myocardial infarction", "start": 20, "end": 22}, {"entity_id": "8610807_3_Ent4", "role": "Treatment", "text": "tissue plasminogen activator", "start": 25, "end": 28}, {"entity_id": "8610807_3_Ent6", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "8610807_3_Ent3", "text": "spontaneous choroidal hemorrhage", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8610807_3_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8610807_3_Ent0", "text": "67 - year - old man after a myocardial infarction", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "8610807_3_Ent2", "text": "man", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8610807_3_Ent5", "text": "myocardial infarction", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8610807_3_Ent4", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "8610807_3_Ent6", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "8641617_2", "wnd_id": "8641617_2_1", "text": "Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .", "tokens": ["Based", "on", "our", "findings", ",", "it", "is", "thus", "concluded", "that", "cisplatin", "may", "cause", "C.", "difficile", "colitis", "."], "event_mentions": [{"id": "8641617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "8641617_2_Ent1", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent0", "role": "Effect", "text": "C. difficile colitis", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "8641617_2_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent0", "text": "C. difficile colitis", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "8641617_3", "wnd_id": "8641617_3_1", "text": "Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .", "tokens": ["Both", "patients", "were", "then", "treated", "with", "a", "carboplatin", "alternative", "to", "cisplatin", "in", "the", "following", "courses", ",", "which", "resulted", "in", "neither", "a", "relapse", "of", "the", "colitis", "nor", "a", "recurrence", "of", "the", "malignancies", "up", "to", "this", "time", "."], "event_mentions": [{"id": "8641617_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 17, "end": 18}, "arguments": [{"entity_id": "8641617_3_Ent0", "role": "Subject", "text": "Both patients", "start": 0, "end": 2}, {"entity_id": "8641617_3_Ent2", "role": "Treatment", "text": "carboplatin", "start": 7, "end": 8}, {"entity_id": "8641617_3_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 7, "end": 8}, {"entity_id": "8641617_3_Ent1", "role": "Effect", "text": "neither a relapse of the colitis nor a recurrence of the malignancies", "start": 19, "end": 31}, {"entity_id": "8641617_3_Ent4", "role": "Treatment_Disorder", "text": "colitis", "start": 24, "end": 25}, {"entity_id": "8641617_3_Ent5", "role": "Treatment_Disorder", "text": "malignancies", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "8641617_3_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8641617_3_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8641617_3_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8641617_3_Ent1", "text": "neither a relapse of the colitis nor a recurrence of the malignancies", "entity_type": "Entity", "start": 19, "end": 31}, {"id": "8641617_3_Ent4", "text": "colitis", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8641617_3_Ent5", "text": "malignancies", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "8641617_4", "wnd_id": "8641617_4_1", "text": "Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .", "tokens": ["Clostridium", "difficile", "colitis", "associated", "with", "cisplatin", "-", "based", "chemotherapy", "in", "ovarian", "cancer", "patients", "."], "event_mentions": [{"id": "8641617_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "8641617_4_Ent1", "role": "Effect", "text": "Clostridium difficile colitis", "start": 0, "end": 3}, {"entity_id": "8641617_4_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 5, "end": 6}, {"entity_id": "8641617_4_Ent2", "role": "Treatment", "text": "cisplatin - based chemotherapy", "start": 5, "end": 9}, {"entity_id": "8641617_4_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 8, "end": 9}, {"entity_id": "8641617_4_Ent4", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 10, "end": 12}, {"entity_id": "8641617_4_Ent0", "role": "Subject", "text": "ovarian cancer patients .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8641617_4_Ent1", "text": "Clostridium difficile colitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8641617_4_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8641617_4_Ent2", "text": "cisplatin - based chemotherapy", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8641617_4_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8641617_4_Ent4", "text": "ovarian cancer", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8641617_4_Ent0", "text": "ovarian cancer patients .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8651254_3", "wnd_id": "8651254_3_1", "text": "The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .", "tokens": ["The", "possibility", "can", "be", "raised", "that", "M", "-", "CSF", "accelerated", "the", "underlying", "renal", "disease", "in", "this", "case", "through", "enhancing", "macrophage", "accumulation", "into", "the", "glomerulus", ",", "leading", "to", "the", "development", "of", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "8651254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 9, "end": 10}, "arguments": [{"entity_id": "8651254_3_Ent1", "role": "Treatment", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent2", "role": "Treatment_Drug", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent0", "role": "Effect", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "start": 11, "end": 32}]}], "entity_mentions": [{"id": "8651254_3_Ent1", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent2", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent0", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 32}], "lang": "en"}
{"doc_id": "8678015_2", "wnd_id": "8678015_2_1", "text": "Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .", "tokens": ["Although", "a", "few", "case", "reports", "link", "metronidazole", "with", "the", "development", "of", "pseudomembranous", "colitis", ",", "albendazole", "has", "not", "been", "associated", "with", "the", "development", "of", "this", "condition", "."], "event_mentions": [{"id": "8678015_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "8678015_2_Ent1", "role": "Treatment", "text": "metronidazole", "start": 6, "end": 7}, {"entity_id": "8678015_2_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 6, "end": 7}, {"entity_id": "8678015_2_Ent0", "role": "Effect", "text": "pseudomembranous colitis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "8678015_2_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_2_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_2_Ent0", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "868978_2", "wnd_id": "868978_2_1", "text": "The ocular motor disturbances are probably an expression of regional 5 - FU neurotoxicity primarily affecting the brain stem .", "tokens": ["The", "ocular", "motor", "disturbances", "are", "probably", "an", "expression", "of", "regional", "5", "-", "FU", "neurotoxicity", "primarily", "affecting", "the", "brain", "stem", "."], "event_mentions": [{"id": "868978_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "expression", "start": 7, "end": 8}, "arguments": [{"entity_id": "868978_2_Ent0", "role": "Effect", "text": "The ocular motor disturbances", "start": 0, "end": 4}, {"entity_id": "868978_2_Ent2", "role": "Treatment", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "868978_2_Ent0", "text": "The ocular motor disturbances", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "868978_2_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "868978_3", "wnd_id": "868978_3_1", "text": "Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU neurotoxicity .", "tokens": ["Two", "patients", "treated", "with", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "for", "disseminated", "adenocarcinoma", "of", "the", "colon", "developed", "cerebellar", "dysfunction", "typical", "of", "5", "-", "FU", "neurotoxicity", "."], "event_mentions": [{"id": "868978_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "868978_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "868978_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "868978_3_Ent5", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 4, "end": 7}, {"entity_id": "868978_3_Ent3", "role": "Treatment", "text": "5 - fluorouracil ( 5 - FU )", "start": 4, "end": 12}, {"entity_id": "868978_3_Ent4", "role": "Treatment_Disorder", "text": "disseminated adenocarcinoma of the colon", "start": 13, "end": 18}, {"entity_id": "868978_3_Ent2", "role": "Effect", "text": "cerebellar dysfunction", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "868978_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "868978_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "868978_3_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "868978_3_Ent3", "text": "5 - fluorouracil ( 5 - FU )", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "868978_3_Ent4", "text": "disseminated adenocarcinoma of the colon", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "868978_3_Ent2", "text": "cerebellar dysfunction", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "8700794_4", "wnd_id": "8700794_4_1", "text": "Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .", "tokens": ["Within", "24", "hours", "of", "fluid", "restriction", "and", "cessation", "of", "desmopressin", ",", "her", "symptoms", "and", "hyponatremia", "resolved", "."], "event_mentions": [{"id": "8700794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 15, "end": 16}, "arguments": [{"entity_id": "8700794_4_Ent4", "role": "Treatment_Duration", "text": "24 hours", "start": 1, "end": 3}, {"entity_id": "8700794_4_Ent3", "role": "Treatment", "text": "24 hours of fluid restriction and cessation of desmopressin", "start": 1, "end": 10}, {"entity_id": "8700794_4_Ent5", "role": "Treatment_Drug", "text": "desmopressin", "start": 9, "end": 10}, {"entity_id": "8700794_4_Ent0", "role": "Subject", "text": "her", "start": 11, "end": 12}, {"entity_id": "8700794_4_Ent1", "role": "Subject_Gender", "text": "her", "start": 11, "end": 12}, {"entity_id": "8700794_4_Ent2", "role": "Effect", "text": "symptoms and hyponatremia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8700794_4_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8700794_4_Ent3", "text": "24 hours of fluid restriction and cessation of desmopressin", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "8700794_4_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_4_Ent0", "text": "her", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8700794_4_Ent1", "text": "her", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8700794_4_Ent2", "text": "symptoms and hyponatremia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8710040_1", "wnd_id": "8710040_1_1", "text": "Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .", "tokens": ["Uveitis", "during", "treatment", "of", "disseminated", "Mycobacterium", "avium", "-", "intracellulare", "complex", "infection", "with", "the", "combination", "of", "rifabutin", ",", "clarithromycin", "and", "ethambutol", "."], "event_mentions": [{"id": "8710040_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "8710040_1_Ent0", "role": "Effect", "text": "Uveitis", "start": 0, "end": 1}, {"entity_id": "8710040_1_Ent2", "role": "Treatment_Disorder", "text": "disseminated Mycobacterium avium - intracellulare complex infection", "start": 4, "end": 11}, {"entity_id": "8710040_1_Ent1", "role": "Treatment", "text": "combination of rifabutin , clarithromycin and ethambutol", "start": 13, "end": 20}, {"entity_id": "8710040_1_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 15, "end": 16}, {"entity_id": "8710040_1_Ent6", "role": "Combination_Drug", "text": "rifabutin", "start": 15, "end": 16}, {"entity_id": "8710040_1_Ent4", "role": "Treatment_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "8710040_1_Ent7", "role": "Combination_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "8710040_1_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 19, "end": 20}, {"entity_id": "8710040_1_Ent8", "role": "Combination_Drug", "text": "ethambutol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8710040_1_Ent0", "text": "Uveitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8710040_1_Ent2", "text": "disseminated Mycobacterium avium - intracellulare complex infection", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "8710040_1_Ent1", "text": "combination of rifabutin , clarithromycin and ethambutol", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "8710040_1_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8710040_1_Ent6", "text": "rifabutin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8710040_1_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8710040_1_Ent7", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8710040_1_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8710040_1_Ent8", "text": "ethambutol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8726608_3", "wnd_id": "8726608_3_1", "text": "This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .", "tokens": ["This", "case", "suggests", "that", "acyclovir", "when", "given", "intravenously", "in", "doses", "of", "10", "mg", "/", "kg", "may", "result", "in", "increased", "serum", "lithium", "concentrations", "."], "event_mentions": [{"id": "8726608_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 16, "end": 17}, "arguments": [{"entity_id": "8726608_3_Ent1", "role": "Treatment", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent3", "role": "Treatment_Dosage", "text": "10 mg / kg", "start": 11, "end": 15}, {"entity_id": "8726608_3_Ent0", "role": "Effect", "text": "increased serum lithium concentrations", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "8726608_3_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent3", "text": "10 mg / kg", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "8726608_3_Ent0", "text": "increased serum lithium concentrations", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "8726608_4", "wnd_id": "8726608_4_1", "text": "Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .", "tokens": ["Until", "additional", "data", "are", "available", ",", "if", "intravenous", "acyclovir", "is", "administered", "concurrently", "with", "lithium", ",", "we", "recommend", "closely", "monitoring", "patients", "for", "signs", "of", "lithium", "toxicity", "and", "measuring", "serum", "lithium", "levels", "every", "second", "or", "third", "day", "."], "event_mentions": [{"id": "8726608_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 21, "end": 22}, "arguments": [{"entity_id": "8726608_4_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8726608_4_Ent1", "role": "Treatment", "text": "intravenous acyclovir is administered concurrently with lithium", "start": 7, "end": 14}, {"entity_id": "8726608_4_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent6", "role": "Combination_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent0", "role": "Effect", "text": "lithium toxicity", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8726608_4_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8726608_4_Ent1", "text": "intravenous acyclovir is administered concurrently with lithium", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "8726608_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent6", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent0", "text": "lithium toxicity", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8726608_5", "wnd_id": "8726608_5_1", "text": "When measured , the serum lithium level had increased 4 - fold during acyclovir therapy .", "tokens": ["When", "measured", ",", "the", "serum", "lithium", "level", "had", "increased", "4", "-", "fold", "during", "acyclovir", "therapy", "."], "event_mentions": [{"id": "8726608_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "8726608_5_Ent0", "role": "Effect", "text": "serum lithium level had increased 4 - fold", "start": 4, "end": 12}, {"entity_id": "8726608_5_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent1", "role": "Treatment", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent5", "role": "Combination_Drug", "text": "acyclovir", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8726608_5_Ent0", "text": "serum lithium level had increased 4 - fold", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8726608_5_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8730143_3", "wnd_id": "8730143_3_1", "text": "We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .", "tokens": ["We", "describe", "2", "patients", "with", "cutaneous", "lupus", "erythematosus", "who", "developed", "severe", "dapsone", "reaction", "after", "low", "dose", "therapy", ",", "with", "a", "fatal", "outcome", "in", "one", "."], "event_mentions": [{"id": "8730143_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "8730143_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "8730143_3_Ent0", "role": "Subject", "text": "2 patients with cutaneous lupus erythematosus", "start": 2, "end": 8}, {"entity_id": "8730143_3_Ent5", "role": "Treatment_Disorder", "text": "cutaneous lupus erythematosus", "start": 5, "end": 8}, {"entity_id": "8730143_3_Ent2", "role": "Effect", "text": "severe dapsone reaction", "start": 10, "end": 13}, {"entity_id": "8730143_3_Ent7", "role": "Treatment_Drug", "text": "dapsone", "start": 11, "end": 12}, {"entity_id": "8730143_3_Ent6", "role": "Treatment_Dosage", "text": "low dose", "start": 14, "end": 16}, {"entity_id": "8730143_3_Ent4", "role": "Treatment", "text": "low dose therapy", "start": 14, "end": 17}, {"entity_id": "8730143_3_Ent3", "role": "Effect", "text": "with a fatal outcome in one", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "8730143_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8730143_3_Ent0", "text": "2 patients with cutaneous lupus erythematosus", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8730143_3_Ent5", "text": "cutaneous lupus erythematosus", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8730143_3_Ent2", "text": "severe dapsone reaction", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8730143_3_Ent7", "text": "dapsone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8730143_3_Ent6", "text": "low dose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8730143_3_Ent4", "text": "low dose therapy", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8730143_3_Ent3", "text": "with a fatal outcome in one", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "8739289_3", "wnd_id": "8739289_3_1", "text": "The association of central diabetes insipidus ( CDI ) with lithium use is rare .", "tokens": ["The", "association", "of", "central", "diabetes", "insipidus", "(", "CDI", ")", "with", "lithium", "use", "is", "rare", "."], "event_mentions": [{"id": "8739289_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "8739289_3_Ent0", "role": "Effect", "text": "central diabetes insipidus ( CDI )", "start": 3, "end": 9}, {"entity_id": "8739289_3_Ent1", "role": "Treatment", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "8739289_3_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8739289_3_Ent0", "text": "central diabetes insipidus ( CDI )", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "8739289_3_Ent1", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8739289_3_Ent2", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8739289_7", "wnd_id": "8739289_7_1", "text": "This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .", "tokens": ["This", "case", "emphasizes", "the", "importance", "of", "the", "evaluation", "of", "lithium", "-", "associated", "polyuria", "with", "a", "direct", "measurement", "of", "plasma", "vasopressin", ",", "interpreted", "with", "simultaneous", "plasma", "and", "urine", "osmolality", "to", "secure", "the", "correct", "diagnosis", "and", "ensure", "appropriate", "therapeutic", "management", "."], "event_mentions": [{"id": "8739289_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "8739289_7_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "8739289_7_Ent2", "role": "Treatment", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "8739289_7_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "8739289_7_Ent1", "role": "Effect", "text": "polyuria", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8739289_7_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8739289_7_Ent2", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8739289_7_Ent3", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8739289_7_Ent1", "text": "polyuria", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8749646_1", "wnd_id": "8749646_1_1", "text": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .", "tokens": ["Improved", "awareness", "of", "and", "further", "investigation", "into", "the", "neurotoxic", "effects", "of", "ofloxacin", "may", "enhance", "its", "safe", "use", "."], "event_mentions": [{"id": "8749646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 10, "end": 11}, "arguments": [{"entity_id": "8749646_1_Ent0", "role": "Effect", "text": "neurotoxic effects", "start": 8, "end": 10}, {"entity_id": "8749646_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 11, "end": 12}, {"entity_id": "8749646_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8749646_1_Ent0", "text": "neurotoxic effects", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8749646_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8771575_4", "wnd_id": "8771575_4_1", "text": "Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .", "tokens": ["Nitrofurantoin", "-", "induced", "pulmonary", "toxicity", "during", "pregnancy", ":", "a", "report", "of", "a", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "8771575_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8771575_4_Ent1", "role": "Treatment", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "8771575_4_Ent2", "role": "Treatment_Drug", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "8771575_4_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8771575_4_Ent1", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8771575_4_Ent2", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8771575_4_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8771575_5", "wnd_id": "8771575_5_1", "text": "We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .", "tokens": ["We", "present", "a", "case", "of", "respiratory", "failure", "occurring", "in", "a", "woman", "at", "16", "weeks", "'", "gestation", "who", "was", "being", "treated", "with", "nitrofurantoin", "for", "a", "urinary", "tract", "infection", "."], "event_mentions": [{"id": "8771575_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "8771575_5_Ent3", "role": "Effect", "text": "respiratory failure", "start": 5, "end": 7}, {"entity_id": "8771575_5_Ent0", "role": "Subject", "text": "a woman at 16 weeks ' gestation", "start": 9, "end": 16}, {"entity_id": "8771575_5_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "8771575_5_Ent2", "role": "Subject_Disorder", "text": "16 weeks ' gestation", "start": 12, "end": 16}, {"entity_id": "8771575_5_Ent4", "role": "Treatment", "text": "being treated with nitrofurantoin for a urinary tract infection", "start": 18, "end": 27}, {"entity_id": "8771575_5_Ent5", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 21, "end": 22}, {"entity_id": "8771575_5_Ent6", "role": "Treatment_Disorder", "text": "urinary tract infection", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "8771575_5_Ent3", "text": "respiratory failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8771575_5_Ent0", "text": "a woman at 16 weeks ' gestation", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "8771575_5_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8771575_5_Ent2", "text": "16 weeks ' gestation", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "8771575_5_Ent4", "text": "being treated with nitrofurantoin for a urinary tract infection", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "8771575_5_Ent5", "text": "nitrofurantoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8771575_5_Ent6", "text": "urinary tract infection", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "879939_1", "wnd_id": "879939_1_1", "text": "Acetazolamide - accelerated anticonvulsant osteomalacia .", "tokens": ["Acetazolamide", "-", "accelerated", "anticonvulsant", "osteomalacia", "."], "event_mentions": [{"id": "879939_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 2, "end": 3}, "arguments": [{"entity_id": "879939_1_Ent1", "role": "Treatment", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_1_Ent2", "role": "Treatment_Drug", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_1_Ent3", "role": "Treatment_Drug", "text": "anticonvulsant", "start": 3, "end": 4}, {"entity_id": "879939_1_Ent0", "role": "Effect", "text": "anticonvulsant osteomalacia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "879939_1_Ent1", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_1_Ent2", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_1_Ent3", "text": "anticonvulsant", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "879939_1_Ent0", "text": "anticonvulsant osteomalacia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8828999_3", "wnd_id": "8828999_3_1", "text": "Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .", "tokens": ["Lithium", "neurotoxicity", "should", "be", "considered", "in", "Creutzfeldt", "-", "Jakob", "disease", "differential", "diagnosis", ",", "serial", "electroencephalograms", "being", "the", "most", "valuable", "."], "event_mentions": [{"id": "8828999_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 4, "end": 5}, "arguments": [{"entity_id": "8828999_3_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent3", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent0", "role": "Effect", "text": "Lithium neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8828999_3_Ent2", "role": "Treatment_Disorder", "text": "Creutzfeldt - Jakob disease", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "8828999_3_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent3", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent0", "text": "Lithium neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8828999_3_Ent2", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "8832451_1", "wnd_id": "8832451_1_1", "text": "A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .", "tokens": ["A", "noninvasive", "method", "in", "the", "differential", "diagnosis", "of", "vecuronium", "-", "induced", "and", "magnesium", "-", "induced", "protracted", "neuromuscular", "block", "in", "a", "severely", "preeclamptic", "patient", "."], "event_mentions": [{"id": "8832451_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8832451_1_Ent3", "role": "Treatment", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent4", "role": "Treatment_Drug", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent2", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent1", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent0", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}, {"id": "8832451_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "8832451_1_Ent8", "role": "Treatment", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent9", "role": "Treatment_Drug", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent7", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent6", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent5", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8832451_1_Ent3", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent4", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent8", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent9", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent2", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent7", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent1", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent6", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent0", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8832451_1_Ent5", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8850251_5", "wnd_id": "8850251_5_1", "text": "Two cases of mequitazine - induced photosensitivity reactions .", "tokens": ["Two", "cases", "of", "mequitazine", "-", "induced", "photosensitivity", "reactions", "."], "event_mentions": [{"id": "8850251_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8850251_5_Ent1", "role": "Treatment", "text": "mequitazine", "start": 3, "end": 4}, {"entity_id": "8850251_5_Ent2", "role": "Treatment_Drug", "text": "mequitazine", "start": 3, "end": 4}, {"entity_id": "8850251_5_Ent0", "role": "Effect", "text": "photosensitivity reactions", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "8850251_5_Ent1", "text": "mequitazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8850251_5_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8850251_5_Ent0", "text": "photosensitivity reactions", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "8862924_1", "wnd_id": "8862924_1_1", "text": "Keratitis in methamphetamine abusers .", "tokens": ["Keratitis", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8862924_1_Ent0", "role": "Effect", "text": "Keratitis", "start": 0, "end": 1}, {"entity_id": "8862924_1_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 2, "end": 3}, {"entity_id": "8862924_1_Ent1", "role": "Treatment", "text": "methamphetamine abusers", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "8862924_1_Ent0", "text": "Keratitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8862924_1_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_1_Ent1", "text": "methamphetamine abusers", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "8864370_4", "wnd_id": "8864370_4_1", "text": "Methotrexate - induced liver cirrhosis .", "tokens": ["Methotrexate", "-", "induced", "liver", "cirrhosis", "."], "event_mentions": [{"id": "8864370_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8864370_4_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8864370_4_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8864370_4_Ent0", "role": "Effect", "text": "liver cirrhosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8864370_4_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8864370_4_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8864370_4_Ent0", "text": "liver cirrhosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8903300_2", "wnd_id": "8903300_2_1", "text": "Tetany in a child with AIDS receiving intravenous tobramycin .", "tokens": ["Tetany", "in", "a", "child", "with", "AIDS", "receiving", "intravenous", "tobramycin", "."], "event_mentions": [{"id": "8903300_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8903300_2_Ent3", "role": "Effect", "text": "Tetany", "start": 0, "end": 1}, {"entity_id": "8903300_2_Ent0", "role": "Subject", "text": "a child with AIDS", "start": 2, "end": 6}, {"entity_id": "8903300_2_Ent1", "role": "Subject_Age", "text": "child", "start": 3, "end": 4}, {"entity_id": "8903300_2_Ent2", "role": "Subject_Disorder", "text": "AIDS", "start": 5, "end": 6}, {"entity_id": "8903300_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8903300_2_Ent4", "role": "Treatment", "text": "intravenous tobramycin", "start": 7, "end": 9}, {"entity_id": "8903300_2_Ent5", "role": "Treatment_Drug", "text": "tobramycin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8903300_2_Ent3", "text": "Tetany", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8903300_2_Ent0", "text": "a child with AIDS", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8903300_2_Ent1", "text": "child", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8903300_2_Ent2", "text": "AIDS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8903300_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8903300_2_Ent4", "text": "intravenous tobramycin", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8903300_2_Ent5", "text": "tobramycin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8912599_6", "wnd_id": "8912599_6_1", "text": "Erosion of psoriatic plaques : an early sign of methotrexate toxicity .", "tokens": ["Erosion", "of", "psoriatic", "plaques", ":", "an", "early", "sign", "of", "methotrexate", "toxicity", "."], "event_mentions": [{"id": "8912599_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "8912599_6_Ent0", "role": "Effect", "text": "Erosion of psoriatic plaques", "start": 0, "end": 4}, {"entity_id": "8912599_6_Ent1", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8912599_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8912599_6_Ent0", "text": "Erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8912599_6_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8912599_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8912599_7", "wnd_id": "8912599_7_1", "text": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression .", "tokens": ["Painful", "erosion", "of", "psoriatic", "plaques", "is", "a", "less", "common", "sign", "of", "methotrexate", "toxicity", "that", "may", "precede", "evidence", "of", "bone", "marrow", "suppression", "."], "event_mentions": [{"id": "8912599_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "sign", "start": 9, "end": 10}, "arguments": [{"entity_id": "8912599_7_Ent0", "role": "Effect", "text": "Painful erosion of psoriatic plaques", "start": 0, "end": 5}, {"entity_id": "8912599_7_Ent5", "role": "Treatment_Disorder", "text": "psoriatic plaques", "start": 3, "end": 5}, {"entity_id": "8912599_7_Ent3", "role": "Treatment", "text": "methotrexate", "start": 11, "end": 12}, {"entity_id": "8912599_7_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 11, "end": 12}, {"entity_id": "8912599_7_Ent1", "role": "Effect", "text": "methotrexate toxicity", "start": 11, "end": 13}, {"entity_id": "8912599_7_Ent2", "role": "Effect", "text": "bone marrow suppression", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8912599_7_Ent0", "text": "Painful erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8912599_7_Ent5", "text": "psoriatic plaques", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8912599_7_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8912599_7_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8912599_7_Ent1", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8912599_7_Ent2", "text": "bone marrow suppression", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8921647_2", "wnd_id": "8921647_2_1", "text": "Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding .", "tokens": ["Caution", "with", "use", "of", "cimetidine", "in", "tolazoline", "induced", "upper", "gastrointestinal", "bleeding", "."], "event_mentions": [{"id": "8921647_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8921647_2_Ent1", "role": "Treatment", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "8921647_2_Ent2", "role": "Treatment_Drug", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "8921647_2_Ent0", "role": "Effect", "text": "upper gastrointestinal bleeding", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8921647_2_Ent1", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8921647_2_Ent2", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8921647_2_Ent0", "text": "upper gastrointestinal bleeding", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8926752_1", "wnd_id": "8926752_1_1", "text": "Zolpidem ( Ambien ) , a relatively new nonbenzodiazepine sedative - hypnotic , was involved in the death of a 39 - year - old obese male who was being treated for depression and insomnia .", "tokens": ["Zolpidem", "(", "Ambien", ")", ",", "a", "relatively", "new", "nonbenzodiazepine", "sedative", "-", "hypnotic", ",", "was", "involved", "in", "the", "death", "of", "a", "39", "-", "year", "-", "old", "obese", "male", "who", "was", "being", "treated", "for", "depression", "and", "insomnia", "."], "event_mentions": [{"id": "8926752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involved", "start": 14, "end": 15}, "arguments": [{"entity_id": "8926752_1_Ent7", "role": "Treatment_Drug", "text": "Zolpidem", "start": 0, "end": 1}, {"entity_id": "8926752_1_Ent5", "role": "Treatment", "text": "Zolpidem ( Ambien )", "start": 0, "end": 4}, {"entity_id": "8926752_1_Ent4", "role": "Effect", "text": "death", "start": 17, "end": 18}, {"entity_id": "8926752_1_Ent0", "role": "Subject", "text": "a 39 - year - old obese male", "start": 19, "end": 27}, {"entity_id": "8926752_1_Ent1", "role": "Subject_Age", "text": "39 - year - old", "start": 20, "end": 25}, {"entity_id": "8926752_1_Ent2", "role": "Subject_Disorder", "text": "obese", "start": 25, "end": 26}, {"entity_id": "8926752_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 26, "end": 27}, {"entity_id": "8926752_1_Ent6", "role": "Treatment_Disorder", "text": "depression and insomnia", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "8926752_1_Ent7", "text": "Zolpidem", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8926752_1_Ent5", "text": "Zolpidem ( Ambien )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8926752_1_Ent4", "text": "death", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8926752_1_Ent0", "text": "a 39 - year - old obese male", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "8926752_1_Ent1", "text": "39 - year - old", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "8926752_1_Ent2", "text": "obese", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8926752_1_Ent3", "text": "male", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "8926752_1_Ent6", "text": "depression and insomnia", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "8933322_2", "wnd_id": "8933322_2_1", "text": "Infants are particularly susceptible to chronic nitrate - induced methemoglobinemia because of their low stomach acid production , large numbers of nitrite - reducing bacteria , and the relatively easy oxidation of fetal hemoglobin .", "tokens": ["Infants", "are", "particularly", "susceptible", "to", "chronic", "nitrate", "-", "induced", "methemoglobinemia", "because", "of", "their", "low", "stomach", "acid", "production", ",", "large", "numbers", "of", "nitrite", "-", "reducing", "bacteria", ",", "and", "the", "relatively", "easy", "oxidation", "of", "fetal", "hemoglobin", "."], "event_mentions": [{"id": "8933322_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "8933322_2_Ent0", "role": "Subject", "text": "Infants", "start": 0, "end": 1}, {"entity_id": "8933322_2_Ent1", "role": "Subject_Age", "text": "Infants", "start": 0, "end": 1}, {"entity_id": "8933322_2_Ent3", "role": "Treatment", "text": "nitrate", "start": 6, "end": 7}, {"entity_id": "8933322_2_Ent4", "role": "Treatment_Drug", "text": "nitrate", "start": 6, "end": 7}, {"entity_id": "8933322_2_Ent2", "role": "Effect", "text": "methemoglobinemia", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8933322_2_Ent0", "text": "Infants", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8933322_2_Ent1", "text": "Infants", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8933322_2_Ent3", "text": "nitrate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8933322_2_Ent4", "text": "nitrate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8933322_2_Ent2", "text": "methemoglobinemia", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8936932_2", "wnd_id": "8936932_2_1", "text": "After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride , her cardiac rhythm progressed to asystole .", "tokens": ["After", "induction", "of", "general", "anesthesia", "and", "administration", "of", "a", "standard", "dose", "of", "intravenous", "esmolol", "hydrochloride", ",", "her", "cardiac", "rhythm", "progressed", "to", "asystole", "."], "event_mentions": [{"id": "8936932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "8936932_2_Ent3", "role": "Treatment", "text": "induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride", "start": 1, "end": 15}, {"entity_id": "8936932_2_Ent6", "role": "Treatment_Drug", "text": "general anesthesia", "start": 3, "end": 5}, {"entity_id": "8936932_2_Ent7", "role": "Combination_Drug", "text": "general anesthesia", "start": 3, "end": 5}, {"entity_id": "8936932_2_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 12, "end": 13}, {"entity_id": "8936932_2_Ent5", "role": "Treatment_Drug", "text": "esmolol hydrochloride", "start": 13, "end": 15}, {"entity_id": "8936932_2_Ent8", "role": "Combination_Drug", "text": "esmolol hydrochloride", "start": 13, "end": 15}, {"entity_id": "8936932_2_Ent0", "role": "Subject", "text": "her", "start": 16, "end": 17}, {"entity_id": "8936932_2_Ent1", "role": "Subject_Gender", "text": "her", "start": 16, "end": 17}, {"entity_id": "8936932_2_Ent2", "role": "Effect", "text": "asystole", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "8936932_2_Ent3", "text": "induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "8936932_2_Ent6", "text": "general anesthesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8936932_2_Ent7", "text": "general anesthesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8936932_2_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8936932_2_Ent5", "text": "esmolol hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8936932_2_Ent8", "text": "esmolol hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8936932_2_Ent0", "text": "her", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8936932_2_Ent1", "text": "her", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8936932_2_Ent2", "text": "asystole", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "8949576_1", "wnd_id": "8949576_1_1", "text": "A potential role for renal and hepatic impairment in the observed protracted course of amiodarone - induced thyrotoxicosis is suggested .", "tokens": ["A", "potential", "role", "for", "renal", "and", "hepatic", "impairment", "in", "the", "observed", "protracted", "course", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "is", "suggested", "."], "event_mentions": [{"id": "8949576_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "8949576_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8949576_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8949576_3", "wnd_id": "8949576_3_1", "text": "We report a case of amiodarone - induced thyrotoxicosis of protracted duration , unresponsive to conventional thionamide therapy , with therapy limited by severe adverse drug reactions .", "tokens": ["We", "report", "a", "case", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "of", "protracted", "duration", ",", "unresponsive", "to", "conventional", "thionamide", "therapy", ",", "with", "therapy", "limited", "by", "severe", "adverse", "drug", "reactions", "."], "event_mentions": [{"id": "8949576_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8949576_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "8949576_3_Ent2", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "8949576_3_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "8949576_3_Ent1", "role": "Effect", "text": "thyrotoxicosis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8949576_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8949576_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8949576_3_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8949576_3_Ent1", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8961730_1", "wnd_id": "8961730_1_1", "text": "Psychotic disorder associated with isoniazid .", "tokens": ["Psychotic", "disorder", "associated", "with", "isoniazid", "."], "event_mentions": [{"id": "8961730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8961730_1_Ent0", "role": "Effect", "text": "Psychotic disorder", "start": 0, "end": 2}, {"entity_id": "8961730_1_Ent1", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "8961730_1_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8961730_1_Ent0", "text": "Psychotic disorder", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8961730_1_Ent1", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8961730_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "897744_1", "wnd_id": "897744_1_1", "text": "Focal glomerulonephritis and interstitial nephritis in methicillin - treated , heroin - related infective endocarditis .", "tokens": ["Focal", "glomerulonephritis", "and", "interstitial", "nephritis", "in", "methicillin", "-", "treated", ",", "heroin", "-", "related", "infective", "endocarditis", "."], "event_mentions": [{"id": "897744_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "897744_1_Ent3", "role": "Effect", "text": "Focal glomerulonephritis and interstitial nephritis", "start": 0, "end": 5}, {"entity_id": "897744_1_Ent4", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent6", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent5", "role": "Treatment_Disorder", "text": "heroin - related infective endocarditis", "start": 10, "end": 15}]}, {"id": "897744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "897744_1_Ent1", "role": "Treatment", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent0", "role": "Effect", "text": "infective endocarditis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "897744_1_Ent3", "text": "Focal glomerulonephritis and interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "897744_1_Ent4", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent6", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent1", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent2", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent5", "text": "heroin - related infective endocarditis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "897744_1_Ent0", "text": "infective endocarditis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "897744_3", "wnd_id": "897744_3_1", "text": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement , emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear .", "tokens": ["Discontinuation", "of", "methicillin", "therapy", "and", "appropriate", "antibiotic", "treatment", "of", "endocarditis", "led", "to", "clinical", "improvement", ",", "emphasizing", "the", "need", "to", "promptly", "discontinue", "potential", "nephrotoxic", "agents", "when", "abnormalities", "in", "renal", "function", "appear", "."], "event_mentions": [{"id": "897744_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 29, "end": 30}, "arguments": [{"entity_id": "897744_3_Ent1", "role": "Treatment", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent2", "role": "Treatment_Drug", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent3", "role": "Treatment_Drug", "text": "antibiotic", "start": 6, "end": 7}, {"entity_id": "897744_3_Ent5", "role": "Treatment_Disorder", "text": "endocarditis", "start": 9, "end": 10}, {"entity_id": "897744_3_Ent4", "role": "Treatment_Drug", "text": "nephrotoxic agents", "start": 22, "end": 24}, {"entity_id": "897744_3_Ent0", "role": "Effect", "text": "abnormalities in renal function", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "897744_3_Ent1", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent2", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent3", "text": "antibiotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_3_Ent5", "text": "endocarditis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "897744_3_Ent4", "text": "nephrotoxic agents", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "897744_3_Ent0", "text": "abnormalities in renal function", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "9022114_3", "wnd_id": "9022114_3_1", "text": "Delay of corneal wound healing in patients treated with colchicine .", "tokens": ["Delay", "of", "corneal", "wound", "healing", "in", "patients", "treated", "with", "colchicine", "."], "event_mentions": [{"id": "9022114_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9022114_3_Ent1", "role": "Effect", "text": "Delay of corneal wound healing", "start": 0, "end": 5}, {"entity_id": "9022114_3_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "9022114_3_Ent2", "role": "Treatment", "text": "colchicine", "start": 9, "end": 10}, {"entity_id": "9022114_3_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9022114_3_Ent1", "text": "Delay of corneal wound healing", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9022114_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9022114_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9022114_3_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9022114_4", "wnd_id": "9022114_4_1", "text": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy .", "tokens": ["The", "authors", "report", "on", "two", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "while", "the", "patients", "were", "undergoing", "oral", "colchicine", "therapy", "."], "event_mentions": [{"id": "9022114_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 17, "end": 18}, "arguments": [{"entity_id": "9022114_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9022114_4_Ent0", "role": "Subject", "text": "two patients", "start": 4, "end": 6}, {"entity_id": "9022114_4_Ent2", "role": "Effect", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_4_Ent5", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "9022114_4_Ent3", "role": "Treatment", "text": "oral colchicine therapy", "start": 18, "end": 21}, {"entity_id": "9022114_4_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9022114_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9022114_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9022114_4_Ent2", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_4_Ent5", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9022114_4_Ent3", "text": "oral colchicine therapy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9022114_4_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9039216_1", "wnd_id": "9039216_1_1", "text": "A 17 - year - old female patient who had been taking oral minocycline ( 50 mg twice daily ) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis .", "tokens": ["A", "17", "-", "year", "-", "old", "female", "patient", "who", "had", "been", "taking", "oral", "minocycline", "(", "50", "mg", "twice", "daily", ")", "for", "3", "weeks", "for", "acne", "developed", "an", "eruption", "that", "progressed", "to", "an", "exfoliative", "dermatitis", "."], "event_mentions": [{"id": "9039216_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "9039216_1_Ent0", "role": "Subject", "text": "A 17 - year - old female patient", "start": 0, "end": 8}, {"entity_id": "9039216_1_Ent1", "role": "Subject_Age", "text": "17 - year - old", "start": 1, "end": 6}, {"entity_id": "9039216_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "9039216_1_Ent11", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "9039216_1_Ent5", "role": "Treatment", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "start": 12, "end": 23}, {"entity_id": "9039216_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 13, "end": 14}, {"entity_id": "9039216_1_Ent8", "role": "Treatment_Dosage", "text": "50 mg", "start": 15, "end": 17}, {"entity_id": "9039216_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 17, "end": 19}, {"entity_id": "9039216_1_Ent10", "role": "Treatment_Duration", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "9039216_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 24, "end": 25}, {"entity_id": "9039216_1_Ent3", "role": "Effect", "text": "eruption", "start": 27, "end": 28}, {"entity_id": "9039216_1_Ent4", "role": "Effect", "text": "an exfoliative dermatitis", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "9039216_1_Ent0", "text": "A 17 - year - old female patient", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9039216_1_Ent1", "text": "17 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9039216_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9039216_1_Ent11", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9039216_1_Ent5", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "9039216_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9039216_1_Ent8", "text": "50 mg", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "9039216_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9039216_1_Ent10", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9039216_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9039216_1_Ent3", "text": "eruption", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9039216_1_Ent4", "text": "an exfoliative dermatitis", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "9042097_1", "wnd_id": "9042097_1_1", "text": "Delayed hypersensitivity to flurbiprofen .", "tokens": ["Delayed", "hypersensitivity", "to", "flurbiprofen", "."], "event_mentions": [{"id": "9042097_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "9042097_1_Ent0", "role": "Effect", "text": "Delayed hypersensitivity", "start": 0, "end": 2}, {"entity_id": "9042097_1_Ent1", "role": "Treatment", "text": "flurbiprofen", "start": 3, "end": 4}, {"entity_id": "9042097_1_Ent2", "role": "Treatment_Drug", "text": "flurbiprofen", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9042097_1_Ent0", "text": "Delayed hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9042097_1_Ent1", "text": "flurbiprofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9042097_1_Ent2", "text": "flurbiprofen", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9100429_1", "wnd_id": "9100429_1_1", "text": "Case study : adverse response to clonidine .", "tokens": ["Case", "study", ":", "adverse", "response", "to", "clonidine", "."], "event_mentions": [{"id": "9100429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "9100429_1_Ent0", "role": "Effect", "text": "adverse response", "start": 3, "end": 5}, {"entity_id": "9100429_1_Ent1", "role": "Treatment", "text": "clonidine", "start": 6, "end": 7}, {"entity_id": "9100429_1_Ent2", "role": "Treatment_Drug", "text": "clonidine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9100429_1_Ent0", "text": "adverse response", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9100429_1_Ent1", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9100429_1_Ent2", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "910864_1", "wnd_id": "910864_1_1", "text": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide .", "tokens": ["In", "one", "instance", "a", "systemic", "hypoglycemic", "reaction", "resulting", "in", "head", "trauma", "and", "confusion", "ended", "in", "an", "emegency", "hospital", "admission", "following", "the", "substitution", "of", "acetohexamide", "for", "acetazolamide", "."], "event_mentions": [{"id": "910864_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "910864_1_Ent0", "role": "Effect", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "start": 4, "end": 13}, {"entity_id": "910864_1_Ent1", "role": "Treatment", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent2", "role": "Treatment_Drug", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent3", "role": "Treatment_Drug", "text": "acetazolamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "910864_1_Ent0", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "910864_1_Ent1", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent2", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9128433_1", "wnd_id": "9128433_1_1", "text": "Its overall toxicity is considerably less compared to standard induction chemotherapy ; however , it is associated with a high incidence of a potentially fatal symptom complex referred to as \" retinoic acid syndrome . \" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis .", "tokens": ["Its", "overall", "toxicity", "is", "considerably", "less", "compared", "to", "standard", "induction", "chemotherapy", ";", "however", ",", "it", "is", "associated", "with", "a", "high", "incidence", "of", "a", "potentially", "fatal", "symptom", "complex", "referred", "to", "as", "\"", "retinoic", "acid", "syndrome", ".", "\"", "This", "report", "describes", "a", "patient", "with", "APL", "who", "developed", "the", "syndrome", "a", "few", "weeks", "after", "initiating", "induction", "therapy", "with", "ATRA", "despite", "being", "treated", "for", "hyperleukocytosis", "."], "event_mentions": [{"id": "9128433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 44, "end": 45}, "arguments": [{"entity_id": "9128433_1_Ent1", "role": "Effect", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "start": 25, "end": 36}, {"entity_id": "9128433_1_Ent0", "role": "Subject", "text": "a patient with APL", "start": 39, "end": 43}, {"entity_id": "9128433_1_Ent5", "role": "Treatment_Disorder", "text": "APL", "start": 42, "end": 43}, {"entity_id": "9128433_1_Ent4", "role": "Treatment_Time_elapsed", "text": "a few weeks", "start": 47, "end": 50}, {"entity_id": "9128433_1_Ent2", "role": "Treatment", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "start": 47, "end": 61}, {"entity_id": "9128433_1_Ent3", "role": "Treatment_Drug", "text": "ATRA", "start": 55, "end": 56}]}], "entity_mentions": [{"id": "9128433_1_Ent1", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "9128433_1_Ent0", "text": "a patient with APL", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "9128433_1_Ent5", "text": "APL", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "9128433_1_Ent4", "text": "a few weeks", "entity_type": "Entity", "start": 47, "end": 50}, {"id": "9128433_1_Ent2", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "entity_type": "Entity", "start": 47, "end": 61}, {"id": "9128433_1_Ent3", "text": "ATRA", "entity_type": "Entity", "start": 55, "end": 56}], "lang": "en"}
{"doc_id": "9149614_2", "wnd_id": "9149614_2_1", "text": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy .", "tokens": ["Nonsustained", "polymorphous", "ventricular", "tachycardia", "during", "amiodarone", "therapy", "for", "atrial", "fibrillation", "complicating", "cardiomyopathy", "."], "event_mentions": [{"id": "9149614_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "9149614_2_Ent0", "role": "Effect", "text": "Nonsustained polymorphous ventricular tachycardia", "start": 0, "end": 4}, {"entity_id": "9149614_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "9149614_2_Ent1", "role": "Treatment", "text": "amiodarone therapy", "start": 5, "end": 7}, {"entity_id": "9149614_2_Ent3", "role": "Treatment_Disorder", "text": "atrial fibrillation complicating cardiomyopathy", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "9149614_2_Ent0", "text": "Nonsustained polymorphous ventricular tachycardia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9149614_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9149614_2_Ent1", "text": "amiodarone therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9149614_2_Ent3", "text": "atrial fibrillation complicating cardiomyopathy", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "9169264_2", "wnd_id": "9169264_2_1", "text": "The ampicillin rash occurring in cases of infectious mononucleosis is well documented .", "tokens": ["The", "ampicillin", "rash", "occurring", "in", "cases", "of", "infectious", "mononucleosis", "is", "well", "documented", "."], "event_mentions": [{"id": "9169264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 3, "end": 4}, "arguments": [{"entity_id": "9169264_2_Ent0", "role": "Effect", "text": "The ampicillin rash", "start": 0, "end": 3}, {"entity_id": "9169264_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9169264_2_Ent0", "text": "The ampicillin rash", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9169264_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9177620_2", "wnd_id": "9177620_2_1", "text": "The authors report a case of acute pancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( CBZ ) for post - traumatic petit mal epilepsy , and review the current literature of drug - induced AP .", "tokens": ["The", "authors", "report", "a", "case", "of", "acute", "pancreatitis", "(", "AP", ")", "occurring", "in", "a", "patient", "under", "treatment", "with", "carbamazepine", "(", "CBZ", ")", "for", "post", "-", "traumatic", "petit", "mal", "epilepsy", ",", "and", "review", "the", "current", "literature", "of", "drug", "-", "induced", "AP", "."], "event_mentions": [{"id": "9177620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 11, "end": 12}, "arguments": [{"entity_id": "9177620_2_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 6, "end": 8}, {"entity_id": "9177620_2_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}, {"entity_id": "9177620_2_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 18, "end": 19}, {"entity_id": "9177620_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 18, "end": 19}, {"entity_id": "9177620_2_Ent3", "role": "Treatment_Disorder", "text": "post - traumatic petit mal epilepsy", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "9177620_2_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9177620_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9177620_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9177620_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9177620_2_Ent3", "text": "post - traumatic petit mal epilepsy", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "9184269_3", "wnd_id": "9184269_3_1", "text": "On the other hand , MTX - induced pneumonitis seems to be very rare in psoriatic arthritis ( PsA ) .", "tokens": ["On", "the", "other", "hand", ",", "MTX", "-", "induced", "pneumonitis", "seems", "to", "be", "very", "rare", "in", "psoriatic", "arthritis", "(", "PsA", ")", "."], "event_mentions": [{"id": "9184269_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "9184269_3_Ent1", "role": "Treatment", "text": "MTX", "start": 5, "end": 6}, {"entity_id": "9184269_3_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 5, "end": 6}, {"entity_id": "9184269_3_Ent0", "role": "Effect", "text": "pneumonitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9184269_3_Ent1", "text": "MTX", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9184269_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9184269_3_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9191742_1", "wnd_id": "9191742_1_1", "text": "Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism .", "tokens": ["Recent", "studies", "have", "shown", "that", "under", "experimental", "conditions", "ferrous", "sulfate", "may", "reduce", "the", "gastrointestinal", "absorption", "of", "orally", "administered", "levothyroxine", "sodium", "in", "patients", "with", "primary", "hypothyroidism", "."], "event_mentions": [{"id": "9191742_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reduce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9191742_1_Ent3", "role": "Treatment", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent5", "role": "Treatment_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent8", "role": "Combination_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent2", "role": "Effect", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "start": 11, "end": 20}, {"entity_id": "9191742_1_Ent7", "role": "Treatment_Route", "text": "orally", "start": 16, "end": 17}, {"entity_id": "9191742_1_Ent4", "role": "Treatment", "text": "orally administered levothyroxine sodium", "start": 16, "end": 20}, {"entity_id": "9191742_1_Ent6", "role": "Treatment_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent9", "role": "Combination_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent0", "role": "Subject", "text": "patients with primary hypothyroidism", "start": 21, "end": 25}, {"entity_id": "9191742_1_Ent1", "role": "Subject_Disorder", "text": "primary hypothyroidism", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9191742_1_Ent3", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent5", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent8", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent2", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "9191742_1_Ent7", "text": "orally", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9191742_1_Ent4", "text": "orally administered levothyroxine sodium", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "9191742_1_Ent6", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent9", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent0", "text": "patients with primary hypothyroidism", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9191742_1_Ent1", "text": "primary hypothyroidism", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9191742_2", "wnd_id": "9191742_2_1", "text": "We describe a patient who became hypothyroid while taking ferrous sulfate .", "tokens": ["We", "describe", "a", "patient", "who", "became", "hypothyroid", "while", "taking", "ferrous", "sulfate", "."], "event_mentions": [{"id": "9191742_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 5, "end": 6}, "arguments": [{"entity_id": "9191742_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "9191742_2_Ent1", "role": "Effect", "text": "hypothyroid", "start": 6, "end": 7}, {"entity_id": "9191742_2_Ent2", "role": "Treatment", "text": "ferrous sulfate", "start": 9, "end": 11}, {"entity_id": "9191742_2_Ent3", "role": "Treatment_Drug", "text": "ferrous sulfate", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9191742_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9191742_2_Ent1", "text": "hypothyroid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9191742_2_Ent2", "text": "ferrous sulfate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9191742_2_Ent3", "text": "ferrous sulfate", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9247841_3", "wnd_id": "9247841_3_1", "text": "Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide - induced reactions .", "tokens": ["Generalized", "maculopapular", "and", "papular", "purpuric", "eruptions", "are", "perhaps", "the", "most", "common", "thionamide", "-", "induced", "reactions", "."], "event_mentions": [{"id": "9247841_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9247841_3_Ent0", "role": "Effect", "text": "Generalized maculopapular and papular purpuric eruptions", "start": 0, "end": 6}, {"entity_id": "9247841_3_Ent2", "role": "Treatment", "text": "thionamide", "start": 11, "end": 12}, {"entity_id": "9247841_3_Ent3", "role": "Treatment_Drug", "text": "thionamide", "start": 11, "end": 12}, {"entity_id": "9247841_3_Ent1", "role": "Effect", "text": "reactions", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9247841_3_Ent0", "text": "Generalized maculopapular and papular purpuric eruptions", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9247841_3_Ent2", "text": "thionamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9247841_3_Ent3", "text": "thionamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9247841_3_Ent1", "text": "reactions", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9253492_4", "wnd_id": "9253492_4_1", "text": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration .", "tokens": ["The", "oligohidrosis", "caused", "by", "zonisamide", "was", "reversible", "in", "that", "the", "patient", "regained", "the", "ability", "to", "sweat", "within", "2", "weeks", "of", "the", "cessation", "of", "drug", "administration", "."], "event_mentions": [{"id": "9253492_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of the", "start": 19, "end": 21}, "arguments": [{"entity_id": "9253492_4_Ent2", "role": "Treatment", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent4", "role": "Treatment_Drug", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "9253492_4_Ent1", "role": "Effect", "text": "regained the ability to sweat within 2 weeks", "start": 11, "end": 19}, {"entity_id": "9253492_4_Ent6", "role": "Treatment_Time_elapsed", "text": "within 2 weeks", "start": 16, "end": 19}, {"entity_id": "9253492_4_Ent5", "role": "Treatment_Dosage", "text": "cessation", "start": 21, "end": 22}, {"entity_id": "9253492_4_Ent3", "role": "Treatment", "text": "cessation of drug administration", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "9253492_4_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9253492_4_Ent1", "text": "regained the ability to sweat within 2 weeks", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "9253492_4_Ent6", "text": "within 2 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9253492_4_Ent5", "text": "cessation", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9253492_4_Ent3", "text": "cessation of drug administration", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "9256906_3", "wnd_id": "9256906_3_1", "text": "Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment .", "tokens": ["Other", "potential", "causes", "of", "renal", "failure", "were", "not", "present", "in", "our", "patient", "and", "his", "renal", "function", "gradually", "recovered", "with", "the", "cessation", "of", "suramin", "treatment", "."], "event_mentions": [{"id": "9256906_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovered", "start": 17, "end": 18}, "arguments": [{"entity_id": "9256906_3_Ent0", "role": "Subject", "text": "our patient", "start": 10, "end": 12}, {"entity_id": "9256906_3_Ent1", "role": "Effect", "text": "his renal function gradually recovered", "start": 13, "end": 18}, {"entity_id": "9256906_3_Ent4", "role": "Treatment_Dosage", "text": "cessation", "start": 20, "end": 21}, {"entity_id": "9256906_3_Ent2", "role": "Treatment", "text": "cessation of suramin treatment", "start": 20, "end": 24}, {"entity_id": "9256906_3_Ent3", "role": "Treatment_Drug", "text": "suramin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9256906_3_Ent0", "text": "our patient", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9256906_3_Ent1", "text": "his renal function gradually recovered", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "9256906_3_Ent4", "text": "cessation", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9256906_3_Ent2", "text": "cessation of suramin treatment", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "9256906_3_Ent3", "text": "suramin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9256906_4", "wnd_id": "9256906_4_1", "text": "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin .", "tokens": ["We", "describe", "a", "patient", "with", "metastatic", "prostate", "cancer", "who", "developed", "nonoliguric", "renal", "failure", "during", "treatment", "with", "suramin", "."], "event_mentions": [{"id": "9256906_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "9256906_4_Ent0", "role": "Subject", "text": "a patient with metastatic prostate cancer", "start": 2, "end": 8}, {"entity_id": "9256906_4_Ent4", "role": "Treatment_Disorder", "text": "metastatic prostate cancer", "start": 5, "end": 8}, {"entity_id": "9256906_4_Ent1", "role": "Effect", "text": "nonoliguric renal failure", "start": 10, "end": 13}, {"entity_id": "9256906_4_Ent2", "role": "Treatment", "text": "suramin", "start": 16, "end": 17}, {"entity_id": "9256906_4_Ent3", "role": "Treatment_Drug", "text": "suramin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9256906_4_Ent0", "text": "a patient with metastatic prostate cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "9256906_4_Ent4", "text": "metastatic prostate cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9256906_4_Ent1", "text": "nonoliguric renal failure", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9256906_4_Ent2", "text": "suramin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9256906_4_Ent3", "text": "suramin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9291634_4", "wnd_id": "9291634_4_1", "text": "Thirty - six patients with AL received , in a three - month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( ARA - C ) ; among them , along with myelosuppression , five experienced fever , infectious complications , gastrointestinal tract symptoms and severe myalgias .", "tokens": ["Thirty", "-", "six", "patients", "with", "AL", "received", ",", "in", "a", "three", "-", "month", "period", ",", "51", "cycles", "of", "combined", "chemotherapy", "which", "included", ",", "in", "all", "of", "them", ",", "cytosine", "arabinoside", "(", "ARA", "-", "C", ")", ";", "among", "them", ",", "along", "with", "myelosuppression", ",", "five", "experienced", "fever", ",", "infectious", "complications", ",", "gastrointestinal", "tract", "symptoms", "and", "severe", "myalgias", "."], "event_mentions": [{"id": "9291634_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 44, "end": 45}, "arguments": [{"entity_id": "9291634_4_Ent6", "role": "Treatment_Duration", "text": "three - month", "start": 10, "end": 13}, {"entity_id": "9291634_4_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "9291634_4_Ent5", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 28, "end": 30}, {"entity_id": "9291634_4_Ent4", "role": "Treatment", "text": "cytosine arabinoside ( ARA - C )", "start": 28, "end": 35}, {"entity_id": "9291634_4_Ent0", "role": "Subject", "text": "five", "start": 43, "end": 44}, {"entity_id": "9291634_4_Ent1", "role": "Subject_Population", "text": "five", "start": 43, "end": 44}, {"entity_id": "9291634_4_Ent2", "role": "Effect", "text": "fever , infectious complications , gastrointestinal tract symptoms and severe myalgias", "start": 45, "end": 56}]}], "entity_mentions": [{"id": "9291634_4_Ent6", "text": "three - month", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9291634_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9291634_4_Ent5", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "9291634_4_Ent4", "text": "cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 28, "end": 35}, {"id": "9291634_4_Ent0", "text": "five", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "9291634_4_Ent1", "text": "five", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "9291634_4_Ent2", "text": "fever , infectious complications , gastrointestinal tract symptoms and severe myalgias", "entity_type": "Entity", "start": 45, "end": 56}], "lang": "en"}
{"doc_id": "9315405_1", "wnd_id": "9315405_1_1", "text": "We report an unusually short lived and asymptomatic episode of severe cisplatin - induced renal tubular salt wasting in a fit 41 - year - old patient with malignant teratoma .", "tokens": ["We", "report", "an", "unusually", "short", "lived", "and", "asymptomatic", "episode", "of", "severe", "cisplatin", "-", "induced", "renal", "tubular", "salt", "wasting", "in", "a", "fit", "41", "-", "year", "-", "old", "patient", "with", "malignant", "teratoma", "."], "event_mentions": [{"id": "9315405_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9315405_1_Ent3", "role": "Treatment", "text": "cisplatin", "start": 11, "end": 12}, {"entity_id": "9315405_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 11, "end": 12}, {"entity_id": "9315405_1_Ent2", "role": "Effect", "text": "renal tubular salt wasting", "start": 14, "end": 18}, {"entity_id": "9315405_1_Ent0", "role": "Subject", "text": "a fit 41 - year - old patient with malignant teratoma", "start": 19, "end": 30}, {"entity_id": "9315405_1_Ent1", "role": "Subject_Age", "text": "41 - year - old", "start": 21, "end": 26}, {"entity_id": "9315405_1_Ent4", "role": "Treatment_Disorder", "text": "malignant teratoma", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "9315405_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9315405_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9315405_1_Ent2", "text": "renal tubular salt wasting", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "9315405_1_Ent0", "text": "a fit 41 - year - old patient with malignant teratoma", "entity_type": "Entity", "start": 19, "end": 30}, {"id": "9315405_1_Ent1", "text": "41 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "9315405_1_Ent4", "text": "malignant teratoma", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "9337441_1", "wnd_id": "9337441_1_1", "text": "Phenolphthalein - induced toxic epidermal necrolysis .", "tokens": ["Phenolphthalein", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "9337441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9337441_1_Ent1", "role": "Treatment", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent2", "role": "Treatment_Drug", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "9337441_1_Ent1", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent2", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "9352164_1", "wnd_id": "9352164_1_1", "text": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure .", "tokens": ["Acute", "hemorrhagic", "gastritis", "associated", "with", "acetazolamide", "intoxication", "in", "a", "patient", "with", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "9352164_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "9352164_1_Ent2", "role": "Effect", "text": "Acute hemorrhagic gastritis", "start": 0, "end": 3}, {"entity_id": "9352164_1_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 5, "end": 6}, {"entity_id": "9352164_1_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 5, "end": 6}, {"entity_id": "9352164_1_Ent0", "role": "Subject", "text": "a patient with chronic renal failure", "start": 8, "end": 14}, {"entity_id": "9352164_1_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "9352164_1_Ent2", "text": "Acute hemorrhagic gastritis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9352164_1_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9352164_1_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9352164_1_Ent0", "text": "a patient with chronic renal failure", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9352164_1_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "9352164_4", "wnd_id": "9352164_4_1", "text": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["We", "experienced", "a", "case", "of", "chronic", "renal", "failure", "in", "a", "patient", "suffering", "from", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "9352164_4_Ent0", "role": "Subject", "text": "a case of chronic renal failure in a patient", "start": 2, "end": 11}, {"entity_id": "9352164_4_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 5, "end": 8}, {"entity_id": "9352164_4_Ent2", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_4_Ent3", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_4_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9352164_4_Ent0", "text": "a case of chronic renal failure in a patient", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "9352164_4_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9352164_4_Ent2", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_4_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_4_Ent4", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9362107_2", "wnd_id": "9362107_2_1", "text": "On the next day , after a total dose of only 600 mg of danazol , gingival bleeding and purpura occurred .", "tokens": ["On", "the", "next", "day", ",", "after", "a", "total", "dose", "of", "only", "600", "mg", "of", "danazol", ",", "gingival", "bleeding", "and", "purpura", "occurred", "."], "event_mentions": [{"id": "9362107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 20, "end": 21}, "arguments": [{"entity_id": "9362107_2_Ent1", "role": "Treatment", "text": "On the next day , after a total dose of only 600 mg of danazol", "start": 0, "end": 15}, {"entity_id": "9362107_2_Ent3", "role": "Treatment_Dosage", "text": "a total dose of only 600 mg", "start": 6, "end": 13}, {"entity_id": "9362107_2_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 14, "end": 15}, {"entity_id": "9362107_2_Ent0", "role": "Effect", "text": "gingival bleeding and purpura", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "9362107_2_Ent1", "text": "On the next day , after a total dose of only 600 mg of danazol", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "9362107_2_Ent3", "text": "a total dose of only 600 mg", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9362107_2_Ent2", "text": "danazol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9362107_2_Ent0", "text": "gingival bleeding and purpura", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "9399776_1", "wnd_id": "9399776_1_1", "text": "Acute pancreatitis after long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "after", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "9399776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "9399776_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "9399776_1_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 3, "end": 6}, {"entity_id": "9399776_1_Ent1", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 3, "end": 11}, {"entity_id": "9399776_1_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9399776_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9399776_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9399776_1_Ent1", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "9399776_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "9399776_5", "wnd_id": "9399776_5_1", "text": "We describe two cases of acute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis .", "tokens": ["We", "describe", "two", "cases", "of", "acute", "pancreatitis", "that", "occurred", "after", "long", "term", "mesalamine", "therapy", "for", "ulcerative", "colitis", "."], "event_mentions": [{"id": "9399776_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "9399776_5_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "9399776_5_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 5, "end": 7}, {"entity_id": "9399776_5_Ent2", "role": "Treatment", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_5_Ent4", "role": "Treatment_Drug", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_5_Ent3", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "9399776_5_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9399776_5_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9399776_5_Ent2", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_5_Ent4", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_5_Ent3", "text": "ulcerative colitis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "9403220_2", "wnd_id": "9403220_2_1", "text": "Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril .", "tokens": ["Acute", "renal", "failure", "with", "severe", "tubulointerstitial", "changes", "in", "a", "patient", "with", "minimal", "change", "nephrotic", "syndrome", "treated", "with", "enalapril", "."], "event_mentions": [{"id": "9403220_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 7, "end": 8}, "arguments": [{"entity_id": "9403220_2_Ent1", "role": "Effect", "text": "Acute renal failure with severe tubulointerstitial changes", "start": 0, "end": 7}, {"entity_id": "9403220_2_Ent0", "role": "Subject", "text": "a patient with minimal change nephrotic syndrome", "start": 8, "end": 15}, {"entity_id": "9403220_2_Ent4", "role": "Treatment_Disorder", "text": "minimal change nephrotic syndrome", "start": 11, "end": 15}, {"entity_id": "9403220_2_Ent2", "role": "Treatment", "text": "enalapril", "start": 17, "end": 18}, {"entity_id": "9403220_2_Ent3", "role": "Treatment_Drug", "text": "enalapril", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9403220_2_Ent1", "text": "Acute renal failure with severe tubulointerstitial changes", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9403220_2_Ent0", "text": "a patient with minimal change nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9403220_2_Ent4", "text": "minimal change nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "9403220_2_Ent2", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9403220_2_Ent3", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9407188_2", "wnd_id": "9407188_2_1", "text": "We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of ritonavir , a protease inhibitor .", "tokens": ["We", "report", "2", "cases", "of", "maculopapular", "eruption", "and", "fever", "in", "patients", "infected", "with", "human", "immunodeficiency", "virus", "(", "HIV", ")", "on", "the", "2nd", "day", "of", "first", "administration", "of", "ritonavir", ",", "a", "protease", "inhibitor", "."], "event_mentions": [{"id": "9407188_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "infected", "start": 11, "end": 12}, "arguments": [{"entity_id": "9407188_2_Ent1", "role": "Effect", "text": "maculopapular eruption and fever", "start": 5, "end": 9}, {"entity_id": "9407188_2_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "9407188_2_Ent3", "role": "Treatment_Disorder", "text": "human immunodeficiency virus", "start": 13, "end": 16}, {"entity_id": "9407188_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2nd day of first administration", "start": 21, "end": 26}, {"entity_id": "9407188_2_Ent2", "role": "Treatment", "text": "ritonavir", "start": 27, "end": 28}, {"entity_id": "9407188_2_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "9407188_2_Ent1", "text": "maculopapular eruption and fever", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9407188_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9407188_2_Ent3", "text": "human immunodeficiency virus", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9407188_2_Ent5", "text": "2nd day of first administration", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "9407188_2_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9407188_2_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "9413296_1", "wnd_id": "9413296_1_1", "text": "A 25 - year - old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide .", "tokens": ["A", "25", "-", "year", "-", "old", "woman", "sought", "medical", "attention", "because", "of", "iliocaval", "manifestations", "of", "retroperitoneal", "fibrosis", "while", "she", "was", "taking", "methysergide", "."], "event_mentions": [{"id": "9413296_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 17, "end": 18}, "arguments": [{"entity_id": "9413296_1_Ent0", "role": "Subject", "text": "A 25 - year - old woman", "start": 0, "end": 7}, {"entity_id": "9413296_1_Ent2", "role": "Subject_Age", "text": "25 - year - old", "start": 1, "end": 6}, {"entity_id": "9413296_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "9413296_1_Ent4", "role": "Effect", "text": "iliocaval manifestations of retroperitoneal fibrosis", "start": 12, "end": 17}, {"entity_id": "9413296_1_Ent1", "role": "Subject", "text": "she", "start": 18, "end": 19}, {"entity_id": "9413296_1_Ent5", "role": "Treatment", "text": "methysergide", "start": 21, "end": 22}, {"entity_id": "9413296_1_Ent6", "role": "Treatment_Drug", "text": "methysergide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9413296_1_Ent0", "text": "A 25 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9413296_1_Ent2", "text": "25 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9413296_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9413296_1_Ent4", "text": "iliocaval manifestations of retroperitoneal fibrosis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9413296_1_Ent1", "text": "she", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9413296_1_Ent5", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9413296_1_Ent6", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9426968_1", "wnd_id": "9426968_1_1", "text": "Vitiligo associated with alpha - interferon in a patient with chronic active hepatitis C.", "tokens": ["Vitiligo", "associated", "with", "alpha", "-", "interferon", "in", "a", "patient", "with", "chronic", "active", "hepatitis", "C."], "event_mentions": [{"id": "9426968_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9426968_1_Ent1", "role": "Effect", "text": "Vitiligo", "start": 0, "end": 1}, {"entity_id": "9426968_1_Ent2", "role": "Treatment", "text": "alpha - interferon", "start": 3, "end": 6}, {"entity_id": "9426968_1_Ent3", "role": "Treatment_Drug", "text": "alpha - interferon", "start": 3, "end": 6}, {"entity_id": "9426968_1_Ent0", "role": "Subject", "text": "a patient with chronic active hepatitis C.", "start": 7, "end": 14}, {"entity_id": "9426968_1_Ent4", "role": "Treatment_Disorder", "text": "chronic active hepatitis C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "9426968_1_Ent1", "text": "Vitiligo", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9426968_1_Ent2", "text": "alpha - interferon", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9426968_1_Ent3", "text": "alpha - interferon", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9426968_1_Ent0", "text": "a patient with chronic active hepatitis C.", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "9426968_1_Ent4", "text": "chronic active hepatitis C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "946400_2", "wnd_id": "946400_2_1", "text": "Methyldopa - induced liver injury .", "tokens": ["Methyldopa", "-", "induced", "liver", "injury", "."], "event_mentions": [{"id": "946400_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "946400_2_Ent1", "role": "Treatment", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent2", "role": "Treatment_Drug", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent0", "role": "Effect", "text": "liver injury", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "946400_2_Ent1", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent2", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "946400_3", "wnd_id": "946400_3_1", "text": "Such a rapid and relentless progression of methyldopa - induced liver injury is undoubtedly rare , but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy .", "tokens": ["Such", "a", "rapid", "and", "relentless", "progression", "of", "methyldopa", "-", "induced", "liver", "injury", "is", "undoubtedly", "rare", ",", "but", "it", "may", "be", "prevented", "by", "careful", "supervision", "of", "patients", "who", "exhibit", "liver", "function", "abnormalities", "early", "in", "the", "course", "of", "therapy", "."], "event_mentions": [{"id": "946400_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "946400_3_Ent1", "role": "Treatment", "text": "methyldopa", "start": 7, "end": 8}, {"entity_id": "946400_3_Ent2", "role": "Treatment_Drug", "text": "methyldopa", "start": 7, "end": 8}, {"entity_id": "946400_3_Ent0", "role": "Effect", "text": "liver injury", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "946400_3_Ent1", "text": "methyldopa", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "946400_3_Ent2", "text": "methyldopa", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "946400_3_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "9466030_3", "wnd_id": "9466030_3_1", "text": "PURPOSE : To present a case of respiratory depression following the administration of nebulised morphine .", "tokens": ["PURPOSE", ":", "To", "present", "a", "case", "of", "respiratory", "depression", "following", "the", "administration", "of", "nebulised", "morphine", "."], "event_mentions": [{"id": "9466030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "9466030_3_Ent0", "role": "Effect", "text": "respiratory depression", "start": 7, "end": 9}, {"entity_id": "9466030_3_Ent3", "role": "Treatment_Route", "text": "nebulised", "start": 13, "end": 14}, {"entity_id": "9466030_3_Ent1", "role": "Treatment", "text": "nebulised morphine", "start": 13, "end": 15}, {"entity_id": "9466030_3_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9466030_3_Ent0", "text": "respiratory depression", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9466030_3_Ent3", "text": "nebulised", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9466030_3_Ent1", "text": "nebulised morphine", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9466030_3_Ent2", "text": "morphine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9494448_3", "wnd_id": "9494448_3_1", "text": "BACKGROUND : Hypersensitivity reactions to cyclosporine are rare .", "tokens": ["BACKGROUND", ":", "Hypersensitivity", "reactions", "to", "cyclosporine", "are", "rare", "."], "event_mentions": [{"id": "9494448_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "9494448_3_Ent0", "role": "Effect", "text": "Hypersensitivity reactions", "start": 2, "end": 4}, {"entity_id": "9494448_3_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "9494448_3_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "9494448_3_Ent0", "text": "Hypersensitivity reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9494448_3_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9494448_3_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "9497597_2", "wnd_id": "9497597_2_1", "text": "We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride .", "tokens": ["We", "present", "the", "first", "case", "of", "a", "patient", "with", "priapism", "after", "oral", "intake", "of", "the", "phenothiazine", "prothipendylhydrochloride", "."], "event_mentions": [{"id": "9497597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "9497597_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "9497597_2_Ent1", "role": "Effect", "text": "priapism", "start": 9, "end": 10}, {"entity_id": "9497597_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "9497597_2_Ent2", "role": "Treatment", "text": "oral intake of the phenothiazine prothipendylhydrochloride", "start": 11, "end": 17}, {"entity_id": "9497597_2_Ent3", "role": "Treatment_Drug", "text": "prothipendylhydrochloride", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9497597_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9497597_2_Ent1", "text": "priapism", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9497597_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9497597_2_Ent2", "text": "oral intake of the phenothiazine prothipendylhydrochloride", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "9497597_2_Ent3", "text": "prothipendylhydrochloride", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9512187_1", "wnd_id": "9512187_1_1", "text": "Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi 's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud 's phenomenon under chemotherapy .", "tokens": ["Because", "the", "combination", "of", "bleomycin", "and", "vinca", "alkaloids", "is", "commonly", "used", "for", "the", "treatment", "of", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", ",", "clinicians", "should", "be", "aware", "of", "the", "risk", "of", "provoking", "acral", "necrosis", "in", "patients", "who", "develop", "Raynaud", "'s", "phenomenon", "under", "chemotherapy", "."], "event_mentions": [{"id": "9512187_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoking", "start": 30, "end": 31}, "arguments": [{"entity_id": "9512187_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent6", "role": "Combination_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent3", "role": "Treatment", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent5", "role": "Treatment_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent7", "role": "Combination_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent0", "role": "Effect", "text": "acral necrosis", "start": 31, "end": 33}, {"entity_id": "9512187_1_Ent1", "role": "Effect", "text": "Raynaud 's phenomenon", "start": 37, "end": 40}]}], "entity_mentions": [{"id": "9512187_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent3", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent5", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent7", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent0", "text": "acral necrosis", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "9512187_1_Ent1", "text": "Raynaud 's phenomenon", "entity_type": "Entity", "start": 37, "end": 40}], "lang": "en"}
{"doc_id": "9512187_2", "wnd_id": "9512187_2_1", "text": "In this report , one patient who developed gangrene after bleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi 's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud 's phenomenon related to the same regimen are presented .", "tokens": ["In", "this", "report", ",", "one", "patient", "who", "developed", "gangrene", "after", "bleomycin", "and", "vincristine", "/", "vinblastine", "chemotherapy", "for", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", "and", "another", "HIV", "-", "infected", "patient", "who", "exhibited", "symptoms", "of", "severe", "Raynaud", "'s", "phenomenon", "related", "to", "the", "same", "regimen", "are", "presented", "."], "event_mentions": [{"id": "9512187_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "9512187_2_Ent1", "role": "Subject_Population", "text": "one", "start": 4, "end": 5}, {"entity_id": "9512187_2_Ent0", "role": "Subject", "text": "one patient", "start": 4, "end": 6}, {"entity_id": "9512187_2_Ent2", "role": "Effect", "text": "gangrene", "start": 8, "end": 9}, {"entity_id": "9512187_2_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent7", "role": "Combination_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent3", "role": "Treatment", "text": "bleomycin and vincristine / vinblastine", "start": 10, "end": 15}, {"entity_id": "9512187_2_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent8", "role": "Combination_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent6", "role": "Treatment_Drug", "text": "vinblastine", "start": 14, "end": 15}, {"entity_id": "9512187_2_Ent9", "role": "Combination_Drug", "text": "vinblastine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9512187_2_Ent1", "text": "one", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9512187_2_Ent2", "text": "gangrene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9512187_2_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent3", "text": "bleomycin and vincristine / vinblastine", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "9512187_2_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent6", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9512187_2_Ent9", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9533061_3", "wnd_id": "9533061_3_1", "text": "CASE SUMMARY : A 25 - year - old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis .", "tokens": ["CASE", "SUMMARY", ":", "A", "25", "-", "year", "-", "old", "postpartum", "white", "woman", "developed", "multiple", "watery", "stools", "and", "abdominal", "cramping", "on", "day", "6", "of", "therapy", "with", "clindamycin", "vaginal", "cream", "for", "bacterial", "vaginosis", "."], "event_mentions": [{"id": "9533061_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "9533061_3_Ent0", "role": "Subject", "text": "A 25 - year - old postpartum white woman", "start": 3, "end": 12}, {"entity_id": "9533061_3_Ent1", "role": "Subject_Age", "text": "25 - year - old", "start": 4, "end": 9}, {"entity_id": "9533061_3_Ent2", "role": "Subject_Disorder", "text": "postpartum", "start": 9, "end": 10}, {"entity_id": "9533061_3_Ent3", "role": "Subject_Race", "text": "white", "start": 10, "end": 11}, {"entity_id": "9533061_3_Ent4", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "9533061_3_Ent5", "role": "Effect", "text": "multiple watery stools and abdominal cramping", "start": 13, "end": 19}, {"entity_id": "9533061_3_Ent10", "role": "Treatment_Time_elapsed", "text": "day 6", "start": 20, "end": 22}, {"entity_id": "9533061_3_Ent9", "role": "Treatment_Drug", "text": "clindamycin", "start": 25, "end": 26}, {"entity_id": "9533061_3_Ent6", "role": "Treatment", "text": "clindamycin vaginal cream for bacterial vaginosis", "start": 25, "end": 31}, {"entity_id": "9533061_3_Ent8", "role": "Treatment_Route", "text": "vaginal cream", "start": 26, "end": 28}, {"entity_id": "9533061_3_Ent7", "role": "Treatment_Disorder", "text": "bacterial vaginosis", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "9533061_3_Ent0", "text": "A 25 - year - old postpartum white woman", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "9533061_3_Ent1", "text": "25 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9533061_3_Ent2", "text": "postpartum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9533061_3_Ent3", "text": "white", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9533061_3_Ent4", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9533061_3_Ent5", "text": "multiple watery stools and abdominal cramping", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "9533061_3_Ent10", "text": "day 6", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "9533061_3_Ent9", "text": "clindamycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9533061_3_Ent6", "text": "clindamycin vaginal cream for bacterial vaginosis", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "9533061_3_Ent8", "text": "vaginal cream", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "9533061_3_Ent7", "text": "bacterial vaginosis", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "9545161_2", "wnd_id": "9545161_2_1", "text": "Administration of lamotrigine , especially in combination with valproic acid , may lead to the development of TEN .", "tokens": ["Administration", "of", "lamotrigine", ",", "especially", "in", "combination", "with", "valproic", "acid", ",", "may", "lead", "to", "the", "development", "of", "TEN", "."], "event_mentions": [{"id": "9545161_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "9545161_2_Ent1", "role": "Treatment", "text": "Administration of lamotrigine", "start": 0, "end": 3}, {"entity_id": "9545161_2_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent6", "role": "Combination_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent2", "role": "Treatment", "text": "with valproic acid", "start": 7, "end": 10}, {"entity_id": "9545161_2_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent5", "role": "Combination_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent0", "role": "Effect", "text": "TEN", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9545161_2_Ent1", "text": "Administration of lamotrigine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9545161_2_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent2", "text": "with valproic acid", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9545161_2_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent0", "text": "TEN", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9550246_4", "wnd_id": "9550246_4_1", "text": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients , especially those with anxiety , may have difficulty managing the increase .", "tokens": ["The", "authors", "suggest", "that", "risperidone", "may", "increase", "affect", "in", "patients", "with", "schizophrenia", "and", "that", "some", "patients", ",", "especially", "those", "with", "anxiety", ",", "may", "have", "difficulty", "managing", "the", "increase", "."], "event_mentions": [{"id": "9550246_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 6, "end": 7}, "arguments": [{"entity_id": "9550246_4_Ent2", "role": "Treatment", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent1", "role": "Effect", "text": "increase affect", "start": 6, "end": 8}, {"entity_id": "9550246_4_Ent0", "role": "Subject", "text": "patients with schizophrenia", "start": 9, "end": 12}, {"entity_id": "9550246_4_Ent4", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9550246_4_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent1", "text": "increase affect", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9550246_4_Ent0", "text": "patients with schizophrenia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9550246_4_Ent4", "text": "schizophrenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9554064_2", "wnd_id": "9554064_2_1", "text": "Putaminal infarct in methanol intoxication : case report and role of brain imaging studies .", "tokens": ["Putaminal", "infarct", "in", "methanol", "intoxication", ":", "case", "report", "and", "role", "of", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_2_Ent0", "role": "Effect", "text": "Putaminal infarct in methanol intoxication", "start": 0, "end": 5}, {"entity_id": "9554064_2_Ent1", "role": "Treatment", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "9554064_2_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9554064_2_Ent0", "text": "Putaminal infarct in methanol intoxication", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9554064_2_Ent1", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9554064_2_Ent2", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9554064_3", "wnd_id": "9554064_3_1", "text": "Theoretical basal ganglia toxicologic mechanisms of methanol poisoning are reviewed , and the role of brain imaging studies will regard to diagnosis , prognosis and impact on management is discussed .", "tokens": ["Theoretical", "basal", "ganglia", "toxicologic", "mechanisms", "of", "methanol", "poisoning", "are", "reviewed", ",", "and", "the", "role", "of", "brain", "imaging", "studies", "will", "regard", "to", "diagnosis", ",", "prognosis", "and", "impact", "on", "management", "is", "discussed", "."], "event_mentions": [{"id": "9554064_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanisms", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_3_Ent1", "role": "Treatment", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent0", "role": "Effect", "text": "poisoning", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9554064_3_Ent1", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent2", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent0", "text": "poisoning", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9562211_3", "wnd_id": "9562211_3_1", "text": "This report presents a potential case of risperidone - induced tardive dyskinesia .", "tokens": ["This", "report", "presents", "a", "potential", "case", "of", "risperidone", "-", "induced", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "9562211_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9562211_3_Ent0", "role": "Subject", "text": "a potential case", "start": 3, "end": 6}, {"entity_id": "9562211_3_Ent2", "role": "Treatment", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "9562211_3_Ent0", "text": "a potential case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9562211_3_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "95811_1", "wnd_id": "95811_1_1", "text": "A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy .", "tokens": ["A", "61", "-", "year", "-", "old", "man", "developed", "clinical", "lupus", "syndrome", "with", "positive", "antinuclear", "antibody", ",", "positive", "lupus", "erythematosus", "(", "LE", ")", "cell", "preparation", ",", "and", "diffuse", "proliferative", "glomerulonephritis", "following", "26", "months", "of", "procainamide", "therapy", "."], "event_mentions": [{"id": "95811_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "95811_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "95811_1_Ent0", "role": "Subject", "text": "61 - year - old man", "start": 1, "end": 7}, {"entity_id": "95811_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "95811_1_Ent3", "role": "Effect", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "start": 8, "end": 29}, {"entity_id": "95811_1_Ent6", "role": "Treatment_Duration", "text": "26 months", "start": 30, "end": 32}, {"entity_id": "95811_1_Ent4", "role": "Treatment", "text": "26 months of procainamide therapy", "start": 30, "end": 35}, {"entity_id": "95811_1_Ent5", "role": "Treatment_Drug", "text": "procainamide", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "95811_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "95811_1_Ent0", "text": "61 - year - old man", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "95811_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "95811_1_Ent3", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "entity_type": "Entity", "start": 8, "end": 29}, {"id": "95811_1_Ent6", "text": "26 months", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "95811_1_Ent4", "text": "26 months of procainamide therapy", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "95811_1_Ent5", "text": "procainamide", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "95811_2", "wnd_id": "95811_2_1", "text": "Glomerulonephritis in procainamide induced lupus erythematosus : report of a case and review of the literature .", "tokens": ["Glomerulonephritis", "in", "procainamide", "induced", "lupus", "erythematosus", ":", "report", "of", "a", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "95811_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "95811_2_Ent0", "role": "Effect", "text": "Glomerulonephritis", "start": 0, "end": 1}, {"entity_id": "95811_2_Ent2", "role": "Treatment", "text": "procainamide", "start": 2, "end": 3}, {"entity_id": "95811_2_Ent3", "role": "Treatment_Drug", "text": "procainamide", "start": 2, "end": 3}, {"entity_id": "95811_2_Ent1", "role": "Effect", "text": "lupus erythematosus", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "95811_2_Ent0", "text": "Glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "95811_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "95811_2_Ent3", "text": "procainamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "95811_2_Ent1", "text": "lupus erythematosus", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "9602881_1", "wnd_id": "9602881_1_1", "text": "We report a 76 - year - old man who developed an acute blistering eruption following high - dose penicillin treatment for pneumococcal septicaemia .", "tokens": ["We", "report", "a", "76", "-", "year", "-", "old", "man", "who", "developed", "an", "acute", "blistering", "eruption", "following", "high", "-", "dose", "penicillin", "treatment", "for", "pneumococcal", "septicaemia", "."], "event_mentions": [{"id": "9602881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "9602881_1_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 3, "end": 8}, {"entity_id": "9602881_1_Ent0", "role": "Subject", "text": "76 - year - old man", "start": 3, "end": 9}, {"entity_id": "9602881_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "9602881_1_Ent3", "role": "Effect", "text": "acute blistering eruption", "start": 12, "end": 15}, {"entity_id": "9602881_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 16, "end": 19}, {"entity_id": "9602881_1_Ent4", "role": "Treatment", "text": "high - dose penicillin treatment", "start": 16, "end": 21}, {"entity_id": "9602881_1_Ent5", "role": "Treatment_Drug", "text": "penicillin", "start": 19, "end": 20}, {"entity_id": "9602881_1_Ent7", "role": "Treatment_Disorder", "text": "pneumococcal septicaemia", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "9602881_1_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9602881_1_Ent0", "text": "76 - year - old man", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "9602881_1_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9602881_1_Ent3", "text": "acute blistering eruption", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "9602881_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9602881_1_Ent4", "text": "high - dose penicillin treatment", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "9602881_1_Ent5", "text": "penicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9602881_1_Ent7", "text": "pneumococcal septicaemia", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "961329_1", "wnd_id": "961329_1_1", "text": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported .", "tokens": ["A", "case", "of", "prolonged", "suxamethonium", "apnoea", "successfully", "terminated", "by", "the", "infusion", "of", "a", "commercial", "preparation", "of", "serumcholinesterase", "is", "reported", "."], "event_mentions": [{"id": "961329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 7, "end": 8}, "arguments": [{"entity_id": "961329_1_Ent0", "role": "Effect", "text": "prolonged suxamethonium apnoea", "start": 3, "end": 6}, {"entity_id": "961329_1_Ent2", "role": "Treatment_Drug", "text": "suxamethonium", "start": 4, "end": 5}, {"entity_id": "961329_1_Ent1", "role": "Treatment", "text": "the infusion of a commercial preparation of serumcholinesterase", "start": 9, "end": 17}, {"entity_id": "961329_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "961329_1_Ent3", "role": "Treatment_Drug", "text": "serumcholinesterase", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "961329_1_Ent0", "text": "prolonged suxamethonium apnoea", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "961329_1_Ent2", "text": "suxamethonium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "961329_1_Ent1", "text": "the infusion of a commercial preparation of serumcholinesterase", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "961329_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "961329_1_Ent3", "text": "serumcholinesterase", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9619226_1", "wnd_id": "9619226_1_1", "text": "Cardiac arrest associated with sulprostone use during caesarean section .", "tokens": ["Cardiac", "arrest", "associated", "with", "sulprostone", "use", "during", "caesarean", "section", "."], "event_mentions": [{"id": "9619226_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9619226_1_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "9619226_1_Ent1", "role": "Treatment", "text": "sulprostone", "start": 4, "end": 5}, {"entity_id": "9619226_1_Ent2", "role": "Treatment_Drug", "text": "sulprostone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9619226_1_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9619226_1_Ent1", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9619226_1_Ent2", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9642842_2", "wnd_id": "9642842_2_1", "text": "We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone .", "tokens": ["We", "describe", "the", "case", "of", "a", "nonatopic", "17", "-", "year", "-", "old", "girl", "with", "bronchial", "asthma", "and", "aspirin", "intolerance", "who", "developed", "a", "dramatic", "anaphylactic", "reaction", "to", "oral", "prednisone", "."], "event_mentions": [{"id": "9642842_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "9642842_2_Ent0", "role": "Subject", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "start": 5, "end": 19}, {"entity_id": "9642842_2_Ent1", "role": "Subject_Disorder", "text": "nonatopic", "start": 6, "end": 7}, {"entity_id": "9642842_2_Ent3", "role": "Subject_Age", "text": "17 - year - old", "start": 7, "end": 12}, {"entity_id": "9642842_2_Ent4", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "9642842_2_Ent9", "role": "Treatment_Disorder", "text": "bronchial asthma", "start": 14, "end": 16}, {"entity_id": "9642842_2_Ent2", "role": "Subject_Disorder", "text": "aspirin intolerance", "start": 17, "end": 19}, {"entity_id": "9642842_2_Ent5", "role": "Effect", "text": "a dramatic anaphylactic reaction", "start": 21, "end": 25}, {"entity_id": "9642842_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "9642842_2_Ent6", "role": "Treatment", "text": "oral prednisone", "start": 26, "end": 28}, {"entity_id": "9642842_2_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "9642842_2_Ent0", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "9642842_2_Ent1", "text": "nonatopic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9642842_2_Ent3", "text": "17 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9642842_2_Ent4", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9642842_2_Ent9", "text": "bronchial asthma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9642842_2_Ent2", "text": "aspirin intolerance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9642842_2_Ent5", "text": "a dramatic anaphylactic reaction", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9642842_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9642842_2_Ent6", "text": "oral prednisone", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "9642842_2_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "9660541_2", "wnd_id": "9660541_2_1", "text": "Mitomycin C - related hemolytic uremic syndrome in cancer patients .", "tokens": ["Mitomycin", "C", "-", "related", "hemolytic", "uremic", "syndrome", "in", "cancer", "patients", "."], "event_mentions": [{"id": "9660541_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "9660541_2_Ent2", "role": "Treatment", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent1", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 4, "end": 7}, {"entity_id": "9660541_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 8, "end": 9}, {"entity_id": "9660541_2_Ent0", "role": "Subject", "text": "cancer patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9660541_2_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent3", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent1", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9660541_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9660541_2_Ent0", "text": "cancer patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9660541_3", "wnd_id": "9660541_3_1", "text": "We report a case of MMC - related hemolytic uremic syndrome , and discuss the etiologic parameters , clinical aspects , prognosis and treatment modalities of this severe syndrome .", "tokens": ["We", "report", "a", "case", "of", "MMC", "-", "related", "hemolytic", "uremic", "syndrome", ",", "and", "discuss", "the", "etiologic", "parameters", ",", "clinical", "aspects", ",", "prognosis", "and", "treatment", "modalities", "of", "this", "severe", "syndrome", "."], "event_mentions": [{"id": "9660541_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "9660541_3_Ent1", "role": "Treatment", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9660541_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "9681092_2", "wnd_id": "9681092_2_1", "text": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol .", "tokens": ["To", "report", "a", "case", "of", "QT", "prolongation", "associated", "with", "concomitant", "cyclobenzaprine", "and", "fluoxetine", "administration", "followed", "by", "torsade", "de", "pointes", "potentiated", "by", "droperidol", "."], "event_mentions": [{"id": "9681092_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9681092_2_Ent0", "role": "Effect", "text": "QT prolongation", "start": 5, "end": 7}, {"entity_id": "9681092_2_Ent1", "role": "Treatment", "text": "concomitant cyclobenzaprine and fluoxetine administration", "start": 9, "end": 14}, {"entity_id": "9681092_2_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 10, "end": 11}, {"entity_id": "9681092_2_Ent4", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 10, "end": 11}, {"entity_id": "9681092_2_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 12, "end": 13}, {"entity_id": "9681092_2_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 12, "end": 13}]}, {"id": "9681092_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "potentiated", "start": 19, "end": 20}, "arguments": [{"entity_id": "9681092_2_Ent6", "role": "Effect", "text": "torsade de pointes", "start": 16, "end": 19}, {"entity_id": "9681092_2_Ent7", "role": "Treatment", "text": "droperidol", "start": 21, "end": 22}, {"entity_id": "9681092_2_Ent8", "role": "Treatment_Drug", "text": "droperidol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9681092_2_Ent0", "text": "QT prolongation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9681092_2_Ent1", "text": "concomitant cyclobenzaprine and fluoxetine administration", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9681092_2_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681092_2_Ent4", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681092_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9681092_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9681092_2_Ent6", "text": "torsade de pointes", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9681092_2_Ent7", "text": "droperidol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9681092_2_Ent8", "text": "droperidol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9681092_5", "wnd_id": "9681092_5_1", "text": "Prior to surgery , the patient received droperidol , an agent known to prolong the QT interval .", "tokens": ["Prior", "to", "surgery", ",", "the", "patient", "received", "droperidol", ",", "an", "agent", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_5_Ent2", "role": "Treatment", "text": "Prior to surgery", "start": 0, "end": 3}, {"entity_id": "9681092_5_Ent0", "role": "Subject", "text": "the patient", "start": 4, "end": 6}, {"entity_id": "9681092_5_Ent1", "role": "Treatment", "text": "droperidol", "start": 7, "end": 8}, {"entity_id": "9681092_5_Ent3", "role": "Treatment_Drug", "text": "droperidol", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9681092_5_Ent2", "text": "Prior to surgery", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9681092_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9681092_5_Ent1", "text": "droperidol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9681092_5_Ent3", "text": "droperidol", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9681092_8", "wnd_id": "9681092_8_1", "text": "Cyclobenzaprine shares anticholinergic effects , tachycardia , and dysrhythmic potential with the tricyclic antidepressants ( TCAs ) .", "tokens": ["Cyclobenzaprine", "shares", "anticholinergic", "effects", ",", "tachycardia", ",", "and", "dysrhythmic", "potential", "with", "the", "tricyclic", "antidepressants", "(", "TCAs", ")", "."], "event_mentions": [{"id": "9681092_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 9, "end": 10}, "arguments": [{"entity_id": "9681092_8_Ent1", "role": "Treatment", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent3", "role": "Treatment_Drug", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent0", "role": "Effect", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "start": 2, "end": 9}, {"entity_id": "9681092_8_Ent2", "role": "Treatment", "text": "with the tricyclic antidepressants ( TCAs )", "start": 10, "end": 17}, {"entity_id": "9681092_8_Ent4", "role": "Treatment_Drug", "text": "tricyclic antidepressants", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9681092_8_Ent1", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent3", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent0", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9681092_8_Ent2", "text": "with the tricyclic antidepressants ( TCAs )", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "9681092_8_Ent4", "text": "tricyclic antidepressants", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9681211_2", "wnd_id": "9681211_2_1", "text": "Leukaemoid monocytosis in M4 AML following chemotherapy and G - CSF .", "tokens": ["Leukaemoid", "monocytosis", "in", "M4", "AML", "following", "chemotherapy", "and", "G", "-", "CSF", "."], "event_mentions": [{"id": "9681211_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "9681211_2_Ent0", "role": "Effect", "text": "Leukaemoid monocytosis in M4 AML", "start": 0, "end": 5}, {"entity_id": "9681211_2_Ent1", "role": "Treatment", "text": "chemotherapy and G - CSF", "start": 6, "end": 11}, {"entity_id": "9681211_2_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9681211_2_Ent0", "text": "Leukaemoid monocytosis in M4 AML", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9681211_2_Ent1", "text": "chemotherapy and G - CSF", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9681211_2_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "968449_2", "wnd_id": "968449_2_1", "text": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera ( PV ) at the time of diagnosis and several times subsequently during therapy with chlorambucil .", "tokens": ["Bone", "marrow", "chromosomes", "were", "studied", "in", "2", "patients", "with", "polycythaemia", "vera", "(", "PV", ")", "at", "the", "time", "of", "diagnosis", "and", "several", "times", "subsequently", "during", "therapy", "with", "chlorambucil", "."], "event_mentions": [{"id": "968449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 24, "end": 25}, "arguments": [{"entity_id": "968449_2_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "968449_2_Ent0", "role": "Subject", "text": "2 patients with polycythaemia vera ( PV )", "start": 6, "end": 14}, {"entity_id": "968449_2_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera ( PV )", "start": 9, "end": 14}, {"entity_id": "968449_2_Ent2", "role": "Treatment", "text": "chlorambucil", "start": 26, "end": 27}, {"entity_id": "968449_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "968449_2_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "968449_2_Ent0", "text": "2 patients with polycythaemia vera ( PV )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "968449_2_Ent3", "text": "polycythaemia vera ( PV )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "968449_2_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "968449_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9695308_4", "wnd_id": "9695308_4_1", "text": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA .", "tokens": ["It", "was", "concluded", "that", "ANCA", "is", "closely", "related", "to", "the", "pathogenesis", "of", "crescentic", "glomerulonephritis", "and", "that", "treatment", "with", "PTU", "appeared", "to", "induce", "ANCA", "."], "event_mentions": [{"id": "9695308_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 21, "end": 22}, "arguments": [{"entity_id": "9695308_4_Ent1", "role": "Treatment", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent0", "role": "Effect", "text": "ANCA", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9695308_4_Ent1", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent2", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent0", "text": "ANCA", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9723127_3", "wnd_id": "9723127_3_1", "text": "Decreased plasma cortisol level during alprazolam treatment of panic disorder : a case report .", "tokens": ["Decreased", "plasma", "cortisol", "level", "during", "alprazolam", "treatment", "of", "panic", "disorder", ":", "a", "case", "report", "."], "event_mentions": [{"id": "9723127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "9723127_3_Ent0", "role": "Effect", "text": "Decreased plasma cortisol level", "start": 0, "end": 4}, {"entity_id": "9723127_3_Ent1", "role": "Treatment", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent3", "role": "Treatment_Disorder", "text": "panic disorder", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9723127_3_Ent0", "text": "Decreased plasma cortisol level", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9723127_3_Ent1", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent3", "text": "panic disorder", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9737132_1", "wnd_id": "9737132_1_1", "text": "A 47 year - old woman who had a 4 - year history of intramuscular pentazocine injections in the lower extremities , developed gradual stiffness and weakness of the lower extremities .", "tokens": ["A", "47", "year", "-", "old", "woman", "who", "had", "a", "4", "-", "year", "history", "of", "intramuscular", "pentazocine", "injections", "in", "the", "lower", "extremities", ",", "developed", "gradual", "stiffness", "and", "weakness", "of", "the", "lower", "extremities", "."], "event_mentions": [{"id": "9737132_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "9737132_1_Ent0", "role": "Subject", "text": "A 47 year - old woman", "start": 0, "end": 6}, {"entity_id": "9737132_1_Ent1", "role": "Subject_Age", "text": "47 year - old", "start": 1, "end": 5}, {"entity_id": "9737132_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "9737132_1_Ent4", "role": "Treatment", "text": "a 4 - year history of intramuscular pentazocine injections in the lower extremities", "start": 8, "end": 21}, {"entity_id": "9737132_1_Ent5", "role": "Treatment_Time_elapsed", "text": "4 - year", "start": 9, "end": 12}, {"entity_id": "9737132_1_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 14, "end": 15}, {"entity_id": "9737132_1_Ent8", "role": "Treatment_Drug", "text": "pentazocine", "start": 15, "end": 16}, {"entity_id": "9737132_1_Ent7", "role": "Treatment_Route", "text": "injections", "start": 16, "end": 17}, {"entity_id": "9737132_1_Ent3", "role": "Effect", "text": "gradual stiffness and weakness of the lower extremities", "start": 23, "end": 31}]}], "entity_mentions": [{"id": "9737132_1_Ent0", "text": "A 47 year - old woman", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9737132_1_Ent1", "text": "47 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "9737132_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9737132_1_Ent4", "text": "a 4 - year history of intramuscular pentazocine injections in the lower extremities", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "9737132_1_Ent5", "text": "4 - year", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9737132_1_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9737132_1_Ent8", "text": "pentazocine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9737132_1_Ent7", "text": "injections", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9737132_1_Ent3", "text": "gradual stiffness and weakness of the lower extremities", "entity_type": "Entity", "start": 23, "end": 31}], "lang": "en"}
{"doc_id": "9770151_1", "wnd_id": "9770151_1_1", "text": "Although praziquantel administration may have been effective in killing the parasite in both patients , we are concerned about the production of marked inflammation as a result of treatment .", "tokens": ["Although", "praziquantel", "administration", "may", "have", "been", "effective", "in", "killing", "the", "parasite", "in", "both", "patients", ",", "we", "are", "concerned", "about", "the", "production", "of", "marked", "inflammation", "as", "a", "result", "of", "treatment", "."], "event_mentions": [{"id": "9770151_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "production", "start": 20, "end": 21}, "arguments": [{"entity_id": "9770151_1_Ent3", "role": "Treatment", "text": "praziquantel", "start": 1, "end": 2}, {"entity_id": "9770151_1_Ent4", "role": "Treatment_Drug", "text": "praziquantel", "start": 1, "end": 2}, {"entity_id": "9770151_1_Ent5", "role": "Treatment_Disorder", "text": "parasite", "start": 10, "end": 11}, {"entity_id": "9770151_1_Ent0", "role": "Subject", "text": "parasite in both patients", "start": 10, "end": 14}, {"entity_id": "9770151_1_Ent1", "role": "Subject_Population", "text": "both", "start": 12, "end": 13}, {"entity_id": "9770151_1_Ent2", "role": "Effect", "text": "marked inflammation", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "9770151_1_Ent3", "text": "praziquantel", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9770151_1_Ent4", "text": "praziquantel", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9770151_1_Ent5", "text": "parasite", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9770151_1_Ent0", "text": "parasite in both patients", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "9770151_1_Ent1", "text": "both", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9770151_1_Ent2", "text": "marked inflammation", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "9776099_1", "wnd_id": "9776099_1_1", "text": "NMS is a drug - related response to various medications , such as Haloperidol , which the patient was receiving .", "tokens": ["NMS", "is", "a", "drug", "-", "related", "response", "to", "various", "medications", ",", "such", "as", "Haloperidol", ",", "which", "the", "patient", "was", "receiving", "."], "event_mentions": [{"id": "9776099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 6, "end": 7}, "arguments": [{"entity_id": "9776099_1_Ent1", "role": "Effect", "text": "NMS", "start": 0, "end": 1}, {"entity_id": "9776099_1_Ent2", "role": "Treatment", "text": "Haloperidol", "start": 13, "end": 14}, {"entity_id": "9776099_1_Ent3", "role": "Treatment_Drug", "text": "Haloperidol", "start": 13, "end": 14}, {"entity_id": "9776099_1_Ent0", "role": "Subject", "text": "patient", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9776099_1_Ent1", "text": "NMS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9776099_1_Ent2", "text": "Haloperidol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9776099_1_Ent3", "text": "Haloperidol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9776099_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9777751_1", "wnd_id": "9777751_1_1", "text": "Methimazole - induced aplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor .", "tokens": ["Methimazole", "-", "induced", "aplastic", "anemia", "in", "third", "exposure", ":", "successful", "treatment", "with", "recombinant", "human", "granulocyte", "colony", "-", "stimulating", "factor", "."], "event_mentions": [{"id": "9777751_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9777751_1_Ent1", "role": "Treatment", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent2", "role": "Treatment_Drug", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}, {"entity_id": "9777751_1_Ent3", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "9777751_1_Ent1", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent2", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9777751_1_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "9792602_1", "wnd_id": "9792602_1_1", "text": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible , and that periodic urine testing in patients receiving pranlukast should be considered .", "tokens": ["The", "case", "demonstrates", "that", "hypersensitivity", "reaction", "to", "pranlukast", "and", "resultant", "ATIN", "is", "possible", ",", "and", "that", "periodic", "urine", "testing", "in", "patients", "receiving", "pranlukast", "should", "be", "considered", "."], "event_mentions": [{"id": "9792602_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 6, "end": 7}, "arguments": [{"entity_id": "9792602_1_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 4, "end": 6}, {"entity_id": "9792602_1_Ent1", "role": "Treatment", "text": "pranlukast", "start": 7, "end": 8}, {"entity_id": "9792602_1_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 7, "end": 8}, {"entity_id": "9792602_1_Ent3", "role": "Treatment_Drug", "text": "pranlukast", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9792602_1_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9792602_1_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_1_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_1_Ent3", "text": "pranlukast", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9796135_4", "wnd_id": "9796135_4_1", "text": "Syncope in a 65 - year - old woman after nitrate ingestion .", "tokens": ["Syncope", "in", "a", "65", "-", "year", "-", "old", "woman", "after", "nitrate", "ingestion", "."], "event_mentions": [{"id": "9796135_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "9796135_4_Ent3", "role": "Effect", "text": "Syncope", "start": 0, "end": 1}, {"entity_id": "9796135_4_Ent0", "role": "Subject", "text": "a 65 - year - old woman", "start": 2, "end": 9}, {"entity_id": "9796135_4_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 3, "end": 8}, {"entity_id": "9796135_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "9796135_4_Ent5", "role": "Treatment_Drug", "text": "nitrate", "start": 10, "end": 11}, {"entity_id": "9796135_4_Ent4", "role": "Treatment", "text": "nitrate ingestion", "start": 10, "end": 12}, {"entity_id": "9796135_4_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9796135_4_Ent3", "text": "Syncope", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9796135_4_Ent0", "text": "a 65 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9796135_4_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9796135_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9796135_4_Ent5", "text": "nitrate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9796135_4_Ent4", "text": "nitrate ingestion", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9796135_4_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9804082_1", "wnd_id": "9804082_1_1", "text": "Three diabetic cases of acute dizziness due to initial administration of voglibose .", "tokens": ["Three", "diabetic", "cases", "of", "acute", "dizziness", "due", "to", "initial", "administration", "of", "voglibose", "."], "event_mentions": [{"id": "9804082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "9804082_1_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "9804082_1_Ent0", "role": "Subject", "text": "Three diabetic cases", "start": 0, "end": 3}, {"entity_id": "9804082_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic", "start": 1, "end": 2}, {"entity_id": "9804082_1_Ent2", "role": "Effect", "text": "acute dizziness", "start": 4, "end": 6}, {"entity_id": "9804082_1_Ent3", "role": "Treatment", "text": "initial administration of voglibose", "start": 8, "end": 12}, {"entity_id": "9804082_1_Ent4", "role": "Treatment_Drug", "text": "voglibose", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9804082_1_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9804082_1_Ent0", "text": "Three diabetic cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9804082_1_Ent5", "text": "diabetic", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9804082_1_Ent2", "text": "acute dizziness", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9804082_1_Ent3", "text": "initial administration of voglibose", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9804082_1_Ent4", "text": "voglibose", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9855339_4", "wnd_id": "9855339_4_1", "text": "We suspect that nefazodone inhibits metabolism of tacrolimus .", "tokens": ["We", "suspect", "that", "nefazodone", "inhibits", "metabolism", "of", "tacrolimus", "."], "event_mentions": [{"id": "9855339_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhibits", "start": 4, "end": 5}, "arguments": [{"entity_id": "9855339_4_Ent1", "role": "Treatment", "text": "nefazodone", "start": 3, "end": 4}, {"entity_id": "9855339_4_Ent2", "role": "Treatment_Drug", "text": "nefazodone", "start": 3, "end": 4}, {"entity_id": "9855339_4_Ent0", "role": "Effect", "text": "metabolism of tacrolimus", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "9855339_4_Ent1", "text": "nefazodone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9855339_4_Ent2", "text": "nefazodone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9855339_4_Ent0", "text": "metabolism of tacrolimus", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "9861579_1", "wnd_id": "9861579_1_1", "text": "We report the case of intoxication of a 41 - year - old female patient suffering from major depression with mirtazapine complicated by severe hypothermia .", "tokens": ["We", "report", "the", "case", "of", "intoxication", "of", "a", "41", "-", "year", "-", "old", "female", "patient", "suffering", "from", "major", "depression", "with", "mirtazapine", "complicated", "by", "severe", "hypothermia", "."], "event_mentions": [{"id": "9861579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 19, "end": 20}, "arguments": [{"entity_id": "9861579_1_Ent3", "role": "Effect", "text": "intoxication", "start": 5, "end": 6}, {"entity_id": "9861579_1_Ent0", "role": "Subject", "text": "a 41 - year - old female patient", "start": 7, "end": 15}, {"entity_id": "9861579_1_Ent1", "role": "Subject_Age", "text": "41 - year - old", "start": 8, "end": 13}, {"entity_id": "9861579_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 13, "end": 14}, {"entity_id": "9861579_1_Ent6", "role": "Treatment_Disorder", "text": "major depression", "start": 17, "end": 19}, {"entity_id": "9861579_1_Ent5", "role": "Treatment", "text": "mirtazapine", "start": 20, "end": 21}, {"entity_id": "9861579_1_Ent7", "role": "Treatment_Drug", "text": "mirtazapine", "start": 20, "end": 21}, {"entity_id": "9861579_1_Ent4", "role": "Effect", "text": "hypothermia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "9861579_1_Ent3", "text": "intoxication", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9861579_1_Ent0", "text": "a 41 - year - old female patient", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9861579_1_Ent1", "text": "41 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "9861579_1_Ent2", "text": "female", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9861579_1_Ent6", "text": "major depression", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9861579_1_Ent5", "text": "mirtazapine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9861579_1_Ent7", "text": "mirtazapine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9861579_1_Ent4", "text": "hypothermia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "9865241_1", "wnd_id": "9865241_1_1", "text": "CONCLUSION : We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning .", "tokens": ["CONCLUSION", ":", "We", "report", "a", "case", "of", "the", "use", "of", "pamidronate", "for", "significant", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "9865241_1_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "9865241_1_Ent1", "role": "Treatment", "text": "pamidronate", "start": 10, "end": 11}, {"entity_id": "9865241_1_Ent4", "role": "Treatment_Drug", "text": "pamidronate", "start": 10, "end": 11}, {"entity_id": "9865241_1_Ent2", "role": "Treatment_Disorder", "text": "hypercalcemia", "start": 13, "end": 14}, {"entity_id": "9865241_1_Ent3", "role": "Treatment_Drug", "text": "vitamin D", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "9865241_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9865241_1_Ent1", "text": "pamidronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_1_Ent4", "text": "pamidronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_1_Ent2", "text": "hypercalcemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9865241_1_Ent3", "text": "vitamin D", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "9865241_5", "wnd_id": "9865241_5_1", "text": "We report the use of pamidronate for acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning .", "tokens": ["We", "report", "the", "use", "of", "pamidronate", "for", "acute", ",", "severe", "hypercalcemia", "secondary", "to", "iatrogenic", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_5_Ent0", "role": "Treatment", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent1", "role": "Treatment_Disorder", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "start": 7, "end": 17}]}, {"id": "9865241_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 11, "end": 12}, "arguments": [{"entity_id": "9865241_5_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 10, "end": 11}, {"entity_id": "9865241_5_Ent4", "role": "Treatment", "text": "vitamin D", "start": 14, "end": 16}, {"entity_id": "9865241_5_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "9865241_5_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent1", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "9865241_5_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_5_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9865241_5_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9870779_2", "wnd_id": "9870779_2_1", "text": "Methotrexate - induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis .", "tokens": ["Methotrexate", "-", "induced", "hepatic", "necrosis", "requiring", "liver", "transplantation", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "9870779_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9870779_2_Ent2", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9870779_2_Ent3", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9870779_2_Ent1", "role": "Effect", "text": "hepatic necrosis", "start": 3, "end": 5}, {"entity_id": "9870779_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 9, "end": 14}, {"entity_id": "9870779_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9870779_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_2_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_2_Ent1", "text": "hepatic necrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9870779_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9870779_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9876812_1", "wnd_id": "9876812_1_1", "text": "Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "possibility", "that", "vinorelbine", "may", "cause", "SIADH", "and", "possibly", "hypokalemia", "."], "event_mentions": [{"id": "9876812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "9876812_1_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent0", "role": "Effect", "text": "SIADH and possibly hypokalemia", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "9876812_1_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent0", "text": "SIADH and possibly hypokalemia", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "9886213_4", "wnd_id": "9886213_4_1", "text": "We describe a case of disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy , an event not described previously .", "tokens": ["We", "describe", "a", "case", "of", "disseminated", "muscular", "cysticercosis", "followed", "by", "myositis", "(", "fever", ",", "diffuse", "myalgia", ",", "weakness", "of", "the", "lower", "limbs", ",", "and", "inflammatory", "reaction", "around", "dying", "cysticerci", ")", "induced", "by", "praziquantel", "therapy", ",", "an", "event", "not", "described", "previously", "."], "event_mentions": [{"id": "9886213_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "9886213_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "9886213_4_Ent1", "role": "Effect", "text": "disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci )", "start": 5, "end": 30}, {"entity_id": "9886213_4_Ent3", "role": "Treatment_Drug", "text": "praziquantel", "start": 32, "end": 33}, {"entity_id": "9886213_4_Ent2", "role": "Treatment", "text": "praziquantel therapy", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "9886213_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9886213_4_Ent1", "text": "disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci )", "entity_type": "Entity", "start": 5, "end": 30}, {"id": "9886213_4_Ent3", "text": "praziquantel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "9886213_4_Ent2", "text": "praziquantel therapy", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "990658_1", "wnd_id": "990658_1_1", "text": "A fatal case of pancytopenia due to levomepromazine .", "tokens": ["A", "fatal", "case", "of", "pancytopenia", "due", "to", "levomepromazine", "."], "event_mentions": [{"id": "990658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 5, "end": 6}, "arguments": [{"entity_id": "990658_1_Ent0", "role": "Subject", "text": "A fatal case", "start": 0, "end": 3}, {"entity_id": "990658_1_Ent1", "role": "Effect", "text": "pancytopenia", "start": 4, "end": 5}, {"entity_id": "990658_1_Ent2", "role": "Treatment", "text": "levomepromazine", "start": 7, "end": 8}, {"entity_id": "990658_1_Ent3", "role": "Treatment_Drug", "text": "levomepromazine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "990658_1_Ent0", "text": "A fatal case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "990658_1_Ent1", "text": "pancytopenia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "990658_1_Ent2", "text": "levomepromazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "990658_1_Ent3", "text": "levomepromazine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
